<SEC-DOCUMENT>0001193125-17-342616.txt : 20171114
<SEC-HEADER>0001193125-17-342616.hdr.sgml : 20171114
<ACCEPTANCE-DATETIME>20171114162933
ACCESSION NUMBER:		0001193125-17-342616
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		16
FILED AS OF DATE:		20171114
DATE AS OF CHANGE:		20171114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Genprex, Inc.
		CENTRAL INDEX KEY:			0001595248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				900772347
		FISCAL YEAR END:			1213

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-219386
		FILM NUMBER:		171202036

	BUSINESS ADDRESS:	
		STREET 1:		100 CONGRESS AVENUE
		STREET 2:		SUITE 2000
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78701
		BUSINESS PHONE:		512-708-0155

	MAIL ADDRESS:	
		STREET 1:		100 CONGRESS AVENUE
		STREET 2:		SUITE 2000
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78701
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d486549d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PROSPECTUS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration No. 333-219386 </B></P></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Up to 4,500,000 Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g486549g08p69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">This is an
initial public offering of Genprex, Inc. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">We are offering a minimum of 2,500,000 and a maximum of 4,500,000&nbsp;shares of common stock in
this offering. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock. The initial public offering price per share is
$5.00. We have applied to list the common stock on the Nasdaq Capital Market under the symbol &#147;GNPX&#148;. If the application is approved, trading of our common stock on the Nasdaq Capital Market is expected to begin within five days after the
initial issuance of the common stock. If our common stock is not approved for listing on the Nasdaq Capital Market, we will not consummate this offering. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in Section&nbsp;2(a) of the Securities Act of 1933, as amended, and we have elected to
comply with certain reduced public company reporting requirements. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:11pt; font-family:Times New Roman"><B>An investment
in our common stock involves significant risks. You should carefully consider the <A HREF="#toc486549_2">risk&nbsp;factors</A> beginning on page 13 of this prospectus before you make your decision to invest in our shares of common stock. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon
the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Public&nbsp;Offering<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Underwriting<BR>Commissions(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Proceeds&nbsp;to&nbsp;Us,<BR>Before&nbsp;Expenses(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total minimum offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">937,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,562,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total maximum offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,687,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,812,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Underwriting&#148; for more information on this offering and the underwriter arrangements. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">We estimate the total expenses of this offering, excluding the underwriting commissions, will be approximately $775,000. Because this is a best efforts offering, the actual public offering amount, underwriting
commissions and proceeds to us are not presently determinable and may be substantially less than the total maximum offering set forth above. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9pt; font-family:Times New Roman">Network 1
Financial Securities, Inc. is acting as the sole representative of the underwriters. The underwriters are selling shares of our common stock in this offering on a best efforts basis. We do not intend to close this offering unless we sell at least a
minimum number of 2,500,000 shares of common stock, at the price set forth in the table above, and otherwise satisfy the listing conditions to trade our common stock on the Nasdaq Capital Market. This offering will terminate on December 12, 2017,
unless we sell the maximum number of shares of common stock set forth above before that date or we decide to terminate this offering prior to that date. The gross proceeds of this offering will be deposited at Signature Bank in an escrow account
established by us, until we have sold a minimum of 2,500,000 shares of common stock and otherwise satisfy the listing conditions to trade our common stock on the Nasdaq Capital Market. Once we satisfy the minimum stock sale and Nasdaq listing
conditions, the funds will be released to us. In the event we do not sell a minimum of 2,500,000 shares of common stock and raise minimum gross proceeds of $12,500,000 by December 12, 2017, all funds received will be promptly returned to investors
without interest or offset. See &#147;Prospectus Summary&#151;The Offering&#148;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Delivery of the shares of our common stock is expected to be made on or
about the closing date of the offering, which must occur prior to December 31, 2017. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g486549g30y40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is November 14, 2017 </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc486549_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc486549_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc486549_3">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc486549_4">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc486549_5">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc486549_6">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc486549_7">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc486549_8">SELECTED HISTORICAL FINANCIAL AND OPERATING DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc486549_9">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc486549_10">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc486549_11">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc486549_12">EXECUTIVE OFFICER AND DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc486549_13">RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc486549_14">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc486549_15">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc486549_16">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc486549_17">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc486549_18">VALIDITY OF COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc486549_19">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc486549_20">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc486549_21">INDEX TO FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Through and including December 9, 2017 (the 25th day after the date of this prospectus), all dealers
effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&#146;s obligation to deliver a prospectus when acting as an underwriter and with
respect to unsold allotments or subscriptions. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No dealer, salesperson or other person is authorized to give any information or to
represent anything not contained in this prospectus. You must not rely on any unauthorized information or representations. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it
is lawful to do so. The information contained in this prospectus is current only as of its date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market data and certain industry data
and forecasts used throughout this prospectus were obtained from internal company surveys, market research, consultant surveys, publicly available information, reports of governmental agencies and industry publications and surveys. Industry surveys,
publications, consultant surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but that the accuracy and completeness of such information is not guaranteed. While we are
not aware of any misstatements regarding the industry data presented in this prospectus, our estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the heading &#147;Risk
Factors&#148; in this prospectus. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc486549_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information that you
should consider before deciding to invest in our common stock. You should read this entire prospectus carefully, including the &#147;Risk Factors&#148; section, our historical financial statements and the notes thereto, and unaudited pro forma
financial information, each included elsewhere in this prospectus. The terms &#147;Genprex,&#148; the &#147;Company,&#148; &#147;our,&#148; or &#147;we&#148; refer to Genprex, Inc. and, unless the context otherwise requires, its predecessors.
</I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genprex&#153; is a
clinical stage gene therapy company developing a new approach to treating cancer, based upon our novel proprietary technology platform, including our initial product candidate, Oncoprex&#153; immunogene therapy, or Oncoprex. Our platform
technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing
or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in
cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hold an exclusive worldwide license from The University of Texas MD Anderson Cancer Center, or MD Anderson, to patents covering the
therapeutic use of a series of genes that have been shown in preclinical and clinical research to have cancer fighting properties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With
Oncoprex, we are initially targeting non-small cell lung cancer, or NSCLC. Researchers at MD Anderson have conducted two Phase I clinical trials and are currently conducting an ongoing Phase II clinical trial of Oncoprex in NSCLC. According to the
World Health Organization, lung cancer is the leading cause of cancer deaths worldwide, killing more people than breast, colon, kidney, liver, prostate and skin cancers combined, and is the second most common type of cancer. Each year, there are
over 1.8&nbsp;million new lung cancer cases and 1.6&nbsp;million deaths from lung cancer worldwide, and in the United States there are over 225,000 new cases and more than 150,000 deaths from lung cancer per year. NSCLC represents 80% of all lung
cancers. According to a 2016 American Cancer Society report, the five-year survival rate for Stage IV (metastatic) NSCLC is about 1%,&nbsp;and overall survival for lung cancer has not improved appreciably in the last 25 years. We believe that there
is a significant unmet medical need for new treatments for NSCLC in the United States and globally, and we believe that Oncoprex may be suitable for a majority of NSCLC patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our platform technologies could allow delivery of a number of cancer fighting genes, alone or in combination with other cancer
therapies, to combat multiple types of cancer. Our research and development pipeline, discussed &#147;Our Pipeline&#148; below, demonstrates our clinical and preclinical progress to date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cancer results from genetic mutations. Mutations that lead to cancer are usually present in two major classes of genes: oncogenes, which are
involved in functions such as signal transduction and transcription; and tumor suppressor genes, which play a role in governing cell proliferation by regulating transcription.&nbsp;Transduction is the process by which chemical and physical signals
are transmitted through cells. Transcription is the process by which a cell&#146;s DNA sequence is copied to make RNA molecules, which then play a role in protein expression. In normal cells, mutations in oncogenes are discovered and targeted for
elimination by tumor suppressor genes. In cancer cells, the oncogene mutations may overwhelm the natural tumor suppression processes, or those tumor suppression processes may be impaired or absent.&nbsp;Functional alterations due to mutations in
oncogenes or tumor suppressor genes may result in the abnormal and uncontrolled growth patterns characteristic of cancer. These </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
genetic alterations facilitate such malignant growth by affecting signal transduction pathways and transcription, thus inhibiting normal growth signaling in the cell, circumventing the natural
process of apoptosis, evading the immune system&#146;s response to cancer, and inducing angiogenesis, which is the formation of new blood vessels that supply cancer cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The most common genetic alterations present in NSCLC are in tumor suppressor genes, against which few targeted small molecule drugs have been
developed. Each of the two sets of chromosomes in the cell nucleus includes two copies of each gene, called alleles, which may be identical or may show differences. In most situations, tumor suppressor genes require both alleles of a gene to be
deleted or inactivated to impair tumor suppression activity and lead to tumor growth. The replacement of just one functional allele may therefore be enough to restore the normal cellular functions of growth regulation and apoptosis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among the genetic conditions associated with lung cancer are the overexpression of epidermal growth factor receptors, or EGFRs, and mutations
of kinases. Kinases are enzymes that play an important role in signal transduction through the modification of proteins by adding or taking away phosphate groups, a process called (de-)phosphorylation, to change the proteins&#146; function. When two
EGFR transmembrane proteins are brought to proximity on the cell membrane surface, or dimerize, either through a ligand, or binding molecule, that binds to the extracellular receptor, or through some other process, the intracellular protein-kinase
domains can auto-phosphorylate, and activate downstream processes, including cell signaling pathways that can lead to either cell cycle arrest or cell growth and proliferation. EGFRs and kinases can act similarly to a switch that turns
&#147;on&#148; and &#147;off&#148; when phosphate groups are either added or taken away. Mutated kinases can have a malfunctioning on/off switch, causing the switch to be stuck in the &#147;on&#148; position or failing to turn the switch
&#147;off,&#148; leading to the loss of cell control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A subset of NSCLC patients (approximately 10% of NSCLC patients of North American
and European descent and approximately 30% to 50% of NSCLC patients of Asian descent) carry an EGFR mutation that makes their tumors sensitive to tyrosine kinase inhibitors, or TKIs, such as erlotinib. However, even for these patients, tumor
resistance to TKIs frequently develops within two years, resulting in eventual disease progression. Erlotinib generally does not benefit NSCLC patients who do not have this activating EGFR mutation. However, our clinical and preclinical data have
shown that the combination of Oncoprex and erlotinib can increase anti-tumor activity even in cancers without the EGFR mutations, as well as in cancers that have become resistant to erlotinib. For this reason, we believe Oncoprex may be suitable for
the majority of NSCLC patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cancer can spread when cells&#146; natural cancer suppression functions are impaired. The tumor
suppressor gene called Tumor Suppressor Candidate 2, or TUSC2 (which was formerly known as FUS1) has been shown to affect both cell proliferation and apoptosis. TUSC2 is a pan-kinase inhibitor, which means that it has the ability to inhibit multiple
kinase receptors, such as EGFR and platelet-derived growth factor receptor, or PDGFR. TUSC2 is frequently inactivated early in the development of lung cancer, and loss of TUSC2 expression in NSCLC is associated with significantly worse overall
survival compared to patients with normal TUSC2 expression. Many types of cancer cells, including approximately 85% of NSCLC cells, lack expression of TUSC2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cancer can also spread when the body&#146;s natural immune functions are impaired, including by the cancer cells themselves. PD-1, or
Programmed Death-1, is a receptor expressed on the surface of activated T cells, which are part of the body&#146;s immune system. PD-L1, or Programmed Death Ligand-1, is a protein/receptor expressed on the surface of cancer and other cells. The
binding of PD-1 to PD-L1 has been speculated to contribute to cancer cells&#146; ability to evade the body&#146;s immune response. PD-1 and molecules like it are called immune checkpoints, because they can impede the normal immune response, for
example by blocking the T cells from attacking the cancer cells. In many cancers, PD-L1 receptors are up-regulated, and substantial research is now being performed in the emerging field of immuno-oncology to discover drugs or antibodies that could
block </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
PD-L1 and similar receptors. It is believed that blocking the PD-1/PD-L1 interaction pathway and other similar checkpoints, such as cytotoxic T-lymphocyte-associated protein 4, or CTLA-4, with
drugs called checkpoint inhibitors can prevent cancer cells from inactivating T cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Oncoprex immunogene therapy is designed to
interrupt cell signaling pathways that cause replication and proliferation of cancer cells, and to target and kill cancer cells via receptor pathways, and also to stimulate the natural immune responses against cancer. Oncoprex combines features of
gene therapy and immunotherapy in that it up-regulates TUSC2 expression in the cell, and also increases the anti-tumor immune cell population and down-regulates PD-L1 receptors, thereby boosting the immune response to cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Oncoprex consists of a TUSC2 gene encapsulated in a positively charged nanovesicle made from lipid molecules with a positive electrical
charge. Oncoprex is injected intravenously and can specifically target cancer cells, which generally have a negative electrical charge. Once Oncoprex is taken up into a cancer cell, the TUSC2 gene is expressed into a protein that is capable of
restoring certain defective functions arising in the cancer cell. Oncoprex nanovesicles are designed to deliver the functioning TUSC2 gene to cancer cells while minimizing their uptake by normal tissue. Tumor biopsy studies conducted at MD Anderson
show that the uptake of TUSC2 in tumor cells after Oncoprex treatment is 10 to 25 times the uptake in normal cells. We believe that Oncoprex, unlike other gene therapies, which either need to be delivered directly into tumors or require cells to be
removed from the body, re-engineered and then reinserted into the body, is the first systemic gene therapy to be used for cancer in humans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical data from the evaluation of 24 patients in our Phase I/II clinical trial, as well as our preclinical data, indicate that Oncoprex can
be combined with the widely used anti-cancer drug erlotinib (marketed as Tarceva<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> by Genentech, Inc.) in humans.&nbsp;Erlotinib is a tyrosine kinase inhibitor, or TKI, which uses a mechanism
of action similar to that of pan-kinase inhibitors to block the action of tyrosine kinases, which are a type of kinase involved in many cell functions, including cell signaling, growth and division. In addition, MD Anderson researchers have
conducted preclinical studies combining Oncoprex with: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the TKI gefitinib (marketed as Iressa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> by AstraZeneca Pharmaceuticals) in animals and in human NSCLC cells; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">MK2206 in animals (MK2206 is an inhibitor of AKT kinases, which affect cell signaling pathways downstream from tyrosine kinases); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an anti-PD-1 antibody equivalent to the checkpoint inhibitor nivolumab (marketed as Opdivo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> by Bristol-Myers Squibb Company) in animals; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an anti-CTLA4 antibody equivalent to ipilimumab (marketed as Yervoy<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> by Bristol-Myers Squibb Company) in animals. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacturers of the marketed drugs were not involved in any of our clinical or preclinical studies. In studies involving marketed drugs,
the drugs were administered concurrently with Oncoprex without being modified in any way, and the antibodies used in our preclinical studies that did not use the marketed drugs were the non-humanized equivalent to marketed drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Data from these clinical and preclinical studies indicate that combining Oncoprex with these other therapies yields results more favorable
than either these therapies or Oncoprex alone, with minimal side effects relative to other lung cancer drugs, thereby potentially making Oncoprex a therapy complementary to these cancer treatments.&nbsp;In addition, based on our clinical and
preclinical studies and on preclinical studies conducted by others, we believe that Oncoprex could be combined with other lung cancer drugs that have similar mechanisms of action to the drugs mentioned above, such as pembrolizumab (marketed as
Keytruda<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> by Merck&nbsp;&amp; Co.), nivolumab (marketed as Opdivo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> by Bristol-Myers Squibb Company) and atezolizumab (marketed as
Tecentriq<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by Genentech/Roche). We have not conducted any preclinical or clinical studies combining Oncoprex with pembrolizumab or atezolizumab. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Researchers at MD Anderson have collaborated with other researchers to identify other genes, such as those in the 3p21.3 chromosomal region,
that may act as tumor suppressors or have other cancer fighting functions. We hold rights to certain of these genes under license agreements with MD Anderson.&nbsp;Data from preclinical studies performed by others suggest that product candidates
that could be derived from our technology platform could be effective against other types of cancer, including breast, head and neck, renal cell (kidney), and soft tissue cancer, as well as NSCLC. Therefore, our platform technologies may allow
delivery of a number of cancer fighting genes, alone or in combination with other cancer therapies, to combat multiple types of cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MD Anderson researchers have completed the first phase of a Phase I/II clinical trial of Oncoprex in combination with erlotinib in patients
with Stage IV (metastatic) or recurrent NSCLC that is not potentially curable by radiotherapy or surgery, whether or not they have received prior chemotherapy, and whether or not they have an activating EGFR mutation.&nbsp;The Phase I portion of the
trial was a dose-escalating study with primary endpoints of establishing the safety and tolerability of the combination of Oncoprex and erlotinib, and establishing the Maximum Tolerated Dose, or MTD. The secondary endpoint of the Phase I portion of
the trial was to assess the toxicity of the combination of Oncoprex with erlotinib. In the Phase I portion of the trial, which began in 2014, 18 subjects were treated, and the MTD was determined to be the highest tested dose: 0.6 mg/kg of Oncoprex
administered every 21 days and 150 mg of erlotinib per day. Toxicities were found to compare favorably with those of other lung cancer drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase II portion of the trial is designed to include subjects treated with the combination of Oncoprex and erlotinib at the MTD with the
primary goal of measuring the response rate, and secondary endpoints of stable disease, time to progression and overall survival. The response rate for cancer therapies is defined under the Response Evaluation Criteria in Solid Tumors, or RECIST, as
Complete Response (CR) + Partial Response (PR); disease control rate is defined under the RECIST criteria as Complete Response (CR) + Partial Response (PR) + Stable Disease (SD)&gt;8weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enrollment criteria for the second phase of the Phase I/II clinical trial are identical to those in the first phase. The Phase II portion of
the trial began in June 2015 and is ongoing at MD Anderson. Of the 39 patients allowed in the protocol for the Phase II portion of the trial, 10 have been enrolled and nine are evaluable for response under the trial protocol, because they have
received 2 or more cycles of treatment. Interim results show that four of the patients had tumor regression and one patient had a Complete Response, or CR under the RECIST criteria. The patient with the CR had disappearance of the lung primary
tumor, as well as lung, liver, and lymph node metastases. The median response duration for all patients, which is defined as the median time between when response is first noted to the time when cancer progression is observed, was three months. The
response rate for the nine patients evaluated to date was 11% and the disease control rate for the nine patients was 78%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The response
rate and disease control rate to date in the Phase II portion of our Phase I/II clinical trial substantially exceeds the response rate of 7% (with no CRs) and disease control rate of 58% reported for a clinical trial of the TKI afatinib (marketed as
Gilotrif<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> by Boehringer Ingelheim Pharmaceuticals, Inc.) in a study referred to as the LUX-Lung 1 clinical trial. A total of 585 patients were enrolled in that Phase IIB/III clinical trial,
whose primary endpoint was overall survival and whose secondary endpoints were progression-free survival, RECIST response, quality of life and safety. The LUX-Lung 1 clinical trial was a randomized, double blinded Phase IIB/III clinical trial
treating subjects with Stage IIIB or IV adenocarcinoma, a type of NSCLC. The Phase II portion of our Phase I/II trial is not blinded, and is designed to treat NSCLC subjects regardless of EGFR status. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preliminary analysis of the early data from the Phase II portion of our Phase I/II trial supports our belief that Oncoprex may provide medical
benefit in several subpopulations of NSCLC patients for which there is an unmet </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
medical need, and may provide pathways for accelerated approval by the US Food and Drug Administration, or FDA. As a result of these initial findings, in April 2016, we suspended enrollment of
new patients in the Phase II portion of the trial to collect additional trial data and have it analyzed in order to seek FDA guidance as to whether the protocol for this clinical trial could be modified to expand enrollment and also to divide the
patients into cohorts with a view toward seeking accelerated approval in one or more of these cohort populations. We have completed the collection and analysis of the additional preliminary data and expect to present our findings to the FDA within
the next several months. Although this clinical trial is currently closed to new patient enrollment, it is not terminated, and is considered &#147;ongoing&#148; because activities such as patient follow-up and further data collection and analysis
continue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we reach an agreement with the FDA regarding expanded patient enrollment and defined patient cohorts, then we plan to amend
the trial protocol accordingly and proceed with the amended protocol at MD Anderson and several additional clinical trial sites. Amendments to the Phase II clinical trial protocol will require approval of the Investigational Review Board, or IRB, of
each site where the amended trial is conducted. If we do not reach an agreement with the FDA on these changes, then we plan to reopen enrollment in the current version of the Phase II portion of the trial at MD Anderson and at additional clinical
trial sites. In that event, we will need to provide MD Anderson with plans and funding to move ahead with the trial. Whether under the original protocol or a revised protocol, we intend to use a portion of the proceeds of this offering to add
additional clinical trial sites. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2012, MD Anderson researchers completed a Phase I clinical trial of Oncoprex as a
monotherapy.&nbsp;The primary objective of this Phase I trial was to assess the toxicity of Oncoprex administered intravenously and to determine the MTD and recommended Phase II dose of Oncoprex alone. Secondary objectives were to assess the
expression of TUSC2 following intravenous delivery of Oncoprex in tumor biopsies and also to assess the anti-cancer activity of Oncoprex. This trial demonstrated that Oncoprex was well tolerated and established the MTD and the therapeutic dosage for
Oncoprex at 0.06 mg/kg administered every 21 days. Although this trial was not designed to show changes in outcomes, a halt in cancer growth was observed in a number of patients, and tumor regressions occurred in primary lung tumors and metastatic
cancers in the liver, pancreas, and lymph nodes. In addition, pre- and post-treatment patient biopsies demonstrated that intravenous Oncoprex selectively and preferentially targeted patients&#146; cancer cells, and suggested that clinical
anti-cancer activity was mediated by TUSC2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that Oncoprex&#146; combination of pan-kinase inhibition, direct induction of
apoptosis, anti-cancer immune modulation and complementary action with targeted drugs and immunotherapies is unique, and positions Oncoprex to provide treatment for patients with NSCLC and possibly other cancers, who are not benefitting from
currently offered therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Oncoprex immunogene therapy technology was discovered through a lung cancer research consortium from MD
Anderson and The University of Texas Southwestern Medical Center, or UTSWMC, along with the National Cancer Institute, or NCI. The TUSC2 discovery teams included Jack A. Roth, MD, FACS, chairman of our Scientific and Medical Advisory Board. We have
assembled a team of experts in clinical and translational research, including laboratory scientists, medical oncologists and biostatisticians, to pursue the development and commercialization of Oncoprex and other potential product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our technology discoveries and research and development programs have been the subjects of numerous peer-reviewed publications and have been
supported by Small Business Innovation Research, or SBIR, grants and grants from the National Institutes of Health, the United States Department of Treasury, and the State of Texas. We hold a worldwide, exclusive license from MD Anderson to patents
covering the therapeutic use of TUSC2 and other genes that have been shown to have cancer fighting properties, as well as a number of related technologies, including 30 issued patents, and two pending patent applications. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing Oncoprex, our lead product candidate, to be administered with erlotinib for NSCLC. We are also conducting preclinical
research with the goal of developing Oncoprex to be administered with immunotherapies in NSCLC. In addition, we have conducted research into other tumor suppressor genes associated with chromosome 3p21.3. Our research and development pipeline is
shown below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g486549g16o08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to develop and commercialize treatments for cancer based on our proprietary gene therapy platform, alone or in combination with other
cancer therapies. Key elements of our strategy include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Conduct Ongoing and New Clinical Trials</B><B>.</B> We plan to continue clinical trials of Oncoprex immunogene therapy in combination with erlotinib for treatment of NSCLC, while exploring pathways to accelerated FDA
approval of this combination in subpopulations of NSCLC patients for whom there is currently no approved therapy. We also plan to pursue a clinical trial of the combination of Oncoprex with anti-PD-1 immunotherapy. We may also pursue additional
clinical trials of the combination of Oncoprex plus an immunotherapy called CTLA-4 immunotherapy, as well as possible multi-drug combinations of Oncoprex with additional targeted therapies and immunotherapies. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Investigate the Effectiveness of Oncoprex in Other Cancers</B><B>.</B> We may also explore the combination of Oncoprex and erlotinib in other cancers such as soft tissue, kidney, head and neck, and/or breast cancer,
and we may pursue development of additional proprietary genes, including genes associated with chromosome 3p21.3, alone or in combination with EGFR TKIs such as erlotinib and/or with immunotherapies. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Prepare to Commercialize Oncoprex</B><B>.</B> We plan to continue to develop the manufacturing, process development and other capabilities needed to commercialize Oncoprex. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Pursue Strategic Partnerships</B><B>.</B> As we gather additional clinical data, we plan to pursue strategic partnerships with other developers and providers of anti-cancer drugs to investigate possible therapeutic
combinations of Oncoprex with drugs manufactured by others, to accelerate the development of our current and potential product candidates through co-development and to increase the commercial opportunities for our current and potential product
candidates. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Develop Our Platform Technology</B><B>.</B> We plan to investigate the applicability of our platform technology with additional anti-cancer drugs. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business and our ability to implement our business strategy are subject to numerous risks, as more fully described in the section entitled
&#147;Risk Factors&#148; immediately following this prospectus summary. You should read these risks before you invest in our common stock. We may be unable, for many reasons, including those that are beyond our control, to implement our business
strategy. In particular, risks associated with our business include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have incurred significant losses since our inception, including an accumulated deficit of approximately $16.8 million as of September 30, 2017, and anticipate that we will continue to incur significant losses for the
foreseeable future. We will require substantial additional financing to achieve our goals. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our independent registered public accounting firm has indicated that our financial condition raises substantial doubt as to our ability to continue as a going concern, in that if we are unable to raise additional
capital in a timely manner, our clinical trials and other operations will be negatively affected. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Immunotherapy, gene therapy and biopharmaceutical product development are highly speculative undertakings that involve a substantial degree of uncertainty. Because our current and potential gene therapy product
candidates are based on novel technologies, it is difficult to predict whether they will show consistently favorable results and to predict the time and cost of their development. We have never generated any revenue from product sales, and we may
never be profitable. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Phase II portion of our Phase I/II clinical trial is at an early stage, with a limited number of patients enrolled, and the favorable results observed so far may not continue in the current clinical trial or be
replicated in other clinical trials, especially those involving larger numbers of patients. Before our Phase I/II clinical trial, Oncoprex had previously been tested in only one prior Phase I trial, which involved 31 patients and tested Oncoprex as
a monotherapy. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our current and potential product candidates.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The FDA may disagree with our plans for pursuing regulatory approval, and we may fail to obtain regulatory approval of our current and potential product candidates. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We rely, and expect to continue to rely, in part, on third parties to conduct, supervise, monitor and maintain data concerning our clinical trials and to manufacture our nanovesicles, product candidates and other key
materials. If these third parties encounter difficulties or perform in an unsatisfactory manner, our business may be harmed. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are more advanced or effective than ours, which may adversely affect our financial condition
and our ability to successfully commercialize our current and potential product candidates. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology and product candidates, our competitive position could be harmed. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The concentration of our common stock ownership by our current management may limit your ability to influence our corporate matters. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in Delaware in April 2009. Our principal executive offices are located at 100 Congress Avenue, Suite 2000, Austin, TX
78701, and our telephone number is (512)&nbsp;370-4081. Our corporate website address is www.genprex.com. The information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information
contained on, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have proprietary rights to a number of trademarks used in this prospectus which are important to our business, including Oncoprex&#153;.
Solely for convenience, the trademarks and trade names in this prospectus are generally referred to without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and &#153;&nbsp;symbols, but such references should not be construed as any
indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. All other trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as the term is used in The Jumpstart Our Business Startups Act of 2012, or the JOBS Act,
and therefore, we may take advantage of certain exemptions from various public company reporting requirements, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a requirement to only have two years of audited financial statements and only two years of related selected financial data and management&#146;s discussion and analysis; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exemption from the auditor attestation requirement on the effectiveness of our internal controls over financial reporting; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced disclosure obligations regarding executive compensation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exemptions from the requirements of holding a nonbinding advisory stockholder vote on executive compensation and any golden parachute payments. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these provisions for up to five years or such earlier time that we are no longer an emerging growth company. We would
cease to be an emerging growth company if we have more than $1.0 billion in annual revenues, have more than $700 million in market value of our capital stock held by non-affiliates or issue more than $1.0 billion of non-convertible debt over a
three-year period. We may choose to take advantage of some, but not all, of the available benefits of the JOBS Act. We have taken advantage of some of the reduced reporting requirements in this prospectus. Accordingly, the information contained
herein may be different than the information you receive from other public companies in which you hold stock. In addition, the JOBS Act provides that an emerging growth company can delay adopting new or revised accounting standards until such time
as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other
public companies that are not emerging growth companies. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Offering </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Issuer </P></TD>
<TD>Genprex, Inc., a Delaware corporation </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Securities being offered </P></TD>
<TD>Minimum of 2,500,000 shares of common stock to maximum of 4,500,000 shares of common stock </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Offering price </P></TD>
<TD>$5.00 per share </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock outstanding immediately before this offering </P></TD>
<TD>11,688,158 shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock outstanding immediately after this offering </P></TD>
<TD>14,188,158 shares (minimum) to 16,188,158 shares (maximum) </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Best efforts offering </P></TD>
<TD>The underwriters are selling the shares of our common stock offered in this prospectus on a &#147;best efforts&#148; basis and are not required to sell any specific number or dollar amount of the shares offered by this prospectus, but will use
their best efforts to sell such shares. However, one of the conditions to our obligation to sell any of the shares through the underwriters is that, upon the closing of the offering, our common stock would qualify for listing on the Nasdaq Capital
Market. In order to list, the Nasdaq Capital Market requires that, among other criteria, at least 1,000,000 publicly-held shares of our common stock be outstanding, the shares be held in the aggregate by at least 300 round lot holders, the market
value of the publicly-held shares of our common stock be at least $15.0 million, our stockholders&#146; equity after giving effect to the sale of our shares in this offering be at least $5.0 million, the bid price per share of our common stock be
$4.00 or more, and there be at least three registered and active market makers for our common stock. We do not intend to close this offering unless we sell a minimum of 2,500,000 shares of common stock and otherwise satisfy the listing conditions to
trade our common stock on the Nasdaq Capital Market. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>Based on the initial public offering price of $5.00 per share, we estimate that the net proceeds to us from this offering, assuming we sell a minimum of 2,500,000 shares, will be approximately $10,787,500 and, assuming we sell all a maximum of
4,500,000 shares, will be approximately $20,037,500, after payment of underwriting commissions and our estimated offering expenses. However, this is a best efforts offering, and there is no assurance that we will sell any shares or receive any
proceeds. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the proceeds from this offering to complete our ongoing clinical trial, to commence additional clinical trials, to conduct preclinical research, including biomarker studies, to prepare submissions to
the FDA and for research and development and working capital and general corporate purposes. See &#147;Use of Proceeds&#148; for more information. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors </P></TD>
<TD>See &#147;Risk Factors&#148; and other information appearing elsewhere in this prospectus for a discussion of factors you should carefully consider before deciding whether to invest in our common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Lock-up </P></TD>
<TD>We, our directors, executive officers, and certain stockholders have agreed not to offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of our securities, with certain exceptions, for a
period of 180 days following the closing of the offering of the shares. See &#147;Shares Eligible for Future Sale&#148; for more information. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Escrow </P></TD>
<TD>The gross proceeds of this offering will be deposited at Signature Bank, in an escrow account established by us. Purchasers are to make payment for the shares they purchase by (i)&nbsp;delivering to the escrow agent, Signature Bank, at 565 Fifth
Avenue, 12th Floor, New York, New York 10017, checks made payable to the order of &#147;Signature Bank, as Escrow Agent for Genprex, Inc.,&#148; or (ii)&nbsp;wire transfer to Signature Bank, ABA No. 026013576, 565 Fifth Avenue, 12th Floor, New York,
New York 10017, for credit to Signature Bank, as Escrow Agent for Genprex, Inc., Account No. 1503084720. All checks received by the underwriter will be delivered to Signature Bank for deposit into the escrow account not later than 12:00 p.m. on the
business day immediately following receipt. The funds will be held in escrow until we receive a minimum of $12.5 million and otherwise satisfy the listing conditions to trade our common stock on the Nasdaq Capital Market, at which time the funds
will be released to us. Any funds received in excess of the foregoing minimum amount and following the satisfaction of the Nasdaq listing requirements will immediately be available to us. If we do not receive the minimum amount by December 12, 2017,
all funds will be returned to purchasers in this offering on the next business day after the offering&#146;s termination, without charge, deduction or interest. Prior to December 12, 2017, in no event will funds be returned to you.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Proposed NASDAQ listing symbol </P></TD>
<TD>&#147;GNPX&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock outstanding immediately after this offering excludes, in each
case after giving effect to the forward stock split described below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">4,700,000 shares of common stock reserved for issuance under our 2017 Equity Incentive Plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">748,060 shares of common stock underlying warrants to purchase shares of our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,628,749 shares of common stock underlying options to purchase shares of our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">235,000 shares of common stock reserved for issuance under our 2017 Employee Stock Purchase Plan; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">between 145,833 shares (assuming the minimum number of shares is sold in the offering) and 393,750 shares (assuming the maximum number of shares is sold in the offering) of common stock issuable upon the exercise of the
warrants issued to the underwriter. </TD></TR></TABLE> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except for the financial statements and the notes thereto, and historical financial
information and unless otherwise indicated, all information in this prospectus reflects or assumes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the conversion of all of our outstanding shares of convertible preferred stock into an aggregate of 1,394,953 shares of voting common stock (before giving effect to the forward split described below) in connection with
the completion of this offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the conversion of all of our outstanding shares of non-voting common stock into an aggregate of 25,611 shares of voting common stock (before giving effect to the forward split described below) in connection with the
completion of this offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a 6.6841954-for-1 forward split of our common stock, to be effected in connection with the completion of this offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise of outstanding options after September 30, 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the filing of our amended and restated certificate of incorporation and the effectiveness of our amended and restated bylaws immediately prior to and upon the completion of this offering; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of 3,500,000 shares of common stock in this offering; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no purchase of shares in this offering by our officers, directors and existing stockholders. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing information does not include any amounts relating to a demand we have received for a warrant to purchase shares of our common
stock.&nbsp;See &#147;Business&#151;Legal Proceedings.&#148; </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Financial Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize our historical financial data as of, and for the periods ended on, the dates indicated. We have derived the
summary statement of operations data for the years ended December&nbsp;31, 2015 and 2016 from our audited financial statements included elsewhere in this prospectus. We have derived the summary statement of operations data for the nine months ended
September 30, 2016 and 2017 and balance sheet data as of September 30, 2017 from our unaudited financial statements included elsewhere in this prospectus. The unaudited financial statements have been prepared on a basis consistent with our audited
financial statements included in this prospectus and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, necessary to fairly state our financial position as of September 30, 2017 and results of
operations for the nine months ended September 30, 2016 and 2017. Our historical results are not necessarily indicative of the results that may be expected in the future, and our interim period results are not necessarily indicative of results to be
expected for a full year or any other interim period. The summary financial data set forth below should be read together with the financial statements and the related notes to those statements, as well as the sections of this prospectus entitled
&#147;Selected Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">354,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,776,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">865,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,416,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,906,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,132,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,069,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,647,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,133,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7.77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of common shares&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">314,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">340,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">311,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,602,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">234,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">373,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,353,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,910,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">410,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,266,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,138,195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,006,036</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,785,779</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,624,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">871,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc486549_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should carefully consider each of the following risks, together with all
other information set forth in this prospectus, including the financial statements and the related notes, before making a decision to buy our common stock. If any of the following risks actually occurs, our business could be harmed. In that case,
the trading price of our common stock could decline, and you may lose all or part of your investment. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Position and
Need for Additional Capital </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will require substantial additional funding, which may not be available to us on acceptable terms, or at all,
and, if not so available, may require us to delay, limit, reduce or cease our operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the proceeds from this
offering to advance Oncoprex through clinical development, as well as for other purposes. Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. We will require substantial additional future
capital in order to complete clinical development and commercialize Oncoprex. If the FDA requires that we perform additional preclinical studies or clinical trials, our expenses will further increase beyond what we currently expect and the
anticipated timing of any potential approval of Oncoprex would likely be delayed. Further, there can be no assurance that the costs we will need to incur to obtain regulatory approval of Oncoprex will not increase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will continue to require substantial additional capital to continue our clinical development and commercialization activities. Because
successful development of our current and potential product candidates is uncertain, we are unable to estimate the actual amount of funding we will require to complete research and development and commercialize our products under development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount and timing of our future funding requirements will depend on many factors, including but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the progress, costs, results and timing of our clinical trials for Oncoprex; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the outcome, costs and timing of seeking and obtaining FDA and any other regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability of third parties to deliver materials and provide services for us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs associated with securing and establishing commercialization and manufacturing capabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">market acceptance of our current and potential product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of acquiring, licensing or investing in businesses, products, product candidates and technologies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to maintain, expand and enforce the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the
licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our need and ability to hire additional management and scientific and medical personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effect of competing drug candidates and new product approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our need to implement additional internal systems and infrastructure, including financial and reporting systems; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the economic and other terms, timing of and success of our existing licensing arrangements and any collaboration, licensing or other arrangements into which we may enter in the future. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of these factors are outside of our control. Based upon our currently expected level of operating expenditures, if we receive the maximum
offering amount, we believe that we will be able to fund our operations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for at least 18 months, and if we receive the minimum offering amount, we believe that we will be able to fund our operations for at least 12 months. This period could be shortened if there are
any significant increases in planned spending on development programs or more rapid progress of development programs than anticipated. We cannot assure you that the maximum offering amount will be raised. In the event that less than the maximum
offering amount is raised, we may not have sufficient capital to execute on our business strategy the way we have intended. We do not believe that our existing capital resources and the proceeds of this offering will be sufficient to enable us to
complete the development and commercialization of Oncoprex, Accordingly, we expect that we will need to raise additional funds in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding,
commercialization, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. Additional funding may not be available to us on acceptable terms or at all. In addition, the terms of any financing
may adversely affect the holdings or the rights of our stockholders. Any new equity securities we issue could have rights, preferences, and privileges superior to those of holders of our existing capital stock. In addition, the issuance of
additional shares by us, or the possibility of such issuance, may cause the market price of our shares to decline. Any debt financing secured by us in the future could involve restrictive covenants relating to our capital-raising activities and
other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to obtain funding on a timely basis, we may be required to significantly curtail one or more of our research or development
programs, our ability to continue to support our business growth and to respond to business challenges could be significantly limited, and we could be forced to halt operations. Accordingly, our business may fail, in which case you would lose the
entire amount of your investment in our common stock </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also could be required to seek funds through arrangements with collaborative
partners or otherwise that may require us to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our independent registered public accounting firm has indicated that our financial condition raises substantial doubt as to our ability to continue as a
going concern. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial statements have been prepared assuming that we will continue to operate as a going concern, which
contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. However, our independent registered public accounting firm has included in its audit opinion for the year ended December&nbsp;31, 2016 a
statement that there is substantial doubt as to our ability to continue as a going concern as a result of our recurring losses and financial condition on December&nbsp;31, 2016, unless we are able to obtain additional financing, enter into strategic
alliances and/or sell assets. The reaction of investors to the inclusion of a going concern statement by our auditors, our current lack of cash resources and our potential inability to continue as a going concern may materially adversely affect our
share price and our ability to raise new capital or enter into strategic alliances. If we become unable to obtain additional capital and to continue as a going concern, we may have to liquidate our assets and the values we receive for our assets in
liquidation or dissolution could be significantly lower than the values reflected in our financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have never been profitable, we
have no products approved for commercial sale, and to date we have not generated any revenue from product sales. As a result, our ability to reduce our losses and reach profitability is unproven, and we may never achieve or sustain profitability.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never been profitable and do not expect to be profitable in the foreseeable future. We have not yet submitted any drug
candidates for approval by regulatory authorities in the United States or elsewhere. From our inception on April&nbsp;1, 2009, to September 30, 2017, we incurred an accumulated deficit of approximately $16.8 million. We incurred net losses of
approximately $4.1 million and approximately $1.1 million for the years ended </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
December&nbsp;31, 2016 and 2015, respectively, and of approximately $2.6 million and approximately $3.1 million for the nine-month periods ended September 30, 2017 and 2016, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have devoted most of our financial resources to our corporate overhead and research and development, including our preclinical
development activities and clinical trials. We have not generated any revenues from product sales. We expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek
regulatory approvals for our current and potential product candidates, prepare for and begin the commercialization of any approved products, and add infrastructure and personnel to support our continuing product development efforts. We anticipate
that any such losses could be significant for the next several years. If Oncoprex or any of our other potential product candidates fails in clinical trials or does not gain regulatory approval, or if our drug candidates do not achieve market
acceptance, we may never become profitable. As a result of the foregoing, we expect to continue to experience net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to
have, an adverse effect on our stockholders&#146; equity and working capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated
with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. In addition, our expenses could increase if we are required by the FDA
to perform studies or trials in addition to those currently expected, or if there are any delays in completing our clinical trials or the development of any of our drug candidates. The amount of future net losses will depend, in part, on the rate of
future growth of our expenses and our ability to generate revenues. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a limited operating history and we expect a number of factors to cause
our operating results to fluctuate on an annual basis, which may make it difficult to predict our future performance. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a
clinical stage gene therapy company with a limited operating history. Our operations to date have been limited to conducting clinical and preclinical research. We have not yet obtained any regulatory approvals for any of our drug candidates.
Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a longer operating history or approved products on the market. Our operating results are expected to significantly fluctuate
from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any delays in regulatory review and approval of our current and potential product candidates in clinical development, including our ability to receive approval from the FDA for Oncoprex; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in the commencement, enrollment and timing of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success of our clinical trials through all phases of clinical development; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential side effects of our current and potential product candidates that could delay or prevent approval or cause an approved drug to be taken off the market; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain additional funding to develop product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to identify and develop additional drug candidates beyond Oncoprex; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competition from existing products or new products that continue to emerge; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability of patients or healthcare providers to obtain coverage or sufficient reimbursement for our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to adhere to clinical trial requirements directly or with third parties such as contract research organizations, or CROs; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our dependency on third-party manufacturers to manufacture our products and key ingredients; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish or maintain collaborations, licensing or other arrangements, particularly with MD Anderson; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to defend against any challenges to our intellectual property including, claims of patent infringement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to enforce our intellectual property rights against potential competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to secure additional intellectual property protection for our drug candidates in development and associated technologies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to attract and retain key personnel to manage our business effectively; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential product liability claims. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, the results of any historical quarterly or
annual periods should not be relied upon as indications of future operating performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Development and Commercialization of Our
Current and Potential Product Candidates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our success depends greatly on the success of our development of Oncoprex for the treatment of
non-small cell lung cancer, and our pipeline of product candidates beyond this lead indication is extremely early stage and limited. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At this time we are actively pursuing development of only one product candidate, Oncoprex for non-small cell lung cancer. Therefore, we are
dependent on the success of Oncoprex in the near term. We cannot provide you any assurance that we will be able to successfully advance Oncoprex through the development process, or that any development problems we experience in the future will not
cause significant delays or unanticipated costs, or that such development problems can be solved. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial
partners, or developing or validating product release assays in a timely manner, which may prevent us from completing our clinical trials or commercializing our products on a timely or profitable basis, if at all. Immunotherapy, gene therapy and
biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of uncertainty. Because Oncoprex and our other potential product candidates are based upon novel technology, it is difficult to predict
whether, either as stand-alone therapies or in combination with other drugs, they will show consistently favorable results and to predict the time and cost of their development and of subsequently obtaining regulatory approval. Few gene therapy
products have been approved in the United States or Europe. We may find it difficult to enroll patients in our clinical studies, which could delay or prevent clinical studies of our current and potential product candidates. We may encounter delays
in our clinical studies, or we may fail to demonstrate safety and efficacy to the satisfaction of FDA and other regulatory authorities. We may not be successful in our efforts to identify or discover additional product candidates, or to develop
product candidates that we have identified. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may
damage public perception of our current and potential product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our current and potential product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the
medical community. In particular, our success will depend upon physicians specializing in the treatment of those diseases that our current and potential product candidates target prescribing treatments that involve the use of our current and
potential product candidates in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available. More restrictive government regulations or negative public opinion would have
a negative effect on our business or financial condition and may delay or impair the development and commercialization of our current and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
potential product candidates or demand for any products we may develop. Adverse events in our clinical trials, even if not ultimately attributable to our current and potential product candidates,
and the resulting publicity could lead to increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our potential product candidates, stricter labeling requirements for those product
candidates that are approved and a decrease in demand for any such product candidates. Concern about the environmental spread of our product, whether real or anticipated, may hinder the commercialization of our products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delays in the commencement, enrollment and completion of clinical trials could result in increased costs to us and delay or limit our ability to obtain
regulatory approval for Oncoprex and our other potential product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Oncoprex has been tested in only one prior Phase I
clinical study, involving 31 patients. In that study, Oncoprex was tested as a monotherapy. We believe that the best path for development is to develop a combination therapy of Oncoprex in combination with erlotinib and possibly other drugs. We have
an ongoing Phase I/II clinical trial testing Oncoprex in combination with erlotinib. Enrollment was completed in March 2015 for the Phase I portion of this clinical trial, in which 18 patients were enrolled. The Phase II portion of our Phase I/II
clinical trial is at an early stage, with a limited number of patients enrolled, and the favorable results observed so far may not continue in the current clinical trial or be replicated in other clinical trials, especially those involving larger
numbers of patients. Even if the Phase I/II trial is successful, success in early clinical studies may not be indicative of results obtained in later studies. The results from our Phase I/II trial may not demonstrate sufficient safety and efficacy
to support the submission of marketing approval for Oncoprex. Before we request marketing approval, the FDA may require us to conduct additional clinical studies, or evaluate subjects for an additional follow-up. Unless an accelerated approval
process is allowed by the FDA, one or more Phase III studies is normally required for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delays in the commencement, enrollment
and/or completion of clinical trials could increase our product development costs or delay or limit the regulatory approval of our current and potential product candidates. We do not know whether any future trials or studies of our other potential
product candidates will begin on time or will be completed on schedule, if at all. The start or end of a clinical study is often delayed or halted due to changing regulatory requirements, changes in the proposed regulatory approval pathway for a
drug candidate, manufacturing challenges, including delays or shortages in available drug product, required clinical trial administrative actions, slower than anticipated patient enrollment, changing standards of care, availability or prevalence of
use of a comparative drug or required prior therapy, clinical outcomes or financial constraints. For instance, delays or difficulties in patient enrollment or difficulties in retaining trial participants can result in increased costs, longer
development times or termination of a clinical trial. Clinical trials of a new product candidate require the enrollment of a sufficient number of patients, including patients who are suffering from the disease the product candidate is intended to
treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, including the size of the patient population, the eligibility criteria for the clinical trial, that include the age and condition of the
patients and the stage and severity of disease, the nature of the protocol, the proximity of patients to clinical sites and the availability of effective treatments and/or availability of other investigational treatment options for the relevant
disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the second phase of a Phase I/II clinical trial, MD Anderson researchers are conducting a Phase II clinical trial evaluating
Oncoprex in combination with erlotinib in NSCLC. Enrollment eligibility criteria for this clinical trial are broad and include stage IV and recurrent NSCLC not potentially curable by radiotherapy or surgery, whether or not the patients have received
prior chemotherapy, and whether or not they have an activating EGFR mutation. The Phase II trial began in June 2015 and is ongoing at MD Anderson. Ten patients have been entered and nine are evaluable for response under the trial protocol, because
they have received 2 or more cycles of treatment. Preliminary analysis of the data from these patients further supported our belief that Oncoprex may provide medical benefit in several subpopulations of NSCLC patients for which there is an unmet
medical need, and may provide pathways for accelerated approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of these initial findings, in April 2016, we suspended enrollment of new patients in
this Phase II clinical trial to collect additional trial data and have it analyzed in order to seek FDA guidance as to whether the protocol for this clinical trial could be modified to expand enrollment and also to divide the patients into cohorts
with a view toward seeking accelerated approval in one or more of these cohort populations. We have completed the collection and analysis of the additional preliminary data and expect to present our findings to the FDA within the next several
months. Although the clinical trial is currently closed to new patient enrollment, it is not terminated, and is considered &#147;ongoing&#148; because activities such as patient follow-up and further data collection and analysis continue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we reach an agreement with the FDA regarding expanded patient enrollment and defined patient cohorts, then we plan to amend the trial
protocol accordingly and proceed with the amended protocol at MD Anderson and several additional clinical trial sites. Amendments to the Phase II clinical trial protocol will require approval of the Investigational Review Board, or IRB, of each site
where the amended trial is conducted. If we do not reach an agreement with the FDA on these changes, then we plan to reopen enrollment in the current version of the Phase II trial at MD Anderson and at additional clinical trial sites. In that event,
we will need to provide MD Anderson with plans and funding to move ahead with the trial. Whether under the original protocol or a revised protocol, we intend to use a portion of the proceeds of this offering to add additional clinical trial sites
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A product candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for product
candidates is high due to scientific feasibility, safety, efficacy, changing standards of medical care and other variables. The results from preclinical testing or early clinical trials of a product candidate may not predict the results that will be
obtained in later phase clinical trials of the product candidate. We, the FDA or other applicable regulatory authorities may suspend clinical trials of a product candidate at any time for various reasons, including, but not limited to, a belief that
subjects participating in such trials are being exposed to unacceptable health risks or adverse side effects, or other adverse initial experiences or findings. We may not have the financial resources to continue development of, or to enter into
collaborations for, a product candidate if we experience any problems or other unforeseen events that delay or prevent regulatory approval of, or our ability to commercialize, product candidates, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to obtain sufficient funds required for a clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to reach agreements on acceptable terms with current or prospective contract research organizations, or CROs, and trial sites, the terms of which can be subject to extensive negotiation and may vary
significantly among different CROs and trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negative or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or
clinical trials or abandon a program; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">serious and unexpected drug-related side effects experienced by subjects in our clinical trials or by individuals using drugs similar to our current and potential product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in enrolling research subjects in clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">high drop-out rates and high fail rates of research subjects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inadequate supply or quality of product candidate components or materials or other supplies necessary for the conduct of our clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">greater than anticipated clinical trial costs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">poor effectiveness of our current and potential product candidates during clinical trials; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site or vendor. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may have difficulty engaging or retaining clinical trial sites and/or enrolling patients in our clinical
trials, which could delay or prevent development of our current and potential product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Identifying and qualifying
patients to participate in clinical trials of our current and potential product candidates is critical to our success. The timing of our clinical trials depends on the speed at which we can engage and retain clinical trial sites and recruit patients
to participate in testing our current and potential product candidates. We have experienced delays in some of our clinical trials in the past due to difficulties with enrollment and we may experience similar delays in the future. We have suspended
enrollment of new patients in the Phase II portion of our Phase I/II clinical trial evaluating Oncoprex in combination with erlotinib in NSCLC, and we may experience difficulties with enrollment upon reopening enrollment for the trial under the
current protocol or a modified protocol. If patients are unwilling to participate in our clinical trials because of negative publicity from adverse events in the industry or in the trials for other third party product candidates, or for other
reasons, including competitive clinical trials for similar patient populations, the timeline for engaging sites, recruiting patients, conducting studies and obtaining regulatory approval of potential products may be delayed. These delays could
result in increased costs, delays in advancing our product development, delays in testing the effectiveness of our technology or termination of the clinical trials altogether. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or our clinical trial sites may not be able to identify, recruit and enroll a sufficient number of patients, or those with the required or
desired characteristics in a clinical trial, to complete our clinical trials in a timely manner. Patient enrollment is affected by factors including:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">severity of the disease under investigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">design of the clinical trial protocol, including the fact that certain of our clinical trials are randomized to current treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">size of the patient population; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">eligibility criteria for the clinical trial in question; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">perceived risks and benefits of the product candidate under study; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general level of excitement for the treatment approach; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">comments on social media; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">proximity and availability of clinical trial sites for prospective patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability of competing therapies and clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">efforts to facilitate timely enrollment in clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patient referral practices of physicians; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ability to monitor patients adequately during and after treatment. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently plan to seek
initial marketing approval in the United States and subsequently in Europe. We may not be able to initiate or continue clinical trials if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials required by the
FDA or the European Medicines Agency, or EMA, or other regulatory agencies. Our ability to successfully initiate, enroll and complete a clinical trial in any foreign country is subject to numerous risks unique to conducting business in foreign
countries, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulty in establishing or managing relationships with CROs and physicians; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">different standards for the conduct of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to locate qualified local consultants, physicians and partners; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatments. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as
planned, we may need to delay, limit or terminate ongoing or planned clinical trials, any of which would have an adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any product candidate we advance through clinical trials may not have favorable results in later clinical trials or receive regulatory approval.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical failure can occur at any stage of our clinical development. Clinical trials may produce negative or inconclusive results,
and we may decide, or regulators may require us, to conduct additional clinical trials or nonclinical studies. In addition, data obtained from trials and studies are susceptible to varying interpretations, and regulators may not interpret our data
as favorably as we do, which may delay, limit or prevent regulatory approval. Success in preclinical studies and early clinical trials does not ensure that subsequent clinical trials will generate the same or similar results or otherwise provide
adequate data to demonstrate the efficacy and safety of a product candidate. Thirty-one patients were treated in our first Phase I clinical trial of Oncoprex used as a monotherapy, and 28 patients have been enrolled to date (out of a possible total
of 57) in our current Phase I/II clinical trial of Oncoprex in combination with erlotinib in NSCLC. Of the 28 patients, 18 were enrolled in the Phase I portion of the Phase I/II trial, and three of these 18 are also enrolled in the Phase II portion.
Safety and efficacy results to date may not continue to be obtained as additional patients are treated, and may not be duplicated in future clinical trials. A number of companies in the pharmaceutical industry, including those with greater resources
and experience than ours, have suffered significant setbacks in clinical trials, even after seeing promising results in earlier clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a
clinical trial may not become apparent until the clinical trial is well advanced. We may be unable to design and execute a clinical trial to support regulatory approval. Further, clinical trials of potential products often reveal that it is not
practical or feasible to continue development efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Oncoprex is found to be unsafe or lack efficacy, we will not be able to obtain
regulatory approval for it and our business would be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some instances, there can be significant variability in safety and/or
efficacy results between different trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in composition of the patient populations, adherence to the dosing regimen and other trial protocols
and the rate of dropout among clinical trial participants. We do not know whether any clinical trials we or any of our potential future collaborators may conduct will demonstrate the consistent or adequate efficacy and safety that would be required
to obtain regulatory approval and market any products. If we are unable to bring Oncoprex to market, or to acquire other products that are on the market or can be developed, our ability to create stockholder value will be limited. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain regulatory approval of our current and potential product candidates, the products may not gain market acceptance among physicians,
patients, hospitals, cancer treatment centers, third-party payors and others in the medical community. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ethical, social and legal
concerns about gene therapy and genetic research could result in additional regulations restricting or prohibiting the products and processes we may use. Even with the requisite approvals, the commercial success of our current and potential product
candidates will depend in part on the medical community, patients, and third-party payors accepting gene therapy products in general, and our current and potential product candidates in particular, as medically useful, cost-effective and safe. Any
product that we bring to the market may not gain market acceptance by physicians, patients, third-party payors and others in the medical community. If these products do not achieve an adequate level of acceptance, we may not generate
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
significant product revenue and may not become profitable. The degree of market acceptance of these product candidates, if approved for commercial sale, will depend on a number of factors,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical indications for which our current and potential product candidates are approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">physicians, hospitals, cancer treatment centers and patients considering our current and potential product candidates as a safe and effective treatment; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential and perceived advantages of our current and potential product candidates over alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of any side effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product labeling or product insert requirements of the FDA or other regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations or warnings contained in the labeling approved by the FDA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of market introduction of our current and potential product candidates as well as competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of treatment in relation to alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of adequate coverage, reimbursement and pricing by third-party payors and government authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the willingness of patients to pay out-of-pocket in the absence of coverage by third-party payors, including government authorities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the willingness, ability and availability of healthcare providers that can comply with the transportation, handling, and temperature-controlled storage requirements associated with our current and potential product
candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our sales and marketing efforts. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if a potential product displays a
favorable efficacy and safety profile in preclinical and clinical trials, market acceptance of the product will not be known until after it is launched. Our efforts to educate the medical community and third-party payors on the benefits of the
product candidates may require significant resources and may never be successful. Such efforts to educate the marketplace may require more resources than are required by the conventional technologies marketed by our competitors and may be restricted
by the allowed label. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our current and potential product candidates may have undesirable side effects that may delay or prevent marketing approval,
or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our Phase I clinical trial of Oncoprex as a monotherapy, the only serious adverse events, defined as grade 3, 4 or 5 events under the Common
Terminology Criteria for Adverse Events, or CTCAE, published by the U.S. Department of Health and Human Services, were grade 3 fever and grade 3 hypotension, and the only dose-limiting toxicities were two episodes of transient grade 3
hypophosphatemia (abnormally low levels of phosphate in the blood). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase I portion of our Phase I/II trial combining Oncoprex with
erlotinib was a dose escalation study with the primary purpose of determining the MTD. Dose Limiting Toxicities were defined as grade 3, 4, or 5 events during the first cycle of treatment that were considered to be treatment related. At dose level 1
(Oncoprex .045 mg/kg plus erlotinib 100 mg), one subject had grade 3 adverse events of fatigue, muscle weakness, and hyponatremia (low sodium level) considered to be related to the study treatment (erlotinib); therefore, three
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
additional subjects were treated at this dose level (six subjects total), none of whom suffered a Dose Limiting Toxicity.&nbsp;At dose level 2 (Oncoprex .06 mg/kg plus erlotinib 100 mg), there
were no Dose Limiting Toxicities.&nbsp;At dose level 3 (Oncoprex .45 mg/kg plus erlotinib 150 mg), one subject had a grade 3 rash considered to be related to the study treatment (erlotinib); therefore, an additional three subjects were treated at
this dose level (six subjects total).&nbsp;No additional subjects suffered a Dose Limiting Toxicity at dose level 3.&nbsp;At dose level 4 (Oncoprex .06 mg/kg plus erlotinib 150 mg), there were no Dose Limiting Toxicities; thus dose level 4 was
determined to be the MTD. None of the 10 subjects treated to date in the Phase II portion of the Phase I/II trial suffered a Dose Limiting Toxicity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional or unforeseen side effects from Oncoprex or any of our other potential product candidates could arise either during clinical
development or, if approved, after the approved product has been marketed. A showing that Oncoprex or any other product candidate causes undesirable or unacceptable side effects could interrupt, delay or halt clinical trials and result in the
failure to obtain or suspension or termination of marketing approval from the FDA and other regulatory authorities, or result in marketing approval from the FDA and other regulatory authorities only with restrictive label warnings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our current and potential product candidates receives marketing approval and we or others later identify undesirable or unacceptable
side effects caused by such products: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to change instructions regarding the way the product is administered, conduct additional clinical trials or change the labeling of the product; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be subject to limitations on how we may promote the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of the product may decrease significantly; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require us to take our approved product off the market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be subject to litigation or product liability claims; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reputation may suffer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us or our potential future
collaborators from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenues from the sale of
our products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may face product liability claims. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event Oncoprex or any of our other potential product candidates is approved for marketing by the FDA and other regulatory authorities,
we may face potential product liability. If successful claims are brought against us, we may incur substantial liability and costs. If the use of our current and potential product candidates harms patients, or is perceived to harm patients even when
such harm is unrelated to our current and potential product candidates, our regulatory approvals could be revoked or otherwise negatively impacted, and we could be subject to costly and damaging product liability claims. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal computer systems, or those used by our CROs, contractors or consultants, may fail or suffer security breaches. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, our internal computer systems and those of our CROs, contractors and consultants are
vulnerable to damage from computer viruses and unauthorized access, as well as being vulnerable to other system difficulties, failures or disruptions. If such an event were to occur and cause interruptions in our operations, it could result in a
material disruption of our development programs and our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our
costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur
liability, and the further development and commercialization of our current and potential product candidates could be delayed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business disruptions
could seriously harm our future revenue and financial condition and increase our costs and expenses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations, and those of
our CROs, contractors and consultants, could be subject to power shortages, telecommunications failures, wildfires, water shortages, floods, earthquakes, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or
man-made disasters or business interruptions. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. Our ability to obtain clinical supplies of our current
and potential product candidates could be disrupted if the operations of our contract manufacturers are affected by a man-made or natural disaster or other business interruption. Unfavorable global economic conditions could adversely affect our
business, financial condition, or results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not carry insurance for all categories of risk that our business may
encounter. In particular, we do not carry product liability insurance covering any clinical trials liability that we may incur. Although we intend to obtain such insurance before we market any product, there can be no assurance that we will secure
adequate insurance coverage or that any such insurance coverage will be sufficient to protect our operations to significant potential liability in the future. Any significant uninsured liability may require us to pay substantial amounts, which would
adversely affect our financial position and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face competition from other biotechnology and pharmaceutical companies and
our operating results will suffer if we fail to compete effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries are intensely
competitive and subject to rapid and significant technological change. We have competitors in the United States, Europe and elsewhere, including major multinational pharmaceutical companies, established biotechnology companies, specialty
pharmaceutical and generic drug companies and universities and other research institutions. Many of our competitors have greater financial and other resources, such as larger research and development staff and more experienced marketing and
manufacturing organizations than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing pharmaceutical products. These companies also
have significantly greater research, sales and marketing capabilities and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate
discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. As a result of these factors, our competitors may succeed in obtaining patent protection and/or FDA
approval or discovering, developing and commercializing drugs for the cancer indications that we are targeting before we do or may develop drugs that are deemed to be more effective or gain greater market acceptance than ours. Smaller or early-stage
companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. In addition, many universities and private and public research institutes may become active in our target
disease areas. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, technologies and drug products that are more effective or less costly than any product candidates that we are currently developing or that we may
develop, which could render our products obsolete or noncompetitive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are a number of drugs approved and under development for
treatment of lung cancer. Treatments competitive with our primary product candidates generally fall into the following categories: chemotherapies such as cisplatin, carboplatin, docetaxel and pemetrexed; targeted therapies such as erlotinib,
gefitinib, afatinib </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and osimertinib (marketed as Tagrisso<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> by AstraZeneca Pharmaceuticals), and immunotherapies such as checkpoint inhibitors and CAR and CAR
T cells, and oncolytic virus-based technology. Data indicate that Oncoprex, when combined with certain targeted therapies and immunotherapies, may enhance the benefit of those therapies; therefore, we believe that Oncoprex could be administered in
combination with targeted therapies and immunotherapies and thus may not be a direct competitor of those drugs. In addition, new drug candidates are constantly being conceived and developed. Any such competing therapy may be more effective and/or
cost-effective than ours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our competitors market products that are more effective, safer or less expensive or that reach the market
sooner than our future products, if any, we may not achieve commercial success. In addition, because of our limited resources, it may be difficult for us to stay abreast of the rapid changes in each technology. If we fail to stay at the forefront of
technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory Approval and Marketing of Our Current and Potential Product Candidates and Other Legal Compliance Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We cannot be certain that Oncoprex will receive regulatory approval, and without regulatory approval we will not be able to market Oncoprex. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business currently depends largely on the successful development and commercialization of Oncoprex. Our ability to generate revenue related
to product sales, if ever, will depend on the successful development and regulatory approval of Oncoprex for the treatment of cancer. Even if we complete the necessary clinical studies, we cannot predict when or if we will obtain regulatory approval
to commercialize a product candidate. Further, if we do obtain regulatory approval, it may only apply to a more narrow indication than we expect. Even if we obtain regulatory approval for a product candidate, our products will remain subject to
regulatory scrutiny. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no products approved for sale and we cannot guarantee that we will ever have marketable products.
The development of a product candidate and issues relating to its approval and marketing are subject to extensive regulation by the FDA in the United States and regulatory authorities in other countries, with regulations differing from country to
country. We are not permitted to market our current and potential product candidates in the United States until we receive approval of a Biologics License Application, or BLA, from the FDA. We have not submitted any marketing applications for any of
our current and potential product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BLAs must include extensive preclinical and clinical data and supporting information to
establish the product candidate&#146;s safety and effectiveness for each desired indication. BLAs must also include significant information regarding the chemistry, manufacturing and controls for the product. Obtaining approval of a BLA is a
lengthy, expensive and uncertain process, and we may not be successful in obtaining approval. The FDA review processes can take years to complete and approval is never guaranteed. If we submit a BLA to the FDA, the FDA must decide whether to accept
or reject the submission for filing. We cannot be certain that any submissions will be accepted for filing and review by the FDA. Regulators in other jurisdictions have their own procedures for approval of product candidates. Even if a product is
approved, the FDA may limit the indications for which the product may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming clinical trials or reporting as conditions of approval. Regulatory
authorities in countries outside of the United States and Europe also have requirements for approval of drug candidates with which we must comply with prior to marketing in those countries. Obtaining regulatory approval for marketing of a product
candidate in one country does not ensure that we will be able to obtain regulatory approval in any other country. In addition, delays in approvals or rejections of marketing applications in the United States, Europe or other countries may be based
upon many factors, including regulatory requests for additional analyses, reports, data, preclinical studies and clinical trials, regulatory questions regarding different interpretations of data and results, changes in regulatory policy during the
period of product development and the emergence of new information </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regarding our current and potential product candidates or other products. Also, regulatory approval for any of our current and potential product candidates may be withdrawn. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to obtain approval from the FDA, or other regulatory agencies, for Oncoprex, or if, subsequent to approval, we are unable to
successfully commercialize Oncoprex or our other potential product candidates, we will not be able to generate sufficient revenue to become profitable or to continue our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the clinical trial requirements of the FDA, the European Medicines Agency, or EMA, and other regulatory agencies and the criteria
these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product
candidates such as ours can be more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory requirements governing gene therapy products have changed frequently and may continue to change in the future. For example, in
January 2017, the FDA Oncology Center of Excellence, or the Center of Excellence, was created to leverage the combined skills of regulatory scientists and reviewers with expertise in drugs, biologics, and devices (including diagnostics). While the
Center of Excellence is designed to help expedite the development of oncology and malignant hematology-related medical products and support an integrated approach in the clinical evaluation of drugs, biologics and devices for the treatment of
cancer, the new Center of Excellence may initially create confusion within the FDA and especially in the Center of Biologics and Research that is the primary review division for Oncoprex. Gene therapy clinical trials conducted at institutions that
receive funding for recombinant DNA research from the U.S. National Institutes of Health, or the NIH, are also subject to review by the NIH Office of Biotechnology Activities&#146; Recombinant DNA Advisory Committee, or the RAC. Although the FDA
decides whether individual gene therapy protocols may proceed, the RAC review process can impede the initiation of a clinical trial, even if the FDA has reviewed the study and approved its initiation. Conversely, the FDA can put an Investigational
New Drug application, or IND, on a partial or complete clinical hold even if the RAC has provided a favorable review. Also, before a clinical trial can begin at an NIH-funded institution, that institution&#146;s institutional review board, or IRB,
and its Institutional Biosafety Committee will have to review the proposed clinical trial to assess the safety of the study. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other
regulatory bodies to change the requirements for performing studies or for obtaining approval of any of our current and potential product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These regulatory review committees and advisory groups, and the new guidelines they promulgate, may lengthen the regulatory review process,
require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our current and potential product candidates or lead to
significant post-approval limitations or restrictions. As we advance our current and potential product candidates, we will be required to consult with these regulatory and advisory groups and comply with applicable guidelines. Delay or failure to
obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient revenue to maintain our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the FDA does not find the manufacturing facilities of our future contract manufacturers acceptable for commercial production, we may not be able to
commercialize any of our current and potential product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not intend to manufacture the pharmaceutical products
that we plan to sell. We are currently utilizing contract manufacturers for the production of the active pharmaceutical ingredients and the formulation of drug product for the trials of Oncoprex currently being conducted or will need to be conducted
prior to seeking regulatory approval. However, we do not have agreements for supplies of Oncoprex or any of our other potential product candidates and we may not be able to reach agreements with these or other contract manufacturers for
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sufficient supplies to commercialize Oncoprex if it is approved. Additionally, the facilities used by any contract manufacturer to manufacture Oncoprex or any of our other potential product
candidates must be the subject of a satisfactory inspection before the FDA approves the product candidate manufactured at that facility. We are completely dependent on these third-party manufacturers for compliance with the requirements of U.S. and
non-U.S. regulators for the manufacture of our finished products. If our manufacturers cannot successfully manufacture materials that conform to our specifications and the FDA&#146;s current good manufacturing practices, or cGMP, standards and other
requirements of any governmental agency to whose jurisdiction we are subject, our current and potential product candidates will not be approved or, if already approved, may be subject to recalls. Reliance on third-party manufacturers entails risks
to which we would not be subject if we manufactured our current and potential product candidates, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possibility that we are unable to enter into a manufacturing agreement with a third party to manufacture our current and potential product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possible breach of the manufacturing agreements by the third parties because of factors beyond our control; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possibility of termination or nonrenewal of the agreements by the third parties before we are able to arrange for a qualified replacement third-party manufacturer. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these factors could cause the delay of approval or commercialization of our current and potential product candidates, cause us to incur
higher costs or prevent us from commercializing our current and potential product candidates successfully. Furthermore, if any of our current and potential product candidates are approved and contract manufacturers fail to deliver the required
commercial quantities of finished product on a timely basis at commercially reasonable prices and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent
volumes and quality and on a timely basis, we would likely be unable to meet demand for our products and could lose potential revenue. It may take several years to establish an alternative source of supply for our current and potential product
candidates and to have any such new source approved by the government agencies that regulate our products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject, directly or
indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and other federal and state healthcare laws, and the failure to comply with such laws could result in substantial penalties. Our employees, independent contractors,
consultants, principal investigators, CROs, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud, misconduct or other illegal activity by our employees, independent contractors, consultants, principal
investigators, CROs, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to: comply with the laws of the FDA and similar foreign regulatory bodies; provide true,
complete and accurate information to the FDA and similar foreign regulatory bodies; comply with manufacturing standards we have established; comply with federal and state data privacy, security, fraud and abuse and other healthcare laws and
regulations in the United States and similar foreign fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval for any of our current and potential product
candidates and begin commercializing those products in the United States, our potential exposure under such laws would increase significantly, and our costs associated with compliance with such laws would likely also increase. These laws may impact,
among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and
services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may
restrict or prohibit a wide range of pricing, discounting, marketing and promotion, including off-label uses of our products, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities
subject to these laws also </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
involve the improper use or misrepresentation of information obtained in the course of patient recruitment for clinical trials, creating fraudulent data in our preclinical studies or clinical
trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the
precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with
these laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending
ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of fines or other sanctions. The laws that may affect our ability to operate include, but are not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Federal Anti-Kickback Statute, which prohibits, among other things, individuals and entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or
rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service for which
payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have
committed a violation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">federal civil and criminal false claims laws and civil monetary penalty laws, including the civil False Claims Act, which impose criminal and civil penalties, through government, civil whistleblower or qui tam actions,
on individuals and entities for, among other things, knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other third-party payors that are false, fictitious or fraudulent, or knowingly making,
using or causing to be made or used, a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of
the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a
scheme to defraud or to obtain any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit
program, regardless of the payor (e.g., public or private), willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making
any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity
does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, which impose requirements on certain covered healthcare
providers, health plans, and healthcare clearinghouses, as well as their respective business associates that perform services for them that involve the creation, use, maintenance or disclosure of, individually identifiable health information,
relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal physician payment transparency requirements, sometimes referred to as the &#147;Physician Payments
Sunshine Act,&#148; created under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively the Affordable Care Act, and its
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
implementing regulations, which require certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s
Health Insurance Program (with certain exceptions) to report annually to the United States Department of Health and Human Services information related to payments or other transfers of value made to physicians (defined to include doctors, dentists,
optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the U.S. Federal Food, Drug and Cosmetic Act, or FDCA, which prohibits, among other things, the adulteration or misbranding of drugs and medical devices; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers. Additionally, we are subject to state and foreign equivalents of
each of the healthcare laws described above, among others, some of which may be broader in scope and may apply regardless of the payor. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent inappropriate conduct
may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure
that our business arrangements will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with
current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our
rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and
other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our
results of operations. In addition, the approval and commercialization of any of our current and potential product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among
other foreign laws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and reimbursement may be limited or unavailable in certain market segments for our current and potential product
candidates, if approved, which could make it difficult for us to sell our current and potential product candidates profitably. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
commercial success of any current or future product candidate will depend upon the degree of market acceptance by physicians, patients, insurance companies and other third party payors, and others in the medical community. Even if we obtain approval
to commercialize our current and potential product candidates outside of the United States, a variety of risks associated with international operations could materially affect our business. Due to the novel nature of our technology, we face
uncertainty related to pricing and reimbursement for our current and potential product candidates. The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and
reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue. If market opportunities for our current and potential product candidates are smaller than we believe they are,
our revenues may be adversely affected and our business may suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Successful sales of our products, if our current and potential
product candidates are approved, depend on the availability of coverage and adequate reimbursement from third-party payors. In addition, because our current and potential product candidates represent new approaches to the treatment of cancer, we
cannot be sure that coverage and reimbursement will be available for, or accurately estimate the potential revenue from, our current and potential product candidates. Patients who are provided medical treatment for their conditions generally rely on
third-party payors to reimburse all or part of the costs associated with their treatment. Coverage and adequate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors are critical to new product acceptance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which drugs
and treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#146;s determination that use of a product
is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a covered benefit under its health plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">safe, effective and medically necessary; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appropriate for the specific patient; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cost-effective; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">neither experimental nor investigational. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, no uniform policy of coverage
and reimbursement for products exists among third-party payors, and coverage and reimbursement for products can differ significantly from payor to payor. As a result, obtaining coverage and reimbursement approval of a product from a government or
other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our products and to justify the level of coverage and
reimbursement relative to other therapies, with no assurance that coverage and adequate reimbursement will be obtained. Third party payors may also have difficulty in determining the appropriate coverage of Oncoprex and our other potential product
candidates that are combination products, if approved, due to the fact that they are combination products that include another drug. To the extent there are any delays in determining such coverage or inadequate coverage and reimbursement for all
aspects of our combination therapies, it would adversely affect the market acceptance, demand and use of our current and potential product candidates. Any denial in coverage or reduction in reimbursement from Medicare or other government programs
may result in a similar denial or reduction in payments from private payors, which may adversely affect our future profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
intend to seek approval to market our current and potential product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our current and potential product
candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in the European Union, the pricing of biologics is subject to governmental control and other market regulations which could
put pressure on the pricing and usage of our current and potential product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In
addition, market acceptance and sales of our current and potential product candidates will depend significantly on the availability of coverage and adequate reimbursement from third-party payors for our current and potential product candidates and
may be affected by existing and future health care reform measures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare legislative reform measures may have a material adverse effect on
our business and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors, whether domestic or foreign, or governmental or commercial, are
developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could affect
our ability to sell our products profitably. In particular, in 2010, the Affordable Care Act was enacted in the United States. The Affordable Care Act and its implementing regulations, among other things, subjected biological products to potential
competition by lower-cost biosimilars, revised the methodology by which rebates owed by manufacturers to the state and federal government for covered outpatient drugs and certain biologics, including our current and potential product candidates,
under the Medicaid Drug Rebate Program are calculated, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate program to utilization of prescriptions of
individuals&nbsp;enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government&#146;s
comparative effectiveness research. The current Presidential Administration and U.S. Congress may seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the Affordable Care Act. There have been judicial and Congressional
challenges to certain aspects of the Affordable Care Act. As a result, there have been delays in the implementation of, and action taken to repeal or replace, certain aspects of the Affordable Care Act. While the extent to which any such changes may
affect our business is uncertain, steps have been taken to repeal and replace certain aspects of the Affordable Care Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have
been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the
initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls
may adversely affect: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the demand for our current and potential&nbsp;product candidates, if we obtain regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to set a price that we believe is fair for our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to generate revenue and achieve or maintain profitability; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the level of taxes that we are required to pay; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of capital. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We and our contract manufacturers are subject to significant regulation
with respect to manufacturing our products. The manufacturing facilities on which we rely may not continue to meet regulatory requirements and have limited capacity. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently utilizing contract manufacturers for the production of the active pharmaceutical ingredients and the formulation of drug
product for our trials of Oncoprex. However, we do not have agreements for supplies of Oncoprex or any of our other potential product candidates. Each supplier may require licenses to manufacture such components if such processes are not owned by
the supplier or in the public domain and we may be unable to transfer or sublicense the intellectual property rights we may have or later obtain with respect to such activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract manufacturers
for Oncoprex, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP. These regulations govern manufacturing
processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead
to the introduction of contaminants, or to inadvertent changes in the properties or stability of our current and potential product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all
necessary documentation in support of a BLA on a timely basis and must adhere to the FDA&#146;s good laboratory practices, or GLP, and cGMP regulations enforced by the FDA through its facilities inspection program. Our facilities and quality systems
and the facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our current and potential product
candidates or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our current and potential product candidates or our other
potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted. If these facilities do not pass a pre-approval plant inspection, FDA approval of the products may not be granted.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulatory authorities also may, at any time following approval of a product for sale, audit
our manufacturing facilities or those of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs
independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and that may include the temporary or permanent
suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA can impose regulatory sanctions including, among
other things, refusal to approve a pending application for a new drug product or biologic product or revocation of a pre-existing approval. As a result, our business, financial condition and results of operations may be materially harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if supply from one approved manufacturer is interrupted, there could be a significant disruption in commercial supply. An
alternative manufacturer would need to be qualified through a BLA supplement which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching
manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These
factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our current and potential product candidates, cause us to incur higher costs and prevent us from commercializing our products
successfully. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed or we could
lose potential revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or
penalties or incur costs that could have a material adverse effect on the success of our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may become subject to
federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of hazardous materials and certain waste products, including numerous environmental, health and safety laws and regulations, such as those
governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations may in the future involve the use of hazardous materials, including chemicals and biological materials. Our
operations may also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of
contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and
penalties. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production
efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our
Dependence on Third Parties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in establishing and maintaining development and commercialization collaborations, which
could adversely affect our ability to develop certain of our current and potential product candidates and our financial condition and operating results. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because developing pharmaceutical products, conducting clinical trials, obtaining regulatory approval, establishing manufacturing capabilities
and marketing approved products are expensive, we may enter into collaborations with companies that have the required expertise. Additionally, if any of our current and potential </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product candidates receives marketing approval, we may enter into sales and marketing arrangements with third parties. If we are unable to enter into arrangements on acceptable terms, if at all,
we may be unable to effectively market and sell our products in our target markets. We expect to face competition in seeking appropriate collaborators. Moreover, collaboration arrangements are complex and time consuming to negotiate, document and
implement and they may require substantial resources to maintain. We may not be successful in our efforts to establish and implement collaborations or other alternative arrangements for the development of our current and potential product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When we collaborate with a third party for development and commercialization of a product candidate, we can expect to
relinquish some or all of the control over the future success of that product candidate to the third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One or more of our
collaboration partners may not devote sufficient resources to the commercialization of our current and potential product candidates or may otherwise fail in their commercialization. The terms of any collaboration or other arrangement that we
establish may contain provisions that are not favorable to us. In addition, any collaboration that we enter into may be unsuccessful in the development and commercialization of our current and potential product candidates. In some cases, we may be
responsible for continuing preclinical and initial clinical development of a product candidate or research program under a collaboration arrangement, and the payment we receive from our collaboration partner may be insufficient to cover the cost of
this development. If we are unable to reach agreements with suitable collaborators for our current and potential product candidates, we would face increased costs, we may be forced to limit the number of our current and potential product candidates
we can commercially develop or the territories in which we commercialize them. As a result, we might fail to commercialize products or programs for which a suitable collaborator cannot be found. If we fail to achieve successful collaborations, our
operating results and financial condition could be materially and adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely, and expect to continue to rely, on third parties to
conduct, supervise and monitor our clinical trials, and if these third parties perform in an unsatisfactory manner, it may harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on CROs and clinical trial sites to ensure our clinical trials are conducted properly and on time. While we have agreements governing
their activities, we may have limited influence over their actual performance. We control only certain aspects of our CROs&#146; activities. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance
with the applicable protocol, legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our CROs are required to comply with the GCPs for conducting, recording and reporting the results of clinical trials to assure that the
data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. The FDA enforces these GCPs through periodic inspections of study sponsors, principal investigators
and clinical trial sites. If we or our CROs fail to comply with applicable GCPs, the clinical data generated in our future clinical trials may be deemed unreliable, and the FDA may require us to perform additional clinical trials before approving
any marketing applications. Upon inspection, the FDA may determine that our clinical trials did not comply with GCPs. In addition, our ongoing and future clinical trials will require a sufficient number of test subjects to evaluate the safety and
effectiveness of our current and potential product candidates. Accordingly, if our CROs fail to comply with these regulations or fail to recruit a sufficient number of patients, we may be required to repeat such clinical trials, which would delay
the regulatory approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our CROs are not our employees, and we are not able to directly monitor whether or not they devote
sufficient time and resources to our clinical and nonclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development
activities that could harm our competitive position. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols or regulatory requirements, or for any other reasons, our clinical trials may be extended,
delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our current and potential product candidates. As a result, our financial results and the commercial prospects for our current and potential
product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely, and expect to continue
to rely, on third parties to distribute, manufacture and perform release testing for our current and potential product candidates and other key materials and if such third parties do not carry out their contractual duties or meet expected deadlines,
we may not be able to obtain regulatory approvals for our current and potential product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to continue to rely
on third-party contract manufacturing organizations, or CMOs, to produce our current and potential product candidates and other key materials and on third-party contract testing organizations, or CTOs, for the establishment and performance of
validated product release assays, but we have not entered into binding agreements with any such CMOs or CTOs to support commercialization. Additionally, any CMO may not have experience producing our current and potential product candidates at
commercial levels and may not achieve the necessary regulatory approvals or produce our products at the quality, quantities, locations and timing needed to support commercialization. We may change our manufacturing process, and there can be no
guarantee that the regulatory authorities will approve any new process in a timely manner or ever. Also, as a consequence of the manufacturing change, there may be a requirement to do more preclinical safety or efficacy studies, develop new
manufacturing and release assays and/or repeat all or part of the ascending dose safety study in animals or humans. Regulatory requirements ultimately imposed could adversely affect our ability to test, manufacture or market products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we intend to rely on third-party manufacturers for commercialization, we currently utilize a sole-source manufacturer to support our
clinical trials. We may be unable to negotiate binding agreements with this manufacturer or additional manufacturers to support our commercialization activities at commercially reasonable terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No manufacturer we know of currently has the experience or ability to produce our current and potential product candidates at reasonable
commercial levels or under full commercial requirements. We may encounter technical or scientific issues related to manufacturing or development that we may be unable to resolve in a timely manner or with available funds. Further, we have not
completed the characterization and validation activities necessary for commercial and regulatory approvals. If our manufacturing and testing partners do not obtain such regulatory approvals, our commercialization efforts may be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we timely develop a manufacturing process for Oncoprex and successfully transfer it to third-party manufacturers, if such third-party
manufacturers are unable to produce our current and potential product candidates in the necessary quantities, or in compliance with current Good Manufacturing Practices, or cGMP, or in compliance with pertinent regulatory requirements, and within
our planned time frame and cost parameters, the development and sales of our products, if approved, may be materially harmed. The facilities used by our contract manufacturers to manufacture our current and potential product candidates must be
approved by the FDA pursuant to inspections that will be conducted after we submit our BLA to the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with cGMPs for
the manufacture of our current and potential product candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be
able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If
the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our current and potential product candidates or if it withdraws any such approval in the future, we may need to find alternative
manufacturing facilities, which would significantly affect our ability to develop, obtain regulatory approval for or market our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
current and potential product candidates, if approved. In addition, any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we
may have to suspend the manufacturing of our current and potential product candidates or that obtained approvals could be revoked, which would adversely affect our business and reputation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any significant disruption in our supplier relationships could harm our business. We source key materials, devices and equipment
from third parties, either directly through agreements with suppliers or indirectly through our manufacturers who have agreements with suppliers. There is a small number of suppliers for certain key materials and components that are used to
manufacture our current and potential product candidates. Such suppliers may not sell these key materials to our manufacturers at the times or quantities we need them or on commercially reasonable terms. We may not have any control over the process
or timing of the acquisition of these key materials by our manufacturers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also expect to rely on other third parties to store and
distribute our products for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our current and potential product candidates or commercialization of our products, if
approved, producing additional losses and depriving us of potential product revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have completed and may in the future complete related party
transactions that were not and may not be conducted on an arm&#146;s length basis. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our leading drug candidate, Oncoprex, is based
upon patents and related technology covered by a patent and technology license agreement between The University of Texas MD Anderson Cancer Center, or MD Anderson, and Introgen Therapeutics, Inc. (such technology license agreement is referred to as
the &#147;MD Anderson License Agreement&#148;), under which we have rights to patents covering use of various genes, including the TUSC2 gene, for treatment of cancer, as well as know-how and related intellectual property. In 2007, the MD Anderson
License Agreement was sublicensed by Introgen Therapeutics, Inc. to Introgen Research Institute, Inc., a Texas corporation (IRI) and in 2009 this sublicense was assigned by IRI to us, and we granted back to IRI a non-exclusive, royalty-free license
to use and practice the licensed technology for non-commercial research purposes. As consideration for this assignment, we agreed to assume all of IRI&#146;s obligations to MD Anderson under the MD Anderson License Agreement, including ongoing
patent related expenses and royalty obligations. IRI also agreed in 2011 to provide additional technology licensing opportunities and services to us in return for monthly payments and our obligation to pay to IRI a royalty of one percent
(1%)&nbsp;on sales of products licensed to us under the MD Anderson License Agreement. We also granted a non-exclusive, royalty-free sublicense to IRI in 2011 for non-commercial research purposes. IRI&#146;s obligations to provide additional
technology licensing opportunities and services to us, and our obligation to make monthly payments to IRI, were terminated in 2012; however, our obligation to pay the one percent (1%)&nbsp;royalty to IRI upon sales of products licensed to us under
the MD Anderson License Agreement is ongoing. This royalty obligation continues for 21 years after the later of the termination of the MD Anderson License Agreement and the termination of the sublicense assigned by IRI to us. IRI is controlled by
Rodney Varner and his immediate family members. Mr.&nbsp;Varner is currently Chairman of our board of directors, having joined our board of directors on August&nbsp;15, 2012, and has been our President and Chief Executive Officer since
August&nbsp;29, 2012; accordingly, in 2009 and 2011, when the above referenced agreements between IRI and Genprex were entered into, Mr.&nbsp;Varner was neither a member of our board of directors nor an executive officer of Genprex. When the 2011
agreement was entered into, Mr.&nbsp;Varner was deemed to be an &#147;affiliate of the Company due to his beneficial ownership of approximately 39% of our issued and outstanding shares. Although we believe that these transactions were conducted on
an arm&#146;s length basis, it is possible that the terms were less favorable to us than they might have been in a transaction with an unrelated party. We have adopted a written related-person transactions policy that sets forth our policies and
procedures regarding the identification, review, consideration and oversight of related-person transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to obtain or protect our intellectual property, our business will be impaired. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to obtain or protect intellectual property rights related to our current and potential product candidates, we may not be able
to compete effectively in our markets. Third party claims of intellectual property infringement may prevent or delay our development and commercialization efforts. We may not be successful in obtaining or maintaining necessary rights to product
components and processes for our development pipeline through acquisitions and end licenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with our obligations in
the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. We may be
involved in lawsuits to protect or enforce our patents or the patents or our licensors, which could be expensive, time-consuming, and/or unsuccessful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining patent protection depends upon compliance with various procedural, document submission, fee payment, and other
requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements. Issued patents covering our current and potential product candidates could be found invalid or
unenforceable if challenged in court, or could expire before we obtain product approval. The scope of our issued patents could be found to be narrower and provide less protection than we anticipate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations in the agreements under which we license intellectual property rights from MD Anderson, or otherwise
experience disruptions to our business relationships with MD Anderson or other future licensors, we could lose license rights that are important to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our license agreement with MD Anderson, we hold a worldwide, exclusive license to, among other things, manufacture and market products
utilizing certain inventions that are critical to our business. We expect to enter into additional license agreements in the future. Our existing license agreement imposes various diligence, royalty and other obligations on us, and we expect that
future license agreements will impose various diligence, milestone payment, royalty and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, the licensor may have the right to
terminate the license, in which event we would not be able to market products covered by the license. See &#147;Business&#151;License and Collaboration Agreements&#148; for a description of our license agreements with MD Anderson, which includes a
description of the termination provisions of these agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may need to obtain licenses from third parties to advance our research
or allow commercialization of our current and potential product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and
resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business significantly. We cannot provide any assurances that
third-party patents do not exist which might be enforced against our current product candidates or future products, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties
and/or other forms of compensation to third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In certain cases, patent prosecution of our licensed technology may be controlled
solely by the licensor. If our licensors fail to obtain and maintain patent or other protection for the proprietary intellectual property we license from them, we could lose our rights to the intellectual property or our exclusivity with respect to
those rights, and our competitors could market competing products using the intellectual property. In certain cases, we control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to
such prosecution, we may incur significant liability to our licensing partners. Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issues and is complicated by the rapid pace of scientific discovery in our industry. Disputes may arise regarding intellectual property subject to a licensing agreement, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope of rights granted under the license agreement and other interpretation-related issues; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which our technology and processes infringe intellectual property of the licensor that is not subject to the licensing agreement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the sublicensing of patent and other rights under our collaborative development relationships; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the priority of invention of patented technology. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property that
we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The intellectual property rights we have licensed from MD Anderson are subject to the rights of the U.S. government. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights we have obtained pursuant to our license agreement with MD Anderson are made subject to the rights of the U.S. government to the
extent that the technology covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government. Additionally, to the extent there is any conflict between our license agreement with MD
Anderson and applicable laws or regulations, applicable laws and regulations will prevail.&nbsp;Similarly, to the extent there is any conflict between our license agreement with MD Anderson and MD Anderson&#146;s funding agreement with the US
government, the terms of the funding agreement will prevail. Some, and possibly all, of our licensed intellectual property rights from MD Anderson have been developed in the course of research funded by the U.S. government. As a result, the U.S.
government may have certain rights to intellectual property embodied in our current or future products pursuant to the Bayh-Dole Act of 1980. Government rights in certain inventions developed under a government-funded program include a
non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us, or an assignee or exclusive licensee to such inventions, to grant licenses
to any of these inventions to a third party if the U.S. government determines that adequate steps have not been taken to commercialize the invention, that government action is necessary to meet public health or safety needs, that government action
is necessary to meet requirements for public use under federal regulations, or that the right to use or sell such inventions is exclusively licensed to an entity within the U.S. and substantially manufactured outside the U.S. without the U.S.
government&#146;s prior approval. Additionally, we may be restricted from granting exclusive licenses for the right to use or sell our inventions created pursuant to such agreements unless the licensee agrees to additional restrictions (e.g.,
manufacturing substantially all of the invention in the U.S.). The U.S. government also has the right to take title to these inventions if we fail to disclose the invention to the government and fail to file an application to register the
intellectual property within specified time limits. In addition, the U.S. government may acquire title in any country in which a patent application is not filed within specified time limits. Additionally, certain inventions are subject to transfer
restrictions during the term of these agreements and for a period thereafter, including sales of products or components, transfers to foreign subsidiaries for the purpose of the relevant agreements, and transfers to certain foreign third parties. If
any of our intellectual property becomes subject to any of the rights or remedies available to the U.S. government or third parties pursuant to the Bayh-Dole Act of 1980, this could impair the value of our intellectual property and could adversely
affect our business. The U.S. government has not exercised any of these rights or provided us with any notice of its intent to exercise any of these rights with respect to any of the intellectual property licensed to us by MD Anderson.&nbsp;We are
not aware of any instance in which the U.S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
government has ever exercised any such rights with respect to any technologies or other intellectual property developed under funding agreements with the U.S. government. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology and product
candidates, our competitive position could be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success will depend in part on our ability and the ability of
our licensors to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to our proprietary technology and products. We rely on trade secret, patent, copyright and trademark laws,
and confidentiality, licensing and other agreements with employees and third parties, all of which offer only limited protection. We seek to protect our proprietary position by filing and prosecuting patent applications in the United States and
abroad related to our novel technologies and products that are important to our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of biotechnology and
pharmaceutical companies generally are highly uncertain, involve complex legal and factual questions and have in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our
patents, including those patent rights licensed to us by third parties, are highly uncertain. The steps we or our licensors have taken to protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information
or infringement of our intellectual property rights, both inside and outside of the United States. Further, the examination process may require us or our licensors to narrow the claims for our pending patent applications, which may limit the scope
of patent protection that may be obtained if these applications issue. The rights already granted under any of our currently issued patents or those licensed to us and those that may be granted under future issued patents may not provide us with the
proprietary protection or competitive advantages we are seeking. If we or our licensors are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficient, our
competitors could develop and commercialize technology and products similar or superior to ours, and our ability to successfully commercialize our technology and products may be adversely affected. It is also possible that we or our licensors will
fail to identify patentable aspects of inventions made in the course of our development and commercialization activities before it is too late to obtain patent protection on them. It is also possible that as research and development progresses, the
direction of our intellectual property strategy and patent portfolio will change, resulting in strategic business decisions to allow certain patents or patent applications to be abandoned or lapse. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to patent rights, we do not know whether any of the pending patent applications relating to any of our current and potential
product candidates will result in the issuance of patents that effectively protect our technology or products, or if any of our licensors&#146; issued patents will effectively prevent others from commercializing competitive technologies and
products. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or in some
cases not at all, until they are issued as a patent. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our licensors
were the first to file for patent protection of such inventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our pending applications cannot be enforced against third parties
practicing the technology claimed in such applications unless and until a patent issues from such applications. Because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, issued patents that we have
licensed from third parties may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in the loss of patent protection, the narrowing of claims in such patents or the invalidity or unenforceability
of such patents, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection for our technology and products. Protecting against the
unauthorized use of our or our licensor&#146;s patented technology, trademarks and other intellectual property rights is expensive, difficult and may in some cases not be possible. In some cases, it may be difficult or impossible to detect
third-party infringement or misappropriation of our intellectual property rights, even in relation to issued patent claims, and proving any such infringement may be even more difficult. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-party claims of intellectual property infringement may prevent or delay our development and
commercialization efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our avoiding infringement of the patents and proprietary
rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent
infringement lawsuits, interferences, oppositions and <I>inter partes </I>reexamination proceedings before the US Patent and Trademark Office, or US PTO, and corresponding foreign patent offices. Numerous US and foreign issued patents and pending
patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our current
and potential product candidates may be subject to claims of infringement of the patent rights of third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may in the
future assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the
use or manufacture of our current and potential product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our current and potential
product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the
manufacturing process of any of our current and potential product candidates, or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under
the applicable patents, or until such patents expire. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, if any third-party patents were held by a court of competent
jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product
candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop
and commercialize one or more of our current and potential product candidates. Defense of these claims, regardless of their merit, may involve substantial litigation expense and would be a substantial diversion of employee resources from our
business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement, pay royalties, redesign our infringing products or obtain
one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in
obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Presently we believe that we have rights to the intellectual property, through licenses from third parties and under patents that we own, to
develop our current and potential product candidates. Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability
to acquire, in-license or use these proprietary rights. In addition, our current and potential product candidates may require specific formulations to work effectively and efficiently and these rights may be held by others. We may be unable to
acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. The licensing and acquisition of third-party intellectual property rights is a competitive area,
and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their
size, cash resources and greater clinical development and commercialization capabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, companies that perceive us to be a competitor may be unwilling to assign or license
rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party
intellectual property rights, our business, financial condition and prospects for growth could suffer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may incur substantial costs as a result
of litigation or other proceedings relating to patent and other intellectual property rights. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may from time to time seek to
enforce our intellectual property rights against infringers when we determine that a successful outcome is probable and may lead to an increase in the value of the intellectual property. If we choose to enforce our patent rights against a party,
then that individual or company has the right to ask the court to rule that such patents are invalid or should not be enforced. Additionally, the validity of our patents and the patents we have licensed may be challenged if a petition for post grant
proceedings such as <I>inter&nbsp;partes</I> review and post grant review is filed within the statutorily applicable time with the US PTO. These lawsuits and proceedings are expensive and would consume time and resources and divert the attention of
managerial and scientific personnel even if we were successful in stopping the infringement of such patents. In addition, there is a risk that the court will decide that such patents are not valid and that we do not have the right to stop the other
party from using the inventions. There is also the risk that, even if the validity of such patents is upheld, the court will refuse to stop the other party on the ground that such other party&#146;s activities do not infringe our intellectual
property rights. In addition, in recent years the U.S. Supreme Court modified some tests used by the US PTO in granting patents over the past 20 years, which may decrease the likelihood that we will be able to obtain patents and increase the
likelihood of a challenge of any patents we obtain or license. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are not able to adequately prevent disclosure of trade secrets and other
proprietary information, the value of our technology and products could be significantly diminished. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on trade secrets to
protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants,
outside scientific collaborators, sponsored researchers and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an
adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce and
determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our reliance on third parties may require us to share our trade secrets, which increases the possibility that a competitor will discover them or that
our trade secrets will be misappropriated or disclosed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we rely on third parties to manufacture our current and potential
product candidates, and because we collaborate with various organizations and academic institutions on the advancement of our current and potential product candidates, we must, at times, share trade secrets with them. We seek to protect our
proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our manufacturers, collaborators,
advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite
the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into
the technology of others, are used inappropriately to create new inventions or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#146;s
discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, these agreements typically restrict the ability of our collaborators, advisors,
employees and consultants to publish data potentially relating to our trade secrets. Our academic collaborators typically have rights to publish data, provided that we are notified in advance and may delay publication for a specified time in order
to secure our intellectual property rights arising from the collaboration. In other cases, publication rights are controlled exclusively by us, although in some cases we may share these rights with other parties. We may also conduct joint research
and development programs that may require us to share trade secrets under the terms of research and development partnerships or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets
through breach of these agreements, independent development or publication of information including our trade secrets in cases where we do not have proprietary or otherwise protected rights at the time of publication. A competitor&#146;s discovery
of our trade secrets may impair our competitive position and have an adverse impact on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be involved in lawsuits to protect or
enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may
infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may
decide that a patent of ours or our licensors is not valid, is unenforceable and/or is not infringed, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question.
An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to
our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the
prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees.
We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that
some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts
or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and
maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for
non-compliance with these requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees
on patents and/or applications will be due to be paid to the US PTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We employ an outside firm and rely on
our outside counsel to pay these fees due to non-US patent agencies. The US PTO and various non-US governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent
application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are
situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter
the market and this circumstance would have a material adverse effect on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issued patents covering our current and potential product candidates could be found invalid or
unenforceable if challenged in court. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we, MD Anderson or one of our future licensing partners initiated legal proceedings
against a third party to enforce a patent covering one of our current and potential product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the
United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or
non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the US PTO, or made a misleading statement, during prosecution. Third parties
may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review and equivalent proceedings in foreign jurisdictions (e.g.,
opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our current and potential product candidates. The outcome following legal assertions of invalidity and
unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail
on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our current and potential product candidates. Such a loss of patent protection would have a material adverse impact
on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed
confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may in the future employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies,
including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims
that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee&#146;s former employer or
other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely
impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other
intellectual property. We may have potential ownership disputes arising, for example, from conflicting obligations of consultants, collaborators or others who are involved in developing our current and potential product candidates. Litigation may be
necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership
of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to
protect our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States has enacted and is currently implementing wide-ranging patent reform legislation. Recent
U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has
created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the U.S. PTO, the laws and regulations governing patents could change in unpredictable ways that would
weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have not yet
registered the trademark for Oncoprex, and failure to secure such registration could adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
applied for, but have not yet received approval of a registered trademark for Oncoprex. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable
to overcome such rejections. In addition, in the US PTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition
or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Moreover, any name we propose to use with our current and potential product candidates in the United States must be approved by the
FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA
objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing
rights of third parties and be acceptable to the FDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property rights throughout the world.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively
expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the
same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our
inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products
to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to
prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property
rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to
biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign
jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing
and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our
intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Employee Matters and Managing Growth </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have no sales, marketing or distribution experience and we will have to invest significant resources to develop those capabilities or enter into
acceptable third-party sales and marketing arrangements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no sales, marketing or distribution experience. To develop sales,
distribution and marketing capabilities, we will have to invest significant amounts of financial and management resources, some of which will need to be committed prior to any confirmation that Oncoprex or any of our other potential&nbsp;product
candidates will be approved by the FDA. For product candidates for which we decide to perform sales, marketing and distribution functions ourselves or through third parties, we could face a number of additional risks, including that we or our
third-party sales collaborators may not be able to build and maintain an effective marketing or sales force, and we may experience difficulty in managing the growth of our organization. If we use third parties to market and sell our products, we may
have limited or no control over their sales, marketing and distribution activities on which our future revenues may depend. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to expand
our operations and increase the size of our company, and we may experience difficulties in managing growth. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
September&nbsp;30, 2017, we had four full-time employees and one part-time employee. As we advance our current and potential product candidates through preclinical studies and clinical trials, we will need to increase our product development,
scientific and administrative headcount to manage these programs. In addition, to meet our obligations as a public company, we may need to increase our general and administrative capabilities. Our management, personnel and systems currently in place
may not be adequate to support this future growth. If we are unable to successfully manage this growth and increased complexity of operations, our business may be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to manage our business effectively if we are unable to attract and retain key personnel and consultants. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to attract or retain qualified management, finance, scientific and clinical personnel and consultants due to the intense
competition for qualified personnel and consultants among biotechnology, pharmaceutical and other businesses. If we are not able to attract and retain necessary personnel and consultants to accomplish our business objectives, we may experience
constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are highly dependent on the development, regulatory, commercialization and business development expertise of our management team, key
employees and consultants. Any of our executive officers or key employees or consultants may terminate their employment at any time. If we lose one or more of our executive officers or key employees or consultants, our ability to implement our
business strategy successfully could be seriously harmed. Replacing executive officers, key employees and consultants may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the
breadth of skills and experience required to develop, gain regulatory approval of and commercialize products successfully. Competition to hire and retain employees and consultants from this limited pool is intense, and we may be unable to hire,
train, retain or motivate these additional key personnel and consultants. Our failure to retain key personnel or consultants could materially harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have scientific and clinical advisors and consultants who assist us in formulating our research, development and clinical
strategies. These advisors are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us and typically they will not enter into non-compete agreements with us. If
a conflict of interest arises between their work for us and their work for another entity, we may lose their services. In addition, our advisors may have arrangements with other companies to assist those companies in developing products or
technologies that may compete with ours. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may use our financial and human resources to pursue a particular research program or product candidate
and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited resources, we may forego or delay pursuit of opportunities with certain programs or product candidates or for
indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and
development programs for product candidates may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that
product candidate through strategic collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate, or we may
allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur
debt or assume contingent liabilities, and subject us to other risks. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may evaluate and enter into various acquisitions and
strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increased operating expenses and cash requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption of additional indebtedness or contingent liabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of our equity securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the diversion of our management&#146;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and marketing approvals; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large
one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain
access to technology or products that may be important to the development of our business </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Common Stock and This Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There has been no public market for our common stock and an active market may not develop or be sustained, which could limit your ability to sell shares
of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There currently is no public market for our common stock, and our common stock will not be traded in the open
market prior to this offering. Although we intend to list the common stock on the Nasdaq Capital Market in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection with this offering, an adequate trading market for the common stock may not develop or be sustained after this offering. The initial public offering price will be determined by
negotiations between the underwriters and our board of directors and may not be representative of the market price at which our shares of common stock will trade after this offering. In particular, we cannot assure you that you will be able to
resell your shares at or above the initial public offering price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The best efforts structure of this offering may yield insufficient gross proceeds
to fully execute on our business plan. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are offering shares of our common stock in this offering on a best efforts
basis. The underwriters are not required to sell any specific number or dollar amount of common stock, but will use their best efforts to sell the shares offered by us. It is a condition to this offering that, upon the closing of the offering, our
common stock would qualify for listing on the Nasdaq Capital Market. In order to list, the Nasdaq Capital Market requires that, among other criteria, at least 1,000,000 publicly-held shares of our common stock be outstanding, the shares be held in
the aggregate by at least 300 round lot holders, the market value of the publicly-held shares of our common stock be at least $15.0 million, our stockholders&#146; equity after giving effect to the sale of our shares in this offering be at least
$5.0 million, the bid price per share of our common stock be $4.00 or more, and there be at least three registered and active market makers for our common stock. As a &#147;best efforts&#148; offering, there can be no assurance that we will
successfully raise this minimum amount, that the offering will satisfy the listing conditions required to trade our common stock on the Nasdaq Capital Market or that the offering will ultimately be completed or will result in any proceeds being made
available to us. If we sell only the minimum number of shares yielding insufficient gross proceeds, we may be unable to sufficiently fund our operations or fully execute on our business plan. This could potentially result in a material adverse
effect on our business, prospects, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our management will have discretion over the use of the proceeds
of the offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the proceeds of this offering to complete our ongoing clinical trial, to commence additional
clinical trials, to conduct biomarker studies, to prepare submissions to the FDA and for research and development and working capital and general corporate purposes. Our management, however, will have broad discretion in how we use these proceeds.
The proceeds could be applied in ways that do not improve our operating results or otherwise increase the value of their investments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market
price of our common stock may be highly volatile, and you may not be able to resell your shares at or above the initial public offering price. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of our common stock is likely to be volatile. Our stock price could be subject to wide fluctuations in response to a variety
of factors, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse results or delays in preclinical or clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reports of adverse events in other gene therapy products or clinical trials of such products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to obtain additional funding; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any delay in filing an IND or BLA for any of our current and potential product candidates and any adverse development or perceived adverse development with respect to the FDA&#146;s review of that IND or BLA;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to develop successfully and commercialize our current and potential product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to maintain our existing strategic collaboration or enter into new collaborations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure by us or our licensors and strategic collaboration partners to prosecute, maintain or enforce our intellectual property rights; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in laws or regulations applicable to future products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to obtain adequate product supply for our current and potential&nbsp;product candidates or inability to do so at acceptable prices; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse regulatory decisions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">introduction of new products, services or technologies by our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to meet or exceed financial projections we may provide to the public; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to meet or exceed the financial projections of the investment community; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic collaboration partners or our competitors; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions or departures of key scientific or management personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significant lawsuits, including patent or stockholder litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the market valuations of similar companies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of our common stock by us or our stockholders in the future; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">trading volume of our common stock. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, companies trading in the stock market in
general, and The Nasdaq Capital Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may
negatively affect the market price of our common stock, regardless of our actual operating performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nasdaq may delist our securities from its
exchange, which could limit investors&#146; ability to make transactions in our securities and subject us to additional trading restrictions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied to list our common stock on The Nasdaq Capital Market. In order to make a final determination of compliance with their listing
criteria, Nasdaq may look to the first trading day&#146;s activity and, particularly, the last bid price on such day. In the event the trading price for our common stock drops below The Nasdaq Capital Market&#146;s $1.00 minimum bid requirement,
Nasdaq could rescind our initial listing approval. If that were to happen, the liquidity for our common stock would decrease, which may substantially decrease the trading price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we cannot assure you that, in the future, our securities will meet the continued listing requirements to be listed on The Nasdaq
Capital Market. If The Nasdaq Capital Market delists our common stock, we could face significant material adverse consequences, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a limited availability of market quotations for our securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a determination that our common stock is a &#147;penny stock&#148; which will require brokers trading in our common stock to adhere to more stringent rules and possibly resulting in a reduced level of trading activity
in the secondary trading market for our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a limited amount of news and analyst coverage for our company; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a decreased ability to issue additional securities or obtain additional financing in the future. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unstable market and economic conditions may have serious adverse consequences on our business, financial
condition and stock price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Global credit and financial markets have experienced extreme volatility and disruptions in past years,
including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. We cannot assure you that further deterioration
in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market
conditions. If the current equity and credit markets deteriorate, or do not improve, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and
on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current
service providers, manufacturers and other partners may not survive difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Purchasers in this offering will experience immediate and substantial dilution in net tangible book value. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial public offering price is substantially higher than the net tangible book value of each outstanding share of our common stock.
Purchasers of common stock in this offering will experience immediate and substantial dilution on a book value basis. The dilution per share in the net tangible book value per share of common stock will be $4.20 per share if 2,500,000 shares are
sold and $3.73 per share if 4,500,000 shares are sold, based on the $5.00 per share initial public offering price and assuming, for purposes of the dilution calculations contained in this prospectus. If stock options and warrants to purchase shares
of common stock are exercised, there would be further dilution. See &#147;Dilution.&#148; In October 2017, we received an informal demand from a former financial advisor, claiming that it is entitled to a warrant to purchase shares of common stock
equal to three percent of our outstanding shares as of December 1, 2015, with &#147;piggyback&#148; registration rights. We believe this asserted claim lacks merit, and we intend to defend the claim vigorously. See &#147;Business &#150; Legal
Proceedings.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have no intention of declaring dividends in the foreseeable future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decision to pay cash dividends on our common stock rests with our board of directors and will depend on our earnings, unencumbered cash,
capital requirements and financial condition. We do not anticipate declaring any dividends in the foreseeable future, as we intend to use any excess cash to fund our operations. Investors in our common stock should not expect to receive dividend
income on their investment, and investors will be dependent on the appreciation of our common stock to earn a return on their investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an
emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take
advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&nbsp;404 of
the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory votes on executive
compensation and stockholder approval of any golden parachute payments not previously approved. We could be an emerging growth company for up to five years following the year in which we complete this offering, although circumstances could cause us
to lose that status earlier. We will remain an emerging growth company until the earlier of (1)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of the completion of this offering, (b)&nbsp;in which we have total annual
gross revenue of at least $1&nbsp;billion or (c)&nbsp;in which we are deemed to be a large accelerated filer, which requires the market value of our common stock that is held by non-affiliates to exceed $700&nbsp;million as of the prior
June&nbsp;30th, and (2)&nbsp;the date on which we have issued more than $1&nbsp;billion in non-convertible debt during the prior three-year period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even after we no longer qualify as an emerging growth company, we may still qualify as a
&#147;smaller reporting company&#148; which would allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the
Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on
these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards
apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that
are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could
significantly affect our financial position and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur significant increased costs as a result of operating as a
public company, and our management will be required to devote substantial time to existing and new compliance initiatives. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a
public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. We will be subject to the reporting requirements of the Securities Exchange Act of 1934, or the Exchange Act, which will
require, among other things, that we file with the Securities and Exchange Commission, or the SEC, annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules
subsequently adopted by the SEC and The Nasdaq Capital Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and
financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive
compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#147;say on pay&#148; and proxy access. Recent legislation permits emerging growth companies to implement
many of these requirements over a longer period and up to five years from the pricing of this offering. We intend to take advantage of this new legislation but cannot guarantee that we will not be required to implement these requirements sooner than
budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead
to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect
the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and
personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce
costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we
may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also
make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be exposed to risks relating to evaluations of controls required by Sarbanes-Oxley Act of 2002.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Sarbanes-Oxley Act of 2002, our management will be required to report on, and our independent registered public
accounting firm may in the future be required to attest to, the effectiveness of our internal control over financial reporting. Although we prepare our financial statements in accordance with accounting principles generally accepted in the United
States of America, our internal accounting controls may not meet all standards applicable to companies with publicly traded securities. If we fail to implement any required improvements to our disclosure controls and procedures, we may be obligated
to report control deficiencies and our independent registered public accounting firm may not be able to certify the effectiveness of our internal controls over financial reporting. In either case, we could become subject to regulatory sanction or
investigation. Further, these outcomes could damage investor confidence in the accuracy and reliability of our financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to
continue improving our accounting systems and controls could impair our ability to comply with the financial reporting and internal controls requirements for publicly traded companies. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we operate in a demanding regulatory environment, which requires us to comply with the Sarbanes-Oxley Act of 2002, and the
related rules and regulations of the SEC. Company responsibilities required by the Sarbanes-Oxley Act include establishing corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. Effective
internal controls are necessary for us to produce reliable financial reports and are important to help prevent financial fraud. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may
need to retain additional finance capabilities and build our financial infrastructure as a public company. Section&nbsp;404(a) of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness of our internal control over
financial reporting, starting with the second annual report that we would expect to file with the SEC. However, for as long as we remain an &#147;emerging growth company&#148; as defined in the JOBS Act, we have and intend to continue to take
advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#147;emerging growth companies&#148; including, but not limited to, not being required to comply with the auditor
attestation requirements of Section&nbsp;404(b) of the Sarbanes-Oxley Act. We may continue to take advantage of these reporting exemptions until we are no longer an &#147;emerging growth company.&#148; If we cannot provide reliable financial reports
or prevent fraud, our business and results of operations could be harmed and investors could lose confidence in our reported financial information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#147;ownership
change,&#148; generally defined as a cumulative change in its equity ownership by &#147;5-percent shareholders&#148; of greater than 50 percentage points (by value) over a three-year period, the corporation&#146;s ability to use its pre-change net
operating loss carryforwards, or NOLs, and certain other pre-change tax attributes (such as research tax credits) to offset its post-change taxable income and taxes, as applicable, may be limited. We have completed multiple rounds of financing since
our inception which may have resulted in an ownership change or could result in an ownership change in the future. We have not completed a Section&nbsp;382 and 383 analysis regarding any limitations on our NOLs and research and development credit
carryforwards and such limitations could be significant. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, our ability to use our NOLs and research and development credit
carryforwards to offset our U.S. federal taxable income and taxes, as applicable, may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, similar rules may apply and
there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of a substantial number of shares of our common stock in the public market could cause our stock
price to fall. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the
public market after the lock-up and other legal restrictions on resale discussed in this prospectus lapse, the market price of our common stock could decline. Based upon the number of shares of common stock, on an as-converted basis, outstanding as
of September&nbsp;30, 2017, upon the closing of this offering, we will have outstanding a total of 16,188,158 shares of common stock, assuming the maximum number of shares is issued in this offering. Of these shares, as of the date of this
prospectus, approximately 4,500,000 shares of our common stock will be freely tradable, without restriction, in the public market immediately following this offering, assuming that current stockholders do not purchase shares in this offering.
Network 1 Securities, however, may, in its sole discretion, permit our officers, directors and other stockholders who are subject to these lock-up agreements to sell shares prior to the expiration of the lock-up agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The lock-up agreements pertaining to this offering will expire 180 days from the date of this prospectus. After the lock-up agreements expire,
based upon the number of shares of common stock, on an as-converted basis, outstanding as of September&nbsp;30, 2017, up to an additional 11,688,158 shares of common stock will be eligible for sale in the public market, subject to Rule 144 under the
Securities Act of 1933, as amended, or the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as of September&nbsp;30, 2017, 8,076,809 shares of common stock
that are either subject to outstanding options, reserved for future issuance under our equity incentive plan or subject to outstanding warrants will become eligible for sale in the public market to the extent permitted by the provisions of various
vesting schedules, the lock-up agreements and Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the market price of our common
stock could decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive
plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to seek to raise additional funds, and we may finance acquisitions or develop strategic relationships, in each case by issuing equity
or convertible debt securities in addition to the shares issued in this offering, which would reduce the percentage ownership of our existing stockholders. Our board of directors has the authority, in some instances without action or vote of the
stockholders, to issue our authorized but unissued shares of common or preferred stock. Prior to the effective date of the registration statement of which this prospectus is a part, our certificate of incorporation will be amended to authorize us to
issue up to 200,000,000 shares of voting common stock and 10,000,000 shares of preferred stock. Future issuances of common or preferred stock would reduce your influence over matters on which stockholders vote and would be dilutive to earnings per
share. In addition, any newly issued preferred stock could have rights, preferences and privileges senior to those of the common stock. Those rights, preferences and privileges could include, among other things, the establishment of dividends that
must be paid prior to declaring or paying dividends or other distributions to holders of our common stock or providing for preferential liquidation rights. These rights, preferences and privileges could negatively affect the rights of holders of our
common stock, and the right to convert such preferred stock into shares of our common stock at a rate or price that would have a dilutive effect on the outstanding shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initially, the aggregate number of shares of our common stock that may be issued pursuant to stock awards under our 2017 Plan is 7,328,749
shares. Additionally, the number of shares of our common stock reserved for issuance under our 2017 Plan will automatically increase on January&nbsp;1 of each year, beginning on January&nbsp;1, 2018 and continuing through and including
January&nbsp;1, 2027, by 5% of the total number of shares of our capital stock outstanding on December&nbsp;31 of the preceding calendar year, or a lesser number of shares determined by our board of directors. Unless our board of directors elects
not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution, which could cause our stock price to fall. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or reports about us, or if they adversely change
their recommendations regarding our common stock, then our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for
our common stock will be influenced by the research and reports that industry or securities analysts publish about us, our industry and our market. If no analyst elects to cover us and publish research or reports about us, the market for our common
stock could be severely limited and our stock price could be adversely affected. In addition, if one or more analysts ceases coverage of us or fails to regularly publish reports on us, we could lose visibility in the financial markets, which in turn
could cause our stock price or trading volume to decline. If one or more analysts who elect to cover us issue negative reports or adversely change their recommendations regarding our common stock, our stock price could decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The concentration of our common stock ownership by our current management may limit your ability to influence corporate matters. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, our directors and executive officers will beneficially own and will be able to vote in the aggregate
approximately 24.5% of our outstanding common stock if 2,500,000 shares are sold and approximately 21.8% of our outstanding common stock if 4,500,000 shares offered are sold. As such, our directors and executive officers, as stockholders, will
continue to have the ability to exert significant influence over all corporate activities, including the election or removal of directors and the outcome of tender offers, mergers, proxy contests or other purchases of common stock that could give
our stockholders the opportunity to realize a premium over the then-prevailing market price for their shares of common stock. This concentrated control will limit your ability to influence corporate matters and, as a result, we may take actions that
purchasers in this offering do not view as beneficial. In addition, such concentrated control could discourage others from initiating changes of control. In such cases, the perception of our prospects in the market may be adversely affected and the
market price of our common stock may decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain provisions in our organizational documents could enable our board of directors to prevent or
delay a change of control. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our organizational documents contain provisions that may have the effect of discouraging, delaying or
preventing a change of control of, or unsolicited acquisition proposals, that a stockholder might consider favorable. These include provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">requiring a majority vote of the outstanding shares of common stock to amend the bylaws; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that the authorized number of directors may be changed only by resolution of the board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that the board of directors or any individual director may only be removed with cause and the affirmative vote of the holders of at least 66-2/3% of the voting power of all of our then outstanding common stock;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">divide our board of directors into three classes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner
and also specify requirements as to the form and content of a stockholder&#146;s notice; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election,
if they should so choose); </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that special meetings of our stockholders may be called only by the chairman of the board, our Chief Executive Officer or by the board of directors pursuant to a resolution adopted by a majority of the total
number of authorized directors; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on our behalf, (ii)&nbsp;any action asserting a claim of breach
of a fiduciary duty owed by any of our directors or officers to us or our stockholders, (iii)&nbsp;any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law or our certificate of incorporation
or bylaws, or (iv)&nbsp;any action asserting a claim against us governed by the internal affairs doctrine. This exclusive forum provision may limit a stockholder&#146;s ability to bring such an action in a judicial forum that it finds favorable for
such actions and may discourage such actions. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, our board of directors has the authority to issue shares of
preferred stock in one or more series and to fix the rights and preferences of these shares without stockholder approval. Any series of preferred stock is likely to be senior to our common stock with respect to dividends, liquidation rights and,
possibly, voting rights. The ability of our board of directors to issue preferred stock also could have the effect of discouraging unsolicited acquisition proposals, thus adversely affecting the market price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Delaware law makes it difficult for stockholders that recently have acquired a large interest in a corporation to cause the
merger or acquisition of the corporation against the directors&#146; wishes. Under Section&nbsp;203 of the Delaware General Corporation Law, a Delaware corporation may not engage in any merger or other business combination with an interested
stockholder for a period of three years following the date that the stockholder became an interested stockholder except in limited circumstances, including by approval of the corporation&#146;s board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc486549_3"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We make forward-looking statements under the &#147;Summary,&#148; &#147;Risk Factors,&#148; &#147;Business,&#148; &#147;Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations&#148; and in other sections of this prospectus. In some cases, you can identify these statements by forward -looking words such as &#147;may,&#148; &#147;might,&#148;
&#147;should,&#148; &#147;would,&#148; &#147;could,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential&#148; or
&#147;continue,&#148; and the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future
financial performance based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause
our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. In particular, you should consider the
numerous risks and uncertainties described under &#147;Risk Factors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we believe we have identified material risks, these
risks and uncertainties are not exhaustive. Other sections of this prospectus describe additional factors that could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing
environment. New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those contained in any forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we believe the
expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy or
completeness of any of these forward -looking statements. You should not rely upon forward-looking statements as predictions of future events. We are under no duty to update any of these forward-looking statements after the date of this prospectus
to conform our prior statements to actual results or revised expectations, and we do not intend to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Forward-looking statements
include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain additional funding to develop our current and potential product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the need to obtain regulatory approval of our current and potential product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success of our clinical trials through all phases of clinical development; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compliance with obligations under intellectual property licenses with third parties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any delays in regulatory review and approval of product candidates in clinical development; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to commercialize our current and potential product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">market acceptance of our current and potential product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competition from existing products or new products that may emerge; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential product liability claims; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our dependency on third-party manufacturers to supply or manufacture our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish or maintain collaborations, licensing or other arrangements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability and third parties&#146; abilities to protect intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to adequately support future growth; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to attract and retain key personnel to manage our business effectively. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
caution you not to place undue reliance on the forward-looking statements contained in the prospectus, which speak only as of the date of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc486549_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the initial public offering price of $5.00 per share, we estimate that the net proceeds from this offering, after deducting
underwriting commissions and expenses payable by us and other offering expenses payable by us, will be approximately $10,787,500 if we sell 2,500,000 shares, approximately $15,412,500 if we sell 3,500,000 shares, and approximately $20,037,500 if we
sell 4,500,000 shares of our common stock in this offering. However, this is a best efforts offering and there is no assurance that we will sell any shares or receive any proceeds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the proceeds from this offering as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assuming</B><br><B>Minimum</B><br><B>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assuming<BR>Midpoint&nbsp;of</B><br><B>Minimum&nbsp;and</B><br><B>Maximum<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Assuming</B><br><B>Maximum</B><br><B>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs to prepare filings with FDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Complete Phase II clinical trial for existing combination trial of Oncoprex with
erlotinib</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commence a Phase I/II clinical trial of Oncoprex in combination with an immunotherapy (including
third-party manufacturing of product candidate)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preclinical research, including biomarker studies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital and general corporate purposes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,787,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,662,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,537,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Expenses associated with completing our existing Phase II clinical trial and commencing a planned Phase I/II
clinical trial generally consist of our estimate of the costs charged to us by MD Anderson or other clinical trial sites to perform the clinical trials for us.&nbsp;Research and development costs generally consist of our estimate of the costs
associated with contractors and advisors retained by us to assist us with development of clinical strategies, monitoring our clinical trials and sites, clinical data analysis and other similar functions related to our current and planned clinical
trials. For this reason, certain estimated research and development costs, as well as certain estimated costs to prepare FDA filings, relate to the existing Phase II and planned Phase I/II trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we complete only the minimum offering, we estimate that we will have sufficient funds to complete our existing Phase II clinical trial
for Oncoprex combined with erlotinib and to initiate a Phase I/II clinical trial for Oncoprex combined with an immunotherapy. Based on our estimate that the total cost of a Phase I/II trial for Oncoprex combined with an immunotherapy to be
approximately $4 million, if we complete the minimum offering of 2,500,000 shares of common stock and raise minimum gross proceeds of $12.5 million, we estimate that we will require additional financing of at least $3 million to complete such a
trial, plus an additional $1.625&nbsp;million for working capital to fund our operations during the pendency of the trial. The timing and costs of clinical trials are difficult to predict and as such the foregoing estimates may prove to be
inaccurate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the net proceeds of this offering, together with our cash and cash equivalents, including the remaining proceeds
from our recent private placements, will be sufficient to meet our cash, operational and liquidity requirements for at least 12 months if we sell 2,500,000 shares and for at least 18 months if we sell 4,500,000 shares of our common stock in this
offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, we cannot specify with certainty all of the particular uses
for the net proceeds to us from this offering. Accordingly, our management will have broad discretion in the application of these proceeds. Net offering proceeds not immediately applied to the uses summarized above will be invested in short-term
investments such as money market funds, commercial paper, U.S. treasury bills and similar securities investments pending their use. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc486549_5">
</A>DIVIDEND POLICY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our capital stock. We currently intend to retain earnings,
if any, to finance the growth and development of our business. We do not expect to pay any cash dividends on our common stock in the foreseeable future. Payment of future dividends, if any, will be at the discretion of our board of directors and
will depend on our financial condition, results of operations, capital requirements, restrictions contained in any financing instruments, provisions of applicable law and other factors the board deems relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc486549_6"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents and capitalization as of September 30, 2017: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on an actual basis; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on a pro forma basis to reflect the 6.6841954-for-1 forward split of our common stock and the conversion of all shares of our convertible preferred stock outstanding as of September 30, 2017 into 9,324,125 shares of our
voting common stock in connection with the completion of this offering; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on a pro forma as adjusted basis after giving effect to the sale of 2,500,000 shares of our common stock in this offering at the initial public offering price of $5.00 per share, and our receipt of the estimated
$10,787,500 in net proceeds from this offering, after deducting underwriting commissions and estimated offering expenses payable by us; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on a pro forma as adjusted basis after giving effect to the sale of 4,500,000 shares of our common stock in this offering at the initial public offering price of $5.00 per share, and our receipt of the estimated
$20,037,500 in net proceeds from this offering, after deducting underwriting commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this capitalization table together with &#147;Use of Proceeds,&#148; &#147;Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations&#148; and our financial statements and the related notes appearing elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>At September 30, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma As<BR>Adjusted&#151;Minimum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma As<BR>Adjusted&#151;Maximum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">373,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">373,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,721,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,971,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.001 par value per share; 4,500,000 shares authorized and 1,394,953 shares
issued and outstanding, actual; 10,000,000 shares authorized and no shares issued and outstanding, pro forma, pro forma as adjusted&#151;minimum and pro forma as adjusted&#151;maximum</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value per share; 5,500,000 shares authorized and 353,676 shares issued
and outstanding, actual; 100,000,000 shares authorized and 11,688,158 shares issued and outstanding, pro forma; 100,000,000 shares authorized and 14,188,158 shares issued and outstanding, pro forma as adjusted&#151;minimum; 100,000,000 shares
authorized and 16,188,158 shares issued and outstanding, pro forma as adjusted&#151;maximum</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,655,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,655,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,442,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,692,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,785,779</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,785,779</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,785,779</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,785,779</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">871,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">871,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,659,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,909,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">871,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">871,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,659,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,909,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of common stock to be outstanding after this offering is based on the number
of shares of our common stock issued and outstanding on September&nbsp;30, 2017, assuming: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the conversion of all of our outstanding shares of convertible preferred stock into an aggregate of 1,394,953 shares of voting common stock (before giving effect to the forward split described below) in connection with
the completion of this offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the conversion of all of our outstanding shares of non-voting common stock into an aggregate of 25,611 shares of voting common stock (before giving effect to the forward split described below) in connection with the
completion of this offering; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a 6.6841954-for-1 forward split of our common stock, to be effected in connection with the completion of this offering; </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">and excludes, giving effect to the forward split of our common stock: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,628,749 shares of common stock issuable upon the exercise of outstanding options as of September&nbsp;30, 2017, at a weighted average exercise price of $1.31 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a maximum of 4,700,000 shares of common stock reserved for future issuance under our 2017 Equity Incentive Plan, which number includes the 465,609 shares of common stock reserved for issuance under our 2009 Equity
Incentive Plan as of September 30, 2017, that will be added to the shares reserved under the 2017 Plan upon its effectiveness; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">235,000 shares of common stock reserved for issuance under our 2017 Employee Stock Purchase Plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">748,061 shares of common stock issuable upon the exercise of outstanding warrants as of June 30, 2017, at a weighted average exercise price of $5.16 per share; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">between 75,000 shares (assuming an offering of 2,500,000 shares is completed) and 135,000 shares (assuming an offering of 4,500,000 shares is completed) of common stock issuable upon the exercise of the warrants issued
to the representatives of the underwriters. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc486549_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchasers of our common stock in this offering will experience an immediate dilution of net tangible book value per share from the initial
public offering price. Dilution in net tangible book value per share represents the difference between the amount per share paid by the purchasers of shares of common stock and the net tangible book value per share immediately after this offering.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2017, our net tangible book value was $574,143, or $0.05 per share of common stock. Net tangible book value per
share represents our total tangible assets, less our total liabilities, divided by the number of outstanding shares of our common stock and preferred stock assumed to be converted to common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dilution represents the difference between the amount per share paid by purchasers in this offering and the pro forma net tangible book value
per share of common stock after the offering. After giving effect to the sale of 2,500,000 shares of common stock and 4,500,000 shares of common stock in this offering at the offering price of $5.00 per share, and after deducting underwriting
commissions and estimated offering expenses payable by us, our pro forma net tangible book value would have been $0.80 (if 2,500,000 shares are sold) and $1.27 (if 4,500,000 shares are sold) per share. This represents an immediate increase in pro
forma net tangible book value of $0.75 (if 2,500,000 shares are sold) and $1.22 (if 4,500,000 shares are sold) per share to our existing stockholders and immediate dilution of $4.20 (if 2,500,000 shares are sold) and $3.73 (if 4,500,000 shares are
sold) per share to new investors purchasing shares at the proposed public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table illustrates the dilution in
pro forma net tangible book value per share to new investors as of September&nbsp;30, 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Minimum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share at September&nbsp;30, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share to the existing stockholders attributable to this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution in net tangible book value per share to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables set forth, as of September&nbsp;30, 2017, the total number of shares of common stock and
preferred stock to be converted to common stock purchased from us, the total consideration paid to us and the average price per share paid by the existing holders of our common and preferred stock and the price to be paid by new investors at the
public offering price of $5.00 per share. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:65.40pt; font-size:8pt; font-family:Times New Roman"><B>Minimum Offering</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average&nbsp;Price<BR>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing investors before this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,688,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,657,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investors purchasing shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,188,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,157,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:66.75pt; font-size:8pt; font-family:Times New Roman"><B>Maximum Offering</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average&nbsp;Price<BR>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing investors before this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,688,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,657,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investors purchasing shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,188,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,157,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc486549_8"></A>SELECTED HISTORICAL FINANCIAL AND OPERATING DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following selected historical financial data should be read together with &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations&#148; and the financial statements, related notes and other financial information included elsewhere in this prospectus. The selected financial data in this section are not intended to replace the financial
statements and are qualified in their entirety by the financial statements and related notes included elsewhere in this prospectus. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have derived the selected statement of operations data for the years ended December&nbsp;31, 2015 and 2016, and the selected balance sheet
data as of December&nbsp;31, 2015 and 2016 from our audited financial statements included elsewhere in this prospectus. We have derived the selected statement of operations data for the nine months ended September 30, 2016 and 2017 and balance sheet
data as of September 30, 2017 from our unaudited financial statements included elsewhere in this prospectus. The unaudited financial statements have been prepared on a basis consistent with our audited financial statements included in this
prospectus and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, necessary to fairly state our financial position as of September 30, 2017 and results of operations for the nine months ended
September 30, 2016 and 2017. Our historical results are not necessarily indicative of the results that may be expected in the future, and our interim period results are not necessarily indicative of results to be expected for a full year or any
other interim period. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">354,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,776,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">865,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,416,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,906,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,132,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,069,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,647,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,133,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7.77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of common shares&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">314,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">340,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">311,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,602,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">234,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">373,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,353,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,910,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">410,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,266,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,138,195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,006,036</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,785,779</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,624,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">871,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc486549_9"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations (&#147;MD&amp;A&#148;) contains certain
forward-looking statements. Historical results may not indicate future performance. Our forward-looking statements reflect our current views about future events, are based on assumptions and are subject to known and unknown risks and uncertainties
that could cause actual results to differ materially from those contemplated by these statements. Factors that may cause differences between actual results and those contemplated by forward- looking statements include, but are not limited to, those
discussed in &#147;Risk Factors.&#148; We undertake no obligation to publicly update or revise any forward-looking statements, including any changes that might result from any facts, events, or circumstances after the date hereof that may bear upon
forward-looking statements. Furthermore, we cannot guarantee future results, events, levels of activity, performance, or achievements. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genprex&#153; is a clinical stage gene therapy company developing a new approach to treating cancer, based upon our novel proprietary
technology platform, including our initial product candidate, Oncoprex&#153; immunogene therapy, or Oncoprex. Our platform technologies are designed to encapsulate cancer fighting genes into nanoscale hollow spheres called nanovesicles, which are
then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities and modulate the immune environment to restore defective cancer fighting functions. We hold an exclusive worldwide
license from The University of Texas MD Anderson Cancer Center, or MD Anderson, to patents covering the therapeutic use of a series of genes that have been shown in preclinical and clinical research to have cancer fighting properties. Researchers at
MD Anderson have conducted a Phase I clinical trial and the Phase I portion of a Phase I/II clinical trial and are conducting the Phase II portion of that Phase I/II clinical trial in non-small cell lung cancer, or NSCLC. MD Anderson researchers
have collaborated with other researchers to identify other genes, such as those in the 3p21.3 chromosomal region, that may act as tumor suppressors or have other cancer fighting functions. Data from preclinical studies performed by others suggest
that product candidates that could be derived from our technology platform could be effective against other types of cancer, including breast, head and neck, renal cell (kidney), and soft tissue cancer, as well as NSCLC. Therefore, our platform
technologies may allow delivery of a number of cancer fighting genes, alone or in combination with other cancer therapies, to combat multiple types of cancer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act and Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The JOBS Act, enacted in 2012, provides that an &#147;emerging growth company&#148; can take advantage of the extended transition period
provided in Section&nbsp;7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. In other words, an &#147;emerging growth company&#148; can delay the adoption of certain accounting standards
until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on
which adoption of such standards is required for other public companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have implemented all new accounting pronouncements that are
in effect and may affect our financial statements and we do not believe that there are any other new accounting pronouncements that have been issued that would have a material impact on our financial position or results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The
preparation of these financial statements requires us to make estimates and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported
expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about
the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the following accounting policies are the most critical to aid in fully understanding and evaluating our reported financial
results, and they require our most difficult, subjective or complex judgments, resulting from the need to make estimates about the effect of matters that are inherently uncertain<B>.</B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We record accrued expenses for costs invoiced from research and development activities conducted, on our behalf, by third-party service
providers, which include the conduct of pre-clinical studies and clinical trials and contract manufacturing activities. We record the costs of research and development activities based upon the amount of services provided, and we include these costs
in accrued liabilities in the balance sheets and within research and development expense in the statement of operations. These costs are a significant component of our research and development expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate the amount of work completed through discussions with internal personnel and external service providers as to the progress or
stage of completion of the services and the agreed-upon fee to be paid for such services. We make significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, we adjust our accrued
estimates. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed, the number of patients enrolled and the rate of patient enrollment may
vary from our estimates and could result in us reporting amounts that are too high or too low in any particular period. Our accrued expenses are dependent, in part, upon the receipt of timely and accurate reporting from clinical research
organizations and other third-party service providers. To date, there have been no material differences from our accrued expenses to actual expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred tax assets or liabilities are recorded for temporary differences between financial statement and tax basis of assets and liabilities,
using enacted rates in effect for the year in which the differences are expected to reverse. A valuation allowance is recorded if it is more likely than not that a deferred tax asset will not be realized. We have provided a full valuation allowance
on our deferred tax assets, which primarily consist of cumulative net operating losses from April&nbsp;1, 2009 (inception) to September 30, 2017. Due to our history of operating losses since inception and losses expected to be incurred in the
foreseeable future, a full valuation allowance was considered necessary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be
realizable or at a minimum annually during the fourth quarter of the year. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset are compared to the asset&#146;s carrying value to determine if an
impairment of such asset is necessary. The effect of any impairment would be to expense the difference between the fair value of such asset and its carrying value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of our Results of Operations and Financial Condition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We classify our operating expenses into three categories: research and development, general and administrative and depreciation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and development</I></B>. Research and development expenses consist primarily of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs incurred to conduct research, such as the discovery and development of our current and potential product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs related to production of clinical supplies, including fees paid to contract manufacturers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fees paid to clinical consultants, clinical trial sites and vendors, including clinical research organizations in conjunction with implementing and monitoring our clinical trials and acquiring and evaluating clinical
trial data, including all related fees, such as patient screening fees, laboratory work and statistical compilation and analysis; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs related to compliance with drug development regulatory requirements. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize all
research and development costs as they are incurred. Clinical trial costs, contract manufacturing and other development costs incurred by third parties are expensed as the contracted work is performed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our research and development expenses to increase in the future as we advance our current and potential product candidates into and
through clinical trials and pursue regulatory approval of our current and potential product candidates in the United States and Europe. The process of conducting the necessary clinical research to obtain regulatory approval is costly and
time-consuming. The actual probability of success for our current and potential product candidates may be affected by a variety of factors including the quality of our current and potential product candidates, early clinical data, investment in our
clinical program, competition, manufacturing capability and commercial viability. We may never succeed in achieving regulatory approval for any of our current and potential product candidates. As a result of the uncertainties discussed above, we are
unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of our current and potential product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and administrative</I></B><I>. </I>General and administrative expense consists of personnel related costs, which include
salaries, as well as the costs of professional services, such as accounting and legal, facilities, information technology and other administrative expenses. We expect our general and administrative expense to increase following the completion of
this offering due to the anticipated growth of our business and related infrastructure as well as accounting, insurance, investor relations and other costs associated with becoming a public company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Depreciation</I></B><I>. </I>Depreciation expense consists of depreciation on our property and equipment. We depreciate our assets over
their estimated useful life. We estimate computer and office equipment to have a 5-year life. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Nine Months Ended September&nbsp;30, 2016 and 2017 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes our results of operations for the nine months ended September&nbsp;30, 2016 and 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Research and Development Expense. </B>Research and development expense was $228,860 for the nine months ended September&nbsp;30, 2017. The
expense is mainly related to clinical expertise to advance development of our Oncoprex treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expense
consists primarily of the discovery and development of our current and potential product candidates; costs related to production of clinical supplies, including fees paid to contract manufacturers, fees paid to clinical consultants, clinical trial
sites and vendors, including clinical research organizations in conjunction with implementing and monitoring our clinical trials and acquiring and evaluating clinical trial data; and costs related to compliance with drug development regulatory
requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expense was $228,860 for the nine months ended September&nbsp;30, 2017
as compared to $225,546 for the nine months ended September&nbsp;30, 2016. This increase of $3,314 was driven by the need for clinical and regulatory assistance for our ongoing Phase I/II trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>General and Administrative Expense. </B>General and administrative expense was $2,416,557 for the nine months ended September&nbsp;30,
2017. The expense mainly included professional fees to our consultants, attorneys, accountants and other service providers, as well as equity-based compensation to recruit management and scientific advisors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expense primarily consists of personnel costs, travel, information technology, facilities, and professional service
fees. Professional services fees primarily consist of legal, accounting and consulting costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expense for the
nine months ended September&nbsp;30, 2017 was $2,416,557 as compared to $2,906,898 for the nine months ended September&nbsp;30, 2016. The $490,341 decrease in general and administrative expense is related primarily to a larger than normal
equity-based compensation amount in the first nine months of 2016 to recruit and retain leadership and technical talent to our team. Excluding this expense, an increase of $726,190 of the nine months ended September&nbsp;30, 2017 versus
September&nbsp;30, 2016 was primarily due to increased headcount, associated employee-related expenses, and additional service providers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect general and administrative expense to increase in future periods due to additional legal, accounting, insurance, investor relations
and other costs associated with being a public company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Interest Expense. </B>Interest expense was $0 for each of the nine month
periods ended September&nbsp;30, 2017 and 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Depreciation Expense. </B>Depreciation expense was $2,213 and $648 for the nine months
ended September&nbsp;30, 2017 and 2016, respectively. Depreciation is generated from our fixed assets, which consist only of computer equipment at this time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2015 and 2016 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes our results of operations for the years ended December&nbsp;31, 2015 and 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Research and Development Expense. </B>Research and development expense was $354,883 for the year ended December&nbsp;31, 2016. The expense
is mainly related to clinical expertise to advance development of our Oncoprex treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expense consists
primarily of the discovery and development of our current and potential product candidates; costs related to production of clinical supplies, including fees paid to contract manufacturers, fees paid to clinical consultants, clinical trial sites and
vendors, including clinical research organizations in conjunction with implementing and monitoring our clinical trials and acquiring and evaluating clinical trial data; and costs related to compliance with drug development regulatory requirements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expense was $354,883 for the year ended December&nbsp;31, 2016 as compared to $201,962 for the year ended
December&nbsp;31, 2015. This increase of $152,921 was driven primarily by the need for additional clinical and regulatory assistance to review and analysis interim data from our Phase I/II trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>General and Administrative Expense. </B>General and administrative expense was $3,776,414 for the year ended December&nbsp;31, 2016. The
expense mainly included professional fees to our consultants, attorneys, accountants and other service providers, as well as equity-based compensation to recruit management and scientific advisors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expense primarily consists of personnel costs, travel, information
technology, facilities, and professional service fees. Professional services fees primarily consist of legal, accounting and consulting costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expense for the year ended December&nbsp;31, 2016 was $3,776,414 as compared to $865,696 for the year ended
December&nbsp;31, 2015. The $2,910,718 increase in general and administrative expense is related primarily to equity-based compensation granted to management, directors, advisors, and consultants in early 2016 for past services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect general and administrative expense to increase in future periods due to additional legal, accounting, insurance, investor relations
and other costs associated with being a public company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Interest Expense. </B>Interest expense was $0 for each of the years ended
December&nbsp;31, 2016 and 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Depreciation Expense. </B>Depreciation expense was $862 and $2,064 for the years ended
December&nbsp;31, 2016 and 2015, respectively. Depreciation is generated from our fixed assets, which consist only of computer equipment at this time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From our
inception through September&nbsp;30, 2017, we have never generated revenue from product sales and have incurred net losses in each year since inception. As of September&nbsp;30, 2017, we had an accumulated deficit of $16,785,779. We have funded our
operations primarily through the sale and issuance of preferred stock. During 2016, we sold 76,577 shares of Series G preferred stock at $35.33 per share to various investment funds for a total of $2,705,465. In the first nine months of 2017, we
sold 22,473 shares of Series G preferred stock at $35.33 per share for a total of $793,971. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2017, we had
$373,945 in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the net proceeds of this offering, together with our cash and cash equivalents, including the remaining
proceeds from our recent private placements, will be sufficient to meet our cash, operational and liquidity requirements for at least 12 months if we raise minimum gross proceeds of $12,500,000 and for at least 18 months if we raise minimum gross
proceeds of $22,500,000 in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not expect to generate revenue from product sales unless and until we successfully
complete development of, obtain regulatory approval for and begin to commercialize one or more of our current and potential product candidates, which we expect will take a number of years and which is subject to significant uncertainty. Accordingly,
we anticipate that we will need to raise additional capital to fund our future operations. Until such time as we can generate substantial revenue from product sales, if ever, we expect to finance our operating activities through a combination of
equity offerings and debt financings and we may seek to raise additional capital through strategic collaborations. However, we may be unable to raise additional funds or enter into such arrangements when needed on favorable terms, or at all, which
would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our development programs or commercialization efforts or grant to others rights to develop or market product candidates that we would
otherwise prefer to develop and market ourselves. Failure to receive additional funding could cause us to cease operations, in part or in full. Furthermore, even if we believe we have sufficient funds for our current or future operating plans, we
may seek additional capital due to favorable market conditions or strategic considerations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our independent registered public accounting
firm has indicated that our financial condition raises substantial doubt as to our ability to continue as a going concern. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the primary sources and uses of cash for the years ended
December&nbsp;31, 2015 and 2016 and the nine months ended September&nbsp;30, 2016 and 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,248,263</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(688,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,960,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(399,620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(89,534</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,284</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71,887</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,705,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">724,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">794,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,205,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,368,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,228,350</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">734,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash used in operating activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities was $1,960,028 and $399,620 for the nine months ended September&nbsp;30, 2017 and 2016, respectively. The
$1,560,408 increase in net cash used in operating activities was primarily due to an increase in spending in research and development, specifically related to monitoring and review of sponsored research performed by MD Anderson, as well as increase
in payments made to professionals and employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities was $1,248,263 and $688,261 for the years ended
December&nbsp;31, 2016 and 2015, respectively. The $560,002 increase in net cash used in operating activities was primarily due to an increase in spending in research and development, specifically related to monitoring and review of sponsored
research performed by MD Anderson, as well as increase in payments made to professionals and employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash used in investing activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities was $62,341 and $71,887 for the nine months ended September&nbsp;30, 2017 and 2016, respectively. The
decrease of $9,546 was primarily due to increased patent prosecution expenses and additional investment in computer equipment in the prior year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities was $89,534 and $21,284 for the years ended December&nbsp;31, 2016 and 2015, respectively. The increase
of $68,250 was primarily due to increased patent prosecution expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash provided by financing activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was $794,019 and $1,205,866 during the nine months ended September&nbsp;30, 2017 and, 2016,
respectively. The $411,847 decrease in net cash provided by financing activities was primarily due to larger investment in the prior year to support ongoing research and development and operational activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was $2,705,872 and $724,912 for the years ended December&nbsp;31, 2016 and 2015, respectively. The
$1,980,960 increase in net cash provided by financing activities was primarily due to cash provided by issuance of Series G Preferred Stock in 2016 to support increased research and development activities and the hiring of additional management.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc486549_10"></A>BUSINESS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genprex&#153; is a clinical
stage gene therapy company developing a new approach to treating cancer, based upon our novel proprietary technology platform, including our initial product candidate, Oncoprex&#153; immunogene therapy, or Oncoprex. Our platform technologies are
designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low
quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and
modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hold
an exclusive worldwide license from The University of Texas MD Anderson Cancer Center, or MD Anderson, to patents covering the therapeutic use of a series of genes that have been shown in preclinical and clinical research to have cancer fighting
properties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With Oncoprex, we are initially targeting non-small cell lung cancer, or NSCLC. Researchers at MD Anderson have conducted two
Phase I clinical trials and are currently conducting an ongoing Phase II clinical trial of Oncoprex in NSCLC. According to the World Health Organization, lung cancer is the leading cause of cancer deaths worldwide, killing more people than breast,
colon, kidney, liver, prostate and skin cancers combined, and is the second most common type of cancer. Each year, there are over 1.8&nbsp;million new lung cancer cases and 1.6&nbsp;million deaths from lung cancer worldwide, and in the United States
there are over 225,000 new cases and more than 150,000 deaths from lung cancer per year. NSCLC represents 80% of all lung cancers. According to a 2016 American Cancer Society report, the five-year survival rate for Stage IV (metastatic) NSCLC is
about 1%,&nbsp;and overall survival for lung cancer has not improved appreciably in the last 25 years. We believe that there is a significant unmet medical need for new treatments for NSCLC in the United States and globally, and we believe that
Oncoprex may be suitable for a majority of NSCLC patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our platform technologies could allow delivery of a number of
cancer fighting genes, alone or in combination with other cancer therapies, to combat multiple types of cancer. Our research and development pipeline, discussed in &#147;Our Pipeline&#148; below, demonstrates our clinical and preclinical progress to
date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cancer results from genetic mutations. Mutations that lead to cancer are usually present in two major classes of genes: oncogenes,
which are involved in functions such as signal transduction and transcription; and tumor suppressor genes, which play a role in governing cell proliferation by regulating transcription.&nbsp;Transduction is the process by which chemical and physical
signals are transmitted through cells. Transcription is the process by which a cell&#146;s DNA sequence is copied to make RNA molecules, which then play a role in protein expression. In normal cells, mutations in oncogenes are discovered and
targeted for elimination by tumor suppressor genes. In cancer cells, the oncogene mutations may overwhelm the natural tumor suppression processes, or those tumor suppression processes may be impaired or absent.&nbsp;Functional alterations due to
mutations in oncogenes or tumor suppressor genes may result in the abnormal and uncontrolled growth patterns characteristic of cancer. These genetic alterations facilitate such malignant growth by affecting signal transduction pathways and
transcription, thus inhibiting normal growth signaling in the cell, circumventing the natural process of apoptosis, evading the immune system&#146;s response to cancer, and inducing angiogenesis, which is the formation of new blood vessels that
supply cancer cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The most common genetic alterations present in NSCLC are in tumor suppressor genes, against which few targeted small
molecule drugs have been developed. Each of the two sets of chromosomes in the cell nucleus includes two copies of each gene, called alleles, which may be identical or may show differences. In most situations, tumor suppressor genes require both
alleles of a gene to be deleted or inactivated to impair tumor </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
suppression activity and lead to tumor growth. The replacement of just one functional allele may therefore be enough to restore the normal cellular functions of growth regulation and apoptosis.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among the genetic conditions associated with lung cancer are the overexpression of epidermal growth factor receptors, or EGFRs, and
mutations of kinases. Kinases are enzymes that play an important role in signal transduction through the modification of proteins by adding or taking away phosphate groups, a process called (de-)phosphorylation, to change the proteins&#146;
function. When two EGFR transmembrane proteins are brought to proximity on the cell membrane surface, or dimerize, either through a ligand, or binding molecule, that binds to the extracellular receptor, or through some other process, the
intracellular protein-kinase domains can auto-phosphorylate, and activate downstream processes, including cell signaling pathways that can lead to either cell cycle arrest or cell growth and proliferation. EGFRs and kinases can act similarly to a
switch that turns &#147;on&#148; and &#147;off&#148; when phosphate groups are either added or taken away. Mutated kinases can have a malfunctioning on/off switch, causing the switch to be stuck in the &#147;on&#148; position or failing to turn the
switch &#147;off,&#148; leading to the loss of cell control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A subset of NSCLC patients (approximately 10% of NSCLC patients of North
American and European descent and approximately 30% to 50% of NSCLC patients of Asian descent) carry an EGFR mutation that makes their tumors sensitive to tyrosine kinase inhibitors, or TKIs, such as erlotinib. However, even for these patients,
tumor resistance to TKIs frequently develops within two years, resulting in eventual disease progression. Erlotinib generally does not benefit NSCLC patients who do not have this activating EGFR mutation. However, our clinical and preclinical data
have shown that the combination of Oncoprex and erlotinib can increase anti-tumor activity even in cancers without the EGFR mutations, as well as in cancers that have become resistant to erlotinib. For this reason, we believe Oncoprex may be
suitable for the majority of NSCLC patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cancer can spread when cells&#146; natural cancer suppression functions are impaired. The
tumor suppressor gene called Tumor Suppressor Candidate 2, or TUSC2 (which was formerly known as FUS1) has been shown to affect both cell proliferation and apoptosis. TUSC2 is a pan-kinase inhibitor, which means that it has the ability to inhibit
multiple kinase receptors, such as EGFR and platelet-derived growth factor receptor, or PDGFR. TUSC2 is frequently inactivated early in the development of lung cancer, and loss of TUSC2 expression in NSCLC is associated with significantly worse
overall survival compared to patients with normal TUSC2 expression. Many types of cancer cells, including approximately 85% of NSCLC cells, lack expression of TUSC2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cancer can also spread when the body&#146;s natural immune functions are impaired, including by the cancer cells themselves. PD-1, or
Programmed Death-1, is a receptor expressed on the surface of activated T cells, which are part of the body&#146;s immune system. PD-L1, or Programmed Death Ligand-1, is a protein/receptor expressed on the surface of cancer and other cells. The
binding of PD-1 to PD-L1 has been speculated to contribute to cancer cells&#146; ability to evade the body&#146;s immune response.&nbsp;PD-1 and molecules like it are called immune checkpoints, because they can impede the normal immune response, for
example by blocking the T cells from attacking the cancer cells. In many cancers, PD-L1 receptors are up-regulated, and substantial research is now being performed in the emerging field of immuno-oncology to discover drugs or antibodies that could
block PD-L1 and similar receptors. It is believed that blocking the PD-1/PD-L1 interaction pathway and other similar checkpoints, such as cytotoxic T-lymphocyte-associated protein 4, or CTLA-4, with drugs called checkpoint inhibitors can prevent
cancer cells from inactivating T cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Oncoprex immunogene therapy is designed to interrupt cell signaling pathways that cause
replication and proliferation of cancer cells, and to target and kill cancer cells via receptor pathways, and also to stimulate the natural immune responses against cancer. Oncoprex combines features of gene therapy and immunotherapy in that it
up-regulates TUSC2 expression in the cell, and also increases the anti-tumor immune cell population and down-regulates PD-L1 receptors, thereby boosting the immune response to cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Oncoprex consists of a TUSC2 gene encapsulated in a positively charged nanovesicle made from lipid molecules with a positive electrical
charge. Oncoprex is injected intravenously and can specifically target cancer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cells, which generally have a negative electrical charge. Once Oncoprex is taken up into a cancer cell, the TUSC2 gene is expressed into a protein that is capable of restoring certain defective
functions arising in the cancer cell. Oncoprex nanovesicles are designed to deliver the functioning TUSC2 gene to cancer cells while minimizing their uptake by normal tissue. Tumor biopsy studies conducted at MD Anderson show that the uptake of
TUSC2 in tumor cells after Oncoprex treatment is 10 to 25 times the uptake in normal cells. We believe that Oncoprex, unlike other gene therapies, which either need to be delivered directly into tumors or require cells to be removed from the body,
re-engineered and then reinserted into the body, is the first systemic gene therapy to be used for cancer in humans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical data from
the evaluation of 24 patients in our Phase I/II clinical trial, as well as our preclinical data, indicate that Oncoprex can be combined with the widely used anti-cancer drug erlotinib (marketed as
Tarceva<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> by Genentech, Inc.) in humans.&nbsp;Erlotinib is a tyrosine kinase inhibitor, or TKI, which uses a mechanism of action similar to that of pan-kinase inhibitors to block the action of
tyrosine kinases, which are a type of kinase involved in many cell functions, including cell signaling, growth and division. In addition, MD Anderson researchers have conducted preclinical studies combining Oncoprex with: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the TKI gefitinib (marketed as Iressa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> by AstraZeneca Pharmaceuticals) in animals and in human NSCLC cells; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">MK2206 in animals (MK2206 is an inhibitor of AKT kinases, which affect cell signaling pathways downstream from tyrosine kinases); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an anti-PD-1 antibody equivalent to the checkpoint inhibitor nivolumab (marketed as Opdivo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> by Bristol-Myers Squibb Company) in animals; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an anti-CTLA4 antibody equivalent to ipilimumab (marketed as Yervoy<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> by Bristol-Myers Squibb Company) in animals. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacturers of the marketed drugs were not involved in any of our clinical or preclinical studies. In studies involving marketed drugs,
the drugs were administered concurrently with Oncoprex without being modified in any way, and the antibodies used in our preclinical studies that did not use the marketed drugs were the non-humanized equivalent to marketed drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Data from these clinical and preclinical studies indicate that combining Oncoprex with these other therapies yields results more favorable
than either these therapies or Oncoprex alone, with minimal side effects relative to other lung cancer drugs, thereby potentially making Oncoprex a therapy complementary to these cancer treatments. In addition, based on our clinical and preclinical
studies and on preclinical studies conducted by others, we believe that Oncoprex could be combined with other lung cancer drugs that have similar mechanisms of action to the drugs mentioned above, such as pembrolizumab (marketed as Keytruda<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> by Merck&nbsp;&amp; Co.), nivolumab (marketed as Opdivo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> by Bristol-Myers Squibb Company) and atezolizumab (marketed as Tecentriq<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> by Genentech/Roche). We have not conducted any preclinical or clinical studies combining Oncoprex with pembrolizumab or atezolizumab. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Researchers at MD Anderson have collaborated with other researchers to identify other genes, such as those in the 3p21.3 chromosomal region,
that may act as tumor suppressors or have other cancer fighting functions. We hold rights to certain of these genes under license agreements with MD Anderson.&nbsp;Data from preclinical studies performed by others suggest that product candidates
that could be derived from our technology platform could be effective against other types of cancer, including breast, head and neck, renal cell (kidney), and soft tissue cancer, as well as NSCLC. Therefore, our platform technologies may allow
delivery of a number of cancer fighting genes, alone or in combination with other cancer therapies, to combat multiple types of cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MD Anderson researchers have completed the first phase of a Phase I/II clinical trial of Oncoprex in combination with erlotinib in patients
with Stage IV (metastatic) or recurrent NSCLC that is not potentially curable by radiotherapy or surgery, whether or not they have received prior chemotherapy, and whether or not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
they have an activating EGFR mutation.&nbsp;The Phase I portion of the trial was a dose-escalating study with primary endpoints of establishing the safety and tolerability of the combination of
Oncoprex and erlotinib, and establishing the Maximum Tolerated Dose, or MTD. The secondary endpoint of the Phase I portion of the trial was to assess the toxicity of the combination of Oncoprex with erlotinib. In the Phase I portion of the trial,
which began in 2014, 18 subjects were treated, and the MTD was determined to be the highest tested dose: 0.6 mg/kg of Oncoprex administered every 21 days and 150 mg of erlotinib per day. Toxicities were found to compare favorably with those of other
lung cancer drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase II portion of the trial is designed to include subjects treated with the combination of Oncoprex and
erlotinib at the MTD with the primary goal of measuring the response rate, and secondary endpoints of stable disease, time to progression and overall survival. The response rate for cancer therapies is defined under the Response Evaluation Criteria
in Solid Tumors, or RECIST, as Complete Response (CR) + Partial Response (PR); disease control rate is defined under the RECIST criteria as Complete Response (CR) + Partial Response (PR) + Stable Disease (SD)&gt;8weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enrollment criteria for the second phase of the Phase I/II clinical trial are identical to those in the first phase. The Phase II portion of
the trial began in June 2015 and is ongoing at MD Anderson. Of the 39 patients allowed in the protocol for the Phase II portion of the trial, 10 have been enrolled and nine are evaluable for response under the trial protocol, because they have
received 2 or more cycles of treatment. Interim results show that four of the patients had tumor regression and one patient had a Complete Response, or CR under the RECIST criteria. The patient with the CR had disappearance of the lung primary
tumor, as well as lung, liver, and lymph node metastases. The median response duration for all patients, which is defined as the median time between when response is first noted to the time when cancer progression is observed, was three months. The
response rate for the nine patients evaluated to date was 11% and the disease control rate for the nine patients was 78%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The response
rate and disease control rate to date in the Phase II portion of our Phase I/II clinical trial substantially exceeds the response rate of 7% (with no CRs) and disease control rate of 58% reported for a clinical trial of the TKI afatinib (marketed as
Gilotrif<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> by Boehringer Ingelheim Pharmaceuticals, Inc.) in a study referred to as the LUX-Lung 1 clinical trial. A total of 585 patients were enrolled in that Phase IIB/III clinical trial,
whose primary endpoint was overall survival and whose secondary endpoints were progression-free survival, RECIST response, quality of life and safety. The LUX-Lung 1 clinical trial was a randomized, double blinded Phase IIB/III clinical trial
treating subjects with Stage IIIB or IV adenocarcinoma, a type of NSCLC. The Phase II portion of our Phase I/II trial is not blinded, and is designed to treat NSCLC subjects regardless of EGFR status. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preliminary analysis of the early data from the Phase II portion of our Phase I/II trial supports our belief that Oncoprex may provide medical
benefit in several subpopulations of NSCLC patients for which there is an unmet medical need, and may provide pathways for accelerated approval by the US Food and Drug Administration, or FDA. As a result of these initial findings, in April 2016, we
suspended enrollment of new patients in the Phase II portion of the trial to collect additional trial data and have it analyzed in order to seek FDA guidance as to whether the protocol for this clinical trial could be modified to expand enrollment
and also to divide the patients into cohorts with a view toward seeking accelerated approval in one or more of these cohort populations. We have completed the collection and analysis of the additional preliminary data and expect to present our
findings to the FDA within the next several months. Although this clinical trial is currently closed to new patient enrollment, it is not terminated, and is considered &#147;ongoing&#148; because activities such as patient follow-up and further data
collection and analysis continue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we reach an agreement with the FDA regarding expanded patient enrollment and defined patient
cohorts, then we plan to amend the trial protocol accordingly and proceed with the amended protocol at MD Anderson and several additional clinical trial sites. Amendments to the Phase II clinical trial protocol will require approval of the
Investigational Review Board, or IRB, of each site where the amended trial is conducted. If we do not reach an agreement with the FDA on these changes, then we plan to reopen enrollment in the current version of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Phase II portion of the trial at MD Anderson and at additional clinical trial sites. In that event, we will need to provide MD Anderson with plans and funding to move ahead with the trial.
Whether under the original protocol or a revised protocol, we intend to use a portion of the proceeds of this offering to add additional clinical trial sites. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2012, MD Anderson researchers completed a Phase I clinical trial of Oncoprex as a monotherapy.&nbsp;The primary objective of this Phase I
trial was to assess the toxicity of Oncoprex administered intravenously and to determine the MTD and recommended Phase II dose of Oncoprex alone. Secondary objectives were to assess the expression of TUSC2 following intravenous delivery of Oncoprex
in tumor biopsies and also to assess the anti-cancer activity of Oncoprex. This trial demonstrated that Oncoprex was well tolerated and established the MTD and the therapeutic dosage for Oncoprex at 0.06 mg/kg administered every 21 days. Although
this trial was not designed to show changes in outcomes, a halt in cancer growth was observed in a number of patients, and tumor regressions occurred in primary lung tumors and metastatic cancers in the liver, pancreas, and lymph nodes. In addition,
pre- and post-treatment patient biopsies demonstrated that intravenous Oncoprex selectively and preferentially targeted patients&#146; cancer cells, and suggested that clinical anti-cancer activity was mediated by TUSC2. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that Oncoprex&#146; combination of pan-kinase inhibition, direct induction of apoptosis, anti-cancer immune modulation and
complementary action with targeted drugs and immunotherapies is unique, and positions Oncoprex to provide treatment for patients with NSCLC and possibly other cancers, who are not benefitting from currently offered therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Oncoprex immunogene therapy technology was discovered through a lung cancer research consortium from MD Anderson and The University of
Texas Southwestern Medical Center, or UTSWMC, along with the National Cancer Institute, or NCI. The TUSC2 discovery teams included Jack A. Roth, MD, FACS, chairman of our Scientific and Medical Advisory Board. We have assembled a team of experts in
clinical and translational research, including laboratory scientists, medical oncologists and biostatisticians, to pursue the development and commercialization of Oncoprex and other potential product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our technology discoveries and research and development programs have been the subjects of numerous peer-reviewed publications and have been
supported by Small Business Innovation Research, or SBIR, grants and grants from the National Institutes of Health, the United States Department of Treasury, and the State of Texas. We hold a worldwide, exclusive license from MD Anderson to patents
covering the therapeutic use of TUSC2 and other genes that have been shown to have cancer fighting properties, as well as a number of related technologies, including 30 issued patents, and two pending patent applications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing Oncoprex, our lead product candidate, to be administered with erlotinib for NSCLC. We are also conducting preclinical
research with the goal of developing Oncoprex to be administered with immunotherapies in NSCLC. In addition, we have conducted research into other tumor suppressor genes associated with chromosome 3p21.3. Our research and development pipeline is
shown below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g486549g16o08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to develop and commercialize treatments for cancer based on our proprietary gene therapy platform, alone or in combination with other
cancer therapies. Key elements of our strategy include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Conduct Ongoing and New Clinical Trials.</B> We plan to continue clinical trials of Oncoprex immunogene therapy in combination with erlotinib for treatment of NSCLC, while exploring pathways to accelerated Food and
Drug Administration, or FDA, approval of this combination in subpopulations of NSCLC patients for whom there is currently no approved therapy. We also plan to pursue a clinical trial of the combination of Oncoprex with anti-PD-1 immunotherapy. We
may also pursue additional clinical trials of the combination of Oncoprex plus an immunotherapy called CTLA-4 immunotherapy, as well as possible multi-drug combinations of Oncoprex with additional targeted therapies and immunotherapies.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Investigate the Effectiveness of Oncoprex in Other Cancers</B><B>.</B> We may also explore the combination of Oncoprex and erlotinib in other cancers such as soft tissue, kidney, head and neck, and/or breast cancer,
and we may pursue development of additional proprietary genes alone or in combination with EGFR TKIs such as erlotinib and/or with immunotherapies. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Prepare to Commercialize Oncoprex</B><B>.</B> We plan to continue to develop the manufacturing, process development and other capabilities needed to commercialize Oncoprex. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Pursue Strategic Partnerships</B><B>.</B> As we gather additional clinical data, we plan to pursue strategic partnerships with other developers and providers of anti-cancer drugs to investigate possible therapeutic
combinations of Oncoprex with drugs manufactured by others, to accelerate the development of our current and potential product candidates through co-development and to increase the commercial opportunities for our current and potential&nbsp;product
candidates. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Develop Our Platform Technology</B><B>.</B> We plan to investigate the applicability of our platform technology with additional anti-cancer drugs. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Current Treatment of Cancer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Chemotherapy is the standard treatment for the majority of NSCLC patients, as it is for many cancer patients. Because it is a systemic, rather
than a targeted, approach to treating cancer, chemotherapy also kills healthy cells and has a number of other side effects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A subset of
NSCLC patients carry one or both of two EGFR mutations, referred to as exon 19 deletion and exon 21 substitution, which make their tumors sensitive to TKIs. Because EGFR is frequently overexpressed in lung tumors, it has become a favored therapeutic
target for pharmaceutical companies. Several pharmacological and biological approaches, including TKIs, have been developed specifically to block activated EGFR for cancer therapy. The class of drugs functioning as protein kinase inhibitors, or KIs,
comprises the majority of targeted therapies for lung cancer, accounting for most sales and use. Of the KIs, the TKI drugs are the most common, with drugs targeting EGFR kinases leading the sector growth. Several EGFR TKI therapies are marketed
commercially including market leader erlotinib, gefitinib, afatinib and osimertinib. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A leading small molecule EGFR TKI is erlotinib,
which is approved in the U.S and Europe as a first-line therapy in metastatic NSCLC patients with an activating EGFR mutation. Erlotinib was previously approved as a second-line treatment in patients with metastatic NSCLC after failure of at least
one prior chemotherapy regimen. Erlotinib has been used to treat more than 400,000 lung cancer patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, while erlotinib is most
effective in patients who have an activating EGFR mutation and are therefore described as &#147;EGFR positive,&#148; it is significantly less effective in overall NSCLC populations and is generally not effective in patients without an activating
EGFR mutation. Approximately 10% of NSCLC patients of North American and European descent and approximately 30% to 50% of NSCLC patients of Asian descent have the activating EGFR mutations. This means that the majority of NSCLC patients do not have
activating EGFR mutations and are therefore &#147;EGFR negative&#148; and not optimal candidates for erlotinib and other TKIs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, even among those patients who are EGFR positive and benefit from erlotinib therapy, most eventually become resistant to and ultimately no longer respond to erlotinib therapy, resulting in eventual disease progression. Furthermore, clinical
trials have shown that combining EGFR TKIs with conventional chemotherapy does not increase survival for lung cancer patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While next
generation TKIs show promise in targeting resistant EGFR positive tumors that carry a mutation known as T790M, only about one-half of EGFR positive patients (5% to 7.5% of all NSCLC patients of North American and European descent and 15% to 25% of
NSCLC patients of Asian descent) carry the T790M mutation. This leaves a significant majority of NSCLC patients&#151;those who are EGFR negative and those who are EGFR positive but have become resistant to erlotinib and do not have the T790M
mutation&#151;without a targeted therapy for their cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinical and preclinical data indicate that the combination of our lead
product candidate, Oncoprex, with erlotinib and other EGFR TKIs may increase anti-tumor activity in cancers with or without the EGFR mutations and in cancers that have become resistant to erlotinib therapy, thus expanding the number of patients who
could benefit from those drugs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TUSC2, the Active Agent in Oncoprex </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TUSC2, which is the active agent in Oncoprex, is a multifunctional gene that plays a vital role in cancer suppression and normal cell
regulation. Key TUSC2&nbsp;anti-cancer mechanisms of action include the inactivation of multiple oncogenic kinases, the induction of apoptosis, the control of cell signaling and inflammation, and modulation of the immune system to fight cancer.
Oncoprex has also been shown to block mechanisms that create drug resistance. Our data indicate that Oncoprex in combination with both EGFR TKIs and with immunotherapies achieve results more favorable than results achieved with either Oncoprex or
such other therapies alone, and may make those drugs effective for patients who would not otherwise benefit from them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Normal TUSC2 function is inactivated at the early onset of cancer development, making TUSC2 a
potential target for all stages of cancer, including metastatic disease. The TUSC2 protein is reduced or absent in approximately 85% of lung cancers. In patients with NSCLC, the loss of TUSC2 expression has been associated with significantly worse
overall survival than when TUSC2 expression is not impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Studies show TUSC2 protein functions as a key mediator in the Apaf1-mediated
mitochondrial apoptosis pathway by recruiting and directing cytoplasmic Apaf1 protein to a critical cellular location and activating it <I>in situ</I> and by up-regulating activity of other proapoptotic effectors. Normal TUSC2 function mediates
apoptosis in cancer cells through interaction with Apaf1 and down-regulates multiple tyrosine kinases including EGFR, AKT, PDGFR, c-Kit, and c-Abl. TUSC2 mediates apoptosis in cancer cells but not normal cells through its interaction with Apaf1 and
down-regulates tyrosine kinases including EGFR, PDGFR, c-Kit, and c-Abl. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In normal cells, the proteins involved in the PI3K/AKT pathway
(also called the mTOR pathway), in which PI3K, a kinase, generates messenger molecules required to translocate AKT, another protein kinase, to the cell&#146;s plasma membrane where it is phosphorylated and activated, play an important role in
cellular function and cellular trafficking. These proteins are often found to be aberrantly active in cancers, causing cells to lose their ability to control cell growth, proliferation, and differentiation. Thus, mutations in PI3K (overexpression)
and its upstream receptors, EGFR, have been associated with many forms of cancers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, proteins in the Ras/MAPK pathway, which is
a signal transduction pathway that transduces signals to the cell nucleus where specific genes are activated for cell growth, division and differentiation, play a critical role in cellular responses to various stress stimuli, including osmotic
stress, DNA damage, and pro-inflammatory factors. As shown in the figures below, the TUSC2 protein, a potent pan-kinase inhibitor, blocks multiple cell signaling pathways downstream of the receptor (EGFR in the figures), leading to cell cycle
interruption and thereby preventing cancer cell proliferation and survival. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, under stress conditions, such as oncogenic stress, cells go through a regulated
process of programmed cell death, or cellular suicide, called apoptosis, in order to control cell development and replication. The TUSC2 protein interacts via various apoptotic signaling pathways to stimulate programmed cell death via the release of
caspases, enzymes that play a significant role in apoptosis. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g486549g70w78.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pan-Kinase Inhibition by TUSC2 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g486549g13l34.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Stimulation of Apoptotic Signaling by TUSC2 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cancer and the Immune Response </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When
functioning normally, the body&#146;s immune system recognizes and destroys cancer cells, as well as other mutated cells and foreign bodies. As cancer develops over time, some mutations in cancer cells enable
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
them to inhibit immune mechanisms, thus allowing the cancer cells to escape detection and destruction by the immune system and leading to the cancer&#146;s &#147;immune tolerance.&#148; Therapies
are being developed to allow patients to overcome this immune tolerance, some by stimulating the natural immune response and others by removing the inhibitions on the immune response created by the cancer. For example, PD-1 is a protein found on
certain types of T cells, which are part of the immune system. Because PD-1 prevents T cells from attacking other cells, including in some cases cancer cells, inhibiting PD-L1 receptors, a process called PD-1 checkpoint inhibition, can facilitate
the immune response to cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to its pro-apoptotic cytotoxicity and tyrosine kinase inhibitory activity, TUSC2 enhances the
immune response to cancer. Data from preclinical studies at MD Anderson have shown a therapeutic benefit from the combination of TUSC2 and anti-PD-1 antibody and a key role for TUSC2 in regulating immune cell subpopulations including cytokines,
natural killer, or NK, cells, and T lymphocytes. In addition, TUSC2 has been found to down-regulate PD-L1 receptors on the surface of cancer cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NK cells, an important part of the innate immune system, have developed several mechanisms to distinguish healthy cells from target cells.
These mechanisms allow NK cells to kill cells that are deemed dangerous to the host, including cancer cells. However, one of the consequences of malignant transformation is the ability of the cancer cell to evade the immune system. Cancer cells do
so via the up-regulation and interplay of receptors, including checkpoint inhibitors such as PD-1 and PD-L1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As shown in the illustration
below, TUSC2 has been found to stimulate the release of interleukin-15, or <FONT STYLE="white-space:nowrap">IL-15,</FONT> resulting in up-regulation of mature NK cells that circulate and target cancer cells. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g486549g64t03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Modulation by TUSC2 of the Immune Response to Cancer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Genprex Platform and Oncoprex </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genprex
is developing a novel approach to cancer treatment, based on our immunogene therapy platform, which is designed to deliver any of a number of cancer fighting tumor-suppressor genes, alone or in combination with other cancer therapies, to combat
multiple types of cancer. The Genprex platform consists of anti-cancer genes encapsulated in nanovesicles that can be delivered intravenously. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, Oncoprex, is the TUSC2 gene, as the active anti-cancer agent, encapsulated into nanovesicles made from fat
molecules with a positive electrical charge formulated for intravenous administration. In our ongoing Phase II clinical trial Oncoprex is injected intravenously approximately every 21 days for as long as the patient continues to benefit, which is
defined as tumor size stabilization or shrinkage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling
pathways that cause replication and proliferation of cancer cells, re-establishes pathways for programmed cell death, or apoptosis, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block
mechanisms that create drug resistance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Oncoprex is a pan-kinase inhibitor shown to simultaneously inhibit the EGFR and AKT oncogenic
kinase pathways <I>in vitro</I> and <I>in vivo</I>. Once the cancer cell takes up the nanovesicle containing TUSC2, it is reprogrammed to die. Resistance to targeted drugs and checkpoint inhibitors develop through activation of alternate bypass
pathways. For example, when PD-1 is blocked, the TIM-3 checkpoint is up-regulated. We believe that Oncoprex&#146; multimodal activity will block emerging bypass pathways, reducing the probability that drug resistance develops. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our cancer gene therapy platform and its delivery system are highly targeted. While the TUSC2 gene induces apoptosis in cancer cells which
have low or absent TUSC2 expression, TUSC2 delivered by nanovesicles to normal cells is not toxic. Moreover, the nanovesicles are taken up by tumor cells after Oncoprex treatment at 10 to 25 times the rate at which they are taken up by normal cells,
because of selective endocytosis, or enveloping by the cell, of the nanovesicle lipid formulation and the enhanced permeability and retention, or EPR, characteristics of tumor vasculature, without the need for external ligands, or binding molecules.
Pre- and post-treatment biopsies following intravenous injection of Oncoprex in a phase 1 clinical trial showed robust TUSC2 protein expression in cancer cells at both primary and metastatic tumor sites. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our preclinical and clinical data indicate that Oncoprex is well tolerated and may be effective alone or in combination with targeted small
molecule therapies, thereby facilitating the action of both drugs, allowing use in expanded populations of patients who may benefit from advanced therapy regimens. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Data have shown that when Oncoprex is combined with EGFR TKI therapy, such as erlotinib, in EGFR mutated resistant cancers, the combination
therapy overcomes intrinsic and acquired therapeutic resistance by simultaneously inactivating the EGFR and the AKT signaling pathways to restore apoptotic signaling. Overcoming EGFR resistance in a clinical setting could provide a path for approval
of Oncoprex for patients who do not have an activating EGFR mutation (90% of patients of American and European descent and 50% to 70% of those of Asian descent) and/or for patients who have an activating EGFR mutation but who have become resistant
to erlotinib. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical and preclinical data indicate that Oncoprex, when combined with EGFR TKIs such as erlotinib and gefitinib,
provides a synergistic effect that could also benefit the larger population of NSCLC patients who are EGFR negative (which means they are not expected to benefit from EGFR TKI drugs alone). Further, our data show that Oncoprex may re-sensitize EGFR
positive patients who become resistant to, and therefore no longer benefit from, EGFR TKIs alone. Thus, Oncoprex may both significantly expand the benefit of EGFR TKIs to the majority of patients (90% of those of American and European descent and
50% to 70% of those of Asian descent) who do not have EGFR activating mutations and would therefore not otherwise be expected to benefit from EGFR TKI drugs, and also extend the usefulness and benefit of EGFR TKIs for the population of NSCLC
patients who are EGFR positive, but who do not have the T790 mutation and who have become refractory to erlotinib, for whom there is currently no well-accepted standard treatment other than chemotherapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many currently approved cancer therapeutics target only single molecules or a single specific genetic abnormality related to driving the
proliferation and survival of cancer cells. In contrast, Oncoprex works by targeting several molecules within the cancer cell to interrupt cell signaling pathways that cause replication and proliferation of cancer cells, to target and kill cancer
cells, to block mechanisms that create drug resistance and to stimulate the natural immune response. Moreover, clinical and preclinical data show that Oncoprex works with other cancer drugs or their non-humanized equivalents, to produce more
effective anti-cancer effects than either produces alone. In conjunction with these other drugs and equivalents, Oncoprex has been shown to mediate an anti-tumor response through up-regulation of NK cells, CD8+ T cells, and down-regulation of
regulatory T cells, or Tregs, and PD-L1 receptors, activate alternative immune mechanisms with the potential to complement checkpoint inhibitors. Published data indicate that effectiveness of these kinase inhibitors and immunotherapy drugs is
enhanced when they are combined with Oncoprex. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delivery System </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Genprex immunogene therapy platform consists of anti-cancer genes encapsulated in nanovesicles delivered intravenously. The Oncoprex TUSC2
gene is encapsulated in a positively charged nanovesicle that binds to actively replicating (and therefore negatively charged) cancer cells, and then enters the cancer cell through selective endocytosis. These nanoscale vesicles differ significantly
from liposomes historically used for drug delivery in that they are true particles encapsulating the therapeutic payload within a bilamellar lipid coat. Our collaborators at MD Anderson have optimized the characteristics of lipids including
N-(1-(2,3-Dioleoyloxy)propyl)-N,N,N-trimethylammonium methyl sulfate, or DOTAP:cholesterol and a DNA plasmid expressing the TUSC2 tumor suppressor gene which form a spherical particle with a hollow center, nanoscale in size, which encapsulates the
TUSC2 gene for delivery as Oncoprex. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g486549g98r06.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Operation of the Oncoprex TUSC2 Nanovesicle Delivery System </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The particle size is small enough to allow Oncoprex to cross tight barriers in the lung, but large enough to avoid accumulation or clearance
in the liver, spleen and kidney. The cationic (positive) charge of the nanovesicle targets cancer cells, and direct nanovesicle fusion avoids target cell endocytosis. A Phase I clinical trial showed that intravenous Oncoprex therapy selectively and
preferentially targeted primary and metastatic tumor cells, resulting in anticancer activity. The nanovesicles are non-immunogenic, allowing repetitive therapeutic dosing and providing extended half-life in the circulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the nanovesicles used in Oncoprex are applicable to delivery of a range of therapeutic and prophylactic plasmid DNAs and RNA
interference constructs. The nanovesicle manufacturing methods we and our collaborators have developed have been optimized and we believe they may be useful for a wide array of disease treatments. Clinical outcomes demonstrated that the delivery
system used in Oncoprex is well tolerated in humans and can deliver high therapeutic doses. The nanovesicle delivery system and safety database may be attractive to drug developers because it overcomes historical technological boundaries with
lipid-based delivery systems. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Platform Technologies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hold an exclusive worldwide license to patents covering the therapeutic use of a series of genes in the 3p21.3 region of the human
chromosome, including TUSC2, that have been shown in preclinical and clinical research to have cancer fighting properties. While we are initially targeting NSCLC, data from preclinical studies conducted by others indicate that product candidates
derived from our immunogene therapy platform may also be effective with respect to other types of cancer, including soft tissue, kidney, head and neck, and breast cancer. Preclinical and clinical data also indicate that our current and potential
product candidates are complementary to other successful cancer drugs. Therefore, our platform technologies may allow delivery of any of a number of cancer fighting genes, alone or in combination with other cancer therapies, to combat multiple types
of cancer. In addition, we plan to investigate biomarkers to predict response and additional immunotherapies to combine with Oncoprex. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preclinical and Clinical Development, Rationale and Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Phase I Monotherapy Clinical Trial </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2012, MD Anderson researchers completed a Phase I clinical trial of Oncoprex as a monotherapy. The primary objective of this Phase I trial
was to assess the toxicity of Oncoprex administered intravenously and to determine the maximum tolerated dose, or MTD, and recommended Phase II dose, of Oncoprex alone. Secondary objectives were to assess the expression of TUSC2 following
intravenous delivery of Oncoprex in tumor biopsies and also to assess the anti-cancer activity of Oncoprex, although the study was not designed to show changes in outcomes. This trial demonstrated that Oncoprex was well tolerated and established the
MTD and the therapeutic dosage for Oncoprex at 0.06 mg/kg administered every 21 days. Although this trial was not designed to show changes in outcomes, a halt in cancer growth was observed in some patients. Tumor regressions occurred in primary lung
tumors and metastatic cancers in the liver, pancreas, and lymph nodes. In addition, pre- and post-treatment patient biopsies demonstrated that intravenous Oncoprex selectively and preferentially targeted patients&#146; cancer cells, and suggested
that clinical anti-cancer activity was mediated by TUSC2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the Phase I Monotherapy Trial, Oncoprex was injected intravenously in stage
IV (metastatic) lung cancer patients who had received traditional platinum combination chemotherapy but still showed tumor progression at the time of entry into the study. Oncoprex was manufactured in GMP facilities to meet specifications of size,
appearance, and transfection efficiency. During the trial, manufacturing was transferred from Baylor College of Medicine to MD Anderson, thus confirming reproducibility of the manufacturing process. Subjects received escalating doses ranging from
0.01 mg/kg to 0.09 mg/kg at three-week intervals for a maximum of six cycles of a dose every three weeks. Fever is a common reaction to intravenous drug administration; accordingly, dexamethasone, a steroid, and diphenhydramine, an antihistamine,
were administered as a standard treatment to prevent fever and eliminated the only clinically significant toxicity of fever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the Phase
I Monotherapy Trial, 31 subjects were treated at six dose levels ranging from 0.01 to 0.09 mg/kg. Seventy percent of subjects had received 2 or more prior chemotherapy regimens. Among 4 subjects treated without the fever-reducing premedications, all
4 subjects developed grade 2 or higher fevers within 24 hours of treatment. Among the 27 subjects premedicated with the fever-reducing premedications, the highest fever was grade 2, which occurred in two subjects. The only serious adverse events,
defined as grade 3, 4 or 5 events under the Common Terminology Criteria for Adverse Events, or CTCAE, published by the U.S. Department of Health and Human Services, were grade 3 fever (experienced by three patients) and grade 3 hypotension
(experienced by 1 patient). The only dose-limiting toxicities were two episodes of transient grade 3 hypophosphatemia (abnormally low levels of phosphate in the blood) resulting in an MTD of 0.06 mg/kg. Twenty-three subjects received 2 or more
doses, of whom 5 subjects, or 22% of the 23 subjects, achieved disease control for periods ranging from 2.6 months to 10.8&nbsp;months. The median disease control period for these subjects was 5.0 months (95% CI: 2.0 -7.6), while the other 18
subjects&#146; cancer progressed during the Phase I Monotherapy Trial. Disease control for cancer therapies is defined under the Response Evaluation Criteria in Solid Tumors, or RECIST, as Complete Response (CR) + Partial Response (PR) + Stable
Disease (SD)&gt;8weeks). Median survival for all subjects in the Phase I Monotherapy Trial was 8.3 months (95% CI 6.0-10.5 months) and mean survival time was 13.2 months (95%CI 8.9 -7.5 months) with a range of two to 23+ months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Two subjects had reductions in primary tumor size of 14% and 26%. One subject with stable disease, a
<FONT STYLE="white-space:nowrap">54-year-old</FONT> female with a large cell neuroendocrine carcinoma who received 12 cycles of Oncoprex therapy, had evidence of a durable metabolic response, which is a lasting reduction of metabolic activity in the
tumor, as shown by positron emission tomography, or PET, imaging. The response was documented with PET scans performed after the second, fourth and sixth doses, all showing decreased metabolic activity in the tumor with no changes in size or number
of metastases by computed tomography, or CT, imaging. The illustration below is of the PET scan of this subject performed after the fourth dose. This subject had received 6 prior chemotherapy regimens. Prior to entry in the Phase I Monotherapy
Trial, 2 hepatic metastases were progressing on gemcitabine. The subject also had a metastasis in the head of the pancreas and a peripancreatic lymph node, shown by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
arrows in the illustration below. Illustration A shows the pretreatment PET scan. The dose of Fluorodeoxyglucose (18F)&nbsp;was 8.8mCi. Illustration B shows the post treatment PET scan performed
20 days following the fourth dose of Oncoprex. The dose of Fluorodeoxyglucose (18F)&nbsp;was 9.0mCi. All scans were performed within a 60 to 90 minute window after injection. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g486549g02x90.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Metabolic Tumor Response in a
Metastatic Lung Cancer Subject </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This subject remains alive after subsequent therapy more than seven years after the final treatment
with Oncoprex, to our knowledge, without evidence of cancer progression in the responding sites. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To test whether the TUSC2 gene
introduced by Oncoprex therapy was expressed following Oncoprex therapy in the Phase I Monotherapy Trial, pre-treatment and 24-hour post-treatment tumor biopsies were obtained from 7 subjects by percutaneous CT guidance from a central tumor
location. A quantitative real time reverse transcriptase PCR, or RT-PCR, analysis using a plasmid TUSC2 sequence-specific probe was performed on samples blinded to time of biopsy. The RT-PCR analysis detected high levels of TUSC2 plasmid expression
in 6 of 7 post-treatment tumor specimens but not in pretreatment specimens or negative controls. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, an <I>in situ</I> proximity
ligation assay, or PLA, performed on paired biopsies from 3 subjects, demonstrated no TUSC2 protein staining in pre-treatment tissues compared with intense TUSC2 protein staining in post-treatment tissues. For the PLA, anti-TUSC2 polyclonal
antibodies were developed to detect the presence of TUSC2. Pre-treatment and post-treatment biopsies were obtained from 3 patients. The top panel for each patient in the illustration below represents the pre-treatment biopsy &#147;controls&#148;
with DAPI, a type of blue stain. The bottom panel for each patient are post-treatment biopsies, and represent overlays of blue DAPI staining and red anti-TUSC2 antibody staining. The blue stains in the top panels indicate the absence of TUSC2 in the
pre-treatment biopsies, and the red and purple (red overlaying blue) stains in the bottom panels indicate the presence </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of TUSC2 in robust quantities in the post-treatment biopsies, showing that TUSC2 was successfully introduced into the tumors in the Phase I Monotherapy Trial. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g486549g02q86.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Proximity Ligation Assay (PLA) for
TUSC2 protein in tumor biopsies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An RT-PCR gene expression profiling analysis of apoptotic pathway genes in a paired specimen showing
high post-treatment levels of TUSC2 mRNA and protein in one subject also showed up-regulation and down-regulation of certain genes involved in both the intrinsic and extrinsic apoptotic pathways. Antibodies to single
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and double stranded DNA were not detected 14 months after completion of 12 cycles of therapy in the subject, indicating that within that period no anti-DNA antibodies had developed. The
conclusion from the Phase I Monotherapy Trial was that Oncoprex administered intravenously in lung cancer patients was well tolerated with demonstrable gene delivery to tumors with protein expression and evidence of antitumor activity. Although the
number of biopsies was limited due to regulatory constraints, the consistent results across test platforms suggests that these observations are reliable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the positive results from the Phase I Monotherapy Trial and preclinical data from studies of the combination of Oncoprex plus EGFR
TKI drugs, we are evaluating Oncoprex as a lung cancer therapeutic to be used in combination with the EGFR kinase inhibitor erlotinib in our ongoing Phase I/II Combination Therapy Trial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical Studies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investigators at MD Anderson conducted preclinical research showing that Oncoprex alone blocked the activation of the c-Abl tyrosine kinase. A
number of other studies at MD Anderson have demonstrated the complementary effects of Oncoprex combined with a variety of targeted kinase inhibitory agents, both marketed and in various stages of clinical development, including erlotinib, gefitinib,
MK2206 and others. Researchers investigated the use of Oncoprex combined with commercially available EGFR TKI drugs erlotinib and gefitinib, and conducted preclinical <I>in vitro</I> and <I>in vivo</I> studies combining Oncoprex with these drugs in
a variety of human lung cancer cell lines, including cancers with activating EGFR mutations and EGFR mutation negative cancers. Lung cancers known to have intrinsic and acquired resistance to erlotinib therapy were also studied, as were
K-ras-related and other cancers. Notably, studies in xenograft animal models demonstrated that Oncoprex and either erlotinib or gefitinib showed synergistic anti-cancer effects, superior to either agent used alone, in both EGFR mutation negative
cancers (generally not candidates for erlotinib) and in EGFR mutation positive cancers (optimal candidates for erlotinib), including cancers known to be resistant to erlotinib therapy. The addition of Oncoprex to either erlotinib or gefitinib
overcame drug-induced resistance by simultaneously inactivating EGFR and AKT signaling pathways and by inducing apoptosis in erlotinib- or gefitinib-resistant cancers with EGFR mutations and with EGFR mutation-negative cancers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In one study, MD Anderson researchers tested the combination of erlotinib and Oncoprex against five human NSCLC cell lines: H1299, H322, A549,
H460, and H1975, the latter of which has the L858R and T790M EGFR mutations and is highly resistant to erlotinib. The results showed that the combination of Oncoprex and erlotinib significantly reduced NSCLC colony formation beyond the effect of
erlotinib, Oncoprex or controls alone (p&lt;0.01 at both 1 and 2.3 uM concentrations for all cell lines). The cooperative interaction between erlotinib and Oncoprex was confirmed <I>in vivo</I> using a lung colony formation metastases model in nu/nu
mice with A549 human lung cancer cells injected in the tail vein. Mice were treated with the combination of Oncoprex and erlotinib and various controls including empty nanovesicles, erlotinib alone, Oncoprex alone, and other controls. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The greatest reduction in lung colonies occurred with the Oncoprex with erlotinib combination (90% reduction) which was reduced compared to
all control groups (p&lt;0.0005). In terms of total tumor nodules, the cooperative effect is greater than 0.9999. This means that there is less than a 1 in 10,000 chance that the low dose erlotinib with TUSC2 combination does not have a cooperative
effect and greater than 9,999 in 10,000 chance that the cooperative effect exists. P-value is the probability that the difference between two data sets was due to chance. The smaller the p-value, the more likely the differences are not due to chance
alone. In general, if the p-value is less than or equal to 0.05, the outcome is considered statistically significant. The FDA&#146;s evidentiary standard of efficacy generally relies on a p-value of less than or equal to 0.05. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MD Anderson researchers also tested Oncoprex in TUSC2-deficient and erlotinib or gefitinib-resistant NSCLC cell lines. Treatment of the NSCLC
EGFR mutation negative cell lines H1299, H322, H358 and H460 cancer cell line showed that the Oncoprex combination significantly sensitized (p&lt;0.001) response of the cancer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cell lines to both erlotinib or gefitinib treatment and synergistically induced apoptosis <I>in vitro</I>. The findings were confirmed <I>in vivo</I> in an H322 orthotopic lung cancer mouse
model. These studies included the K-ras mutant cell line H460, which is significant because patients with K-ras mutant tumors are generally unresponsive to erlotinib or gefitinib. Synergistic induction of apoptosis was observed with the combination
of Oncoprex and concentrations of erlotinib or gefitinib similar to steady-state serum concentrations achievable with oral dosing. The combination of Oncoprex and either erlotinib or gefitinib induced similar levels of tumor cell growth inhibition,
apoptosis induction, and inactivation of oncogenic protein kinases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Data from these and other MD Anderson studies suggest a combination
of Oncoprex with gefitinib or erlotinib can promote synergistic tumor cell killing and overcome drug-induced resistance by simultaneously inactivating the EGFR and the AKT signaling pathways and by inducing apoptosis in resistant cells with
non-mutated EGFR. These data suggest that NSCLC patients with an activating EGFR mutation, whose cancer progresses on erlotinib, may potentially benefit from Oncoprex with erlotinib combination therapy. These data also suggest that NSCLC patients
without an activating EGFR mutation (generally unresponsive to erlotinib) may potentially benefit from Oncoprex with erlotinib combination therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In another study, MD Anderson researchers analyzed the effects of TUSC2 re-expression on the sensitivity of tumor cells to the AKT inhibitor
MK2206 in vitro and in mice. The AKT pathway is an important intracellular, converging positive regulator of apoptosis. AKT stimulates apoptosis and is frequently dysregulated in cancers, and this has been associated with reduced sensitivity to
anti-tumor drugs.&nbsp;The study showed that the combination of TUSC2 transfection with MK2206 treatment suppressed tumor cell viability in vitro and effectively inhibited xenograft tumor growth in vivo more effectively than either agent alone. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical Study Showing that the TUSC2-Erlotinib Combination Significantly Inhibits Tumor Cell Viability and Colony Formation in NSCLC
Cells Without an Activating EGFR Mutation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Previous research has shown that NSCLC in cells that lack the activating EGFR mutations
exon 19 deficiency and exon 21 substitution is not halted or inhibited by erlotinib at pharmacologically relevant doses. In one preclinical study, MD Anderson researchers tested a group of EGFR negative NSCLC lines for sensitivity to erlotinib after
restoration of TUSC2 expression, both transiently and stably, and found a significant benefit resulting from the combination at micromolar ranges between 1uM and 2.3uM. These concentrations are achievable in patient serum with standard dosing
regimens and are pharmacologically relevant. Cell viability was evaluated in 3 TUSC2 Tet-On stable clones that had been treated with doxycycline to induce TUSC2, and combined with erlotinib. As expected, the cells that had not had TUSC2 expression
restored were not sensitive to erlotinib alone, and the viability of cells in the A549, H1299, and H175 cancer cell lines was 92%, 90%, and 98%, respectively. Induction of TUSC2 with doxycycline alone showed more cytoxicity than erlotinib alone,
resulting in 16%, 22%, and 5% cell death, respectively. However, when cells were exposed to doxycycline and treated with 2.3 &micro;M erlotinib for 48 hours, a growth inhibitory effect was observed for all three cell lines (p&lt;0.05), with the
relative survival of the A549, H1299, and H175 cancer cells being reduced by 48%, 42%, and 38%, respectively. Similarly, as shown in the graphs below, colony formation was significantly inhibited in cells transiently transfected with TUSC2 and
treated with erlotinib. The ability of A549, H1299, H322, and H460 cells to form colonies was reduced by 90%, 80%, 93%, and 85%, respectively. In dose titration experiments erlotinib also mediated increased inhibition of colony formation at
nanomolar concentrations. Taken together, the results clearly demonstrate the superiority of the TUSC2-erlotinib combination treatment over each agent alone, and indicate that the effect is independent of the technique of exogenous gene expression.
For both viability and colony formation assays the probability of a cooperative effect was greater than 0.99, on a scale from 0 to 1. Zero means no probability of a true cooperative effect, and one means 100% probability of a cooperative effect
given the observed data. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g486549g37j02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inhibition of Colony Formation by a Combination of TUSC2 and Erlotinib </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the graphs above, &#147;EV&#148; means DOTAP: cholesterol (DC)&#151;empty vector (EV) complex (the Oncoprex nanovesicle without the TUSC2
gene), &#147;PBS&#148; means phosphate-buffered saline, and &#147;EV + PBS&#148; means EV and PBS, acting as a control; &#147;ER&#148; means erlotinib; &#147;*&#148; means p&lt;0.05; and &#147;**&#148; means p&lt;0.01. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>TUSC2-Erlotinib Combination Significantly Inhibits Tumor Growth and Metastasis and Induces Apoptotic Activity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In another preclinical study, MD Anderson researchers analyzed the effect of the combination of TUSC2 and erlotinib on inhibiting tumor growth
and metastasis in two NSCLC mouse xenograft models. Mice with established flank tumors of equal volumes were divided into different treatment groups: PBS, used as a control; DC-TUSC2 complex (Oncoprex), referred to in the graphs below as
&#147;Fus1&#148; or &#147;TUSC2&#148;; erlotinib alone, referred to in the graphs as &#147;Erlo&#148; or &#147;ER&#148;; DOTAP:cholesterol (DC)&#151;empty vector (EV) complex with erlotinib, referred to as &#147;EV + Erlo&#148; or &#147;EV +
ER&#148;; and Oncoprex plus erlotinib, referred to as &#147;Combo,&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;TUSC2 + ER&#148; or &#147;TUSC2 + Erlo.&#148; In the H322 subcutaneous xenograft model, the combination of intravenous Oncoprex and erlotinib was significantly superior (p&lt;0.05) in
reducing tumor volumes than either agent alone, as shown by graph A below. With adjustment for multiple comparisons, the tumor growth rate of Oncoprex and erlotinib combination was the only group significantly smaller than the PBS control group
(p&lt;0.01). The mean tumor volume was 421.25&plusmn;89.27 mm3, compared with 1082.50&plusmn;338.69 mm3, 801.25&plusmn;144.60 mm3, 675.00&plusmn;228.80 mm3, and 875.00&plusmn;267.85 mm3, in their counterparts receiving PBS, Oncoprex, erlotinib, or
EV + erlotinib, respectively. In terms of tumor size, the posterior probability of cooperative effect was 0.9928, which means that there were less than 100 in 10,000 chances that the effect of TUSC2-erlotinib combination was not cooperative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MD Anderson researchers also developed a lung metastasis xenograft mouse model, using the human TUSC2-defective, EGFR negative A549 NSCLC cell
line. Animals were treated with the same protocol as their subcutaneous counterparts. The number of tumor nodules on lung surfaces was reduced by 82% after TUSC2-erlotinib treatment, compared to 41% and 54%, for TUSC2 alone or erlotinib treatment
alone, respectively, as shown in graph B below. The overall difference of the tumor nodule count among the five groups was significant (p&lt;0.0001), as was the difference between the Oncoprex and erlotinib combination group compared to each of the
other groups (p&lt;0.01). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As shown in graph C below, in resected tumor tissues assayed by TUNEL, the average number of apoptotic cells in
the TUSC2 + erlotinib group was many times higher than in any of the other groups, including the groups receiving erlotinib alone and TUSC2-nanovesicles alone. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These results show that the growth inhibitory benefit of TUSC2-erlotinib <I>in vitro</I> could be
reproduced <I>in vivo</I> and validate the effects of this combination. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g486549g61b08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inhibition of Tumor Growth and Metastasis, and Induction of Apoptotic Activity, by a Combination of TUSC2
and Erlotinib </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In graphs B and C above, &#147;*&#148; means p&lt;0.05; the values in graph C above represent percentages from at least
1000 counted cells. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Phase I/II Combination Clinical Trial: TUSC2 Nanovesicles with Erlotinib </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase I Combination Trial </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase I
Monotherapy Trial showed that Oncoprex is well tolerated, that high levels of TUSC2 expression are detected in the tumor post-treatment, and that there is evidence of tumor growth suppression. Based on the positive results from the Phase I
Monotherapy Trial and substantial preclinical evidence that Oncoprex is complementary with EGFR TKIs, we obtained permission from FDA to begin a new Phase I/II trial at MD Anderson combining Oncoprex with erlotinib in patients with Stage IV
(metastatic) or recurrent NSCLC that is not potentially curable by radiotherapy or surgery, whether or not they have received prior chemotherapy, and whether or not they have an activating EGFR mutation.&nbsp;This trial is referred to as the Phase
I/II Combination </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Trial. Enrollment in the Phase I portion of the Phase I/II Combination Trial, referred to as the Phase I Combination Trial, commenced in 2014 at MD Anderson with Dr.&nbsp;Charles Lu as the
Principal Investigator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the Phase 1 Combination Trial, 18 subjects were treated with the following dose levels: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="81%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Dose&nbsp;Level</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Drug Doses</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">erlotinib (100 mg/day) + Oncoprex (0.045mg/kg)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">erlotinib (100 mg/day) + Oncoprex (0.06mg/kg)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">erlotinib (150 mg/day) + Oncoprex (0.045mg/kg)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">erlotinib (150 mg/day) + Oncoprex (0.06mg/kg)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As in the Phase I Monotherapy Trial, subjects received a pre-treatment regimen of oral and intravenous
dexamethasone and diphenhydramine to reduce fever, along with an infusion of Oncoprex every three weeks. Subjects received oral erlotinib daily during each three-week cycle during the treatment period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase I Combination Trial was also a dose escalation study with the primary purpose of determining the MTD. Dose Limiting Toxicities were
defined as grade 3, 4, or 5 events during the first cycle of treatment that were considered to be treatment related. At dose level 1 (Oncoprex .045 mg/kg plus erlotinib 100 mg), one subject had grade 3 adverse events of fatigue, muscle weakness, and
hyponatremia (low sodium level) considered to be related to the study treatment (erlotinib); therefore, three additional subjects were treated at this dose level (six subjects total), none of whom suffered a Dose Limiting Toxicity.&nbsp;At dose
level 2 (Oncoprex .06 mg/kg plus erlotinib 100 mg), there were no Dose Limiting Toxicities.&nbsp;At dose level 3 (Oncoprex .45 mg/kg plus erlotinib 150 mg), one subject had a grade 3 rash considered to be related to the study treatment (erlotinib);
therefore, an additional three subjects were treated at this dose level (six subjects total).&nbsp;No additional subjects suffered a Dose Limiting Toxicity at dose level 3.&nbsp;At dose level 4 (Oncoprex .06 mg/kg plus erlotinib 150 mg), there were
no Dose Limiting Toxicities; thus dose level 4 was determined to be the MTD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once the MTD for the study treatment combination was
determined in the Phase 1 Combination Trial to be Dose Level 4, accrual proceeded on the Phase II portion of the study. Since the eligibility criteria, drug administration details (other than dose) and evaluation details were identical for the Phase
I Combination trial and the Phase II Combination trial, three subjects in the Phase I Combination Trial who were treated at the MTD were included in the Phase II Combination Trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Four patients in the Phase I Combination Trial had stable disease ranging from 12 weeks to 36 weeks. The following observations from our
preclinical studies and from the Phase I Combination Trial provided the rationale for proceeding with the Phase II Combination Trial combining Oncoprex with erlotinib: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">TUSC2 inhibits a variety of tyrosine kinases including EGFR, PDGFR, c-kit, and c-abl; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expression of TUSC2 in NSCLC cells combined with TKIs is complementary <I>in vitro</I> and <I>in vivo</I>; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">intravenous administration of a nanoparticle encapsulated TUSC2 expression plasmid effectively delivers TUSC2 to distant tumor sites and mediates an anti-tumor effect in orthotopic human lung cancer xenograft models;
and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">when the TUSC2-nanoparticle is combined with a TKI, the suppression of tumor growth in mouse xenograft models is synergistic. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase II Combination Trial </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase II
Combination Trial is designed to include subjects treated with the combination of Oncoprex and erlotinib at the MTD with the primary goal of measuring the response rate, and secondary endpoints of stable disease, time to progression and overall
survival. The response rate for cancer therapies is defined under the Response Evaluation Criteria in Solid Tumors, or RECIST, as Complete Response (CR) + Partial Response (PR); disease control rate is defined under the RECIST criteria as Complete
Response (CR) + Partial Response (PR) + Stable Disease (SD)&gt;8weeks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enrollment criteria for the second phase of the Phase I/II clinical trial are identical to those
in the first phase. The Phase II portion of the trial began in June 2015 and is ongoing at MD Anderson. The first subject enrolled in the Phase II portion of the study began erlotinib on Day 8, and subsequently every other enrolled subject began
erlotinib on Day 8. The rationale for delaying erlotinib was to allow exploratory analyses of potential differential effects of Oncoprex nanoparticles alone and in combination with erlotinib on downstream pathway activation and potential biomarkers
of erlotinib resistance. In the Phase II Combination Trial, subjects will continue to receive three-week cycles of Oncoprex in combination with erlotinib until the occurrence of progressive disease (PD), unacceptable toxicity, withdrawal of consent,
or study treatment discontinuation for other reasons, whichever occurs first. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the 39 patients allowed in the protocol for the Phase II
portion of the trial, 10 have been enrolled (three of whom were also subjects of the Phase I Combination Trial) and nine are evaluable for response under the trial protocol, because they have received 2 or more cycles of treatment. None of the 10
subjects treated to date in the Phase II portion of the Phase I/II trial suffered a Dose Limiting Toxicity. Interim results show that four of the patients had tumor regression and one patient had a Complete Response, or CR under the RECIST criteria.
The median response duration for all patients, which is defined as the median time between when response is first noted to the time when cancer progression is observed, was three months. The response rate for the nine patients evaluated to date was
11% and the disease control rate for the nine patients was 78%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patient with the CR, a 58 year old female, upon enrollment in the
study had metastatic NSCLC status following 6 cycles of pemetrexed and carboplatin and 2 cycles of maintenance pemetrexed with cancer progression. The patient&#146;s tumor has EGFR exon 18 and 20 missense mutations, which are not sensitive to
erlotinib. As shown in the illustrations below, this patient had disappearance of both the lung primary tumor and the lung, liver and lymph node metastases. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g486549g49p57.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Subject with RECIST Complete Response </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preliminary analysis of these data further supported our belief that Oncoprex may provide medical benefit in several subpopulations of NSCLC
patients for which there is an unmet medical need, and may provide pathways for accelerated FDA approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of these initial
findings, in April 2016, we suspended enrollment of new patients in the Phase II Combination Trial to collect additional trial data and have it analyzed in order to seek FDA guidance as to whether the protocol for this clinical trial could be
modified to expand enrollment and also to divide the patients into cohorts with a view toward seeking accelerated approval in one or more of these cohort populations. We have completed the collection and analysis of the additional preliminary data
and expect to present our findings to the FDA within the next several months. Although this clinical trial is currently closed to new patient enrollment, it is not terminated, and is considered &#147;ongoing&#148; because activities such as patient
follow-up and further data collection and analysis continue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we reach an agreement with the FDA regarding expanded patient enrollment and defined patient
cohorts, then we plan to amend the trial protocol accordingly and proceed with the amended protocol at MD Anderson and several additional clinical trial sites. Amendments to the Phase II clinical trial protocol will require approval of the
Investigational Review Board, or IRB, of each site where the amended trial is conducted. If we do not reach an agreement with the FDA on these changes, then we plan to reopen enrollment in the current version of the Phase II Combination Trial at MD
Anderson and at additional clinical trial sites. Assuming enrollment of two or three patients per month, we estimate that enrollment of the remaining patients for the Phase II Combination Trial could take a year, but because enrollment in clinical
trials is uncertain, that estimate is also subject to substantial uncertainty. Any estimate of the duration of the trial would also be subject to substantial uncertainty, because treatment generally continues under the clinical trial protocol until
the patient dies, experiences a serious adverse event or withdraws from the trial, or until cancer progresses.&nbsp;Even after completion of treatment, patients continued to be monitored. If we reopen the trial, we will need to provide MD Anderson
with plans and funding to move ahead with the trial. Whether under the original protocol or a revised protocol, we intend to use a portion of the proceeds of this offering to add additional clinical trial sites. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical Studies of TUSC2 in the Immune Response to Cancer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Previous research has shown that TUSC2 regulates cytokine expression <I>in vitro</I>. Cytokines are proteins that stimulate inflammation as
part of the immune response.&nbsp;Stable expression of TUSC2 in H1299 NSCLC cells altered expression of a wide spectrum of cytokines including IL2, IL7, IL8 and 10, GM-CSF and PDGF-beta. TUSC2 is a positive regulator of innate immunity via
regulation of IL-15 expression. IL-15 induces NK cell differentiation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The systemic effect of the TUSC2 and anti-PD1 antibody combination
was examined in 2 immune-competent, syngeneic mouse models of Kras and p53 mutant lung cancer. C57BL/6 mice were subcutaneously injected with murine adenocarcinoma lung carcinoma CMT/167-luc cells (KrasG12V mutation). CMT/167 cells do not express
TUSC2. Tumors from untreated mice, isotype antibody control, or those treated with anti-PD1 were used as controls. 344SQ (KrasG12D allele and a knock-in Trp53R172H<FONT STYLE="FONT-FAMILY:SYMBOL">&#068;</FONT>G allele) adenocarcinomas which
metastasize to the lung in 126S2 mice were also used. When tumors reached 50-100 mm3, mice were either injected intravenously with DOTAP:cholesterol (DC)-TUSC2 complex alone (at a dose of 25 &micro;g of plasmid DNA and 10 nmol DC, every 48 hours for
three injections), or (DC)-TUSC2 complex combined with anti-PD1 antibody (250 &micro;g for four injections) alone or combined with anti-CTLA4 (100ug for three injections). Tumor growth and development was monitored by scoring ex-vivo luminescence
using the IVIS Imaging System 200&nbsp;Series. All tumor measurements were blinded to treatment and results were analyzed independently by biostatisticians. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical Study Showing that the TUSC2 and Anti-PD1 Combination Cooperatively Inhibits Growth of CMT/167
Lung Adenocarcinomas </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mouse experiments showed combined treatment with TUSC2 and anti-PD1 antibody superior to anti-PD1 alone in five
independent experiments in two different tumor models. Results of a representative experiment is shown in the graph below. By week 3 the reduction in tumor image intensity by the combination of TUSC2 and anti-PD1 and TUSC2, anti-PD1, plus anti-CTLA4
was greater than the reduction with TUSC2 alone, anti-PD1 combined with anti-CTLA4, or the isotype control. Spleens and blood were collected for immunological analysis profiling by multicolor flow cytometry. Immune profiling panels were designed to
evaluate response and major changes of specific regulatory innate and adaptive immune cells to TUSC2 or anti-PD1 treatment in peripheral blood and spleen. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g486549g42f86.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>12-Preclinical Study Showing Effect of TUSC2 Anti-PD1 Combo on T Lymphocytes </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical Study Showing the Effect of the TUSC2 and Anti-PD1 Combination on T Lymphocytes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The population of natural killer cells (NK), cytotoxic lymphocytes critical to innate immune function, was assessed in peripheral blood
mononuclear cells (PBMCs) in tumor bearing mice treated with anti-PD1, TUSC2 alone and the combination. As shown in the graph below, the NK cell population increased strongly in the TUSC2 alone and TUSC2+PD1 groups which correlated with tumor
regression. Anti-PD1 alone had no effect on NK cell proliferation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Tumor free mice without mutations that lead to metastasis were
injected intravenously with TUSC2 which caused a threefold up-regulation of NK cells in the peripheral blood of TUSC2 injected mice as compared with non-injected mice. CD8 T cells, which are cytotoxic T cells (CTL) for tumor killing, act as a
prognostic marker of tumor regression. Increased numbers of CTL were found in the TUSC2 and TUSC2+PD1 groups as compared with that of the control group which directly correlated with the anti-tumor effect, as shown in the graph below. Lower levels
of CD62L expression on T lymphocytes in TUSC2 treated mice suggests that TUSC2 regulates T&nbsp;cell activation. Moreover, TUSC2 induced down-regulation of regulatory T cells (Treg, CD4+CD25+). TUSC2 was shown to down-regulate checkpoint markers
such as PD-1, CTLA-4, Tim-3, and LAG-3. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g486549g85w22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>13-Effect of TUSC2 with Anti-PD1 on Immune Cell Populations in Peripheral Blood (Large) </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical Study Showing that TUSC2 Immunogene Therapy is Synergistic with Anti-PD1 in Lung Cancer Syngeneic Mouse Models </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the prolonged responses that were observed in TUSC2 clinical trials, which suggest that TUSC2 may modulate the immune response, and on
the fact that checkpoint blockade immunotherapy against PD1 and PD-L1 has yielded durable antitumor activity in a subset of NSCLC patients, MD Anderson researchers conducted a preclinical study to investigate the immune response to TUSC2 in immune
cell populations and the synergistic antitumor effect of TUCS2 in combination with anti-PD1 checkpoint blockade in syngeneic mouse NSCLC models. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Two Kras-mutant syngeneic mouse models were used to explore the effect of TUSC2+anti-PD1 (+/- anti-CTLA-4) on immune cells infiltration into
the tumor micro-environment. Activating Kras mutations are the most common driver mutations in lung adenocarcinomas. Lung cancer with mutant Kras has a poor prognosis, is often resistant to conventional therapy, and readily becomes resistant to
targeted therapies with kinase inhibitors. Studies by researchers not at MD Anderson have found that PD1 expression was highly associated with the presence of Kras mutations and that PD-L1 expression was elevated in premalignant Kras-mutant cells,
suggesting that Kras mutation may affect the function of the PD1/PD-L1 immune checkpoint pathway. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The first syngeneic mouse model used a
murine lung carcinoma cell line CMT/167-luc with a Kras G12V mutation and a low level of TUSC2 expression, implanted subcutaneously in C57BL/6 mice. The second syngeneic mouse model optimized an aggressive experimental metastatic lung cancer model
using 129SvE mice injected with SQ344 lung cancer cells, which contained KrasG12D allele. The SQ344 tumor model was found to be less sensitive to anti-PD1 single agent treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The graph below shows the protocol for and results of this preclinical study, in which anti-PD-1, TUSC2 and anti-CTLA-4 treatments were
administered in the SQ344 metastatic lung tumor mouse model. Figure A </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shows that SQ344 tumor cells have less expression of PD-L1 than in the CMT167 model, as determined by flow cytometry.&nbsp;The level of PD-L1 expression in SQ344 cells was only 4.5%, which was
significantly lower than the level found in the CMT 167 mouse tumor model (23.7% vs. 4.5%, p &lt; 0.0001), suggesting that SQ344 would respond less strongly to an anti-PD1 agent than the CMT167 model. Figure B shows the protocol for the experiment,
in which treatments were administered every three or four days in the mouse tumor cells. Figure C shows the survival of the mice with the lung tumor cells treated with (a)&nbsp;no treatment, (b)&nbsp;a combination of anti-PD-1 and anti-CTLA-4,
(c)&nbsp;TUSC2 alone, (d)&nbsp;a combination of TUSC2 and anti-PD-1, and (e)&nbsp;a combination of TUSC2, anti-PD-1 and anti-CTLA-4. Figure D shows samples of untreated lung tissue and lung tissue treated with TUSC2.&nbsp;Figure E shows tumor sizes
after each of the treatments shown in Figure C after two weeks.&nbsp;Figures F, G and H shows the infiltration by NK cells, the concentration of T regulatory, or Treg, cells and the concentration of myeloid-derived suppressor, or MDSC, cells, a type
of immune cells, in each case after treatment with (a)&nbsp;no treatment, (b)&nbsp;TUSC2 alone, (c)&nbsp;a combination of TUSC2 and anti-PD-1 and (d)&nbsp;a combination of anti-PD-1 and anti-CTLA-4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of this preclinical study indicate that TUSC2-sensitization to anti-PD1 could be produced in both Kras-mutant lung cancer mouse
models. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g486549g82r79.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>14-Therapeutic Efficacy of TUSC2+Anti-PD1 in a Lung Metastasis Model (Large) </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical Studies of Additional 3p21.3 Genes with Cancer-Fighting Properties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have licensed rights to a group of candidate tumor suppressor genes, including 101F6, NPRL2, CACNA2D2, PL6, BLU, RASSF1, HYAL 1 and HYAL2,
in addition to TUSC2 (which is also referred to as FUS1), all of which are located in a sub-region of human chromosome 3 known as 3p21.3. Using a number of techniques, MD Anderson researchers and their collaborators have identified these genes as
potentially having cancer-fighting characteristics. MD Anderson researchers have subsequently conducted a number of preclinical studies on certain of these genes, particularly 101F6 and NPRL2, as well as TUSC2, both alone and in combination with
other compounds, in order to assess their actual effects on NSCLC. Three of these preclinical studies are described below. We plan to support continuing research into the cancer-fighting properties of these and other genes in the 3p21.3 sub-region
as an important part of our strategy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical Study Showing Expression of Several Genes in the Human Chromosome 3p21.3 Sub-region by an Adenovirus
Vector Results in Tumor Suppressor Activities in Vitro and in Vivo </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MD Anderson researchers conducted preclinical studies, both in
vitro and in vivo, of several of the licensed genes located in the 3p21.3 sub-region, in order to assess their effects on tumor cell proliferation and apoptosis in human lung cancer cells. The researchers used adenoviral vectors to introduce
individual wild-type genes into 3p-deficient tumor xenografts and tumor cell lines. This &#147;forced expression&#148; of the wild-type forms of TUSC2, 101F6, and NPRL2 resulted in inhibition of tumor cell growth by induction of apoptosis and/or
alteration of cell cycle pathways in vitro, compared to control. Intratumoral injection of 101F6, TUSC2 and NPRL2 with adenoviral vectors, as well as systemic administration of these genes in an experimental mouse model, suppressed the growth of
tumor xenografts (in this case, human tissue grafted onto the mouse model) and inhibited lung metastases. The results of these studies showed that the genes 101F6, NPRL2 and TUSC2 had the most significant anti-cancer effects of the tested genes and
were therefore the most promising genes for further study. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical Study Showing that Tumor Suppressor 101F6 and Ascorbate Inhibit Non&#150;Small
Cell Lung Cancer Growth </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the promising tumor suppressor gene candidates, 101F6, expresses a protein found in normal lung
bronchial epithelial cells and fibroblasts but whose function is impaired in most lung cancers. This protein is involved in the regeneration of ascorbate, a well-known antioxidant that has been tested as a supplemental therapeutic agent for human
cancer prevention and therapy. MD Anderson researchers studied the effect of 101F6 in combination with ascorbate on human lung cancer tissue, both in vitro and in vivo. In the in vitro portion of the study, 101F6 was transferred via nanoparticles
similar to our Oncoprex nanovesicles, and in combination with ascorbate, selectively targeted cancer cells and inhibited lung cancer cell growth to a greater extent than either 101F6 or ascorbate alone. In vivo, the systemic injection of 101F6
nanoparticles in mouse tail veins, together with the intra-abdominal injection of ascorbate, inhibited both tumor formation and growth in human NSCLC H322 lung cancer xenograft mouse models (P &lt; 0.001) with greater effect than either 101F6 or
ascorbate administered alone. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical Study Showing NPRL2 Sensitizes Human Non-Small Cell Lung Cancer (NSCLC) Cells to Cisplatin Treatment by
Regulating Key Components in the DNA Repair Pathway </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Another of the promising tumor suppressor gene candidates, NPRL2, interacts with a
kinase that is activated by cisplatin, an anti-cancer drug, leading to downstream activation of apoptosis in response to the presence of intracellular high-molecular weight DNA fragments, which themselves result from the breakup of DNA molecules
induced by exposure to cisplatin. Mutations in the NPRL2 gene are associated with resistance to this cisplatin-mediated apoptosis. MD Anderson researchers have conducted preclinical studies of NPRL2 with cisplatin in vitro in lung cancer cell
cultures and in vivo in an experimental mouse model of chest cavity cancer dissemination. Data from these studies suggest that the systemic introduction of the NPRL2 gene and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
resulting expression of the NPRL2 protein in cancer cells activates the DNA damage checkpoint pathway in cisplatin-resistant and NPRL2-negative cells. These studies suggest that the combination
of NPRL2 and cisplatin could resensitize cisplatin nonresponders to cisplatin treatment, helping to overcome resistance to cisplatin. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Process
Development and Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through years of Oncoprex process development, including production of multiple clinical material
batches in compliance with current Good Manufacturing Practices, or cGMP, we have developed a robust manufacturing system for Oncoprex. Unlike gene therapy agents in the past, which needed to be prepared individually for each patient or required
viral vectors for gene delivery, we believe that our nanovesicle delivery system is scalable for commercial production, and the final product can be stored for later use. Manufacturing advances have resulted in improvements in scale, quality and
formulation for cGMP clinical materials. We have worked with multiple contract manufacturing organizations, or CMOs, to use our proprietary processes and protocols to supply our clinical materials. We anticipate that our commercial product will
continue to be manufactured for us by CMOs or pharmaceutical partners. Our management is experienced in securing, producing and releasing GMP materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The production process for Oncoprex utilizes well-defined steps of fermentation using master cell bank, or MCB, stocks, purification, and
DOTAP:cholesterol (DC) nanovesicle production to incorporate the TUSC2 plasmid into nanovesicles for final formulation, packaging and storage. We have produced Chemistry, Manufacturing and Control, or CMC, documentation to the satisfaction of the
FDA for our Phase I and Phase I/II clinical trials, and we have produced and tested and released MCB stocks for use. We intend to continue to improve our process development, formulation, packaging, storage, long-term stability, and distribution as
part of our ongoing technical programs to coincide with our pivotal clinical and commercialization goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our CMOs have demonstrated the
ability to scale sufficiently both in timeliness and quantity required for clinical application, and based on our experience with those CMOs, we believe they will be able to scale production of Oncoprex in the future, both with respect to capacity
and technology. Production by outside CMOs requires advance planning to schedule their production lines in coordination with other manufacturing orders they may have, as well as cost negotiation. Production costs may vary due to competition for
production lines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, a CMO completes production of the TUSC2 DNA plasmids and transports them in a climate-controlled setting to
our clinical test site at MD Anderson, where they are stored in cold storage until needed. Pursuant to our research agreements with MD Anderson, MD Anderson has developed thorough standard operating procedures for thawing, stabilizing, final
formulation required for application, and short-term storage prior to administering Oncoprex. This standardized process is both transferable and replicable at other clinical pharmacies, and we plan to scale this process for expanded clinical and
commercial use outside of MD Anderson. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MD Anderson is currently testing the shelf life of the final formulation of Oncoprex. A shelf life
of at least one year has been established to date, and testing is ongoing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hold a worldwide, exclusive license to 30 issued and two pending patents for technologies developed at MD Anderson and UTSWMC. These patents
comprise various therapeutic, diagnostic, technical and processing claims. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows our families of issued patents and patent applications, together with
information about the type of patent protection, the jurisdiction and the patent expiration dates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Patent</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:23.95pt; font-size:8pt; font-family:Times New Roman"><B>Family</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title and (Description)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Type&nbsp;of&nbsp;Patent&nbsp;Protection</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Jurisdiction</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Patent&nbsp;Expiration&nbsp;Dates</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">Chromosome 3p21.3 genes are tumor suppressors</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">(Use of our platform genes, including TUSC2, and use of our non-viral nanovesicle delivery system)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">The patents in this family have claims directed to compositions of matter, uses of the compositions and processes for preparing the compositions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">United States (2 issued)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">United States (1&nbsp;pending)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">Australia (2 issued)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">Japan (1
issued)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">Canada (1 issued)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">Europe (1 issued; validated in Switzerland,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">Germany, Denmark, Finland, France,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">United Kingdom, Ireland, Sweden, Netherlands)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7/10/2021, except for the issued US patents, which expire on 5/15/2024 and 7/29/2022</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">2</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">Bioactive FUS1 Peptides and Nanoparticle-Polypeptide Complexes</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">(Pharmaceutical formulation of TUSC2 (also referred to as FUS1) nanoparticles, method of delivering TUSC2 to cancer cells, and method of
treating cancer patients with TUSC2 nanoparticles)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">The patents in this family have claims directed to compositions of matter, uses of the compositions and processes for preparing the compositions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">United States (2 issued)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">Korea (1 issued)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">1/23/2030, 3/14/2026</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">7/29/2022</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">3</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">Methods and Compositions of Non-Viral Gene Therapy for Treatment of Hyperproliferative Diseases</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">(Methods of delivery, including our nanovesicle delivery system, of a series of genes that are licensed to us, including TUSC2, and genes that
are not licensed to us)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">The patents in this family have claims directed to compositions of matter, uses of the compositions and processes for preparing the compositions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">United States (1&nbsp;pending)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">Canada (1 issued)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">Europe (1
issued)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">Belgium (1 issued)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">France (1 issued)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">Germany (1
issued)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">Italy (1 issued)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">Liechtenstein&nbsp;(1&nbsp;issued)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">Spain (1 issued)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">Sweden (1
issued)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">Switzerland (1 issued)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">United Kingdom (1&nbsp;issued)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/24/2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">4</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">Methods and Compositions Related to Novel hTMC Promoter and Vectors for Tumor-Selective and High-Efficient
Expression of Therapeutic Genes</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="center">(A genetic technology to improve the effectiveness of gene therapy, relating to our platform genes and
other genes)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">The patents in this family have claims directed to compositions of matter, uses of the compositions and processes for preparing the compositions</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">United States (1 issued)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8/24/2029</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the use of our platform genes, including TUSC2, and the use of our non-viral delivery
system to deliver them, are covered by Family No.&nbsp;1, we believe that expiration of the patents in Family 3 will not affect our intellectual property protection for use of the genes which are licensed to us and are part of our platform. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also hold a non-exclusive license from the National Institutes of Health to 15 patents that expired on August&nbsp;1, 2017. We are aware
that others have also licensed these technologies from the NIH.&nbsp;These patents relate to the DOTAP:cholesterol liposomes for delivery of therapeutic DNA, which is the basic delivery system embodied in our nanovesicles. Through our license from
MD Anderson, we have separate patent protection for the combination of our nanovesicles with the genes we have licensed from MD Anderson, as well as for improvements that MD Anderson has made to the nanovesicle delivery system.&nbsp;Because the
license from the NIH is non-exclusive, we do not expect the expiration of the underlying patents to have a material effect on our business. We have an ongoing obligation to pay the NIH a total of $240,000 (together with an additional $20,000 each
year starting in 2018) upon our receipt of regulatory approval for our current or potential product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the
current licensed patents, Genprex is currently evaluating additional patent licenses from MD Anderson to add to the patent portfolio and expand our commercial potential. We expect to evaluate technology transfer opportunities to leverage the
commercial potential of our platform delivery system and also seek complementary oncology therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed a trademark
application for our company name and for the drug name &#147;Oncoprex&#148; for added protection of future product branding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Licenses and Research
Collaborations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Agreements with MD Anderson </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hold our Oncoprex technologies under a Patent and Technology License Agreement, referred to as the MD Anderson License Agreement, with MD
Anderson and The Board of Regents of the University of Texas System. The MD Anderson License Agreement was originally entered into as of July&nbsp;20, 1994 between the Board of Regents of The University of Texas System, MD Anderson and Intron
Therapeutics, Inc. (which later changed its name to Introgen Therapeutics, Inc.), or Introgen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The MD Anderson License Agreement
originally covered a number of patents and technologies unrelated to TUSC2, but the TUSC2 technologies were added by Amendment No.&nbsp;3 to the MD Anderson License Agreement dated October&nbsp;4, 2001.&nbsp;Under the MD Anderson License Agreement,
we have rights to patents covering use of various genes, including the TUSC2 gene, for treatment of cancer, as well as know-how and related intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exclusive licenses under the MD Anderson License Agreement, as amended, extend to the end of the term or terms for which patent rights
under the agreement have not expired, and expire on the expiration of all patents covered by the agreement. The last licensed patent under the MD Anderson License Agreement will expire in January 2030. Upon the expiration of the exclusive licenses,
the licensee will have a non-exclusive, fully paid-up right and license to use and otherwise exploit the technology rights licensed under the agreement. MD Anderson may terminate the agreement in the event of the licensee&#146;s voluntary or
involuntary bankruptcy or if the licensee&#146;s business is placed in the hands of a receiver, assignee or trustee.&nbsp;In addition, MD Anderson may terminate the agreement in the event of the licensee&#146;s uncured breach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to a Technology Sublicense Agreement dated March&nbsp;7, 2007, referred to as the Sublicense Agreement, Introgen sublicensed its
rights under the MD Anderson License Agreement to Introgen Research Institute, Inc. or IRI, a company formed and owned by Rodney Varner, our current President, CEO and Chairman of the board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to an Assignment and Collaboration Agreement dated April&nbsp;13, 2009, referred to as
the 2009 IRI Collaboration Agreement, IRI assigned its rights under the Sublicense Agreement to us, and we granted back to IRI a non-exclusive, royalty-free license to use and practice the licensed technology for non-commercial research purposes. As
consideration for this assignment, we agreed to assume all of IRI&#146;s obligations to MD Anderson under the MD Anderson License Agreement, including ongoing patent related expenses and royalty obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2009 IRI Collaboration Agreement was amended by an Amended Collaboration and Assignment Agreement dated July&nbsp;1, 2011, referred to as
the 2011 IRI Collaboration Agreement. The 2011 Collaboration Agreement provided that IRI would provide additional licensing opportunities and services to us, in return for monthly payments and our obligation to pay to IRI a royalty of one percent
(1%)&nbsp;on sales of products licensed to us under the MD Anderson License Agreement. In 2012, IRI&#146;s obligation to provide those opportunities and services, and our obligation to make monthly payments to IRI, were terminated. The 2011 IRI
Collaboration Agreement had an initial term of two years and renews automatically for additional consecutive periods of one year each unless either we or IRI gives prior written notice of termination to the other party. In addition, either we or IRI
may terminate the agreement in the event of the other party&#146;s voluntary or involuntary bankruptcy or uncured default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to a
Technology Sublicense Agreement dated June&nbsp;1, 2011, we granted to IRI a non-exclusive sublicense, for non-commercial purposes, to the rights under the Sublicense Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the time that we entered into the 2011 IRI Collaboration Agreement, Mr.&nbsp;Varner was not an officer or director of Genprex, but he was
deemed to be an &#147;affiliate of the Company due to his beneficial ownership of approximately 39% of our issued and outstanding shares. At the time we acquired the Oncoprex technologies under the 2009 IRI Collaboration Agreement, they were the
subject of the Phase I Monotherapy Trial. We completed the Phase I Monotherapy Trial and did substantial process development, manufacturing and regulatory work necessary to bring the technologies into the currently ongoing Phase I/II Combination
Trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the MD Anderson License Agreement, the Sublicense Agreement and the 2009 IRI Collaboration Agreement, we are obligated to
pay all fees, patent related expenses, royalties, and other amounts that become due with respect to the licensed patents, patent application and other technologies. We are also obligated to pay to MD Anderson royalties of 1.5% of net sales
attributed to sales of the licensed products, as well as 1.5% of advance payments received by us (excluding amounts paid to us in reimbursement of development or other costs) from third parties pursuant to sublicense, marketing, distribution or
franchise arrangements. Under the 2011 IRI Collaboration Agreement, we are obligated to pay to IRI a royalty of 1.0% of net sales of licensed products and 1.0% of certain other payments received by us. This royalty obligation continues for 21 years
after the later of the termination of the MD Anderson License Agreement and the termination of the Sublicense Agreement. We have no other payment obligations to IRI under the 2009 IRI Collaboration Agreement or the 2011 IRI Collaboration Agreement.
We were not required to make any up-front payments to MD Anderson or IRI when we entered into the MD Anderson License Agreement, the Sublicense Agreement or the 2009 IRI Collaboration Agreement.&nbsp;Under the 2011 IRI Collaboration Agreement, we
were required to make payments of $30,000 per month to IRI. We made 14 of these monthly payments, totaling $420,000, to IRI in 2011 and 2012, and our obligation to make such monthly payments was terminated in 2012. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our rights under the MD Anderson License Agreement are made subject to the rights of the U.S. government to the extent that the technology
covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government. Additionally, to the extent there is any conflict between the MD Anderson License Agreement and applicable laws or
regulations, applicable laws and regulations will prevail.&nbsp;Similarly, to the extent there is any conflict between the MD Anderson License Agreement and MD Anderson&#146;s funding agreement with the US government, the terms of the funding
agreement will prevail. Some, and possibly all, of our licensed intellectual property rights from MD Anderson have been developed in the course of research funded by the U.S. government. As a result, the U.S. government may have certain rights to
intellectual property embodied in our current or future products pursuant to the Bayh-Dole Act </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of 1980. Government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any
governmental purpose. In addition, the U.S. government has the right to require us, or an assignee or exclusive licensee to such inventions, to grant licenses to any of these inventions to a third party if the U.S. government determines that
adequate steps have not been taken to commercialize the invention, that government action is necessary to meet public health or safety needs, that government action is necessary to meet requirements for public use under federal regulations, or that
the right to use or sell such inventions is exclusively licensed to an entity within the U.S. and substantially manufactured outside the U.S. without the U.S. government&#146;s prior approval. Additionally, we may be restricted from granting
exclusive licenses for the right to use or sell our inventions created pursuant to such agreements unless the licensee agrees to additional restrictions (e.g., manufacturing substantially all of the invention in the U.S.). The U.S. government also
has the right to take title to these inventions if we fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. In addition, the U.S. government may acquire
title in any country in which a patent application is not filed within specified time limits. Additionally, certain inventions are subject to transfer restrictions during the term of these agreements and for a period thereafter, including sales of
products or components, transfers to foreign subsidiaries for the purpose of the relevant agreements, and transfers to certain foreign third parties. If any of our intellectual property becomes subject to any of the rights or remedies available to
the U.S. government or third parties pursuant to the Bayh-Dole Act of 1980, this could impair the value of our intellectual property and could adversely affect our business. The U.S. government has not exercised any of these rights or provided us
with any notice of its intent to exercise any of these rights with respect to any of the intellectual property licensed to us by MD Anderson.&nbsp;We are not aware of any instance in which the U.S. government has ever exercised any such rights with
respect to any technologies or other intellectual property developed under funding agreements with the U.S. government. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current Phase
I/II Combination Trial is being conducted at MD Anderson pursuant to a Clinical Study Agreement between Genprex and MD Anderson dated February&nbsp;10, 2014. Under this agreement, MD Anderson agreed to conduct the Phase I/II Combination Trial under
the study protocol, which includes treatment of up to 57 patients, and Genprex agreed to pay up to $1,738,818 to MD Anderson for conducting the clinical trial. As of September 30, 2017, we have paid approximately $492,000 to MD Anderson pursuant to
this agreement, and a total of 28 patients have been enrolled in the Phase I/II Combination Trial. This Clinical Study Agreement has a term of five years and may be terminated earlier by us upon thirty days&#146; notice, with due regard for the
health and safety of the study subjects.&nbsp;In addition, we and MD Anderson may terminate the Clinical Study Agreement immediately by written agreement, MD Anderson may terminate the agreement immediately if the principal investigator of the Phase
I/II Combination Trial is unable to continue to serve and we and MD Anderson cannot agree on an acceptable successor, and either we or MD Anderson may terminate the agreement if necessary for the safety, health or welfare of the clinical trial
subjects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2015, we entered into an option agreement with MD Anderson. This option agreement grants exclusive rights to us to
negotiate, until December&nbsp;31, 2017, an exclusive license agreement related to patents covering both a method for treating cancer and biomarker technology that would allow us to identify patients who might benefit from this treatment. We paid MD
Anderson $10,000 for this option agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2017, we entered into a second option agreement with MD Anderson. This option
agreement grants exclusive rights to us to negotiate, until December&nbsp;31, 2017, an exclusive license agreement related to technology that would provide patent protection for the use of TUSC2 with checkpoint inhibitors. We paid MD Anderson
$12,803 for this option agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement with P53, Inc. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;26, 2010, IRI and P53, Inc. entered into a Technology License Agreement, referred to as the P53 License Agreement, pursuant to
which IRI granted to P53, Inc., or P53, a worldwide, exclusive license under certain patents related to the nanovesicle delivery system that we are now using for the delivery of TUSC2, but </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
only for P53&#146;s use in gene therapy products in which the sole active genes are p53 and MDA-7. As a result of the 2009 IRI Collaboration Agreement, we are the licensor under the P53 License
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The P53 License Agreement authorizes P53 to develop, make and have made, use, offer for sale, sell, import and otherwise
distribute the licensed products. P53 agreed to submit quarterly reports of activities to IRI including at least such information as would allow IRI to calculate the amount owing to IRI on account of such activities, as well as P53&#146;s
calculation of such amounts. As consideration for the P53 License Agreement, P53 agreed to pay IRI one-half of all amounts invoiced by MD Anderson to IRI, up to a maximum of $15,000 to be paid by P53, for patent prosecution expenses incurred prior
to the effective date of the P53 License Agreement, as well as two-thirds (2/3)&nbsp;of IRI&#146;s ongoing patent prosecution expenses, in each case with respect to the licensed patents. Additionally, P53 agreed to pay all amounts that become due to
IRI as a result of the P53 License Agreement or the sales, licensing, or other activities of P53 under the P53 License Agreement. Pursuant to the P53 License Agreement, P53 has granted to IRI a fully-paid license with respect to improvements made by
P53 to the technology licensed to P53 under the P53 License Agreement. The P53 License Agreement remains in effect until the expiration of the last of the patents licensed under the agreement. The last licensed patent under the P53 License Agreement
will expire in May 2020. We may terminate the agreement in the event of P53&#146;s voluntary or involuntary bankruptcy or dissolution, assignment for the benefit of creditors or if a receiver or trustee is appointed over P53&#146;s business or
properties.&nbsp;In addition, we may terminate the agreement in the event of P53&#146;s breach of the agreement or if P53 challenges the validity or enforceability of any of the licensed patents. P53 may terminate the agreement upon 90 days&#146;
written notice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Grants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
received grants from the following entities: Texas Emerging Technology Fund, SBA&#151;Small Business Innovation Research, or SBIR, program, the National Institutes of Health and the United States Department of the Treasury. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and
pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. We have competitors in the United States, Europe and elsewhere, including major multinational pharmaceutical companies, established
biotechnology companies, specialty pharmaceutical and generic drug companies and universities and other research institutions. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unmet medical need for more effective cancer therapies is such that anticancer
drugs are, by a significant margin, the leading class of drugs in development. These include a wide array of products against cancer targeting many of the same indications as our drug candidates. There are a number of drugs approved and under
development for treatment of lung cancer. Treatments competitive with our primary product candidates generally fall into the following categories: chemotherapies such as cisplatin, carboplatin, docetaxel and pemetrexed; targeted therapies such as
erlotinib, gefitinib, afatinib and osimertinib, and immunotherapies such as checkpoint inhibitors and CAR and CAR T cells, and oncolytic virus-based technology. Data indicate that Oncoprex, when combined with targeted therapies and immunotherapies,
may enhance the benefit of those therapies; therefore, we believe that Oncoprex could be administered in combination with targeted therapies and immunotherapies and thus may not be a direct competitor of those drugs. In addition, new drug candidates
are constantly being conceived and developed. Any such competing therapy may be more effective and/or cost-effective than ours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of
our competitors have greater financial and other resources, such as larger research and development staff and more experienced marketing and manufacturing organizations than we do. Large pharmaceutical companies, in particular, have extensive
experience in clinical testing, obtaining regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research, sales and marketing capabilities and collaborative arrangements
in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the
product candidates that we develop obsolete. As a result of these factors, our competitors may succeed in obtaining patent protection and/or FDA approval or discovering, developing and commercializing drugs for the cancer indications that we are
targeting before we do or may develop drugs that are deemed to be more effective or gain greater market acceptance than ours. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large, established companies. In addition, many universities and private and public research institutes may become active in our target disease areas. Our competitors may succeed in developing, acquiring or licensing on an
exclusive basis, technologies and drug products that are more effective or less costly than any product candidates that we are currently developing or that we may develop, which could render our products obsolete or noncompetitive. Any product
candidates that we successfully develop and commercialize may compete with existing and new therapies that may become available in the future. The availability of reimbursement from government and other third-party payers will also significantly
affect the pricing and competitiveness of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial opportunities could be substantially limited in the event that our
competitors develop and commercialize products that are more effective, safer, less toxic, more convenient or less expensive than our comparable products. In geographies that are critical to our commercial success, competitors may also obtain
regulatory approvals before us, resulting in our competitors building a strong market position in advance of our product&#146;s entry. We believe the competitive factors that will determine the success of our programs will be the efficacy, safety,
pricing and reimbursement, and convenience of our current and potential product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the U.S., at the federal, state and local level, and other countries extensively regulate, among other things, the
research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, recordkeeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as
those we are developing. The pharmaceutical drug product candidates that we develop must be approved by the FDA before they may be legally marketed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the Food and Drug Administration, or FDA, regulates pharmaceutical products under the Federal Food, Drug and Cosmetic
Act and implementing regulations. Pharmaceutical products are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local
and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, the approval process or after
approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or
partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within the FDA, the Center for Biologics Evaluation and Research, or CBER, regulates gene therapy products. CBER works closely with the
National Institutes of Health, or NIH, and its Recombinant DNA Advisory Committee, or RAC, which makes recommendations to the NIH on gene therapy issues and engages in a public discussion of scientific, safety, ethical and societal issues related to
proposed and ongoing gene therapy protocols. The FDA and the NIH have published guidance documents with respect to the development and submission of gene therapy protocols, including informed consent documents. The FDA also has published guidance
documents related to, among other things, gene therapy products in general, their preclinical assessment, observing patients involved in gene therapy studies for delayed adverse events, potency testing, and chemistry, manufacturing and control
information in gene therapy Investigational New Drugs, or INDs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ethical, social, and legal concerns about gene therapy, genetic testing, and genetic research
could result in additional regulations restricting or prohibiting the processes we may use. Federal and state agencies, congressional committees and foreign governments have expressed interest in further regulating biotechnology. More restrictive
regulations or claims that our products are unsafe or pose a hazard could prevent us from commercializing any products. New government requirements may be established that could delay or prevent regulatory approval of our current and potential
product candidates under development. It is impossible to predict whether legislative changes will be enacted, regulations, policies, or guidance changed, or interpretations by agencies or courts changed, or what the impact of such changes, if any,
may be. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Biological Products Development Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process required by the FDA before a biological product, including our Oncoprex product candidate, may be marketed in the United States
generally involves the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">completion of preclinical laboratory tests and animal studies according to good laboratory practices, or GLPs, and applicable requirements for the humane use of laboratory animals or other applicable regulations;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission to the FDA of an application for an IND, which must become effective before human clinical trials may begin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">performance of adequate and well-controlled human clinical trials according to the FDA&#146;s regulations, commonly referred to as good clinical practices, or GCPs, and any additional requirements for the protection of
human research patients and their health information, to establish the safety, purity, and potency of the proposed biological product for its intended use; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission to the FDA of a BLA for marketing approval that includes substantive evidence of safety, purity, and potency from results of nonclinical testing and clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the product is produced and tested to assess compliance with current Good Manufacturing Practice, or cGMP, requirements to
assure that the facilities, methods and controls are adequate to preserve the product&#146;s identity, strength, quality and purity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the BLA; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">FDA review and approval, or licensure, of the BLA. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before testing any product candidate,
including a gene therapy product, in humans, the product candidate enters the preclinical testing stage. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as
well as animal studies to assess the potential safety and activity of the product candidate. The conduct of certain preclinical tests must comply with federal regulations and requirements, including GLPs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where a gene therapy study is conducted at, or sponsored by, institutions receiving NIH funding for recombinant DNA research, a protocol and
related documentation has to be submitted to and the clinical trial registered with the NIH Office of Biotechnology Activities, or OBA, pursuant to the NIH Guidelines for Research Involving Recombinant DNA Molecules, or NIH Guidelines. Compliance
with the NIH Guidelines is mandatory for investigators at institutions receiving NIH funds for research involving recombinant DNA; however, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.
The NIH is responsible for convening the RAC, a federal advisory committee, which discusses protocols that raise novel or particularly important scientific, safety or ethical considerations at one of its quarterly public meetings. Current NIH
guidelines specify that RAC review of human gene transfer protocols should be limited to cases in which an oversight body, such as an Institutional Biosafety Committee or an Institutional Review Board,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or IRB, determines that a protocol would significantly benefit from RAC review, and has been determined to meet certain additional criteria. The OBA will notify the FDA and the sponsor of the
RAC&#146;s decision regarding the necessity for full public review of a gene therapy protocol. RAC proceedings and reports are posted to the OBA web site and may be accessed by the public. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any
available clinical data or literature and a proposed clinical protocol, to the FDA as part of the Investigational New Drug application, or IND. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes
effective 30 days after receipt by the FDA, unless the FDA places the clinical trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can
begin. With gene therapy protocols, if the FDA allows the IND to proceed, but the RAC decides that full public review of the protocol is warranted, the FDA will request at the completion of its IND review that sponsors delay initiation of the
protocol until after completion of the RAC review process. The FDA may also impose clinical holds on a product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold,
trials may not recommence without FDA authorization and then only under terms authorized by the FDA. We are conducting a Phase I/II clinical trial pursuant to an IND. However, we cannot be sure that issues will not arise that suspend or terminate
our IND or that submission of any new IND will result in the FDA allowing new clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the product candidate to volunteers or patients under the supervision of qualified
investigators, generally physicians not employed by or under the clinical trial sponsor&#146;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, patient
selection and exclusion criteria, and the parameters to be used to monitor patient safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events occur. Each protocol and any amendments to the protocol must
be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA&#146;s regulations comprising the GCP requirements, including the requirement that all patients provide informed consent. Further,
each clinical trial must be reviewed and approved by an independent Institutional Review Board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of
clinical trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the
informed consent, which must be signed by each clinical trial patient or his or her legal representative, and must monitor the clinical trial until completed. Clinical trials involving biological product candidates also must be reviewed by an
institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees basic and clinical research conducted at that institution. The IBC assesses the safety of the research and identifies any potential risk to public
health or the environment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase I.&nbsp;The investigational product candidate is initially introduced into human patients and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product
candidate may be inherently too toxic to be ethically administered to healthy volunteers, the initial human testing is often conducted in patients; gene therapy is usually administered to patients in Phase I trials. This is also true in situations
where toxicity can only be judged in patients with disease. An evaluation for preliminary evidence of efficacy can be performed at this time. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase II.&nbsp;The investigational product candidate is evaluated in a limited patient population to identify possible adverse effects and safety risks, to evaluate preliminarily the efficacy of the product candidate
for specific targeted diseases, and to generate hypotheses for the dosage tolerance, optimal dosage, and dosing schedule. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase III.&nbsp;Clinical trials are undertaken to evaluate further dosage, clinical efficacy, potency, and safety
in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
are intended to establish the overall risk/benefit ratio of the product candidate and provide an adequate basis for product labeling. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval clinical trials, sometimes referred to as Phase IV clinical trials, may be conducted after initial marketing approval. These
clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up. The FDA recommends that sponsors observe patients for potential gene
therapy-related delayed adverse events with agents such as those we are developing for a period of up to 15 years, including a minimum of five years of annual examinations followed by ten years of annual queries, either in person or by
questionnaire, of clinical trial patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During all phases of clinical development, regulatory agencies require extensive monitoring
and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the
FDA, the NIH and the investigators for serious and unexpected adverse events, any findings from other trials, tests in laboratory animals or <I>in vitro</I> testing that suggest a significant risk for human patients, or any clinically important
increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies
for expedited reporting. The sponsor must also notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#146;s initial receipt of the information. Phase I, Phase II and Phase
III clinical trials may not be completed successfully within any specified period, if at all. The FDA, the sponsor, or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the
patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if
the investigational product candidate has been associated with unexpected serious harm to patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are also requirements governing
the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of clinical trials of FDA-regulated products, including biologics, are required to register and disclose certain clinical trial information,
which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial is then made public as part of the
registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved. The NIH and
the FDA have a publicly accessible database, the Genetic Modification Clinical Research Information System, which includes information on gene therapy trials and serves as an electronic tool to facilitate the reporting and analysis of adverse events
on these trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with clinical trials, companies usually complete additional animal studies and also develop additional
information about the physical characteristics of the components of a product as well as finalize processes for manufacturing the components in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction
of adventitious agents with use of biological products, the Public Health Service Act, or PHS Act, emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be
capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final product. Additionally, appropriate
packaging must be selected and tested and stability studies must be conducted to demonstrate that the components of a product candidate do not undergo unacceptable deterioration over their shelf life. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Review and Approval Processes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the completion of clinical trials of an investigational biologic product, FDA approval of a BLA must be obtained before commercial
marketing of the product may begin. The BLA must include results of product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development, laboratory, and animal studies, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information. The testing and
approval processes require substantial time and effort and there can be no assurance that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee. The FDA adjusts the
PDUFA user fees on an annual basis. PDUFA also imposes annual product fees and annual establishment fees on facilities used to manufacture prescription drugs or biologics. Fee waivers or reductions are available in certain circumstances, including a
waiver of the application fee for the first application filed by a small business. No user fees are assessed on BLAs for products designated as orphan drugs, unless the application also includes a non-orphan indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within 60 days following submission, the FDA reviews the BLA to determine if it is substantially complete before the agency accepts it for
filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to an initial filing
review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe and
potent, or effective, for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#146;s identity, safety, strength, quality, potency and
purity. The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a
recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations when making decisions. During the product approval
process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy, or REMS, is necessary to assure the safe use of the product. If the FDA concludes that a REMS is needed, the sponsor of the BLA must submit a proposed REMS; the
FDA will not approve the BLA without a REMS, if required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving a BLA, the FDA will inspect the facilities at which the
product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in substantial compliance with cGMP requirements and adequate to assure consistent production of the product
within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites, to assure that the clinical trials were conducted in compliance with GCP requirements. To assure cGMP, GLP and GCP
compliance, an applicant must incur significant expenditure of time, money, and effort in the areas of training, record keeping, production, and quality control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory
criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently from how we interpret the same data. If the agency decides not to approve the BLA in its present form,
the FDA will issue a complete response letter that usually describes all of the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example,
requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the
applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a
product candidate receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the
FDA may require that certain contraindications, warnings, or precautions be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a risk management plan, or otherwise limit the
scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as Phase IV clinical trials, designed to assess further a biological product&#146;s safety and effectiveness, and testing and surveillance
programs to monitor the safety of approved products that have been commercialized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the performance goals agreed to by the FDA
under the PDUFA is to review 90% of original standard BLAs within 10 months of the 60 day filing date and 90% of original priority BLAs within six months of the 60 day filing date, whereupon a review decision is to be made. The FDA does not always
meet its PDUFA goal dates for standard and priority BLAs and its review goals are subject to change from time to time. The review process and the PDUFA goal date may be extended by three months if the FDA requests or the BLA sponsor otherwise
provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drug Designation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition,
which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making a
drug or biological product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan product designation must be requested before submitting a BLA. After the FDA grants orphan product
designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.
There can be no assurance that we will receive Orphan-Drug Designation for any indications or for any of our current and potential product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product candidate that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has
such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication for seven years, except in limited
circumstances, such as a showing of clinical superiority to the product with orphan exclusivity. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for
the same product but for a different indication for which the orphan product has exclusivity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Expedited Development and Review
Programs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has four programs in place intended to facilitate and expedite development and review of new drugs and biologics
intended to address unmet medical needs in the treatment of serious or life-threatening conditions. These are Fast Track Designation, Breakthrough Therapy Designation, Accelerated Approval Program, and Priority Review Designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Fast Track program is intended to expedite or facilitate the process for reviewing a new product if it is intended for the treatment of a
serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. Fast Track Designation applies to the combination of the product and the specific indication for
which it is being studied. The sponsor of a new drug or biologic may request the FDA to designate the drug or biologic as a Fast Track product at any time during the clinical development of the product. Unique to a Fast Track product, the FDA may
consider for review sections of the marketing application on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of
the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A new product can receive Breakthrough Therapy Designation if it is intended, alone or in
combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that it may demonstrate substantial improvement over existing therapies on one or more clinically
significant endpoints, such as substantial treatment effects observed early in clinical development. A Breakthrough Therapy Designation conveys all of the features of Fast Track Designation in addition to more intensive FDA guidance on an efficient
development program, organizational commitment involving senior managers, and eligibility for priority review. Specifically, FDA intends to expedite the development and review of a Breakthrough Therapy by, where appropriate, intensively involving
senior managers and experienced review staff in a proactive collaborative, cross-disciplinary review. Where appropriate, FDA also intends to assign a cross-disciplinary project lead for the review team to facilitate an efficient review of the
development program. The FDA notes that a compressed drug development program still must generate adequate data to demonstrate that the drug or biologic meets the statutory standard for approval. Omitting components of the development program that
are necessary for such a determination can significantly delay, or even preclude, marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Breakthrough Therapy Designation
indicates that preliminary clinical evidence demonstrates the drug may have substantial improvement on one or more clinically significant endpoints over available therapy. Breakthrough Therapy Designation intensifies FDA involvement to ensure an
efficient drug development program and is an organizational commitment from the FDA to involve its senior managers. A sponsor receiving Breakthrough Therapy Designation has up to six months after receiving the Breakthrough Therapy Designation to
request an Initial Comprehensive Multidisciplinary meeting to discuss the drug development program. This initial meeting is a Type B meeting, used to discuss the overarching, high-level plan for drug development. These discussions include topics
such as planned clinical trials and endpoints, any resizing or adaptations to the trials, plans for expediting the manufacturing development strategy and studies that potentially could be completed after approval. When Breakthrough Therapy
Designation has been granted, the FDA is encouraged to meet regularly with the sponsor and subsequent meetings are considered Type B meetings and are established based on the needs of the program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may grant accelerated approval under its Accelerated Approval Program to a product candidate for a serious or life-threatening
condition upon a determination that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or an effect on a clinical endpoint that can be measured earlier than an effect on irreversible
morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of
alternative treatments. Accelerated approval is usually contingent on a sponsor&#146;s agreement to conduct adequate and well-controlled additional post-approval trials to verify and describe the product&#146;s clinical benefit. In addition, the FDA
currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fast Track Designation, Breakthrough Therapy Designation, and Accelerated Approval do not change the standards for approval but may expedite
the development process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An application for a product candidate may be eligible to obtain Priority Review Designation if it is intended
to treat a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA will attempt to direct additional resources to the evaluation of an application for a new product designated for priority
review in an effort to facilitate the review. A Priority Review Designation means FDA&#146;s goal is to take action on the marketing application within six months (compared to 10 months under standard review) of the 60-day filing date. Priority
Review Designation does not change the standards for approval but may expedite the review process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that Oncoprex represents a
breakthrough, in that the TUSC2 gene is delivered with a non-viral lipid-based nanoparticle, rather than a viral vector. In addition, Oncoprex may have broad applicability to many </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cancers, and we believe that Oncoprex represents a significant improvement in safety for systemic use over previously approved products. For these reasons, we believe that our ongoing Phase II
clinical trial may provide sufficient data to support Accelerated Approval as a Breakthrough Therapy for Oncoprex immunogene therapy combined with erlotinib for the treatment of Stage IV non-small cell lung cancer patients with unmet medical needs
whose cancer has progressed on approved therapies. We intend to enroll specifically patients with an EGFR mutation but without a T790M mutation. Patients in this group have benefited from Oncoprex + erlotinib therapy in our ongoing Phase II clinical
trial, and they have no approved treatments and thus have an unmet medical need which we believe could qualify for Fast Track or Breakthrough Therapy designation. The current Phase II trial results represent a substantial improvement over the
results of the Lux-Lung afatinib trial, which we believe may qualify Oncoprex in combination with erlotinib for Fast Track or Breakthrough Therapy designation. We believe that the unmet medical need may qualify for Priority Review based on a
surrogate endpoint such as clinical benefit, response rate, or progression free survival (PFS), with eligibility for Accelerated Approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Maintaining post-approval compliance with applicable federal, state, and local statutes and regulations requires the expenditure of substantial
time and financial resources. Rigorous and extensive FDA regulation of combination products continues after approval, particularly with respect to cGMP. We rely, and expect to continue to rely, on third parties for the production and distribution of
clinical and commercial quantities of any products that we may commercialize. Manufacturers of our products are required to comply with applicable requirements in the cGMP regulations, including quality control and quality assurance and maintenance
of records and documentation. Other post-approval requirements include reporting of cGMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects,
reporting updated safety and efficacy information, and complying with electronic record and signature requirements. After a BLA is approved, the product also may be subject to official lot release. As part of the manufacturing process, the
manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA
together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#146;s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products
before releasing the lots for distribution by the manufacturer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also must comply with the FDA&#146;s advertising and promotion
requirements, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#146;s approved labeling (known as &#147;off-label use&#148;),
industry-sponsored scientific and educational activities, and promotional activities involving the internet. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on
the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or
after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical hold,
warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors,
debarment, restitution, disgorgement of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturers and other entities involved in the manufacture and distribution of approved products are required to register the establishments
where the approved products are made with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs and other laws. Accordingly, manufacturers must
continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including withdrawal of the product from the market. In addition, changes to the
manufacturing process or facility generally require prior FDA approval before being implemented. Other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review
and approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Patent Term Restoration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration, and specifics of the FDA approval of the use of our current and potential&nbsp;product candidates, some of
our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration
term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the
product&#146;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that
application. Only one patent applicable to an approved biological product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The U.S. Patent and Trademark Office, in
consultation with the FDA, reviews and approves the application for any patent term extension or restoration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Biosimilars and
Exclusivity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated approval pathway for
biological products shown to be highly similar to, or interchangeable with, an FDA-licensed reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in
terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that
it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched
after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structures of
biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BPCIA includes, among other provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A 12-year exclusivity period from the date of first licensure of the reference product, during which approval of a 351(k) application referencing that product may not be made effective; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A four-year exclusivity period from the date of first licensure of the reference product, during which a 351(k) application referencing that product may not be submitted; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">An exclusivity period for certain biological products that have been approved through the 351(k) pathway as interchangeable biosimilars. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BPCIA also establishes procedures for identifying and resolving patent disputes involving applications submitted under section 351(k) of
the PHS Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted,
adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric clinical trial in accordance with an FDA-issued &#147;Written
Request&#148; for such a clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BPCIA is complex and only beginning to be interpreted and implemented by the FDA. In
addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a
result, the ultimate effect, implementation, and meaning of the BPCIA is subject to uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Additional U.S. Regulation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in
addition to the FDA, including but not limited to, the Centers for Medicare and Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services, for instance the Office of Inspector General, the U.S. Department of
Justice, or DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments. For example, sales, marketing and scientific/educational grant programs must comply with the anti-fraud and abuse provisions of the Social
Security Act, the false claims laws, the physician payment transparency laws, the privacy and security provisions of the Health Insurance Portability and Accountability Act, or HIPAA, as amended by the Health Information Technology for Economic and
Clinical Health Act, or HITECH, and similar state laws, each as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the foregoing, state and federal laws regarding
environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, may affect our business. These and other laws govern our use,
handling and disposal of various biological, chemical, and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could
be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith is unlikely to have a material adverse effect on our business. We cannot predict,
however, how changes in these laws may affect our future operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Federal and State Fraud and Abuse Laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the
FDA, including but not limited to, CMS, other divisions of the U.S. Department of Health and Human Services, for instance, the Office of Inspector General, DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments.
These federal and state laws, which generally will not be applicable to us or our current and potential product candidates unless and until we obtain FDA marketing approval for any of our current and potential product candidates, include, among
others, anti-kickback statutes, false claims statutes, transparency laws, privacy and regulation regarding providing drug samples, sales and marketing activities and our relationships with customers and payors as follows. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits, among other things, individuals and entities from knowingly and willfully offering, paying,
soliciting, or receiving any remuneration, directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, recommending, ordering, or arranging for the purchase, lease, recommendation or order of any health care item or
service reimbursable, in whole or in part, under Medicare, Medicaid, or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers,
purchasers, and formulary managers on the other. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and practices
that involve remuneration that may be alleged to be intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Additionally,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the intent standard under the Anti-Kickback Statute was amended by the Affordable Care Act to a stricter standard such that a person or entity does not need to have actual knowledge of the
statute or specific intent to violate it in order to have committed a violation. Further, the Affordable Care Act codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes
a false or fraudulent claim for purposes of the federal civil False Claims Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIPAA created additional federal criminal statutes that
prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the
control or custody of, any healthcare benefit program, including private third-party payers, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme
or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity
does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Federal
false claims and civil monetary penalties laws, including the federal civil False Claims Act, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false, fictitious or fraudulent claim for
payment to, or approval by, the federal government, or knowingly making, using, or causing to be made or used, a false statement to get a false claim paid. Several pharmaceutical and other health care companies have been prosecuted under these laws
for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the company&#146;s
marketing of the product for unapproved, and thus non-reimbursable, uses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The majority of states also have statutes or regulations
similar to the federal Anti-Kickback Statute and false claims laws, which apply to items and services, reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also be subject to data privacy and security regulations by both the federal government and the states in which we conduct our
business. HIPAA, as amended by HITECH, and their respective implementing regulations, including the final Omnibus Rule published in 2013, imposes requirements on certain types of entities, including mandatory contractual terms, relating to the
privacy, security, and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#146;s security standards and certain privacy standards directly applicable to business associates, which are independent
contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also created four new tiers of civil monetary
penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA
laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions. In addition, many state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other and from
HIPAA in significant ways and may not have the same requirements, thus complicating compliance efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the federal
Physician Payments Sunshine Act under the Affordable Care Act, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the
Children&#146;s Health Insurance Program, with certain exceptions, annually report to CMS information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at
the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members. Failure to submit timely, accurately, and
completely the required information may result in civil monetary penalties of up to an aggregate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of $150,000 per year and up to an aggregate of $1 million per year for &#147;knowing failures&#148;. Certain states also mandate implementation of compliance programs, impose restrictions on
pharmaceutical manufacturer marketing practices, and/or require the tracking and reporting of gifts, compensation, and other remuneration to healthcare providers and entities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of the exceptions and safe harbors, it is possible that some of our business
activities could be subject to challenge under one or more of such laws. Such a challenge could have a material adverse effect on our business, financial condition, and results of operations. If our operations are found to be in violation of any of
these or any other health regulatory laws that may apply to us, we may be subject to, without limitation, significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines,
disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or
restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as part of the sales and marketing process, pharmaceutical companies frequently provide samples of approved products to
physicians. This practice is regulated by the FDA and other governmental authorities, including, in particular, requirements concerning record keeping and control procedures. Any failure to comply with the regulations may result in significant
criminal and civil penalties as well as damage to our credibility in the marketplace. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In many of the markets where we may do business in the future, the prices of pharmaceutical products are subject to direct price controls (by
law) and to reimbursement programs with varying price control mechanisms. In the United States, significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain product approval. Often private
payers follow the coverage and reimbursement decisions of the Medicare program, and it is difficult to predict how CMS may decide to cover and reimburse approved products, especially novel products, and those determinations are subject to change.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the process for determining whether a third-party payer will provide coverage for a drug product may be separate from the
process for setting the price of a drug product or for establishing the reimbursement rate that such a payer will pay for the drug product. Third-party payers may limit coverage to specific products on an approved list, also known as a formulary,
which might not include all of the FDA-approved drugs for a particular indication. A decision by a third-party payer not to cover our current and potential product candidates could reduce physician utilization of our products once approved. A
payer&#146;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payer&#146;s determination to provide coverage for a drug product does not assure that other payers will
also provide coverage for the drug product. Coverage and reimbursement for new products can differ significantly from payer to payer. As a result, the coverage determination process will require us to provide scientific and clinical support for the
use of our products to each payer separately and will be a time-consuming process. Additionally, third-party reimbursement may not be available or may not be adequate to enable us to maintain price levels sufficient to realize an appropriate return
on our investment in product development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The marketability of any product candidates for which we or our collaborators receive
regulatory approval for commercial sale may suffer if the government and third-party payers fail to provide adequate coverage and reimbursement. In addition, an emphasis on cost containment measures in the United States has increased and we expect
will continue to increase the pressure on pharmaceutical pricing. Third-party payers are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost-effectiveness of drugs,
medical devices and medical services, in addition to questioning safety and efficacy. If these third-party payers do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after FDA
approval or, if they do, the level of payment may not be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sufficient to allow us to sell our products at a profit. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is
attained for one or more products for which we or our collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Health Care Reform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2010, the Affordable Care Act was enacted, which affected, and may further affect, health care financing and delivery by both
governmental and private insurers, and therefore the pharmaceutical and biotechnology industry. The Affordable Care Act has affected and may continue to affect existing government healthcare programs and may result in the development of new
programs. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among the Affordable Care Act&#146;s provisions of importance to the pharmaceutical and biotechnology industries, in addition to
those otherwise described above, are the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some
government healthcare programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped
the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including our current and potential product candidates, that are inhaled,
infused, instilled, implanted or injected; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extension of manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals
with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage
gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending that began on
January&nbsp;1, 2011; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a licensure framework for follow on biologic products. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been judicial and
Congressional challenges to certain aspects of the Affordable Care Act. As a result, there have been delays in the implementation of, and action taken to repeal or replace, certain aspects of the Affordable Care Act. In January 2017, President Trump
signed an Executive Order directing federal agencies with authorities and responsibilities under the Affordable Care Act to waive, defer, grant exemptions from or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
delay the implementation of any provision of the Affordable Care Act that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers or manufacturers
of pharmaceuticals or medical devices. Further, in January 2017, Congress adopted a budget resolution for fiscal year 2017, or the Budget Resolution, that authorizes the implementation of legislation that would repeal portions of the Affordable Care
Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. For
example, in August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2
trillion for the fiscal year 2012 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of
up to 2%&nbsp;per fiscal year, which went into effect in April 2013 and, due to the Bipartisan Budget Act of 2015, will remain in effect through 2025 unless additional Congressional action is taken. Further, in January 2013, President Obama signed
into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period
for the government to recover overpayments to providers from three to five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that the Affordable Care Act and other
legislative reforms will result in additional downward pressure on the price that we receive for any approved product, if covered, and could seriously harm our business. Any reduction in reimbursement from Medicare and other government programs may
result in a similar reduction in payments from private payers. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. In
addition, it is possible that there will be further legislation or regulation that could harm our business, financial condition, and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Environmental Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational
Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, may affect our business. These and other laws govern our use, handling and disposal of various biological, chemical, and radioactive substances
used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material
compliance with applicable environmental laws and that continued compliance therewith is unlikely to have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Foreign Corrupt Practices Act </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. Foreign Corrupt Practices Act, to which we are subject, prohibits corporations and individuals from engaging in certain activities to
obtain or retain business or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any foreign government official, government staff member, political party, or
political candidate in an attempt to obtain or retain business or to influence otherwise a person working in an official capacity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Government Regulation Outside of the United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other
things, clinical trials and any commercial sales and distribution of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be subjected to different types of restrictions in different
countries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not we obtain FDA approval for a product, we must obtain the required approvals from
regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical
trial application equivalent to an IND prior to the commencement of human clinical trials. In the European Union, for example, a clinical trial authorization, or CTA, must be submitted to each country&#146;s national health authority and an
independent ethics committee, much like the FDA and the IRB, respectively. Once the CTA is approved in accordance with a country&#146;s requirements, clinical trials may start. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The requirements and process governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary from country to
country. In all cases, the clinical trials are to be conducted in accordance with GCP, applicable regulatory requirements, and the ethical principles that have their origin in the Declaration of Helsinki. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension, or
withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution in those countries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2017,
we had four full-time employees and one part-time employee, and accordingly, a high percentage of the work performed for our development projects is outsourced to qualified independent contractors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not subject to
any litigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2017, we received an informal demand from a former financial advisor, claiming that it is entitled to a
warrant to purchase shares of common stock equal to three percent of our outstanding shares as of December 1, 2015, with &#147;piggyback&#148; registration rights. We believe this asserted claim lacks merit, and we intend to defend the claim
vigorously. We have not reflected any expense or any effect on our capitalization or otherwise related to this demand because it is not yet possible to determine whether any effect is probable or reasonably estimable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Properties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate and executive
offices are in located in a leased facility in Austin, Texas. The current lease is month-to -month but is expected to be renegotiated in the next six months. We believe our facilities are sufficient to meet our current needs and that suitable space
will be available as and when needed. We do not own any real property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc486549_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding our executive officers and directors as of September 30, 2017. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="59%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:27.50pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive&nbsp;Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J. Rodney Varner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer, Secretary, Director and Chairman of the Board of Directors</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Julien&nbsp;L.&nbsp;Pham,&nbsp;MD,&nbsp;MPH</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Operating Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ryan M. Confer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-Employee&nbsp;Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David E. Friedman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert W. Pearson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other Significant Contributor</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James E. Rothman, PhD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Strategic Advisor to the Board of Directors</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below is biographical information about each of the individuals named in the tables above: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>J. Rodney
Varner</I></B> is a co-founder of Genprex and has served as our President, Chief Executive Officer and Secretary, and as a member of our board of directors and as Chairman of our board of directors since August 2012. Mr.&nbsp;Varner served as a
partner of the law firm Wilson&nbsp;&amp; Varner, LLP, since 1991. Mr.&nbsp;Varner has more than thirty-five years of legal experience with large and small law firms, and as outside general counsel of a Nasdaq listed company. Mr.&nbsp;Varner has
represented for-profit and non-profit companies at the board of directors or senior management levels in a wide variety of contractual, business, tax and securities matters, including technology transfers, licensing, collaboration and research
agreements, clinical trial contracts, pharmaceutical and biologics manufacturing and process development contracts, state and federal grants, including NIH and SBA grants, corporate governance and fiduciary issues, and real estate matters.
Mr.&nbsp;Varner served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. Mr.&nbsp;Varner is a
member of the State Bar of Texas and has been admitted to practice before the United States Court of Appeals for the Fifth Circuit and the United States Tax Court. He is a registered securities representative and founder of a company that is a
licensed securities broker-dealer. Mr.&nbsp;Varner holds Series 7, 24, 63, and 79 securities registrations. Mr.&nbsp;Varner received his BBA, with high honors, from Texas A&amp;M University and his J.D. from The University of Texas School of Law.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Julien L. Pham, MD, MPH </I></B>has served as our Chief Operating Officer since October 2016. In March 2013, Dr.&nbsp;Pham
co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases, and served as its Chief Medical Officer from March 2013 to September 2016. Prior to co-founding
RubiconMD, Dr.&nbsp;Pham served on the faculty at Harvard Medical School&#146;s Brigham and Women&#146;s Hospital, where he joined as a fellow in July 2008 and became an Associate Physician in the Division of Nephrology in August 2011. Dr.&nbsp;Pham
has over fifteen years of leadership experience in clinical settings and in emerging medical technology companies. During this time, he has held various research and teaching positions including Chief Residency in Internal Medicine and Pediatrics at
the University of Illinois at Chicago Medical Center, and has received multiple awards including excellence in teaching awards from AOA and Harvard Medical School. He is a board-certified internal medicine doctor and nephrologist. Dr.&nbsp;Pham has
received NIH research funding for translational research while at Harvard Medical School, and he has published in basic science, translational, and health policy fields. He holds a BS in Cell and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Molecular Biology from University of Washington and received his MD from the University of Washington School of Medicine and his MPH at the Harvard School of Public Health. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ryan M. Confer</I></B> has served as our Chief Financial Officer since September 2016. From December 2013 through September 2016, he
served as our Chief Operating and Financial Officer, and from June 2011 to December 2013 as our business Manager. Mr.&nbsp;Confer has served us in a variety of strategic, operations, and finance capacities since our inception in 2009 both as a
consultant through his own firm, Confer Capital, Inc., and as an employee. Mr.&nbsp;Confer has over ten years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating
and chief financial roles for non-profit and for-profit entities since 2008. Mr.&nbsp;Confer has also served as an international business development consultant for the University of Texas at Austin&#146;s IC2 Institute, where he focused on
evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Mr.&nbsp;Confer holds a BS in finance and legal studies from
Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Mr.&nbsp;Varner, Dr.&nbsp;Pham and Mr.&nbsp;Confer is currently a full-time employee of Genprex.&nbsp;Mr.&nbsp;Varner spends fewer
than 10 hours per month on duties relating to Wilson&nbsp;&amp; Varner, LLP; Dr.&nbsp;Pham spends fewer than 10 hours per month in continuing medical practice to comply with licensing requirements; and Mr.&nbsp;Confer spends fewer than 10 hours per
month providing financial consulting services to other companies that are not competitive with us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Non-Employee Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>David E. Friedman</I></B> has served as a member of our board of directors since August 2012. Since August 2010, Mr.&nbsp;Friedman has
served as a partner of TCG Group Holdings, an Austin, Texas based SEC-registered investment advisor to separately-managed institutional and private client accounts. In addition, since January 2012, Mr.&nbsp;Friedman has served as a managing partner
of ACM Investment Management, which manages hedge fund assets acquired from KeyCorp, the bank holding company parent of KeyBank. From 2006 to 2010, Mr.&nbsp;Friedman served as the Chief Operating Officer of Austin Capital Management, which was owned
by KeyCorp, where he led the company&#146;s non-investment functions, including all legal, finance, investor relations, technology and operations teams. Before joining Austin Capital, Mr.&nbsp;Friedman was a Director on the Global Prime Brokerage
desk of Citigroup in New York, and an associate at the law firm of Proskauer Rose in its New York headquarters. Mr.&nbsp;Friedman received his BS in management from Tulane University and his JD from Duke University School of Law. He is admitted to
the Bar of the State of New York and holds FINRA Series 4, 7, 24 and 63 securities registrations. We believe that Mr.&nbsp;Friedman&#146;s unique and valuable mix of high-level and relevant finance, legal and operations experience makes him a
well-rounded business leader and a valuable member of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Robert W. Pearson</I></B> has served as a member of
our board of directors since July 2012. In June 2009, Mr.&nbsp;Pearson joined W2O Group, a global network of complementary marketing, communications, research and development firms, and has held a number of senior positions at W2O Group, including
Chief Technology Officer, President and since February 2017, Vice Chair and Chief Innovation Officer. From March 2012 to February 2017, Mr.&nbsp;Pearson served as President of W2O, and from June 2009 to March 2012 as its Chief Technology&nbsp;&amp;
Media Officer. From 2007 to 2009, Mr.&nbsp;Pearson served as Dell Inc.&#146;s Vice President, Communities and Conversations, and before that as its Vice President, Corporate Group Communications. From 2003 to 2006, Mr.&nbsp;Pearson served as Head of
Global Corporate Communications and as Head of Global Pharma Communications at Novartis Pharmaceuticals, where he also served on the Pharma Executive Committee. Before joining Novartis, Mr.&nbsp;Pearson served as President, The Americas and Chair,
Healthcare Practice for GCI Group, a global public relations consultancy, and was responsible for creating and building the firm&#146;s global healthcare practice. Mr.&nbsp;Pearson previously served as Vice President of Media and Public Affairs at
Rhone-Poulenc Rorer, or RPR (now Sanofi-Aventis) and worked at RPR and Ciba-Geigy in communications and pharmaceutical field </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sales. Mr.&nbsp;Pearson holds a BA from the University of North Carolina at Greensboro and an MBA from Fairleigh Dickinson University. We believe that Mr.&nbsp;Pearson&#146;s senior management
experience at international pharmaceutical companies and public relations/ investor relations firms, as well as with start up businesses, and his knowledge and personal contacts in the pharmaceutical industry, and his business management acumen,
make him a valuable member of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>James E. Rothman, Ph.D.</I></B> has served as a Strategic Advisor to our
board of directors since July 2012. Dr.&nbsp;Rothman serves as Sterling Professor and Chair of the Department of Cell Biology at Yale University School of Medicine, where he has been employed since July 2008. From 2003 to 2007, he served as chief
scientist and executive committee member at GE Healthcare, a unit of General Electric Corporation, and held similar positions at Amersham plc prior to its acquisition by GE. Dr. Rothman was awarded the 2013 Nobel Prize in Physiology or Medicine and
has received numerous other honors including the Lasker Basic Research Award. Previously, Dr.&nbsp;Rothman held endowed chairs at Memorial Sloan-Kettering Cancer Center, where he also served as Vice Chair of the Sloan-Kettering Institute, at the
College of Physicians and Surgeons at Columbia University, and at Princeton University. He is a member of the US National Academies of Sciences and Medicine and a Fellow of the American Academy of Arts and Sciences. Dr. Rothman received his B.A.
from Yale College and his Ph.D. in Biological Chemistry from Harvard University, where he also attended Harvard Medical School. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Scientific&nbsp;&amp;
Medical Advisory Board </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive team is supported by our Scientific&nbsp;&amp; Medical Advisory Board, or SMA Board, the members
of which include scientists experienced in epidermal growth factor receptor mutations, molecular and cellular oncology, molecularly targeted therapies and non-small cell lung cancer research. We have compensated the members of our Scientific
Advisory Board, other than Dr.&nbsp;Pasi Antero Janne, with grants of options to purchase our common stock. We have agreed to pay Dr.&nbsp;Janne cash compensation for each meeting of our Scientific Advisory Board that he attends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Jack A. Roth, MD, FACS,</I></B>&nbsp;is the Chairman of our SMA Board. Dr.&nbsp;Roth is an internationally renowned cancer expert and
oncology pioneer. He is Professor and Distinguished Chair of Thoracic Surgery, Professor of Molecular&nbsp;&amp; Cellular Oncology, Director of the Keck Center for Innovative Cancer Therapies, and Chief of Section of Thoracic Molecular Oncology at
The University of Texas MD Anderson Cancer Center. Dr.&nbsp;Roth is a prolific inventor and the author of more than 600 peer reviewed publications. He is a pioneer in the clinical use of DNA as a therapeutic agent. He is the first clinical
investigator approved by the FDA and NIH-RAC to conduct direct patient gene therapy clinical trials. Dr.&nbsp;Roth has over 20 years&#146; experience in developing new cancer therapeutics for commercial application and is an inventor of our key
intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Pasi Antero Janne, MD, PhD,</I></B> is an Associate Professor of Medicine at Harvard Medical School and a
clinician at Dana-Farber Cancer Institute Lowe Center for Thoracic Oncology. Dr.&nbsp;Janne is a leading researcher in medical oncology and lung cancer and is Co-Leader of the Lung Cancer Program at Dana-Farber Harvard Cancer Center. His research
includes the study of epidermal growth factor receptor mutations in non-small cell lung cancer and their impact on the efficacy of EGFR-targeted therapeutic agents, as well as mechanisms of sensitivity and resistance targeted cancer therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Tony S.K. Mok, BMSc, MD, FRCPC, FHKCP, FHKAM (Medicine),</I></B> is a professor in the Department of Clinical Oncology at the Chinese
University of Hong Kong in Prince of Wales Hospital in Hong Kong. Dr.&nbsp;Mok formerly served as President of the International Association for the Study of Lung Cancer (IASLC), Vice-Secretary General of the Chinese Society of Clinical Oncology
(CSCO) and Co-Founder of the Lung Cancer Research Group, a multicenter organization serving the Asian-Pacific region. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>George Simon,
MD</I></B>, is a Professor of Medicine and Section Chief, Translational Research, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, where his principal focus
includes translational research in lung cancer to predict the most effective therapeutic options based upon a tumor&#146;s molecular profile. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary responsibilities of our board of directors are to provide oversight, strategic guidance, counseling and direction to our
management. Our board of directors meets on a regular basis and additionally as required. Our board of directors currently consists of three directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with our amended and restated certificate of incorporation, which will become effective immediately prior to the completion of
this offering, our board of directors will be divided into three classes with staggered, three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election
and qualification until the third annual meeting following election. Effective upon the closing of this offering, our directors will be divided among the three classes as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class I director will be David Friedman, and his term will expire at our first annual meeting of stockholders following this offering; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class II director will be Robert Pearson, and his term will expire at our second annual meeting of stockholders following this offering; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class III director will be Rodney Varner, and his term will expire at the third annual meeting of stockholders following this offering. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to and
upon the completion of this offering, will provide that the authorized number of directors may be changed only by resolution of the board of directors. Any additional directorships resulting from an increase in the number of directors will be
distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our
management or a change in control of our company. Our directors may be removed only for cause by the affirmative vote of the holders of at least two-thirds of our outstanding voting stock entitled to vote in the election of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the
completion of this offering, we anticipate that our common stock will be listed on The Nasdaq Capital Market. Under the listing requirements and rules of The Nasdaq Capital Market, independent directors must constitute a majority of a listed
company&#146;s board of directors within 12 months after its initial public offering. In addition, the rules of The Nasdaq Capital Market require that, subject to specified exceptions and phase-in periods following its initial public offering, each
member of a listed company&#146;s audit, compensation and nominating and governance committee be independent, and that a listed company&#146;s audit committee must have at least three members and a listed company&#146;s compensation committee must
have at least two members. Under the rules of The Nasdaq Capital Market, a director will only qualify as an &#147;independent director&#148; if, in the opinion of that company&#146;s board of directors, that person does not have a relationship that
would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to rely on the
phase-in rules of The Nasdaq Capital Market with respect to the independence of our board of directors and the audit committee. In accordance with these phase-in provisions, our board of directors and the audit, compensation, and nominating and
corporate governance committees will have at least one independent member by the effective date of the registration statement of which this prospectus is a part, at least two independent members within 90 days of the effective date of the
registration statement of which this prospectus is a part and all members will be independent within one year of the effective date of the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Audit committee members must also satisfy independence criteria set forth in Rule 10A-3 under the Exchange Act, or Rule 10A-3. To be
considered to be independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of a company&#146;s audit </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
committee, the company&#146;s board of directors or any other board committee: (1)&nbsp;accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company
or any of its subsidiaries; or (2)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors
has undertaken a review of its composition, the composition of its committees and the independence of each director. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations,
including family relationships, our board of directors has determined that other than Rodney Varner, our President and CEO who serves on the board of directors as the Chairman, each of our directors does not have a relationship that would interfere
with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#147;independent&#148; as that term is defined under the applicable rules and regulations of the listing requirements
and rules of The Nasdaq Capital Market and under the applicable rules and regulations of the SEC. In making this determination, our board of directors considered the current and prior relationships that each non-employee director has with us and all
other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each non-employee director. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors
has established an audit committee, a compensation committee and a nominating and corporate governance committee. Our board of directors may establish other committees to facilitate the management of our business. The composition and functions of
each committee are described below. Members serve on these committees until their resignation or until otherwise determined by our board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Audit Committee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit committee
consists of David Friedman and Robert Pearson. The chair of our audit committee is Mr.&nbsp;Friedman, who our board of directors has determined is an &#147;audit committee financial expert&#148; as that term is defined by the SEC rules implementing
Section&nbsp;407 of the Sarbanes-Oxley Act, and possesses financial sophistication, as defined under the listing standards of The Nasdaq Capital Market. Our board of directors has also determined that each member of our audit committee can read and
understand fundamental financial statements in accordance with applicable requirements. In arriving at these determinations, the board of directors has examined each audit committee member&#146;s scope of experience and the nature of their
experience in the corporate finance sector. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The responsibilities of our audit committee include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appointing, approving the compensation of, and assessing the independence of our registered public accounting firm; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overseeing the work of our registered public accounting firm, including through the receipt and consideration of reports from such firm; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and discussing with management and the registered public accounting firm our annual and quarterly financial statements and related disclosures; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">monitoring our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discussing our risk management policies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving or ratifying any related person transactions; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preparing the audit committee report required by SEC rules. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation committee consists of David Friedman and Robert Pearson. The chair of our compensation committee is Mr.&nbsp;Pearson. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The responsibilities of our compensation committee include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving, or recommending that our board of directors approve, the compensation of our chief executive officer and our other executive officers; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and recommending to our board of directors the compensation of our directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">selecting independent compensation consultants and advisers and assessing whether there are any conflicts of interest with any of the committees compensation advisers; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving, or recommending that our board of directors approve, incentive compensation and equity plans. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nominating and Corporate Governance Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our nominating and corporate governance committee consists of David Friedman and Robert Pearson. The chair of our nominating and corporate
governance committee is Mr.&nbsp;Friedman. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The responsibilities of our nominating and corporate governance committee include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identifying individuals qualified to become members of our board; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommending to our board the persons to be nominated for election as directors and for appointment to each of the board&#146;s committees; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and making recommendations to our board with respect to management succession planning; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developing and recommending to our board corporate governance principles; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overseeing a periodic evaluation of our board. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of the Board in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee of our board is primarily responsible for overseeing our risk management processes on behalf of our board. Going forward,
we expect that the audit committee will receive reports from management on at least a quarterly basis regarding our assessment of risks. In addition, the audit committee reports regularly to our board, which also considers our risk profile. The
audit committee and our board focus on the most significant risks we face and our general risk management strategies. While our board oversees our risk management, management is responsible for day-to-day risk management team processes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the effectiveness of the registration statement of which this prospectus forms a part, we will adopt a written code of business
conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Following this
offering, a copy of the code will be made available on the Corporate Governance section of our website, which is located at www.genprex.com. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics
for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form 8-K filed with the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the members of our compensation committee has ever been an officer or employee of Genprex. None of our executive officers serves, or
has served during the last fiscal year, as a member of the board of directors, compensation committee or other board committee performing equivalent functions of any entity that has one or more executive officers serving as one of our directors or
on our compensation committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation of Liability and Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, limits
the liability of directors to the maximum extent permitted by Delaware law. Delaware law allows a corporation to eliminate the personal liability of directors of a corporation to the corporation and its stockholders for monetary damages for breach
of their fiduciary duties as directors, except for liability for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any breach of his or her duty of loyalty to the corporation or its stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of the Delaware General Corporation Law; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any transaction from which the director derived an improper personal benefit. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and
restated certificate of incorporation does not eliminate a director&#146;s duty of care and, in appropriate circumstances, equitable remedies, such as injunctive or other forms of non-monetary relief, will remain available under Delaware law. These
limitations also do not affect a director&#146;s responsibilities under any other laws, such as the federal securities laws or other state or federal laws. Our amended and restated bylaws, which will become effective upon the completion of this
offering, provide that we will indemnify our directors and executive officers and may indemnify other officers, employees and other agents, to the fullest extent permitted by law. Our amended and restated bylaws also provide that we are obligated to
advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding and also permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of
his or her actions in connection with their services to us, regardless of whether our amended and restated bylaws permit such indemnification. We have obtained a policy of directors&#146; and officers&#146; liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into, and intend to continue to enter into, separate indemnification agreements with our directors and executive officers, in
addition to the indemnification provided for in our amended and restated bylaws. These agreements, among other things, will require us to indemnify our directors and executive officers for certain expenses, including attorneys&#146; fees, judgments,
fines and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of their services as one of our directors or executive officers or any other company or enterprise to which the person provides services
at our request. We believe that these bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated
bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful,
might benefit us and our stockholders. A stockholder&#146;s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that these provisions in our amended and restated certificate of incorporation and amended and restated bylaws and these
indemnification agreements are necessary to attract and retain qualified persons as directors and officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At present, there is no
pending litigation or proceeding involving any of our directors or executive officers as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for
indemnification. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc486549_12"></A>EXECUTIVE OFFICER AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers for the year ended December&nbsp;31, 2016, which consist of our principal executive officer and our two other
most highly compensated executive officers, are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">J. Rodney Varner, our President and Chief Executive Officer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Julien L. Pham, M.D., M.P.H., our Chief Operating Officer; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ryan M. Confer, our Chief Financial Officer </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Compensation Table </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:97.90pt; font-size:8pt; font-family:Times New Roman"><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards</B><br><B>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All other<BR>compensation<BR>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>J. Rodney Varner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">763,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">868,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Julien L. Pham</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Operating Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">436,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">486,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ryan M. Confer</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">In accordance with SEC rules, this column reflects the aggregate grant date fair value of the stock option awards granted during 2016. These amounts have been computed in accordance with FASB ASC Topic&nbsp;718.
Assumptions used in the calculation of these amounts are described in Note 5 to our financial statements included elsewhere in this prospectus. These amounts do not reflect the actual economic value that will be realized by the named executive
officer upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">This column reflects medical and term life insurance premiums paid by us on behalf of each of the named executive officers. The insurance benefits are provided to the named executive officers on the same terms as
provided to all of our regular full-time employees. For more information regarding these benefits, see below under &#147;&#151;Perquisites, Health, Welfare and Retirement Benefits.&#148; </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Annual Base Salary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The base salary of
our named executive officers is generally determined and approved periodically or in connection with the commencement of employment of the executive, by our board of directors. As of December&nbsp;31, 2016, base salaries for our named executive
officers, which became effective as of October&nbsp;1, 2016 for Mr.&nbsp;Varner and Mr.&nbsp;Confer, and as of October&nbsp;23, 2016 for Dr.&nbsp;Pham, are provided below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016&nbsp;Base<BR>Salary</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J. Rodney Varner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Julien Pham</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ryan Confer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bonus Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time our board of directors or compensation committee may approve bonuses for our named executive officers based on individual
performance, company performance or as otherwise determined appropriate. In 2016, our executive officers were not entitled to any target or minimum bonus and no specific performance goals or bonus program were established for our named executive
officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Dr.&nbsp;Pham&#146;s employment agreement, he is entitled to a bonus in the amount of
$65,000 in the event he is employed by us for at least one year and during his first year of employment we receive at least $12&nbsp;million of funding from sources other than government sources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Mr.&nbsp;Varner&#146;s employment agreement, he is eligible to receive an annual cash bonus in the amount of $357,646 upon the
achievement of performance objectives mutually agreed between Mr. Varner and the board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Mr.&nbsp;Confer&#146;s
employment agreement, he is eligible to receive an annual cash bonus in the amount of $120,399 upon the achievement of performance objectives mutually agreed between Mr. Confer and the board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity-Based Incentive Awards </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
equity-based incentive awards are designed to align our interests and those of our stockholders with those of our employees and consultants, including our named executive officers. The board of directors is responsible for approving equity grants.
As of the date of this prospectus, stock option awards were the only form of equity awards we granted to our named executive officers in 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have historically used stock options as an incentive for long-term compensation to our named executive officers because they are able to
profit from stock options only if our stock price increases relative to the stock option&#146;s exercise price, which exercise price is set at no less than the fair market value of our common stock on the date of grant. We may grant equity awards at
such times as our board of directors determines appropriate. Our executives generally are awarded an initial grant in the form of a stock option in connection with their commencement of employment with us. Additional grants may occur periodically in
order to specifically incentivize executives with respect to achieving certain corporate goals or to reward executives for exceptional performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, we have granted all stock options pursuant to our 2009 Equity Incentive Plan. Following this offering, we will grant
equity incentive awards under the terms of our 2017 Equity Incentive Plan. The terms of our equity plans are described below under &#147;&#151;Equity Benefit Plans.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All options are granted with an exercise price per share that is no less than the fair market value of our common stock on the date of grant
of such award. Our stock option awards generally vest over a four-year period and may be subject to acceleration of vesting and exercisability under certain termination and change in control events. See &#147;&#151;Outstanding Equity Awards at
Fiscal Year-End.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2016, the board of directors granted an option to purchase 645,572 shares of common stock to
Mr.&nbsp;Varner and an option to purchase 161,396 shares of common stock to Mr.&nbsp;Confer. Each of these options has an exercise price equal to $0.96 per share, was fully vested on the date of grant, and may be exercised with respect to vested
shares subject to the option for a period of five years following the cessation of the optionee&#146;s continued service with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
November 2016, the board of directors granted an option to purchase 162,800 shares of common stock to Dr.&nbsp;Pham and an option to purchase 86,894 shares of common stock to Mr.&nbsp;Confer. The options granted to Dr.&nbsp;Pham and Mr.&nbsp;Confer
have exercise prices equal to $5.29 per share. The option granted to Dr.&nbsp;Pham is subject to a 48-month vesting schedule, subject to Dr.&nbsp;Pham&#146;s continued service with us. The option granted to Mr.&nbsp;Confer was fully vested on the
date of grant. The options granted to Dr.&nbsp;Pham and Mr.&nbsp;Confer may be exercised with respect to vested shares subject to the option for a period of five years following the cessation of the optionee&#146;s continued service with us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreements with Named Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employment Agreement with Julien Pham </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
October 2016, we entered into an employment agreement with Dr.&nbsp;Pham, our Chief Operating Officer. Dr.&nbsp;Pham&#146;s employment under the agreement is at will and may be terminated at any time by us or by him. Under the terms of the
agreement, Dr.&nbsp;Pham is initially entitled to receive an annual base salary of $285,000 and an option to purchase shares of our common stock under our 2009 Plan, which was granted on November&nbsp;3, 2016. The agreement provides for a target
bonus of up to $65,000, as described above under &#147;&#151;Bonus Compensation&#148; and provides for an option to purchase shares of common stock described above under &#147;&#151;Equity-Based Incentive Awards.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement provides that during the term of Dr.&nbsp;Pham&#146;s employment with us and for one year after the termination of his
employment, Dr.&nbsp;Pham will not encourage any of our employees or consultants to leave Genprex and will not compete or assist others to compete with us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Dr.&nbsp;Pham is employed by us for at least one year and we terminate Dr.&nbsp;Pham&#146;s employment without cause or if Dr.&nbsp;Pham
resigns for good reason, we are obligated to pay Dr.&nbsp;Pham, subject to our having at least $5&nbsp;million in cash or cash equivalents and a net worth of at least $5 million on the date of termination, a severance payment equal to six months of
Dr.&nbsp;Pham&#146;s base salary then in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of Dr.&nbsp;Pham&#146;s employment agreement, &#147;cause&#148; means
the occurrence of any of the following events: (i)&nbsp;his failure or inability to perform his duties as described in the employment agreement; or (ii)&nbsp;his breach of the employment agreement. For purposes of Dr.&nbsp;Pham&#146;s employment
agreement, &#147;good reason&#148; means the occurrence of any of the following events: (i)&nbsp;Dr.&nbsp;Pham is not paid compensation under the employment agreement when due; (ii)&nbsp;Dr.&nbsp;Pham&#146;s job title is changed without his consent;
(iii)&nbsp;we or stockholders acting in concert sell a majority of our issued and outstanding shares in one transaction or a series of coordinated transactions to a single buyer or a group of buyers acting in concert with each other; or (iv)&nbsp;we
sell substantially all of our assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employment Agreement with Rodney Varner </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to enter into an employment agreement with Mr. Varner, our President and Chief Executive Officer, which will become effective upon the
closing of this offering. Mr. Varner&#146;s employment under the agreement is at will and may be terminated at any time by us or by him. Under the terms of the agreement, Mr.&nbsp;Varner is initially entitled to receive an annual base salary of
$476,861. The agreement provides for a target bonus of up to $357,646, as described above under &#147;&#151;Bonus Compensation&#148; and provides that the Company may grant to Mr. Varner options to purchase shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement provides that during the term of Mr. Varner&#146;s employment with us and for one year after the termination of his employment,
Mr. Varner will not encourage any of our employees or consultants to leave Genprex and will not compete or assist others to compete with us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, prior to a change of control, we terminate Mr. Varner&#146;s employment without cause or if Mr. Varner resigns for good reason, and Mr.
Varner delivers to us a signed settlement agreement and general release of claims, we are obligated to pay Mr. Varner: (i) a severance payment equal to 18 months of Mr. Varner&#146;s base salary then in effect; (ii) a payment equal to Mr.
Varner&#146;s then applicable annual target bonus, calculated at full attainment; (iii) reimbursement of COBRA premium payments made by Mr. Varner for the 12 months following such termination; and (iv) acceleration as to 100% of Mr. Varner&#146;s
unvested equity awards from us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, within 12 months following a change of control, Mr. Varner&#146;s employment is terminated without
cause or Mr. Varner resigns for good reason, and he delivers to us a signed settlement agreement and general release of claims, we are obligated to pay Mr. Varner: (i) a severance payment equal to 18 months of Mr.&nbsp;Varner&#146;s base salary then
in effect; (ii) a payment equal to Mr. Varner&#146;s then applicable target bonus for 18 months, calculated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
at full attainment; (iii) reimbursement of COBRA premium payments made by Mr. Varner for the 18 months following such termination; and (iv) acceleration as to 100% of Mr. Varner&#146;s unvested
equity awards from us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of Mr. Varner&#146;s employment agreement, &#147;cause&#148; means the occurrence of any of the
following events: (i) a determination by our board of directors that Mr. Varner&#146;s performance is unsatisfactory after there has been delivered to him a written demand for performance which describes the specific deficiencies in his performance
and the specific manner in which his performance must be improved, and which provides 30&nbsp;business days from the date of notice to remedy such performance deficiencies; (ii) Mr. Varner&#146;s conviction of or plea of nolo contendere to a felony
or a crime involving moral turpitude which our board of directors reasonably finds has had or will have a detrimental effect on our reputation or business; (iii)&nbsp;Mr.&nbsp;Varner&#146;s engaging in an act of gross negligence or willful
misconduct in the performance of his employment obligations and duties that materially harms us; (iv) Mr. Varner&#146;s committing an act of fraud against, material misconduct or willful misappropriation of property belonging to us; or (v) Mr.
Varner&#146;s material breach of his confidentiality, invention assignment and noncompetition agreement with us or of any other unauthorized misuse of our trade secrets or proprietary information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of Mr. Varner&#146;s employment agreement, &#147;good reason&#148; means the occurrence of any of the following taken without Mr.
Varner&#146;s written consent and conditioned on (a) his providing us with notice of the basis for such resignation for good reason, (b) our failure to cure the event constituting good reason within 30&nbsp;days after notice and (c) his termination
of his employment within 30 days following the expiration of the cure period: (i) a material change in Mr. Varner&#146;s position, titles, offices or duties; (ii) an assignment of any significant duties to Mr. Varner that are inconsistent with his
positions or offices held under his employment agreement; (iii) a decrease in Mr. Varner&#146;s then current annual base salary by more than 10% (other than in connection with a general decrease in the salary of all of our other similarly situated
employees); or (iv) the relocation of Mr. Varner to a facility or a location more than 50 miles from his then current location. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employment Agreement
with Ryan Confer </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to enter into an employment agreement with Mr. Confer, our Chief Financial Officer, which will become
effective upon the closing of this offering. Mr. Confer&#146;s employment under the agreement is at will and may be terminated at any time by us or by him. Under the terms of the agreement, Mr.&nbsp;Confer is initially entitled to receive an annual
base salary of $300,997. The agreement provides for a target bonus of up to $120,399, as described above under &#147;&#151;Bonus Compensation&#148; and provides that the Company may grant to Mr. Confer options to purchase shares of common stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement provides that during the term of Mr. Confer&#146;s employment with us and for one year after the termination of his
employment, Mr. Confer will not encourage any of our employees or consultants to leave Genprex and will not compete or assist others to compete with us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we terminate Mr. Confer&#146; employment without cause or if Mr. Confer resigns for good reason, and Mr.&nbsp;Confer delivers to us a
signed settlement agreement and general release of claims, we are obligated to pay Mr.&nbsp;Confer: (i) a severance payment equal to 12 months of Mr. Confer&#146; base salary then in effect; (ii) a payment equal to Mr. Confer&#146;s then applicable
annual target bonus, calculated at full attainment; (iii) reimbursement of COBRA premium payments made by Mr. Confer for the 12 months following such termination; and (iv)&nbsp;acceleration as to 100% of Mr. Confer&#146;s unvested equity awards from
us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of Mr. Confer&#146;s employment agreement, &#147;cause&#148; means the occurrence of any of the following events:
(i) a determination by our board of directors that Mr. Confer&#146;s performance is unsatisfactory after there has been delivered to him a written demand for performance which describes the specific deficiencies in his performance and the specific
manner in which his performance must be improved, and which provides 30 business days from the date of notice to remedy such performance deficiencies; (ii) Mr. Confer&#146;s conviction of or plea of nolo contendere to a felony or a crime involving
moral turpitude which our board of directors reasonably finds has had or will have a detrimental effect on our reputation or business; (iii)&nbsp;Mr.&nbsp;Confer&#146;s engaging in an act </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of gross negligence or willful misconduct in the performance of his employment obligations and duties that materially harms us; (iv) Mr. Confer&#146;s committing an act of fraud against, material
misconduct or willful misappropriation of property belonging to us; or (v) Mr. Confer&#146;s material breach of his confidentiality, invention assignment and noncompetition agreement with us or of any other unauthorized misuse of our trade secrets
or proprietary information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of Mr. Confer&#146;s employment agreement, &#147;good reason&#148; means the occurrence of any
of the following taken without Mr. Confer&#146;s written consent and conditioned on (a) his providing us with notice of the basis for such resignation for good reason, (b) our failure to cure the event constituting good reason within 30&nbsp;days
after notice and (c) his termination of his employment within 30 days following the expiration of the cure period: (i) a material change in Mr. Confer&#146;s position, titles, offices or duties; (ii) an assignment of any significant duties to Mr.
Confer that are inconsistent with his positions or offices held under his employment agreement; (iii) a decrease in Mr. Confer&#146;s then current annual base salary by more than 10% (other than in connection with a general decrease in the salary of
all of our other similarly situated employees); or (iv) the relocation of Mr. Confer to a facility or a location more than 50 miles from his then current location. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any potential payments and benefits due upon a qualifying termination of employment or a change in control are further described below under
&#147;&#151;Potential Payments and Benefits upon Termination or Change in Control.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential Payments and Benefits upon Termination or Change in
Control </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regardless of the manner in which a named executive officer&#146;s service terminates, each named executive officer is
entitled to receive amounts earned during his term of service, including unpaid salary. In addition, each Dr.&nbsp;Pham, Mr. Varner and Mr. Confer is entitled to receive certain benefits upon our termination of his employment without cause or his
resignation for good reason, and Mr. Varner is entitled to receive certain additional benefits upon such a termination or resignation within 12 months after a change of control, all as provided above under &#147;&#151;Agreements with Named Executive
Officers.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of our named executive officers holds stock options that were granted subject to the general terms of our 2009 Plan.
A description of the termination and change in control provisions in our 2009 Plan and applicable to the stock options granted to our named executive officers is provided below under &#147;&#151;Equity Benefit Plans&#148; and &#147;&#151;Outstanding
Equity Awards at Fiscal Year-End&#148; and above under &#147;&#151;Equity-Based Incentive Awards.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at Fiscal Year-End
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding equity awards granted to our named executive officers that were
outstanding as of December&nbsp;31, 2016. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>securities<BR>underlying<BR>unexercised<BR>option (#)<BR>exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>securities<BR>underlying<BR>unexercised<BR>option (#)<BR>unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option</B><br><B>exercise<BR>price</B><br><B>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>expiration<BR>date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J. Rodney Varner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/11/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">645,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/11/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Julien Pham</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/3/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,023</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/3/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ryan Confer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/25/2012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/25/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/11/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/11/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/3/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/3/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">All of the outstanding stock option awards were granted under and subject to the terms of the 2009 Equity
Incentive Plan, described below under &#147;&#151;Equity Benefit Plans.&#148; As of December&nbsp;31, 2016, each option award becomes exercisable as it becomes vested and all vesting is subject to the executive&#146;s continuous
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
service with us through the vesting dates and the potential vesting acceleration described above under &#147;&#151;Potential Payments and Benefits upon Termination or Change in Control.&#148;
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">All of the stock option awards were granted with a per share exercise price no less than the fair market value of one share of our common stock on the date of grant, as determined in good faith by our board of
directors. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">3,362 shares will vest each month until October&nbsp;25, 2020. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option Repricings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not engage in any repricings or other modifications or cancellations to any of our named executive officers&#146; outstanding equity
awards during the fiscal year ended December&nbsp;31, 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Perquisites, Health, Welfare and Retirement Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers, during their employment with us, are eligible to participate in our employee benefit plans, including our
medical, dental, vision, employee whole life, disability and accidental death and dismemberment insurance plans, in each case on the same basis as all of our other employees. We do not provide a 401(k) plan to our employees at this time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally do not provide perquisites or personal benefits to our named executive officers, except in limited circumstances. We do, however,
pay the premiums for medical, dental, vision, employee whole life, disability and accidental death and dismemberment insurance for all of our employees, including our named executive officers. Our board of directors may elect to adopt qualified or
nonqualified benefit plans in the future if it determines that doing so is in our best interests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nonqualified Deferred Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not maintain nonqualified defined contribution plans or other nonqualified deferred compensation plans. Our board of directors may elect
to provide our officers and other employees with nonqualified defined contribution or other nonqualified deferred compensation benefits in the future if it determines that doing so is in our best interests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Benefit Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2017 Equity Incentive Plan
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors and stockholders plan to approve and adopt the 2017 Plan which will become effective upon the closing of this
offering. No awards may be granted under the 2017 Plan prior to the completion of this offering. On and after such date, no further grants will be made under the 2009 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Awards</I>. The 2017 Plan provides for the grant of incentive stock options, or ISOs, nonstatutory stock options, or NSOs, stock
appreciation rights, restricted stock awards, restricted stock unit awards, performance-based stock awards, and other forms of equity compensation, which we refer to collectively as stock awards. Additionally, the 2017 Plan provides for the grant of
performance cash awards. ISOs may be granted only to employees. All other awards may be granted to employees, including officers, and to non-employee directors and consultants of us and our affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Share Reserve</I>. Initially, the aggregate number of shares of our common stock that may be issued pursuant to stock awards under the 2017
Plan after the 2017 Plan becomes effective is 7,328,749 shares, which is the sum of (1)&nbsp;4,234,391 new shares, plus (2)&nbsp;the number of shares reserved for issuance under our 2009 Plan at the time our 2017 Plan becomes effective, plus
(3)&nbsp;any shares subject to outstanding stock options or other stock awards that would have otherwise returned to our 2009 Plan (such as upon the expiration or termination of a stock award prior to vesting). Additionally, the number of shares of
our common stock reserved for issuance under our 2017 Plan will automatically increase on January&nbsp;1 of each year, beginning on January&nbsp;1, 2018 (assuming the 2017 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Plan becomes effective before such date) and continuing through and including January&nbsp;1, 2027, by 5% of the total number of shares of our capital stock outstanding on December&nbsp;31 of the
preceding calendar year, or a lesser number of shares determined by our board of directors. The maximum number of shares that may be issued upon the exercise of ISOs under our 2017 Plan is 9,400,000 shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No person may be granted stock awards covering more than 1,175,000 shares of our common stock under our 2017 Plan during any calendar year
pursuant to stock options, stock appreciation rights and other stock awards whose value is determined by reference to an increase over an exercise or strike price of at least 100% of the fair market value on the date the stock award is granted.
Additionally, no person may be granted in a calendar year a performance stock award covering more than 2,350,000 shares or a performance cash award having a maximum value in excess of $2,000,000. Such limitations are designed to help assure that any
deductions to which we would otherwise be entitled with respect to such awards will not be subject to the $1,000,000 limitation on the income tax deductibility of compensation paid to any covered executive officer imposed by Section&nbsp;162(m) of
the Code. In addition, the maximum number of shares of our common stock subject to stock awards granted under the 2017 Plan during any one calendar year to any non-employee director will not exceed $1,000,000 in total value, or, with respect to the
calendar year in which a non-employee director is first appointed or elected to our board of directors, $2,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a stock award
granted under the 2017 Plan expires or otherwise terminates for any reason prior to exercise or settlement, the shares of our common stock not acquired pursuant to the stock award again will become available for subsequent issuance under the 2017
Plan. In addition, the following types of shares under the 2017 Plan may become available for the grant of new stock awards under the 2017 Plan: (1)&nbsp;shares that are forfeited to or repurchased by us prior to becoming fully vested;
(2)&nbsp;shares withheld to satisfy income or employment withholding taxes; or (3)&nbsp;shares used to pay the exercise or purchase price of a stock award. Shares issued under the 2017 Plan may be previously unissued shares or reacquired shares
bought by us on the open market. As of the date hereof, no awards have been granted and no shares of our common stock have been issued under the 2017 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Administration</I>. Our board of directors, or a duly authorized committee thereof, has the authority to administer the 2017 Plan. Our
board of directors may also delegate to one or more of our officers the authority to (1)&nbsp;designate employees (other than officers) to be recipients of certain stock awards, and (2)&nbsp;determine the number of shares of common stock to be
subject to such stock awards. Subject to the terms of the 2017 Plan, our board of directors or the authorized committee, referred to herein as the plan administrator, determines recipients, dates of grant, the numbers and types of stock awards to be
granted and the terms and conditions of the stock awards, including the period of their exercisability and vesting schedule applicable to a stock award. Subject to the limitations set forth below, the plan administrator will also determine the
exercise price, strike price or purchase price of awards granted and the types of consideration to be paid for the award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The plan
administrator has the authority to modify outstanding awards under our 2017 Plan. Subject to the terms of our 2017 Plan, the plan administrator has the authority to reduce the exercise, purchase or strike price of any outstanding stock award, cancel
any outstanding stock award in exchange for new stock awards, cash or other consideration, or take any other action that is treated as a repricing under generally accepted accounting principles, with the consent of any adversely affected
participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Options</I>. ISOs and NSOs are granted pursuant to stock option agreements adopted by the plan administrator. The
plan administrator determines the exercise price for a stock option, within the terms and conditions of the 2017 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our common stock
on the date of grant. Options granted under the 2017 Plan vest at the rate specified by the plan administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The plan administrator
determines the term of stock options granted under the 2017 Plan, up to a maximum of 10 years. Unless the terms of an optionholder&#146;s stock option agreement provide otherwise, if an optionholder&#146;s service relationship with us, or any of our
affiliates, ceases for any reason other than disability, death or cause, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the optionholder may generally exercise any vested options for a period of three months following the cessation of service. The option term may be extended in the event that exercise of the
option following such a termination of service is prohibited by applicable securities laws or our insider trading policy. If an optionholder&#146;s service relationship with us or any of our affiliates ceases due to disability or death, or an
optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 12 months in the event of disability and 18 months in the event of death. In the
event of a termination for cause, all options generally terminate immediately upon the termination of the individual for cause. In no event may an option be exercised beyond the expiration of its term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the plan
administrator and may include (1)&nbsp;cash, check, bank draft or money order, (2)&nbsp;a broker-assisted cashless exercise, (3)&nbsp;the tender of shares of our common stock previously owned by the optionholder, (4)&nbsp;a net exercise of the
option if it is an NSO, and (5)&nbsp;other legal consideration approved by the plan administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the plan administrator provides
otherwise, options generally are not transferable except by will, the laws of descent and distribution, or pursuant to a domestic relations order. An optionholder may designate a beneficiary, however, who may exercise the option following the
optionholder&#146;s death. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Tax Limitations on Incentive Stock Options</I>. The aggregate fair market value, determined at the time of
grant, of our common stock with respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all of our stock plans and the stock plans of any of our affiliates may not exceed $100,000. Options or
portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any
of our affiliates unless (1)&nbsp;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant, and (2)&nbsp;the term of the ISO does not exceed five years from the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Awards</I>.&nbsp;Restricted stock awards are granted pursuant to restricted stock award agreements adopted by the plan
administrator. Restricted stock awards may be granted in consideration for (1)&nbsp;cash, check, bank draft or money order, (2)&nbsp;services rendered to us or our affiliates, or (3)&nbsp;any other form of legal consideration. Common stock acquired
under a restricted stock award may, but need not, be subject to a share repurchase option in our favor in accordance with a vesting schedule to be determined by the plan administrator. A restricted stock award may be transferred only upon such terms
and conditions as set by the plan administrator. Except as otherwise provided in the applicable award agreement, restricted stock that has not vested will be forfeited or repurchased by us upon the participant&#146;s cessation of continuous service
for any reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Unit Awards</I>.&nbsp;Restricted stock unit awards are granted pursuant to restricted stock unit
award agreements adopted by the plan administrator. Restricted stock unit awards may be granted in consideration for any form of legal consideration. A restricted stock unit award may be settled by cash, delivery of stock, a combination of cash and
stock as deemed appropriate by the plan administrator, or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in respect of shares covered by a restricted
stock unit award. Except as otherwise provided in the applicable award agreement, restricted stock units that have not vested will be forfeited upon the participant&#146;s cessation of continuous service for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights</I>. Stock appreciation rights are granted pursuant to stock appreciation grant agreements adopted by the plan
administrator. The plan administrator determines the strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of our common stock on the date of grant. Upon the exercise of a stock appreciation
right, we will pay the participant an amount equal to the product of (1)&nbsp;the excess of the per share fair market value of our common stock on the date of exercise over the strike price, multiplied by (2)&nbsp;the number of shares of common
stock with respect to which the stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
appreciation right is exercised. A stock appreciation right granted under the 2017 Plan vests at the rate specified in the stock appreciation right agreement as determined by the plan
administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The plan administrator determines the term of stock appreciation rights granted under the 2017 Plan, up to a maximum of 10
years. Unless the terms of a participant&#146;s stock appreciation right agreement provides otherwise, if a participant&#146;s service relationship with us or any of our affiliates ceases for any reason other than cause, disability or death, the
participant may generally exercise any vested stock appreciation right for a period of three months following the cessation of service. The stock appreciation right term may be further extended in the event that exercise of the stock appreciation
right following such a termination of service is prohibited by applicable securities laws. If a participant&#146;s service relationship with us, or any of our affiliates, ceases due to disability or death, or a participant dies within a certain
period following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation right for a period of 12 months in the event of disability and 18 months in the event of death. In the event of a
termination for cause, stock appreciation rights generally terminate immediately upon the occurrence of the event giving rise to the termination of the individual for cause. In no event may a stock appreciation right be exercised beyond the
expiration of its term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Performance Awards</I>.&nbsp;The 2017 Plan permits the grant of performance-based stock and cash awards that
may qualify as performance-based compensation that is not subject to the $1,000,000 limitation on the income tax deductibility of compensation paid to a covered executive officer imposed by Section&nbsp;162(m) of the Code. To help assure that the
compensation attributable to performance-based awards will so qualify, our compensation committee can structure such awards so that stock or cash will be issued or paid pursuant to such award only after the achievement of certain pre-established
performance goals during a designated performance period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The performance goals that may be selected include one or more of the
following: (1)&nbsp;earnings (including earnings per share and net earnings); (2)&nbsp;earnings before interest, taxes and depreciation; (3)&nbsp;earnings before interest, taxes, depreciation and amortization; (4)&nbsp;earnings before interest,
taxes, depreciation, amortization and legal settlements; (5)&nbsp;earnings before interest, taxes, depreciation, amortization, legal settlements and other income (expense); (6)&nbsp;earnings before interest, taxes, depreciation, amortization, legal
settlements, other income (expense) and stock-based compensation; (7)&nbsp;earnings before interest, taxes, depreciation, amortization, legal settlements, other income (expense), stock-based compensation and changes in deferred revenue;
(8)&nbsp;earnings before interest, taxes, depreciation, amortization, legal settlements, other income (expense), stock-based compensation, other non-cash expenses and changes in deferred revenue; (9)&nbsp;total stockholder return; (10)&nbsp;return
on equity or average stockholder&#146;s equity; (11)&nbsp;return on assets, investment, or capital employed; (12)&nbsp;stock price; (13)&nbsp;margin (including gross margin); (14)&nbsp;income (before or after taxes); (15)&nbsp;operating income;
(16)&nbsp;operating income after taxes; (17)&nbsp;pre-tax profit; (18)&nbsp;operating cash flow; (19)&nbsp;sales or revenue targets; (20)&nbsp;increases in revenue or product revenue; (21)&nbsp;expenses and cost reduction goals;
(22)&nbsp;improvement in or attainment of working capital levels; (23)&nbsp;economic value added (or an equivalent metric); (24)&nbsp;market share; (25)&nbsp;cash flow; (26)&nbsp;cash flow per share; (27)&nbsp;cash balance; (28)&nbsp;cash burn;
(29)&nbsp;cash collections; (30)&nbsp;share price performance; (31)&nbsp;debt reduction; (32)&nbsp;implementation or completion of projects or processes (including, without limitation, discovery of a preclinical drug candidate, recommendation of a
drug candidate to enter a clinical trial, clinical trial initiation, clinical trial enrollment and dates, clinical trial results, regulatory filing submissions (such as IND, BLA and NDA), regulatory filing acceptances, regulatory or advisory
committee interactions, regulatory approvals, and product supply); (33)&nbsp;stockholders&#146; equity; (34)&nbsp;capital expenditures; (35)&nbsp;financings; (36)&nbsp;operating profit or net operating profit; (37)&nbsp;workforce diversity;
(38)&nbsp;growth of net income or operating income; (39)&nbsp;employee retention; (40)&nbsp;initiation of studies by specific dates; (41)&nbsp;budget management; (42)&nbsp;submission to, or approval by, a regulatory body (including, but not limited
to the FDA) of an applicable filing or a product; (43)&nbsp;regulatory milestones; (44)&nbsp;progress of internal research or development programs; (45)&nbsp;progress of partnered programs; (46)&nbsp;partner satisfaction; (47)&nbsp;timely completion
of clinical trials; (48)&nbsp;milestones related to research development (including, but not limited to, preclinical and clinical studies), product development and manufacturing; (49)&nbsp;expansion of sales in additional geographies or markets;
(50)&nbsp;research progress, including the development of programs; (51)&nbsp;strategic partnerships or transactions (including in-licensing and out-licensing of intellectual property; (52)&nbsp;filing of patent applications and granting of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patents; and (53)&nbsp;and to the extent that an award is not intended to comply with Section&nbsp;162(m) of the Code, other measures of performance selected by our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The performance goals may be based on a company-wide basis, with respect to one or more business units, divisions, affiliates, or business
segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise (1)&nbsp;in the award agreement at the time the award is granted
or (2)&nbsp;in any other document setting forth the performance goals at the time the goals are established, we will appropriately make adjustments in the method of calculating the attainment of performance goals as follows: (a)&nbsp;to exclude
restructuring and/or other nonrecurring charges; (b)&nbsp;to exclude exchange rate effects; (c)&nbsp;to exclude the effects of changes to generally accepted accounting principles; (d)&nbsp;to exclude the effects of any statutory adjustments to
corporate tax rates; (e)&nbsp;to exclude the effects of any &#147;items of an unusual nature or of infrequency of occurrence or non-recurring items&#148; as determined under generally accepted accounting principles; (f)&nbsp;to exclude the dilutive
effects of acquisitions or joint ventures; (g)&nbsp;to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such divestiture; (h)&nbsp;to exclude the effect
of any change in the outstanding shares of our common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate
change, or any distributions to common stockholders other than regular cash dividends; (i)&nbsp;to exclude the effects of stock based compensation and the award of bonuses under our bonus plans; (j)&nbsp;to exclude costs incurred in connection with
potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; (k)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally
accepted accounting principles; (l)&nbsp;to exclude the effect of any other unusual, non-recurring gain or loss or other extraordinary item; and (m)&nbsp;to exclude the effects of the timing of acceptance for review and/or approval of submissions to
the FDA or any other regulatory body. In addition, we retain the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of the goals. The performance goals may differ from participant to participant and from award
to award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Other Stock Awards</I>.&nbsp;The plan administrator may grant other awards based in whole or in part by reference to our
common stock. The plan administrator will set the number of shares under the stock award and all other terms and conditions of such awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure</I>.&nbsp;In the event that there is a specified type of change in our capital structure, such as a stock
split or recapitalization, appropriate adjustments will be made to (1)&nbsp;the class and maximum number of shares reserved for issuance under the 2017 Plan, (2)&nbsp;the class and maximum number of shares by which the share reserve may increase
automatically each year, (3)&nbsp;the class and maximum number of shares that may be issued upon the exercise of ISOs, (4)&nbsp;the class and maximum number of shares subject to stock awards that can be granted to any person in a calendar year (as
established under the 2017 Plan pursuant to Section&nbsp;162(m) of the Code), and (5)&nbsp;the class and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding stock awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions</I>. In the event of certain specified significant corporate transactions (or a change in control, as described
below), the plan administrator has the discretion to take any of the following actions with respect to stock awards: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">arrange for the assumption, continuation or substitution of a stock award by a surviving or acquiring entity or parent company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">arrange for the assignment of any reacquisition or repurchase rights held by us to the surviving or acquiring entity or parent company; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">accelerate the vesting of the stock award and provide for its termination prior to the effective time of the transaction; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">arrange for the lapse of any reacquisition or repurchase right held by us; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cancel or arrange for the cancellation of the stock award in exchange for such cash consideration, if any, as our board of directors may deem appropriate; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make a payment equal to the excess of (a)&nbsp;the value of the property the participant would have received upon exercise of the stock award immediately prior to the effective time of the transaction, over (b)&nbsp;the
exercise price otherwise payable by the participant in connection with such exercise. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our plan administrator is not
obligated to treat all stock awards, even those that are of the same type, in the same manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2017 Plan, a corporate
transaction is generally the consummation of (1)&nbsp;a sale or other disposition of all or substantially all of our assets, (2)&nbsp;a sale or other disposition of more than 50% of our outstanding securities, (3)&nbsp;a merger, consolidation or
similar transaction following which we are not the surviving corporation, or (4)&nbsp;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our common stock outstanding immediately prior to
such transaction are converted or exchanged into other property by virtue of the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Change in Control</I>.&nbsp;In addition
to the above, the plan administrator may provide, in an individual award agreement or in any other written agreement between a participant and us that the stock award will be subject to additional acceleration of vesting and exercisability in the
event of a change in control. Under the 2017 Plan, a change in control is generally (1)&nbsp;the acquisition by a person or entity of more than 50% of our combined voting power other than by merger, consolidation or similar transaction; (2)&nbsp;a
consummated merger, consolidation or similar transaction immediately after which our stockholders cease to own more than 50% of the combined voting power of the surviving entity (or its parent); (3)&nbsp;a consummated sale, lease, exclusive license
or other disposition of all or substantially of our assets; (4)&nbsp;a complete dissolution or liquidation of the Company, except for a liquidation into a parent corporation; or (5)&nbsp;when a majority of our board of directors becomes comprised of
individuals who were not serving on our board of directors on the date of adoption of the 2017 Plan, or the incumbent board, or whose nomination, appointment, or election was not approved by a majority of the incumbent board then still in office.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment and Termination</I>.&nbsp;Our board of directors has the authority to amend, suspend, or terminate our 2017 Plan, provided
that such action does not impair the existing rights of any participant without such participant&#146;s written consent. No ISOs may be granted after the 10th anniversary of the date our board of directors adopted our 2017 Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2009 Equity Incentive Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of
directors and our stockholders approved our 2009 Plan in November 2009. The 2009 Plan was subsequently amended by our board of directors and stockholders, most recently in August 2012. As of September&nbsp;30, 2017, there were 465,609 shares
remaining available for the grant of stock awards under our 2009 Plan and there were outstanding stock options covering a total of 2,628,749 shares that were granted under our 2009 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the effective date of the 2017 Plan, no additional awards will be granted under the 2009 Plan, and all outstanding awards granted under
the 2009 Plan that are repurchased, forfeited, expire or are canceled will become available for grant under the 2017 Plan in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock awards</I>.&nbsp;The 2009 Plan provides for the grant of ISOs, NSOs, stock appreciation rights, restricted stock awards, restricted
stock unit awards, performance stock awards and other stock awards, or collectively, stock awards. With the exception of ISOs, all stock awards may be granted to employees, including officers, and to our non-employee directors and consultants and
those of our affiliates. ISOs may be granted only to employees. We have only granted stock options under the 2009 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Share Reserve</I>.&nbsp;As of the date of this prospectus, the aggregate number of shares of
our common stock that have been reserved for issuance pursuant to awards under the 2009 Plan is 3,802,879. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a stock award granted under
the 2009 Plan is forfeited to us or repurchased by us because of the failure to meet a contingency or condition required for vesting, such shares will become available for subsequent issuance under the 2009 Plan or the 2017 Plan, after its effective
date. In addition, shares withheld to satisfy income or employment withholding taxes and shares used to pay the exercise price of a stock option will become available for the grant of new stock awards under the 2009 Plan. Shares issued under the
2009 Plan may be authorized but unissued or reacquired common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Administration</I>.&nbsp;Our board of directors, or a duly
authorized committee thereof, has the authority to administer the 2009 Plan. Subject to the terms of the 2009 Plan, our board of directors or the authorized committee, referred to herein as the plan administrator, determines recipients, dates of
grant, the numbers and types of stock awards to be granted and the terms and conditions of the stock awards, including the period of their exercisability and vesting schedule applicable to a stock award. Subject to the limitations set forth below,
the plan administrator will also determine the exercise price, strike price or purchase price of awards granted and the types of consideration to be paid for the award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The plan administrator has the authority to modify outstanding awards under our 2009 Plan. Subject to the terms of our 2009 Plan, the plan
administrator has the authority to reduce the exercise price of any outstanding stock option, cancel any outstanding stock option in exchange for new stock awards, cash or other consideration, or take any other action that is treated as a repricing
under generally accepted accounting principles, with the consent of any adversely affected participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Options</I>. ISOs and
NSOs are granted pursuant to stock option agreements adopted by the plan administrator. The plan administrator determines the exercise price for a stock option, within the terms and conditions of the 2009 Plan, provided that the exercise price of a
stock option generally cannot be less than 100% of the fair market value of our common stock on the date of grant. Options granted under the 2009 Plan vest at the rate specified by the plan administrator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The plan administrator determines the term of stock options granted under the 2009 Plan, up to a maximum of 10 years. Unless the terms of an
optionholder&#146;s stock option agreement provide otherwise, if an optionholder&#146;s service relationship with us, or any of our affiliates, ceases for any reason other than disability or death, the optionholder may generally exercise any vested
options for a period of three months following the cessation of service, with respect to employee optionholders. The option term may be extended in the event that exercise of the option following such a termination of service is prohibited by
applicable securities laws. If an optionholder&#146;s service relationship with us or any of our affiliates ceases due to death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may
generally exercise any vested options for a period of 12 months following the date of death. If an optionholder&#146;s service relationship with us or any of our affiliates ceases due to disability, the optionholder may generally exercise any vested
options for a period of 12 months following the cessation of service. In no event may an option be exercised beyond the expiration of its term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be as determined by the plan
administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the plan administrator provides otherwise, options generally are not transferable except by will or by the laws of
descent and distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Tax Limitations on Incentive Stock Options</I>.&nbsp;The aggregate fair market value, determined at the time
of grant, of our common stock with respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all of our stock plans may not exceed $100,000. Options or portions thereof that exceed
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined
voting power or that of any of our affiliates unless (1)&nbsp;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant, and (2)&nbsp;the option is not exercisable after the
expiration of five years from the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure</I>. In the event that there is a specified type of
change in our capital structure, such as a stock split or recapitalization, appropriate adjustments will be made to (a)&nbsp;the class and maximum number of shares reserved for issuance under the 2009 Plan, (b)&nbsp;the class and maximum number of
shares that may be issued upon the exercise of ISOs, and (c)&nbsp;the class and number of shares and price per share of stock subject to all outstanding stock awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions</I>. In the event of a change in control, unless otherwise provided in a stock award or other written agreement
between us and the holder of a stock award, each stock award will be treated as the plan administrator determines, arranging for the assumption or substitution of a stock award by a successor entity. If the successor entity does not assume or
substitute for the stock award, the vesting and exercisability, if applicable, of the stock award will accelerate in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our plan
administrator is not obligated to treat all stock awards or portions thereof or all holders of stock awards, even those that are of the same type, in the same manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2009 Plan, a change in control is generally the occurrence of (1)&nbsp;any transaction or series of related transactions in which in
excess of 50% of our voting power is transferred; (2)&nbsp;the replacement of a majority of the members of our board of directors during any 12-month period by directors whose appointment or election is not endorsed by a majority of the members of
our board of directors prior to the date of such appointment or election; or (3)&nbsp;the acquisition by a third party of our assets that have a total gross fair market value equal to or more than 50% of the total gross fair market value of all of
our assets immediately prior to such acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Change in Control</I>. The plan administrator may provide, in an individual award
agreement or in any other written agreement between a participant and us that the stock award will be subject to additional acceleration of vesting and exercisability in the event of a change in control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment and Termination</I>.&nbsp;Our board of directors has the authority to amend, alter, suspend, or terminate our 2009 Plan, provided
that such action does not impair the existing rights of any participant without such participant&#146;s written consent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2017 Employee Stock Purchase
Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors and stockholders plan to adopt the ESPP. The ESPP will become effective when the Board determines to make
this benefit available to employees at a time after the completion of this offering. The purpose of the ESPP is to retain the services of new employees and secure the services of new and existing employees while providing incentives for such
individuals to exert maximum efforts toward our success and that of our affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Share Reserve</I>. Following this offering, the
ESPP authorizes the issuance of 235,000 shares of our common stock pursuant to purchase rights granted to our employees or to employees of any of our designated affiliates. The number of shares of our common stock reserved for issuance will
automatically increase on January&nbsp;1 of each calendar year, beginning on January&nbsp;1, 2018 (assuming the ESPP becomes effective before such date) and continuing through and including January&nbsp;1, 2027 by&nbsp;2% of the total number of
shares of our capital stock outstanding on December&nbsp;31 of the preceding calendar year, or a lesser number of shares determined by our board of directors. The ESPP is intended to qualify as an &#147;employee stock purchase plan&#148; within the
meaning of Section&nbsp;423 of the Code. As of the date hereof, no shares of our common stock have been purchased under the ESPP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Administration</I>. Our board of directors has delegated its authority to administer the ESPP
to our compensation committee. The ESPP is implemented through a series of offerings of purchase rights to eligible employees. Under the ESPP, we may specify offerings with durations of not more than 27 months, and may specify shorter purchase
periods within each offering. Each offering will have one or more purchase dates on which shares of our common stock will be purchased for employees participating in the offering. An offering may be terminated under certain circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Payroll Deductions</I>.&nbsp;Generally, all regular employees, including executive officers, employed by us or by any of our designated
affiliates, may participate in the ESPP and may contribute, normally through payroll deductions, up to 15% of their earnings for the purchase of our common stock under the ESPP. Unless otherwise determined by our board of directors, common stock
will be purchased for accounts of employees participating in the ESPP at a price per share equal to the lower of (a)&nbsp;85% of the fair market value of a share of our common stock on the first date of an offering or (b)&nbsp;85% of the fair market
value of a share of our common stock on the date of purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Limitations</I>.&nbsp;Employees may have to satisfy one or more of the
following service requirements before participating in the ESPP, as determined by our board of directors: (a)&nbsp;customarily employed for more than 20 hours per week, (b)&nbsp;customarily employed for more than five months per calendar year or
(c)&nbsp;continuous employment with us or one of our affiliates for a period of time (not to exceed two years). No employee may purchase shares under the ESPP at a rate in excess of $25,000 worth of our common stock based on the fair market value
per share of our common stock at the beginning of an offering for each year such a purchase right is outstanding. Finally, no employee will be eligible for the grant of any purchase rights under the ESPP if immediately after such rights are granted,
such employee has voting power over 5% or more of our outstanding capital stock measured by vote or value pursuant to Section&nbsp;424(d) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure</I>. In the event that there occurs a change in our capital structure through such actions as a stock split,
merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, liquidating dividend, combination of shares, exchange of shares, change in corporate
structure or similar transaction, the board of directors will make appropriate adjustments to (a)&nbsp;the class and number of shares reserved under the ESPP, (b)&nbsp;the class and maximum number of shares by which the share reserve may increase
automatically each year, (c)&nbsp;the class and number of shares and purchase price of all outstanding offerings and purchase rights and (d)&nbsp;the class and number of shares that are the subject of the purchase limits under each ongoing offering.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions</I>. In the event of certain significant corporate transactions, including the consummation of: (1)&nbsp;a sale
or other disposition of all or substantially all of our assets, (2)&nbsp;the sale or other disposition of more than 50% of our outstanding securities, (3)&nbsp;a merger, consolidation or similar transaction where we do not survive the transaction,
and (4)&nbsp;a merger, consolidation or similar transaction where we do survive the transaction but the shares of our common stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the
transaction, any then-outstanding rights to purchase our stock under the ESPP may be assumed, continued or substituted for by any surviving or acquiring entity (or its parent company). If the surviving or acquiring entity (or its parent company)
elects not to assume, continue or substitute for such purchase rights, then the participants&#146; accumulated payroll contributions will be used to purchase shares of our common stock within 10 business days prior to such corporate transaction, and
such purchase rights will terminate immediately after such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Amendments, Termination</I>.&nbsp;Our board of directors has
the authority to amend or terminate our ESPP, provided that, except in certain circumstances, any such amendment or termination may not materially impair any outstanding purchase rights without the holder&#146;s consent. We will obtain stockholder
approval of any amendment to our ESPP as required by applicable law or listing requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, we have not paid cash compensation to any of our non-employee directors for service on our board of directors. As set forth
below, we did pay equity compensation to our non-employee directors in 2016 for service on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2016, we
granted David Friedman an option to purchase 24,146 shares of common stock and Robert Pearson an option to purchase 24,146 shares of common stock, each at an exercise price of $6.45 per share. Each option was fully vested on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have reimbursed and will continue to reimburse all of our non-employee directors for their travel, lodging and other reasonable expenses
incurred in attending meetings of our board of directors and committees of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth in
summary form information concerning the compensation that we paid or awarded during the year ended December&nbsp;31, 2016 to each of our non-employee directors. None of our non-employee directors earned or was paid any cash during the year ended
December&nbsp;31, 2016. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David E. Friedman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert W. Pearson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">In accordance with SEC rules, this column reflects the aggregate grant date fair value of the stock option awards granted in 2016 computed in accordance with FASB ASC Topic 718. Assumptions used in the calculation of
these amounts are described in Note 5 to our financial statements included elsewhere in this prospectus. These amounts do not reflect the actual economic value that will be realized by the non-employee director upon the vesting of the stock option
awards, the exercise of the stock option awards or the sale of the common stock underlying such stock option awards. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2016, the aggregate number of shares outstanding under all options to purchase our common stock held by our non-employee directors were: Mr.&nbsp;Friedman: 45,946; and Mr.&nbsp;Pearson: 45,946.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors plans to adopt a new compensation policy in September 2017 that will become effective upon the
execution and delivery of the underwriting agreement for this offering and will be applicable to all of our non-employee directors. This compensation policy provides that each such non-employee director may receive any of the following compensation
elements for service on our board of directors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual cash retainer of $30,000; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an additional cash retainer of $15,000 to the non-executive chairman of the board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an additional cash retainer of $15,000 to the lead independent director of the board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an additional annual cash retainer of $8,000, $5,000 and $4,000 for service as a member of the audit committee, compensation committee and the nominating and corporate governance committee, respectively;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an additional annual cash retainer of $20,000, $12,000 and $7,500 for service as chairman of the audit committee, compensation committee and the nominating and corporate governance committee, respectively;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for each non-employee director who first joins our board of directors, an initial option grant to purchase shares of our common stock with a value of $175,000, pro rated monthly for the period between the date of our
last annual meeting of stockholders and the date such non-employee director first joins our board of directors, on the date of commencement of service on the board, vesting on the earlier of the one-year anniversary of the grant date or the day
prior to the next annual meeting of stockholders; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual option grant to purchase shares of our common stock having a value of $175,000 for each non-employee director serving on the board of directors on the date of our annual stockholder meeting, vesting one year
following the grant date. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the option grants described above will vest and become exercisable subject to the
director&#146;s continuous service to us, provided that each option will vest in full upon a change in control (as defined under our 2017 Plan). The term of each option will be 10 years, subject to earlier termination as provided in the 2017 Plan.
The options will be granted under our 2017 Plan, the terms of which are described in more detail above under &#147;&#151;Equity Benefit Plans&#151;2017 Equity Incentive Plan.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc486549_13"></A>RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following includes a summary of transactions since January&nbsp;1, 2014 to which we have been a party, in which the amount involved in the
transaction exceeded 1% of the average of our total assets at December&nbsp;31, 2016 and 2015, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of any class of our voting securities or any
member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under
&#147;Executive And Director Compensation.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuances of Securities to Domecq Sebastian, LLC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2016, we issued an option to purchase 161,396 shares of our common stock with an exercise price of $0.96 per share, to Domecq
Sebastian, LLC, the beneficial owner of more than 5% of a class of our voting securities which is affiliated with David Nance, a former director and officer who is now deceased, in exchange for services provided by that entity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuances of Securities to Jack A. Roth, MD, FACS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2009, pursuant to a Consulting Agreement between us and Jack A. Roth, MD, FACS, the beneficial owner of more than 5% of a class of
our voting securities and the Chairman of our SMA Board, we issued to an entity affiliated with Dr.&nbsp;Roth 1,336,839 shares of our Series A preferred stock at a purchase price of $0.0001 per share. Also pursuant to the consulting agreement, we
issue to Dr.&nbsp;Roth an aggregate of 133,683 shares of our common stock each year, pro rated in the case of 2010 for the portion of the year during which the consulting agreement was in place. We issue these shares to Dr.&nbsp;Roth at the
beginning of each calendar quarter. Under this arrangement, we issued to Dr.&nbsp;Roth an aggregate of 133,683 shares of our common stock in each of 2014, 2015 and 2016, and another 100,262 shares of our common stock in 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuances of Securities to Viet-An Hoan Ly </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Series G Preferred Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From February 2015 to September 30, 2017, we entered into a series of subscription agreements with various investment funds affiliated with
Viet-An Hoan Ly, who is, together with his affiliated investment funds, a beneficial owner of more than 5% of a class of our voting securities, pursuant to which we issued and sold to such entities an aggregate of 687,621 shares of our Series G
preferred stock at a purchase price of $5.29 per share, and received gross proceeds of approximately $3.6 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Warrants to
Purchase Preferred Stock and Common Stock </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2014, we issued to an entity affiliated with Mr.&nbsp;Ly a warrant exercisable for
19,290 shares of our Series E preferred stock, with an exercise price of $5.18 per share, and a warrant exercisable for 26,790 shares of our Series F preferred stock, with an exercise price of $3.42 per share. Each of those warrants was exercised in
full in February 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2015, an entity affiliated with Mr.&nbsp;Ly exercised a warrant that we had issued to a different entity
in December 2013 and that had been transferred to the entity affiliated with Mr.&nbsp;Ly in December 2013. The warrant was exercisable for 66,841 shares of our Series B preferred stock, with an exercise price of $2.59 per share, and was exercised in
full in February 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2016, we issued to Mr.&nbsp;Ly a warrant exercisable for an aggregate of 542,656 shares of our voting
common stock, with an exercise price of $5.29 per share. The purchase price of the warrant was $8,119. That warrant is currently exercisable, expires on November&nbsp;1, 2026, and is currently outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Options to Purchase Common Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2016, we granted to Mr.&nbsp;Ly an option to purchase 56,815 shares of our common stock, with an exercise price of $0.96 per share.
This option was fully vested at the time of grant and is currently outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuances of Securities to the Texas Treasury Safekeeping Trust
Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2010, pursuant to a Texas Emerging Technology Fund Award and Security Agreement, as amended, between us and the
Texas Office of the Governor Economic Development and Tourism, or OOGEDT, we were awarded a grant in the aggregate amount of $4.5 million. The award was received in two tranches of $2.25 million each during 2010 and 2011. In consideration for the
award, we provided the OOGEDT with an Investment Unit, consisting of a promissory note and a right to purchase shares of our preferred stock at a price equal to $0.0001 per share. In March 2014, upon receiving a Notice of Purchase from OOGEDT, we
issued to OOGEDT 1,235,219 shares of our Series B preferred stock pursuant to a cashless exercise. In September 2015, the shares were transferred to the Texas Treasury Safekeeping Trust Company, which is a beneficial owner of more than 5% of a class
of our voting securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Services Provided by Confer Capital, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We paid $32,500 in 2014, $0 in 2015 and $65,000 in 2016 to Confer Capital, Inc., an entity affiliated with Ryan Confer, our Chief Financial
Officer. Confer Capital, Inc. provided strategic, financial, and executive managerial services to us at times when Ryan Confer was not our employee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Royalty Payments to Introgen Research Institute, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to an Amended Collaboration and Assignment Agreement dated July&nbsp;1, 2011 between us and Introgen Research Institute, Inc., or IRI
(the &#147;2011 IRI Collaboration Agreement&#148;), we are obligated to IRI a royalty of 1% of net sales of licensed products and 1% of certain other payments received by us, with respect to intellectual property owned by MD Anderson and licensed to
us by IRI. This royalty obligation continues for 21&nbsp;years after the later of the termination of the MD Anderson License Agreement and the termination of the Technology Sublicense Agreement. IRI is affiliated with Rodney Varner, our President
and Chief Executive Officer and the Chairman of our board of directors. We made no payments under the 2011 IRI Collaboration Agreement in 2014, 2015 or 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment and Consulting Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2016, we entered into an employment agreement with Dr.&nbsp;Pham, our Chief Operating Officer. This agreement is described in the
section titled &#147;Executive and Director Compensation.&#148; In September 2017, we plan to enter into an employment agreement with each of Mr. Varner, our President and Chief Executive Officer and Mr. Confer, our Chief Financial Officer. Both of
these agreements will become effective upon the closing of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to a Consulting Agreement dated November&nbsp;5, 2009,
we pay to Jack A. Roth, MD, FACS, annual cash fees at the highest amount which is consistent with the policies of MD Anderson, increased annually by a percentage equal to the automatic cost of living adjustment set forth for Social Security. Under
this arrangement, we paid Dr.&nbsp;Roth an aggregate of $313,789 in 2014 (which includes an amount carried over from 2013), $185,826 in 2015 and $192,191 in 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Options Granted to Executive Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted stock options and shares of our common stock to our executive officers and directors, as more fully described in the section
titled &#147;Executive and Director Compensation.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered, and intend to continue to enter, into separate indemnification agreements with each of our directors and executive officers,
as described in &#147;Management&#151;Limitation of Liability and Indemnification.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Transactions with Related Persons
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a written related-person transactions policy that sets forth our policies and procedures regarding the identification,
review, consideration and oversight of &#147;related-person transactions.&#148; For purposes of our policy only, a &#147;related-person transaction&#148; is a transaction, arrangement or relationship (or any series of similar transactions,
arrangements or relationships) in which we and any &#147;related person&#148; are participants involving an amount that exceeds the lesser of $120,000 and one percent of the average of our total assets for our last two completed fiscal years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Transactions involving compensation for services provided to us as an employee, consultant or director are not considered related-person
transactions under this policy. A related person is any executive officer, director, nominee to become a director or a holder of more than five percent of our common stock, including any of their immediate family members and affiliates, including
entities owned or controlled by such persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the policy, where a transaction has been identified as a related-person transaction,
management must present information regarding the proposed related-person transaction to our audit committee (or, where review by our audit committee would be inappropriate, to another independent body of our board of directors) for review. The
presentation must include a description of, among other things, all of the parties thereto, the direct and indirect interests of the related persons, the purpose of the transaction, the material facts, the benefits of the transaction to us and
whether any alternative transactions are available, an assessment of whether the terms are comparable to the terms available from unrelated third parties and management&#146;s recommendation. To identify related-person transactions in advance, we
rely on information supplied by our executive officers, directors and certain significant stockholders. In considering related-person transactions, our audit committee or another independent body of our board of directors takes into account the
relevant available facts and circumstances including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risks, costs and benefits to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the impact on a director&#146;s independence in the event the related person is a director, immediate family member of a director or an entity with which a director is affiliated; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms of the transaction; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of other sources for comparable services or products; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms available to or from, as the case may be, unrelated third parties. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event a
director has an interest in the proposed transaction, the director must recuse himself or herself from the deliberations and approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc486549_14"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information as of September 30, 2017, regarding beneficial ownership of our capital stock by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each person, or group of affiliated persons, known by us to beneficially own more than 5% of any class of our voting securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our named executive officers; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our current executive officers and directors as a group. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The percentage ownership
information under the column entitled &#147;Before Offering&#148; is based on 11,688,158 shares of common stock outstanding as of September 30, 2017, assuming conversion of all outstanding shares of our convertible preferred stock into 9,324,125
shares of voting common stock, and the conversion of all of our outstanding shares of non-voting common stock into an aggregate of 171,188 shares of voting common stock, which will occur in connection with the completion of this offering. The
percentage ownership information under the columns entitled &#147;After Offering&#151;Minimum&#148; and &#147;After Offering&#151;Maximum&#148; is based on the sale of 2,500,000 shares and 4,500,000 shares, respectively of common stock in this
offering. The following table does not reflect any potential purchases in this offering by any of the stockholders listed in the table, which purchases, if any, will increase the percentage of shares owned after the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information with respect to beneficial ownership has been furnished by each director, officer or beneficial owner of more than 5% of any class
of our voting securities. We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with
respect to those securities. In addition, the rules include shares of common stock issuable pursuant to the exercise of stock options or warrants that are either immediately exercisable or exercisable on or before November 29, 2017, which is 60 days
after September&nbsp;30, 2017. These shares are deemed to be outstanding and beneficially owned by the person holding those options or warrants for the purpose of computing the percentage ownership of that person, but they are not treated as
outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as
beneficially owned by them, subject to applicable community property laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise noted below, the address for each person or entity listed in the table is c/o
Genprex, Inc., 100 Congress Ave., Suite 2000, Austin, Texas 78701. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:134.80pt; font-size:8pt; font-family:Times New Roman"><B>Name and Address of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B><br><B>Beneficially<BR>Owned</B><br><B>Before<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of<BR>Shares<BR>Beneficially<BR>Owned</B><br><B>Before<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;Shares</B><br><B>Beneficially Owned</B><br><B>After Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Minimum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% or Greater Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Domecq Sebastian, LLC(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,117,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jack A. Roth, MD, FACS(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,282,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Viet-An Hoan Ly and affiliated entities(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,494,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Texas Treasury Safekeeping Trust Company(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,235,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Named Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J. Rodney Varner(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,794,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Julien Pham(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ryan Confer(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">438,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David E. Friedman(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert W. Pearson(9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current executive officers and directors as a group (5&nbsp;persons)(5)(6)(7)(8)(9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,891,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than 1%. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;2,421,563 shares of common stock issuable upon conversion of Series A preferred stock, (b)&nbsp;534,735 shares of common stock, and (c)&nbsp;161,396 shares of common stock that Domecq Sebastian, LLC
has the right to acquire from us within 60 days of September 30, 2017 pursuant to the exercise of stock options. Domecq Sebastian, LLC is affiliated with David Nance, a former director and officer who is now deceased. Christy Mallinson Nance holds
voting and dispositive power of the securities held by Domecq Sebastian, LLC. The address of Domecq Sebastian, LLC is 8203 Scenic Ridge Cove, Austin, Texas 78735. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;1,298,999 shares of common stock issuable upon conversion of Series A preferred stock held by JREG Investments, Ltd. (b)&nbsp;949,590 shares of common stock held by Jack A. Roth, MD, FACS and
(c)&nbsp;33,421 shares of common stock that Dr.&nbsp;Roth has the right to acquire from us within 60 days of September&nbsp;30, 2017 pursuant to a consulting agreement between Dr.&nbsp;Roth and us. Dr.&nbsp;Roth holds voting and dispositive power
over the shares held by JREG Investments, Ltd. The address of JREG Investments, Ltd. and of Dr.&nbsp;Roth is 6516 Brompton Road, Houston, Texas 77005. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Consists of (a)&nbsp;87,696 shares of common stock issuable upon conversion of Series B preferred stock, 485,666
shares of common stock issuable upon conversion of Series C preferred stock and 9,645 shares of common stock issuable upon conversion of Series D preferred stock, all held by Inception Fund LP, (b)&nbsp;37,839 shares of common stock issuable upon
conversion of Series A preferred stock, 5,300 shares of common stock issuable upon conversion of Series C preferred stock and 570,335 shares of common stock issuable upon conversion of Series G preferred stock, all held by Inception Tech Fund 7 LP,
(c)&nbsp;13,368 shares of common stock issuable upon conversion of non-voting common stock, 350,686 shares of common stock issuable upon conversion of Series A preferred stock, 66,841 shares of common stock issuable upon conversion of Series B
preferred stock, 19,290 shares of common stock issuable upon conversion of Series E preferred stock and 20,487 shares of common stock issuable upon conversion of Series F preferred stock, all held by Tangletrade Fund LP, (d)&nbsp;32,171 shares of
common stock issuable upon conversion of Series A preferred stock, 52,223 shares of common stock issuable upon conversion of Series G preferred stock and 17,606 shares of common stock, all held by Inception Incubator Limited, (e)&nbsp;65,063 shares
of common stock issuable upon conversion of Series G preferred stock and 40,860 shares of common stock, all held by Inception Beast Genprex LLC, (f)&nbsp;6,303 shares of common stock issuable upon conversion of Series F preferred stock held by
Blackbox Data LLC, (g)&nbsp;13,535 shares of common stock held by New Path Mining </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
LLC, (i)&nbsp;542,656 shares of common stock that Viet-An Hoan Ly has the right to acquire from us within 60 days of September 30, 2017 pursuant to the exercise of a warrant and (j)&nbsp;56,815
shares of common stock that Mr.&nbsp;Ly has the right to acquire from us within 60 days of&nbsp;September 30, 2017 pursuant to the exercise of stock options. Viet-An Hoan Ly holds voting and dispositive power over the shares held by Inception Fund,
LP, Inception Tech Fund 7 LP, Tangletrade Fund LP, Inception Incubator Limited, Inception Beast Genprex LLC, Blackbox Data LLC and New Path Mining LLC. The address of each of these entities and of Mr.&nbsp;Ly is 5400 Carillon Point Road, Building
5000, Kirkland, Washington&nbsp;98033. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 1,235,219 shares of common stock issuable upon conversion of Series B preferred stock. Paul Ballard, the Chief Executive Officer of the Texas Treasury Safekeeping Trust Company, holds voting and dispositive
power of the securities held by the Texas Treasury Safekeeping Trust Company. The address of the Texas Treasury Safekeeping Trust Company is 208 East 10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Street, Austin, Texas 78701.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;1,734,207 shares of common stock issuable upon conversion of Series A preferred stock held by Laura Lane Biosciences, LLC, (b)&nbsp;414,680 shares of common stock held by Mr.&nbsp;Varner, and
(c)&nbsp;645,572 shares of common stock that Mr.&nbsp;Varner has the right to acquire from us within 60 days of September&nbsp;30, 2017 pursuant to the exercise of stock options. Mr.&nbsp;Varner holds voting power over the shares held by Laura Lane
Biosciences, LLC. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 44,091 shares of common stock that Dr.&nbsp;Pham has the right to acquire from us within 60 days of September&nbsp;30, 2017 pursuant to the exercise of stock options. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 73,526 shares of common stock and 365,263 shares of common stock that Mr.&nbsp;Confer has the right to acquire from us within 60 days of September&nbsp;30, 2017 pursuant to the exercise of stock options.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 307,111 shares of common stock that Mr.&nbsp;Friedman has the right to acquire from us within 60 days of September&nbsp;30, 2017 pursuant to the exercise of stock options. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 307,111 shares of common stock that Mr.&nbsp;Pearson has the right to acquire from us within 60 days of September&nbsp;30, 2017 pursuant to the exercise of stock options. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc486549_15"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon filing of our amended and restated certificate of incorporation and the completion of this offering, our authorized capital stock will
consist of 200,000,000 shares of voting common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. All of our authorized preferred stock upon the completion of this offering will be undesignated.
The following is a summary of the rights of our common and preferred stockholders and some of the provisions of our amended and restated certificate of incorporation and amended and restated bylaws, which will become effective immediately prior to
and upon the completion of this offering, respectively, and of the Delaware General Corporation Law. This summary is not complete. For more detailed information, please see our amended and restated certificate of incorporation and amended and
restated bylaws, which are filed as exhibits to the registration statement of which this prospectus is a part, as well as the relevant provisions of the Delaware General Corporation Law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Outstanding Shares.
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2017, there were 328,065 shares of voting common stock issued and outstanding held of record by 10
stockholders and 25,611 shares of non-voting common stock issued and outstanding held of record by two stockholders. This amount excludes our outstanding shares of convertible preferred stock, which will convert into 1,394,953 shares of voting
common stock in connection with the completion of this offering. Based on the number of shares of common stock outstanding as of September&nbsp;30, 2017, and assuming (1)&nbsp;the conversion of all of our outstanding shares of convertible preferred
stock into an aggregate of 1,394,953 shares of voting common stock (before giving effect to the forward split described below), (2)&nbsp;the conversion of all of our outstanding shares of non-voting common stock into an aggregate of 25,611 shares of
voting common stock (before giving effect to the forward split described below), (3)&nbsp;a 6.6841954-for-1 forward split of our common stock, (4)&nbsp;no exercise of outstanding options after September&nbsp;30, 2017 and (5)&nbsp;the issuance by us
of 3,500,000 shares of voting common stock in this offering, there will be 15,188,158 shares of voting common stock outstanding upon the completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2017, there were 2,628,749 shares of voting common stock subject to outstanding options under our equity incentive
plan. In addition, as discussed below, as of September&nbsp;30, 2017, after giving effect to the forward split mentioned above there were 542,656 shares of voting common stock issuable upon the exercise of outstanding warrants and 205,404 shares of
non-voting common stock upon the exercise of outstanding warrants, which will become exercisable for 205,404 shares of voting common stock upon the completion of this offering, as described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Voting </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our voting common
stock is entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including the election of directors, and does not have cumulative voting rights. Accordingly, the holders of a majority of the shares
of our voting common stock entitled to vote in any election of directors can elect all of the directors standing for election. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No holder
of our non-voting stock is entitled to any voting powers.&nbsp;In connection with the completion of this offering, each share of non-voting common stock will be converted into one share of voting common stock. Each share of non-voting common stock
will automatically convert into one share of voting common stock in connection with an initial public offering of our voting common stock at a price of at least $4.00 per share, with aggregate proceeds of $12,500,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Dividends </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences that may be applicable to any then-outstanding preferred stock, the holders of common stock are entitled to receive
dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Liquidation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation, dissolution or winding-up, holders of our common stock will be entitled to share ratably in the net assets
legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Rights and Preferences </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions
applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may
designate and issue in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Fully Paid and Nonassessable </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our outstanding shares of common stock are, and the shares of common stock to be issued in this offering will be, fully paid and
nonassessable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2017, after giving effect to the forward split mentioned above there were 9,324,125 shares of convertible preferred
stock outstanding, held of record by 15 stockholders. Of the outstanding shares of preferred stock, 6,695,332 were designated as Series A preferred stock, 1,389,756 were designated as Series B preferred stock, 490,966 were designated as Series C
preferred stock, 9,645 were designated as Series D preferred stock, 19,290 were designated as Series E preferred stock, 26,790 were designated as Series F preferred stock and 692,346 were designated as Series G preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Series A and Series D preferred stock have voting rights; the shares of Series B, Series C, Series E, Series F and Series G
preferred stock are non-voting. Each share of Series A preferred stock is convertible, at the option of the holder, into one share of voting common stock; each share of Series B, Series C, Series D, Series E, Series F and Series G preferred stock is
convertible, at the option of the holder, into one share of non-voting common stock. Each share of Series A preferred stock converts automatically into one share of voting common stock on the date specified by the holders of a majority in voting
power of the shares of Series A preferred stock then outstanding, or in connection with an initial public offering of our voting common stock at a price of at least $2.00 per share (before giving effect to the forward split mentioned above), with
aggregate proceeds of at least $20,000,000, referred to as an automatic conversion event. Each share of Series B, Series C, Series D, Series E, Series F and Series G preferred stock converts automatically into one share of non-voting common stock in
connection with an automatic conversion event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the completion of this offering, all outstanding shares of convertible
preferred stock will be converted into 9,324,125 shares of our common stock. Immediately prior to the completion of this offering, our certificate of incorporation will be amended and restated to delete all references to such shares of our existing
convertible preferred stock. Under the amended and restated certificate of incorporation, our board of directors will have the authority, without further action by the stockholders, to issue up to 10,000,000 shares of convertible preferred stock in
one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or
restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may authorize the issuance of preferred stock with voting or conversion
rights that could adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among
other things, have the effect of delaying, deferring or preventing a change in our control that may otherwise benefit holders of our common stock and may adversely affect the market price of the common stock and the voting and other rights of the
holders of common stock. We have no current plans to issue any shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2015, we issued to an entity two warrants, each exercisable for 102,702 shares of our non-voting common stock, and each with an
exercise price of $4.86. One of the warrants is exercisable beginning on the earlier to occur of June&nbsp;17, 2017, and the first anniversary of the effectiveness of the registration statement of which this prospectus is a part and the commencement
of trading on our securities on a national securities market, and the other warrant is exercisable beginning on the earlier to occur of June&nbsp;17, 2018, and the second anniversary of the effectiveness of the registration statement of which this
prospectus is a part and the commencement of trading of our securities on a national securities market. Each of those warrants expires on the fifth anniversary of the date on which it first becomes exercisable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2016, we issued to Viet-An Hoan Ly a warrant exercisable for an aggregate of 542,656 shares of our voting common stock, with an
exercise price of $5.29 per share. The purchase price of the warrant was $8,119. That warrant is currently exercisable, expires on November&nbsp;1, 2026. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of these warrants contains provisions for the adjustment of the number of shares issuable upon the exercise of the warrant and of the
exercise price in the event of stock dividends, splits, mergers, consolidations, conversions, reorganizations, reclassifications, asset sales, reorganizations, liquidations or the like. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As additional compensation to the underwriter, upon consummation of this offering, we will issue to the underwriter or its designees warrants
to purchase shares of our common stock as described under &#147;Underwriting&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing information does not include any
amounts relating to an informal demand we have received for a warrant to purchase shares of our common stock.&nbsp;See &#147;Business&#151;Legal Proceedings.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except with respect
to the shares of common stock underlying the warrants to be issued to the underwriter, as described under &#147;Underwriting,&#148; none of the holders of our capital stock has any rights with respect to the registration of their shares under the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2017, we received an informal demand from a former financial advisor, claiming that it is entitled to a
warrant to purchase shares of common stock equal to three percent of our outstanding shares as of December 1, 2015, with &#147;piggyback&#148; registration rights with respect to the common shares underlying the warrant. See
&#147;Business&#151;Legal Proceedings.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Provisions of Our Amended and Restated Certificate of Incorporation, Our Amended
and Restated Bylaws and Delaware Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Delaware Anti-Takeover Law </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, or Section&nbsp;203. Section&nbsp;203 generally prohibits a public
Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a period of three years following the time that such stockholder became an interested stockholder, unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prior to such time the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (1)&nbsp;by persons who are directors and also officers and
(2)&nbsp;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at or subsequent to such time, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at
least 66-2/3% of the outstanding voting stock which is not owned by the interested stockholder. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Section&nbsp;203 defines a business combination to include: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any merger or consolidation involving the corporation and the interested stockholder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested
stockholder; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding
voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amended and Restated
Certificate of Incorporation and Amended and Restated Bylaws </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions of our amended and restated certificate of incorporation and
amended and restated bylaws, which will become effective immediately prior to and upon the completion of this offering, respectively, may delay or discourage transactions involving an actual or potential change in our control or change in our
management, including transactions in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect
the price of our common stock. Among other things, our amended and restated certificate of incorporation and amended and restated bylaws: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate (including the right to approve an acquisition or other change in our
control); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that the authorized number of directors may be changed only by resolution of the board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that the board of directors or any individual director may only be removed with cause and the affirmative vote of the holders of at least 66-2/3% of the voting power of all of our then outstanding common stock;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">divide our board of directors into three classes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner
and also specify requirements as to the form and content of a stockholder&#146;s notice; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election,
if they should so choose); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that special meetings of our stockholders may be called only by the chairman of the board, our Chief Executive Officer or by the board of directors pursuant to a resolution adopted by a majority of the total
number of authorized directors; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on our behalf, (ii)&nbsp;any action asserting a claim of breach
of a fiduciary duty owed by any of our directors or officers to us or our stockholders, (iii)&nbsp;any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law or our certificate of incorporation
or bylaws, or (iv)&nbsp;any action asserting a claim against us governed by the internal affairs doctrine. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amendment of
any of these provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights, preferences and privileges thereto, would require approval by the holders of at least 66-2/3% of our
then-outstanding common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and Indemnification of Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and bylaws limit the liability of our officers and directors and provide that we will indemnify our officers
and directors, in each case, to the fullest extent permitted by the Delaware General Corporation Law. We expect to obtain additional directors&#146; and officers&#146; liability insurance coverage prior to the completion of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Capital Market Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend
to apply to list our common stock on the Nasdaq Capital Market under the symbol &#147;GNPX&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is V Stock Transfer, LLC. The transfer agent and registrar&#146;s address is 18 Lafayette
Place, Woodmere, New York 11598. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc486549_16"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to this offering, there has been no public market for our common stock. Future sales of substantial amounts of common stock
in the public market could adversely affect prevailing market prices. Furthermore, since only a limited number of shares will be available for sale shortly after this offering because of contractual and legal restrictions on resale described below,
sales of substantial amounts of common stock in the public market after the restrictions lapse could adversely affect the prevailing market price for our common stock as well as our ability to raise equity capital in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the number of shares of common stock outstanding as of September&nbsp;30, 2017, upon the completion of this offering and assuming
(1)&nbsp;the conversion of all of our outstanding shares of convertible preferred stock into an aggregate of 1,394,953 shares of common stock, (2)&nbsp;the conversion of all of our outstanding shares of non-voting common stock into an aggregate of
25,611 shares of voting common stock, (3)&nbsp;the 6.6841954-for-1 stock split of all outstanding shares of our capital stock (including the shares of voting common stock issued upon conversion of our outstanding shares of convertible preferred
stock and the shares of voting common stock issued upon conversion of our outstanding shares of non-voting common stock), (4)&nbsp;no exercise of outstanding options or warrants, and (5) the issuance by us of 3,500,000 shares of common stock in this
offering, an aggregate of 15,188,158 shares of voting common stock will be outstanding. All of the shares sold in this offering will be freely tradable in the public market without restriction or further registration under the Securities Act, unless
held by an affiliate of ours. Except as set forth below, the remaining 11,688,158 shares of common stock outstanding after this offering will be restricted as a result of securities laws or lock-up agreements. In addition, any shares sold in this
offering to entities affiliated with our existing stockholders and directors will be subject to lock-up agreements. These remaining shares will generally become available for sale in the public market as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no restricted shares will be eligible for immediate sale upon the completion of this offering; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">up to 11,688,158 restricted shares will be eligible for sale under Rule 144 or Rule 701 upon expiration of lock-up agreements 180 days after the date of this offering; and </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 144 as
currently in effect, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, any person who is not an affiliate of ours and has held their shares for at least six months, including the holding
period of any prior owner other than one of our affiliates, may sell shares without restriction, provided current public information about us is available. In addition, under Rule 144, any person who is not an affiliate of ours and has held their
shares for at least one year, including the holding period of any prior owner other than one of our affiliates, would be entitled to sell an unlimited number of shares immediately upon the completion of this offering without regard to whether
current public information about us is available. Beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is an affiliate of ours and who has beneficially owned restricted securities
for at least six months, including the holding period of any prior owner other than one of our affiliates, is entitled to sell a number of restricted shares within any three-month period that does not exceed the greater of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1% of the number of shares of our common stock then outstanding, which will equal approximately 15,188,158 shares immediately after this offering; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the average weekly trading volume of our common stock on The Nasdaq Capital Market during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of restricted shares under Rule 144 held by our affiliates are also subject to requirements regarding the manner of sale, notice and the
availability of current public information about us. Rule 144 also provides that affiliates relying on Rule 144 to sell shares of our common stock that are not restricted shares must nonetheless comply with the same restrictions applicable to
restricted shares, other than the holding period requirement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the availability of Rule 144, the holders of substantially all of our restricted
shares have entered into lock-up agreements as described below and their restricted shares will become eligible for sale at the expiration of the restrictions set forth in those agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Rule 701, shares of our
common stock acquired upon the exercise of currently outstanding options or pursuant to other rights granted under our stock plans may be resold by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons other than affiliates, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, subject only to the manner-of-sale provisions of Rule 144; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our affiliates, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, subject to the manner-of-sale and volume limitations, current public information and filing
requirements of Rule 144, in each case, without compliance with the six-month holding period requirement of Rule 144. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
September 30, 2017, options to purchase a total of 2,628,749 shares of common stock were outstanding, of which 2,424,770 were vested. Of the total number of shares of our common stock issuable under these options, substantially all are subject to
contractual lock-up agreements with us or the underwriters described below under &#147;Underwriting&#148; and will become eligible for sale at the expiration of those agreements unless held by an affiliate of ours. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lock-Up Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our officers
and directors have agreed to certain restrictions on the sale or other transfer of shares of our common stock, as described under &#147;Underwriting.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After this offering, certain of our employees, including our executive officers and/or directors, may enter into written trading plans that
are intended to comply with Rule 10b5-1 under the Exchange Act. Sales under these trading plans would not be permitted until the expiration of the lock-up agreements relating to the offering described above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except with respect
to the shares of common stock underlying the warrants to be issued to the underwriter, as described under &#147;Underwriting,&#148; none of the holders of our capital stock has any rights with respect to the registration of their shares under the
Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentive Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to file with the SEC a registration statement on Form S-8 under the Securities Act covering the shares of common stock reserved for
issuance under the 2009 Plan, the 2017 Plan and the ESPP. The registration statement is expected to be filed and become effective as soon as practicable after the completion of this offering. Accordingly, shares registered under the registration
statement will be available for sale in the open market following its effective date, subject to Rule 144 volume limitations and the lock-up agreements described above, if applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc486549_17"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an Underwriting Agreement with Network 1 Financial Securities, Inc. (the &#147;Underwriter&#148;) to conduct this
offering on a &#147;best efforts&#148; minimum/maximum basis. The offering is being made without a firm commitment by the Underwriter, which has no obligation or commitment to purchase any of our shares. Accordingly, pursuant to the Underwriting
Agreement, we will sell to investors that complete a subscription agreement with us up to the 4,500,000 shares of common stock offered hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Underwriter is an &#147;underwriter&#148; within the meaning of Section&nbsp;2(a)(11) of the Securities Act and any commissions received
by it and any profit realized on the sale of the securities by them while acting as principal would be deemed to be underwriting discounts or commissions under the Securities Act. The Underwriter is required to comply with the requirements of the
Securities Act and the Exchange Act including, without limitation, Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of shares of common stock by the Underwriter. Under these
rules and regulations, the Underwriter may not (i)&nbsp;engage in any stabilization activity in connection with our securities; and (ii)&nbsp;bid for or purchase any of our securities or attempt to induce any person to purchase any of our
securities, other than as permitted under the Exchange Act, until they have completed their participation in the distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Underwriting Agreement provides that the obligation of the Underwriter to arrange for the offer and sale of the shares of our common stock, on a best efforts basis, is subject to certain conditions precedent, including but not limited to
(i)&nbsp;receipt of a listing approval letter from the Nasdaq Capital Market, (ii)&nbsp;delivery of legal opinions, and (iii)&nbsp;delivery of auditor comfort letters. The Underwriter is under no obligation to purchase any shares of our common stock
for its own account. Since this offering is being conducted by the Underwriter on a &#147;best efforts&#148; basis, there can be no assurance that the minimum offering contemplated hereby will ultimately be completed. The Underwriter may, but is not
obligated to, retain other selected dealers that are qualified to offer and sell the shares and that are members of the Financial Industry Regulatory Authority, Inc., or FINRA. The Underwriter proposes to offer the shares to investors at the
offering price, and will receive the underwriting commissions, set forth on the cover of this prospectus. The gross proceeds of this offering will be deposited at Signature Bank in an escrow account established by us, until we have sold a minimum of
2,500,000 of shares of common stock and otherwise satisfy the listing conditions to trade our common stock on the Nasdaq Capital Market. Once we satisfy the minimum stock sale and Nasdaq listing conditions, the funds will be released to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate the shares of our common stock will be listed on the Nasdaq Capital Market under the symbol &#147;GNPX.&#148; In order to list,
the Nasdaq Capital Market requires that, among other criteria, at least 1,000,000 publicly-held shares of our common stock be outstanding, the shares be held in the aggregate by at least 300 round lot holders, the market value of the publicly-held
shares of our common stock be at least $15 million, our stockholders&#146; equity after giving effect to the sale of our shares in this offering be at least $5 million, the bid price per share of our common stock be $4.00 or more, and there be at
least three registered and active market makers for our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discount, Commissions and Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Underwriter has advised us that they propose to offer the shares of common stock in this offering to the public at the public offering
price set forth on the cover page of this prospectus and to certain dealers at that price less a concession not in excess of 6.5% of the offering price. The Underwriter may allow, and certain dealers may re-allow, a discount from the concession to
certain brokers and dealers. After this offering, the initial public offering price, concession and reallowance to dealers may be changed by the representatives. No such change shall change the amount of proceeds to be received by us as set forth on
the cover page of this prospectus. The shares are offered by the Underwriter as stated herein, subject to receipt and acceptance by them and subject to their right to reject any order in whole or in part. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table and the three succeeding paragraphs summarize the underwriting compensation
and estimated expenses we will pay.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Public<BR>Offering<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Underwriting<BR>Commissions(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Proceeds&nbsp;to<BR>Us, Before<BR>Expenses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total minimum offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;12,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">937,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,562,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total maximum offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;22,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,687,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,812,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consists of an underwriting commission of 6.5% and an advisory fee of 1.0% of the gross proceeds raised in this offering less aggregate expenses incurred by the Underwriter relating to the offering, including, among
other things, due diligence costs, the Underwriter&#146;s &#147;road show&#148; expenses, and the fees and expenses of the Underwriter&#146;s counsel which, in the aggregate, shall not exceed $100,000. We estimate that the total expenses of this
offering, excluding underwriting commissions and expenses described above, will be approximately $775,000. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Underwriter Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also agreed to issue to the underwriters the Underwriter Warrants to purchase a number of common shares equal to an aggregate of 3% of
the Shares sold in this offering. The Underwriter Warrants will have an exercise price equal to 125% of the initial public offering price in this offering and may be exercised on a cashless basis in the event there is no effective registration for
the underlying shares. The Underwriter Warrants will be exercisable 180 days following the closing date until the fifth anniversary of the date the registration statement on Form S-1 (of which this prospectus forms a part) is declared effective
under the Securities Act by the Securities and Exchange Commission. The Underwriter Warrants are not redeemable by us. The Underwriter Warrants also provide for unlimited &#147;piggyback&#148; registration rights at our expense with respect to the
underlying common shares during the five-year period commencing on the closing date of the offering. The Underwriter Warrants will provide for adjustment in the number and exercise price of such warrants (and the common shares underlying such
warrants) in the event of recapitalization, merger or other fundamental transaction. The Underwriter Warrants and the shares issuable upon the exercise of the Underwriter Warrants have been deemed compensation by FINRA and are therefore subject to
FINRA&nbsp;Rule 5110(g)(1). In accordance with FINRA&nbsp;Rule 5110(g)(1), none of such securities may be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that
would result in the effective economic disposition of such securities by any person for a period of&nbsp;180 days&nbsp;immediately following the date of effectiveness or commencement of sales of the offering pursuant to which the Underwriter
Warrants are being issued, except the transfer of any security: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by operation of law or by reason of our reorganization; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any FINRA member firm participating in this offering and the officers or partners thereof, if all securities so transferred remain subject to the&nbsp;lock-up restriction described above for the remainder of the time
period; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the aggregate amount of our securities held by either an underwriter or a related person does not exceed 1% of the securities being offered; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">that is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages or otherwise directs investments by the fund, and participating members in the
aggregate do not own more than 10% of the equity in the fund; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the exercise or conversion of any security, if all securities received remain subject to the&nbsp;lock-up restriction set forth above for the remainder of the time period. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in accordance with FINRA Rule 5110(f)(2)(G), the Underwriter Warrants may not contain certain terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made available on the website maintained by the Underwriter, or selling group members, if any,
participating in the offering. The Underwriter may agree to allocate a number of shares to selling group members for sale to their online brokerage account holders. Online distributions will be allocated by the Underwriter, and selling group
members, if any, that may make online distributions on the same basis as other allocations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lock-up Agreements</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our officers and directors have agreed to not: (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of our company or any securities convertible into or exercisable
or exchangeable for shares of capital stock of our company; (ii)&nbsp;file or cause to be filed any registration statement with the SEC relating to the offering of any shares of capital stock of our company or any securities convertible into or
exercisable or exchangeable for shares of capital stock of our company; or (iii)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of capital stock of our
company, whether any such transaction described in clause (i), (ii)&nbsp;or (iii)&nbsp;above is to be settled by delivery of shares of capital stock of our company or such other securities, in cash or otherwise, in each case without the prior
consent of the Underwriter for a period of 180 days after the date of this prospectus, other than (A)&nbsp;the shares of our common stock to be sold hereunder, (B)&nbsp;the issuance by us of shares of our common stock upon the exercise of a stock
option or warrant or the conversion of a security outstanding on the date of this offering, hereafter issued pursuant to our currently existing or hereafter adopted equity compensation plans or employment or consulting agreements or arrangements of
which the representative has been advised in writing or which have been filed with the SEC or (C)&nbsp;the issuance by us of stock options or shares of capital stock of our company under any currently existing or hereafter adopted equity
compensation plan or employment/consulting agreements or arrangements of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement provides that we will indemnify the Underwriter against certain liabilities, including liabilities under the
Securities Act, or contribute to payments the Underwriter may be required to make in respect thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing and Transfer Agent</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied to have our common stock approved for listing on the Nasdaq Capital Market under the symbol &#147;GNPX.&#148; If the
application is approved, we anticipate that trading on the Nasdaq Capital Market will commence on the day following the completion of the offering made by this prospectus. We will not complete this offering without a listing approval letter from the
Nasdaq Capital Market. Our receipt of a listing approval letter is not the same as an actual listing on the Nasdaq Capital Market. The listing approval letter will serve only to confirm that, if we sell a number of shares in this &#147;best
efforts&#148; offering sufficient to satisfy applicable listing criteria, our common stock will in fact be listed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and
registrar for our common stock is V Stock Transfer, LLC. The address of the transfer agent and registrar is 18 Lafayette Place, Woodmere, New York 11598. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Public Market </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering,
there has been no public market for our common stock. The initial public offering price has been determined by negotiations between us and the Underwriter. In determining the offering price, we and the Underwriter have considered a number of factors
including:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the information set forth in this prospectus and otherwise available to the Underwriter; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our prospects and the history and prospects for the industry in which we compete; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an assessment of our management; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our prospects for future earnings; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the general condition of the securities markets at the time of this offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the recent market prices of, and demand for, publicly traded common stock of generally comparable companies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other factors deemed relevant by the Underwriter and us. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the Underwriter can
assure investors that an active trading market will develop for shares of our common stock, or that the shares will trade in the public market at or above the initial public offering price. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc486549_18"></A>VALIDITY OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities offered hereby will be passed upon for us by Streusand Landon&nbsp;&amp; Ozburn, LLP, Austin, TX. Magri Law
LLC, Fort Lauderdale, FL, is acting as counsel to the underwriters in connection with this offering. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc486549_19"></A>EXPERTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial statements at December&nbsp;31, 2015 and 2016 and for the years then ended that are included in this prospectus have
been audited by Daszkal Bolton LLP, an independent registered public accounting firm, as stated in their reports appearing herein (which report expresses an unqualified opinion on the financial statements and includes an explanatory paragraph
referring to our ability to continue as a going concern). Such financial statements have been so included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc486549_20"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form S-1 under the Securities Act, with respect to the securities being offered by this
prospectus. This prospectus does not contain all of the information in the registration statement and its exhibits. For further information with respect to us and the securities offered by this prospectus, we refer you to the registration statement
and its exhibits. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an
exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You can read our SEC
filings, including the registration statement, over the Internet at the SEC&#146;s website at www.sec.gov. You may also read and copy any document we file with the SEC at its public reference facilities at 100 F Street NE, Washington, D.C. 20549.
You may also obtain copies of these documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of
the public reference facilities. You may also request a copy of these filings, at no cost, by writing us at 100 Congress Avenue, Suite 2000, Austin, Texas 78701 or telephoning us at (512)&nbsp;370-4081. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, we will be subject to the information reporting
requirements of the Exchange Act, and we will file reports, proxy statements and other information with the SEC. These reports, proxy statements and other information will be available for inspection and copying at the public reference room and
website of the SEC referred to above. We also maintain a website at www.genprex.com, at which, following the completion of this offering, you may access these materials free of charge as soon as reasonably practicable after they are electronically
filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not incorporated by reference in, and is not part of, this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc486549_21"></A>INDEX TO FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin486549_1">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin486549_2">Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin486549_3">Statements of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin486549_4">Statements of Changes in Stockholders&#146; Equity</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin486549_5">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin486549_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin486549_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors and Stockholders </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Genprex, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Austin, Texas </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying balance sheets
of Genprex, Inc. (the &#147;Company&#148;) at December&nbsp;31, 2016 and 2015, and the related statements of operations, changes in stockholders&#146; equity and cash flows for the years then ended. The Company&#146;s management is responsible for
these financial statements. Our responsibility is to express an opinion on these financial statements based on our audit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audit in
accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material
misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing
audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An audit
includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the
overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion, the financial statements
referred to above present fairly, in all material respects, the financial position of Genprex, Inc. at December&nbsp;31, 2016 and 2015, and the results of its operations and its cash flows for the years then ended, in conformity with accounting
principles generally accepted in the United States of America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared assuming that the Company will
continue as a going concern. As described in Note 1 to the financial statements, the Company has no revenues, sustained recurring losses from operations and increased accumulated deficits since inception. In addition, commercialization of the
Company&#146;s patents is dependent upon successful completion of clinical trials. These conditions raise substantial doubt about its ability to continue as a going concern. Management&#146;s plans in regard to these matters are described in Note 1.
The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to this matter. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Daszkal Bolton LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fort Lauderdale, Florida </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;16, 2017 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Genprex, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin486549_2"></A>Balance Sheets </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,602,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">234,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">373,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,638,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">559,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intellectual property, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">857,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,910,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">410,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,266,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and Stockholders&#146; Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">285,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">363,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">395,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment unit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock $0.001 par value: 4,500,000 shares authorized;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A, 1,001,667 shares issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B, 207,917 shares issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C, 73,452 shares issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D, 1,443 shares issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series E, 2,886 shares issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series F, 4,008 shares issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series G, 81,107, 5,946 and 103,580 shares issued and outstanding, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock $0.001 par value: 5,500,000 shares authorized; 327,676, 307,676 and 353,676 shares
issued and outstanding, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,761,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,398,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,655,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,138,195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,006,036</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,785,779</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,624,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">871,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,910,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">410,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,266,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to the financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Genprex, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin486549_3"></A>Statements of Operations </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost and expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">354,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,776,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">865,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,416,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,906,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total costs and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,132,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,069,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,647,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,133,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,132,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,069,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,647,630</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,133,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest Income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,132,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,069,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,647,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,133,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7.77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of common shares&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">314,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">340,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">311,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to the financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Genprex, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin486549_4"></A>Statements of Changes in Stockholders&#146; Equity </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="54" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="6" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Series A</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Series B</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Series C</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Series D</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Series E</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Series F</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Series G</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="border-bottom:1.00pt solid #000000" ALIGN="center"><FONT STYLE="font-size:7pt"><B>Additional</B></FONT><br><FONT STYLE="font-size:7pt"><B>Paid-In</B></FONT><br><FONT STYLE="font-size:7pt"><B>Capital</B></FONT></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Accumulated<BR>Deficit</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:7pt"><B>Total</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance at December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">277,430</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">278</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1,001,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1,002</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">197,917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">73,452</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1,443</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt"> 9,231,929</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">(8,936,314</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">)&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt"> 297,167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of stock upon exercise of warrants for cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">10,246</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">10,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">2,886</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">4,008</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">4,530</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">724,880</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">724,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of stock for services</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1,416</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">440,379</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">440,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">980</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">980</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">(1,069,722</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">(1,069,722</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance at December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">307,676</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">308</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1,001,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1,002</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">207,917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">208</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">73,452</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1,443</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">2,886</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">4,008</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">5,946</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">10,398,168</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">(10,006,036</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">)&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">393,737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of stock for cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">76,577</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">77</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">2,705,795</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">2,705,872</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of stock for services</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">(1,416</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">419,431</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">419,450</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">2,237,968</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">2,237,968</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">&#151;&nbsp;&nbsp;</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">(4,132,159</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">(4,132,159</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">327,676</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">328</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1,001,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1,002</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">207,917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">208</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">73,452</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1,443</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">2,886</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">4,008</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">81,107</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">82</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">15,761,362</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">(14,138,195</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt">1,624,868</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to the financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Genprex, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin486549_5"></A>Statements of Cash Flows </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,132,159</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,069,722</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,647,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,133,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,657,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">441,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,100,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,316,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,703</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,019</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,050</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred operating costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,507</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(534,303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">269,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">428,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,248,263</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(688,261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,960,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(399,620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from investing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions to property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,978</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(919</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,998</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions to intellectual property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(84,556</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,343</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71,887</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(89,534</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,284</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71,887</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuances of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuances of preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,705,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">524,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">793,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,205,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,705,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">724,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">794,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,205,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,368,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,228,350</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(734,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,602,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,602,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">234,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">373,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">968,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to the financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Genprex, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin486549_6"></A>Notes to Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(information at September 30, 2017 and for the nine months ended September 30, 2016 and 2017 is unaudited)</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Note 1&#151;Description of Business and Basis of Presentation</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Genprex, Inc. (&#147;we&#148; or &#147;the Company&#148;), is a privately held, clinical-stage biopharmaceutical company developing immunogene therapies for
cancer.&nbsp;Our first product candidate, branded as Oncoprex&#153;, is in phase&nbsp;II clinical trials for lung cancer patients in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to all the risks inherent in a start-up company in the biopharmaceutical industry. The biopharmaceutical industry is subject to rapid and
technological change. We have numerous competitors, including major pharmaceutical and chemical companies, specialized biotechnology firms, universities and other research institutions. These competitors may succeed in developing technologies and
products that are more effective than any that are being developed by us or that would render our technology and products obsolete and noncompetitive. Many of these competitors have substantially greater financial and technical resources than us. In
addition, many of our competitors have significantly greater experience than us in pre-clinical testing and human clinical trials of new or improved pharmaceutical products and in obtaining FDA and other regulatory approvals on products for use in
health care. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Capital Requirements, Liquidity and Going Concern Considerations</U> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of
assets and liquidation of liabilities in the normal course of business. However, as shown in the accompanying financial statements, we have sustained substantial losses from operations since inception and have no current source of revenue. In
addition, we have used, rather than provided, cash in our operations. We expect to continue to incur significant expenditures to further clinical trials for the commercial development of our patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management recognizes that we must obtain additional resources to successfully commercialize our intellectual property.&nbsp;To date, we have received funding
in the form of equity and debt, and plan to either continue obtaining funding through 2017 or until we have secured a capital market transaction. However, no assurances can be given that we will be successful in raising additional capital.&nbsp;If
we are not able to timely and successfully raise additional capital, the timing of our clinical trials, financial condition and results of operations will continue to be materially affected.&nbsp;These financial statements do not include any
adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Note 2&#151;Summary of Significant Accounting Policies</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#147;U.S. GAAP&#148;) and reflect all
adjustments, which are of a normal and recurring nature, that are, in the opinion of management, necessary for a fair presentation of our financial position and results of operations for the related periods. The results of operations for any interim
periods are not necessarily indicative of results to be expected for the full year. A summary of our significant accounting policies consistently applied in the preparation of the accompanying financial statements follows. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Restatement of Balance Sheet at December&nbsp;31, 2016</U> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the auditors&#146; issuance of their report on our December&nbsp;31, 2016 financial statements, management became aware of a scrivener&#146;s
error in the terms of certain options granted, resulting in a $136,810 increase in share based compensation (accumulated deficit) and additional paid-in capital during the fourth quarter of 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Genprex, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Note
2&#151;Summary of Significant Accounting Policies,&nbsp;continued</U> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Use of Estimates</U> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of our financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.&nbsp;Actual results could differ from those estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Cash and Cash Equivalents</U> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consider all highly
liquid short-term investments with an initial maturity of three months or less to be cash equivalents.&nbsp;Any amounts of cash in financial institutions which exceed FDIC insured limits expose us to cash concentration risk. We have no cash
equivalents, and had $118,950 and $1,351,868 in excess of FDIC insured limits of $250,000 at September 30, 2017 and December&nbsp;31, 2016, respectively. There were no cash balances in excess of FDIC limits at December&nbsp;31, 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Fair Value of Financial Instruments</U> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying
amounts reported in the balance sheet for cash, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASC 820 defines fair value, provides a consistent framework for measuring fair value under GAAP and expands fair value financial statement disclosure
requirements. ASC 820&#146;s valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. ASC 820
classifies these inputs into the following hierarchy: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Level 1:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Quoted prices for identical instruments in active markets</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Level&nbsp;2:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers
are observable</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Level 3:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Instruments with primarily unobservable value drivers.</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Property and Equipment</U> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furniture and equipment are stated at cost. Depreciation is calculated using the straight line method over the estimated useful lives of the assets, which
range from three to five years.&nbsp;Routine maintenance and repairs are charged to expense as incurred and major renovations or improvements are capitalized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Research and Development Materials Costs </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research
and development expenditures are comprised of costs incurred to conduct research and development activities. These include payments to collaborative research partners, including wages and associated employee benefits, facilities and overhead costs.
These expenditures relate to Phase 1 and 2 clinical trials and are expensed as incurred. Purchased materials to be used in future research are capitalized and included in prepaid expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Awards</U> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2010, we were awarded $4.5 million from
the State of Texas Emerging Technology Fund (&#147;TETF&#148;).&nbsp;The award was received in two tranches of $2.25 million during 2010 and 2011.&nbsp;The award proceeds were used for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Genprex, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Note
2&#151;Summary of Significant Accounting Policies,&nbsp;continued</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Awards,&nbsp;continued</U> </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the development and future commercialization of our nanomolecular therapy product for the treatment of cancer.&nbsp;In consideration for the award, we provided the TETF with an &#147;Investment
Unit&#148;, consisting of (i)&nbsp;a Promissory Note (&#147;Note&#148;) and (ii)&nbsp;a right to purchase our equity shares (&#147;Warrant&#148;).&nbsp;The funds received for this award were assigned to the Investment Unit, and classified separately
from equity as &#147;mezzanine&#148; in the balance sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2010, we also were awarded approximately $244,500 from the U.S. Treasury Department for our
QTDP Program Nanoparticle Therapy for Lung Cancer.&nbsp;The award was received during 2011 for our historical activities, and required no prospective expenditures.&nbsp;We accounted for these funds received as revenue at that time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Intellectual Property</U> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellectual property
consists of external legal and related costs associated with patents and other proprietary technology acquired, licensed, or maintained by us that we believe contribute to a probable economic benefit toward such patents and activities. These legal
costs incurred in connection with the patent applications and patent maintenance are capitalized. Intellectual property is stated at cost, to be amortized on a straight-line basis over the estimated useful lives of the assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Accounting for Stock-Based Compensation</U> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We use
the fair value-based method of accounting for stock-based compensation for options granted to employees, independent consultants and contractors.&nbsp;We measure options granted at fair value determined as of the grant date, and recognize the
expense over the periods in which the related services are rendered based on the terms and conditions of the award. Generally, where the award only has a service condition, the requisite service period is the same as the vesting period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Financial Instruments</U> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have elected the Fair
Value Option to account for the Investment Unit at fair value as a combined hybrid financial instrument containing a Warrant and a Note (see Note 4).&nbsp;Prior to its exercise, the Warrant component was not classified within equity, as the exercise
price of the warrants was affected by the market price of our stock in a future qualifying financing transaction and was not considered to be indexed to our own stock. The Note is not classified within liabilities, as our management can determine
the timing of the repayment obligation, if any. As a result, the Warrant and Note that comprised the Investment Unit were aggregated and classified within the mezzanine section of the balance sheet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to the contingent terms of the financial instruments, changes in the fair value of the Investment Unit were calculated and realized in
earnings.&nbsp;There were no changes in the fair value of the Investment Unit at September&nbsp;30, 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Long-Lived Assets</U> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We review long-lived assets and certain identifiable intangibles held and used for possible impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Genprex, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Note
2&#151;Summary of Significant Accounting Policies,&nbsp;continued</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Long-Lived Assets,&nbsp;continued</U> </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
evaluating the fair value and future benefits of its intangible assets, management performs an analysis of the anticipated undiscounted future net cash flow of the individual assets over the
remaining amortization period. We recognize an impairment loss if the carrying value of the asset exceeds the expected future cash flows. During the period ended September 30, 2017 and the years ended December&nbsp;31, 2016 and 2015, there were no
deemed impairments of our long-lived assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Recent Accounting Developments</U> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounting pronouncements issued but not effective until after September 30, 2017 are not expected to have a significant effect on our financial condition,
results of operations, or cash flows. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Note 3&#151;Intellectual Property</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have exclusive license agreements on thirty (30) issued and two (2)&nbsp;pending patents for technologies developed by researchers at the National
Institutes of Health, The University of Texas MD Anderson Cancer Center, and The University of Texas Southwestern Medical Center.&nbsp;These patents comprise various therapeutic, diagnostic, technical and processing claims. See Note 9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These license rights will be amortized on a straight-line basis over the estimated period of useful lives of the underlying patents or the license agreements.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Note 4&#151;Investment Unit</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Texas Emerging
Technology Fund (&#147;TETF&#148;) was created as an incentive for economic development to the Texas economy by providing financial support that leverages private investment for the creation of high-quality technology jobs in Texas.&nbsp;The award
received required us to comply with certain performance conditions to ensure the monies the Company received were used for development activities in the state of Texas, and that we maintained our corporate nexus in Texas. Further, in connection with
the award, the Company issued an Investment Unit to the TETF. As further described below, the Investment Unit consists of a Promissory Note and a Right to Purchase: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Promissory Note</U> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Promissory Note is an
obligation to repay the $4.5 million principal amount, with interest accrued at 8%&nbsp;per annum, but only if an event of default occurs prior to August&nbsp;13, 2020. If no event of default occurs prior to August&nbsp;13, 2020, the Promissory Note
and all related interest will be cancelled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consistent with the stated objectives of the TETF, an event of default that would trigger the repayment
obligation under the Promissory Note is our failure to maintain our principal place of business or our principal executive offices headquartered in the State of Texas (referred to as the &#147;Residency Requirement&#148;) until August&nbsp;13, 2020.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Warrant</U> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Warrant is an obligation to
issue (a Right to purchase by the TETF) shares of the same class of stock to be issued in a &#147;First Qualifying Financing Transaction,&#148; at 80% of the per share transaction value (effectively a 20% discount). Alternatively, the TETF could
exercise its right to purchase at any time prior to the occurrence of a First Qualifying Financial Transaction for $0.001 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Genprex, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Note
4&#151;Investment Unit,&nbsp;continued</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Warrant,&nbsp;continued</U> </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Warrant included a provision that required changes in the strike price, driven by the pricing of the
&#147;First Qualifying Financing Transaction.&#148; As a result, the Warrants embedded in the Investment Unit were accounted for as a derivative financial instrument and classified outside from equity under ASC 815-40-15 as the settlement adjustment
from the future transaction did not permit for the strike price to be considered fixed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;12, 2014, the TETF exercised its Right to Purchase
for $0.001 per share, and we issued to the TETF an aggregate of 184,797 shares of our Series B preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Accounting for the Investment
Unit</U> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We accounted for the Investment Unit as a hybrid financial instrument under FASB Statement 155, and measured the Investment Unit at the
amount of proceeds received from the TETF award. The First Qualifying Financial Transaction occurred during December 2013, resulting in an adjustment to the fair value of the Investment Unit in the amount of approximately $2.5 million. The TETF
exercised the Warrant for $0.001 per share. We received notice of purchase from the TETF during March 2014, and issued 184,797 shares of series B Preferred Stock. Upon exercise by the TETF of the Warrant, the remaining component within the
Investment Unit was the Promissory Note. The Investment Unit was valued at zero, because our obligation to repay the Promissory Note arises from an event of default (a failure to maintain the Texas Residency Requirement), which is an event which
rests entirely within our control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Note 5&#151;Equity</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Stock Issuances </U></I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the period ended September
30, 2017, we issued (i)&nbsp;26,000 shares of Common Stock for service provided to us, valued at $918,580, and we issued (ii)&nbsp;22,473 shares of Series G Preferred Stock for cash of $793,971. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2016, we issued (i)&nbsp;20,000 shares of Common Stock for service provided to us, valued at $469,450, and we issued
(ii)&nbsp;76,577 shares of Series G Preferred Stock for cash of $2,705,872. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December 31, 2015, we issued (i) 10,246 and 20,000
shares of Common Stock for cash of $200,000 and services provided to us, valued at $390,400, (ii) 10,000 shares of Series B Preferred Stock, (iii) 2,886 shares of Series E Preferred Stock, (iv) 4,008 shares of Series F Preferred Stock, and (v) 4,530
and 1,416 shares of Series G Preferred Stock for cash of $524,913 and services valued at $50,000, respectively.&nbsp;During 2016, the 1,416 shares of Series G Preferred Stock issued for services were cancelled due to nonperformance of services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2016, we hired a Chief Operating Officer.&nbsp;Under the terms of the agreement, we granted options to purchase shares of our Common Stock equal to
one and one-half percent (1.5%)&nbsp;of our issued and outstanding common shares then outstanding.&nbsp;These options will vest ratably over 48 months. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Preferred Stock</U> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have 4,500,000 shares of
preferred stock authorized with a par value of $0.001. The Board has the authority to issue the shares in one or more series and to set the designations, preferences, powers and other rights, as it deems appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Genprex, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Note
5&#151;Equity,&nbsp;continued</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Preferred Stock,&nbsp;continued</U> </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series A Preferred Stock is convertible by the holder into Voting Common Stock on a 1:1 basis, and is
converted automatically upon a public offering of securities resulting in a capital raise of at least $20 million at a share price of at least $2.00 per share.&nbsp;The Series B through Series G Preferred Stock is convertible by the holder into
Non-Voting Common Stock on a 1:1 basis, and is converted automatically into Voting Common Stock upon a public offering of securities resulting in a capital raise of at least $20 million at a share price of at least $2.00&nbsp;per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series A Preferred is voting and carries a non-cumulative dividend of $0.05 per share, if, as and when declared by the Board of Directors and carries a
liquidation preference of $1.00 per share upon a &#147;Liquidation Event&#148;, as defined in our certificate of incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series B Preferred is
nonvoting and carries a non-cumulative dividend of $1.91 per share, if, as and when declared by the Board of Directors and carries a liquidation preference, subordinate to the rights of the holders of Series A and D Preferred Stock, of $38.11 per
share upon a &#147;Liquidation Event&#148;, as defined in our certificate of incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series C Preferred is nonvoting and carries a
non-cumulative dividend of $.19 per share, if, as and when declared by the Board of Directors and carries a liquidation preference, subordinate to the rights of the holders of Series A, B and D Preferred Stock and pari passu with the rights of the
holders of the Series E and F Preferred Stock, of $19.06 per share upon a &#147;Liquidation Event&#148;, as defined in our certificate of incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series D Preferred is voting and carries a non-cumulative dividend of $3.46 per share, if, as and when declared by the Board of Directors and carries a
liquidation preference, subordinate to the rights of the holders of Series A Preferred Stock, of $69.29 per share upon a &#147;Liquidation Event&#148;, as defined in our certificate of incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series E Preferred is nonvoting and carries a non-cumulative dividend of $2.08 per share, if, as and when declared by the Board of Directors and carries a
liquidation preference, subordinate to the rights of the holders of Series A, B and D Preferred Stock and pari passu with the rights of the holders of the Series C and E Preferred Stock, of $34.65 per share upon a &#147;Liquidation Event&#148;, as
defined in our certificate of incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series F Preferred is nonvoting and carries a non-cumulative dividend of $1.37 per share, if, as and
when declared by the Board of Directors and carries a liquidation preference, subordinate to the rights of the holders of Series A, B and D Preferred Stock and pari passu with the rights of the holders of the Series C and E Preferred Stock, of
$22.87 per share upon a &#147;Liquidation Event&#148;, as defined in our certificate of incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series G Preferred is nonvoting and carries a
non-cumulative dividend of $1.06 per share, if, as and when declared by the Board of Directors and carries a liquidation preference, subordinate to the rights of the holders of Series A, B, C, D, E, and F Preferred Stock, of $35.33 per share upon a
&#147;Liquidation Event&#148;, as defined in our certificate of incorporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Genprex, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Note
5&#151;Equity,&nbsp;continued</U> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Common Stock</U> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have 5,500,000 shares of Common Stock authorized (4,500,000 voting and 1,000,000 nonvoting) with a par value of $0.001. Each share of voting Common Stock
has one vote per share for the election of directors and all other items submitted to a vote of stockholders. The Common Stock does not have cumulative voting rights, preemptive, redemption or conversion rights.&nbsp;For all periods presented,
25,611 shares of our total number of shares of Common Stock outstanding were nonvoting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Preferred Stock Purchase Warrants</U> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There was no preferred stock purchase warrant activity for the period ended September 30, 2017 or for the year ended December 31, 2016. For the year ended
December 31, 2015, 10,000 preferred stock purchase warrants were exercised at a weighted average exercise price of $17.33. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Common Stock Purchase
Warrants</U> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There was no common stock purchase warrant activity for the period ended September 30, 2017. Common stock purchase warrant activity for
the years ended December&nbsp;31, 2016 and 2015 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Avg.<BR>Exercise Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at January&nbsp;1, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled or Expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19.52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,246</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19.52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled or Expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled or Expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at September 30, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During November 2016, we granted warrants to purchase 81,185 shares of our voting Common Stock, with a per share strike price
of $35.33.&nbsp;We received $8,119 for the issuance of these warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During December 2015, we granted two warrants, each to purchase 15,365 shares of
our nonvoting Common Stock (a total of 30,730 shares) with a per share strike price of $32.54.&nbsp;The first warrant vests 18 months from the grant date, and expires five (5)&nbsp;years after vesting.&nbsp;The second warrant vests 30 months from
the grant date, and expires five (5)&nbsp;years after vesting.&nbsp;Compensation expense related to the vesting of these warrants was approximately $31,105 and $70,329 for the period ended September 30, 2017 and year ended December&nbsp;31, 2016,
respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Genprex, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Note
5&#151;Equity,&nbsp;continued</U> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Stock Options</U> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have outstanding stock options to purchase 393,280 shares of Common Stock that have been granted to various employees, vendors and independent contractors.
These options vest over periods ranging from twelve (12)&nbsp;to forty-eight (48)&nbsp;months, are exercisable for a period of ten years, and enable the holders to purchase shares of our Common Stock at exercise prices ranging from
$0.001&#151;$35.33. The per-share fair values of these options range from $0.001 to $17.91, based on Black-Scholes-Merton pricing models with the following assumptions: volatility (76.74%); risk-free rates (1.77%&#151;1.82%); and terms (3&#151;10
years). The weighted average remaining contractual term for the outstanding options at September 30, 2017, December&nbsp;31, 2016 and 2015 is&nbsp;7.49, 8.24 and 6.44 years, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock option activity for the period and year ended September 30, 2017 and December&nbsp;31, 2016, respectively, is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Avg.</B><br><B>Exercise Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at January&nbsp;1, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">292,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at September 30, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Note 6&#151;Related Party Transactions</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Introgen Research Institute</U> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Introgen Research
Institute (&#147;IRI&#148;) is a Texas-based technology company, currently affiliated with Rodney Varner, our CEO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2009, prior to
Mr.&nbsp;Varner becoming an officer and director of our Company in August 2012, we entered into an Assignment and Collaboration Agreement with IRI, providing us with the exclusive right to commercialize a portfolio of intellectual property. This
agreement was amended in 2011 to include additional sublicensing of additional intellectual property made available to IRI from the University of Texas MD Anderson Cancer Center (&#147;UTMDACC&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Confer Capital</U> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Confer Capital, Inc. (&#147;Confer
Capital&#148;) is a technology commercialization advisory services company affiliated with Ryan Confer, current CFO. From time to time since the Company&#146;s inception, Confer Capital provided strategic, financial, and executive managerial
services to the Company when Ryan Confer was not considered a payroll employee. Additionally, Confer Capital has also incurred corporate expenses on our behalf and was reimbursed for these expenses. Mr.&nbsp;Confer provided $65,000 of consulting
services to the Company during 2016 while not on Company payroll. These services were booked in account payable when the service period concluded in August 2016 and paid out in December 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Genprex, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Note 7&#151;Commitments and Contingencies</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Commitments</U> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a clinical trial
agreement with the University of Texas MD Anderson Cancer Center to administer a phase I/II clinical trial, combining FUS1-nanoparticles and Erlotinib in Stage IV lung cancer patients. The trial is expected to run through the end of 2018 with a
projected total cost of approximately $2&nbsp;million.&nbsp;Payments are due and payable when invoiced throughout the clinical trial period.&nbsp;The agreement may be terminated at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2009, we agreed to assume certain contractual and other obligations of IRI in consideration for the sublicense rights, expertise, and assistance associated
with the assignment of certain technologies and intellectual property. We also agreed to pay royalties of one percent (1%)&nbsp;on sales of resulting Licensed Products, for a period of 21&nbsp;years following the termination of the last of the MD
Anderson License Agreement and Sublicense Agreement, to IRI and we assumed patent prosecution costs and an annual minimum royalty of $20,000 payable to the National Institutes of Health (&#147;NIH&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our $191,393 payment obligation to the National Institutes of Health (&#147;NIH&#148;) represented a current obligation, of which $15,393 of 2016 patent
prosecution costs were paid in the fourth quarter of 2016 and $176,000 was included in Accounts Payable at December&nbsp;31, 2016 (consisting of accrued annual royalties of $140,000 and patent costs of $36,000). During the first quarter of 2017, we
modified the terms of our accrued royalty obligation to NIH. Under the modified agreement, NIH agreed to extinguish $120,000 of the accrued royalties payable to them in consideration for payment by us of (i)&nbsp;accrued patent costs of $36,000,
(ii)&nbsp;a royalty payment of $20,000, and (iii)&nbsp;a contingent payment of $240,000, increasing at $20,000 per year starting in 2018, to be paid upon our receipt of FDA approval. The payments for the patent costs of $36,000 and royalties of
$20,000 were paid during the second quarter of 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of our modified agreement with the NIH, we have recognized the exchange of the $120,000
fixed obligation for the $240,000 contingent obligation as a $120,000 reduction to intellectual property expense (classified within General and Administrative Expense) during the first quarter of 2017. The $240,000 contingent obligation (and related
expense) will be recognized when we obtain regulatory approval (the event that triggers the payment obligation). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Contingencies</U> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time we may become subject to threatened and/or asserted claims arising in the ordinary course of our business. Management is not aware of any
matters, either individually or in the aggregate, that are reasonably likely to have a material impact on our Company&#146;s financial condition, results of operations or liquidity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Note 8&#151;Income Taxes</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provision for income taxes
differs from the amount computed by applying the statutory federal income tax rate to income before provision for income taxes.&nbsp;The sources and tax effects of the differences are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provisions at the federal statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of operating losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-34</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2016, we have a net operating loss carryforward of approximately $6.8 million for Federal and state
purposes.&nbsp;This loss will be available to offset future taxable income.&nbsp;If not used, this carryforward will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Genprex, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Note
8&#151;Income Taxes,&nbsp;continued</U> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
begin to expire in 2029. The deferred tax asset relating to the operating loss carryforward has been fully reserved at September 30, 2017 and December&nbsp;31, 2016 and 2015.&nbsp;The principal
differences between the operating loss for income tax purposes and reporting purposes are shares issued for services and share-based compensation and a temporary difference in depreciation expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Note 9&#151;Subsequent Events</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During October 2017, we
received an informal demand from a former financial advisor, claiming that it is entitled to a warrant to purchase shares of common stock equal to three percent of our outstanding shares as of December 1, 2015.&nbsp;We believe this asserted claim
lacks merit, and we intend to defend the claim vigorously. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Up to 4,500,000 Shares </B></P>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g486549g08p69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g486549g30y40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through and including&nbsp;December 9, 2017 (the 25th day after the date of this prospectus), all dealers
effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&#146;s obligation to deliver a prospectus when acting as an underwriter and with
respect to an unsold allotment or subscription. </P> <P STYLE="font-size:80pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g486549g02q86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g486549g02q86.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2Z 4&AO=&]S:&]P(#,N,  X0DE-! 0
M     +8< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP!6@ #&R5'
M' %:  ,;)4<< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP!6@ #
M&R5'' %:  ,;)4<< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (2F%N($=O
M<F4< @4 +49I9W5R92 Q($]L:6YK(%!A=&EE;G0@4V%M<&QE<R!I:2!E9&ET
M,3<N<'!T>#A"24T$)0      $-P(EWNID@P%I658L\;Z/*(X0DE-!#H
M 1L    0     0      "W!R:6YT3W5T<'5T    !@    !#;')396YU;0
M  !#;')3     $5#35D     26YT965N=6T     26YT90    !#;')M
M $UP0FQB;V]L      ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R
M3F%M951%6%0    . $P 80!N &D 90!R "  3 !$ #, ,P U &,       ]P
M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q >/            IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ /      0 ! \     !  $X0DE-!"8       X
M        /X   #A"24T#\@      "@  ________   X0DE-! T       0
M  !X.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@             +,   "%<          0
M                   !              A7   +,
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   +,     !29VAT;&]N9P
M"%<    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P  "S      4F=H=&QO;F<   A7     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
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M# P,# P,# P,# P,# S_P  1" "@ '<# 2(  A$! Q$!_]T !  (_\0!/P
M 04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !
M  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!
M,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?2
M5>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'
MEZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12A
ML4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+R
MLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'
M_]H # ,!  (1 Q$ /P#N/0ZZW)=A-ZS3ZGI"VL/QVONB2RVQS&VTL]'U=FS_
M +:_X1%ZMG9G2.CY>5ZU=^56YUE+;1M:&/M#*JW-K._;4RS9ZBT+_L6/9]LM
M;6R[;Z3;G;0\@G<VAMCO=M<__!KEOK#;?D4W/OJ#'G'R&,;9%0+&YF)73ZKK
M?WF^_P#T%J= 7*(/4A(<JWZ^=0S*FU748VI!#0;6'<TRT^JRQCJ>/:J]'UPZ
MC@/<[&PZ6N$L!>_(>""0YT>K>_\ D^]9-F$-['-H#JK@Z+ 2UI=M]1S:VVN]
MOH?N5[]ZHV.'MKV^ZOVNUW?V&Q_*5F6. &L1]%X .SWW7?K3F5=-Z8Y^/58S
MJ6)]HNDVM#+ *;:=CZ7>HVOU7K ?]9\@5;!B5[G#<XB_*')#G!NW)]3Z6S\]
M&^LA8.E?5S?! P&NB>8;CGV._>;_ ."_06(RFTO+!$/ #)(K <=NQOY_^D^G
M;_VXHX8Q*.R@!V=SIGUYZGCVU8E&)CLJNO8'R;GN_2.96\[[KGN^C]%:_P!:
M_K+U#$ZA9A#'JMQ:BPL>3:QX=L;9K9197M_G/8N)QV;>H8L B,BEI:>018P.
MW#\WW+IOK58!]8<QCOYL^EOXC2JMSG=]VUOYCTL>,&9C+L@C4:-#_G/=Z?IC
M#JV1!'K9)D?^Q"Z#H?UQZEF4]0%E%#!@8;\BD,WZN8#M99O>[V>U<S<RE\M>
M-]E@(=8UC0:WAVX.=M+&>HYO\[77^9_-JY]56O:WK1(&O3;(\/SN=1M3LN*(
M&@5H1LG;_C)ZM8TAV+C /$<V:2/I?20<7Z\=5P:C3CXN.ULR\6/OL(<0&_2O
MN>]OM:WV+G&-8 "8=]$@CZ)!V^V-'-_E*5P^DXDEQ.LS)CV_G^Y$XHT= N$1
MV?6.B=5R^I=%Q>HNK8+KVN<^IDQHXL_1EQ_=;^<K.1BT9-].1:QQ?CD.KA[F
M;3(<[?6UXKLV_P MJR_J<YS/JMTUH@$M?)/  LLW?UEORUP58K#OMU0C(=O=
M6YNH$AP^CJ.Y23.KK]5I?(=KLDF"Y)+16G;H_P#_T/0^O/->$Q[1)]>@< Z.
ML96[Z37_ )CE0^M]?2W]+S!DC?>S';N8U^Q_I&VMVCG-N8W?=4W_  2W,C&H
MR&M;<P/V.#V$B=KQ]&QO\MJXSK0R;,#,&4+!8[%+OTIVO:W[<YU0LVS7[*?3
M^BB-PNA\T>NH>:J.!=#6U9/JU@%C3E-.T@L]O]#]ON3Y]F :V66X=[7@['U_
M:6M'=S;&;<5V_P#.W_N*N*;_ $+'4DM8-U9,"7;?I-U._P#-_P &B6_K6-91
M6TEPL:YI=.@.X/M<_P"BQOT_8I#DD0?4?M;9Q0X?D(G7I/[_ /==WKC>GOZ;
M]7GWT6FO[$!6&WM:&C;C_H[RZAWJ[F_X1OHK'?B=*V'U<>_L ?M;)$?FVM;B
M>WVN]3W_ ."6KUPG]E_5RL"+#@C1T00&XX>PRLAS!C7.L.UU! K>X<-$_3_>
M]EK/_!%'Q2 -$^2L..!C$RCN:E*Y>G_T5EMZ;5E8;VXU[@;JPTG);H0]AA[6
MXGN_>^DM/ZSNQ+OK5FXUF-;8X,8]]E>0VN0RD7._1NQ[=GL]ONL_2/68VAK2
MQITL&37: !I]*O=M_KL=O5[ZVN:?K-G;&@V-%3'-(F=U+'>I_9;[6L_/3X&Y
M63T63QUD JA6UM&O(Z=DG;7C6[Q(8X9, D1N]0?9&[OI?X-7?JQGX[V==J;A
MOI=3T^YS]]VXF-P=7_1Z_3_KN]7TUE.R*F48F(RUHO:TD%KG/+;'.(]/U/\
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M;MW?2234==NC_]'U587US.!1]7<_*R]U3!6QEE]5;;+0PV,VL:U[JM[=[_\
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M?@/>W8\]6>7-B#,Y<[EFXF2#FGI/20+,3.JK#F7RST\@L'J746?3KVW.V_\
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M300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M     0 X0DE-!"(      9Y)22H "     \   $#  $   #V"0   0$#  $
M  #D#    @$#  ,   #"     P$#  $    %    !@$#  $    "    $@$#
M  $    !    %0$#  $    #    &@$%  $   #(    &P$%  $   #0
M' $#  $    !    * $#  $    "    ,0$" !X   #8    ,@$" !0   #V
M    .P$"  D    * 0  :8<$  $    4 0  0 $   @ "  ( /#A/  0)P
M\.$\ ! G  !!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$W.C Y
M.C U(# W.C X.C,P $IA;B!';W)E   #  &@ P !    __\   *@!  !
M5P@   .@!  !    , L           8  P$#  $    &    &@$%  $   ".
M 0  &P$%  $   "6 0  * $#  $    "     0($  $   "> 0   @($  $
M             $@    !    2     $    X0DE- _T       @      0
M /_A :!)22H "     \   $#  $   #V"0   0$#  $   #D#    @$#  ,
M  #"     P$#  $    %    !@$#  $    "    $@$#  $         %0$#
M  $    #    &@$%  $   #(    &P$%  $   #0    ' $#  $    !
M* $#  $    "    ,0$" !X   #8    ,@$" !0   #V    .P$"  D    *
M 0  :8<$  $    4 0  0 $   @ "  ( , #   !    P ,   $   !!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$W.C Y.C U(# W.C X.C,P
M $IA;B!';W)E   #  &@ P !    __\   *@!  !    5P@   .@!  !
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M 0$! 0$! 0$! 0'_P  1" *Q @(# 1$  A$! Q$!_\0 'P   00" P$!
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M6;O,1@A.8;'NI.)B^'6K*8E0R1X.0%/->2B55S&W%FC9@A0*W/CEE7D=9_\
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M9WSJQ[8:>WK6VI)U[DL2S15H^;S&"O)P:/N&+BAYR*SJ'4*@(7T <949BOT
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M<5X6G'C\J^W[?Y_75;WS_I:'ZUT/MC^_+Y_C[ZD5\9Y._P ,WJB1/SIN.?\
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M9/MG]?8@>/?WX^?<GY_7(S%"1206,;M$'9GU2))ZPU*>-6&RN5JI$UI9@%E
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M>%BDD8AL)X5V:3*A4;'J"@<B@5@YX(Q$8Y <0=>1'-.6,A("C+2REN*J![#
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M^+CCE0+.4CE+"-Y1$W!7XE<Y\X!/%FX@Y!QK/6:ZDJMM\:RVA_NXVQAE)"R
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M+O2)&9*RYPAE>#LX965SDKK \M=+7[)\E7Z\S=UMF'9W5C7Q5RBC : ,( Y
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M@Y9+[$FS98&2INVU-0:TIGL5Z_PT<SR -<=K*U93V4*1EO2C2EG@8D5YN!B
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M%0"H(DC"MF&6O*TBPLDD?.*22*5%D'%S&ZX:-C\G&""H(]]/C)H\7R)%4_.
M+0&!RE!3"UA0@<<T1S)G)(YA,<@DO<F=ZHZ6)C((4:,U\2>67Q/I)'NTS\V/
M)\K%"TS#@Y1E$G/V( \>WAF\ AR#>JS[!/L,(ENVJNX4I)#//,BVNY4*N[CX
M>)(6L,\2")&9C*DA4@D85F_UV'N\)9H3!8Y^\%0.$IY%"8VT"@CD\\+P3T="
MQBF0LC[F-'4H:-LJ>F4[\2MPRU9ZCFQ'Q[<?AE"MC"CB>2-DD%?+'RI'(>/R
MZJZ+?:O]ZQ5)HJ)=A&UR)(Y)X1Y%@5R[N(94(*LZJ/#+XP,K2$'D7DV"FXSH
MRJ.2#'UN@T%;5$F9;*M(&.B$MK&)]D<ZIDT=P2K8XP*\TDXUPT30ZUOI-6))
M6U(]MBM94B,0KOP8S3)( JI&AC17XJ6+=PA(X@&Y2MD\S%[LE?8)+5R9YNY?
MDJQ6Y(A/*HB>/E K(.7:B1'//@@0,<@DE1K&C<@FW.+WD1N6IY;BP*R,2:2A
MI(:&3-YVK98 -SX8><& J8*JX(/%ELE*&<0:75@>H1/*^;U->K))-0O2LS))
M&[1.L8&).Z\4<2 C+D5P+!3#E1'+(.)\'6&G2IUI8)&GE<CNK#4GD,IEG=EE
M>Z9)G::22NL9XA/$?<8X1<C74E)V-!%H,I=):92GNK7.3SU-H*775XLRBSP5
M.HMA'02&(T&ELII()61/=/!9N6-DGK,\V(BTLEB2>)*T$I2O5=%C$:)E8YK#
MR L>:I"G<0RH"Z>L(0IU(QSQM'N6]5U>P1"]6D8.V5>/NDR\F/, +)71 5*R
M,X5#)PY!T;>5552T\-TRW)TU@S:7N: +6 >3,'T61!I?E"H4++6\D^H,M@E&
M#,K*X *J@CAB(/)F*&J*S;$>VQQ[G+C<)4M3542R!+4*5E:&*-T)(D7';>/M
MS< @9 /"2-5Z\C2R21-&($-2.9U!9;"36WGR"57MKP,<A9@S.\IR0F%+M^?8
M0&RSSI7""/F;&CF#>LR""2-55SQH5D<D;)F]D?%(Z5K7>98U8Q48RH[QO-?<
M6GE;:JL,T]>K$'A>54K35RQ:6M$,*B3QE(Y(I#/C@7$@+X&U%'(N.5B20 L<
MN$+,&  61@HY&/!P1Q)!'+R"3:I\$%%3XFW3;[?WO+OV[?A_S#>2/?\ ?V7[
M)W[??^OOS_<_,6?HRGW/MD@>!XSY_P"6OFX$_==WQXX19.,@?VJ >3]<^/EY
M./.O0.\0.J1I"<C;^@XWS;]!H3V 0$6%?25\CV>HDEQ<DL!KF.C\S%6%D\B$
M&/1>T 4!)#OP1.\;52I-<F[4*\V6.29AG&(X4+N<X.#@87ZN57W(UM4ZLENP
MD,:,_D,RJ"6*<E#!0 26/(!0![D>WOIBLS4-W@E5I='DI83:'N=G7_3*YA(@
MS#Z\N(]"!!AY2RBBPH+;NRJKIQ%GL!F59#DC(EWII6JM)!!/Z)<+.0[\7)1U
M9,%F"JJR-&1W'#\5;N $JMDGX52R"RC"8O&\,DLI7EQ*@ ,Q[85%X(2Y&3$3
M(N,:D^TB10YB&BR2%PQ22?(Q3Q*^:2%LGHQPRO?% D97D11I)5@8K7L<0D+V
MR-9$\1R +8!(!8@X .,D@ GTY]0&3D8&?&:J5 8 MA20.94^ <9Y#WY)G# 9
MP1@$C!/>8J/:U_E5OF:UW9R=G)W;]G)]T<B+V5/NGNGCSKP?!(SG'CQ[>_R_
M3YZ^_P#I_P O_3_ GAKYKY<JM:YR-5RHU51J*U%<J)W1J*Y6M15^R*YS6]_N
MJ)[^&FL98W =9Z?S*%N65'+&P0 TZ1_D?%&_RQA#SO7R^JCU141?3;)(U',B
MD<SVD;29X\1CW+.J >"1Y8@><8^F<9QG61(V<$KQPN,Y95]P3_>(S^4_QP/G
MKXGM%$M&A$C^F).$I(QK%DF60B&9S3!YH(H'?+MBB>))&0^563OG=#V9(QB2
M_0@9.0.6#89<  *1Z6#$^23R!7'@ ')R<%C+J64@E2 5\ X/L020#DY&!DC&
M3XUA=3G8]=60- M2JDR L4N"SK97#%^4=_J/ GGC\I+!2.Z(4-YF*JM:V:-[
M4?$_)!*:[Y:-9%*D%)!R7U>.8!])8 >EO./<'(!&6&=JY=2O-'5E:-OR\L$+
M(!Y7FA]FP3QY $9R%EXU]:VCPTT>&FCPTT>&FCPTU7#RY8\F8CH1Y!ON  -@
M!R@;HR18+/B3 56^Y,!JM#U"MI-]J\?BSJ:[K];L<WA+;5:.E"MJ>V%ELZ^*
M8P,F%LL;FFFE^%WH8(ZK1<?ZSISYQQ')N5M.5XJSGCF'I"H^GNWY*X9@Y2E;
MQ<)K-5D<-A,C;\B%8TW*SW]+345,VT(SY]^14Q&"%R>&FH,_%+X,7.]36RY6
MQG29E.2*C;<1\8KR=K==D^M?E<7D7233=1 -'Q]28/@#D[)X 5L%KF,%C+\"
M\J+ 2TN.H+-7VH@J\N%JKXAIJR'XNN4_6[H1Y!KHZZ$V("\X^O):*>T;0)9"
M4VHK3":B(UD[$@*G&CDA$AC8=ZA*11- /1?EY.@?9A.M?K';Y&=H_P *XJNL
M9EX,]:1%9D (*!B.9; 5<GDI 89H'*2 #BK2@PK*PY" RCCWPN5Y-$"61<CD
MV!GSK5]Y Z5^*N"^([#J+MLH^R'VE-1"X?$BZT;1&\=ZR*6."WM[DN:RJV:C
M.Z/M:#@A2TI5C7-BC>4*,Q)SAOT/#N,NX[G)5KL5LUV=[-M:Y@:[" Q2* !6
M,4\?*,RN) LF1Q9SA#YVKJ#<;FYU=D8IVZ\LZW9IZP2&W5D5C%QA12D5FJ!W
M,K*J,Q Y<T')-Y_28\_A<VRI^)C\E&[.Z+,W7($6BV+<I>4EY-)F ]GJ<KEV
MWKZ+]7KJQ#OB\T^F55^L4Z@DO'M(A[*0ECM_'H'NI*#)',E0PUS8AFB_&->*
M:?M"43Q*T8D[@([<@<*4)3Q-56+<#7EOK<M)<AE@C,<*MQ2,2M!!9F,+-*%7
M@C]_#A6#Q!X5Q$R_XKN[/)<2Y7@^]DUE'RS7UUONJ07Y66',<ETU@13'NO[B
M(*/Z'FW#?)W-:EJ8-&&)(84; ,C&2.PWH;<;VUK1Q[<D-II1*&9'>%EBE1X.
M4A+EF3@ZUXV;N1JJDJY42<&XQ17-PL[M&T$^W.\55WY(\M*3,D8CB9\2S@ED
M9E5B^5PS>=-ZWI-ZB/UFL\\+QMH"CJ::=Q]B"@Q=+",-/#$1:178LT@!%;$A
M$$[C!9I6M@ECE7RM>BK7DH3B5;!NP1&5N8L=\(Y:0DMA 1.KG#$H4#%@P(R<
M:W_]IMG$*S_&*I<<EC*2+-R(8\./'(8D8PV%S['4I-KTP\N\=<)H#MM=7<:Z
MEWU6QN)=;R< 'F>0<%)7U-C0T&4:(TB:_M@)X"2R:9SR(QH2 I('1*7(.R8C
MLB>L8*]OOLAXFS'38O7F[LRV#8>15:&)XF$?>"AW*$'TC)A8^HZ.X[IW!5GO
MQ!88X3%4YV(+"2,'>R2YP@)012$@A@5(/%&$=='TX9*DX1K.5!>=^.[S1%TP
M5R9@:>9QUA73V%K7 19PB<6:8H._%#/DLBX[.KKP/+7V@T!<KPV3E0#[*D\<
MG9[W.%ASMMP^#9.V6Y#B.83F. D#R,Q*9AC!/&4K[Y8EW8[<VUV8HFDDC2S+
ME.0B1V:8!PJM$> "\79N+KX/+BL226.B5S7/[JCO*JHG]\B+W8O=/R^WXOX+
M[^*EN=:2I*\4LJRE25Y(6893P4]7$Y7&"<<?^$G5EXG /OGR"#[C)]L>"//R
M^7Z<M8Q_?NJ>WW3W7[IW]_;[+_>^W9?;M_OUZ5\DGR0/&,>^"?./8^/?(]M>
MU&/?P3_E[?M[G]?^68,KJZ*DI;(4^4DPZ>U&LPI!A8(ZV8%XKA4'D98$&&Q%
MB%Q3R$35U>/'-YQ!I#)("7PX;<,"4*UM9&=IYK$$T>%5H7@[;+P',R.KI('+
M$!%8E,E@=84DD:::,H%1%B:)PS$NLG(,3F,*A5D("K([%0&95Y*3.[X=M8/;
M]:W1574%O8W-P/U1\?VUA1D 0@@5]#1:'*7+KX2P(/<V8Z<$"[2PKF0I*V*E
M"06<UY<,,6SOEF.]M$U#;]U;=H:L-JW+#:IQ5# D,!E^(@>Q&]@RHH9)%CL3
M-)B-0T<448;3LS=B&_+9JPP1RTEKQSJ_=E:>3O0)"P5,B,R21NK^!F1BP7#$
M>D#XY#JF:TL?CD\AVW&_Q(%M::LH[(NYZ;,/EI%NA89)1 +VZUXUE/26$LD3
M\]=S ^O7C:,1\=A40&DDUY A:1%0=&Z%W5]ODXK7KV6FF2-%L3FJJL\D9\3\
ME2-68)W>[^$RJHD!0$&:K4EO[>('>5 +7=4Q$#,L8';$BX/=CY'FT+>B0HH8
M$9!J]P/&.3Y8XBY9*:=CS><,\Z'0CC:'?;,$[.<>Y 0(*S2F!?DB,=?$D,FD
M=+-9<D)*R$,4.ESB2I&TCKMZE5W9[36*]-]PG8Q2+5=K45&S_NJJ/:6T+0$:
MJQ<0TS5ELMF1PH].!ULT]PVZ$-.-MFXPLT-:%_B+=EF=!(BR"S&P/%>VE,2?
MF+,<EM18S#52S  M/K,V;^KCGV]*$=+53V"5G\X8R"1P]B,#:,!E)A%L2:\K
MY3UGO])_9T$E>V*I8:U#5D>W#46Q(XKLL\0$M=5D<,D<W-'4A&9\QE\'$L3@
M8MOW<\JR+"RQR%9(XGFA\A@%Y!@I+87*OP9D60  $' #RWE;R F4!T!%5<K1
M;:TL+C$65W<R:$^W93O;66!D\))DI0DY?JUKT.L*JK98O"ADKEE$:D<-Z66Y
M-#;^ 1D([;4N\[6%:,#\.5_B'=H'E!$R*6(1E!8<FUL;1)50VZM 0->I"*.8
MI5*1R-Q9HPC"(*HSW76)9&,1YESR.!S<=<"<H<J$&'::[K^/,2^4@JZY#Y7L
M2:#'C6T%?868PB$$,ELK2V,@:9\L'1@V!C8YI)I(FCN>]:VM+<P)5W&::>"R
MIGEJ.B2@2=X(1'"+$<D:A9&/=,U>$#*EG $;0=_=%J2"O(OQ<QR11K1+))"K
MR@.J\2#74OQY#G%&SA 0Q PYG!5MQ_PO>61_(N*!Y>RJI/&RC#MGA5=T*0YP
MT[I[BN]8N&"!C1[(*,@=B$^M#%+$$8SM%:J^V-6I"MMUIZT*RM.ECMI*\&<,
M8PO)@Z^DD.&& [*"1@&>MT+-O:33VZY]VRRYE26:/\:,O'DPE>3\S&%8NPY#
MB?3D'#//F^E/CGF7"F6/&V?U<^]UM+?Z]A)OUAF<XLK:"Y)LH&R?*5-B9MX-
M'0O93>I' XJ&S^1-@8R%Q/;3W"EM[3223QTZY9H%BM((GLV+%F/PXCED$4#1
MS,9'5U(>(%2P=8V%'W#=[M"VJ7VB[-1DJ2=F-%;<VX*IG+2'$,A)[^ 5 _W?
M#PN*Z[ F"!8:0Z2Z4BKKU$E'NX6,<#;1%O<;7JV)WSS*=L,<:#,=,R:(ATLD
MD#(G(QE+MV%K3/M;FX6@@XP_&*&6*ROKDC=E(E:E)'&C5QW3Q#AV!0@#H%*^
M)HGKS2+84H_P,@!D4("OX=B5<R/$51PAAD*IE3^4D:<V7CN[T><H: ";BV2^
M=3LW:W=ALH\OH:NE1JU\6-+?K+B@RGIK++%>AC5@ED<<XUDH=S/!&=7@[&[[
M3;MT*,(GVY=Q@A@F1T;$Y@X<TB3MB3C7$C.>Y))V3)&I"1KB1H*[8DEEDO2-
M>1:/';EJ+5,T$LB2R$6::U4F<1*R20R.\BJKH%909(],FR*O/ID@CJ3(]%&8
M25-;NMD6O-KDA:K (JA:[SML(9E=.TUEOZ4PZ*/].6=$G7GDE6.S1*Q4I/O#
MG)*+:SEX;,0),D*Q#FO>7D>!5AE8F!RV<;=>A=M2RSEP5=7D$3( "ZN"P2P'
MQE@Q_"://)2 X*E=/1T?)VZNNEA%14_SR/!B_B^_^B?ET7M]D7O[_?\ UOMV
M]_%*NJZ\PZLIX>.8(8J5R,Y^1]P1C/@_/6O9'&"?TLN8I/<^0.#8!)QGR,'P
M#XQX]CZ<GB-U1]:I_P ?6KC+Y]XPLFQ_,3T_!$3Y()DA^58*;OM:.TQKWN]5
MI0YC!T:V.-['Q2/29?(GD?W/[*40[5NTO:YR+::/+E5C*2UX6 #$.5=.U(V0
MGY"5/+(XV/9,,HC><1CXAI8HQSYR2PQ"1@P,;0F Q@HX>17YF/@K ,5I%'R-
MOB,Y4:^_D$GLKR8:>FRUY5R60AE64!%/$=*7)%+2MAD<K&35LS8S612#2Q,>
MQSG1=1KPA(I5FE;OR1\9G[_JBD;B$@# +X+"0^F-E]916_#'.:VW=GOV9ZHK
M-:IIR17L2 1F9&X/&JLPDC'/@T<\1'KBXME P+AXFAR.D'T&J^A4U<ZL"MWV
M]-G+77!$@6555+< :*F<%/\ 1H!QBH5E95V;6C.>PM@9$/>)POU1#6$44CK\
M098$D8!$#]R5$$3Q9C;.)1B58^6""0?4'C-QAOBU*U!+ @19)(F=*]JI&T4;
MO8KM:FC:63E#$TI')F5"$=6'G7?K==U :^KA""UA9\QY,5[73SEUU::(&)#%
M+]3E+MI PQ@B?E8Y7$L*<6VQ&0ARQ^JZ0G;6C3J$LD$42F0\3$CR+P;WCD4E
MGD+@L.''"AP% "X32W#<=JLSDWW8R)7%2=>URKEHBG".!(AE)HF Y2J(59.:
MMR+,#('@>\S.,?R1GMWH=#D,MR3B*G91VB$5Q4]WIZN>Q*8^.0%SP@X4MH;6
M'M./&0<&!)+,0)-(UDNINQ>4TY*\<,UFG::$1N"H2&4*K^" S^ED/I. S' 8
M D0\VU7MPKP35H8[2P23UI7A20&M$%C=%8N"<]L%L!CQYJ" O$ZC3S%R)<Z^
MN)P;[2GHLUEX=#H%MZVYM#H=I96$5+-%1DI(6M4RU1P0TB  1Q^1Z%$3_-RM
M1SO4\8$CG+HLD2%G=4!4Q=P+ N$5@&,A)Y2.[IQ"A5)UL;)32FJ6A%)/9L21
MP&%XUC>M&78-:'+DYB  '/BH)]/CSIE\MQ9RAO\ +;"UQ=1::'&\?"A7VM=!
M8"1C4C2!I/[:96%'02F%1L85 OTX8HIK&^FY$;*U'Z4KJC15WL_[QEC2&1F#
MM*JYDB48PO!F(P_!2< $L#BSSSTJMBOW2JS6R(H9EA9C)G@2AE12/=E/!G'M
MG "^'E'_ &OXCC[+\:871Y:OGY*Y"RNM!&R>C-KMS%;_ *G,7)17]RXP"CI:
MXBOV!7<<@J(N.R^9:>1$((QJ9K" L7CBX&".:LI:(E!$7:24E"&>21C4'-@G
M%DXB,'D3J+G7;[E^Q>L5;!@IU+-833P!J4BQ67%AXE*L\TR&/&4+!5P O,@F
M/E7FM'RYRF1G+G35Z[G6WMO&7HMI>%>G=ZPEQ9$<9]^D5@V6TT5RU*X8XUZA
M265A!)8'B"+.;!7;%6K9EDAECCY5XRF8^0D$2A5C:%$XJ1"%.(P' BC95C:3
M$9D9GK;=3,T<!:M!&@5*R#*0 J.XB%DQ'&AYLI&>"L0I.-)_]D>S.*U(U94S
MDS8X4XK2#3HP(ZJ2H=Z=LDX);HBT^1(5T4JM@[(^-[%3U&.1(:WT=:G[CTIX
M)(QQ2)9V:*2:<IDQ1CM\#SP3'(Y2-\CU'\VEJ]2J?"DS\X[80UIDC<Q2=P#R
M'"X&.04C(;RI( &MP?\ 1\D[="E^G[NH+D!/W>_ZJ\>=_;\O?V\<-W<%;L@(
MP0J@C&,8R/EJ&WO_ *7'CS_9T_\ B2_U^WG4MOBS9NRV'P]^HO,TSY&6US68
M$.N]-DSW2&.Y8P;QQW>A^.*(F1C1YB'?S(L,LA)']KQ2^)3HV.:7J7:T@F>O
M-SL,DR$JR%*=ASZE9" P4JQ!\*Q.&_*8VO/'5GCL3*&BB8,X./R^Q(#>&*YY
M*ONS *OJ(UHH<2:_CS+Z*VQ/->"#.I+B>>HN]"^:[K]7B+49I \Q84]1/(^6
M)AC8FV<$E?93-@0B08<J5$&G_3$N^<S'4Y&K,83'<R$(:U)RCF$A?FTD<R!3
M'/'+&1(P+LRGFMDW&KN%B*'<-GN2 JJ-%73@:=J/*R1AHVXQAN)]);(.%4E#
MY&$WE!@<F:RTX]O*S1T%YQ[7D-'T0GU@L&[NG%U-E7HX.%PU%I@&"+I 839G
MQUB2_*1V5FL(LUCAL;:*D-J[6$"5G5H41D,\3EN,@,3EN2DKQ6-G7#LSJ4CS
MP10LWKF*UR.6O;CNR]Q8)1 &AAX2++AF5IJ[EQ"_;!$A"OQ 9N+:83.QZ;:4
M.;*&M)F7![ %'JAI2;15*8](7AAL:Z0F5CU9-Z#&>:=K5C9_2:J1.W4V>]V)
MD[6(IG82\H#A87<%O/H0%4)!\>3X.=2M^VU.E/:BDCS %<%SA6"N@(;&??)'
MDX!P/EC77(N;<,JW L1Y I9(7U9]<H4(#Q"1(6A/;((T>'Y4ECX5::BQQDRS
M>HXA7$.>_P 99[[O9L"2)E66-8C"JJI63MJG-05R Y)8% &925!&=25*\T$$
MD22F6M8CD7D[BP668\\K+*7(!!PI0C$9"H0F%5X,KNI<73BEB<:4ANVM*8T^
MGW=Q9FV<U'7*5+55EC54<1;JP(H&(*Y :V]&/FG<\"P#A"G#'(,F.\\<$8%1
MHYQ7R7)B"-&0V&=@'LF+#)P16B/H>/,BLX6)GHW>H;4[MN-DU*[Q1STDC*IQ
MA1&[4T[9D="K0<,'BJ\HAGD.*4I]?+CLA8T6?OE<#R35QU.YKNY,1D0U1>U]
MR-%\O$[Y!X4QH LH;YYR3I'B$3.!KV2"K/KT)*$)JQO+"T4\TDEAY@!-$>$D
M4C1)_P"+_"9P,DRN&5T4MXUGGK\GB>6,O+2>6>@48!))+$+PE6=SW"ZIZF"I
M%&G-1SG96XJX?6BWW'8=-JME6OMKN[^AP$' F$6])0#NKVB6-W8Q57<ZF%EB
ME;&UUH19CPM11QG#Q*._/(U>2!FNVT06#=2J9!Z5$DC5X9)(N</J$:JW?FCC
M1VEYR-R'(>JNZV*&W[I0AJ3A+"5Y6=>PM>9:_>D^#KQN2T,DD\BV'DB1>;P"
M)F7N%F:LW'"1X?0:,8\X\G.ZG+U!4@H$C\],!K:*XLP"&GR.B("L82: T5X9
M(BM+BD1T<@\H;XB*3N^VQ5]JL!;<DSU[$$A4_P"Y9;->O,KQ)YXR 3".9C(<
M!$RH[B:A8KDC6XJ[1K&D\%AUY.!,LE6=8Y RY(>-DD5E*G*^001@JV+%17+[
M>?O]D553V[^Z)[M1/;M[=E]_X=U\<]PAY*R!SX(_-G&,L0%9<LH&57(+#QD9
M\S-;B>0,:R,P] )*ACG\HXX/+WQ['Y>01BW3X*XH0?Q1NG*&L*F-!]/E=\!<
MXWRDI$<G W(\JN<.LLZQ=I'N9Y$FD1JL_IO[*Y8CJF"I5L204)Y+-7\!XYI(
MS$S\XU<^@@%5!8@9&?&"6P&;5W3N)MME'B,!DKU9)(F82<6::!\)( .2 G*D
MA6^3J&! W_O%/U1M1STKJ3F&8FOD0B4'C_8$"657&-.0^4^ON)J DTAPLD,L
MD,8?U$P,2&>-6M'FD/#LX)Q(TDX^[0 884VJZE9,@>AXUE"J&R >7 ,Q4^<!
M61@V;%4C;;.W*2O>O4P\#%Q$J"2,RH S$8;G&D;$E<]T=MAQ8EWJYM?5#^2K
M("2B@"C:YC'$2&(L$<D?J0R^:12&K$R-&-\KG=XW(QZ-1J)H,2QRP/-FS[!1
MY/MC 'O^WOYU'2B:8XGCF^+,AP2%[>&*X5PWY2#G.3\P7R==8:U2!"M$3$<*
M&\<B!U:6%"EQ']-8Y[(HQ0'2/G?-Y3"H!I'$$*TACA_20B2!/97)$2\">0(=
M6Q'ZO<EGP !E59O2H*^<X!/EH.06! &E&'Y(Q:(K(<%^1SD =M2R^/!#>5R5
MI)(R.-\KU[1L8Z1RHBN_"U/,JHC45SE[)[(U%5R]D1%54\8!Y\?76B 20![D
MX _4^-< 1HMB,PL*:,@:1TC8YHG(^.3TI7PO5CT[M>WSQN1'-56N1.Z*J+X]
M,K(>+ JPQD'P1D C(^7@CQHRE2588(\$'Y:[7\/_ )'[^_Y_;\OM^7MW^Z>/
M.OFCPTTE[B<*TG(RDGSPY=K1V"?4!H8/\KX"V2!?S9$[9&,,F1I$PT?H3QN:
M'(^=&HD39,T?) )QP(CD0]MB?65(;R!C*CP&]0/J&/F1L1I(D8LCB8TF12I)
M'-EP^"HP2H\!B#XY#'N#I$7U:3B[2VUU29/Z-R6%8Z00ET;PB9:VN"J1E1S6
MMGKE<(+&J.&60>652)"A9W+ V/,DO>2.O(H;M*R0%?#KS=I"/F'')CX;R!@*
M5]1,E22"_&*KA8YHU989/4Q*N[2'*YPW$D@>S %0"3G2FR_(%%J&MC'D<,=Z
MQ,$@<B.E;')!(J,3YR)BB*XF!T)(\;I62RQ2IY&.='*C,<M:2+!(RI4,#[$@
MCSZ3ZO2<J3C (R?!&=2WMUFHS!UYHN"73VP1G)!]0 .0<C (.3[97/C7UH:/
M#31X::ZISO($8_YME?Y!2'?/RI$L87EB>OS<B3JD"L&[>L])E2)6L7U%1G?P
MTUKR]/U3PQ/N>E*7._%PXQYRZEJOD[),Y @=\0FUY2!U^;%J-+'R-D.(^#V\
M@EU6G,ZA-$M!86N1V55<!\01EEP<2FC5^(Q]-(TU>%P+_H7T_P#X\WG_ *_Z
MCPTT\7AIK74^*%-B+KK>P>4T76GP-TKWD/3KG":XCJ&W=_A)*&CWEEU/<7W6
MVZ="*3EW'U]KRLIFAI;O15^GH*-GU3BSA>>HV5[5Q;3-5C34HOCH7%KF_AV[
MBUIK,H*T!W_$3AK&!S6DH]-I6L=(JL:D;O5;YO49Z?I/1RM]/RKY?%PZ%G>M
MU'6E1^#=BVN< @AJ[@A@<C&/J#Z@-2&V(LEM$=%D4I)E'4,IPA(R""/! \_+
M6EEG^J#D0=K@-B-G.4Z9\4[(Z+?U2656.5*PKT#6, EK95F")*0L=)9I&,=!
M%"Q&0^=COT#MVZ3RSQQ@B-YI$B$T#?#L"[( &9(Y!VV "OB,DKD@\AD3D^RU
M)0AB$M.9"'2Q4E,4J@##+GU *ZY5B K>HY8^=3HXSS&YR/3/MM;R3J-314?)
MUQ0B?1LG=H<W58X2&@A(!% #H2\G4G!3D5DIAMKK*:T$&JGL.J#'"QRLLT\L
M5C=*=>."M+:I1S.S.C!*UA^Z1EVD2Q+&RK((PE:16,F4<<SFIW+5:?>($V^K
M79*R/^-8BC#165>5@_=ED$S Y(XF(I)R(RH;&IJ<E\S=/'$?%YHG'1^PS7'6
M)L,$"07C:?1)JK?2.6DUT_%PVGETM('D;&SS5I8CV.NJH!)V#T5C55T]N/0B
MJ; 10;G+,;.XK7EGF2W(1-)"T,=<&6LM[X=893819TC*0R-Q'?667M-(X6H5
MMNW6_>5; BEN65L.5L/'V8D'*%[3Q=MY)0LR'$3]S+.CD*LF4IAT%MU(\C!6
MG)H1?*T?%=CKK06DM])L+F3/0N9:3W\=+]=M#:^NOC:GY<>:W,%A<_ZDT4DQ
M@YQ@C9)6O9LRV(H:\.WH@:%R$A@2<PH>V',29F6*7BRA0N'0O&&:-6X](AAV
M.J4V^2.@^X)70RK#64S$&-8FDXHLDD*RESP4L!AL+Z <3&+ Q7./33 3;<M:
M:78IILI:Z[#V^ZH3C)A0JR2CGO,W^NXF=!/N7VI,1"9/+7%A9#AW$0]A:OC'
M<Z;9MUR+\E5Z,8I-'*L5F"NZ\7$HG6&<UOB6BC"IYGFC16,9"(.X1JJ1FWM&
M\E8:<9C6.>.&Q\/.%.7#\7$!9E4(K(9Y41,QA^TN1QC#S?PO@@,YE1^+VGQZ
MZB=+F-Y7EP#&U>AOI"V*/;9'65US;U-M6R)%-\LYDD4#QF.E@LS'O9 S3M[9
M9M06(:D=&K#-%F,!.$CU@T,H2P)(XYH+$3QY9WY,_-T< ^=6':-UM=R:3<G+
MP6!\1#(&*-651)RCFKE$?+9'H 9@>.8U]PRU7TW\J6DU4VYH),13W0-L=4ZO
M:0GT^4/2H9,D@8UU#7G#2&&SCH'70-:JF%SBQL>UA,+W5F7IZU:#PLU;E7$0
M_ FADG7DH0#X>(L_E0))'9 0!S+<@Z-/S[YMD<321R/9:-TC>&LH>=>?]XHY
M0\$&"[9] R#\\)2BXH0S)ZK9Z>\7'4]/,M7FW6=7*Z;;:D4NJ==9FGA<2.3&
M934=BZY/)<,2*(OT^O+40JW!5\/%TW!)//\ %W'@I12H@GDKB">; D+]FO++
MW"[F,Q0*%=I9&Y+&PAF5?,VZ,D]>M4KFY-*.Y,L4@X586#=J>:149!')( @]
M0)'-EY!2-(_*U>1FU-&)M;2RJ<P^Z$'T9=/! 9:!U#Y&H:6!%*DD3YH(U5[(
MY(G^HB=HXI'HC'1=G8=HCLM!;O/#+7NR5IZQ,09XHT&9OB%=P@$W@DPAF1@$
M4ODZEK264JSO56-[BIF&&;*H\@!QS/(87(\98><$L!YU*WX=U45/UX=)<U2V
M8\2HZD.$CK J&-S&"U[^4\I4H3/YG+Y892K (7NU?>0MK?+Y5=VI6^[977[U
M^Y[%B]#ML0>:VBBM%'!)-\/)$4=NY,'[G$LI'=C,C=@1A^/F_)!'3F25U$D]
M>=(T_,K3+6FDX@XP658F=6'IROCCD8]*?QSS7/\ 6C3^D,)_G_QO;V_8-QOW
M7]W^7.V_WD3\_P"'?_!-[:?P3_Z0^WOY ^6,'_/V^F-67:?^BG_TK_Y+JE&O
MH[Y!I+,$2P<&P)2#;$$(DJ  25TL2O/G%CD^1:_T).SI/)WC3S([MW\O4=FV
MW<8*B7H)K%>*[7D5[5:M-:6K6+X<RF!3)'(6C.2B,8XCW.0!)27#B@T0EMK4
M>[#^"WNSH2#A/*MS;Q@H&QX\ALX[XAHP)XC*\TBZC;,1(]28"AFI!YO45C8(
MB))4EGB9)Z[&3.C5\GI^:5421;'0LP4;M2IM]JQND1:RTMEH[$2HL:\U1$),
MC3R!7ROH#N_%1D#4M5M(AKPB22V[*TD[$S%8L+R9(^6&D_*_D*A8XRJ^VI0\
MZ\IY_DGCKC.WS%C59LS(1.S1.!^G*)I,RP>@SH\)=3HW%GV&MQ-^94&7((5O
M)"3C+VQM088Y + (E]EL6H_@YK"S6*DH99UD,Y@LGNLS"/X'B(S*%>.)P%,<
M\0AE9EE@>+52VRG?H[E?D>><QS]RVEOD&CLCOR ))6"\:]U1,(\X*RQJOLT9
M&DOH]I2<E8,IO(N]V=ON*+/92GXT#LC0W9@0&HG:'=#FPS(,2 .+4-E95C@P
MK*=:L[3N+=W=XV++;78J04I9Z48O+)+)\4Q@MM8*-&)U@05Q+,)S)E)4"NZ]
MM%; &I6Q3CIM72HM*.O=EFENR!9([+3.A$+8+NW!93^,SLL:,IXK$H.N3?7/
M&E+Q)7\;O&T9VEJ+.DTF1O*D*?,YS3TFJIQ;+06VF$MQ!+6RL*M(P<_G#&5C
M1IH?J=@-9E"20L\:F_7=GVRG42:"<TYHS#!!%,([$C5EB46>4.(2DBREYS-'
MW&L'MQK%(LDL=2HK>^]'M2RH8<R16XUE$C1=N1E%>O,CNB*^.XX#>/0&3(P>
M]TH]5>IZ>KRQ% T.GH:#22B1FV.3GH1+ZG+'\\05M#87>>OWD UR33J7GF,@
M M(99DF7U&QJM.VOJ';FC^"W2N'A[R_#/9:>TD*2820RE[*%4'"(AE0M$>3H
MN!P;<WC;Z>Z5\NA-B \HTG:>:"Q"%;N03+'- 4,A5>$R_B)DJ/'Y?GGFW3D_
MD*WU^=I:<FQD^JD27V/HYW!\D251!27^SL W.(A:;8K$0?;/ ]"KBE:9*$,-
M' D3+)N%,6%@N;7+W'BB[U5X%@G2R@(@DJS2=L"6*#Q!#W92X 8J9)%1=6S8
MEIU=FJR)9$$\7%OAYY87:,2=F)=ND#,&$<;,@K&4AV68-GF!R8UN4M1*6WV%
ME53OI!)PZ\<UH5F^J=;6,[9/H3#AZPJHAL&U_P Y81#'FUZ*,$5,*LY/H0RU
MVSM\M*I=W6XE=U1HA#$L@Y)WG42 1%&7LQF0(),((F 8 F1<R,MZI2O+7LK\
M1// +$,43(>S7+$EF1F'.)94*(8DR)#W#@9(Z1"$6T-;654$3CIYP_0J0QVQ
M&H9)!$*-"'\M*UQTIBM8]T?RRE(4]>[Y'RNDD@[T\]HTTVTK!;B[,D->HD<4
MD,_:6-#6>*3DTCA2Y)0%).0Y-DNTI:$$>W"-)HD$;/;E6T4CDK<@[ +/\0BF
M/'E>ZB_#!>()4&1GPZ5J6>JZPNE^O+*"F/$ZCN"VDQ"DP',$DCY-RKW"/,%D
ME%DF&[>C+&//.V.3O'YW/9(QE&WZI-6=TLW8+EM(1'+B;XAZW9_#%:27)'<K
MJ%CX*9$C55C5@JD" >.O:VJU+!*&,<-@HDL AE[8#2&3\^2KLS,I]98MD 9;
M7I=^*EKFFM3_ ./8ZABZK.#RM'+8I5B<#2D$BUB-4DIL6ZV+HF+YYH$2#YI!
MHRGHY7Q#332QL>Z-&+U?[-;<-87Q8DD6$EI#&I<I(8(EE)=$R&*QK)P# 9Y-
MAUP3JU[)#-)MMZ2K)&MJ.6/MB0NH6*3MQS2ET5F C1L@<6!<IS5DY#5(%OO8
M]\< (KXQAL\(LE%33QV,^>KF1>5Y$=<-#-(6UTK((1W$/1LTOEB?([TV*J=4
MH[M3W69H(HB+>1,DLL8F5Y%(9G/^Y;\%0<,7B8(W%5(R&LL5;:ZJR25IA)8A
MK1"1[2+!'(\;.6[#1L4625Y% [D4:2RGN,JECG.Q$TM+7W4U%>5H^KTE,53W
M$4-V ^D'IKT%?FBY9$G>R"RA"F>"2,/)WCD9&,Z%)TG1\E.E&Q>EY6*T<ZJG
M(-,%8-%Q4.R<V'X#+W%\!O3Y++B36N;K0;=.U>.Q/7LEDF #&RDL=F?!%9@D
MA2Q $0S!)('B<EI*[<HAFN!R<Q#RK!4"V9Y.=AO0CPZ.Q<YXUFVGA+/$N+@B
MOF;!Z(1 @R$@1/59/J#7PMGC$?XS)/41K%2O<<RI"J*O-959Y45)&KR8+9XJ
MR\7( 8 @*'3%.W>O>FV]K(J1M+#7[UJ>/!:O \D:/&(V'(C\<!I?S(JN&QR.
MFZU=N+K]YHG4N-'LC=#/9ACTM>V[66M/AF]1+2DA#>*UR>G#,C 2V6$48:D-
M(B]96$L]VI(GM5:XBDL\%,-AWS"0L+$^)F(B; =@3R4Y !90>#;5&.:GMT!L
M7.Q'#VY^9$7;:.4#^SR<N;>DD*'0H<E0F0..GRSHL0'#S*\&RH3K@UNC'T>7
MUD=88'E\W<DT(8]MGAR95)!VWS8+'DS1EU%FT8@=10"ZSZE:@R$Z)WA&(FB@
MB6#MF-G!9PKLR6>/+N0+&[87+JS<N4R/P#1J.)=T>62"5D=HUK68N<9GM11R
ML84DQP->0D!5=9 PC4Y4@QNC71,9:<E:3CV6]S^:QD\;RLQ3:+O<0$@DA)FM
M/>P:%3P;ZHLM"\F.>H!*MCZJ65D,RR#S"R6,8[DR.'E_&A5A*(D<M(TRF8KR
M88RR,X3T*' R#R9D3>>9^S0HV5@G-C)BGLUD"!3D2PQ=@"6M-%$$9)B(UD Q
MR"H.&6L0N+['.<0C.%2^NTRVXL^1(*721X6WE6.SM;>E;:V5\)H,K&=3U7G*
MA_5^<V<Z"-V7L*NMNX&3D^B)'DG[DC 2+#V1+CAQ"0=U\0.DBJ)6(8,ZI$Y:
M8,\+E$S1W=R,6[,[_#I%/3AHJ8FLH<E8F1(PT=IN9X\7DC(X-S$C)Q(8ZLU,
M6,M.,>1,;GQ4L,Q%Y3G6\$U_1F;,"TMIQ4)$MA$K)5=3R4Q<U4'(4(D;F2*^
M$N::-E8M6%,E2Y2J2-$19I=I'DYK-,IA5$E3BQ+,S2\X\ %L CCR?=[7Q(NT
M=PG:5'7E$(NW#*M5E3 !C8L(TG5T+R!6<*Q'N"$OH=)J+*X()LW%U9-M,Z&T
M(D=."R5]G,LY+SIFM:KX"'S.(EC<Q6*S\:QK]DQ[A9ZEAN01O%+MM:PT%9YS
MR-5!*RJA:>,LB\ 6!PX=<..0U(37*5N*L$BK3PT*ZQUXXPDK8K)P4(?)Y@C&
M<YY'WRWG='^"#3P4'1]HJ<:TR]X,!SAKH(;K'M)^A6:,QG'22S0D%#"2'E0$
M),#8'L@2 DX0A\#Y8D9*_DWVE*J]0P\8H8E.UU>/9B2%7"RV8^;(DLRALH5_
MWA(555@I4J*/:D$LG<"68N89S#;</-#RDD81G 7BG$JZ(0"JL,C3Z_%E%O"O
MA[=1Z9JU?27PM-A[.JLX;5:0H8RGY2PUK'\A9MG'D&LY_DE'K/1GCGGL)1AX
M%6:5B+$=$P]_JC:(N;1\YI_4F>7BI8;AX!P),=LL0556+,K*"#]IO#'9A:S$
M)H.7&6(QB561P4/.,@AHUY<I!@^A6.#KSR3IG&^<^:P(,-+-*<2TM9YBWM5(
M'QFD&2*K2IBW2RLF<K_58\=9']TE8K>O6#$[O96>1Y9+,J]JPI:<5UQ\/)++
MZHY&*_AL!QX.N0&1@=7T.R@0K$L<4:Q\1%Q6(N,JR)%CT\%1/5G#!L#U(P*O
M[)0&8TW29]EEF+,&LM2!*NQ*K6["H$MSQC7-LY(BTK[*"<0S.ESB@HP0NK=*
MX,F59""[2-WLPLD%D0VJMJM!S[8$B2M$F(K CPA2>/\ #$R$@R-%AF"MD1@'
M?6V:\S16XI98TFEB5VJO(B$* 3ZXI%XSQAV]4;@94* BM/H.4ZZ6NV 51JZJ
MF)C958_4VE41 I*"LF,'KZ#02@M0ZXJHP96P%UQ*6 /R;88R!GI%$LS=AMO?
M,=>RI054A7N&(68VG_%>!@ 9#R"Y9Y>.?*.[%O7IUI=N*R5IGJ2,6>Q:C@E!
MCC<$1M-+#W<)$Y<%XG!1N18JP!;3?W-YH]-K3M+I+<JTU-A9.M+B\OB9;(JQ
MMUD]:4JS)(CGD)G*G:UKTG;+YY%2.1/+YG)$K4L-NT0@ACKR4U@CE:0M)5$D
M"*$(,:X59C&%6- "C85<8SJ52O#!7%>",BOV^"15PN1&? ,04J.*@DY!!P"?
M4/!D7I)[WAFXTNDW>=Q-]J>5PM0<#5QM$)IJ8;0$RHFHK*4=[&UP\CCSILDP
MR"$=T<41PXLX#1WR[$LU:D \\DDKO(O>BC9U5$B*_P!GYS<F*EF/?P,NY920
MW,C/MMRO-M9AIV=TJBI)206(Y#&UE((G2>G+-[R'AVA;$9(//@1G(#9"5V7K
MQ0SA<Y^L\Y3X"YI![ID+ 8('^J3 '$J>28V5KEA?&0).D#6J]D7F8CG^KL.W
MUF9J56&ZW<+(>]%^$N">419\,<D811EL'D5('*QUZ+ROM^YQU'GC2*R\U82P
M R3*7CR\<I5PL1XS)!$_=E!]3A<*N6-DFNL?S-K,+QWG0\3%;XNILGZ%(-/M
M\.!9F:26LGHC910V B&S!BTNJOQ*P=4.FH18?D)+E6/KURQ;EH6)U3Q,>%DR
M"0R?AI'W"%/X:X$D3+$'9DR[\69#*E6WN[1L;KM<866C86FY:" R5:=NS&$6
M9I*QEE[1/^\CJF5T!6:3DQ\&/<EF=]-6K^=,2L<:AR@)-+\BXQ(5@4MP_F])
M2DA\L+9EC61L2O8CFM>J.I5NW/\  -"7F[9L\E7 ,+,T>)BSY\R#C7XI@@*6
M)X''+$8E5Q+P02E.'+P9 O(GB#[\,\L>?S>3G&BO<'Z:,D;"A#BX'/E(558@
MK4>DK&L:B]U<]S7O5J+,K&HD"M[N1?.W3TA42,&FED[C%\;);B$SG:^'XPIA
MU9%E5N3-CC(2(Q&X E!VJJNUE,<#Y'%7\(3R#') Y> ",)AL<L MC%Q7P<_I
M(?Q0NF8"J8-**F;WKT*9(Z=[C"^G[>V1J))(YZLECG(E@G9&C&-ECE1L<37*
MQ(/KQ]NCLR5-N:.2O'!2*S(>1D?BC$LW)O)1@64^1)RR V1K+O%E_N>]6L0<
M9"N8'DPTA@&[@UO(!P'JA'5AQYH0S#+$MOJ>.:ZYQIE!P#ZK<WQAKS'TI,GE
M&!BISY$GGL9B"%5IZBDQ3LF+GC8C!)TD#D;(XF0$9P@\FX2K01JH'<]19C(H
MP$ 'Y>0(P 3ZAA@PXAF#'5E:Q'/ML$<9C$T2Q%I#,O)!$BQDF(,A]**<\E<,
MN  [<RO6L:NY?>O0.N-6KD@%/J02+P:LH_JP)<ROFA(IHYM2#8CP+&XR.2&W
MH;)(1HX75\LA9<GM'C$(8NHDY.DC+$TDO:=!@%92*[(S#TD&.9.3$\P%48!-
M&T96216=%1)) AY\6< JPE412*06*#\)T'NKD<-*,UU9$$(9=%$C=RYE"?(]
MR#H?)*1 JJI+A5=.9$AD@Q#I8F^@0Z6L,5'0$MP /R8( ?2"^,'"X4C\O+ 4
ME>0_X@!(O@C7F/G),R5HXR5';<,2LI15\A1AP40A%,?%R>"B6(+R4YVDLK6Z
M.E(286&K"G^4\H!0YX=EY(I5]9A$@,1@Q$;YHHS@O.^**>"*,<Z3TCFD?'5$
M4+Q)=AR)=61DR1XQS*LI )5\ D,25_(5T+$$=<88R=R1>2*X :,!R/6 Q#<P
M"5<?( F->8(523PQQ-6)K?(YBOAC:L<*R,[M\SHVRNB;Y>\C/Q*K6JY[?=$<
MBKA.23G.<X).3Y^A/GZ?X:U AS@^,'!."0#@GSQY'Y'. 2,'Z'761WJF/(@E
M(8X:&<:<2:":" I_F9(/*R2>%/,D*I*UA OJ12-(E;)ZCHF)'ZR O$@>2&##
MRRCR", _WO!(;SZ01@$Y^E>('+B>6""KHQ QY!522#Y'I;B01\LZ[H\WS \!
M'IR0^O#%-Z4S'1S1^HQK_3EC<B.9(SS>5['(CFN16N1%14\>2,$C(."1D>0<
M?,$>"-?&'%F7(/%B,@Y!P<9!^8/R/S&N-[12)%:KFNE@5K7I'*YDL2N\DK8Y
M%B>U[6R(C'K$]?+*WRJK7-[=WD#]#_+Z9'_,:^JSH,CP&S^90RGY$@,".0R0
M&'J7)P1G2#U5WFK,4K.2:6AKIW'#A3N/,&:L14/H%CP#I+-'$ZQ0E15@AD5[
M_,R56PR/A>C,\<4RD2"&1AQ+#BK8*'*EC@$\,<@3X'ZX/F1H)-7ECN?#SS*J
MLR+$I.>7*,\_22$XECD#YKZAR&6.U7'-944U?!$=;K0&LKHF352ODM@):Y(V
M,G7YQ5<9!*-%'#..3.^9[F1NF82G\W'O0VV:5G98S("Y(D'X;!B<KA1Z"&)(
M90 //$KX)LE3<9;DDL:Q*EB .W%V"(X<DXY>0"2<Y*<>.!@:E-3L;'4U<;))
M)FLK@F-FF1K996M&B:DDK6-:QLCT1'/1K6M1RJC6HG9/$6YR[' &68X'L,D^
M!^@U3)_]_-D 'NR9 ]AZSX'@>!\O \?+61\>=8M'AIH\--5,\&=:'PS*;D8_
M@G@.41_(YO4/H,H_"9SB[>DV8')^VN8]5MK^O9;4*P9'' 7NBL[G2$"D4>?S
M94>A*BJQ(F3/F?U_7\M-6"<"?Z%]/_X\WG^,#4>&FGB\--5\\M=#&WY9Y:Y,
MY ?UU=7O'F+Y*QN4Q<O$/&EEPM3YG+5U"_7K<+D-!?\ #FGV68)T;-9--)HL
MY=TW( !\*2IN#*^JPU5AV/?]=-1H^/8Q(_AN<AQHYRHS>\1L1TCE>]4;M:UJ
M.<]W=SGKV[J]5[J[NJ]_?Q8^E#C>ZQ/_ ).Q_P# ?4GL_P#T^+_S9!_^ VM%
M#,W(5%;#V9E7#<,&5LC0B9/(/)+&]DD?K?@57QJYB-D8WR.5CG>1S7*CF]WV
M'=(=MEFFEA:4O"T<+J5!B<LI#CGD#VQR&60Y8!O;5NF031/'S9"PP67W (PP
M/E?=?&<^DGV(\:<2HY(/U.RSZ\J:_8OPOZP0E:4?/DHXZ"EG(5UQ%G:TE_TN
M*PE"<0* XB)PX[GQK*U\,?D63H;U,UAGDM1U@JR2)D,$,B*>S$>RC2NI<J#G
M+<<GF&P3&VZ?:J2KM]:J+1BX0=Q552R^$,[*%D*KX9P&RQ4C))R%UM>I35Z_
M,U>2*M]!8TF;LB1Z "V?1K72YT2)@.<6]K!*B(2XU -0WZ:;?6,1=@0+!7#"
MF!AUWRI,K%U!1@DFFCIAYI9"'DC9HE=&D8N4+-)(BOD,($"1B0R.V6;TZ%38
MHJL[V.W7Y31HTK!9VD2=L&;X>227\. R>M8UP!ZN2,6#*EM5:9P+CK /IM<^
MWN[*6W-.Q,4ETVJXV<(5$')$X:S>;5V<VV?"Z]*466)HGHCQO@C@D:,S>M=2
MQ0PF:E#$LKB$1J7A)!XM(YEC@"N.PS&)5D8,Q;N D*0V:LEM[UU9:ZPP*.W\
M6%C2>^KANV1+#VI(_A4;MJ5'D$^HR#EI<]*N]X6P^_=I.<JNWT%+6% 6=5GJ
MJN (&NCW%H-8B69)18T(,$=:1,:"Q1U'EL114F.J8XUG?$5-YL35[=;XR"K/
M>L-+\3(76.-Y0>3#MHW$-(L8<L%5(RQP_P M7J&CN<]41;2RQR=J2*1F<\Q&
M%!0IR!9R2.+'GR*,1Q8,0;'!:NZM.;^/[3I I*_DCASD6MJICPM"5DR-32NJ
MGUU=R6191RI;P8%CWE_*-<%]4!19II:)8PRXQVR0G1MMF.\2I!;KO(!-6DL?
M"R*YD>GV&54%[P@8AFB8,"LOJ4DU$35XMKM1[\\M7<ZA?X<K&ZI*I'*M'(,*
M9FP,DN8F52"6=AQU&WK,.AQNBN:9VDT0'S,\-OQQ'FMSEM90U5.MR2EM7VM'
M1$S3YFQC/'F^B$J2"58@P))+'Z$38E^-<6+:UD+O5=@$L6DVV8SM*@C90K3]
MM)5DB?\ $Y,$C8GB_/(,]THGQ:+((JS(&D2V+=>6.7DT9"M!+(A6PI4J)8V7
MC&7##!8N*[K*VTNIO*F'2WAC76!HZBVFH.L9!1([0F%)[B8@MQ4D8Y#XT*/,
MA;(LK8GO19%8C6T.WN%^QO%,S2"E&LL(IR3IVEKP!T*3Q\_2KR=L%I.1#,Q0
M,(\$7A14J1V)*<$68PQ9*L<8=WB&0@5..9#GBJ$X4GB,#R?V?)40E[7A66[H
MIZFQ&KYG:"KBLS(:]"XD:^.R!=7LMHR*N3NPX:(&:61L+E%?.V:&1V&?IK:S
M/8L;QU+ T81(JIK]MK<C!5BC,L(D?M=I54GD6=T(+O'*V$U/BK,E9Y5IS]Y&
MX"O-VHG<H Q"N)"A5T/%)>14O@,",ZD]T  0A]>G1ZP2PALAX^J/AB&*>.*>
M%\X\?(] C"OEB8HIH89O9T:2-1[6^7U&QN\B+1>K-M>E5D^"W07:X B[$:3P
MSBLAY/8LP3*O&%G#)$5,J<41^XO- V_90MM,\K+PD-.QSA9E=XV->3D,J"IX
M'T\U9@WN"!@:]*;QS'7-]:-7Z0S_ '?PW[_V#\;JB+]O:XV_?\OO]O?O[=O9
M/?WF*#8B/G'K8^Y^@U9-J_Z(?_2M_DO_ #_C\_TI0I]3>U3/E!+<D8#RD*@<
M_P#;M;YIO2=,Y:PILX;G3N@B9,YPSO5C18I%=$YS%Z=T;OUBI;CJ3[VVW4$J
MV1$TT9LUXY6Q,%6%LQJSR LK>X=B!@R-G-;JP6!^)'DCCZU/"0<>6,N"C^,D
MJ.6/FN6]G@V'&29?*9'7,TT0VBO,?4\@:@6R," :HVTO[47+CYBL%1;*T5*R
MO2SOG-$:VM^>&<R/Z<\4HBYP5(8:8WAMW>"ZTL6YWI9$LM!:CL&,I')2KQK%
M$KR2R*I02R*R%654D41Z-#<I19FKKSBK=Z2C"\0<C%>$=\SOR)0>M4B.,MAL
M$N&&E'E.HJW2RO+CEJ&'DFVE"B_5\S4T&:O31"D"(&KW.N[:N72P5 $KJ\L:
MMJ[449(!R((8Q93%+CQ[;OXJM?BWJ5*Q#03T9(8V0=NRS-SAJEX6:.1"KAI/
M7&N>6'])RV-J'9A6HRTH82K25A--7^(0DD!4CRCLP+=R:1'8C@2Y5,:8?&9#
M9<FZX7-X^G+TVIM76)\%>*Z%DD[  RKBS,EE(F'&&&"!$+.,*((A@@&@EDEE
M8UO=*97-B_N[3PLMJR99+2M9(2-G#&1>?)VQF5@BQ\\-*57D.1.LMFY7JAK5
MMU[*,H//D4R[A50A0&/)V"\5SDG SYS@;NFNZ*VMZB^KCJVWI;,RIN03H)8B
M0+8.:4<P(MCD_FBH9XI8Y8W*KO,QW])$7QI74W)VE:VEB0PS,DTF#)%'(^&(
M[B<HLN K*P8B1?6"P;)\I)',J/&RLLJ]R/AQ :-AE65?^'!'L/&<$#VUB(HY
M)I(XHT<^1[DC8QONKW/<C6,:B=_=7*C6I[*JKY?NGXHR*.6Q/%7@4O--(D4:
MX)Y2.P51_$D?+Y_KXR*N6QE1R/NQ"J,_-B?2J_-F)  !)./9\L79TH&;MZ#:
M5]Y;53Q2):\+/:FHJ+.MT;IFI66\XYE7:FG5E>*^U4B@@^6',GG:3/. 6V$E
MW3ML)@V0[5:9G^'DDFGCKW&DL1!Y&YF&HLBRQ&!3W<+SB$B\IJ_-N1EH]FM0
M.ENO)!\9*K1M%(C2P/4* M$[P2C$LKB*2*1O5QA9 KJ.)[EB)27Q*9>LVAE+
M5D:RJCFLMS9V\$FJ'O"S8*K:ZBIK9-)GLG)FXWR2W<!5R98@BW<KA'V<D!CE
MB-SCJW(8:$MR>IVVK]YK6XO:EMI>XB"Q9B)$=:19UYLDJQ2QP/&THB/!6TXE
MN5E>>[6FG^'A:-Z]:LBFA%"G)*T$MD1RS+8=B(3'$(^<0)",R ,7/)-YD9(J
MJZ%%B:[V_"R-7)Y$7V[HUSG=N_Y=D[=D3MS.U+9K3M5FDD1ZLDE8L#^)'VW9
M&0>%/AN?$G#><>!J1:S+*L3\N7!,1.?!$8]48)QGT\B<G) .!\AJ6'1=0S']
M5O2\< 2&3 G4OP\.*"XN&702K7\@YBQFE=2 _-640B ,E(6SE';3-^5,@ELH
MIX?3=F?:X;-"Y<J;C 43O)6HVFD?<ITAAFGD+P55F$7&&$R*Q'PG  /;C8!6
MTY-T:!+$%B&20O2E5['D0H94,2!)Y"H8!RBE.9F*\0B%6)'I:>*9JD:U/?T@
M@JR#YWXM6K$C*>=P-+76/G!&,=!7/VFP*EG']3SD12Q,%GE>3%$C HF.G=-&
M]8W-ZUT%%9&P[[:I(DU@3B"2+BK2QU7K@R3Q@2"3D 60#MLA!8DDK@6C9YF3
M;Y8F,L4$FX0.\R@I%)+&@$%6:?AQ];OW$K&5>^ZANV_;'&A?ANRGK[W02"96
MEU)DV-T@H[+JU^DQ5$I0#X%MQ7*3".8:.R5T$ ,[)DF<0KHFP$11%0VOI(S2
M7; BB6600\^9D6-AQ8<8E8JY5)Y.,<C(@* !BX0,K^MX8+7CYVI:L9L0!^U$
M9>]Q<,(W4 E5Y+S+>W) "KY"Z:VP%EKSB@I_268:9T4OR\\14"R-5?,D9([Y
M(9V>_M)'(YC_ .DCE1>_B)W*"6I>LUYBG<1R2(Y#(JB0"10'(1FXJP4EU!R#
MD ZWXG6:,2IR"R+D<D925]_*/AAD^<$?+'ZG/XO0.S-\)8LDEAB5S8B9(/3;
M,D+I&/1S)5:Y6(R6-CI58G>2!LD2HY)%8[;VC<C2L%I>1@=0LP"ACQSE77)#
M!E?BP*L"..0&_+K>H2Q16D-@(\3))$W,!X\2QM"3*A5@T)Y_CIQR\)=%*LP8
M31K]E"NJKRL?@*^YS[,\6E.0=76EX9&>X.2GM2*N8<<PB8"0N?U(JXA\L(!D
M[UCD<D3)_'08FL3H)H[1>N[%I7@<*25D#+CB1$&(4!N+*\@!\.OC6?<*>U]G
MX7=;]"!WB1TLK,$[B!F9*[_@LMN%%';2P8XFQ&"BJRM&&GWF"KH:>&UUUWL:
MW;V==;6PI.CK8X1+LH.PKX/E"K$RZD-_M 2,@<5S U.L)YZYC:T>"&4B;U=I
M)>XQ"<URO+MSL_&)>XRX20", X8Q@(Q0\>;AG*$"KQVQ%8E%";;[M*.:*-(:
M1G,\2,LA[@3X6* %\!Y")F2,JXYMS&& O:70Y2YDK- *;56T+1R)XR&N;.UD
M[8BH95[JCI.Z*QR/:Y?+(Q6JJ/C=VI5R2[M5M8I)0SCMN9(B[K+&6!+=TE0Y
M#(%)Y*5*@!ACQ+0VJ]^-9HW$L;LP+L,Y )1BRD<L^"<$>0<X(8#3I:)]_HY:
MU\.4''S=!2A'C"26I+1$I:D F_MB*J;5'FO&AO?DKRR0(5I,,MG*<%6 $3,0
M=]GW"2^U=9HZD3T(RMF21^R)"D1BF8=O"E5:+^SAE,K,$RT@7+ZU3:H5DGHB
MU%-9GF=/C(ZI20RR.(D7,*1D=I7B4B0(R+Q+!5*D)0NQ9J9K\UI%U19ZYTN@
MN:?.0RO*JA"8X4(:Z>R(4(*<FOBL:X(PB$%A;QYV3>@+',,.^*HVX;IFLW=P
ML5(7L6)*D,!51'+4BKR/9DFF#(BLTJGLY/*1B/ UFJU+#RPUJR59)X:D$4]B
M5EC8U%)[F% :10W:=T#'@SX7+ORT^7&?*&-O<OI.)M]GZ_0F:'655O1;59>U
MT.E9! ')3R'EDPP0#F@0*/4E,K3)8BSITDK+![Q_E)':.H1NVX-7DG1WB[R1
MQI&K4IXTQ+'(RE5/?$@$H X=PJ.+1F-B]>WW9#M\IW#:IN$=;NQ/%$7R8R['
MXB/$89HR'Y.9.VO%01C! VO_ ('^,N<-T?:BIN*2UH6D\][RTIPKJ,:*Q?1E
M9K!1UY$[1'O'<]Z#R1ODC\C998I)4CC\_D3AOVB5S7ZFL*&A:)J]9X.R(U01
M<2A4I$2JNLJ2!CX:0CNL.4ASI6K<-SL2Q.LA$"I,R=SAW@\A?CW55^.&4@'/
M$'B"0-/#\8$T"O\ AP]395E7-M0V46%CD"=,Z#SO(Y7P0P\[9&M?V>&3+";&
MQS712R#MBE:L3WIXC.C;<='J;:K4L(L1Q32EH2%(<-6G0>'5ERI8,,CW (P<
M$>MO4O=K*)6@S(#W47FR@9) 7DN>8!0^H$!B0<C6A)H=KF+S+. DXXS=?JG'
M"%#;?/$6%&5,+"Q\!@=QF(2"<O,PV)!I(Y*6NSL@AD1$TGSS25C9W2WN=*S
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M8/(L $\9;&<A<<5 '@(GSQX &-B%)96$01N8D+^8W9?(!8.$4NJX7)XJ<CW
M !&.;?%SV 4-9 ^6H/;/Z]RKXIXJZ=ORZC"_)12/G_RP0B>44^54 :HK8NTC
M2@UD]=M0C%CAU*XC\@N#RY,&/CT84%!ZCRSXXMC.]7MJW>/XT8/X*@J9  <L
M9& 4A GK1<R^3D*P8#YMH1(/2<6\R.)EB\[O"R6&(@Z&&:1LQK1H6QSPQ0PH
M1YBV-BD,BB5'2O8/&GQ2QS@*?1Q]1!(!8?DR<\B? X^0I/RR=9*^7.(Q$7:-
M4(.&98WPI526Y(SNQ0<6Y*AP>.6.OO-CY_W@JAV(^,=CCBI(X9C;%TC&L26Q
M.D=,:3.]J(K_ %IY'IV6*5R>FQGC[*\K>)&R,GBH\(OGR$0851GY  9]OF=8
M[D5B'US8R[XCP7 CX?*, *H"X4 X]@"HP<CZLZBJBE<-&.(]+-C82A)HDE1\
MT<;!P#'/1S2(D&[QPND:]_:+RNC8V5KI5\AFP/)].<'Z9.6&,$'/DX\>?.<>
M->Z]BR1WFDD7L-S65?3Z68M-$/'!C)CD%88)7!/'TZ5HK$C%&C16N2."%B.8
MY7,<C8VM16N<YSG-5$[M<YSE5.RJY5]_&,^YU'2'E(['/J=CY\'R2?('@'Z_
MKKG\->-'AIH\--46P:+5 ?$ZW6.OMUIM*PCF3 W6<I:CXBP7'-%C\E><79N:
MMRNAZ,*&$8#5V,I>;U^A'I[Z<G4[Z@<V_*@6O&A)D::MPX$_T+Z?_P >;S_U
M_P!1X::>+PTT>&FHA=<EGT^T_3SHK'J>X[GY1XA'N\PMUDAPQ3Y"+%UO VE-
M^5+O,]#(VOL%B(=_EDQ[?+YF0S*GD\;%6=J\PE6Y%19$D83S2=M?3&S% V&R
M[JI5$QEVPJ^H@&W]#=)[UUKU%5V#I]X(MRL16)4ELM,D$<<$9>5I&@@LR*N/
M!80LJYY.416==>N[ZIO@+44$4I/0]JI7S%,'@%'PU"A4D#XG3+8>B1R\.L(+
M4]-BN(6$ATDS6QCO2(A89^K:W^6N+,NX2T6^,>D:]TM%826-09G9%BD3L1EE
M1Y5D8=QL '#$2?4'2W4/3MB.O8W6C;[L:RQS49YVB:*3U1,19JU9H^ZF9$2:
M&.0*")$C;"GMKU*_ G^@5VDAZ$=:166)K*]CH<7EW30&2?,*L$\#^96/=Z$4
M$<Q<@WS$(;#06$R13$I$DJM?J26&M)5WN&VUNS#4A@AGE25K$QF"IF>M#".)
MA;F>[[21D9#'CX7I3JSX*MN32+'M]EY(X[G?$D2M%'!),'$"R2KVQ8"D=OD7
MBFPI$?(Y\+G3X&UA6D6XO0CJW@BMB?+,N'S[$:Z5/P1JC^7V]G*[S-5'>5OG
M:K>ZN<U'5N[O_46WUVLV9]Q2-)HHI%#0M+&ME.Y6M-").X*=D$""TJF)W(CY
M!P0.@[7]AWV@;Q0FW*CO&Q/3AK&=IGO7H4=D:))*J-+MBJ;<32 /$Y3 5V#$
M<2V:;RO\#Z2L?:1]#=Y)%%"\F0;]3J.(QK&,?)^&"?EF+UG.2*9&?+NF:KX9
M&JY%1OFE=NL]4;M2:Y1OS2O&8S8H2SQU;U>*;DU>U+';$,)K3QKWH9HIY0\3
M*1Z@ZIJWOL9ZZVV<17MWVF&&:LT]2\DN[VZEV9%A:;;XI:6SV)(MPA>4PO#=
MCJHTL,RQ2R(%9VKM.K/X#U-8'U=IT$[P.PKI%B(&FP69219&N8B-C5.9U:[N
MQR3,>YS(W0_C:]?,U'>'N=2036(+.XRU)ZT?=:*Q*(V8@H>W%Z"KR%).Z@!Q
M(BGMLS&-6YW/LV]P.T;;C6<JY4=J65PV,^I3V!Z/ !)QP\"3AAL.+1=9'P6<
M='"?D>C?E&G!M0V3S6V9S58(.P:5K/FHSGU_,\94?RK?PV$2PN1B1N8Y)/*C
M?'RQU9U+MH>N-_FFB1UX+%,DL4C%1(G8[Z*H9N8!7\-UDRDJJZL!9Y/LFZQM
MT]NW%C0N[7>J_&IN*K9N5:D4;E+1ME*$LM=Z1RUHB)@J?B(TJ,K-)2AV7PI"
M<MH:VBZ.]*N0U]+57MV"%GZR6GU-;4S%6-045 /R?+ 1)5SK9$BO,;#*%&AY
M$;F"2222[.X]7=9Q[53WJ?>-QN5YJ1MCLJLT]*&Q'&TD4[-$L<+E&D[T<<S*
MGPDXD*F-.4W0^PCJK=-[FVR/J'HZ+<-LW&;;*4UK=+<"W+7*.&4[63M9GEK3
M+/MC0VGABK7$W3;EK232O-'!$7DKKY^"9?W(E1R+T0<GW5GQ_5C\>5D1N'QL
MS:.DRY!(H=""Z#FID25]?-(5\NUBN172RRHYRR.<Z'/46\[I!#,^Z33PRYM1
M%B%R;01F<J(U/)PJ \AXXA1X&-<QO].[STKNF\;+8,=.]3W2[7W..&4NC7Z\
MS5[+]Q4*R\I(R ZDAU (\8.F_CZT?@&M<V1G0-R U['?A<F#RB*UW;^E_HV_
M?]SONBIW]OOXPINNZ5Y4FCNSQS1DR(ZN0Z,1Q+J<>&QXY#R /!\:Q)][M@B\
MJ^K )D*X8@G.>UX]O?ZX&GLZ<NLGX*^EZA.%,YQ+T4;C*\K:7ECCS/\ '>OL
M,+D8H,YN+7655=E+TBP;RY;FB055T0$9*6+7G$PP0/=$(2K4@?[L;[N]E9EM
M79;!M1A)VL+%+-*GG DED1I24Y'BW/DA_*1XUAL2;JRS&:\T@[;K)B5_Q(^)
M#J<(.2E<CU>#G]=;2WB(U":H;^(;S=\,'&]4-3A.K;IBT7*_,%IBL<\;: Y^
MIL:J#,VMG=BT-:0:5R)FRX_D3(K&29K:=[(VE-<TB=7.;'AL[@:%>:;$SI#&
M\K1PJ&=@J\B$5F4,Q \+D9(U;^DNG-VZGW3:MEVV]2I2[ON=?;*\M^:6&K'9
MMRQ01/8>*O8=(>Y(@=U1R@RW' U&[1[?X)./L+"JT_0]=TME7I4R(*7CPG,/
M'N 6V,!=8=!RC-6EPP"S"2$-88DZ(9$Z"&9L)CQ=J_N$^UBW'9G[=ZJM21-M
M[]=+=R"[)%#'8I&62.M-'')(RSAK$<L0KV)&C[<3-KH=;[&>L;=JM'#O>RMM
MEAMQKR;\QWP;35O;9WS;VZT!L9W$6E,#*G:V^:N\DD$8G[D\2MR6O/7P?[VM
M";K.AOE$FFPB39&J304-1;@9:L%@,LX@*Z).:[&.DI"81C2ZH>%@HQS8B)0(
M96Q3.9K7.NMRH]QGL;T[;7/'M\KP#TT[<LC5!1^),J0B?G7D@*I,4*P.H<HF
M-;NS_P#@\]>7>$WQO36T)N*;AN$+W[TT,M[;=LHI?M;Z*M7;K-UMN%6>LZV9
M:RR-\94!C!L1Y;_2\\_!"S=3]<)^'YN;"C8E:LMM687-3ACMN8IYJAY$LG,4
M#XH[*,<APDCT2.5\,D:N;,WT_&?:^HMPWNE9N0&^*VWV%J6GF2(-6G;EQCE[
M;R,F6)7DQ[9<@!B67-=ZV^RWJSH>7;4W7==EO)N](7]NGVNY/9AM4'6-X[47
M?I5G:&1)492(\H&X2+&ZNBYK)\^?!&+K*[54G1'K*B,V:<"$B/,48Q8T<K2!
M3?G)0>8)&C#^E_-F02S>K(,9$JCRP32*Q#UFU&U(D&^25-TAEBA6L'EKV)$G
M21A/',Z)6-51&4F=K"A&9 ZX.1+[-]@_V@]1['M_4%5]G?8MQ^*Y7WMR6(:,
MM*S% T&X0TZ=NS!9?F)X8E@D=H8VD])"!GKUO/'PE;+::;3:'HZT&POJ62*Z
MO]'%F,=JZ,DB9D%<TPB6+E0VDLG2_.#BRE2C3#RRD/\ 6F<^(Q\,DW7_ %'
M=U6'==UE.Q5J\]X49X9((JML(JLLL4HK.563#Q!C..+A8RT;\=P?^#EU?5AV
M.)M[Z7H0]0R6*VSI:FW[;[4]RJMF>2G\):V"#<JKK'3:9;$\$-$))"?BU[F
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MFEG@18B[40K2B613+%(W='99G7 CYUO9OO3=C=.TT;TWP-:QN5XUJAD$,%9
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MD%LLH_.5LV+P5C:Y6Q)BK:NZKI*&H#L[,*$65OJC7-E#?W4@E;.EP&EE8H/
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MLL<1<F]U<OF:B.?(R22)K$?YH8V2-C8C)W/8L:3NRVD#/4,H5_\ ?JA9P"K
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M?/G^O<#S\A\O!U*_H)]^N;HY5??MU1\!_P"-++)W[)V_XT^WF[^W;MKR  '
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M;,YKS%#:K-)%:^-B>!EA657FLNJIJ],4I;]\[WTE!7W5]UCVZ+?^@J^UQBU
M=OD2S;WS80\HAFDK2KWZLL4JV_BFBJ6ZDE/E9+C;[E6QX3QO&5C@K<JOU>AH
M3+1; &$<#RQF%/ M8GD1P5]P5 #:U959,!90$CP7(-E+6%SU)L#'57>JLNU_
M[)UMBE-&O5V-=P;<*JD/;FOF-Y82\KRI9KSE19,-V$F+E"5+".)8)W<.MX:_
M3_6+]3[71W?>MXZNDV.KT_NB":#:-KV6HDM6_/0!5:5\KNG&*ULUA5L,I%F.
MM9.X?&Y3*=0/&>WJ>2LYR$6^KM=%EL\W.;(^!PUL/L(+3TS8TLWDS(-E+ 0N
M4ZZ%(&G<\]LUE7B#/?(QV*ONMG>MDL=/=1R5Z_Q,==*EZ&*2VGQ-:59DFW-H
M(TF*S6TAM%'9JE=OB.,L8EAC39;J'IM>K:74?3>Z6]NJ[?0-3>-LW::/91=H
M[C3M4'BZ7AECL48+.R4S7H49F&WW;]65DLB>NEABV5[- VTDLY;6%ME%>C@-
MCKZV9<T565[ !JW4@6)/G)(CLO1(-L$^FC3R.,%-1[G%S!A4O<8*>[WIHKMR
ME5MW[RTIYHJEB.E'3%>."/=()>]S:.Q+$S3K*I_#<V(>?)ECO6U-N/3<=:W'
M6W)J]&&MNNVK9LP7+$UIK[6TK.&KK69*]>2%8[=>U(L[SQPRF/LI+,EA-9J>
M-^0+4P"T67C_ )V (AU=2B-+$MPK.6:6RH3H8T:K#ZRVEF8&4D7FB\\)\$<R
MJUBS6US6>G:U8Q7I([6W[=!(+5&.O-'?I\3A.W;+U983/ ]2R6+=F6&=HF(*
MB2@[_0B'VD07MRV^ON?1'VA[^^Z-5W&.1GV[>&:;XR*K/1X6ZNZ;>VY3_ V(
M/PKE"]"+4,RR30Q=V@W.*H*NY*WI-K.XJF^BU=!3Q0#RGBMO)II8B;PH&TEJ
M_P!7_1#EJV2!%2$R^DA$JP"+#-?JO6&V[L=XM7ZT[F9BE:I$J*T]6^W>:.:R
MB+WONXQQ-0#2P]HJ"H;)C2M;K/-TW5Z>B>]3CB2KN"V+EZM/=NUK6UW;B5(Z
M\*B/X:2\UJ>I=;(C2O-/.B=]EE5X>G,C0\DV]?8#3T.IMZ@W3!4-#?OD*!6O
M_5WR)7Z($@X-GT\ZN$!KR"X) XX 1H?5M UA0AFMT??L;AU#:&Y;MN#-M.U/
M+LU*]90QS2W@:4@[@@:66&&.,+.J L)9#,(N4@!L.ZMMFZ?9A=WF*IM/>W#J
MY]MW/<MBJS0[YM.RKN$&\)<NA)UCL[H+,L<^V\T='".K6)7:='A7S#1LK;.I
MLG# UIUN/9PW-6$3-.@]G1VI-9*6L1'FE'CLX(QBXT;,4/,Y99H2&J^40..W
M.O!$E6>*O3J&<6@U*G/)+7A^%O6*):%)5[D<4K5F*$R2J\BRE#'P[2\2ZXK2
M1;LTLPMBU,3'>>S46 SV8HJ\IG#H4C>6>*S&\B?#UVC3M%TE,HL2X[@[S+S7
MP_V[_P"BEQ^JI]O==;4?;NB]NWV_K7MW]NWB(;W^7\/('[_]@_[:!,&$4H!Q
M^&V1[ CBWRQGSYSX(R<9\:]-_P 9M4W6G!^D@;N]Q'5CTSVE$T!QE/P]%?!,
MM*X2YKY[ 3D34H*AE19PE59\(TL<1#8BQ"6>KZ?GB<SV\6_I.-*]D[HB12VX
M)!#"DL?,+R1N+@C#!CW'*$.C(\:R(W-1BY[=NEL]*W=A$DT="SN4EJPL-B>$
MVC)!2A:%NW(BA4$$3<T!ES)P/H8$:^L_&?*5HMYO-&',^E%U,53I=! T<:GC
MUEQ7/ORLXKHHQQENE:67%:5X0T\=<1$6TJ-@Z-DEMNY[;;KW;-BU)#"\UQ4N
M7X'4]J>XT!G/9AX6&6MW@LHAB*E@T<189(L/2T;[J:5=)>U'!5[L%)P8Q)MM
M-FJQN&DS&5N2N(4ED8AB6EGPO-]7/_#CN:SB;CO5[:.EIK.M$OZDRVO]56)Z
M]9K3B#Z\3#Y=6,AFA+NN.RJS3E6L9"!Q/(D&]-D@[&R3>Y[-'5I5=O@>]RD:
M*1UF9>8-B.%W4K_]YN(:_;RY>5W'ANXB6JC6%_?;.WC<9%::KOCP[=2M/#C:
M=MI17*VY[LJDU4CELB=)(E12J4>9,:M$XK4ZE-:%K+N\KQ>.::K)ATC'UE#H
M;WYZP@GN$-OI;L.:F@S:-6T%.IA#ZTUDZ0S^CYR"YG=Q*YNO3\=?K26G6+;>
MVZ;6]N_;M6HTANW26,/*S/WXJKD+*:L?<XF3FC&!9"LMRGZUL[Y]E5;;-PVG
MHWK2WL?45#9NE8JFWW-KGI[=2I-6L6*%/;K.W;ANC32QU*E^:T8(K)->3X>[
M+&D]>'NCJ.4R7 NUM3J @C#7CPOL*NS@#8L9(<,\4;Y(HX','>6+"H[9_4@?
M+# [TEEA\^,[4^VQPUXJ"U>_R^#3M(CVI<<2L$S9>1F(#.063\3N^S$ZX_O-
MKK7>[QAZDL;NYHRP07JMA+C1[+6GD40K<K9 J5ESVJL$KQG$+0QA6'F>]]@^
MJ+I"@P?)CJ6\X=B)OK7&":"2[B+;=$D H3,!9T,=S9EK2F5,4OD#)#C@C>I/
MRDL!P,4T62CM-_IF%]Y:<69VDK/?VE'K2PM .\W;=X$CB=^88-,99&#*CJT>
M<M8MXZKZ)^T2G1Z)VXQ)3VZ25K&Z?_-J6"W/W4AI;JD.X3SM"M6(%8*D<,3P
M)=GA4/%*>.1XJAT='!QIE[$7CFTK>9QM%G0*>&Y<<0&Z[MJ7/21<CTHQGST@
MD6BI*SDK.YB0H=QAD5I+0_+17#HEO^T=1594HU[4]5X=PBL20RPGBL<D,"/)
M#85D9#-96S)7MR1=HK:(2?DSR-'7.I>C-T9-VMQ4MRH7]CKTK<2357A%Z)4E
MGD;8;$@Q.9Z$YF' ORK1SJA=:]8S30G:8%Q;I\YLN+NFOE?B' ;>D$Y.J\?J
MQ+^PPA)TP'&^JL:0"&%V@XX$LR\+6:":WKX1R8+S1FW$*6.=M+1*K8WI!9EI
M6=O[MJHZS17Z8CEL2S1QL\T1KQQ0R17;6W"V[35"%L/'6:% MH(9*OTPO3NY
M?%[!O5G>=NZRW2M"G26Z[S%7H;/5MHPM+3WF>U,BS5K]9FVZ"U/+#6I UY+)
MBC@,JU8=6?$F7L+.#4]/'%H4'%E#DQ#[F[P.@N.0G5M8A0]7'<\G/66<C'&S
MVS2PP"[JDR#+\-HY;JZ2PC.D2H[]MBR\31V]0D8):Q5D1UL(R*T;"K'S[2HB
MNX;NS22!I6D<=IN,6];[H2N+NYO/=N23=RM-3:E%5F0!FJU9G58KQC5U$LE6
M6Q!'("B2NI5GKSEC6-SF.]NR(B+]D[>R=E3W1$3OW]T1/9?WIXHDBX8@@^_S
M\?U_7O[ZVT8G! ]_X_/SY]OY?J/;6^W^C+)V^'CK_M_=/<D+[+W3WP?$_P"?
M_&O[U[KXK-[_ *2_UPN?E_=!^@_[M1MXYL,1_P *_P"6I,_'BB=-\,WFJ-K_
M $U74<-+ZG=$]-&\N8URO3O^[M]O[Y.[?S\6[[-H38ZPVR$2+$'2Z&E;P(U%
M*=B^??(Q[#RV>/SU"[DQ2G*X!8KP8 >Y(=?;R/W_ --:?_#UI?<4]37"E3?
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M?B8@^@WQKX 5@*I]%>1R415DYQ@Q:SU!1;*JJ> +<$E5\\DEFM4.,(R3[O\
M3@WCIP3UH^WN73$D,4J+)'S?:[CR%9262,&$V ZPUP\CQ.DI(82,Z]9^S[>[
M5.SL[[GO!W79>M]HL5Z45N&Q))2ZHZ6KUJ^X;8M>M+;X\-B%/<6W6==O2:L(
MXXDGL+-'&WX&:-M1S0@JFILUKB:FTII[82,F%IDI@X=?..)-#,Q&S6<<,<XS
M4D%*'G>A4,@\TL45 V.>VBMNM6M)9L;?;VV)XUFY20M/=81U7HN36OUK;.L,
ML<B)-'+V3&^#,)>Y;_LVW7:,_1]]=L,%^O8W?IS<=RCLUX^=6FD<FXT]QK@V
M-HL5WA%M6@F2O+ 9I9D$3!*["\R92Z&)L3+ >NHGUDC[.7/H5$/*.%H3("HV
MU5<BMCF"%)/5&M%C:R =_HM1Z!3M'ZI-3GEO;G9BHFK5%/;-R$0$BQ)%N" D
M5^<:K'VK<LT4U3D)()%F_#*K(^OR/]H&V2P;50C;=ZEUMEN[KM]F"&Y\3:4"
MRLK"6)9IA/&DCETW)0*UQ)8FBFDY(H[_ $YV&L"L]2[,UNH>>%FS=5'9920L
M8ZF SZODL+J:45S'_3*V)Z&&^5[.\8KX6.=+,V)WFE3W<7/BMGKR2V#M>YP(
MX>&%HC)$@CLQ2V"B2-%*Z(8HB\K-.G;')1I]G74.U;9MF_[1U-7X[3O\VR&N
M[TY+<%B5-R6N:C5<B*99N8LIW,JC49 .3,4=8<WX+(R<99[DG*V4TAD][('J
M*>ZM1"KIDLE)2RRWU:&.QLTF;/T1%G7Q&SN=,R481#(QC2Y6R8MSJ[?5.TW*
M@OUGW>.TDM;<Y8/BK$OBU!<AC$DDKUC%\8C3.[%I(E0EF'(R77VV[C:V[=;<
MM+;9JNT6J6ZP;KM"[G-26EN$]O:[&WVK%DM6BW))$Z?L6:D/;"#=(["H@EE"
ML/P?^+FSAY>W9%Y1P';_ %J]M93I[?;[]D[_ &[]_=?OXU",#&<^?)^F<>_N
M?EC_ $\#7 +#%DD;B%!C?VSCVQD>_P";WQX&?.??7IP>,FJ7K4K_ $B"CXO+
MYQX2U&]AMS2<7QKGRW9D,PH:#?92XY(U FDHA; 856Y:ZIQQ&V8-T021!82F
M05[JYWR_JNZ-T6^RI4L#<%#6VNKV8LN&L1]E4$?H>/*Q-(\V3)"%(PTG&0@6
MW:MEZCW'8;MW;T4;1M]F;XBX_!Q0MRUX&!%>24?%&V8JD(BBB,@,8=Y$C')=
M>N3(7/'F5UV:7, ZG5Z,4;54M_5DFFR8O/9G0WF?T,P$R#A5=[]4+:,-9V=;
M)9!B""$O6%I#9" >IOTQ#M]6US"VI [717BQ+(B*89*B=ZV8V"!I1\3-P$W:
M!*5G_#99?:NHIBL;UKDL5J6=J-.H((8TM36:Z\I["J\K5^W"6$%0*C3V9L]\
M(G":2%!3QYWI]IL3R%S"537>SY&HM'583-G4^T;;VEMEKBMI;71&B6T5?CBJ
MB6N"IK(:>RENXPKR \FI8RB"\D=MBV5CX;]&@2M+;IUR_#O*)X4B6JSO#([R
M+)9EW"!QW(P8%!D ] O<5F39-RV239HG.[[_ +-52[NDDUNB)8(NH(+LJ4((
MJ1EW&*>&LM(O7RM:\'>M>=9)HE8'J9J]7PQI>)5L!<X:925\MI4:&K+B/FTI
MM3.!6"VN@>A=JR<X&&H JS!%)>),0 4^!SPBHE?6.HJSV-WO6&DL/#;V_:JL
M36(?5\' MANU(9'D1[9EDE$]B()SC%<B('!.!][_ -D=F^S^YMD=62UT]U+U
ME=L*))XW'4PN;3.MDB>G5N?=;;8=HL4JUD22@O:CGFAF,E:OVNF?D_9Z'F#/
ME:2E*V>/=I:E >/[.ST;<^78W!XHU=DZ$6OF<0PBZ<P%! XF$B&SU53]:#L*
M@6<9^Q6W'[TWO::&X203PS?%1/'+#'9CK)%#/.MUQ+R&:MC$*O8+<([#Q!@>
M##7I[YU:=@^U#J/9IK72Z6J%&VV\5)C1DJVIK\ 2AMEF01M))?VY[%N1*SBX
M\=)K\3B2$R+;+SQ59W;\2:#DW6\8Z.X%S$E-JH*DO23VM72DB'X)EV!FW4)4
M$*T5AF;75.#DT% ,/2AQ#FY.[!"GJP9>DVJT$JBE**]N,K*!&*P,DJM%<3DR
MR DSH JYBD9Y"[=R,NKNOY]Z;L6Z.]5ZM7<8J<TYEA,SQ"%FD597K//W%9A*
M+$4# 0R/SE"K,C-R.JR,UAV"\DZS*6,!NY"93.&XYTU<4^OC=]:8%I\3H0&%
MPK\^S0TP) 8M Y6G!PV5EY7,+J61NJNV]%3;:)0D,3)';>P6:/#Q"*-A&[8X
MAC,2U:RL;E!/7223@&C,OZ?Z>^T>DU_9]YW^[)!6HF&&Q4L()[=>G\9!6W.O
M3G(+U[&RVFBMU9E&!5BL5E CN860G3[SQ5MYA;Q1G*O*<39^6M[[/DW<E5VT
M(_69Q,1#]W2!;4S.5M*1>PU^<J;/.1V5I2W%?6+&VFL"Y@F#1J=14]MG@J0(
ML-&XMVU;22Q)4[%OX5WEA[<DCE)(K(E$L0!D6:4R*(1#,TL/]H'1<G6'5WV@
M,AO]0[EL^Z4KW3DU",P?[0[-NNZTX*5!EV^DQM0FEN9O;5O:/&BTZN,M%;B:
M"4G#W%D>,P>8S)7,9MM9\0QKR$9N>$[Z*[O\O8[[ZM,_A4G(!-W&8OLBTZE?
MLJ,]*=<PZX"D&+I*Q]G'9S6^K9J;A7 V^[WXWFD7D7C"2A3(198^.V!%9,"U
MW)?@D<D7/M<-?G[J7:-ZV+>[5?J#IBQM=JTK1)MG4$%B@)54(J;FD\IIS&7F
MP657D,A!P[$(0NO/U#YN#+\Q\C5@NUS?(XC-1:'"[G*DAE4NC&N9EMX+&%:\
M4$$<IT)R,MJ\0,<:MM(S ((DA'8J\GZ@@,6Y6LR+*7E,O)60L!*3)Q<1 ()4
M+<9 H"A\E5"D$RVUS&2G7)AEKL(U0PR@AD*#@0"Y9N.1E22Q92"3G.MW#]&7
M_P!+RU_^Z>Y(^_\ Y!\3_P $^WB@;C_TI_\ S4_]T:6SF8_^:H_P]OX:EQ\;
M=X4?P\^3);.IGOJN#?<&D6E(+,\<BUK!^8\5/8U\)$;7R#R%A1SP-(8USH%>
MDK6JK43Q=?LL1Y.N-H2,J&:/<0&?!5,[;;!=@?!" E^)_-QXYR=0NZ!S1G"!
MB^%(" LWA@3@#.? )/Z9UJ#]0/3JW4<A<*Z#BN6OK<9S=FZZ>B#GOY"UQY--
M7OLM%73RV!$DT55FZEOFA6!88V*"2%$-!/$Q)?T[%)*S6/BYG67:I^U,4B"-
M-ZR89(PJ<6>=@5QX*DAR2'8BG)(562.12'7TDE2&\CQZ<Y!(P0 1],#R=/!-
MK\?D>O3#&1EI8V>MS&4QN\+C*BM:T'9W><;F0;JOG<$HYZ%A1YB_(#(%FBK[
M"R,!)FDG"E='D6%Y-@N(08\.T]5,!":]>::PT<J]P/&?58@1U]3HBL %D!&O
MEU4JI]/)\^GB2"X=![,3QP%.'7/AO^KIJH>G3GC <PD9.3+.VMFL5Q8@G SK
M69GDG!13PNN@WFQ35K [<*0P3RBN=') 7(WU8IQ602S&L4K^US23W(ZH%@-!
M,J*T]&XXS6F[+"3TC@T<A7*2(JNA5V<)T?8.O[.V25)+$:W((8(MNMU9,I'N
M6U=PB6E9D0%EL0AB]2T%YYRC\X^0;.\HWG4MQN=EZ7CKZQOL13AVFMX]L+##
M_KEH,95VT+9KG-6Y5U66LR/SHKI Y$,4B!@;HY1Y(_+"T:+H7JMZ"R)8ZR[F
MLBU=R1+/PZ6)(CP6W72*2)'CG<-(G !@^492%#2>.LNDALTJ[S0@DCZ>WJ1I
M]MYL3/6CDQ/'3LMS9Q+'"Z!6)+21 $L3DZ;GAW1<N9GB_D>ZT.?HEXRZ@K#Z
M!H=G<TK5IZ\VRMC:HVXE(HW-920UTEA8/04FOA@&G://7P(UO\Y/15XK7PJV
MYT:]0$LT52#"N\''F(IA( )WF]"'SR" QR,6)Q1&[/,DE@5(91GDS,<*<>Y$
M8X^YP.7D$ G+M6W31RMDN#0:?CJTM;BC.TU];7?ZN;RKEPFQS9<0@U4&P:L4
M=]O96C!F1)-;C1N%9%  C7,2"2/'3O[9%<*-$D+5X42NEBJWQ,$W-WD61G5N
M$4?,JG LV.+DY!S\Y1R.06PP!\$$.1@YR67M^P4D#WRQR/&&"(Y7X9Y*W>@L
M=SQ+]!XWSN,Q]0S 4%];NFUFSS:T&:R=E8S$5%A066EILV)8/H1;.NJ0I J:
M<0FU((F(D-B)=I@:SNE)HXK-BY;@2Y+- O&R_+XF!0O=@X!'@C5"DAXY+(0C
M*$R(TJ1QR([%O65!4EH@W+DF$]6"6/S/J( 48.&6M:[DW=\3<I4%#]#ON*Q^
M3B>2AL=H[?-B\BYXR.RM=3)L\]EAS198_JGZQ%$:4K-#%#E%+8(P=HJ%/=3]
MWV'=!5N4_NRO)#+=-NI!P<7(FDG:W)+"T(,,LDDS2,O=GDL.3,H1R_'4G$\*
M/!+()HY&A[?>X/V) H6/@S,,84+@9QCQY^KY9?)9VTY(AX@37<[9RMU6/J^1
M>G"W2QN(HETYV)BMO4)I_-%&>86H\N%K[O.0B1D24P\7D:PJ0E)<RU8;"4F>
M[%/<A;\:"Y:2-*D:KW/Q/BI(A/$,3M%-$\(50K)'+EK&%GDDB$O9J,:_IE_#
M0NP5N/+PGIXIZV!(/YSDDG4LOA"S:#/=:_15DZ[-<GX/!Z+D3DVZY L^1 I;
MK*[?F:BXEY!&J0L+,,%!)D[M*H;3R6<UO-_EB""56RQRE5PI'CF/6B&#8)8!
M4MT(Y6[\\NX<II[UTV:IPI%B4P23%9[ D>*M'+$A"Q2.R.LG3 :YW&D@FD1>
M$0@PABKE&!9PP D3EP50O(J2#R7U#6_)XXGJ=U3+\0^C<S<Q_2,=:2VIV0EL
MY]J,"I"##''14D-77S0."(>4-9L!MGMCD,^D1A?.3^@VSC=XNG3K 52TDZ<%
MM*%K,^ S11F625QA@%:$O" P7NLX5>0C8#O7V6WW:HT1LHBHWP;Q+GGB8Y@\
M%S_XWC(95  2.12%*H74W1Q@^*><Z.\K^6N.LI;[O+))6R:$.R)F2]$-BB2^
MC#E#^GN4.ONN\D:HLA%?9DFP1O@]'S38MYLVZ#Q&E:L1UYL3K#(BJT)&5@[B
MDN.;08SGTO'Q;U!O&M]H-W>MBLQ6=JNRPT;.:SHJ)- LT9$W<@EE1R!(S20D
M83Q6"X/'TSAX7Z8,!PAI--J,LTEUAHVS!N^:?\P@=7\VTD<>&6;SS^OV9&PP
MA9/,9Z4*R)_--[PE[=K5^*&&9APAP?2,<GX\2S >#[GCX].3CW.N;;YU1;WV
MO!!8CC3M%)))$R#+,(RCDKGB$).47^[_ ""R3\1>JOKJG3.'%GF8UKGLC>YC
M7^S'.:U7(UR]T5K7=O*KD[JG?NB.7V4/<:R0H))8T)(#LJDCW )P2/!R1[X^
M?Z#R.G4G0'0,)@E&D9*QL2**[U8FRP+(V>%)D1OG]%_F8U%:URM8Z3RIYW-9
M]8%3@C'[^/'R/\=9+$3PR-&RR JQ)[G@D-CB_')QR !)#-ACP)RH)RR(B(B(
MG9$]D1/9$1/LB)X^:U]-CM[TB.: *F)KGEAFA-M8G33J= (7*+&6UHK48(8D
M58:^Q<"9.V-ZQ"S.CD_FVKL0HOEI P5D8H<#!9<\?)R0"ZA.2C/EAD8U-;75
M#AI98W*,K=L^D1%T!();/<B8.O!9$0L.1"^Y(;OA&J#J9-<9\U8,@.O+8<.H
M,DDD"AI'W]D=0F@MF1$:.746(<B-:R%!D<ZO?'Y@>T>UN$G<,(PAXPQ%I H5
MC*(8TF5L?-98V'G\Q'<!]>I+?'L2PT4:->Y&@=IU8\^8CPZ.?DX9#]2?1@C.
M-</$V?BP^_U>;K:Z2&F-;/9@D>5K&*,9+&<&]G9JH\>-LA-<C_.V5LXOIS1N
M<BO1;F-B&&61^4@ 0CW\KZ6^?@G ?VQZL^/GL;[.+^S4;+NO?A=8ID'RD56C
ME!]O46"R#P048%6Q[R8\1NJ7H\--'AIH\--'AIJM?JGX.ET71YR%BN3^GWB/
MJ#&P^J&WN0R5[0?MAB-#3DPJXO->-@=)68&%FVR?'UY?FT^=K-=.S1G,,R\U
MT^KM"(+)II$_"+SFSSO!N^?J.$>$.$:W3<@5.XSE'P/Q3QYQ/CW,VO&>$TMY
MF'"\:V5E1[DWB>\LB^)3>127#V=[:XNUK"&&1T,-Q:--1*X1UP5E\3CDBJT^
MZXU(U(/4KRI5T.8V/5-UB$<SP9X3'E.I@J+A&N''Z3K#.Q >H5EJN!GR]%C5
M%CT$Q?*-'<ESM-2Z^,[4T5[T,Z>FTYRUE!:<E\1U]I9M;YG5@AFWK1I+)K41
M>[JY)?G4:J>5RP>5_P"!SO$CM,E:/<J9N*IJO-V9BS%5C2=6A,Q960CL%Q,/
M5C*#(894V7I6F]_<IJT63.VV[@]>,< 9[,5=I(*P=T=8C9E58!,5Q"9!(64*
M6&CR?Q;'5\?RZ%=+6690?(EUA;FFJD]>:M,IQ*PD2T88LZ1FUMU&9:15Y<0Z
M"OEJB&L+F25%6P[OMJ;?$MN.PEHK9FIDH&6$A8^Z#$QRS]MU[<XPH1BO::9#
MR'0]IVU;^SS1RQS"*,4Y9FC1B]:U)/9KBM8R4$,Q@@,T)7O+(DLD4C0R)B10
M9Z7&9O%:D,FM2PTQX;A@KXTP(:*J :0+.X0(22 I2+&>:.;UG-8TGY-SH1_(
MYLDCL^W=2QK29I:D\^[15)MMJ&.)6AJTI5?C8F>8,G;629D[?:)D!6(RQK)X
MNT6RT*.T2QU[M6$QJ+=JW=:*.:>&)XT39ZR_$$M/(S/<8B$S@0KPAD"91-6Q
M%\3EZ:E8 +7T% //9?- V#[@.QM-L -<.)6:,LVL NH\T^CJ;2K!0(T9:-D%
M[ EN(^,;[N@MU]EVVK)3@6JEE9Y-QB*R+<O30)/'$\O'FDD4"A9((V,8<*\A
MX]HFE[<1N5K=+L-AH0M.2K%3ECCBE@I"6Q Y@1@99HS++8EBL3#SW7[3'DFF
M@%D+&F_M"=[45_X521(FO]E]WHKD8OLW\7J(K51/=>R]O&A#5^,EC@(B69\@
M&:6*! 0,C\>=XHT^BEI%RV /5CE7J[;A3D?[NGE[7(X"R<6D!SCG"3@@J,,K
MJPQX.NVEB>--*TF-OS22Q_SCXVI(&^"59&O'>B]F.5R*UWD_ YJ]U[]F^,S1
M3[=+-3(C7MS(;%>1*]I)98.85)"RS))&!(Q(0M%*I]7,8QNP;O;5U:P@[Y=.
M$S(89*P#AQ) R\.#EACSC! .1@ 6*<6XSZ'Q61N-7-/J+O;T.B%6#06:RB5H
M10CZX*YJRR&EMAO8GDP0CI-#(V27N(5(*$]9H[#TSM6T3[;,FW1.ILPV8)(!
M7>KMYM0,\?PSGLJ_"/O,T4T*L97^)[3DH2.^K_MA2I5EWB_9O6=U'3V]6[T^
M]3;WNR[3NCS6HFJ;=)RJ1]VC1-?>'W"<_"57IF1)1,E0]+ANQ#.XB/SK;F:4
MW&Z$#2UD\,!'SQ%!:7(T1;_)-Y@AX&S./0MY(KG,)&!9\S&/*6"75-LFVRM=
MZHI7MM?<J8CJ75AAJ"TU@[1=2.<+#,DD$8>NU&PW=:(2P\XIEFA$H$_L";[?
MZ:Z*CZ>ZBCVZWM=W=:,MB]NTVU<-OZKJ7+NV6[0J307[5REND&\[1'6V]K,=
M>>R]J!X;8@GCD7E]$%IN-.2A-_*-/2-Q.Z4BLG+=7QT0! 5./$96)+*LL5X-
M8S@RD"),2(L$Q,;HV22&SS>M^Z<.S4'>&J.4&[;K8V_8[EFG%%7VJ5:=^&SM
M_"O9O16ZL\L4,%:U))XM.H6,SQ.UAK=71]2+N%+<KOQ&R6NENGZO4W5FVT]T
M%[<=RICJ#;+VV;^SM#LS;==V2&Y=DWG:8*T$=RHG*W8@I".M2I)Y/.Y(_-Y>
MZ^17]O/Y?-W;YNWMW[?=&JOO[)W3[Q[?J,>^1G/@>/? S['S@$_0?/\ #$YC
M[CA&;@6;M\@.7'/I# 'P2,9X^ 2<$>^I;=!4/EZX.CER?=W5'P(O9.WLG[4<
MOW7V_A_7V1>_B.D8$L//CQ[_ -[S_+]1\\?KKS/ 5IRN2.1AD)'@G 1OX^<J
M?YY_7TF_&OJJZU+OC=5VFJ.K*NN6GU==F-GQ;A*#U3V5IS'V6<O-%:><BO<A
M-K#$-\["C;" %8UB)+!BED<7-!XLG3[V:,]>U(:U;;;^YT:4MR5([+=Z!NY&
MAJRQLJ]ONR2+*#E@'0\"(B>\_9^:=KI2S76U8.Y41O%N&""O8B9$L5Q%V$OH
MT44DE_L=L5GD;M/VIA&SLK0T:R@:#=V-E-5!36EZZ1LYD:3!07,TJ0M^9)'$
MC=";8$(R)\[I(!R3)8HFEEP^6>5_C'U#<I;W?^^-FA W5PDS;?6C,5NB^T*!
M8E"0JL6X1W))XYD9 E^-JTA"!(I%2Y0U)8-MFJSK!!!#:6G)8N7ZT0(W(S+$
MI-IULPJL,(BC,W=@16I5O4EJ!7<?&\BWWZDV%#4[!*2YK9QF*%>9EEY76 (K
M)8#EELI(2IZ/Y7YEKC85#40T>!A$LC98&H17Z5-H-LW2/;KK2[E(R;S+7HPV
M:VXK&P1)JM'<08"75FXVZ=E9(;#!!6L8:2(]#J?:!O$\>Q[4-U7:(J->QL+6
MNHE.[=/RRQ-'/&=YV:2"RM8]Q.%/=*\;RU KBQ!&)WM/\<@YV@%X7$W?IYF3
M5F[6OQQT&?*6#U1WY2RM3S[&D>1/#-&EA%5MI+T%!9O-/=P%Q1JE>UMK@W G
MHM'6)Z-N.T-KOPRU((Y+5>%I9 +L,AG62P)HHK+V1'#*',(A"+[\YZ_J#:NL
MJI=MMW27=.GIMPMR[7&@VJKO$[5(2NVO"(8^W&C3(D?)Y%1Q:)#LP$;)1)-'
M7NBE%CKC*@+U:YK9IUB+%6:><@9_S<DSTG55E)C6-_I+,V:)L<4<D#(ZENFZ
M4C;@LTJ,-&*QQBNUZ@=H4LA57XF+N.\BI(>(:&263MJ5$;<%*B&AVBQU#L\M
M6Z\B;EL=*2QM<UB7!NT7M6+4]"0<(T$\(EEEK2Q(H<Q21R9,B.LJ.C'04E(3
MO)=IN",S0!Y6T/SE;'-! RTY'@:,W(MFE?&XF*. UL94;8'Q-()&';,JM:K5
MU6L;53MM<N37XK$%8VX(J+VE%V2GW9Z\4XA8PS=J?#Q)9ADA#,Q=DC!23H/V
M.2=0/MMNC!<V!MAL;WMFV[E3Z@EV^N*E'>[-;;=_OT+%AX;T-R;91)0";;9C
ML3F=2B220QX=ITJ1[NQU5)6GT%+:; B89H\;(F5)$=X^SKJL?OZ8KX@!8QFA
MCQJUL3(V(GK>5/F.>;QN-J5[W46T0RT]HGW?G77,3P"2-8=R2.U!$SH)DD<V
M4CF1HF((B.(I&C_5W2W3U?;I=MZ8WR5=UW4;)#0W.Y-WJU^2S'-9V9K%.2<P
MV13O0US56>F\;1K(4F[CSPI:C)>:+6W16OUY$)RA%[2WPZ9TA"9VRUY:.M"J
M0D>5K%(\AJ"&1CK$^6*YFBG^7BFD8YW2-FW/>J4NU/';EW&/=(Y(IJYE>5-Q
MEFL0SV*:5,21"O:^\2 D0 1G+QA7P3^2^H&I[D>K=\N;37J5]DZKM['6VR6L
M8ON_:SMMJ!FGLLM:9;%=-LB1'=_B%F<PR$P2/&RGX:%NLMOY+_/4OSU+9QCY
MK.072R7L%:-IKL2">O:+$X:$V4L&,ZNDB>HPQPYA,!,:CDDM2^=([C'NMO>#
MM55Z5FE AVZ*S))N-:CV[=07$G9G@DCFGB>6Q5/.NO<CD0M(%9EA9>CK^SFG
M=W22Q+T?;7X62>*W\%,U*>*[.PHP]R\T:U;E6*3\-;30YAE9LJ[Z?;GW,7&4
MHK]G(>GS<1]#FM?4TN,&KH6)6KI]);6;BE?7"S!&0VV@,+LJ%"IV'!U_TB1K
ME"@@>VN_:=4FFL]*/7M[?^'*MAZ-9WBM._<A&XV:N0^8B3SF622-U1I43O.L
MV+ET;+L2=+?:SO$]?=:U6;I^3;J%K>:7';;$MG:JE/9X9(YK;2V-S+U8(@]6
M@U9=SJ"\]E!P&H'\*#R1<T<,/>C/*3R=Q_-%^-KU6--A5L_$UKG.C57M=[2(
MU5^_E[>(DQR+'%*R,L<O/ML<8?MOVW8#R<*P*9(_;(P-?E[<*DL$"EE3%JL\
M\(5T<]O#KZ@C9C(96RK!6\9\#W]-;Q[US[6L#\? #/@7UAI=7F)[9+7IVR>*
MP%D\&$D,38S<V6-_=*/(23"QMJ'EJZ5T#QA;(@>.P[20CP%.=/U'H*#9S6DG
MW18R/O"6N68H)8X7VR9B*[O@1RR-Y'XD+S&$1PN\O%#T+I67J.?9[VW;%N21
M4X[+;MO^U)8*S[A2JOMM6@TE+ ^.AAW2Y7>*,F<1S*9VK\(GE778Y/+O?VBT
M&/RUP&3B\3QD'Q*W0V<]I98[(46F9/9ZV5UL!%*2;39+9:ZP!K+V)DS[9E-3
MR2#6'S"CF7\[M5&[30;7-7S5HK"K&4F+;^,I2:U*W,B5D@@HQ%';@9)#&TGI
M++KT^FMWVS:HMZW#:+=:U<W)[_(UTCM6R50THHXYH^$=BU5@DE:-9$DK@RE1
M$RLR/#A.7KC3\,3\4:MF!W=A!RF'M\[H[630.NK\VJ$H,K$?5B5-;5Z:*U^D
MNC/".U9E*4;4UY =;-ZDT@MCL57$ALSVYZL]1:_<^,01+3:ND\TC22Q,JB-:
MDT#QNT@)88<F:/#QV[:NG7M7NG=YVD[CMG54%T[3]WP4TFDC>94W*EN$%JU:
MD@BO7[5R."E6VF&9!:,4[24D*RRQ,V,X.LM;->1 UL;:32@T@Y[YSZR7*4KY
MIDM; 089\D+Q19G),VMLJ\I\;Y7Q0.EED21U'GW.SNNY,8%CW"&S3EK4XU^)
MAB2S)(L>VS58(C)V%0!5E3E.LZ$^G)#)=]TZ9V5*/W=U/5GH[GM?5FUU;MF-
MEBW.IM!>PW5<]^W8A,-^26Q(9VDW*LE]+\L7;NRP"2M)8/T4G<9:EH>*X=Q@
MMUJ@[;0UML1R%1B;7!TV?TL\PU7>7$!Q559'_(#1@SSE4AU"56((0I0IHT2B
M%S6P;7MFRV9S)O:[EO<^VUY]T>CW*R.M,<W^[3) 8HN<\T4,T+&3NR.&?';!
MCH_7G5GW]T?9V[8]JEV'[,.ENJ8H^G)3N%U>I;>\;R+'8BW9TM6Z]GO[50OR
M*1#-'2@KP4XK"265-EV-)H.;N.+')\/\:\2Y"C'P^8N]!I4KFC&5VPQ8%G86
MU1HZ\:[UF=MI[DP4@ZP'J66%-?G6X @C"F-K(FUUDI[O3L[E81WM2%E+Q;?V
MHJ\\2R21589ZTW)JLM/N12Q6!''*L!+-(463,]8W7HG:EZ7'4&X7EW!KMFO4
M/4$6YRVJ]#>!M\UF3IN_6K[<T^V;@R"%X'O1-7LUY :\;A'E,6]G91=2]Q=W
MG#MO2R<WX3%0L=A\C2W0N-Y@X^(KU+L9,MCGQDVV/Y5H;D^QL--F8)WUR6T[
M;/)726 :$6$BUIV59]LO<IXHV8]Z8]MEF+<:]LB5#VO2B5K)=9ZS8BL?AS!H
M^=PEMHX4-RBGAVQKS,'LM$UK;-P#)&6FD98XYZLBP(@D,0/;3C/$0>(A#E=X
M-3)>9'D7+*?8H"F?"LRD?2:;-%"VL1)HEL.T3OHQ$(CD62HO(?J09XM<0%:"
ML!) /Y9NMB=VEAW2D+%J/FL<LL==;=9W1HF>*>>,@F:NS1M.S+/QE=HK"=QF
MU^C.D^IDJ2TX+-FO:V>Y6DHWN[%\58M;78:M82*">.:*0?=MZO5W/;*_<>F)
MH0+%2T.VT,T^E[E3C;C 9NCN[K;2ZJCV./T.8TV,#'834@O#L,[J:W5 V5V!
M8%0K3Z;TZ/Z0<(ED;'"-8S2"$2 0[FS]0=.]-+/LYM0V:6ZAK"--#(IADGCB
M[M>53'V8GI/1:>=X18)@,LB(O&,R:'670O5W7VS5MVV7<JEP4?O#;=VH7)^S
M;$%6SM\O3>XBPT\\\R;E/?@VZLMR"!*E@1QQR,7FDA>#D_CSB'J'P7($6HZ>
MI:S=<=\:;+74W4-P%7UD.+U[Z4HFEKK6\IZV!IFA&./JZ:6W8:M]I86W.CT
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MD')X4$E9K4<3J\C+PD<L]0>OSYU>S.:!EB(/6G5]//06%*,VK-F" CC0(TY
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M"<+&^O0=IR^(^*[MUG;ZU79MQD@<;I8@N[#+:B:RDW>>X)NXY5X*M@2!HQ(
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M;IFO6KHY-GM,.4R!UXE0%(*JR99& UIY%$ZAXU8!"H+#P6<^I0Q!4> ,@ D
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MAPQ3N.^?)@]]NV)J5"C'2NQ)!SEM6Y1)VK-J"**O$S.I**8H&8Q*Q4IW9D7
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MZ=J.U86<7(Y9P8_QFCSQ[N2LPVZREC)*)4:%/DSB(_YLVJ.AFC>*=$]456)
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MS2?-,)E?"0B2M55C]^W'OK4>.LL43<WKN(RCO"Y'&-HQZ!\.Z21AD9@5XE<
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M*V+O6BACV&92)3,8SWFC3NS1MW $R@'-8PJ*W./PG$#D))$!<G66<FL/(HM
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MS?U6%HME66N> @L30A["'UIHNK=,;E3MV9-NK0UXBDM83%9YE(68M/$51V9
MKR6FBD/:>-Y."?A !-;O4>T;E_8-Y:G9^#OT-KAM7&3C$MH0O%6CPGX8$]>,
M/$W%>\K'F6=<F FVJN/>"DY,Z=8<>S=;+75BQ2;;N^UEB&E6KU> L*8<-7S@
MW$01EE5Z"$.1E>>]E18.:?#&Z!\W22C/(M/XB>$V4EFEAX2-R#?$0E;4GE2
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MA$\+7M21&HC61=_4>KD3S/D<Y9)Y)IG/E?$V[DUR3NS<<^<!1@ 'Y?X  >P
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MB%"Y(15 8@>I@ 6/EB22=4J'=MR@8-%<G1@$ (;/B, 1J<@Y5  %4Y    P
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M%#<<@$C(&OBK^'MT.4=VFEI.E7@ZFODB*'^K5.!HZTUXYPY 9H\DP0T#I8#
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MU_W:\=M/^!?_ &1_RTJ4^']T1I1U^9_DK\&KG:F6RGJZ->/<^ZJKIKA$;:R
M@*&HPKK)J(AJP1L^93OZWG\SN^Y5Z@WNEW?A-UOUN^%6;LV98S(JY*ABK D
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M>)DS6RQ/1DD39$[/B:K:A;@,<3%HPK>G!X8..0\C*C QC&/&#GV.M;J*&O\
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M'M#.4Z'DO39G6AT[JZUS4N=I(06*52VL4\"F6+#J_0)$,UTD-G \!1)!RO-
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M<\H[<<I:$&)HVF/>FG,DOX?PF8F15[F749*J-(\H['<ED5N$> "H#^HG!\>
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MM>UWXFHYOE5._B/M6(Z^R[O5DI579Z]B6&RZ+\5!)\/* (9,^8F! =7!'MQ
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MMYLI/'96KR"VYEJ112N?[:)4Y2/W9$5&P(U4ZET=$1R'QJXV!R//F<4>"R>
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MLU1VUV=';1_-Q2C24M?38T^CG0-K4F!G0NTO872R*K+"-C/0[*%/X@>H=B^
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M!L@<6P?=1V8>E6QY,Y-TLF+U&@X:VG*5]<WC>.'UMC%48JN78VU/<56KL11
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MB^)LUZ,3"&4PQ-)_N0[+SY\?."<DJX4MZC@8P/;&M,-:<<T[CJ"0Q!P& ;.
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MCN<2 #G!4C7V&1)(XY!Z>XH=5; ;R,@>_OY\@$^<?+6Z]^C9Z]-MT^=1-O\
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M;X<65I!&9I$CKJH.3EI>WCMNQXCC("77BG'B5!$U!54@\8@ZL?9CZ2?J?KC
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MSM\<:4K)*KV$=9L&*"*%6$C0H,D&08Y*&QR'+/RUMI:KR\TDCP"$2-<LS,/
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M2RPRM=XY)U-7%@SS3JK<HVGALHK2I.2Q5DL1QA!'!.J%TG55(E+<SXQJ;J.
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MF!CN/+W$DMQ/P/-%ARC2B+"A@\'=%Q.5D0+9<2LJ01,P05SYB9D8-RE!\.4
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M&V19&N17*U(T=W<U&(GNJ>W9KE5$3[(Y4<J+[>V_+$>PEAI8R"SQ) &#.JQ
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MA1S-=)&PDR<A$RAAV;WD?'X("UFT UY8QA1B.?#";#"V:RFF,CD=,\H@&K"
M%=/%')/*Z%L<ST8P>8> 9R?*\2$^4D8E<<>XX#8/YI",YP"<X3Q\AC!&*CTQ
MO74%BFNW2[?5:=I@))(6<Q54CA9>"PQV+4]B41NRHO,LBEC(DLLH+>5/)!,<
M0M7N::'1A6VBM;*L,^0'K[7+59/;Y8)\U?(@MG85+46,>P7T);<3T63/]5GJ
MOV7*IE>!XGR2<''@<F#X4>3@J)"2!Z6;VXS\_2OJLV]DW-Z-BK1K030"5Y:F
MY3H<L1',IE@K6#YDA]0J2\F52.0TD; 3;DRRW%9O\4E 7=RCT*@\?A4O( =>
M./\ +2#3MMQ'F$EQF0SEP7@(8,4L$T?HE2*UL[_AX\0H9PY)#_DSG!(*LH'%
M2N <LWJ!]6/2)NG+LD7*G=Z?WIKT5-);8FW^S<Z=DE=E;GSJ6C!VY W!J4TC
MLF.V]8%3R3U-6WTC<R;>Z"[BJ<596=S;9YEC,$-LSYX%D@-T!B-CDG?7P),X
M&&4CY9)U;YXG2.C>SPR@(Z..3.JJ6+-Z?8Y4G Y$>,D9QD?,@R5^;;^YN,>W
M4*AN;S6KTJ>X=A)6V: -VY*]*METQ,Y3O,L8<*,JP QIZJCEB8P>F)T^AB+"
MEL#JP,,!H56)IF6$$$0+;L3YD2:>Q\\98#0@H#ZZ"...>5KW20N6.6.T1VY)
M Z>H"-3Q#H2/Q'"X[IPN"6!1 %XC).:3=Z-B@DNQ[3MK06$K5[4\]EI[<VU-
M5=VL? S&*=(ZQ5X;/Q$TE>U(SO&I0*X'*0=6Z^JCSFI((IZ"HM2IV6\3XRGP
MVHS7QPM<.-$DDLDK"W/DE5&M[>JJM1SG*FY&PBPBL0N"" I/N/+<<KRSCSY)
M/C'MKQ'6L[-;;=-HBBN[E<IQ1M2D5H0]24AG*RROP14,(54&3G@,E0 4KIEF
MJ<O<28F3CKF2WLJ@;,7F"UM<ZH#O\/.49%H:(,QT9#6R6 DD;'LO(R@6HV9)
MAE7LQ?D;".4.'*'('-HR5!!Y*P* N I 8$'FI/IPP)&PD!W.U!6WREOO2VWQ
MV;-^#=:-I+O9W7X:/X.>S S+&51P5_LH1G5P.?%N2MGS;=8&GP-7]8XRFH5T
M62H!MSF\^V_TE;C; \<.+Z8!/G0&N-90Q.E%^;JH:^&)T$<J2 N1[F^+)62P
MZQ.)%5RQDD]*2NK,3(O?<%>>58!V)Y%DR<>;/T#3ZBMWIQ]_+.-OOVAL\LOP
ME>WN<"&17+"9^<8M.5([RRMVR[%7CU(O$\;8_A+C'.7&%EMR)6CU-FR,=0WF
MZ&.RA@C@!)_6*4HX<&:-[4D2 U+%9%<1+,1/YT72N@QK!:28+,S!E@411 <R
M>;.H/B,A67T+C/CP%.N?;OU%NW6G4M[9]ZBIP5H?B-O0S/::+:Q0+@SI)0"Q
MV+4?#TO8B>!@JIA%()?[/6LQ^?HSB:YXA)E/6%D"N<Y[AIR H)I1W/\ *GF=
M#(]T:N[)YE;W[)W\3M/_ *)5RZG^S0>03@_A+Y&&QYUSW<ZBUMRW"O#:$T4%
MZW#%,,*)8XK$B)(!YP)%4-C)QG&3IQ?$IJMZ/#33?<M@W]GQ5R;6Y0UE;J+#
MC[9@YNQD@IR8P+\O.60].;(-H98* A@MC(-.Z"\GAIY6QK'9RQA.G>C35+_1
MGMK_ &_3+U0V%SL>0-I_G:;B3ZMI>N#A?J^R998M-RGDKBPQ0G$<(L6-JY-;
MC=91?4R@ JRZ,S5E2UL$)>5M!16FKX?#31X::/#357'QB.!/Y2/1'I.-)3^'
M0ZY_*'"VHO!^>>3R>'.,KRBR/)6?OK7,WG(8=3=ET$NB%#?4U\HU=-/.:5"/
M$L<DC7IM49H*]NO/:K"Y7BD5Y:Q?MB95\\"_%\ G&058$ J1@G6.56>-T23M
M.RE5D"ABA(\,%. 2/?&=:461^!%HB]Y(1MNJ[X9.?PEGH+,[Y7*]8 %U99FH
ML9)7#U]?#;9(%MQ!5-^6AA::7%/+&V=RSI/(UR3U/<=A-\O=V^>"A)//(8J8
MADF@BD5C'%$TY56"-P4\Q^4LRX;&L;I.(>,3JTRJH#29"NPQEGX@D9R3@#Z?
M+QI[>//@HZ'%9C?0U75/\/2[TY%Y!#C= WJTII:!N4.%LJO0A7-/)C)GCW#V
M$U]G06L1<L]60%\D^.9LOS#;1M'4.T;?#N#U=LW"[*'D@JVC4_"%.<+$PECB
MLM'7F$9>1,B?\7@H<(C"74L06)6B#2QI'QS(@;U&12"A1BH)4$88''@C'L=.
MEQM\!#JR(TF8UUCRMT?ZCC2>ZI)+63+=0UG,EK4J9#]1 I;F/C0D#Y^P@]04
M";SRMC)D:YJ/;V:W;VSJB7:]W2Y]U[S%%P#-%\([MQ$?+EPD=.Y'SXL.3@\,
M@.H(Q@F@CFB:!;-8V"&X R+G)_*Q5<MX'N ,'W&-+7EWX-'5!FK*\T&EYUZ#
MN,:Z_F2*JJ]%SR5E*T>LC:\44*":ZP(\#RJT& *.0J!'2E3D%3^>)5<V:_3?
M:Y!%1M/%M^^<'"*TTM!8HU:7D&$ED6V5)% 0*>+"4NV%3MH&T(]I+2*IF@++
M^94EY'QY\IP_?Z%<>Y!;2,XV^%W;T%C=D<A]3GPZ-> 5F;X&G J^M:JI90=,
M8&L5%<3%IAY9)!:DI?F)1(_3^:<V))'.B9+!/K5?MJVZ!)#\/N:3/)$Y9*]:
M4=I"><"E[D?:#IA.XJ,5!RJ@@$^Y=CE?CQ>' (R&#'P2.1_*?40".62022,Y
MQKI7_P ,WD4K2UNARG4_\,K&LKJO("155;UG12QNL\Y55H-Q=/+DR<9CBM39
MAE6Q+63Q/"0]PD4ZO@84NN?MFH+W7CIWWDFD!+2K6*Q1B5W9>V9&2<R0F.OE
M^!2./R7+<E]+L<@"@RQGCR_XE)Y$E1E0,"//L >7@_+!1_-/PH]KM=W<Z7CG
MJ6^&GB:&WAK2&YN?K6"L8 K=U6*V^<,87D"37 $W#3R@8R)9R(Q9(VS2J_SH
MR@[[UK1W*[):K5K*]U$,ID2&-I)A^>5DC<QJ6&%)15#E.Z45I& D*E&6&%8Y
M9%<KD<@/=>1*CV]\8R?'D>/&,(O(_"9ZE\!7WVJPO7Q\,O.\@V 5CD6U<W5)
M0W%*?CM946M3J'SVQV.E04N,686 ,=*2:5TY<MB-8UY-6*A,96ZJ^"CELTY+
M$-\GMI&8(F@:%L,S&?O\TD1PK(H@<%E#%A^4YI*BS%8Y(U:$$2$\V#<T*E %
M"@$'!R>0]@,'.-,$-\!7E>TQN_$T76G\,*#9'75%I,A:@]7<4X\TC"3 ])GK
M)OZKBAUU>8!8QW(UA'561GU&B&KO,,*=-/' "Y3GH;E':B<7YK5>W3L1Y*#'
M=2U7F5I,+'(CI(DBHTG=B"N>#978(<21<".VJNLBDC(R 48>"205XD9 PQ/N
M,&5?PY/@W<^\-]?O2-S7N>LCX?7(%3Q9RCB"Y,U@>JJ#9;^TI:$?Z759W&YQ
MV.!=;V,8R"@U-2PP?SLCC@C>WLU/$=/9L63&;$KRF&&*O%S.>W! @CAB7Z)&
MBA5'T&L@55SQ ')BQQ\V8Y8_N?<Z]";Q@UZUK+_%XZ==IRUUB8?65.IZ/1,]
M1\(T=3-EN=><,=QEM+6Q,T'(L4Y!-/=NDLCLF..<'/1%1P,%ENQK9B/D<+(Q
MO:/L]^T+9^E=AN;9?>]'/8W%[225AE8XS'47QG(#,8'5C@'B0/GXC;>QW]SG
M26I7DG4((\1PR2'D"S%?0K@@AAE2OT/R&JBJWX7V[++K:O9]071/)D@0RE%M
M,MU,\05EP&981M(8P\HD3YR\KJTM9(6Q%F)+Z'J/"DC:K(/'1#]M71W-S#->
M=0RN@>LP52"R\>W'9XQY7'!DP"Q_%1V'<&,]#=2=L,^S[@ 5PS_ W.)48_OM
M6/CPV2??W\#*ZRYOPBJ^,2_D ZYNC$NR&0EV:J/VY8&-UJYL<+Q(SS)-(QE;
MZSW2PR2,'+2/T6RHQS941GI/MNZ/9H@U3<@IQW6"QD19/J*1@DR 84X9USRX
MY'DMH_[']0%^ H6N9_NFM.7'O@$"+DQ_547.<X\8TT[_ (8?-50HTX_4?T,T
M;XVM8I,75YQ\"\F5LDSD)DE<8WRS-BG6'^8\D?D8U?361TDC_C_;3TLLADJK
M91'54EB:@#$\BD>IN+ \NW[KEB2>1/A..S)T=OL$:?$T;T.,\'>&W"3[G')X
ML$@GP0/ \8\G.9UWP_N;]L^FFTG5=T)VL])3AT09!?6'Q9)*P"O65!8&O;-"
MOIQQ/:UB2^K*B-5%E5O9&R,'VV=#5$9*L>X()9&FEXTB%[C<?4%[YR&(\CP!
MG&#C.H^3I7>9N/.!@$SCT2DLS$EG)$(XDY'MDG&?&=9B^Z(>>-!GJ#*%=4WP
M_A*7.)7OKXP.K?B@0AAE>+*&T^0F(MDTA<L,Z^I(KD[^D.B>58D5=>'[9^AH
M;,LXBW+E/S[LC5C)Z9&5V58W?CQ!_*#X\G/AO&23IG>GC4=IE*\<8BF!RH*@
MEP@]P1^4#S_'*^XUZ ?DJ&S$W'4AT0UFKK[$C246WI.K_BT^WT<D_P J.=B-
M(TTU\;:6X!4]''=B6133*TL(N*63S8[7VU]*/*A@EW!Z[(*\E6:D.W$@Y-';
MAX3+B:-^![8QX XR9 Q\CZ8W9.)-=BW($R!).1]R<DQ$L/ 4@GROD!6&2C.2
MOAU&[N[W.KJ>H;H,QQ!5I3IC\O6]5_#L-.ZGC&E#M)[:80Z&(6WD]$,]S@AO
ME""ISFI&Q%A<S0F^UWI%ZL,)EW2Q+'&RR6)*[!G8NKI@EV(0<I$7D68*D7G!
M8:SQ=.;LC-FNV&() BE!!Q@GQ'YS[@Y!QA3DCEID9?A@\JO1K6]3G0"C.[N_
M?K'XO5'-]O+Y44A>W;\T1>WLGY+V\1$WVK;$Z+&9;Q3)Y!H6.1CT@<F&,8!
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MR<E,GA9!R]##U*V&4A@#K;H7=WVZY7N;&JON,,@,:O(L2F)@5L<I&=.*]AI
MW%PS#*KY;&M/CJ"Y.YB(M^'^KZ@NZG+Z,?1-XSY#Z=: Z;(R[RC$M27C3WU0
M06:BYR22"6G+*M!1XZ>1]01.Q&$>HWM>U[C0CE;9VW*0QT9[7P522L#-9-V(
M1TX'>0-)!9B[;VH[+"*%_P 1C)%#EM=&^T3['+]<+N>R;!OVY;2^P5-XW?JT
MN^Z;8VYRRUZ^YM!8KU(:M94L6$%"K#8NR3Q!@\XECD59H\!\3#V07)G,.8,L
M;#?<F9M,EJ"M39;*TTO'NI@^7AM\C2:VRTAQ=MEZ#8UWH657YG/!'*816:"\
MI6,C+LENY &JPF.-889N^C1&LRV85:0IWD2(]J18Y9.TJL8ED$B]B&1B5_->
MYQ2T+$%2W!8@1#'9A6:!8'L4Y@)*]AJY!6/OUF62,J[H^??/J# \<<A9OB+G
M4?C>ZXVO:?*%\G;:UNL;+"EOM*"^O0LO<Z"J#V=7<62[&I@U%75:\.I-DE2.
MGNJ BTG[CB_+T[KB[NE2?:8:=.6Y2W';Y)X-VH=UBMRG8GE(DIF-%KK)5GF<
MD.&9X+"UH3P<#]>_8/TETGUAT1U+<DZKVO:^K]KB7;9-NZAL5JO3M[I^[RCK
MWG^.K,E:_)-:L[,ER"6)H3-#&0BVU,KX<RPY[D38<N\D7]%85?&O''%M-])%
MMK>QH9:"]L[RSL!C'DYQ*^X@L?K<8\@A,X&JKL\VQMI91H/J4,LGCH;J:[N-
M6REA+6W\-R6!GW&"&'OQ)6_$LQQS!A' T13\\\32% G:C:-P*_\ :I]F^U_9
MI7^S[;-@:EO/4>^S;[:G.R@[K'9K4IJ214W2>:W6NQ10&X&>*M1FF18Q++(L
M)!4-3R?QN;PXM-IMF>-7<?P4EEJ-! =#L+#99**F4GSU5X#='94BTJ[LI\,J
M!E>:<,2$F2GK)"/DV?>J[-:N+%2P46TU?O/0<".S H!Y2%.*V2KQH?Q8V+"4
M,BR/X9LWV1]%];U>MJWVC;%M55=AW2UU(FT;Q%)9VKIZC:JV9([(M4WJ_&UJ
M*5?7#6W"DL1@?P97KR=O7=Z[.IGHXZMJ=W G1_TI Z#EZTUD,9O4GJ0EJ-03
M"PUGXX_DVP-'DL)5^0D^=G)KG1*LL(KI)O4;S6LU6[-)L.VP4+UK=3&L%RRD
M=9()R!/+-#=M*-SEF4*R-W7A0J'41V(^*F+^T3?YNN][GWDE[VY10D64VC:U
MKU56OR20NT,49M1I'&'CL2P"=U;,TP$>#%+-T'4A\+BWLSMKJ#<O-N:MF=T^
M!S-Y ;$6+8(XD$PV",KY$]T0L<D[6/C&(:,2KXI7-<K5R3;6NQ5?A[V_TIJ>
MX2"+=MIVJ6*?<?A7CLPK;@2U$O;9""HL(:T@Y\8YB0W'#TO;W;[/[6S];MMJ
MSO')+)LL>XU["UFN1\3\1PE2..=*TT85^'?A::(QR!N#+J+G+?5/U):SCVTP
M=ORUM'<+\@:,R_&XY*,&@JS8P3(3!3[$$-K6>IZ[AGJUKWL)F&9*0Z62%CO%
M8AW$[?3L[#LLUB#8%=XZ]:<1-86IW2\<#S\6F6-CB26&.80-(6)1B6)KO5>[
M[WU7N*=3]46SN.\7#(1:E4&;MG!.9 %9E7EVX@ZDI$%52J@*(:^-'5;U9-\(
M,DF?XHO0#'//-,P;J?XEB';+(][8(OUK#=Z<2.5?3C\RJY&-[-15543W\?22
M<9).  ,DG 'L!GV \^!X\GZZ]%F(4$DA00H/L 3D@?Q.=>O%X^:\ZT4/TD5>
MWQ",M_'I?XR_+O[?M YA^WO_ %JB?=??LGW\;$'D-^C?4CW4?3^'U]OY7/I[
M_H4A_P#OAQ]/';B^?S]_;Z?MJH_@;EV^XSL;B"J$S<OZQA,JI"[P,Z>4#S2M
M[.!>%9UT<;IU5(2WV33!6#^>1L+9VMF2V;5M>Q]2Q34.H:^SI!6A#4[$E6Q'
M?-MPT4*Q6:$M8Q1MSY6+$[&)0B-+RRZOUGH7KGJSHO<8WZ:W1J$-JS7DW.%Z
M=*Y5MP0,6$5I9Z=JXT:!F*1T'BGY-Z64JI5^M+G\[")3%5=V\HWY8B#14Z'!
M3-K+IDKDF?63U+'@G54R>1]>1%86I#X4[E2LF<Z%DKU+LO3-.DL%?J65[ZNT
M]:M+;K3QO?F2)FGFF C6K'QC897M11N4"LA+J_2^F+&[=43;Q:WZF^WUJ\LL
MVV+!(=OBL0796,?"F^+OQ5<E?B(['<F9<,6E4&1WHR?*&ICX^DX^)JLZ73G!
M$@-URU]L(32/,-B&=^L)0S4%D%'BE83]0B#^8C;/&PD@N1CAX:=M73FT=0%K
M?4G3\S-)#8@I=1Q3O+')- O*"YN_;O2E8Z\RQPBU,L3"*-$P8%#ZZA%UMUUT
MRU*QM_4]7=(*U:D#M%C;B$1:JSU5V;;<4:3O>O4JG?XQ231=R3E,U6U/)8+K
M9C #UMQ..-)D^59V5Q+3<YE-K'6YPR(=(NQ%O"'4+,;7O<C&&QN0-Q/X$;,-
M(K"%UMGWN3[.KVZ;'MNW[GU?3MT:\S-65;D-:>4.DL4[B2S"*[J451*J.!@,
MLHD(6_\ 6FQT/MFZ"V'=*LT/V;;S]Z^L[YMS5[45IS.MJ':X7D4T=RMO&7^+
MAKS3S0Q%7>1(M5R<[\7:V.QM=.-BCZ>G&(FF/#" +=54DDS_ %GQQR2>M(.!
M$V=C!HRIR)8(DC28N=[7/=[@I;YNOQ5I]@-4!IK!CVVDXIPUR#*O 1SV8Y!'
M$<S20,L>0SA(QZ5_*'VK]#?[*S;<\-@24FI5H8Y+>\;=?OW)HE^&LW66K'4D
MC6S:AE=(9*8= Q0O(5Y:B41%Y$5%3MYG=E7V545/=53NG;W7[I[=D[>ZKV1N
M@T9&" ? \C(Q_#QX]Q\C[>!@^>+,<9^0S[^#\C\B/G\_;Y?PZ,B)]T[*C43V
M3OV3V1W?\2+^:=^_=O;S*Y.Z+W\? A^?S\'TCV\8S_/'L?UP =8C[X&/Z \9
M/]?+]-=95_).[D]F^Z=O=%151>R?B3W^Z=G)[^R_;Q\XY&1XP?/GZ9/CZ?($
M 8Q_A\S@CW_R\>_DC'SQ[#Z>WC0BIW[=_9/W*GW_ ,/Y=T[_ )>_?MV]O'S]
M1C_G_7^OSQKV/<8_P\?J!YS^Y_4_H-2(Z0NZ=6?2Y^:+U&\']N_O_JG9=&]_
MW=T]NWM_O=N_PC^8Q]/;()_?Y>WZ^VM:W_T6UX_^AIOGY'X38/\ R&/G^HUZ
MHWC[KGNM#/\ 2MXDDZSNGASE5&MZ8@6KV15_I\K\D=OX-]V^R]U55[)V]NZ3
M&VY[<F/^,?X@#_'4G0;BDF,9+>,^PPO^/^@SY^6J5N,N%,52<4Y_EZ]L2CKW
M5'V%1AVUIU2@N=U&=O*>(U^@JIRIRBHVU9GU"%"8!@&O>-$3\RPR)4[)T_L.
MPU-BAZEW&]82QW$:.6"![";9-\1+%#**\:L+,D+P">6.8F,P\D6*1RG/7B-O
M==U&TQ!$5I51XY3VQ826-V"]]PD40+>C)D0X)8-A6"S?KMV^/B*CU'(UI8':
M<H[6Y[,:71AE'G1':.4.QCNP:FI+99DYL>GS,@@4Q;X0_KQ(E36A 5% :85T
M7;;/PVV5GDO6;;W)YXJ6XR;>TKVHYFLVJS"I!Q80S+'%*D9[3+'&@FQSC(BK
M%:2/=)*U*K'6[*0)9KUY#Q':#5YA++,9$2PSS.'[?I"!G!+R :Q),=AO*6NR
MW'B\A:JKN,\/B\H_1Z6NRE;G),K7D6)B6-:&Z'-V$Q4#2;$6(ESK$^O?"UM@
M3.YT;ZX\>[ST[]>18C#N$EVA5DAMR59XX8C'#6-F%XHHK4TT<<LTL\);XNOB
M)7-8KPZ]:;H^IMNT6]HEW@[[5VJA/OLNZ4EW*M5D$<PW%]FDAMV;U.@E^>"-
M6DJ)' 8Y3Q43'#3DY7E',UE,FA#6B&A<9:A594@)E4(RM.;3%6]=6NL;-[&O
MLPI8)S7B(IIDILD,A<4CW)##;]YFM[;*^X-LQVI1+/M[1'[IV^O2,7"U5X/:
M29I1(&D:?^U6)+)2$-$MADV-ICBBVRU*L%+<GW%Y*<EA6JVMRN26Z_=:$DB*
MQ4->M 6RCJ*T,<DA>)FB5U.QN M38*?1\F33V=45?VR65L-%)QQ;1%1!RS1Y
M*KK*JR,%OCKZ$V(DRT#KQ+NK$CL"30B6C0.L,\5"[N^S0[ONEFS,E=KL)!VJ
M+:-U@)9)^<"$Q21^74E^S.Q21U:5435-@EM5*]Z?;-IJ(]TI22 =T;I0F+N\
M3RSV)(XX$@K!&18))>R[B)@RAW5A.<.!EY,YMS_'OZUAXB@T%+6:.M&N["_T
MTU$-+62,"K);- %GN'Q!"M4.<81!&0RC"*1"R!R1P?4W2K;UU/#M4>YJL!V\
M6(NZ99; C@=X)$B6:P>[ZXYI8DDLJ%C5TY>$5ZJ-V>.DTT\)E83NC"$"&&6=
MF'=G,7(K!)(>/<XA?*YX^=0CY#Z<K3B2V)K=_<0T\)]1+?9 B9L0\^DI/6GA
M$LH@YYO- TQL37Q!22J6SU&)(QJ(US^;[STF^PW+52_>KKVHY):S!XB]E$D>
M,?A*TAB=^'(1.P;'S)P3M1SM*D4BP3<))#&SD'LAUP).W,%,<W!CAFC) ]FP
M=1G>U%543NJ(J^5>W?LOV9W:WV55[=O9W;O[=U1/>G$ Y\'YGS^_C(^?CW&?
M\LG/^W\/'[?]_O\ IK D1HU/?NU??^DJ)[M\W94;W=V:J>Z=E[^[5:B(Y.^D
MZ_P)^I^G\?8C^'M]=8F Q^OCYCP5^?OCV]L9^6-;^'Z'XGEZ6.K=.RIVZ@<S
M[+[=O\SJN]OW?Q]OW^,0^?[_ ,_W_P OX?+VUK2>_P!/'^IU9K^D?M<_X-O5
MRUJ=U67@GV_JZC>)%5?\"(J_X/'H DX'O_R&=>->6"U%15[*O;\T;]_NB]NW
MW5/-[?=??W^WA[^/T_H?SQ_'SIJ8'3_R5O8HW8F,RI,R#4>2ZKM:D0R2 TB&
M4,<L*2-8#Y2X4*D41)B9HAI'(]L4:KV=T/I7J7=**?=I%2WMU@F T[6VPWL2
MV&0+-&GX<SS*44QJ\Q7SQ"<69=94AFL>E+$L(A/Q&?BI8$4HG , "RABOIYA
M,A0,,H&I.]1 06:XYT&9N:V:+:HM2';!L$')JH[;Y&5Y%I76,%H5 RQ(\H,>
MECE8V>&W;&YO9))(Q[SU-/5VOIANG)-CGK79XZ\L<\$$#[1'/6]+M699%-6Y
M:@FA>:&%'C7BZ%0IAE?+8@%V6?=_ORO<L?$P12UY(IX;MI9ZTTCW >RL4T5>
M:(P32S2)9GEEAM 2]V7MUH5F$U=]&5/44AIL0;?.5)!"Y8XD54]U<O9/S[=N
MZN]T54]V^.*P;1N%I97KU994A'*9D1BL:DXY,<85,^.1.,XSC(&M1F5"%=@I
M;P W@G]AI+E E!S2CD02Q2PO=&]CV*CFN8Y4<BIV_I-7V5._?O[?E[:$D,D3
M%'1E*G!RI_[O\=?==94[+V]^_P!OZ_NGV\8]-?/AIK[>U&O<UKVRM:Y4;(U'
M(UZ)[(YJ/:QZ(J>Z(YK7?DK47V\-?2 "0"& /@C.#^HR ?/Z@'78& --5R""
M$$^1$5_HPR2(Q%7LCGJU%1J=U1.Z]D^WC(D4DF>W&[X]^*DX_<CV]_GKYK89
M_1L>/]72?%HZ:])85;HJ8_(<Z*.:R:&5B+)PMMT8V5K)%DC<KE1BM>WNUZHQ
MW9_LDC:V3<Z=.#<+%21*=GEV;!![;\&$;@-C&4D(C<9]+$ X)&<:RQL[1AAS
M3PR?WAGR/'ZCR/T\Z].3Q%:R:1^[LJ&MR]M+HVK+6O#);)!' XHF58X))NXH
M\;))GD0)&I$;X6.DA=$DK>SF(OC-761ID$7Y^0 )8*/)QAF)  .<') (./GK
M>VZ&>:W$*Y*NC*Y?/$(H8 DGS[YXXP0<X(XYU7!<1V.GSKKA#2--GA!817"W
MA%C41W4+K<F*:SFJ665=7/MJB%\,<-BZI&DB*KXR1_2]=9![4A2O-V0@JSLY
M?\$1R=INTI5%E*22]J0YS&)F#*_%\\3RZ/"$29"_%_ Q+Q_*5]4B,  N>2<L
ME0R^> 8E0&.L\#:Y[< 6X!BRPFO*-J]#1CQ6->QE]YG("@I<-@#*)%.TB>61
MY@3!@[&9H_IN>U_B02Y'-3>-T&4"I)!*QCDS7&.X61HW5BI1>(1^31 ORXD:
MG4F2="N)5[9\]WGY$KJW$9[G(%PYY^GB)0L84LK:R!MR/^L65,J2*^WAE(!?
M7/>+:4U'/;VSC'/<4"T.!PL=9;Q2$15TYELI=,Y1 8IOD(6+Y2$]FRLG*(JK
MB0<HI)5CBXX"OR;DSPL%+K'%PE'-R Y.O/*4PE&1@6& 48R2%2A&26<!5;AG
M'<!9F)'K+9F7G^4L J1Y0NG!J[:LR--;7%R/IJ^ *%NC)MY81'DAJMTR6M+)
M.EKO4C"A"/=,/!( Z)8U@)J5H*LX>1UDL2QPQ-78DB%8@7PWX1#H$#@%RR@%
M@X.J7+1N/9N-%90P--AX\%IEXL(V'%B D<AC=>X1^(JD@%O.E%QCNA,4 T?2
M!W@18E.'5#CD2QW(MC\LG>&SCT"QG7MG)9%+,DQ=G*$^%7,B+"..3YZ3#;A[
M[LT+1.KRO*653"4Y'S%V1PAC5!@A8PZ^/0ZIZ->=QV:U?[?8D0QQM@J9'9E
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M\'M/1=RQ3K0TMTO4+MZ2=K$=J#;9*Q81"**5/AN^AM+&\\9A('XE<2$(9%E
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MVM/&WPBI8D/.TU2K :\*Q<8I7<\5K_1&Y=/[7T=5Z,^S3>^G[G4&\49-QO\
MVE]4UZ.PR?$SQ-879ZE0S6[=2+X>054O"2PDMQ)HI1&8IVKU-8_I&Y9T<$!7
M5O4: L[)Z,P1XA0CI!9I6SD!#OBA8/$%.BM<C//-&STE?&LD;9OZ?/.J-YN=
M/P03[3M-N(;LS(MJ>G.K]^-D66)XY2D[602L8C?'G'N% :W?9Q]@O4/7MI;G
MVM;I9LUMHF18:U;<JNYRWZK]Q:LM!JSVH!1E_,ED (R>8E9LE7BXF^"=R!U
M<S7FBYST!'3YP,S/277']I<UCA"=17U<8Q1E77Q%+ V)$#E)L7FQ-EE-B\SA
MVHL7;QV'HS;8IMKK7>H*VX/8*U@VUU#%!<GGFR7>RTHG>C K 1]IXOB&+CCV
MU4.WYH^T?[.-QK=6[[6V2SMEC:J6ZRTJRU;T&YV*=+F5@,\=%WB[G+$<S-,B
MI/R67@1Q$%^LKX9.JX<U6FL.#I2^1>.Z8""R1L:22Z"$!5(BD.454>Z2&1X9
M$L8Z2RD>1BHQ99%]!D9U5O?3VW=0? 5:U[;*DL-<Q2V^Y8H_%L@,]>'<NVJ-
MV^4982MS1I.+,05S*[S_ .#5]I>S=,Q]215(M[@CAFFW&G1!3=]N6*23_I&U
MR<;$GX"=\M569!'YSD'3=_"!8^/XI?05'(QS)(^J7B9CV/:K7L>S4AHYKVJG
MF:YKD5'-5$5%147MX?KGZ>?Z^ORUP$@@D$$$'!!\$$>X(^1&O7F\-?-:*/Z2
M&J_V0C+=N_MTP<9=_*GOV7D#F'V]T5/NG?V[]^_W[IV\;$ !5LG^]D?IZ1]#
MG^AY^ESZ>_Z%)]?B&/Z_DC_P\?7.?.JB^G3D['\8;ZHOMIG3KBIB.$D(+J3(
MX+2N@;(UT\XXI<,H-G_-]T<"9Y!YV^I',KV.[>)K:-RW#:[B2U-UN[?7976U
M!3CJR"]Z'6&*<60T:P=Q@9&3$JC#1,CKKJ/2N\],4*^ZT>H^D]OZA&Z1UX*=
MW<+FY5EV1Q.K37%BVMX;-B18P>TJ30O%(H8%PQ0V6'<E<6\U<D469;H,4'QA
MHDM3P[_Z//1Z[&L^29##$KP$M30F5QC7EQUTD;J.PADF&G8UD0I@W48]GJ;W
MMTM>6O'9;<*LEF)7L1795LQM$&EJGGBH))'YD\E(*.G;*Y5[WO/53;5'M&\;
M9O";W9V*."&P=BEW';Y-QV>66SF.^MVI2%R_6V^2O0-XQ&QW8*[,79K/.0.*
MQ9V/XHY/O\UR74W-%G9QP,E<#Y*&VJ]6QI)K3@QS*N7ZH.;WGC;$NDJIPIY7
MJYD*P1.E\5>OT-N.Q4KU&CO%C;9+=@[C'9A@2PZ!:T =I:4B31L9'A[1%.5C
MV5Y*HE<A;A-]M_2O5/4/06V[MT.-V9*\M+=J^\[A!3W#IZ":>N*RPVN.W5+<
M<=&/XUYOAJMDSS1QEV*DRQFI-WCM#-;UEZ%"%M*0&M3$ZWCVN>(MF_\ "YX=
M\-5E9@J2Q&AE05]@'6RG'$12,FC<_P I,VY%NPH1R$[9#ON]UHX*5NQL*31)
M?FFCDF#2VHXC)2*&NZ3P.DR*W(PJ5YP1SVV;%N'4.[;MM^V]4-L/04UVYN=[
M9^NMVJ;G'MNW%GB$&VT+J;A5DD,ZO<K_ !&[UEK5Y(GA=Y SZA[S1<Z87*R!
MNLWS5Q!LTT%(<7:2&TH\;4:U\+RX(!I1#$*?!VB?-.]XTBD10=F23PTMJ/::
M33[=LT>R-NUJQ9FIW(+R;I6M]L036Q;85EG2Q%R+I+WX>,P':+ %*9]J6_[W
M=J? MU1-OU';Z\,+/#;K';9&D9ASB@6Q8FY1-$6"V.$M83+%$[1EDC@^1YGJ
M[OW7N[NJKV^Z]^_MV[(BJGW^R^Z=_=$6H#!]O/S_ $)QGS[?OG&OSFY/']S\
M_P#/S]?K]/WUT)&(K6I^%G?RKW143\^_W1R>R*WOV^Z]O;^CX\L@\>,'/SS[
M@8QD>1X\>?G[_+&#VQ^OR\>_O\R,^?/L?;^76>U?S3V[^R?N_=^2]T5.R_;O
MV7OW1?MX*GSXP/\ G[# /Z 8 \?/WT_C_'!_3/\ V_\ 9K@5'>WMW]E7OV3[
M>W;LB)_#V1$3M^?W]L7'Y_N<')_G@^_GQX/GYYP=>OZ^0_AG_7!]OUU(?I!5
M4ZL^ES[*G\H[@[W[JG^JAET]U7[??MV_?]O];X\%1[Y\>?\ #/TQCVSG'T ^
MHU[9/PEH?_>\W@_^B?'[>^O5(\>=<^UHE_I4D#I^LKI^1'.1%Z8@D5&JUOVY
M4Y(5%1RIYD<BK[=G(WLJJ[OY?::VQ<Q2>?[_ )]_^$?P^?CS_#6[58*K>WYA
M]?'C_+Q_W>^J+N%,CLK4:E;14TA;"K=I*1EPDS5EA'3RBGS./'''FD^FQOA@
MC,*8U@\:.8R:6-CG*WN'1>V[O]T16ZD,<-:7=JQEDL2E$LI4DCLQY3X>:18A
M+$4%B$>),QD$!]89;,$;R<YYE[0+((I&4)-(IB4HW-5$X5BRYR_'VS@8GE3E
M<<*1GG0E59.&^E7\^TR=C7F VE-JW&06 =6 XP"6VBI=!-3UJRS4<H@8TQ!0
M\QBR++6271MWKUMTCCAD::O>F:I!22N?B*UL3=\[@E25(;3UG-F6.9NT8(Y4
M@D&!R:.][=TYU#U'L]R"O4VS:[W3M.;=&ZANV;%5-ZJ68ZM4;=->[TFRM;K+
M':DHI=->>Z9+$"-/,T*Z0]48?87=</7W<L7%V4MQ+4/%R5ULZ^DSNC,64FGG
MC"CH['26PKR9Z2*2.Z%*(C;"T6T^7].:*&MU8>H-Q86+M2WL73C0[JT8@GDM
MQW4AMJD4IC9I5DJ/%.\0CYX#*L\%J3DFO>V1[WTK4-JL^Y;?U5U34N[6L=56
M@:>G-$B<YQ/&T I[@A$R]N.4,O/FJ J&5..H=1=WA7(N0K)\ABPJ32T(1G(E
M]0DPSVH;R6& 5:G5DQ=2)&!8*R(0N(F867YE?U@,E[O;%4]CW*S9;<^G+=G8
MX)8^U"NZ1G<>Y66V7C-6G([&C6S#Z&F5FC!(BAX.6.[%U9MM*S-MGV@4+'44
MB5V@GVO9I;>SV1=^&,5.SN-RO*LEI:M@L]BM#)6%KA#&R*J85E+?/ YD;D2B
MTU-5Z&JT=I3.J.70*B]KC\M:>@RX/9CQIOU?%O231)R*^>B*C8$6UH]I!/ *
MZ,IWNWT]9;<-TV[=Z<%NK=(M1[[)%5@NI;M02E:E&I DLUN8S5V,=:G*J1MS
M-IF[IC%+>UW:U7<]NM6*$L32I%LZR]]9:D;"(3VIEYF/MDH&L..X[94AFY8@
M4/B.0R+^ST%45I[D7/S/F%+/ -,C;21SK'%-:*Q\OTT69&(DCFSHR-/,ULJO
M8C_'.(:6]"ZUBI%N=H;:Z"">:M:PM6)F['=RS?#0F*-B4[@6-%<*V$8C#/QE
M@+SA MCD97,B9,K84\6;+2R<F\8!RWDC&3I,]1G)^[Y,T!C=N)3YU**9C*N@
MHU,L:ITZ1H&636VI9=J0\8B.!)T8ZRE#]D:*U&-C8V'ZF62UON[;G<KQU=QL
MO$MM89WM12-6C$(,<O.6/MD*63LN80&/;)7P=^7>=PO;)LVSS6S9VS9(9(]L
MB$,-=8$E9I)2\<:18FE\&=N*O-(._,7F>262+K?9554_"ONJ*O;\U[?FOOW1
M?O\ ;MW_ (>*Z/V_4#/R&<_X^?;SYQJ*P 1GS]1G'Z>_GW]_'[XQKJS#MF5%
M[^1$<G;S(J_=?]>B(C$=W7S+W7[?;NO=<<D?(YR 0?GGR?'C/C'Z_P \9U\(
MY'QD 8]S[?+RWRR3@^P_;6_+^B$I&G2]U;I$C4;^WW+IV:[S>Z<=5[555[JG
MF=V15[+V^R]U7OXU90H;TXQ@>V<9]C[_ -?QUJV,<Q@ >D9P<Y(R"?<^3CSC
MYZLQ_2-IE@^#GU;R(QCU]3@QB->WS-_G>HGB>+S=O]<SS^=B^_E>UKNR]NR_
M(V*.& !/D>1D>I2OM^F<_I[ZP:\R'A;A^YYIW%7BJ4^LK#+66.!AMN3$(#"Z
M5Z,:Z8B9T<,+4\WF>^1[&HUOMW5R,=9.F^GK'4>XI1KR11.Z2N9)>14+%"\S
M^F-7=G[<;85%9B0, <M8IY5@B,K*S 8&%\GR0 ?V\_X'Z8U9_P =]/?&/3^;
MLX-EJZ?D8@7,'Q,@RMBXRG=I)0I&U,CS6TII3XZZR>B2C-@"A))AB>^S;7LE
ME?WC9NBMFZ8VS<-QOVUW+C4/QU-Z,,YA@[\1618F:6>.>1D5(9OP1&O-W4CE
MQQQ26YYJH1&JYL1^J1N$@!'(X3DF4:,@YPPSC'J(!QCZ^O!KJZ3DRG+T4+*\
M1<B).6H5!]$;8&/N(R%I@(IM!9Q6#XF02RV,PU<6.="6PPGRCP5?8MSV^UM]
M>QU+!?FHTZTJ;#6W"-ZD%V);,:2"$5HA+=P520-<PC*%96;N(39=\V">E:E6
M*U3ELS+%/<%*Q!>:K)/"L\<=F6.4QUI523C+#&"Z.QCD[;I(@0(O#6CW4NBS
MW$N]LE L#KJ8G+P3BXUI]!2M&/AN;@:4P>MB!EG+8-6A%6ITS"(70^FU61O?
MIQ[+:W2'<HNG-V/;LW)FDV4 4&DKH%=)Y($E"B$RV5KUTD4IQ*DE>$@2'8PP
M-"^X0X=8XU%G+3 .<@*C<&?FH7DS<2<8]@02DN/\)B<)HJFZTF?3E1AOS$6G
MR)<=B!8U(L9#W36@5I&[\9(PL+B_.D5B(@BRL,'1S4?%J[?0I;19K/;K??-O
ME*NY[1/2L++MZ1D,UA79PD_;6/FR\7C[0DY\!B1?%N.657$96NH($,X<,LY;
M(" 8]CY7 8/R(XZCURWQ<RWV6_M./0&+G [V6:M!A&< X:G-)\E9'Z$Y$[E>
MD3VM=Y9I4>B+)ZBJKFLK74&RBWN&^VMG@4T*5CN$PHT<,=:><108$CF3BSNL
M:>#R_-A0<+X3*154D)[TJE<$@EG5<OD^!D>^/E[>3Y+,%<8;,%W:QJE 114+
M20B<=(UA_$G9'QR/9ZR.8K%&[_,-<G9\;4]_%2&VVR3RC,?G'X@*9/OZ00.0
M/]TKD'Y'6Q)7EB9$=0&=0P =&P"2,-P9N#!@5*-AU/N!G.GHX@Z=MKJ[VBEC
MSA%BVU,'BSX,B-B?HRW$-C5E/!(BK;0BN:Y;#T.T8L7FD)>R)K^T[3V*2K6.
M[7WJU:,/%OB-PL14J\B\RKO"UIHA86+BW>[?)8ACN%690VWM.U7M]W6KL>T5
M9]RW6])V:M*DG=E>4J6PS>$B15!>265DBBC5I9'6-'97]V62+(K"[FJ=38G1
M&-CKNV<'12+0> 6-T0K(P&1@5Q$$#!7VZD-2S0HU5\ST;,C>C;UMDC;8FZ(E
M#9KMIC7$.V/W)+<?P]<BO\/6)AHM%"8I+:6 +,D\[DNH"QK75+QSR57[CK"3
MR$P(X2*S*Q+L,R>L<5X^E<#QDEA=K\!.@CQWQ)^E_)M;-;7H5-SO8:J_4^(F
M4?ZEPUL":VI,0,B461K&O9,]SN[XS97#.]-PC4?%]844VGIFGM<:?%7XYC9W
MFY&Y,E+NRQB#;[8C)C(9A%*P?.+ 3@0P;E]K,9IY)B>"85(D(\/@8+QY'R\^
M?'I/GY#7H6^.0ZD--!R7ESK976:N;/4"5ZNGB;>7M,?6$0/EE?95SJTB(.>-
M\"MA.%*41L\3?4F,=% T:3<K3*@XCQ(6].8HI48-A>+AU+>/)5ASXG\J@DL)
MS9[4<3K"<H\LH!=41A*A'IB=F]2^O\AC&26P?.#J'FJ;I=8'+")3UUC3##P/
MD@M 38K86V%7UJJ82VIB;. -T@,L1M?;USI8:DE8Y2@V).\9)JMV*S@O+(DI
M.,Q,C1M"WIE#QRJC. X*20OCNKX5B!R-V1HE4@@AV+F/UJJ!LYY$.N?5XPQ]
M8(/GF !CK')EY[+W945PL\,TOZYP6,PJVS*V2$.L]6"$&28HFQA**6<R4>IC
M#>.PI\,, J?S[0L">:)1" P'PICY"'N O)@\P%6,JI50TI8$IR=F]M;U:Q&]
MH+*'6/S "O-W! ]/(+ZF')"0%*E@.,9SC+6+$'?YJ>YAU%317C(Z6.]G^1L@
M@O4@,8P$KY2YE&</0WD GR3WQPCCCW$;Y*^Q>DYL4N^<QS+&:TL\1[QA7G&[
M@E"7'.(,#/"S<QR+$Q'$D?I0C=CEDJ3K$&]*L64@!0\9=>:<&8-P(\*JD,5;
MY,N=870T3=*V#2VE2>1#B  JYDSI"Z71EF_/2_+U<D$(PP\5.(3:#H)?3CV^
M>^EVUI 2R2:TFG"SP3&N#7295-EFE])2:!(P@YR EF9I&2-N5=6BG,L4+*1V
MU63$_9-@/!&A>:P3PE65$:4<S$2X,:\R3@DDADDE4J(BSZS@=V;=L9?9W,R_
MK%49R:M=9$Z&MM"'VXLAL;JLB0*>NAL W1MKGS/*-@EB;ZRRCSR$&$#ZS)'&
M>S+.1!+860QB!XT,3+&1*H=9#&_(N $1E.  0%0-D-22NA,[5RI+<4#,SQDN
M3VY'#E'X8+ -ZAS&64D@-R*%*$+37CX :4,(JCE?<8TJLN+,*XLR6QPG+;O.
M@"/H5)*CAG%/ENR')ZP0K?,,DD<B[<I)(<RSNZS@1VQ+%&T48Y,AB"%TL%$+
M!HQ  2'<GF<_0\9BD[;1\6["F%2J$J0Z_AF7T%%/@@.X?P47**=.<[0?JXMT
M\3Z;=DG7BG7=<RLJ)ZJX9'.^NOX%DKIJN J)8E\D-I82&7 *I,TZ AGIQ"Z(
MB^(,(D6:%8X D,O<E#1Y7G7;#B5HSG.8T"0R97MLGEGTW@+0DPSQ('9G =L3
MKGRZCTGG^7U+C*A2"S\>&E!ES3#*:47*HE11UUGZ&EU%'ILT.11"1E2MD$EE
M/Q4P(X4#[.<:5!*-T+Y%@C(OAYU)D=XG0+.LEC,TLL0>"O-7G(F9EPKKQM\R
MS]H-EI@P!;A P"#6E;$;0]MIUC82-%&HC)63CAI4*X57<+@*I+' +,!EG%FF
M1M8+2H@2!Y$[ 8QA&FD2CD+91L%A\EA&2*JC$,(7SHY\:I_/1RHK4]E6HS*5
M=L@*6))4 KQ))].&\C'RS\L:YS?K-6F]10B7E( @9>!+',;(^&1E\'!&.+*0
M?HJ/&+6CH\--'AIH\--)?;Y,#>8O7X:U)/"J]GE[_)V1E6\6.S$ T5273F$U
MTAPE@%&? .9)*&\P T5A#(W$"$Q(^%[35('Q2]=RGQ1HN':(3J\'XTS.LP6_
M3575IR05Q)RT?#A+<#?CD#6_#/"EK-F,3HM2)QOQOL>72Y<;DN)<5::@K00Z
MDK8(-X::GMUCYS3Z#X=O,V8L["FWVTL.GB2N/N8*JGMZG6ZG]7P6DW=/26MK
MGLU9R7%NQ]GG:N]LP<N:;/7B7J24<AHTK32-^'$-95.5Y2S]\#NJ;0U>GS\U
MC2<B=.G3[TUZ,&"PH/5 (DR/ %M:5EL*?'%+)!<Z-HASECD&K8Y (O.C36=^
M)S1P7W2K9PD'6X+:WDKB/11_J_5VMQ?'$YO?TEV+3TH%-'(;+;7) ,=77O\
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M;;80#<$DM)8K1/QBBBAM?$J(45V!X2JZ,KL&*KZ6F5C.F#,<OXZ,K4\YBP[
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MYO%?88(]YL136Z&^)N-NFL56LHBL[=3:GN5*QO$]N%9+,-]XJLG-XX9E65A
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M]T]T[?;NB]E7W^WV1?;]_;OV\1_MAO8C'D9## R,8/AOU./;Z8U[!R2,_/\
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M."-C\. ,J#U?B,Y,C9FCL]KI X$II5OPR*6RH6 EE3WIU)2")YB7N&G7Y&M
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M(!7RT)905@;%(617B6#JVW3R"C"N:@%C9-9% M>K/3=8))N3"2>%(:V!52!
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M?M.RW;\^SE_/]_OX\2!>#D^6"-Y_7!'R]OXX_P -8+3/\)9 9L&O,#AL^\;
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M,206A4C57.)6G58W%@%<&.)U,0=0S*75'2+AZGKPHQK6)*=LR*XNG;:MZ9%
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MD \C&#CV^K>?;'RP,8^>L []%O\ BFJO?Z9T_P#V3_5>3O\ O55_ZEU1??\
M+\T_-%]_&MWT^88_R_Y_UY^?D8S84_\ %_(?K]6/U_K U\_Y%N^*?^59T_\
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MOD' ')?IG/Y/ SX]]?/^2,NOK\\ATPK[I_J<<AI[=_?W7F+_ .0G_*GCS_\
M)OL/RGW/_P"WU_\ ^%UY%.(@>9//S!4X]O?T?N?^>OU?TC'KZ]^V0Z8OOV_T
M-^0_W_PYB7_?]^W?W\>&^SC8QG$VY>X_\= ?'\*ON/V'^NO0I1?5L_3D/H<_
MW?H,_OGY:&?I&'7VYZ)^J'3"J?GVXVY$[K_4G[8_=?W=O9>R=E5%54UG^SW:
M!GC+?^?O/!D8('_TL/\ OS\L:V*NV0V)E1C,$.<E,%L 9\93P3CYY_U"AK?T
MA#X@UM#9DAXOIH=%4!M/.1.+^3YD@$1R1RD$$C\LS#!1-F=".R0V2!LI!8T$
M2ODE1K=O;?LOVR]W6-J]&D14Y[D0$HRQ=4<UBJR"-6900V3[*0"=;US:-NKM
M"%-H&=Q$B23UPYE('I X*6]V?"JQ6-2S\?&92],/QJNL[F;EKI]S^I#Z70<E
MRKU'8#AN_P U397<P<B#9S4W5.'8:2LD)Y+.KQHFCV$X(1Q-<5"VTA:]X4\'
M=BZ?4OV?;-M>VW+]*;<N4$$D\44\L$ZE$[@!EDBJP<&!52Z<?RL&#^0-8Y-F
MBCCLY@O!:^WM:^.?BE&2<# KQ/P)>8M^(8E+<(_#2YP3M?>.-ZK.M<GXHWQ@
M.HKHAZGV\)\7X/AC19A>.<EL%L=W2[4^]6QOBKZ$P=)Z'>9P! XF58ZCL6O]
M9CI)5DGE16(RX[#T[3W6DUF>:S&XL/%B)H@G%5B()YQ.W++MGR!@# U:-FV.
MMN-1K$TLZ,)GC B,84A50CPT;'EEB/?'MC5<R?I'_6@JHG[)>F;[K]LORA^[
MNG;_ #6>W[_MW]NR_O\ $^O1&UDX-G</X/7]L?/-?Y^,?Y:ECTG1^5BUCZ\X
M1_\ L?E\]??^2/>L[[?LFZ9^_;OV_5?D_P#A^?[653^*^_M^?\<Z]![6?>UN
M&?/@25_X'_HI(_B-?/\ 96A\I[?OC/.'R?T'9'\/)^7ZXY&_I'76<Y>W[)^F
M?V_^U?D_LO[^W^:ROY_O^WV7\O'L= [5[FUN/U_WE;V_3^R^?K\L#]]>QTG0
M./[1<\X_O0_/_P"P_P"&N9WZ1MUG-^_$O32BK[I_U,<G?;^/^:POY]T3W]U_
MP^"] [0<_P!KW#Q_]4K9^7R^%_E]?'C7M^CZ:8Y3VP?_ #H3X\^<]G],?/\
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MQ6RV6CM&2.D,$;($P%T82,[%%6&.&Y'##+;6$"U'\35,,L;\ZK.\:/(B22/
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MO(J"*M9+'F@!+H ,<0Q8\H/XJWNR<TL6-MF'(-!S9AP0 N\:(D4K/DKG+#W
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MC*4#(#VT9 Q #ECJ+DZDV[;[K4]P6Y3C'+M69ZLO8LNO'G'6XAYI>/-07$7
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MG1@(C&EP:+-1Y>ZC.E+G4DOYMTR6$\<#+,N=(8C9(VY$T4T<MN6*"O/+)S2
MO:GD8Y\20S=^+M\5."./;!;@%\KK-O\ L<SO#;L2(MJ_-VVJ4*UN=[MZ0\GC
MA2625&D7FL86-LL?5'"S,4#=<G=1/&E%<8FJ'S6@W-SCJV<30[G1\EZ*QMC#
MSF.:3)0'9.]K@9!/0(G:Q&SL&1LBBKZKDDL9M-[2QK8 GB[=J2/C7I5X(XHX
M5;&)&E5W:1"H)"XR1DL#Z!FVCIV[3AELWK<.W&3G+7VZSM\-Q>X!F)[%"_7>
M*,,V,,T4LF")/3A5:,_(W(_"MA;WWZD<;%D5-K5PQU-CI;#2U-YE[1'^<J4(
M4/=Z*GM 9'>>1C;2)TR*1*V7SK&V27Y]XQ1J@[G*4NQGE5(V$N0!&6:6&*;F
M![\"HPJ\0<X$I3W/=96KR;K<DF:#\):U1*,5*2JB%$A6&.A!\,H#/DPG'DL
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M,+"Q'$H Z9&,8^?+>:7KA'3])Z=IN44%1)C(EF,G$H9IT'!V0CTA@H7P0/G
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MR\CE64X(+.Q7\V,YU9+$=&U4K\X4E6O)'9B(D$:M*BL4$AXMW(DD (*KR#*
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M[))'2O9"QZJR%LDKG2O1B-1\CG/<BO=W71ELRNJ(TDA1,\%+LRJ#@>E6)49
M&< #P/?QK5">HE  2?40 "_@ 'Q^; P,Y.!^FNK+(Y>WG5SD1J-_%W=^%$1$
M1OF[JC6)V:C6^S4]D_)/&E-.[ !GD8*.*ACRXC!P!DG&/;&,#Q[8ULJ%7U
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M3)&K5E25TC' S,^5?+)Z<,F.E%=?<-UBO[CMMJO,)4BH"S'+)E2W&-X?3)"
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M0R1-:4[-B%R/V%\E*GE20ZS2L2SC'D40$2*2&3QN*O<5C+#P"JPKK Y[BXY
M&4Q#X>)68^8X2Y0MY<D,->*M_<8Q8+PUJM1U)BJ]Q(G?#J5Y^/AX>X!XXH2A
M(SG)UF]!Q3M(+NWXUQ%]976?JF V-Z[5TC.(8*HTL)Q,0^JAW=C7""'0PI*1
M7PDVY[)A4<: B/0B*.)M1VY(X2DL<$;HPQ6(G,OK5>7=KAY)N?@.$P<CA*N
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M#F2)R%9U%&4/0P%.A&^GT@!3SIXIHGS2UD3YG)ABBFI 4]LJ_=58NTMJ[/%
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M1CK4(DL5$,!BAF1\$#R)8T'C?*GV!K->$3JL9J@JZ]SCGF$/%HN2ED?B_HD
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M:/;;S>K%85YI%'%$\B%LL!I:W/S;8(ECC)&'<YC[##8D[*0-+8*84*G<[80
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MQUT<?$)S0)&1V_2OUF:#CIE<; %C,,;<82O<87-Z[VG/*S&I'FJB72$)8 C
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M^7^7R^0^5^&9\014]^D#GCV[?;!6Z_N[I_UOO]^_V^_[_P!^-M^VCY;E5_\
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MEJOW_P"YU.W=.W;_ +>_9>Z^;LGW_/\ =\_VGV0>VY5_F?[_ +G_ -3)P?\
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M?XE7W3HGZ@%7O_?80]._?V[K[HO\5]U_->_=47PXM]#_ "TY+DY_U^GD>?\
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M"3G/'.1DYP ->;'4+6(^U/=KNS8+O&O;"CR5A7!8%85Q'S7/<*E@0&XZ1?\
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M'<1[,8;RW-%*\8W+29S75/U1O+HL]J>L7FC 8T21FSM.>C.=.HFX%O:HX.&
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M,3%9!&\@B<H%E#QED;S,K RV*F<+8SV13;(<*0VO+N)$K[2Y;)85%7<'$O-
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M2LERRJEL998XPN.,[$RD_D_]1>[+O>N/<Z;=5551TU#I.-K7;Z:F7DUE<'/
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M(Y[*RK0""/7KIY))6F11>NXG!V?69%Y1LXCYY=B"%/Y57F%5F]*NX7U@ $'
M"R(W'C!%4D2&U#6:TU<I!&DB-*&Q-/+V7>S#$#+-!7DDS [2-&Z<Y'DY=614
MS%UCZ:9+"UEBKC)B*<D06F@":,RQ)!$%A:/8#$#DS1_/DVD0[T+ -L'1L=.0
MZ'["' ;D"J9=0KY,A(8J&9CE2"N2O$D<2H&<#/V^U=G@%=EGG9(9'>LT<558
M^VLSQ1QH$F216(69YU1NY%+,P!=RJOP>-Y!YHT%)49>6ZL-80(\8""M N[I+
M,BMFL;BPEL"$@F@ELG,D2S=(^681D$<I110SHDC;@L6*U")Y)BD<"L"S,0O
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M>[/$G&O'/:D$I0JI$<;,TZ,J#U*LD9QQ9<TB:18G6)X5KI:66>I >7+LH[1
MP2V.Y8F@@:,PEVED):-@\AEY-KUI/&GK#K2D^.OQ#K^5OB$W<&4S-S9OS_31
MB]):GCUS75@]+4F;"::4FW(6(4-SRV1!B#H^8DPUZ#BQ/(<V-TYMVQ[G?KR7
M:\20T:T<\L]ZW)+%6YP(6:&$I$XEG>/TK&",-EY62%9)(^H=#MMMN.CL;O.=
MZWS>H]GV:C6K16)=QO[@U6"I 'DFB%=/B9(N[)QD$<0:3!?MQO#/3=/OZB<7
M<*%<O\N_6J+ *8P#C"FS+0LOB:F[//M],63IE>/#H-I>=V3(L5:45YG!B$V$
M3:\(-)+J7<O_ .G-BBLCDBW]MJ2[?59*YLJ[\9N;QS-(S10K(UBS%*0&:58X
M$^(DG/Z,Z!^QROT]UEU;N'4JP4J.QTIK2]0W9EL[=:O5A6J()*+5I+_P"":=
M-K$T-!;TU=9JL=GC*B1^Z@NI;/\ *N[?38@3D5O#-#1YC/Y[.Z+7K]9MC\C0
M)GA-8>KQ["GI"#D;&J4M.!% -4CC50A JL:2/[OW]MCDIUXFMR;16IFK)6J3
M3U8+<H23MQDRR3RR0Q!JZM/:$]B;MR2R)&\[ <S;JGJ#>&W0;B=LL;C>WBQN
M$=R#:Z,$T(L;G8N30U[45:G:B@L&]=;X>.2!6G>K)8$_P</&8'%G5+RCCLMP
M[19+(X?D+ \5&WT][D];G*BE-VVOT%0>7?B:JVDO+(4FQS38;JMQYL+!2S*V
M* 0NK-+,'J_&]36]*[;#L^UVH-MVZ6'9MTGL7:M5C<CJ36&I0P$NJUFL,LT\
M@R+-\PH95 >0VFYM%."@_P!HNY]40V^IMWI3-'4HR7[>[[95VN[M] [EMU^#
M;XZ]&U3JG;DGKEYQ#0DO25080TT=9M]I<]>;0#5 YXAL#[9YME4'2*> 0]YS
MIQ XI5DC*(!F8J02Q.2!Z01^FU[7.69.>4Y[5&Q;E:/;YH1<EMTJDT)-=(F8
MNU>S#$80R1YQQ23#YY$8RAQ]2;CL74.YT-PIU-YJ=R,0;N39CGF:P7*06-OM
MV!.3W(RN%FK*L)01JA&9-.P'H]MQEE-AD1Z#)7C"K^H/JN2(OG+2]I8::)Y[
M0<[>5%TF;6DLFE#R7 9M?8R*YR^26$F!&P[6Y6=CK0;ITCN6W[7/N=PUK;6H
MI(3+&MI*[H:\O9^)8/ I6!HI:YC,LHE1F90LOM$GVB;#9K]9]-;_ -3KTWML
MUW:ZP6"Q'L5]:<S6XFW"C-$:P:K,89S#8R )"J!X^ZKIMW/G(=C94%O46(55
MJN/R"M'2;&?1&AV4<38'?,A#UUE=NH##GRD+*-%75?U@ED:PH\IK7N=-=.1U
MJNVE:,-.MNFW1269=VW#<Y&L7*<(E4;7%!<9UF#(T:1UX\*>TIX*[EFK?6_V
MC=4]6[M#8WO<9;] H:<&TUZ%>/;8I+*H)[D\="",Y9>:R6+$CA(G51(%C3"A
MXPXB9SN2_1SD3P6%K>%9QU10QV#K%Y%;0BVQVLD0RJL:\P%M:PV:V%%M&'0F
M(PV9@ 4D4D\3+7DV[I[<-]L#<MYLW+6Y4=OJTXU-B'=I8CN26+A#QL^W01O,
MTZ11\EA,<:N[959WIS:J_P!J/6<5>2?;.EDA@VZYOMN3,-";:D9-HD>BLAFC
MJ;SN%CX6&L++_!V=PG/:57;M"4W(4S>GC5\?\J5'+Y5[N,#6XQE/FCOIVOHW
M 5>>&KXZ]EG6S)44]@#G10!1ZET ]A&^%&&,$,@9#-6ZF^;Q4W:2SU'4AM]0
M2;=1^[TKQ1PUTVR]7L1?VIX6$I2'N(\)C#9:5II.<;F376.I.E>B^G=HJ6M@
MWS=Z_2=*]O&V;EL=^:SW=UO4]RC3>HZ!>C#7VZ[N45>^;%AC$DT\%9*XGCF[
M,<S,GS%F]GB+;F$L6KTV=EH2^+"+G;7DP@>/BOY%B98U8R$IZ!CCI1YGQ*,P
M>U('CCL5FB&B:W/LO5O65#;=VWZS7DN25+B0QQK9BB^[G80GFU&&!UGJRM/5
M$CAQ:*QHJ$*'F%OWWI?[)^I(-AV^IN^W[%M6]R#?4M0;;' _4,&U69X'VNSN
MVX&)J;UI8[\*1R3*(NXTB12<H^4)IL_;\1\R]/W%6L=7:^EN[#AK6\=:V"0@
M,>HI+;D"LM:N8>LJ9&P%D3PM-K)I+:6TBD9:.(9(Y\4!#/=EKT,U'<-Y@JW9
MK^R4*%:-H&@M;-&E@2RF*3N1)-9B$C=T31\SA4$G'DDO%.L[6UT.F-SZ(VVQ
M:EVRE?ZAW#[Y6:O\+=W&L+-)Z<U(UMRF2DQCA:K-3OUQ-W()9&4?$1KZ%GB0
MU^'M:$/Z6#P8S3=8?"G)IVJ"SJ&=*H60S()T*$1Z&[Q.^YHVEG61-$FDL@Y9
M0;X$:&PG 6HC-+"'),@6=SXY^GL0M[6^Z/N%:LB3[C7[,L<K2,U#:SN8*L@8
M'XC_ *.@"G@X+.1RB238B^!DAFC-B5=S5JYKU! 6BL13SQP9-GD$A:/,TA#_
M )EC55!+EDUYNE?I/XWUC[K1]16HT6291,;99KC"EJF2Z/D:("$@P@5UE(1V
MI@;&<6.C$<.*38&$G-F%2-D<2D6?ICHJ/<8+-C='EBLQPPV:6S+)%7NWZ\X+
M065CDS/+6L,KQ1+!&DDO!RD\>8B_V")X]PK"U /@(9W.YS,Q(@AJLAM1E8SG
MNA74 %E Y@L57DZN:#Q_QE9V5#GL!@)[N_V7)AE!C,Q#CKIY!E(,;5"%;=MH
M1!,.+0QW=J'GZUD\LI#SVE1RNKT%@0RDOTSOFY4X=R2J^W[EN%ZQ5@Z8H06+
M,5:&BL<%VQ)N%BQ+PAKW9H:SRNSP-(9V,T21%%OMW>>BMNWBWMM""*WLT$W>
M@W^VK5S+"\JRP2+2$?<59JBO812@F5&B18V=P \FS-#R\G'6Q$T-5>Y>OBEL
M-/@\<2Z<*FVM->:&ALL_+9_/03F5*T0!FHDM!,Z55BNNJ9\2SR(-*=DW#8;F
MPKTM/O._1=5;;MVYI5=OBUD6G#]Y?$7-LVZ"4R/V^SMU6"5G2NCR\>2*LJ%I
M]^K(=[DW([/MDO2JS;>;<.WTH6>&SN=?:THKO%R>)ZTD*B2_N=J"!H[$M944
MQ<P3A8<C]6'$^LS)G!ZC:>ZEYEVS='S)RF8;&!I=Z)2BPG<88_,,LJD@8+/Q
M7LX*EQ)*K21*N,89OTT-(8[[<ZQZ.<[G!&G44^W[I/>?>+)-.*V(:T,B5$IG
MN!16<UJZ5X9(:YJU&<2+)8MSXH%_9[UG<MIJ_&[(PHU((MJ6&&^M>:]=>*Q/
M)9EE'=MV9'L"L9HS'6=H&D2$11]]\7Q-PNG(W'/(]KB;R8#<XZFET<^5T4#
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MU.+T\<O()%*YZ]FN?Y7$.BC:V".9\B0,CC1L;>8_:UOTEQ9-JBD0UJTR--V
MHCGM<D[LA(P9 ),K&WG 0D'U-RAUJB*NDSA!-(H+A,?F+'+,% XD^PR2Q4@D
MDG7H)^.#:Q:J:U,N/TNNU1L6,J.0!:'2$UMG>$7U3<6 1\]HO8ITB;DX:*EC
M]<H<IEF+7%ASBEQI7""C,:^U0F:.&)?B'K%XA)&BHT:,HC\C_HX)E)"E>!9&
M\'F['.N[T8K53;:'*W+MPNU(^U M.6**9$B5?=J$?<E0%6S"\Y998R9&9FPI
M+K7<FXZDMHLQ4AZ*U&9"?3T=+539^CIZ]AT(<8@NCG-*"EN A)I3A(Y81&'.
M%,A?)4#O';'B2*I.R-*S0H<K(\DBS22OQ+<NT%0B-F 1L%N&5/XAY'6K#2VV
M[-$+4G:C<R(\UB7E),Q3EB6$)(ZQN1P) 8+R0X;#,(X<H=?V^P-%K,MHZ?9B
M6]"5="K=QDO; </6'5P81M=>9N(&<M+.*YS)CX:2RGGKET0HY2L:CGR;L.RP
M.5LHT)B_#/$KDY=68J8YB1Z0DH_$50QB8?FQBS[9]F_3=QZNY27:,<,U1;<M
M".&:6Q C-,AC:N_>56YQ31HS1>>V'(7UF)U[W)W-Z8#FQ>9,]6\A25E$?L 8
M=.W1&Q2WM<200",-L0;PV9\Q*.D$#.>XM8A&C$ 20O4=^*.>.(M*]&5ZX=Q
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M">4=Q S@+ ! R' ^HYJ/V]TZ.O; EK=JNW[9:VZTL5:.?=H3=O;'VI)(\5+
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MXJ(&/ZD01/YWQ0/,D'A;$K)6+,Z/THK/WHCRW6Y(QK]X((>TSY!)X*H/H55
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M7<-MF"([/6:6E)82:P\M<J\/Q"S5E@>&Q"C*HCZV1S.YV&HRYF%RT@2R'(R
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M((ZFWB:*-#6>*-(%EG=[(D-V>1HI>/* ,'?:.KU%@!J^;QK%C+VW4.ST%/\
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M<,4I7/H4G,CI'$)79G9^"@L0!AJO'O4-H_Z?]/R\--'AIKT(?T/O^XRZH_\
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MXPV:J\WDLU+=U7&W&PU-9"I%95 EJ"'0UUA9D-%B,L8I&ULVC:#GTD'FN+:
M"".2>T^@@'2D"%M PEI)%B>U:+1MR60PEII(T&2JD<UA#3<2L4;2%N,8E9 K
M(7\V=SW*Z5?<MR>SQ"Q/,T[R9C];+"#W'B9Y <)&0ZY19F7+$:DC3\;'6$7S
M!QQV5=))6RE29V*FK;:X06-S2HCI_I)!%;"4QS8/F@2H=!$QJO!LJF1%=/'F
MPJ'PBS8#!1,9'2//L542*KE3Y <-$?9XW'@4Z]NT*_A0!;?E\M.TLD*9(*A
MTF),$$\2H@Q@%)0?0[TE-7O@B@B@:(@Z2(-(&C8)AO5C=%(L,C6JK%>QRH[N
MBHY>RN15:BII\CG).<XSGSG'U_EJ 6U.'9V?N=S'<67UI)Q8, ZD^<,,C&"/
M(! )!R:)V1$]U[)V[K[JO;]Z_FOCYK7U^^&FCPTT>&FCPTT>&FCPTT>&FCPT
MT>&FCPTU5%\:#,\F:WH:T=/Q-QWM.4M>[D_B$N/'\?YZUTVH+JP]O73VQ@59
M3!6!JQ5XC7E%D?*R#P#1R.)5L*O<FCN55[E.2")N$S%#"V%($JNIC)#@KX8
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M7?#1^(6J=F]%'4_^[_06WGY>WO\ Y2)W_+\O=.Z^Z]O&)MPI^,6$_0^21_\
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M/#31X::/#31X::/#36,N;JFSE69=Z&VK**EKHO7L+>Y/%JZL"#S-9ZQAYLL
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M\;1OZ6*DX/N,@@,I*D@@'P=;%?B!UZT>&FJS?BA?$OQ?PP>)./>6=MQAJ.5
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MDD]/Y:(-S)V3(U566)T:N:J]JWU/TS8Z8L5:UBU!9>U7:P.RLBF-!*\(#K(
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MXL,\T\:=U>Q$3QV#8?LTVW>MK^-&_M%;1V6>BM>!Y(UXJ4EX_$B3@Q++EHP
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M)+.%/J5(I+->4\5#,Q"$J%)*X!.HK?\ ;I.GIKM6Z\?QE1D45T=9!(6.#B:
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M=N[B8W[.3%#0B5%8RN6)H<\Z&#F[]_)$DZH&B;*1MQ2$O&\:K'[-YRY)8$>
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MC#2YXN8!Y;?EFAL=Z\,;U=W[=^RKW<Y(TE]%7M:U(VMB<Y[47S/>C;6J%D+
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MZ8VY-QWJA2E;,<MB%),CR%++RQGYD>/++^X(&<%R4QUY'0#(5N/ZMY^?Z-]
M<:O3RO'5-Q]QW5"U;H8"IQ!Y[ B3R*\B::-%<W[*OLJ]FM1$6-$1&M\K$1?T
M)W><PAC3A7@'9KQ+X5(T]@,8^0]1QY)).2<Z@5\-Q]SY)/S9SY9CY)]1SCY
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M[>?GX\:LAX&X#ULV.;9:RN".I'Q1]A[:M4A2&121/D+#A]16AO5T*1B)ZO\
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MEL8"YR!!^<,>+"2R=&#?.J1Z2SOD%'2)B2HK6I#Y%7\TP]X11"P LY13*H7
M5R 6 &6  )P/4<_4ZV=VKUJVY[C!1;E3JW)H(':=)VDBBD:)).ZBQK+W./,M
M'&%]7@<<'7K^>,NHW1X::U:?TK9\[>CSITC@:]RD=2202+'(V-[(7<7[MTKV
M(_LDCVL8[R1^9JN=V5J^=&HLQLI(M28^==QYS\Y(OT/^G[YQKQ)[#]_]-:)9
M2$O;Z8C>Y,21/E=!+%V[MA3RO?##%/ZK)6I$J1/61\4#&2N]:14:MIQYQCV
M\#S_ (@#^8\_(^^L(QX^G^/T^>G.Q,EO$ ZOG!\L<")&BL7V61'.9(R-$9Y&
MP-:UCF/_  .<C^RQ(K>RS&VR73')7BBDE5_=8T9N7GSZ0#G.?J?)^?OK6G$>
M59F .,Y)   Q_B1IPL:='GMA5VUI!W%%,$GDA>J=I8X)_4<SS.]E_"G;W_O>
MR?N[6#IBVNS]14[%]37B4LLA="#&LJ/&)L-Y(CY"0'Q^7^.M2R!- 5C]1]+
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MO('*X]7-U92<?L??SK\JF/@[GYN<X\X&,C S^WG'C.=;1IW_ &$9_P""D?\
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M*SKR(0 <LL/<YU#>L#HTUO1'U'!F\?:G34G%^QL9W8O39N6-UO4F3/<K,J;
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M7GVVY'-Z2R12QLF3GD%+@$*/[H)8GV)'YC'&C-D M$P'C)#*V, ^<<O<$\L
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M$79R[J.,:@".**,>0D,:^A%SY(51EO4?))TB@2)<)XSY8^[GY>2?)_X<?+P
M/EK'^5T[D1KVKW\R/;W7LG^M3V<J]D7MW5.R=U545.WE\1ZJ9&"@_F8C(SXS
MGZ>0/;/U /[:R9Q@D>WS]O;WQGZ>WD^WTR==E8V1^[/Z7X?-W5??R(B=U7RK
M[)V[^Z+W]D_/QE953' ECXR21@8 ) !]\^/<>/'G3W/GQ[X_3.<^_P SY&?J
M?E@#7RC&>_9_XG*G=>R.[_;LJJONO;W[)W_@O=5\>1QSY8^X.>(/YA@?,8_E
M[>/.OOR)Q[^1EO/S_0^V#@GV_@==MT2-9W1S?OV[=T7^'?V[*G9$15\W\/\
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M7S(WQ^C8NL.C.H-C6>2W!MF^UJRI9H6YOA(IYV"J7K3>*\T4C>5!X2*2%,9
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MWPM=9W]"5@[JDT\4;V!A:2$K/"%G6U/>"UK34U@#P;4 *TJS1+*LLA!CZZQ
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M\Z],/3_SVP:YYCXHR/(=KF*6U#H#]&"\HBJ%*3YHB 21DT2QQRDPQS.1>_\
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MKR%R&<9<$WMJV_TLPU=85^>K:2CK&FI5]'/]R)TK_P"YPX/_ ,668\--2/\
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M,CR*'/7$5>-10PI.8;9M-6N>&FCPTU$#XA']P5UL?[DSJ)^W_FCUW[_;_?\
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M-$*Z,:%KI9G,8BN\--1@^)'QORAR3Q]Q6%Q@[E:2>KY*.EV-=Q5M.,</:V^
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ML;DZ6>MERI6,H7'O&;RYT%NL>[]%=4=>RACK$-FVS(B9+0G"QZ4.GC@M"!+
M)II;R-R:4K'2%\<15"8L J;YV'C2?"/XT=56_P!+MK)&;6.6+HNE+16XG/P^
M;0CZ14E(8^H8;6&--,7SC%$SG3HA2'ZNZPAZU:U-,,L^#715T\O3?SV_/.YN
M*HM+9G7-N33IWX<^EP205_'DDD6B=-8L#)@::MS\--'AIKY?_0=_]R[_ )%\
M--42=$'$W"5OTA].5A;<>\.F6IO$/' -W*9C.'[*V.U6FS^ /K*S46-YHTM7
M\_:MI,5GP2<8/'4C9XRM@U@,AZUR5S^OZ_?34J(N#N!BIQ@X.*>*CI"S2*,"
MJSN%X$@T9-[1S;*>]S^(+*T:C?M\S\4,Y?/91T2YPJC'LX,T/ :VSE.::T_N
MH\3C 7J&YY&J+;I8$J1^9^48*L7-X&H_5T:NBW%Y&$/0_*[. ;Z+",V*.K^7
M@A@^1;!Z44<?E8C37H;>&FCPTT>&FCPTT>&FCPTU5[A^BRWH.M'E3J"L>5>%
M(M-JN5!^2\[E1^".*M)S 'Q61Q]B\%+3$\NWM8+RAF0[>WRFM';] ),I11"Y
M8PC9"B;0(9_7]?PTU9[-!"3%(.1#%/!,QT<L,T;)8I8W)V<R2-Z.8]CD]G-<
MU45/94\--04YRI*;-=1_PW<[G*FLH,_0\F<STM'14H M734M/6=)7+@5;555
M8#% %75M>'!"(""'#",(-%%!!%'%&QK6FIX>&FCPTU7AUX$2B;SH$,@,-K9P
M^KG9%P6=73'Z6VK)A^AGK+EBL*C+5E/?':JT#>U)P<R-5DRWD[&US/3<0DC6
MOGS'['_33CK&8)/ QKK.NBK#)0XH:TK>Z8&CAU.D DFKJ N3C6>'D&JW8\DJ
M[K3S1N9TZ#SF0!/KZT&=5:^ZB#UK*>'P-0)(5?A-BZA.B3+/:L&STCH8*SJS
MX6,=@H)+?# B6'']/.D-B'U&V!HIN[/B!RY=H682&QK^OI_W::N&\--'AIH\
M--5 =(@I,^,YIBB'((9<];?7O4.$GT&OJ*[0H%UJ=35I^K]I9TF(LQ>+J:MG
M>+?UW)HUPA6KTTC>.C"V.&J10&FI7NEL295,6PTQTALK=,MC856^HKBPGH69
M@>+;S9EG&D;,KLLHV,L+,\ ,6,/F2M81>SA%2%7+BFFFLZ)H9(NHSXA[Y8&1
MR&<S\+6#YUL[:P-LE/Z;.-2_J]N'<U5,9E[BT25#K'$L!8'CIYG9T)WRU?&Q
MC35D?AIH\--'AIJC[KGX-T.;X^ZB,Y_([Z2-WP%U8<J<(\;\F+9]2'/''7)/
M)E_R]SGD\9E=AMA,GP;<ATMQF.2.38[::WS^XL+8?(TE36!3D@T.?S%>TU(C
MX8_0)CN@;!\FY+)\#<2\'+O]94:&Q'XKYWYIYZBTOTJH?7"$7E]S5B\7:TDM
M9ZQ,-?44@AE;)&64;-.PN9[%::GQRUF+C;<5\F8W/$ "7^MX^V>8HRK5%6K&
MN+[.6556$62((>J@0FEP2&(@)JJ.V3L(2O\ ,O::A;T ]&ESTCY@X$^[Z;[&
M70Y?(UFE;P+TST/"))NORXCPK*PTNOI]K?3[YD),UE )]0SV=D&)G./:&!,>
M4 QIJ=.FPV+VCZ*37Y/.:B3,7U7J,W)H*6NMY*#249P]G37U-(>/.^MMZNQ$
M%. L UA*%+&@GAE9+$QS6FHC<$_W:W7I]O\ L7I6_K_T,=)]_P#Y'AIJ<?AI
MH\--5<$#V)?Q%.J.O C.*2UZ8^B@*2HKSM;1F:!T.JZ[CV5H>US$HK.-SAT%
M?9CZHTR)+.$0K'Q-8^^0P/Y]?Z_Q^O\ V::D$CM 2]AOSE\8P\>73I805/*M
M&MHVA9DQ7;:OS'SS(<A2Y5R.$M^ 5>Q>9%B)OFB$2SF1WOW34=AGV3/B/]*X
MQQ5IY9^DCK9O(@K2KULDQ*W7+?2!,NG9?Z66>&I$TK(F$UW$83XY.*A($JYH
M!Q[$($!IJT[PTT>&FH?_ !"/[@GK8_W)?43^7?\ U(M=^7Y_U>&FL30MT =5
M6$.)TE<VKKZBZ0D\/E+43T::@K0PLTA=,A#!N0:_;>9D%1Q<QDS. )Y0K)E8
M*/"*%3M-9!@.A';*&X;5#*-#'COID-URM;&A26E%FC4XZ-U<MI&EYI+M9''B
M=4#"7/P#'2YCZM 0*4?;--)GX9<3X>A#INADB6"2+%'1/A4V>R6%\>JT#71+
M8E(A)ZQJBL4TE$(*5/7F1))')X::G9X::/#355?+E+!=_$<L@YZQ+5IW0WEZ
M5*^(.^(L+E;7F[DE?U<K;:C6%W'Y5RH:>7E,@P/]2W!L://!+<J6*TT^3,'7
M'$I"_)PV:W-@P)8PZC?YF#0LQ>CL&LKXRI/2=QS^SR,=C[^_0*.'J*&':(P4
ML2PCHAFFHYWE5!5]8O0*1%!"))H]9SQH9R(L7JJ:'6/(Z8M7!^MM<Z_>^/C6
MO)6)P7[&7>0NK+'(T2(2AQ-G9--/=UW]+I/4LS@IYVXXGQ6&XRY T&DVS^7N
M-</RQG[>+1X2^Q&8 "QW)%<;C"[1-7?U3QB+0@ @95\]5*19?+"3--2^XHQI
M_'G'&.P]C>5FD)RU(+2MN*7(T.!IR0PO-%715>-S#69_.UX-<@M>'65#&!0C
MBQK$QB.5J--)CF;.Y\'B_G72!4=.'HK[B+55UY?"U@0]U<U]%F-5/1@VMI%"
MPZP#IIKRZEJABYYH:^2WLWB,A<>4LK329Z.?[D3I7_W.'!_^++,>&FI'^&FL
M7>?]I;C_ ,5V'_QI-X::J2Z$&FD]"G2"R*6X)9)TE<#Y9D([]S20RP6?!N .
M3!3&UW'DD 6 NB9)[6QZC*^:<K 6LY^/!N&$ E/G::EQY#"YYXW/MK&*T,A&
MDAL2-YF*^]BRNE.=#7Z$R/C2&+CVMP0[(UPFCA8R+J-'BA@.^H5I@ZM::07P
MTBI3> .03)["TMIRNL3KF(FL[K.E9&V/EFZN.8GO+L,L:!5FYTJ=SEDEI3*\
M,JM<[Y0B!DT3T\--6#>&FCPTU6=U+0/)^(!T@1,BG(5O2UUI$K##:V=(WR \
MS] 9TA<EA44&A+DDJV#.M0:)XD0.PL@@L=8RS WY !K33MK/9,"A.^I::*2&
M%FP2T%I.0BBH3#:>T$=R.[(OXTE?8<B64[H0K'I:5C(,I$Y-$T.&SC"/'::C
M;ST(3'S-T#Q2B*V"GZTFPPBS:76EU692YZ>N?[%H^2M+;(TP/*Z:/R2V]Y:3
MGR/XK+;/B*ID Q!0KVFK:/#31X::^7_T'?\ W+O^1?#35/O05\X_HOZ7O2(N
M'1P<$\?T$<8D.T% &BT5!B"9<DU0./3!+;+[!SS#]CS0)8%2\'6LQ^?!LX81
M+CYAIJ6WH'DR-&<VQ.:>D.>=7V=KR#04MI%GB=21%CSK]G&S),=D\AY!#,CS
M@A#">;SXA*0LPH8JGBA::TT^I^\-FZENH>:7;<M3R2\Y<M2R3KPO8U:S/DWV
M@>^5:POC=2J[U'*K_D"54@3O\O,JR1N7PTUO]>&FCPTT>&FCPTT>&FCPTU0?
MUY5G%.P^)ETQ8;F/"4?)E+>Y'A[/XMI6NYRX\O>']ULN1N;H8=KGM%Q]'48J
M^TNPJ,R8F9I;?3_K%1NXQO+@,:J'-A,/::MJZJL)K^2.G;E+!\?Y3&[K9Z#-
M,!S.3Y+UNKQ_']]:PV(!0H6]O<<.;I2L@YPWJ:?.C0RC[:GC-Q]RYE/?6$K6
MFJ_ZWAWE'B3F_P"%-GMAR1<'460K=KQV_BVQ+I=VRCU^6Z/N3J^VU;^99<ID
M-CMS+-H4\,J6-%1T_8A9@*&L9$.-"TU8/R_U6=-'3]:UM'SCSQQ1Q+<7-9)=
M5-9R#N*#*G6-1$3*')9AC6YPLLX+"H)QW$QM=$V:*2-7>9CD1IKH<1=8'2MS
M]?R97A#J'X=Y9TD5)-I9*/C_ '^;U5HW/CS@BS72AT]@5-],B(LZZ%YJ,6!L
MAHS5?WF9W::C[UX)*N]Z VC07)13^KK8M##S,U8)JC2UZ&>LOY83*'W=UGZ:
MMTY$WDCHK"WMA:P2Q6"4Y7C-DC<U\^8_8_Z:6,+:EQE>X&.A*1Y=XZFGR0^2
MK1K,.+7USMF9QH,1RK&7097,D(]>J.OL7?4MW90F+0,)/G!A\-?=1#ZQXP$X
M'S258@LBKS=T)SCIC9<B&DN,_E:\._1M34R#<AV98G2R68JC<:X < S0UNIF
M87,#%3PGS-::N,M1C3*NR$KK%]/8% &# 6\0PQLE6;./)$+8QAF,D$+>#.YA
M+!BF/&G=$D4['1/<BM-56769ZUZOJEXTX#BZ[[Z6CW' /.'+YMZ_IRX&2V"M
MN*^1.GO&5E2+$W/H&ZOM ^9+<P^26-Q+":BN:.]D4A+7M-6?8^JOJ/+9^GU.
MIGV^CK:H,.[UY515T!&DLH(6L*N)J6DA@J*N0Z5'3N!K88@QU=Z<#&L1$\--
M5'=*#:1,;STX]V,A9_++Z[G:$C1A4=A65]"O6SU3QUUCS")8;^F-NN(C+52*
MG%45=3M-J^3$M]#)#/3SVI,[3^OZ_K^6I7S1!-(,84"\4Q;JLBL@-$1A;#50
MZ]\&)=FL_M+6+E9XI74K<BM%*X+V@R.H,QG4IJ^YFAGBI_(TTW'0W\FG41\1
M)H<E&[R<X<1,-AI0PQB@;5.G;CKZK7ZV>ON;X&VY #L/F(-[=B6#A[76-M2X
MXHDD[*TU9;X::/#34)NN#DWE?C_-<&YWAW4Q8K4\S=0-#Q45IXLEG=KH :>7
MC7E/D*8#&4>RNZ'&.UVGLN/:O(U!VN,?05Z7Y!9D+7QPE"M-0KY!X*ZLN8*2
MBQ^PZ]-)IJD7DS([6NK,ST]]*U79ZS5<.<LU?(6=I<J5+N4CCN^$]5@:*PYJ
M&NO)578@-I795A3II0X&FL!RWMNN+A?C1W*@_6V[E=*"/CXV7+@=/O33456_
MS]_M\12VO*5):5NQ.NP>'9!]&9FXVQ#R[^/1_*$C!RUCHB2&FKS/#35!/PVQ
M>(M5UO=8%F+GZ</FS%<A\JVV@Y"XXY.Z@<SF>2LS;<P<F8>H TG ][PYPYP9
M>$9,>GCSM]O\U9<NV5CR#D)+0C6M5*R9[^OWTU81U>\4<M\E<H=(MEQOFKT^
M@X_YEKM=R5K:/FFWXX+Q^5J;[&W,D8>+&.&HN1)M6E,3FM%]>$MY*_C [D?(
M48$-ER0EQ4M-([I$I>0:'JUZ^0N2]U3\AZ)QW325%?4>(3 !14Y''&C?5U*T
M2:;6>H16#_S$]HMHQ;%_\\H0G;TU?/\ E_KIJQ_PTT>&FJG=(RKD^(-U8LN?
MU76GDZ5NB>.\CVPN3FX\EK4VW7)+#%RK+HI?J ^+DLHP_I4U!!\U'N69M#)W
MU\A5=8--/L0VO<>7(;%7OL7WE01:LTHG#K-E-MX <8S)D;N:!/0'ZGH GBKP
M$*(.F?)S$=='=(LL@4](TTQ5"D3?B,],B!1^F([IAZ[IC64S,0F<;IY>9>D#
M]9':&3+K\[+SA,:QDG-#9VI1#WWR,=&WU7V91S35L/AIH\--0_\ B$?W!/6Q
M_N2^HG[??_0BUWV\--('*QU3 \TZN'HH3HR3Y:.#&0<1$Z&/3DD:ENYDXP++
MFG]3FF6-I#>J"*U5:Z*MEL):$MID)I]J_P M/Z_[O\M?0T688#&T4?C"2K;B
M#Q@XJ*'B@?$P<;2568EO1<Y-(V4J?HT>8YO[3RYX_P!9&:ILGTZ+Z:X"NJVF
MNQ\,!!V] _3,T1:M16X,A!EI&,CI5'337R0K41Q/DC95K'Y?D&1R/8T3TFL>
MYJ(Y6FDCUFW/6)Q'067*?&'43QC396RY=Z>N/:/ Z/IQ?J#*.NYEYPXLX6LS
M2ME%S'127)5.FYL-.&U<_71DS"C5$OI0J\WP_C_7C^OXZ:F%Q!EN9\M6W _,
M_+F8Y<LRCH)J6RS/%"<4PU +(%80$57IO-VEM+.1VGC,^:KU@8BPJ/+W]1&F
MH#\PM"=\131H>VIF"?T"4\-R-=Q97]7)\U)S9R&MVWDHO4K(T3A=$8(G)"TX
MTUN_S9Y856&.80QII[9HJ)TM@VQBQ<K)2\O'?R; /B<<) Q=6<SC].680Y72
M.S(A*1.Z2TK3FG'6+JUFB+>4TJY(::C_ '?9.L;H86!MAYYN1.?9])+'!QX.
M01JG=+&B^8EYFBR36E#<^?3U$CN1Z](\TN5CIYHH!"'05X333X_$[G=#T4<L
MQHP<N*PM^):8NB)AW,K-D!>\R<?TQ_'\,G&U;:[:O,Y"#.GQ-?<T(T9%(=?#
MV\IU<*%.>.TUS?#/H^):WHTXCO.$\/7<;X+=5YFO Q=#N-WO<O2SSE/HY4S%
MMR&>;>C51\5$/9S MBKAW6YMI9S I:65D66TU';0=,O4!1&_$7Y %NJ'@:LY
M9JGV&#U6&W%CS(?K\GDZSDFWNS^0N/>4L7#39C?:R3635$US1Z6\K\OQW4<>
M\:XZMI*OCUEEH6FI?=.^]RW&'0ITY[S:G%5N7SG3/P47<' TMYHBAQYN/,@%
M&^&ES5;;WA[E)*A8Z.OK2I6,<Z9[&PQRR,::18WQ-.BHVS/I1.5[XFXJHZ^6
MTJH.%>>9+&LBM4(=5RV(3>,5(!BL6B%N!E*CBC+:*0L#I$AD5K34W+B1LM#:
M2L559)4&R,56N8JM>'*YJJUZ-<U514[M<U')]E1%14\--4_]#S:Q_0ITCK80
M52M3HUX8FG?IVY)X<6-3@_CIMWJ+1A/)@IA?2V%8-<'R=@2H!-'<;* FPAK6
M4T]>C&FI<2LJ6E'O.BI!$871.MR==%D;$6K%EV%B[%E<F"#<K2%:#-Z:?R.Z
M6 :YRV.#L'BKH&C6+#8O#328^&FTEG '(33!-&"6G6)US?,AZ\ZLL]4-/_*Y
MYB66'1'TMA;4Y=TQ_F2RFJK(ZN>5ZOR1,HWIN\--<G6WREU@<!\:\R\[\267
M38?QQQ1QK;[MN0Y%PW)]CM[<G-4\UC:@.TN:Y+H*$> ^:!65\B9UT@<3T0GY
MMS5>YIJ1O#8?4P+/?NZ@=)P7?"R0UWZK,X<Q._R4XTZ/,6V=?R;;D#:QG12Q
MK7I7,KHJ]\#V&.)D(;+ V)IY^?\ GG_0:AOU2-KW=?71[]3^@H,G3+UAJQ^F
MC&GJ6GKSI\/MM5'# 3HLTQ=.7:*&%@2FFS/JM^1F+AHZ?(*2,TTZ*1B.B%5H
M!$MDEE)#! %/Q^/M/U\3+W7U#)UA:<K1UG\KX2N2279<ARO=C[#'(8 )/(',
M:/(_[?Z_YZ:C;SA]$3FSX?KA)<-VEZS;-*$NKK*6.OO!6\#\[KHW\."5^WO;
M/*4]7;I +S2RXKD?I.1&@6,+_E_E9E::M8V>:78Y:\R[=#ILFZ[ E 328RS9
M3:FF67R_V[1VLHIL8)\7E_FB'B$(SN[O&O?PTU5ECN ]K=]7W/W#!W6#UD.Q
M''? O3#R%FX(N7JF.RBT?*NUZH:/6R&6"8E7EB3 <4Y%H(KF-:%+"?(QSE.>
MC6FK:1A_E 8!/7(*^5%B'^:,D28LGT86Q^N5*C6)*1-Y?4GD1C$?*YSD:WOV
M1IJG3H58"[HVZ77%#BOE3IXR3X9K/]4VN=F8Z/CQFJNZF ODL I.!: MJ!]0
MN7L*T2\V>FA^J4P"P.HFHTU*Q[:1BD/*3)"#?2Z:2S.T8>1L<T+E9#MHW+7N
MYJH.57SG]/=\4KA>GS) PNN\AH976%S!$GUQS6FM.[J?!N%ZENH=9LCSFDR\
MY\M+*EGR+DDLDE7?:!9$L$KN1UKT.1W="T!50_7]3Y95@\B^&FM_KPTT>&FC
MPTT>&FCPTT>&FJ2^:.1NH9OQ5^-\]D3.:,KPW8YKA/)'M R7+5CQALC<OKN6
MM#R,2>(?T2<H8:$MM!MZ+.S[7*]1_#88%7,,5I=A:1@-H\ZT_K^O\]6O<V<O
M4/!?'%OR/H:F_P!",!:9'.5.8RD5/+IM9K^0-C0\?87(T":&YSF>CM]5M-10
MT !6@T-#0AD6+#+JYJZR HZ!IJG'K?\ B4]-V!!Z,>J6GW&'O"LCD.=^HNMX
M:T7(V1Q')=K4671ES%;8[,6]*2;<V6;M]?>2!8RLG^DVXY.E-BKZAET1(/"2
MTU3#K/TP?,Z7+:7.-Z!- &Z_H+FE:6[J,KYVBNM:XD%"5A3A2)94@6=)5B26
M-9$9Y4D9W\R--(O@O]+:S?#?"7#O$4O0G?Z"7BOBSC[C>6_CZA *UEW)A\E4
M9A]NRO=PT:X!EDZK4UH3C2W"I,D"E$+'ZKVFKLN5_B)=+/4QQ]\+[EA_,O3_
M )*[WG+$?).XXDONH_"5YG&WZ]=!G52+-C^2]8! 5>8BOK]3JZC#W6PER-78
MU5Q8!H,&!<$!B^&OGS_@?]-2@?UM='!Y+9/Y8G3O:1VQ[3VDV_/6&H"-&S&Z
M0!76NH&AQ"!8FTXW'@D;Q=G@&P5W.PPT,]TXBM,.-:_K^OZ^>ONHI=875WTI
M:OA&C I.J+IZUAR\^]'/(TU?^W;+ 3$5<'4]Q(9>\MV8#,Q4N#Y(DJPRG[+A
M.8^LSG'F>'L-H;\L57AM5_G\M-4'_I)7Q+>9*7K&X>HNBCKCUU?Q+#TVT%K=
MQ],//Q$62?R#8\F<GB7#[^QXMTWR96A_5VIR;7!VQ<Q(-<@,PXX\1[Y"6FM<
M2;XB?7^1I:[9$=:O59-KZFBNLQ5:>7GOE&305V;T1]#:Z"A!MWZ93Q:>ZL\M
MF;"VKH)V"'FT%,25%+-6AOB::OW_ $=[XD/.5YU^V8767US<C'\0IP#R--#!
MU)=1=XO'GZWLT&#;2OB_:5K6YW]8FANM4K?(OU'Y9;#Y;^:^8\--;'W2MUD=
M)V=R7+BVO5QPAF)@>LCK@W84D7*V%6PHZ/8]774A+0<@8VK7-7T/)]KM:8ZF
M"DQLML=65^!*I>2JYT!=A0OF::DU_+/Z.Q7*%_*RZ9:YU>C\BM55]263MZ2K
M=I&Y8MO'M;>S8EQFFXWV:*78[?FR2=UQQ5:R&T]83"./=QCM--'TL==?1EA.
M8_B%;#9]7?!%?G(.1N,+0 RVY5PS89:/%]-^"K+FNX^2-M'=\DYS+%5!N>H]
M%44EO::]:YA,4UD><R-S34?N8OTG/H SIU/%P5R/QQRE7S"FOT!?([.K3ATN
MK-AFB:"-4!4/15S'!>#EPNFDF,*L:)PDD<<312F3+/$TTC>#OTHWHLV9E*3S
MI:<<\(YNTS,5L?'G;[JDY>WF<OR10R(<I;9P3HDQ>-)(#DG*"N;>AY,NJD<L
M)74T]^%/"8K34K^I_P"()T0<]9/H;W/&O5-P3>Y^^ZG*34K77/+>?XZN1,W:
M]._451QMY K+V-^ZXKI;*TN:S-Z*\NLB%<Y:*[:7!"+;- >C^OZ_;WTT]$?6
MIT<F$)#_ "NNFNSCMSHJ_P"3M^H;%YZMT3,=?W,KZ74$#XF"+&9_C@9(9>,M
M2+Y'\[PQ AWI)-60',0T_K^OZ_Y:B?UE]7G2GLNFC;U-%U3<!;>TO+/B_:#U
M1/.&5J3="P/><:0E\EVU,'DJE^<Y1$:.8!-P4A 5(RE@(VYBCVXQTHS36P-9
MV0M166%P8I"@U@!=D4H01MH6HH0\A4ZB5M8.98V)"PQN] *O$*-+D\D @\\\
MD<;FFJ7/A9\E\[[SESJ7&Y<J^4Z*O T&X-I:?E'+EQ%@"W?//*6DSM1FM[8=
M+'#]UILC3YS0PS9ZKTG+G(=A0A7B" T-.(R:=C35D_,O5)Q3P3N>)>/=Z3?1
MW_,EQ%59UU-1D6U=3#D;CCGC .^UQL,C&T6?,Y+Y?XNP@QRL*E=?;>KDD%CI
MQ+RUJ6FJDN8?BH=&G07U%=9W*?-/(KKVCV.EZ6\3FJSB>&NY$T%G="<3[(NT
M5H59;0"" 4T-<2RU.L+ 2$8OT*Y%DL"1Q9']?RTU6#R=^E,XR+23$\0<HXB;
M(6.Z@&!IMST-<HD:7*\=FV$R2V-IHZCKBJ*O8::@J_068>OR^2"T1B2N'BH8
MGMAC::F7TG?I+W1IR5JL3Q%ROR#H=#R;R;RAGL1D]3D.FZTX1XUIA->=19ZD
M37MVW41S":%&!>&''WNI;?#5PU+,.B4<4E:278--3%/Z@N& ?B!=3>K&YPX]
M!IP^FGHV]#55N[;<UM68+JNMP0TB/)Y@HD3E62!+JLK;/&3DRS4,=]6;-@<$
MM6+:A?/X_P"O\ /X>VFGS_E"\-BR?(+S9QX&M>U<BM<O->IOQ*J321Y4N/$2
MZGYMR[)VL1\QK.H5I,J\+$>M0?,P.%LQ;C[IIA:_G;AJ3XAO3)HB^8>,WT]1
MTK=9V/+T!7+LB5559!<K])C0L7]-U9XX)T]2,$6P;EF*53>9889;I))P:,:&
MO::K]ZQOTI;I=X@W'*?"7#F6Y5,Y&XNY'ML*9R5;\18KE7B*]=DK4NFTTV;J
MJCJEX8TEJ"4>)-%0:!]T"(0/"E@E8:*7 K6FH(8[]+4T*:19.0*.H?D0]97H
MT7']()<>CT6&C@IY[61Q]U\1J2MQNK*)??U=?"E=NJ@" 6GOB"+&0\W.US35
MQ\7Q?.E+XC?PS>O[<<;DWG$LN=X/ZA>-H<;SE<<<97::2Y(X)LK@0W,TM%N]
M0ZTK#%O1ZL61DS"IK4<H6,1RL8Z1IJ9E!U"\-%5=6$[F_CBP=;AUV>:'#R]J
M,H#=/QQ.A?+FUN'2")QRW#MCB(CY68K&=0HR)7+&6.36 5S37=9U+\,DL=8-
MZ@..RD)#_7KZD9M]74-,CIZ3.!/Y%@R328'42TDK)JUO2JY8Y>0WP2:=8GF3
MV%C9M-4>]9GQ$M[TH_ PZ;]KTD=1&2R_.ANYQ>2LRZC]0-'M@LI<6')UQ=OF
MQ&H!O9*"<HFIIOG)#,_"961D."[BN)5/#/\ /36JGO/CF?%8Y.S[,KNNKS3Z
M"@CTF*US*Z;C[AL1C=%QUM*#D/&6?K5W'(9/J4>RR]#=Q0+.HI4M>P4^ L"8
MD69II_.&?C\?%IO>8.**/5=:6CGR]SR5A:K20&<?<'AAS4-CJ*L2XB+,CXU'
MD%&DKYB&3DL(@?!$KI6S1.:CVM-;PW)_/W"_]D*MM#7\U<:K5U?1-F3'7X7(
M\4U+3&TO-'(I4MI.%D3YW<B6E' ?!.-P[,4R3;16+IXQG/J(S FFGV9U'<,
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MZ#+.Y(UY>HY"L:,>"O.U97JVQ-NTU-S:;3+<=Y:ZVFUNP,[F,^)\Y:V]E.V
M8>-\L8P\+/,OG(-/,G&KZP =LIMG9%"5P$!!I4$$C35&=#U6:7K?YG@UW >
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0T>&FCPTT>&FCPTT>&FO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g486549g02x90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g486549g02x90.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1I^4&AO=&]S:&]P(#,N,  X0DE-! 0
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M4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     X 3 !A &X
M:0!E '( ( !, $0 ,P S #4 8P      #W!R:6YT4')O;V93971U<$]B:F,
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M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$!Y            "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D            08W)O
M<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M   ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M        "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !
M  $#P     $  3A"24T$)@      #@             _@   .$))30/R
M   *  #_______\  #A"24T$#0      !    '@X0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          $X
M0DE- _0      !( -0    $ +0    8       $X0DE- _<      !P  /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      S4    &
M      :    )@0         !                          $
M    "8$   :                       $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   :      %)G:'1L;VYG   )@0    9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   &@     !2
M9VAT;&]N9P  "8$    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     <X0DE-! P     #\     !    H    &T   '@  #,8
M#Z0 &  !_]C_[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( &T
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M[0SW?]*Q)3:I)%G&OA\5:[+-PFN]<EMCO0CV-L9[O\\V[MO]9BTX;KKV\/\
M:DI__]DX0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M "  0P!3 #8    ! #A"24T$(@     !GDE)*@ (    #P   0,  0   +@+
M   ! 0,  0   ,H(   " 0,  P   ,(    # 0,  0    $    & 0,  0
M  (    2 0,  0    $    5 0,  0    ,    : 04  0   ,@    ; 04
M 0   -     < 0,  0    $    H 0,  0    (    Q 0( '@   -@    R
M 0( %    /8    [ 0( "0    H!  !IAP0  0   !0!  !  0  "  (  @
M  D] ! G    "3T $"<  $%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,3<Z,#@Z,C@@,3$Z,3@Z,S, 2F%N($=O<F4   ,  : #  $   #__P
M J $  $   "!"0   Z $  $   " !@          !@ # 0,  0    8    :
M 04  0   (X!   ; 04  0   )8!   H 0,  0    (    ! @0  0   )X!
M   " @0  0              2     $   !(     0   #A"24T#_0
M"      !    _^$!H$E)*@ (    #P   0,  0   +@+   ! 0,  0   ,H(
M   " 0,  P   ,(    # 0,  0    $    & 0,  0    (    2 0,  0
M       5 0,  0    ,    : 04  0   ,@    ; 04  0   -     < 0,
M 0    $    H 0,  0    (    Q 0( '@   -@    R 0( %    /8    [
M 0( "0    H!  !IAP0  0   !0!  !  0  "  (  @ P ,   $   #  P
M 0   $%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3<Z,#@Z,C@@
M,3$Z,3@Z,S, 2F%N($=O<F4   ,  : #  $   #__P   J $  $   "!"0
M Z $  $   " !@          !@ # 0,  0    8    : 04  0   (X!   ;
M 04  0   )8!   H 0,  0    (    ! @0  0   )X!   " @0  0
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M 0$! 0$! ?_  !$( 8\"2 ,!$0 "$0$#$0'_Q  ?   !! (# 0$
M   '  4&" 0) @,* 0O_Q !8$  ! P(% @0$ P4$! L$!@L! @,1!"$ !082
M,0=!$R)180@4,G%"@9$)%2.AL212P? 6,V+1"A<:-%AR@I?7X?$E0U.2-6-T
M=:2RM"@W15159Y2BQ[7_Q  6 0$! 0                   0+_Q  F$0$
M 0(%! ,! 0$         \ $1(3%!46%Q@;'!D:'1\>%"_]H # ,!  (1 Q$
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M3_>3X32X,V$J23)[CM@'2DS#,%T[2WU *4G<I?AI1)6?((*-OE!$Q!E,$\G
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MP\NB9HVPI(2VVG:H%*@K9<D*'K=(!%X/YS6?F/SI0'_3M?\ ,% "B=R5)$7
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MUEE2@,VE:L+2A+?D=0I*@LQM )M,VL5";S8R1.*#=E=86G$L+(6ILI)/""J
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M5!* 3Q*@5;1R"1VP'A#Z[]%]5=$M>9SI74F6U%%\M75"*9;K:TH6T'5;-JB
M%6C@^GM(!/ + <@E1"B!(3&XVM/'^1@.. 6 [6 T74!Z?#*@%08@&TSZ P3[
M3@'2JI&EO-4=!3N.5"U)C:5+W;Q9,29,D7 @>MXP'H6_9!?"9JYO4*.I6>96
MZUEIV/T9J&BE*U !2" I/MS)@"3P<![,^A[M3X%,PD2XTI+*MAEOPTI4FT02
M$@*!/?F_!3H+UZ$RY*#N65)4^\@E9 5";)00),W<4HW!FP[' 2?,T-H="0M2
MEI4M!!3 V)40E4WNN)(O!O,&P0#/ZUL)6TE1#JD;3;<"DD%0MQ,%-H()/I@
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M*I7%I2ZAA:FUI2H@&=LW$01N'/,8  NZ=SQA:FW<JK4+02%)4PL$$<VB3^6
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MM*HJ;RGM=*)O?DS^N KQKCH/TWK<Q%(_HC+'PM!'B"F0DI(,#_5@"W8E/Y'
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M_P#-2NC_ !P%:7J)"$J*9,W! DBYL?8^OTF, R9A2J53.!25*)2>!! CN#[
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ML%]WS^&0I0A1 W7(008, SWP$/S+,*6@I%LU"J>N25;-J97X6X04H!B1;=Z
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MV85566*P*-,5A>Y:0@H2H\B"8O'E*A9/ Q1&=*Y=\_7JK'GJ(LO.%22PM96
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M^I\BK%I;2&4I)*%E26TI["QY( $'VMVP$\T=U2S6B4AUS^UT#O\ [Q*MP!]
M1)"A8S,>AP%O]":]RG-J>5J<<<=!1L<))18S 5$IOVXXM@'#-Z 4SSC],AQQ
M#BMXA1( )L+VM/K, &YP$4SBFI<YRJHI7Z=P*"5>5"@%E6T\'@DR?OW@B,!K
MRZJZ5H,EKEOM*>A[?O8VJ6)*IO"8!$_5ZB(C@*XYK4T] N<NIW_%4/."H;28
MDB(3R;P ;<G "'-,[S"KSAE"\@2T\AP'YEX((4.21:1:X),Q;TP%BM(YXMQE
MMBK4G:&D0(&UI7)(]BJQBWOZ!9?IVNK<J634)IBV'D>$H-18* !W3-K3?FV
MV/:+J$IH&BZE!)80KQ 0 /*)%R+=[=A[X"<Y3F-2^\H*'AL!1"".%\\GO-CQ
M'$6. DS3]9N)#L-H4;#</+-C>U_6Z9XYPG\R]CL>6NO:(\1(3$%*@841*3$[
M;B!'Y&\S@!?J?)F%!86XEML_7MD;S<@C;ZCN?>^%!"ZBKR3+J%(6YM\ &2LP
M3%X$W)D&(,V-K1@ )K37F1)IZVK8K'@IAMQ1:4HA"@D$B/P^LP 3_0-9=5K,
M]1.H2J,*>:::KDMA2%;?+XI X^HP+\7BY(C ;:.F].WDVELLHDMK<3X2?XJS
MO/T@7-R"=O)L2;Q@#-E*$>(VX $I$%12;"?:9XGCN>!? '72H+B%!D1(\TR)
M](X].8_4@X ITE$&FDE1_B743['@?X3^5CR!!T*@(U7DX!G_ )[_ /\ .J_\
M\?>#@+'8!8!8!8!8!8!8!8  9TI#=44*5$NOI 4=J2?$@7GZB! M)F >Q!I4
MM"!+A@$PD]@LF8)A5H!)X ]>("-Y^4(9#C?A %+VY25 G=!CB0G<8,B-Q$&]
MR !S)T&H?<4DP-Q6XM,"!*E%/8@IGDP<2NDGKC, ;/\ -F&GWFJ9#+REJ7=8
ML$D0%$$$25$&"/\ LGA-%8->YMF>75 ?0REX""+#8$>4 **$^@)5W(F.V :L
MGZBJ88IWBZR')*%4P<W(WIO&U0)"@1V_6]P/.B-0M9HA;E8ND;4ZDJ6%.K'E
M.TS!/W\H'E($?58#9D>79* IZ@<0\I1@MMJE*E=X-U3<]YY'TD@I.HD)R*I0
MOYVF>#"@$G:)@[1&R22+FV\=C L#B=:>PZ-5CE53>%4L.H=2%)4KPS*X&W?*
MK1<<#D6.'&>_>?Z!ZXBF9-0TVAU3P=LHWV$+N!"Q$PKE))49M$XH"_6)5/FV
MG:EJL;+2VDPXXM&P.HVF3N!&XW(5P 1(  G :G]39%E]/G;R\N73J<0X5 !1
MV\FROPV$0>0"!@.TYQEM%1EK,:6BJU)G="4$)7 @*ALJ,&""8(^PP#<:H5-*
M:NAHJ-M!%FZ<0;<@6Y_.Y)[02#2JKK6DL5C+'A)#DU3)0$NQ("5B #*4F1W[
M7[AL ^&NIR3,U,O5-,7'TA*R2D@I<W) (@][JCDP+S!P&P!VI8:ITO.O+A&T
M,, &2@P$A 48L%0OND2#,@D.S3>0A)J\SJER*@EZG;41N0"!"19/'_NTD&!)
M,2<2N0D+S5+4(2FH"76TF %K@3:Q@CTB/_/#'?Z^L_8;LXI*5%"I7RM.2U)2
M%J*#M2DDP0H*/ZW$^@.%.M^;5I.DH5OUGKZDRXFDHZ5141M<\)*E#<F=O))D
MP3<BQ!)!$8H!U5J3,,S>75U##R:9M02DO)4D"> ((Y(/$R29\Q$@):Y^LS?4
M24ONNMT[;@*4FP4E*C9(_$8N.XX$6P%S.FS+3%!3,I2E*?#6 5*(<)"ANCGE
M"1N))C@'@8"QF34W@[7F4MDKA("%'<OR^99-_J4)29@1 %\+@N:94J7'CN9+
M8!4%^7=.X028Y)F?4<"!*DT! I\R2&VE4]CNE3H$E1!X /L0#%C< W. >$UR
MWZ1X-L%LI&Y2P3PI<K5>1N5M,A7E,Q$8"<=/ 5UE.\6U!3CZB5$$%02A8W0#
MM  (3QVOS@#S@%@%@(QJ2C0Y0+4D72J8YLJRH^XYO]O3 5VS*G^5JGFP/+,I
M$=B9M$3]/,S_ %P'"G0E9 5_#D64 1/N>09 G@W@]Q@.]]#)"D%85M1"4FRB
M;Q(@C@W& #>K,GJ?%>J$JW-%/^K @=P%3S!YN>?U"HI1U=:2UEU6PZZIMQW<
M @>Z5>IF1//O[X"C53EJZU=12+4'$ME4*6VE15NX\Q$]XYO/O!#-T[H]W+*@
M52:MQH*)/RZ/HB;[4DS>Q/;C@6P#QK'2F3YM1M5%<IIMX3M'B;5*BWF@I$'T
M[3/I@&'2;1R1MZE33)=I DEHDE22H^A,DGO;WP!RZ?N9M4U:'Z=D,MLO).Q!
M,!.X CNGZ;'MV^X7AHJ9BHR-M?A?Q5,D.;TC:I0!N%<R>?OQ@!Q7,LTCBI\I
M7NW!(D BQ[7]N3@*@=7$,,MU2D>"\)6H*,%WZS%HYO;BY@^F I-GU"QF:'7V
MV32O(^C9^)797YS<<&(P DS71VJ\P4TZE26F4K!#RO*%!)^G>!>8[6YGO(%K
M2N4[&F6:AH(J4H"5*;DI6I,&2>P)Y/K@+&:%S!ZGK4,*2AQ#>Q24F04F4R;7
M$$#GN;<S@+W::S(UF64K=.HI(0@+*)(D@6W3$D1($^G: !RTPRE;*6WZM:""
M"F0D*'K ]S<'OS? 3\4J D +40+%2@(4F.][38\^DX"):FS6FR^F4D+#*[D+
M!N"/O:_YB#WG  '5'4*FH&%N*6Y6O)20E392MMKMN<(LFY@BYM[C 53U#U!J
M<XS1;#==4O;U1\NTF6D@\CR<1WF3:\G@!YU+TUG%7I1]67.@5U4A3@:*BE>T
MW(@03/8'D3<' 5'Z4]/<_8UA\Q4-U#9%4E3R_".T0X5$R1VDGGB+=L!MMT95
MKHZ2FH:APE7AH GL2.P_/T]2#@#'D;@-4VTKQ"5*L$R1>UH]S<0;8"S&EZ4L
M--N/%0*DI"01!5)M^7:?7O? $BBJ%*!:*1M"1?G@FYD?D"3$^ER G.A #JS*
M57$?.V["<NK.?>/R_,Q@+(8!8!8!8!8!8!8!8 $ZK0RS75!&T[77PA&W\4I*
M0)L+D F>Y,VD .7\R>0XL%"3N20M"SNV+GE,6'&W[=X-P9ZE_>5H\RW/#64A
M4E.V"9[B.8O)GTM@ KG:O&75;"I9*7 IM/DW&_E1-A((_0CWQ-<.+UMIM+^
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M#[*T+ (@F_V,_P IP 'U?EC=.IQW=M4VHA)'*DJ-DS%OO8 $&\X"!?,01%A
MB1(]9]3/8< >^ Q*BL"5#RA2C^(2+>HGO/<_:(P$9SJLR\TK@J:P-*4-H25
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MN%I=,4"JAT5%(/">=$*;6=RAMC@VL;$<F_. M1I*OS'*\M0TFE-0\B% )6$
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M-;U(AX&2@$@S!MQ'8_GW#89TER2CS1^E*ZEMRI4$>* L;E6DB!P4BT S-C.
MM/F>F&<NH ]3>&VXV M$+@F+F;FT23Q^5X!C3JZE8:+;M0IIY(VJ+204R!ZD
MCDQV@\V@8#,I^I5/2TA!KW'DM*_B(3&Y*1,DP>_H#WL,!(&>I&09UE:FD5(W
MK24K0HRX>1=-[">0?2(N,!7G4>D0Y5U%;E\I34.+6V3,>96XR3QS$>QOVP$.
MJ\GK:()?<<0TXV)"DJ!"R+@<D382;^O%\!.-*:U8:IG67UTR:\&&U%7F6 (
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M$-'PTP>2;24VVDS>RB1Q0-JS0;6HW$UU(^II]A(=6I@PXL)E)E"5 @B8[SW
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M@U "Y\L"-H\HD[29!B85(P%0-4TCKU554U'54U$VIQ15X0*0F204BPA0/,0
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MJG=<&"$I[$$B9P$%SJE<JV5H4"4$*2F!(D3N38VG@2>PN>TQO?3':VF?W+W
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MN4Q>7)"2$SY0/8 ^D?K/W ,ZSS;4%31N,TK3CS24DKV*A)$<*!,@>H/,#M;
M5I7JVOKJYS(*C)Y8;F%%D; H2"1[B+$0?3 2"BR^@JLM=89R]:*FZG%)2$D<
MP 3 %B8')@P21. %.;9=7*KW* %RD004HW$C?<CS%)]X\W':>,!7;4?3;7E/
MJ=54S6H51%6[PT)5N*"02%<#V))[V/& )5!1_*T].A]E/SJ$I0IQM!W$_29(
M )F9,^GW& E>7:>JJ>H8S#,&?X"E!R  -P!L(/I]OUYP!4=H\FS>A(V/LI""
M%(;4-I*18@6*9@=S_3 1W0N7-G4J,LI\L=?9<>V+>6 L!*EQ,QP!YKDS8'C
M7TR_+ZC(Z2FI*$/4X(0H*9E!)-H)3>WIZ_E@"P3EE3D 7GBWGJMK80\I7\1)
M@0"LSZ#O?@&.09Z3)LNSUMVH::?IDT:8:=\1)\8(%AM YCO$Q/I@&:H3F5/5
M,M?,.II65^5960")X]SRFXO8=\!*-6U3BM.TKJFG%(!VB#,Q!E28Y/"OUOP
MG/2.IK32MJ;'B-I<3#9F4F;@<$VCM_7 6<0U65#M&]35#C']H1XB$$[2(!4-
MH]Y_GWP%@&<N\:@IPDJ2O8@K4)\Q%C)]S,GN3>)P#OE]0EE2&KE;=B%3?U,G
MT]R/3[ 0,I 6LNB?/V)[B.!SPJ!^<6%@,^5)4ANG2;'820#ZI)@_RD>N ?,
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MC>E7@M+""XH*Y5'.P)\L6$Q. HCJ2ES/-\VJ$!PMAI95*3 VA138FVXJ)[R
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M/]Y"HIE#^&I)3N'V(!G[$&(F..^ H[UBR=O)*:IJJ,AU;B_.M9)L1(2 28
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M/:WI/I? $+2I2^&#$A3B01S-Y_G CFV -=(F%H X2DVX@;=O]2!Q@'/ + +
M+ + + + + #?6 *J-E(/_P <^O"6S,$CL/43@*_9P[4.NN4SJU'PY2-L0D$
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M\@B)N/M]@EZ4AEJ  =HD@?BL)%O;V$W[VP'/)$$5:RA*AN6V4Q,;B1.WV[#
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M0EUBK4/#@I;W$I\H$ =S^7ZX DZ/ZSYS05Z2^X\S3MJ"7% '<J($IXF9F0>
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MM/;W]#ZX#NP"P"P"P"P"P"P"P$$U(TI5(TZ%)&QTI()(5YTF"+018S>8O&
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M@@8#+P"P'%1VI4KG:DG]!. :29)/')_7^6 7:#?M]\!%,_4PPRJ2"NZE':+
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M21 [03 D3>(A7'#O3M7ITWZ#2_\ 'X\H,U_S68N,)*W4E*75+(3M@0@&P4+
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MLO[% O%.TK%P0 H3<BR8M:WH M/H_(\NR>DIA2--4SB @HIWVT.$ 09A7J+
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M!)\OIWV*AAW>E 5M5;SK!*D;+P-L&.]X_,!:72#F]IS<HJ -.H().U*E[AO
M%B;1(D6\W8X">X!8!8!8!8!OJUK:2I2U2W!5P!](F+"?MZ_? !?5&8ATNI)6
M"XH@%*>$I];?8QZ<]\ .GEJW>5 6!SMNJ_)CF>WM?CG 8!14(<+J&@D$2J8D
M"T$R?4 CUD2!@ YK]2?[2^IS?#)*DJ( *@%>4'U/?]/3 :*?C?S1ZL%2V*MN
M@;2%MI:E*E.[04SYKRHV'/)%^,!I[*$./O-EP*@KVN*(0E2KP?:_Y'[8"/\
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MK3((\H"^"(,'[8#?EF%=FU'I2G<;=:HW/W8P77E.#RN> @JW%1YD*[CBQP%
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MG ?*/]RK<:74*+>T[4NPJ)[3Y1)!MQ ['C %[(\H53TCO[O>8?55(EO:G^T
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M .>F5@TJ4A4D*6%#](''%K&>Q'M@)3@%@%@%@%@%@%@%@%@.EY*"DJ4DJ(!
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M,I7'EB">8YB/UXC 6'T^T6Z5KBZ5*(,!7FMQS8B_H.]\!(L L L L L L L
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MP$,HVDH#CE.^VX;^(E05Y;S;C\R!%O0C )Z@<='CN+4F?,"@D D>H]!Q[7[
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MY3I5;YK\U6^5TX+*UL)=6 ML;846P4V)%KCWYD*K:T=R-%?5JI7ZQ:;II4^
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M-WOR 1MY2"1QM(O,00LMI/+<GHT(#(:-0E:-B5>5:!!WJ&[_ %JP9(<!)3:
M($ 1Q$0#,6YGBU_?UP'W + + 8.:.!K+,Q=)@-T-6X3Z!%.XHG^6 KRR\JL=
MJ765;%$P"94.8$B8]^#<>M\ W5U8HTZZ-:_$<6=JG(B +Q:\V^YO>(. AE)2
MJI7E)#DH=*C%A^4>LV^]AWP#^^N&"TE*5$(L1<@GM:# GN(X]H"M6?U)8U([
MXC#@=[N!2B@I' (!VB!S:;_? .F6YJ:]WY7+D%22=KRRCR[NXW$&.>00 (XG
M 1?.LBK<QS%;566T,HLT?*25#E)B/2W-B;1, -M4:4S>I!88:<VH6#*4E04E
M/8) N3;UO]Y(2+(],O5;3+5>P"TTV 2\D(*5!(F! XN/<_G@&+.FZ7*:JKH,
MFJ=E:^VMK>VL*V%0VA6P&  8GM-K8!BT<WFFDUU-7G.?_/!UQ2PRM"5*1N)\
MJ5*)4 +6X! V\G 3>KSZBJF%U[;7S%0BS.U(!!Y25%-C!]1R+X#S1?M+=7:O
MS3JKD=!ER:AP(K6E%M"W(;"W@ #'9($'CC 6'TSU3=T=HC3N39O64[%:K+:=
M3JI;4ZE7A))"@0D[A/U$SQZ8 ;ZNZ_:)R^L8>I:6@S&N4K:ZMU#>_P 0>LC^
M]>0DD]S%B!VZ?=>\ASS+Z2ES!W+\OJW$I#;25,H5/"$< F9]((MR, 1LWUIG
M*\VRC(J5#:J3,5,J4_3+L&G((WENU@#,S>T\G 7.9U119/I/+,NIZQ/S%.P%
M5 3'\3=N6I'C R.0"0;08(M@&S/V:+JIH][)Z-VG:S1*7$BG6I#ZG4E&VQ=N
MD'D7M'V. H$OX/,WIL_>=:R11><J-Y6*52@253*5;(CTBTS!P%^>D7P_YGI/
M3=559BRS4.*8AEAY"4JI5';#D7,B(";CF2#; .K6GM19?4.OO5"6:!M2B27$
MI2!P !;]!S,8!IS75JO"=R=DL[WD$>,VM*W H29B3>0"?UG 4EZEYQF2\Q?I
MO+4-(W25D)*3)"KP?2>9_*V *WPX9<BN?;<-/XA^:W+1XBBG:D DCOZ=[X#;
MMTW73J;13OTP;*0$MR/J,>]Y%[F;][V"PJ66$4B.$[()2;V]?2TC[S]H" :H
M>9??IV&D'QUJ3M493;@B]O-;[1VXP!KT/5IHJ:E8<2 \C:H!(F1M@W'!^Y]K
M8"PE!4(>ITK\H*D[A/EF;$3Z@B/M'I@.]MM0<2K8$I -@LJ@D'S"3>08CB\\
MX#*P"P"P"P"P"P"P"P#7FF8(R]@NK!4. E-E+4>$A1,)3_?5V!$7. !N>9@_
MF%:M*O$"%.DK4FX )6 V"00E"9VI%K1R%6!@<:IZ5 /<R$(7&P D[B2-D$3(
M@SN,P1. @&>T[M2HJ64EI*CN\,I"E;E'S"Q24F1<000";8"/^=EDME*EKA:$
M%"5$I2)V[B8%K21))X!B< -,\H6*JGJLOJ%^(7VUA*E1]1D!0!%H!@V].1.)
MC>GWE?O]94T[#2S\87PV?O.M>SK+*+YI+2UO/(ID!PJD$[H2+P8!!(E(OZBC
M6I3=&JVLKD5)RZJID4[OA*;<9@;I@*C:;$IN"4\]Y)P&PGI'TAT\O1]12:W=
M^4I76?X*P$)6$;!L$J $$[2H@_\ S$8"5Z<Z(Z&16..:<A2*594IUP-_Q(]"
MD1<2 1(YW3$$+%Z2Z;T&9.-HI\S0VZC:V64+ 6L3)@<0# W"23:YP%K],=)<
MM9:IWZUSQBVF?,D*W"!P2(, ;3 M-A@)7K+*LLI-'9W34GATR#0O(*D[);AO
MZC"2+  GW DCG$UZ=?G::9#63HO+,I<?U+25^9)K6EU3NUIU049+I,MA4W4>
M )YO&*.6:=-\IJ:+,:AC*&&G?!=--4E(W%P)\A2. )L#_(W "J.5:'>8U27:
MQV:CYH)2CRP4A15,$  1," .Y-MN V1Z17DFFZ6D<>^7/@TJ7G%&-R"E"5GG
M^\ 0!Y8DD8 )T'43*^M75MS2-.ZZRQE=6I0"BGP2$/>#(/N(YC=<FQL%YLQZ
M!Z?SC+%,M%MI_P"5"/%0E)4I01MA=OQ 0;2)'!XE_C>3,:9?B<^"JFSS5I?7
M0!35,_9QMHE2P%$FYA)&XS(]Q>!%''I%\$=379K1,MY>INB96R)6WY8%I "1
M!D7D&_$VP&U@]!\ET#TZ^08IF&P:?=5*A'F=">.!)(!D$]K0!@-5/6#(6LIS
M"J1E880XXXXA,F LW(,)@$7!.V\& +"0K/DV5T_[Q<&:TQ57;]R5)3Y;F9 D
MB53,1$ >^ VM_!]09M25"2A+OR:SY4#=N0F01N2+2"+S /((C ;8<H9"*X+9
M96M*@@002F=E@!(@ RD^LG$E>/[V_ E53"VZ-:EE+:W&R0A9,F1>Q\H3[SW%
MIMBC*T*Y5T5:XIQI+86M(2HA0$'>+S)N%38$$GU)@#O1UJE%+[)V*;6DA:3P
MH&0M"@38*'>#:/<@4\AS4US,+*?%;(#J9,D*'D='9.]4A0!C<+)3. DF 6 6
M :L]MDF<&QC*LPL>/^:/<^WK@*XBJ724R/"2C<ZHD_8&/R,'[DBQO8&&K0I]
M\N%2T&?,00!>9$?>>)@7]<!\2S2OH4GQ4I4U>4SNF3W'KW)][S(P&.JK91*-
MRCL&TK,7@1R1S/)MW^^ #^MV:5(6ZE"G7'.2T07+G@FW([3_ $P#-H\N4[B4
M)3X;+BK@_P"L\W=1_O"_F[Q@)UF>44Z4?-)5N*1OE1! (XY$\]@?O(F0@&:Z
MC:RJB?K*UZD0 %A+J4[4) !C>HB( %X@=S& HCJ+XB<]I]9JHLO>9JLO^9*%
MEA8*=@7 *O/(M-HLF"0;2%AM/9UE.>MG.*BD8;744I6'4@>+OCN02;JDVMQ8
M3@!+JW*ZZK?=KVJZHIV4.*V-!Q02K:>4H!MN]XF38WP&9D>JZ?*\GJCF50TR
MIA)0VM2@%N @JD@F\?F-ML!HF^*O4&C\TZV4[B,W^>KE53"G*=+B%I2?%D@"
M/O,*-N;<@+OB7UG0Y(K*F*6B6*IR@:*E,IB90D()/;Z9/],!3++LASO4%2C,
M_GO]8X5AI2EEQM,[D@?X=OM@#3THR2LS3J729=FF:5-&PTXA3:W72&E*1!2A
M([*41M''ZX#;8G3^;.YKDU!EKJH1E["/FFU>=)0@DD+!F3,1Z>TP$YR+-LVR
MM^KRW4U013MRVR]4*)*MUDF0?L>._([@2]#USF25R\UR]QVJ9'G"FG)\L$JX
M];6[VF<!=+I;KW)M8Y?5N+8J*2NHE);+E3M(43NDI$;OPGL8][8 B4K^;9HZ
M[2-J#;!5M4ZN-BVR8M:9_(<W]@A'5YK)LATNXBNJ"R@J2I;K:MJUJ!!*9(CD
M$0+0"9%\!1S-,\RTM.YEDJ%50I9W$*2IP_A)W"T^8GBP_D%<]9M5&=YE3-Y8
MV\I^K6/%8L5E2U3"H[>95IXL;8"\OP\]-\UTS1T^9YPTF@IG(4E12I.\K";V
M!) !G@3V$<!LRT'E:7VD5:$MK:@!MP"^VU_:P'\Q$3@"DBG)4IL3$[H))YCC
MFP'K? -^8Y>P\6UI80X\A7^L"02F".#%OU_I@)MD[W@"E2ID!13"W+R>;#M
MM)C[P3@#3D=8FHI@@F[=@> 4_D.W?DQ? 2]D)"(2O?')G@P+#T'H/O@.W +
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MXD;!("TI(,_BE6Z+$\"_). MHQG3F=94Q^Z7$_Q $K\(C<@* 5! !(M:T\F
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M.)23;;03M^A>5!#B%F"DA1/Y"5=@2?T%C;%#IE[106FG(0=XWE*Q>\A4F4V
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M_P!25%0D2"2!'H! ]@\\>A76L_\ C2S.H?<!IZC-*X\P4[UOD1/>_P"1@^F
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MJW*)Y_<X5)2 $N7/F@F?P$)F8[B3,7C ,-<[3['/"W);"' -T&ZD[?3N2GU
MY/. %]26R\4I4I4K4=TW40HGUM-P!^(Q(DV#ZA"09<BX24DWYX^GO$?SO. K
M+\1&5"LR@O-NE"PTXA"1.XFTBQ@2503:9()X(#3OU%S;4>A6\S=4E8#Z7"Q*
M0=J))"^3^&(DB"1WX '].LFU-U)SQ;M>TM^G6X%;W4E6QNYM,D>H)@ SMM$A
M>&FZ&Y+E66,9BM*UI2@*<6@;-JHW*$D<6B"38R>X 6*Z#Z\R9-<[D5&DH71I
M#9420" "GS"VX;1>.!VO. +_ %$S')\V:#;R9=;^GRD@J!'=238_BW'DDW)
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M@D.I41N6"0D'< 5;C<S @6G -CM&V6MRW/%?<25[1"4H4=T>8?BD ;2F "3
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M:@ GGC 8+M!4L0KD*'<F;"38@21:2#(M/N&)4YFY3(!*00@@%6TDJ,20M15
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M<V:I=55H=50(4DD)D(W*%MH4E2B05#GZ;!))/H&565(!*UE:4-V"3<A0'F
ML5$CG[28& D^BZUVIKVG5[!%92A*0+[2YMOM@ B3:TDS'; 6$P"P#3G]LBSK
MO_[)S*WK_8WL!5V4!L+LDA1MZGM!)]+7XFP[8#N8>6IY)LJ.T B+D?;L8]9,
M8#KJ MY9W),%1D $C:.9[7M^0B9. A.HJ8.)#384D[DE1%K1<$&;2)BUQ[X
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M0=VU!D GF%$V)Y]+X#>1H.K+V14XV>'L2A)@3^&"KL!Q?GO,' 3"X,3$V]@
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MW35!%8Z\ESQOX;:%0)!*O.5D>4RG^Z(_%? 8&:URA5%;*5HC:VH) \\$7(@
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M4\[L< 44[4\'E41?_$=Q@!1_HG65#KM6*M+%078:90$J*N2=Q%C>/J'<$CC
M.&9.)R2C"JIYMFH;;.Y26T%:Y'VW#\[B;$Q@*4=7SF&KZ*HI\E"GWRZM"T*;
M (2002-PO$=I%L!KSS70>=9'\^NMKWZI2'5J-&IB A17YTA4GCO;MQQ@#O\
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M*VJ<4E32E!2DJ@_4#]20/PV%Y,"< -M0T^7,+=:I0\EY)WN@;N(#B$MGL.!
M)L3)B2 Q=+90_J&L8?&]FG8>0VMMTA17N4"2I*H_ND<\3%R 0LE34?R5,VPV
MI*MA-@V+S$[>P@6 '<7BT X4=34L(ARH;5X9)4VILID'_9F9@"Z5;B"(( ,
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M9P5)*J=2 L?0I24VW$F.\F;1/V(4LTGT2R:NU*[F"6J>14%04@ J.Y94#'>
M#/81(%A(70R7I4QIZC8S)BG6WM"5^)M +D&9[D]K"Q];7"P&B\V0_3Q6(9;:
M;2&@K:=^^-J/O>),<&3@)53Y%F[M:JJJG&FZ"0IL))'B-WBTR;$=A]NV <W<
MPJ,MJV$4;1#6X>(I(A"@2)4D\@@3>1'$1. )%-5*KA3,-/J2A>TK4#?<;'C_
M ''N+F3@+!Z/IJNG51HIG%.(  <)^H)$ A1[B;CT]\!8>G0A32&WE$+4 9/J
M ((^T0!^?? 9C67,E&UQXDK.Z.X!F.\#[=_2<!V&F;80IH+6$JY4J+DGA(OY
M2)]..<!B/^ &PRTH;T7/$S'_ *\F]K# 3[092BKI4H5NW%\*)[$L.*(__P 1
M/WGO@#)@%@%@%@%@%@%@%@*:5;,5"H"5J*U1MA29L!![6-^]N>^ ZGJ-3?\
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M,F:=-/\ /4*@.5'Y@DB!-RU(XY[=H[!WLZ#KF$D(J:*_,J?N;G_X-KGL/O.
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(02848^D/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g486549g08p69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g486549g08p69.jpg
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M 0$! 0$! 0$! ?_  !$( $$!( ,!$0 "$0$#$0'_Q  >  $  P #  ,!
M        " D*!@<+ @0% __$ $ 0  $$ @(! P," 0<("P    0" P4& 0<
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M]<>Y,,3@.?93ZI]Q$4TC*OC6M*M"ZE[7#=NSLMC87WW4)+(XJ8CDQR%(#8D
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MS6$W4/+C\EDRM$_O;'^NM'Q#TF2.V,B,3*AG)TFE]A8<5'HCG\V"NQ/]"_\
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MT"T)D3 +ENO3=(%'J)>%[($AF"&9@AF)B)B$.F5*MD-][<JVUBY$W&/)9Q!
M9TZEFXF"&?0AAR%S(S$P41Q,3$S&O2*WM!15HTCN.M3H3$E"6#5FP827CRFT
MO#'1DI4Y<$X1]I>,H<9(&?=:<0K&<*2K.,XY0[#N96RV+L),EN1D:3E&,S!
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M_P#L5K_@,USHQO\ "-#^VU?^.O6UOZI+^IWU_P#[RP?^%VQ>5-^'?^-.;_N
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M+,%A^X7HQ4S[C<L,%=K*1$\"U=6IQW4C8VX#D :M-IQIIQIJ)O:?HUU6[I0
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MZCYT+_I+A?\ ;Q_^*SS:.IW\$6/ZD_\ <+6J=*OX:K_UJO\ ?#6NP7_5A_\
MV&O^&GE$S_&7^D7^V== P_ /^B/^R-?WY_.OZTXTTXTTXTTXTTXTTXTTXTTX
MTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTXTTX
&TTXTU__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g486549g13l34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g486549g13l34.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2%:4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !\< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @   #A"24T$)0
M    $-/)GTL]C>HHA4@U:H05G"LX0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /      0 ! \
M   !  $X0DE-!"8       X             /X   #A"24T$#0      !
M !XX0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              .'   $HP         !
M                  $             !*,   .'
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   .'     %)G:'1L;VYG   $
MHP    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   #AP    !29VAT;&]N9P  !*,    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     0X0DE-! P     %M0
M   !    H    'H   '@  #DP   %K@ &  !_]C_[0 ,061O8F5?0TT  O_N
M  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43
M$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-
M$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,
M# P,# P,# P,# P,#/_  !$( 'H H ,!(@ "$0$#$0'_W0 $  K_Q $_   !
M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MHSK:F:N>UH$\D#CZ2@[,Q&3OOK;$@RX"(^EW7G#:G&-V76V=LD![HD;?Y/\
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MVWX#\BDG8\<(#TBK69,DIGU&W(^ML_\ -OJ$?Z$_E"UB8$K)^MW_ (F^H?\
M%'\H5#ZU5_6(9%=^!0<_IPJ+;L.IXKL%NX/]?W.9Z]7I#TO2_P &_P#2>FG'
M;1876Z=D-?DY8V6M]6WU&%]-K 6BJBOZ=M;&_3:[VK07F6'T_P"LF1D%_3.E
MY/3,LQ&7:\U4M=NGU;<=UCO5KV_]I_2RUZ"^OJYOL++\=M!+?1::7N>!M'J>
MH_[0QC_TGT-M;/8FPNM4F?&;X>'0"KX_E]._#!N*ETD6#%>+*WU.^T9)#7@
MD&^YS'Z%WLL9[Z_^#6%]9ZOK8W'Q;<5E?4*V&T9V+0#27M)G$?6VVU^_TF-V
M7,]3^<_2,I_T61]5L/K]G6*,K%PK>E8+7O\ M_K/.RP!NST:\5[W/=9Z^_\
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M-E=36N?9Z5F/_.^G_@ZOT^PJ?3^E8G3_ %'4!Q?;M]1[C)(8-K!M&VMC6_\
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MD DM&NP_R5-)3"NC5-WKNQ%=8$!H  @:=AI"?A.DBA22222G_]DX0DE-!"$
M     %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M   3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    !
M #A"24T$(@     !?DU- "H    (  P!   #     03B   ! 0 #     0.V
M   ! @ #     P   )X!!@ #     0 "   !$@ #     0 !   !%0 #
M 0 #   !&@ %     0   *0!&P %     0   *P!*  #     0 "   !,0 "
M    '@   +0!,@ "    %    -*':0 $     0   .@   $@  @ "  ( "W&
MP   )Q  +<;    G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P
M,3<Z,#@Z,3<@,#DZ-#0Z-#D     !)    <    $,#(R,: !  ,    !__\
M * "  0    !   $HZ #  0    !   #AP         & 0,  P    $ !@
M 1H !0    $   %N 1L !0    $   %V 2@  P    $  @   @$ !     $
M  %^ @( !     $              $@    !    2     $X0DE- _T
M  @          /_A 8!-30 J    "  , 0   P    $$X@   0$  P    $#
MM@   0(  P    ,   "> 08  P    $  @   1(  P    $      14  P
M  $  P   1H !0    $   "D 1L !0    $   "L 2@  P    $  @   3$
M @   !X   "T 3(  @   !0   #2AVD !     $   #H   !(  (  @ "
M \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R
M,#$W.C X.C$W(# Y.C0T.C0Y      20   '    !# R,C&@ 0 #     ?__
M  "@ @ $     0  !*.@ P $     0   X<         !@$#  ,    !  8
M  $:  4    !   !;@$;  4    !   !=@$H  ,    !  (   (!  0    !
M   !?@("  0    !              /      0   \     !_^%*JVAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B
M(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX\>#IX;7!M971A('AM
M;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R
M92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @
M(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO
M<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z
M0W)E871O<E1O;VP^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+WAM
M<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,3<M
M,#<M,314,3@Z,C8Z,3 M,#4Z,# \+WAM<#I#<F5A=&5$871E/@H@(" @(" @
M(" \>&UP.DUE=&%D871A1&%T93XR,#$W+3 X+3$W5# Y.C0T.C0Y*S U.C,P
M/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^
M,C Q-RTP."TQ-U0P.3HT-#HT.2LP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z
M<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B/@H@(" @
M(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.D5#,45!14-%,#$X,T4W
M,3$Y0T8S.49&1#DV-D)!1C)#/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @
M(" \>&UP34TZ1&]C=6UE;G1)1#YA9&]B93ID;V-I9#IP:&]T;W-H;W Z8C@Y
M.39C-60M86,W8RTQ,3=A+3DW8F$M8SDV-#DV8CEC.64Y/"]X;7!-33I$;V-U
M;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM
M<"YD:60Z9&5F-#EA9#4M-6,T9BTT9&0R+6(W9F4M-60T9#DR9F5A,3@U/"]X
M;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T
M;W)Y/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^8W)E871E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F1E9C0Y
M860U+35C-&8M-&1D,BUB-V9E+35D-&0Y,F9E83$X-3PO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C Q-RTP-RTQ
M-%0Q.#HR-CHQ,"TP-3HP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-#(#(P
M,3<@*$UA8VEN=&]S:"D\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F9D,V%F-#5C+64S8S8M-#(X
M.2UB9C9B+35D.&%E.3%E8CAA-SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C Q-RTP-RTQ-%0Q.#HR-CHQ,"TP
M-3HP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-#(#(P,3<@*$UA8VEN=&]S
M:"D\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C$U9C(W9C<W+3$Y9C,M-&-B82UB-31B
M+3(U-S(Q83$X8F1B,#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.G=H96X^,C Q-RTP-RTQ.%0Q-#HR,3HS."TP-3HP,#PO
M<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E
M06=E;G0^061O8F4@4&AO=&]S:&]P($-#(#(P,3<@*$UA8VEN=&]S:"D\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV
M97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G!A<F%M971E<G,^9G)O;2!I;6%G92]P;F<@=&\@:6UA9V4O:G!E9SPO<W1%
M=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^
M8V]N=F5R=&5D(&9R;VT@:6UA9V4O<&YG('1O(&EM86=E+VIP96<\+W-T179T
M.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N
M:6ED.F0Y-S!E9C V+69F8C,M-&5A-BTX8F)C+3DX-C4W-F-E865D,SPO<W1%
M=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^
M,C Q-RTP-RTQ.%0Q-#HR,3HS."TP-3HP,#PO<W1%=G0Z=VAE;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S
M:&]P($-#(#(P,3<@*$UA8VEN=&]S:"D\+W-T179T.G-O9G1W87)E06=E;G0^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H
M86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C-"
M,3-"-#@Q,# X,T4W,3$Y0T8S.49&1#DV-D)!1C)#/"]S=$5V=#II;G-T86YC
M94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$W+3 X+3$W
M5# Y.C,Q.C,R*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7
M:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&EM86=E+VIP96<@=&\@87!P
M;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<#PO<W1%=G0Z<&%R86UE=&5R
M<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R
M;VT@:6UA9V4O:G!E9R!T;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S
M:&]P/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A
M;F-E240^>&UP+FEI9#HS0S$S0C0X,3 P.#-%-S$Q.4-&,SE&1D0Y-C9"048R
M0SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.G=H96X^,C Q-RTP."TQ-U0P.3HS,3HS,BLP-3HS,#PO<W1%=G0Z=VAE;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@
M4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H
M86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D5"
M,45!14-%,#$X,T4W,3$Y0T8S.49&1#DV-D)!1C)#/"]S=$5V=#II;G-T86YC
M94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$W+3 X+3$W
M5# Y.C0T.C0Y*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7
M:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA
M9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R
M<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R
M;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E
M<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A
M;F-E240^>&UP+FEI9#I%0S%%045#13 Q.#-%-S$Q.4-&,SE&1D0Y-C9"048R
M0SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.G=H96X^,C Q-RTP."TQ-U0P.3HT-#HT.2LP-3HS,#PO<W1%=G0Z=VAE;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@
M4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H
M86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @
M/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#I%0C%%045#
M13 Q.#-%-S$Q.4-&,SE&1D0Y-C9"048R0SPO<W12968Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO
M=&]S:&]P.F(X.3DV8S5D+6%C-V,M,3$W82TY-V)A+6,Y-C0Y-F(Y8SEE.3PO
M<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#YX;7 N9&ED.F1E9C0Y860U+35C-&8M-&1D,BUB-V9E+35D
M-&0Y,F9E83$X-3PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @
M(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @
M(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q
M+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M
M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H
M;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @
M(" @(" \<&AO=&]S:&]P.DQE9V%C>4E05$-$:6=E<W0^0T1#1D9!-T1!.$,W
M0D4P.3 U-S W-D%%048P-4,S-$4\+W!H;W1O<VAO<#I,96=A8WE)4%1#1&EG
M97-T/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H
M;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R
M9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 2$!? ,!$0 "
M$0$#$0'_Q  ?  $  00# 0$!            " 4&!PD#! H" 0O_Q !D$  !
M! (! P(# P0(#0L1"0 $ 0(#!08'  @1$@D3%!4A%B(Q%R-!81@9,E%QE['7
M"B0Y6%EV=X&1EJ&XU"4G-SA"57*4M\'P)C-$4E169WB$DK;1TM76X?%'5V)F
M=8*'F*?_Q  = 0$  04! 0$             ! (#!08' 0@)_\0 81$  @$#
M P," P0%!081"00+ 0(#  01!1(A!A,Q(D$'%%$C,F%Q"!6!D? 60J&QP1<D
M,U)RT3555E=B=7>"DY67M;;2T]3A)30V-T-VDM;Q&"8XPB<H1%1S=(.BL]7B
M_]H # ,!  (1 Q$ /P#W\<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4KHV=D!35MA<6I@]?5U0)=E9'ERL@%! !@D*,,)FD5L<(XP\4D
MTTKW(R.-CGN5$15XI7BSTSZNO41K+9G6AU2Y':;CM==]4O3QU-;YZ2\(Z@\&
MVQ1Z QC,.EZQR$W3V&Z=NKM*+&,EH=K=.H(NQ,W9J^YB<;?!D$'D_-9$G<I6
MP,7UCNH%[+/!/FW1C<6=KN[I[UU5=7N/V>:%='NK*;?.H<XVF35;5(ES=#B-
M@8 9A(V%$@1;"Q,"\L\YQ$HZ/%"2'TTJE8DRGUU.I,*LDN@8.C/$8,/Z2\RZ
MB"@L[M<^CCZF<@UEU4;QT"7C/2]:Q9=5+85^Z<;U;2YAJF4RKRNS#GOV0N%R
M^O)B-#4JY,&]2GJTP+/NIO#,QW+T\"6V5^I NBL-R'J"JLAQW7W2/KBSZ9:[
M<U25L8(/9M;9.QO*BJC\GVOJDVYQ,>RV;+F-BN6%CD!8O5*\S4?]L^I]U6["
M R/:UYFN X/KS*/2_P!T;3I]'T-SM+# MA[ U=U.3ZKDV%J+96';3P/8JIE5
M?2?E&Q7(L6*#LQ=-'3UDK2)Y5S)BO:VR=+OJ,[5WCU:6>HKVQZ9\0PR#;&[]
M, Z#/NL_;UCTL.E*(:Q$W!?U[7W>-DX7GRN985P-S1X<$'C=S16@.?93;&-I
MB%*UV]4_4OF>N/5'R"_EZD-CYIB-1U-=-&I*31NJ>IG+]1;=T[)D=!A-1;8H
M3T2YQ1%:RZL=)[(M<E?F^2[4Q2K-RZNJ#+F"BS"E7#YY U><^W\?Q^W\C6)Y
M_4UZLM%KMW.,SV'KC>NR=*V'K!6%3426.U\=IL59T][GU/2X1AN=:WH-SOQ:
M[HR*O()3L"ES#'BLNP_"9:H+&LC\S[^[R)7M3M%]2[KPPW=1N#;/Q+I5N\2P
MKK;Z=^D;,W8#2;8K<DO6]4NG,<VSAV1XK/>YE9U]9)KAN1BTF01V8-G]N7ME
M*KAL/2)D,ZE19SSU=]K]2VHM(XMBV7Z]QG),JT-T/;_W!8Z.R3)*C,->;@R?
MU(=!Z:SK4)QE=FMB;C6/&81?6E?D>$9"V3(B!;.46Y,FIK%X)"E2QS7J:WN_
MT1K_ 'MK:XRW!LSGVCFN+YKGV+WV?;&S;6&F8>MG)M:[:V7C=YL6^V%FLMOA
M6HQK_(@"2;6R'PN(3W<:#IJ+'JFNK%*BV+UE9ETT=2&58)Z>?4=9=:_3?E6/
M]'^*6V5]0F[,^ZH=?:KZE.H#JBQK3\./TVY79'8Y..3DFJ<B.SNZP87*K8/'
MK"G#/BI (CDK'*9Q_'X9_LK,=SZO757C=EDVI,W*Z*=0[&U+LCK"Q3/=Z[AF
MV?B73GL-_2[-J&>GU_KFMCR@[+:39&Q:K;3;&00B^S@^DJ\2M;.GQ'+I"VUP
M2E9 ?ZP&[8>H!,:^QFB;'%(NHNGZ;UZ:::RS8CJ^O!++08FXW]2&-"V4]2.1
MIMQI+@J\:PU<%*3BT2WI64 6OE0L4J(P/KY]30F*3Y9)C72;M%N4=*VN-^U]
M+J0_+YR>GG)MK]1V$:7APWJ-L;W8#*X1=1T63DW6>^]-KU]C:L%B+)P:H22R
MF4K-E/ZMG75L''<$K<$P'I9I\Q)U#UX;+R3,,@FN,WU[FE?T>6.J2*2\P 74
M^Y<J%IA\XK\YM\6N\;LM@Y.5BN5U91BWQP=6E7<*5;N,>K%N)<LRQ^,MT?IF
M3?&[M9>.W^I_/MN7O3_J&K/].C1?4O/C5@%8[&KZ?'+[+[G)S<3Q"BP,S6^,
M6,P-QEMACU_ET]M/=*5+OU$M]YQFWIX],VPZ??>$=/>4;OV%HZPN+JIV7N34
MFH-EU]I0V^47>I$ZG<9QK&-BZ$P[9#06MQO;%P%AI+G#5>/%DBRY'[<RE:L-
M:^HWU*:]H-#Y?@VY[,?7F"Z"]58ZQP/J9V#%U&#;?VKTN08OEN,4F%]1^,Y!
M@*[XP46.S&J=19DHMEERX]3Y\+>VV7&2AV6/*5*3-?6$Z[=5YMHG#LYT[TTG
MV^Q]2Z)Z@"Z2GOY\2;G^&[[S&+%@-8:PR3:6W<+278N ""&65_=U&,[)%NKR
M\QO&&8=CPTT6162E5FT]9_J0J<DZL\9(Q/I@^TVM,2W!DFF,8DRY$HE%U?OW
M =/)8[$VT%M*QQ0-TE5FR6MYC&QJGIUMP<NB Q2K*MJPHW)JY2MO/IW=5%[U
M?=.WY3LJ?C$F64>Q]AZUR:7#Z&WQS'Y+?!KU]>]P==99)G(23(),(P^;&-A;
M!Q9U@TIE1EUBD<\(BE3JXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4
MXI3BE.*4XI3BE.*4XI3BE.*5QOEBC5C9)(V.E=X1M>]K5D?V[^+$545[NWU\
M6]U[?HXIFNF8VJL6%4A[:\Z,X.> ZH,08IAE>3&Z F$H";S:0&1#(^&>.:)\
M,L;W1R(YKE16#C../&?;/TS7F1G;D9\XR,X^N/-8*W)H3I]Z@M-99HS8^+8C
M<ZOM,0O,&LJ>M=75#L6QZ_HB\:LQ\;LZKX<O""EHRRZV ZDFK"Q!9'PP2QQ]
MV\JV/Z1M;+X*C:?5GQMXYS[8S5/<CPQ[B83(<[EPA')#'.%P/.<5=86+:3Q_
M7S\9BJ=;C:VL>XQX!@^-/Q:^)5L,!$URTEBU=W9%O$B4\H]"C#2(4D)?)*WN
ME0AE+F,12%QR4",7'ORN,CCGQ5MKFV6(3M<0+"V LS2QB(Y.!B0ML.3P,'D\
M5C\_0'38S>]5OFWH<1=M4K56(::QI;:Q!DJ8<%PW,[[/<0'Q;$#)EI1;:IR;
M)+8JMOZ>OCMHH)HPH"VC011M\6*1E9UC=D3[[*C%4_RF PO[2*]:XMT>.)YX
M4DE_P,;2HKR\9^S0L&?C_%!XK)IN/Z:O[/+:JQI-975SD@P29W6FUN*V-G?!
MTK6_+DRT.>&8JT&J6^'P7SB.>(!OC['M)VX,4@02&-Q&QPKE&",?H&QM)_ &
M@N+=I7@6>%IXUW/")4,J*?YSQAMZJ?J0 :X[2ITKEH#+"ZK=79-5XP&521FV
M@>)W(&/5]C!$,=4L)+C)'J0SA8X1R@&O'@)@9%%-$^-K&IZ89@P0Q2!VY5"C
M!F'U"D9/[!7BW-LT;RK<0-$A*O*LL9C0KY#N&VJ1[@D8]ZKL(^NPK5N:#P86
M)>9  /3,RV&.C@M;NL$?[@E4V^8UAED -(BO'!0J8>%Z>4437)WYYVY,LO;?
M<F=XVME<>=PQE<>^<57WHMJ/W8]DF!&V]=LF>1L;.&R/&TG/M7,308&7E]?D
M)E+B).?5M;*'57A-=339>!4$+*Z86OLY8770M;.Z2=TL T\8LJOE5[7*Y_>G
M!QNP<>,X.,_3/BJMR[MNY=V,[<C=CZX\X_&J21K'4UN;=G%:]UW9V-S\QAR,
MPC$\:--M?F\ (UM%=D2 23G?,QJJM'L6'OE^-@K08B4DC#@;'Y7N0?H<>?PJ
MM/PC""")#Y,0Q6<LBZJLEE-?05$I$^140D0%'?R$.$=++=4P(\ 55:N>XZN$
MAB&$GAAC8QJO:I<>JM70RD3PZWP&*<N=2BYH\/QZ.4HE;L7)5((D;7(^:=<C
M!"OUFD5TBW88MJKOCAXIV*5@?$.IG2E9GU]HJPJ$U#=4EU:@T]-D%378WC63
MQE'D$S6>/DB>%/(EX45/8.@E="6807-+(R4B295T.V^(>AGJ*XZ6U:.\Z=UA
M;B2/38]:A%K:Z] K;8[K1K\,]E=B7(Q:B=;Q&RC0;D<#H5U\-=?'3-KU=H\E
MCU-HC6\<NJ2Z%.;N[Z>N&3=+::YIQ1+ZR,."#=M UDXPZ7!5T+2%K]?Z_KJ<
M:BJ\)PX&@&MQLB#IJ_&Z46G'OA38[,.]&KQPF!16XUC%#8#6<4+3(38HRXIV
MSL;(F^5SVOHK7V!'1R1&X1B!D4N2IF<L96-4Q$<F8-1C6Y7(R4)[7Y*UL<;4
MO7(MHB1L1"NS6]E*[L^(8J3>291-C=&_*):B2@?DZ503,D^1S/662H9?1PMM
MHZYTSEF^#C,; DR^\UB2HC^*5%;170/TS].^7YGGF XIDUIEF=8T7A%Q<[+V
M/G^VBA\%/ORLHL<*IW;'R/)DJ\:M,A+DMK<$9$?<EQB.MIS6@!,'4J3L&O\
M Q8*T4;"<1'%IJ2QQJG&@QNFA@JL<MT@2VH*V&,)L8-):(,,EC5"MB!-0>!"
M8)?:C\5*ZTFL];RU)]#+K["):.UEJY[2FDQ2A?4V4]&&#7TDQ]<X!0S):<"L
MK0:N0B&1]>'7@C"+#"(.R-2KAN*&CR*H,Q_(*:IO*&P'^$/I+BN#LZ@X7NU?
MAC*TV&<,D?NQJ^S-"^/NUOW?HG92J'8:YU[;5=/1VN"8;9TN/0S#4%188Q2&
MU=&.37S5)$%/7D@R"5D,]401631!10,EKYY@WM<-*^-RE=XC#<0+FQP@K%<;
M)(PYWGB,Y%'6338L_P"&:%Y8Y+(*Y]&[X-C1/*L<*OPS6P=_:1&(I7RS"L-C
M-R&S9B6,LLLM'C$RNP90U33<F%B@<-$-D):")/=#Q#N</'#92$QL@<Z)K4C5
M6\4JI4E'28U5!46.4]704E;%[%=3TE>)550$'DY_LA5X,, @L7F][_;@AC9Y
M.<[MW<JJI54XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7"X@=LS!W3PM(D:
MKV0.E8DSV-[]WLB5WFYJ=E[N1JHG9>Z_1>>X.,X. <9QQGZ9\9KPLH(!8 GD
M D G\AYJTB=BX$(XN.?,<;2<&%Y!(L=P#.9'#&Y&/>T.":0J7L]4C1L,,CW2
M*D;6J]4;R_\ *W("$V\P$AQ&S1NJN?\ 8LP /[_'-0CJFFKWP;^SS;+ON%%S
M"6A7ZR*'+(/ ]0') \FL8V_5%H^GB+2;.JN>T#3N_'(Y&#9'(U4<L4D-19O
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MAWDPB1Q3Q0<SRVFEN+C(N5.6[ 5@=A_FJP9/4!_.)8'GG&.=<FZRZI@.F?\
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MB"TN;ES'!"\CCRH&"/SSC'Y'DU!O-3T^PB$UY=P6\39VN[C#8P#M R2!D;B
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ML@R"JK0;)EM8I9Y@<1$BK.P\L,4>$*!;<9DKRV0RRE2S5(DC&-F5 R8UC8V
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MJB2I9X"7CP#68XJ!5]78'QM\A(_C9(QR96J0CY4(@]DN;.*.!UD+DR*'PH!
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M\D:TD62&2!G<LL3HP6)$5>V6C<[EF;,@"CDG!KO9+OS.,ILJ/+H3;X?,QFF
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MI/@9K9U&&^4E.U$Z+$-0C*QB1=LFS@[1*V68#(+<G[Q-7[ +U'OS.JRR_P
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M(W8\A3DYY YS7!/B$EM'U1?7+A^X+>S7TRHJD_+H(T!*[HA(<*Q#!6(!8G
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MGB;,C8!&MC29$1&-BC[C-B5K._WV(G=/HU$\7.=W?2-4$RAEED]0&YU  /'
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MV*Q31H]%<IR,D4@%?)/)T2S->CY5;&O=(5>B/>QPZJO&T]E28FV[QEMQP2&
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M+=C EB&QRF932>F.LKN*T2?J#4K:QU Q2P_+:A>3J]XS:5$B,KSVUO)(L%[
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M="9'!%(&V+S@A>$.9-Y31N>2B##\R1*R@3+W)' ^VP%2-5SA0FWZ9P??!.,
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MV1&JJ_?_ $+^]RW)-%",RRQQ ^#(ZH/WL0*C75[9V,9FO;NVLXAR9;J>*WC
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MM@RP4C#,%#>DFM(NJ]Y:[ZOZS(,HN,WRO/K\'),$Q')\IM,<L,G2B+V(W*I
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M+4V^( HC/@AF.E(<N.""Q>U*Z0EJ)X)AM5U]M-N8K*1(S?3!76T61=T<9_\
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M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5!;T\/]@"Z_N\]1/\
MRQY?S3NAO]!9O]N]?_YWNZ^A/TF?_6/I_P#N<_##_H+H=3IYN-?/=.*4XI3B
ME.*5\O\ W#O^"[^1>*5IV]!'^I=:*_M[ZG/\Z3<G%>#W_/\ L%;B^*]IQ2G%
M*<4IQ2G%*<4IQ2G%*U?^F_OG7>ZLO]003 R;XF?#.N#-P<F9<XO?XY\KMY-=
M:UI9Z21UV $TBVKC\6LVV8@BD?!P25I4DGPUH#+.I6T#BE0B]2!$7H?ZB$7L
MJ+A@B*B]E3LN347?NB_14_A^G%*FE\ #_P!Q"?\ %H?_ &.*4^ !_P"XA/\
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MO;3J<-9W,*V&L0;EFM5D$L$IC^^UO*.#C!)C)+  E6=02)3>I!].B#J(7_\
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M.(6LU9DA&)8]*F>XB,'FC6[5/TM+D,*6^1!3XQB4V>U-W0U^49/#5 6EA3V
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MX<UVO=MV$8\\<_R^QWWM"6OF]MR.]DB(>_&FEA?V\7L6=%<U517<L?JVQ/\
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ME:5W)FF0YS/CNR\MS'&KG6MIF5[/?Y)50"5&.Y0%D5#'9GV)U86"34V+F31
M&U[I(I+4CK73OQ3U#1=&71Y%EDA@A,-OVY=F4W>E&&P[0 S>I3G@#!SD<"ZT
M^ O3_5?49ZC'9ANKJ=9;WNVL4^XJGJE0L5S(S)&-L@D49+@@C:=Y'2YZ;^DM
M-=).F^F3=F)ZYZFYM7IE]O/D^T-<8WDPDN6;"RFVS#+CL<JLJ%OWT($UC;N
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MQ2G%*<4IQ2G%*<4IQ2J-?8YCV55I%+E%#39)3EM5A53?58-Q6DL7\6D V$!
MLS5_2V2)R+^]QC/!Y%>$ C! (^A&1^XU!;T\]3ZLQ#2AM[B>M-?XO=D;TZL0
MI[G'<-QVEM9PJWJJW+6UPDUA6UHQ<@M?7!!@!#OF=$*$(,+ R.""*-GFT Y
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M2M/6T^J[<6T8+ C%LE+U?B,JJVMJ<=E@AR28=BO\";/)&1_,8BIT5KI!ZB4
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M:)T) \T$<L,T,K'1RPRPR-<R2*2-ZL>QZ.8]BN:J=E7G1M,Z;AM54]L# 'D
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MO]/4[[5KA;J9]UR MG ;6X,MVQ%M$B&1W6,JS4KJ-F^2DI?$:.6$4O\ /V;
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M4R>E#Z:5I/\ ]?S?_P!,KSGZG=&?^B'2O_NYHG_-EM7#M1_T0OO_ .<N?_\
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MIQ2G%*<4IQ2NC9!H<',,J]O<8YJ*GZT5.6Y%WH0/X_C^ :KC?8ZM]#6LK?\
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JXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g486549g16o08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g486549g16o08.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[11:4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &8< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP!6@ #&R5'
M' %:  ,;)4<< 5H  QLE1QP"   "   < @4 (C(P,3<M,#@M,3$@1V5N<')E
M>"!2)D0@4&EP96QI;F5?5C4X0DE-!"4      ! RPV)4+J_5MJR'_XWB!HT-
M.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
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M;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6)
M;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M        0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M            4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O
M;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2
M;'0               !4;W @56YT1B-2;'0               !38VP@56YT
M1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O
M<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M  UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M   X0DE- ^T      ! #P     $  0/      0 !.$))300F       .
M         #^    X0DE-! T       0   !:.$))3009       $    'CA"
M24T#\P      "0           0 X0DE-)Q        H  0         !.$))
M30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       !
M #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M  !P  #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@  #A"24T$"       $     $   )
M   "0      X0DE-!!X       0     .$))300:      ,U    !@
M       #?P  "=H          0                         !
M      G:   #?P                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   #?P    !29VAT;&]N9P  "=H    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   W\
M4F=H=&QO;F<   G:     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3001       ! 0 X0DE-
M!!0       0    &.$))300,      F-     0   *     Y   !X   :N
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M(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\
M<    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@
M  $ .$))300B      %^34T *@    @ # $   ,    !# 4   $!  ,    !
M!>4   $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,
M   !  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q
M  (    >    M $R  (    4    TH=I  0    !    Z    2  "  (  @
M/0D    G$  ]"0   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD
M,C Q-SHP.3HP-2 P-SHR-3HP,P     $D   !P    0P,C(QH $  P    '_
M_P  H ( !     $   G:H , !     $   -_          8! P #     0 &
M   !&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $
M 0   7X" @ $     0              2     $   !(     3A"24T#_0
M    "      !    _^$!@$U- "H    (  P!   #     0P%   ! 0 #
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M__\  * "  0    !   )VJ #  0    !   #?P         & 0,  P    $
M!@   1H !0    $   %N 1L !0    $   %V 2@  P    $  @   @$ !
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M0!XVQ@K%EK8<2FLA%3:1N@@QS#46)0,;>YL[$!:_8\<\.EIMFI&QL;3['#6
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MLEOO,?XL=]\P\5$I^<&O_2VG1I]KJ]WD?"CK7>R6^\Q_BQWWS#Q42GYP:_\
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M&#;!3NS*2QM"SOQ=40 6-?9U62LJEME@+758Y16()0\T>FO8,VW!$8 =/E@
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M=,Q":F-H0=%,O' CD;"B+:9Q+9.MC.*ARUL6M&< NO$W*O,HW45*G;DHX;*
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MJKQY4*ZQ6;M)H]> X^8</HVN)DB2[\"705&+(ZIQ-)=L=^M2S55U5U$W5/\
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MRKWMJ7DVP;>]@_>&V'#C7>S5MPW9*^@G&LMLR]T,Y':@A>L]+1DC"W<W)QZ
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MEF1?A7:ZH8@P=9Q-J^R[6N[CK5)N_8(H.W0^P:+:J+6MZUK5CO54*^HJK;Q
MJR.*L '4CJ$>.S^().S0VN5,[.V.UALR4MN-IK=GI)Y78^[*=T8;U#R!J\&
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M4EL/I]?J]?EY;[#\OXO#RG36Q(Q25V>K\O\ 1.[#[&W[^_25RO[_  _I]_\
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M?3;X;?CM6=C]!_-&Q^@_FG/'[*W]?Z*Q(-]Z?R?KG=6=C]!_,95L?H/YC%9
M.X\#YCU3(!W'@?,>J*NF-C]!_,8I&Q^@_F,ITV^&WXZ3!\C]/C*TE&Q^@_F,
M4F-C]8_']?X_&5MZ]OCM^FDQX_\ VV_V>K]MSX3NZ;?#:DS'3;X;?CM2(O\
M8W^*_P"BLCS'XQ^N1(]#;ZA^W[?S^4XHWMUU_#_HW^#X;?#\7_E5C^7Y?Z#*
MO']M_P!O7_/+GIM?U[V_';[_ ,?[_!ZU51Y?T_S?B_5^?SG36Q,13?;SE;CR
M_+.W&_1:UKWM:_P7\%Z2N<NFWPV_'^_12)]1G4+.I5$97)0W-+D?#G3"(Q9X
M@0T#!9.,7;*RZ1H=8X;[3*#7R:>647C^?8E(1BJEG@?/XWD&%TAH(=D=\O[<
M]JUJJLT33;@;;1QU"^I@>E7[*C*=NI9_S^Q]!/F_%G;AZSV![(M;8FN:I0RU
MU'EIV/<A'5?;<9;HWCTT\.AN/3?YT>BB%_L-KQ^>SQ2(I$4B*1%(BD12(I$4
MB*1)'UY[.4\DU^FO2)=;#]@%^5=?00I$BZD12(I$4B*1%(BD12(I$4B*1%(B
MD12(I$V8I$4B*1%(BD12(I$4B*1%(BD37?E5Q:TWS+T=,^/V]8W:10.9M,<<
ME&RF#0[&CC2V>827Q0IDDOD(D\?=Y]MBWUD5T,_^V8$FA 0^(#G<E=T/)'9&
MVVY(Q5MCYC=2#(LB..+JKKOOLRAAN/([$$;B?.CU)3J6$YX"\A^=FJ=YQ2/[
M)@I1OH(UHO:Y2,," &>1"S[=Z3U=DB31(8Q^6B>O$LIU%\7"BXM]D/<I."0$
ME'S!*:Y.4"=\G(/EM\]9]?\ VI7W;& &V/1Z]_FJ]_5_V?R_[9^ZWJ-ZA\56
MM_F-&/V74N]9/M%_O;/M1W?'_P"@I]TGV8]1O4/BJUO\QHQ^RZ=ZR?:+_>V?
M:CNV/_T%/ND^S'J-ZA\56M_F/&/V73O63[1?[VS[4=VQ_P#H*?=)]F/4;U#X
MJM;_ #'C'[+IWK)]HO\ >V?:F.[8WL]'NJ_LROJ.:B\5>N/F/&?V73O63[1?
M[VS[4=UQO9Z/=5_9CU'=1>*S7'S'C/[+IWK)]HO][9]J.ZXWL]'NJ_LQZCNH
MO%9KCYCQG]ET[UD^T7^]L^U'=<;V>CW5?V8]1W47BLUQ\QXS^RZ=ZR?:+_?6
M?:CNN-[/1[JO[,>H[J+Q6:X^8\9_9=9[UE>TY'OK/M1W7&]GH]U7]F/4<U%X
MJ]<?,>,_LNG>LKVG(]]9]J.ZXWL]'NJ_LQZCFHO%7KCYCQG]ET[WE>TY'OK/
MM1W7&]GH]U7]F/4<U%XJ]<?,>,_LNL=ZRO:;_?6?:CNN-[/1[JO[,IZCFH?%
M7K?YCQC]EUGO>5[3D>^L^U'=<;V>CW-?V97U'-1>*O7'S'C/[+IWO*]IR/?6
M?:F.Z8OLV/[FO[,SN!:6TXN_>V6U-K-:V+3&^-E8'%E+8W[-A;IM;,5?HOT>
M#IM[U.]Y7M.1[ZS[4=TQ?9L?W-?V9;3G2^G43"6".I]:(X=H(9=:E!(LGCTW
M6<6O?K<!5K=/1:UNGHZ>BUK>]3O>4?/)R/?6?:F>ZXWL]'N:_LS#?4=U%XK-
M<?,>,_LNL=ZR?:;_ 'UGVICNF+[-C^YK^S'J.ZC\5FN/F1&?V96>]Y7M.1[Z
MS[4SW7%]FH]S7]F/4=U%XK-<?,>,_LNG>\KVG(]]9]J.ZXWL]'N:_LQZCNHO
M%9KCYCQG]ET[WE>TY'OK/M3'=,7V;']S7]F/4=U%XK-<?,>,_LNG>\KVG(]]
M9]J.Z8OLV/[FO[,>H[J+Q6:X^8\9_9=.]Y7M.1[ZS[4=TQ?9L?W-?V97U'M1
M^*S7/S(C/[,IWO*]IR/?6?:CNF+[-C^YK^S'J.ZC\5FN?F1&?V93O>5[3D>^
ML^U'=,7V;']S7]F/4>U)XK=<_,B,_LRG>\KVG(]]9]J.Z8OLV/[FO[,IZCNH
M[>MJS7'S(C/[,IWO*]IR/?6?:CNF+[-C^YK^S*^H]J3Q6ZY^9$9_9E.]Y7M.
M1[ZS[4=TQ?9L?W-?V8]1[4GBMUS\R(S^S*=[RO:<CWUGVH[IB^S8_N:_LQZC
MVI/%;KGYD1G]F5GOF9[5D^_M^U'=,7V;']S7]F/4>U)XK=<_,B,_LRG?,SVO
M)]_;]J.Z8OLV/[FO[,DV Z6TXNW(W6U-K-:^*R%L;JP.+*7QM=-3IM:^8J_1
MT^_T4[YE^U9/O[?M3'<\0^>+C>XJ^S+&?:7TZ@Z'61U/K1&V3=:^5DH)%D[9
M7LICT7O; 5;IZ/>Z:QWS+/GE9'O[?M1W/#]DQO<5?9F >H]J3Q6ZY^9$9_9E
M.]Y7M.1[ZS[4=SP_9,;W%7V9V(ZDU2V62<-]9:]0704P5171AD<26153RMDF
MHDI@-QS34PRM;+#/#*V6.5K7M>U[4.5E$$')R"#X$&ZP@@^8(Y3(P\0$$8N.
M"#N"**@01Y$'CX$20K6Z/!;P6MX+6M[U:\V(I$4B*1%(BD12(I$4B*1%(BD2
M1]>>SE/)-?IKTB76P_8!?E77T$*1(NI$4B*1%(BD12(I$4B*1%(BD12(I$4B
M*1-F*1%(BD12(I$4B*1%(BD12(I$4B1AL3V03_,>_2:TB1M2(I$4B*1%(BD1
M2(I$4B*1%(BD12(I$D#7ON@_^1X^>PI$M9[[M)?@]#SSFD3":1%(BD12(I$4
MB*1%(BD12(I$4B*1%(DIZ\]K$_+M_-J4B6&P_;0WY.OYS"D2.Z1%(BD12(I$
M4B*1%(BD12(I$4B*1%(DCZ\]G*>2:_37I$NMA^P"_*NOH(4B1=2(I$4B*1%(
MBD12(I$4B*1%(BD12(I$4B;,4B*1%(BD12(I$4B*1%(BD12(I$UG-;?UM-]@
M336<2EPF0S;3W<%#9@06M=VK#7\U8*EXX)-.$L<FK8R]$#\RJ@GLUR#(<[&/
M'K=!$FQR7N>BZNJFYZV2N_F:68;"P5D*[+ZRH8\>7D2" 20=H*Z,SHK LFW,
M#^26W(!^O8;[?BBJ9.*1%(BD12(I$4B*1%(BD12(I$4B*1) U[[H/_D>/GL*
M1+6>^[27X/0\\YI$PFD12(I$4B*1%(BD12(I$4B*1%(BD12)*>O/:Q/R[?S:
ME(EAL/VT-^3K^<PI$CND12(I$4B*1%(BD12(I$4B*1%(BD12)(^O/9RGDFOT
MUZ1+K8?L ORKKZ"%(D74B*1%(BD12(I$4B*1%(BD12(I$4B*1%(FS%(BD12(
MI$4B*1%(BD12(I$4B?EGU8OF7LG@YPEEVU].L!"VT)/)@>K(2;.VLX%PHQ+Q
MYUUE-51639RB<=@& -ZJ($N\<1RYI4<L4P>#&[L<\^P[#]F/[+==32S<E*)C
M79EA?F!970U2FH,BLR%S:-VV\%!VV8@SYWM/KJ=GM+;/>JRWE=7C*M?'DKVJ
MY#[.5!"\#X;^9$^0'J27508QP/#\CUN0(+:&YISOS9 38A"7 "(DF2>E&S$S
M@>(2<E+3(Y^_,%R1;)\J[M=SDOGDLHNK93*ULO:>T'W'-7U8X7=-1TK&JQ*&
MJ%;+E !6*%0@2@@*H7;Q/XIYO@?=1TS#%_5P-1M>VP.6!Q]]P""26NW)),_8
M2WU2+QBZ>B^AM\6^#_+U]?I_%+/O7_>]?/#[@7:$G;Y;T;?_ !<W\O\ >_[?
M5-T_=@T8';Y+U/?\>-_3<)R_A(G&+Q#;X_Y]?>EM2_X .T6_\=Z+M].V=_5O
MV^F0;[L>BH-SI6I^>WGB_&E+_5(G&*W3?U!M\>#_ /?7W]?_ 'L_?[U9'[G_
M +1';^W>B^/U9Q^C_P V^N1_X9=%VW^2M3\-_P"5B_1OZ[A_NC^$B<8O?T-O
MBW3?H^SU]_A+:RO[G[M$QV^7-%\M_+.]7GYXPE+?=LT-1N=)U7;ZCB?TW"/X
M2+QB\0V^??\ ]/7OO?\ ^M_]_O5/_B]]H_PWHO\ ^G._JW[>,C_PW:%OM\D:
MMX'8^.)\?R\_S>,[/X2#QCMZ^A][_P#/K[TLJ0_<]=HSX_+FB?FS_P"K3+_=
MLT.M>1TC5=O\;#'Y?X><;_5(7&*W^H?>_P#SZ_\ 2S]^B_OU8O[G3M*PW&NZ
M'M]8S_ZK*3]W/00"?D?5O#?^5A^KS_Y_]CX3A_"1N,'B'WQ_S:_]+*L_XN':
MC\.:%_\ '_U6:O\ P_=G/P-K/Y\+^L3EC]4B<8<NGHT/OCP='^EK[W_CEMJD
M/W-_:<^>O:$/R:@?U8OT>,FGW>^SSD@:-K'A])P_Z,@RO\)#XP^(??/_ #:^
M]+JD/W-G:<@'Y?T'\VH?U3Z9"S[OW9VOCOHNM'DO(%3@^7EZ\D1_"0^,/1T^
MH/OGHMZ_^5K[TN_?_P JD/W-?:@G;Y?T'\VH?U24M^Z$[-J-SHFM^KP'<-_'
M_O6W\\?PD/C#XA]\_CU]Z75(?N:.U1_\?]G]_5_&/]3D/^,1V9_ FN?_  /]
M:FQO&/JY7$;DALX%J=R'V)J"22U\V$Q$EL1G'.]8X=>JXMV$?R-@) 6R$EB;
MC/!N+[JLFHMXYRP9]U$GR[-JZ^<[5?<&[8]F=*OUA;M-UG%Q*VNS*]-?)[WC
MXZ L^1T,G&IZM-:@M;TG>U%]/I%%=U^B[,_=K[*=H]2ITLU9^DY.2ZU8KZBN
M.,:^YB E'6HOM%5MC'C4+51+&V0/S95;]GJ\1GL$D#7ON@_^1X^>PI$M9[[M
M)?@]#SSFD3":1%(BD12(I$4B*1%(BD12(I$4B*1%(DIZ\]K$_+M_-J4B6&P_
M;0WY.OYS"D2.Z1%(BD12(I$4B*1%(BD12(I$4B*1%(DCZ\]G*>2:_37I$NMA
M^P"_*NOH(4B1=2(I$4B*1%(BD12(I$4B*1%(BD12(I$4B;,4B*1%(BD12(I$
M4B*1%(BD12)\^_U2I_)WA/Z1VM?[K;'KU_[B7]V;_P"9L[_78D\Y^ZC_ ',K
M_G+$_P!7D3X'Z_8 \A^(?JGYN/F?QG]<[+?98_S?_7\7[VZ*FOWP_;U368>D
M?R?2#X\OS_L9V5=*;_O1_C#]1_;_ &>NE_6O\5ZL4^ !\@=]_#P_;Q_$/'?:
M4#P7?8>1W)\/I]?U>'X_5Y2F=^BUK_!>W^-*_OOR'ZIHV>*[?7_09Q\-KW]:
MU^GU_P#U][IZ/#?P=%O7Z/#X+@/'SV\/#;?SV\O5X^OZ/SRAOOCXGS/YP?R?
M3ZCX[[#P\)=9^M^_[_>_KJY?(?B]7XOV_)+,C^"(W]:^9\_V'E_LG5?WOWZ?
M#?P^_P"O][IM6W5OP^O<_7^*:)^\;?Z&_+X$[^._X_#<>N6U;LX<[D?7R^+^
MOUK_ -7X_!61_L_6/R_F\9?C_?G_ !?_ *E_+^;QG._O?%;]_P!_?_'5J>7[
M?M_N_-*<C_FO_1+^W[>K\T7^PO\ '_A5B??#\OZC-&[[P_C$I5X\Q^,34ERB
MIFEDFJEGFDHGGBHFHGG?%1-3#+KL,\,\;VRQSPRM;+'+&]LL<K6O:]KVJXA6
M!! *L"""-P0? @@^>_B"#^631BI#*2K*RLK [$,#N#N/$;;;@@[@^7G/N0ZC
M;U1G#EOJG'3NU#>"O(C4@9NF]>/E\>W=GP-ID@P'3=.ZG0HY/BLU6@>:XV[*
MHL\4&R+)6]S[AJ/_  5]VO[FA[':P=9TF@CLWK%S-6E:^AI>>X9[, @>"X]H
M#W81\ $%N. .[JUG[:^Y%]T$=K-*^2M3N![0:54HM9V]/4<-=DKS1OL6NK)6
MK,&V_,UW?\\53][]>^Z#_P"1X^>PKPV>QRUGONTE^#T//.:1,)I$4B*1%(BD
M12(I$4B*1%(BD12(I$4B2GKSVL3\NW\VI2)8;#]M#?DZ_G,*1([I$4B*1%(B
MD12(I$4B*1%(BD12(I$4B2/KSV<IY)K]->D2ZV'[ +\JZ^@A2)%U(BD12(I$
M4B*1%(BD12(I$4B*1%(BD12)LQ2(I$_('7_)G?Q"+\:^1)G: @T(Y$\E,=*%
M^,^$,BC(? P1B8SF*9M(Y)VC5+8[C9.J&L63/[(5DA@P">HA)HDA%XRA@P<#
M?3,W0=&3(U[1*M/LJMT/03JU>O'*R7LS+JL7$R0UU#-W!<#4FR>A@"BFNY3;
MB$Y%[%Q9YUB:YJ[4:)K%F=7=7K.NC2[-$7&H1,2FW)RL;C3<J]];.TY<?K9Y
MOMLI<5906C'4(4]J+]5'P.1N#EB?'N1 S6Y8+HV;Z. WV)&7Z$Q1WMLU'4\>
M8RT[B-:,=>=S9&Y:DWKMRD?LM&W**K=OWS9=ZM59'W/33D9E2:U1;5I67K&)
MJ]W<LA#BMHVGG4KVQJ>;/FBRA6K0 T[7J0QZ'[XF<?M^MU&)8^CWU6ZIB:3E
MZ35WRAQE#5\\:=0F3:$"812]E=V/6!I8%=[OF#*TLYVEH'+2,9ENCGS1'7JV
MAV&\"@K8\=+=XI3D9L4KK?7B,-&7%LG^SV21$:D5D3IMA&'C$:^P:"Q9N1,2
MP-ASL;LA7FXU>1C:LC'-&L/I-=F#?7WNO0\&O/SCE6<W33V*6&NA6.0CV)RL
MLIH>NY^ED]K+,/(>C(TIE&&=)35;$S:+.Z/K6;9@X8QDZ:OG*'K%ES 4,B/Q
M1++DLJ6)WO53606&ISX_H&2-HY)8IMR3:RL'V%$SAB9*Z0V['=0SD.6&8-66
M$,<+%9,Q*1IZ0>/QQ%JDY8&'$=+=KLW'27[GEEN4<.G6<=K\?)TS'S^KA9-5
M6*-6TR_4\.VNS=SE**Z'KR$1$LK8J]2WU;N.>W;^NK%&9=I&0M%^/J-^"*\O
M&MNRCI6I4:;EUO6 HQF-F0EE#/8R.H9+319LAD^-\ZIO)MKRG43'B_.,CL')
MO83,2Z4@7>1&,;/3T_AN4;'SLT:0Q6&#HF_$/@$96F"TCL2:2H\UNE#'T525
ME-<V_LCB4:=CZD^OX@IRZUR\6LTA<G(T\ZH=*>ZG%;*&4^2EJ79 Q5H*-CTN
M#E)D;8\Z%/:K*OU"_3DT+*-N+8V+DVK<6QZ,_P"31J:4VY"XQQDQVK>F@Y+7
M!QD6C;&;''7,G<6.948Y6:FF6[XA"I&*@$7>NQ3%*SL;+9M(#$>C+ U-!S2&
MPO,XY37$E7N4?C3=N^($)[VNE(8ZPSC9N,$CFCVA[+Y'9S4L72<K*HLS<A$M
M<\7Q\2FJ^]ZL5VRLH4J194@NO+(B8?(T7N+Z<BNG=[/]IL?M#IV3JN-C75X=
M#M4HY)D9-MM-"6Y2+C8QM8&NQS32 SOE\1?0IHMH>W+>,G)D7R6!2\N/U_LF
M!J1&=SV'JHSN"3:*,R;>([%FL&8O19.61F.-R!9PWB%G\LC3#%V_@!DAE%CR
MMR#.ZR^MK^@6:#=BU/FX&8,G#P\H'#S,3):LY.#BY;I97C9%[)6K9/#'O?BF
M94G>*1P8 ;&A:[7KM.1;7AYV)W?+R\8C,Q,G&5QC9F3BJU;Y%-(=R,?E?2G)
M\6QNA=LZ^.SE<"=V*1/GW^J5/Y.\)_2.UK_=;8]>O_<2_NS?_,V=_KL2><_=
M1_N97_.6)_J\B?%?H?B[LKD;&]UG=9V$DB.DH*TV 5B:[K-"22T0J:;BWS"$
MM.PY(FI -9*.SN0.RZ) F-&/D J)$M=H-=?J35M?P=$MTFK.ZB)JN4<.O("[
MTX]@J-B/E-OO72[!:NKL4K=U:TI7R=? M/TC*U1-0?$X,^!C]Z>DG:RZOJK6
MRT#;9[5#&SI[AG56"<GXJ?8EW#G?<=5,N@4"DNP8U&-=ZQV-)9A"8X=*1L$*
MV9I:)[U08/GV3!/_ .)16$2U![*TD<5<!34:1,JYV!)8$<\8G:?1[C2+LS'P
MK[\[/P:,;*OI2^VS U/)TEG50YVKORL<KCDD&PNE8^=)K$+] U.MK'IQ;\NB
MK$P\N[(HJ=ZJDR\&K4 K-Q'IU47J;0H/#BSGYO9I'FP-!;MU2 !2K96JIY!8
MW)ETFH W*(T3#CBKE<0QD#5!JY>-TD\E7H(DP-,$\KXYOQ+I(BSLNSOV:W3P
MM:TG4KKL? U'#S+\<%KJL>^NUZU%C4LS*I) 6U&J<_R;%*-LWA.?J.E:E@T4
MW9F#E8U5S@5/=2Z*Y-?4 4D>;(P=1_*4\EW'C)@D7#F9QK4.LMF$96#4.;E$
M1XYJ_6XZ)[8*F)LSE$H5B0H0 FP[7CG5#V:V>H.2!"&XSS$H,&MEVSW)*487
MC5<['[4XMVI9V F-:*=+MOJS\ZS)TZNO$./CC(MMMQ'SEU%<3BP1,GN9K>Q@
MR@T'KS;L[.9-6G8F8]]?4SZJK,/$KHSK'R!?<::Z:\E,9L,Y)8%FQ^\<U"\6
M/4!JF)2GAURKA@=V>EG'?<$?#,;C^VR)2!R%JV;Y$Y)A#6F"F2C'I[+:8+-H
MH[1MC=0?)7K $0P:E'[)JOMXG:?L[E6K3CZWI=UK]0*E>90S'I4]Z<@!_5C*
MV0I/@]"M<A:M&=>5E=FM?QZ6MOT?4*ZTZ99FQK  +;>@F_AN";B*3_@6LJ/Q
M9E!EC6?4]]]3MX1&R,=AJ<HRD>LP30=L0:=&KFFFTA&XRH61!\F@QXB_!L5]
M*2P(3=(*YY(G+6&XX9.AY5-CIY_;;1L2M+*+#J53X^H7-9@V4V+4^G6:77;1
M9SL0K<PU7%M12-C5Z?@K5%]G%['ZKDVV4Y%?R?8+\.M4S$M1K%SJ\]ZKJRJL
M'J4Z;<CL"?G/1V+(X$5ZTX\X377+_;DVVMK_ $QKE*;XZT!R*<LM@&U)1/<0
M2,E(!Q ;6\*FYI,?' CT21DYU^Q:,1J1P,W9V*$'^#''KY^N]TSZ]+Q--S=5
MSCA?*%M&(V#4,?"ZQQZ[;;<_+PZ2]]RV)CTUNSN:;6;IHG.:5&CC*T]L_+U#
M%TW#&4,*J_*7*L-V4*UN:NNO$HR+ E-;(]MK*%06(!S9N,]?7/#?>&PW4==6
MB1B,P>7 ]A'8OLR1@)"R@QYOK_6VP-GWP'D[B;+YWE8/6LG1B2CAHWP,N&#U
M1&_:PHNJQEF=KM&T^NY.]59.;BWX-.3I^/=0^90<[4,+3M[*^J!^];L_'[R%
M9ND&4'TK*@].'V7U;,",,:VC"R*,V['U"ZBY,2],/"RLTBNSIACWBK#M%!95
MY[$^*H^U2O$.9B=D[GUFM)HPH4TGI3/>!Y^E<KW/+1_")0V7W$"+Y#L7'=B[
M*:L&MK/$&S+MIJ[Z75DK(J*[5/:S$MT[2-2&-D"O6-8&C4H>GSJO.7E8G5MV
M?CTN6([>@6?BR^AON!RK.RV37J.KZ><F@OI&E-JUM@%G&VE<?&R376.&_5*Y
M*J.05.2MNP&Q,2QC1NXY:U#/8OK&;2!I)0R\AC[D5'23Y$R#9S5EKET6'*-T
M,\78]O/B0^'K.4;YI82)XV$Y96>+8)7Z]VMZ/B/<F3J6'0V-<N/>ME]:-3>^
M&^>M3AB.-C85=F2JGQZ*-9]ZIFAA:/JM_2MIT_*LKR:&OHL2EF%M*Y28365G
M;9D&58F.6'@+F5=]Y(*W#KE4A(<8HMQZVZC)+QEY,+AE8,>P?81L<>[U'Q15
M+)G:Z*;65WPBRR"U\'>$F6;1[M?NPY;LE-5.U_9?NPRAK^E''[RF'UAFTE.\
MV4]Y2H'EXEL8'(!&Z&@-?RZ09Q=D=E.TQOKQ?D+5!>N&<DUG$LY=W2SHM;X#
M8!;2*2I(?JE:^/48*>K7_&B92D_MT5.2@G28C0#%5YNJ0[+'R=&T"=XS 7 &
MT:<QJ-@3\M)3$E,2[4$SC@\(JX362(/BJPL0)*$FEN;VEP\6G2+L*JW6;=><
M)H^/ISXY[\AQ+,ULE<C(NHQ:L2O$K:Y\BRX @UI4MEMM=;:>+V<R\J[5*LVZ
MK1ZM$KYZM?J"7_O-N\IB+C]"BJW(LRK,AQ6M"5D[JSN:ZZW=?)=\=-DOV$PE
M6M@Q3<.KX<30&O-L0"+S*\,<YN, ?^7AC)XY')"SR8N)*#'&$R8-G<41)L47
M&78"(QT^VT[1:979B8NI7U:/J>74UJ:5GY.(,Q54W#SQK\BAPZX]UE1KN?JU
MUNRC>NQ4TV[-:G:F5DZ91;K&FXMU=+:G@8V4<5FL%7$;7TTWH5:^JMP]2\+&
M )V9&;)W7#'EB-D+.)$>.VW1\C>C)"91$OH0<:.<!<4*L0<E?.[N&B:3! $9
M+!A93)\HVNS?G 35:V"QL5@\BG;3LG9COEU]HM)LQTNHH:U,VEUZN579?CHG
M%B7-U-5ME7 -RKIN8>%-O"YNQW:JO(3%?L_JB9-E=UZU-BV(>CC65U7N^X 1
M:K;*JWYE=GNI'G;7RDKC[K7FYH_9.IMVZ<TWN%A,FDK=6@#EC I,[M)B0MC)
M7)N,J"D&=G)<>9 Q6;L2(G)*V)L0"EC=IV?N03NTY7:/4.P^OZ9J^A:SK&D6
MX5F(GR@CYV.IQ:[+,=:,H6LY6FVC(R<*RJT'>FV[%+;=5.?4T'3^V6AZCI>M
MZ3I.JUY*93#"=<.\KDV5)>U^,:^.]M=U%&4EE6VUM5=X7?IN5_H$\#^2T8Y3
MZSPV$'8.(S*!F;N'[3UT4RO:0:QV='ET&TLA)Q#/!)?!8<\RLN-=+H-\R85T
M.(W;MLW*C9#^??:_LME]DM9MTR]UR<6RM,S2M1J'[WU32\C=L3-H8;J18@XV
MJK,*KTLKY,%#']R=E^T6-VGTFK4*4;'R$=\74<"PCKZ=J-&PRL.X>8:MB&K8
MA392U=G%>7$;&3WW:2_!Z'GG-?+SZ*832(I$4B*1%(BD12(I$4B*1%(BD12(
MI$E/7GM8GY=OYM2D2PV'[:&_)U_.84B1W2(I$4B*1%(BD12(I$4B*1%(BD12
M(I$D?7GLY3R37Z:](EUL/V 7Y5U]!"D2+J1%(BD12(I$4B*1%(BD12(I$4B*
M1%(BD38[%\RS>+#L'C7,@W;(/%V&+A+)X@T=*.$6SI9K;.ZZ;9PJT=)(+YX8
MI+*-G&">662*EL9<6"ARK<"Q4/L>)90"RAO(LH920#N P)\Q(\E+%.2\P Q7
M<<@K$A6*^8!*L 2-B00/(RZJ,E(B%: T8"V,2W %T[K(3M4SVY<KL8;!XVRF
MI#,BG9$BLZDK<<F65<DD;8HD763J[A^CCBD[563QQQMTK-9U:[!KTR[4\^W3
MJN/2P;,N]\2O@=T"8[6&I50^**%V0DE0"29S:]'TFG.LU*K3<&K4+>74S:\6
MA,I^0V8M>J"PEQX.2V[#P8D2R<\;N/SR.I1%[I75[V+(00=J]&./(1'G81+7
M0@HD<$PE,8X8*,\(R+--VY<:(Q2LS8DT$'[5))TBFKC,:[K2WG)75=07(.8^
MH&]<N];CG6UFJS+-BN'.194379;OS>LE&)4D2)T31VI&,VEX#8XPTT\4MB4-
M4,&NP6UX@0H5%"6@6)5MQ6P!U 8 RV:<8N.+ K 3C+0^H6AK5;1-CK4JWUW%
M$2,%:(OG11!O%7B8K%<(FW*/GQ5M9@HCVN4?/22-TWKMPNI)M?UQZ\VE]8U-
MJM18OGUMG9)3,8JJ$Y"FS:TM6B5MS!Y5HE9W1% BN@Z(EF':ND::MNGJ$P;!
MAXX?$4,SA<=A7O4 [,X"$;.S.-F8DQKJ_A9Q7U*#)0H9K*!'B\N8G;RD[+HU
M#B,]G8-S.E)RX:28FV"#G9\*#DI079FFNVS;LL1\;3<Y*NV3-Q??U#M7VBU*
MVO*LU#,JKQGJ[O3C9&4F'AW+AC##8];6NM%MU%=G,JP+%[RNRNPFE@=E] TZ
MI\:O Q+7R5MZ]N11C/EY=1RCEE;[!4C75TW6)P!!"<:=]V53)5E?''0,ZEC^
M>S+2VKY/."D=?Q(E,3<(CI"4/HR5$/(^2!NCS@?F47&OH^2(@7351UDFL$(/
MA.=KCWCANISL;7=:P\9,/%U74,?$KO3)3%JR[TQTR*[%NKN6E7%8L2Y$N5@N
MZVHEH]-58=#(T72,K(?+R=,P;\JRA\:S)MQ:7O?'MK:JREK2A<UO4SU,I;8U
MNZ'T68',XMK?7\&?FRD,A47B9"2-X\U/NHZ$'AE3+>)"< $82(W'MV]G>( $
MDB&$]FME=B*;MA[>^#1L@DGJ9&=FY:55Y67D9*4->U*WW/:*FR;#=D%.;-QZ
MUQ-MFWW]C,[;LQ)V<?"P\5[;,;%HQWO6E;FIJ2LVKC5BG'%G #GT:@*J^6Y2
ML*B[*H ]3/.*0D:HHIE'HD'<&5EU5,\AH$:O(9<=S7764RRNT:JF9/)BZBRR
MF5\GIHZ4S4SNY(/<KJU@9&4X ZV18*PH YVN*<>H*H ])A7116 !][556 .*
M+X6_,XZ'^"H0V,Q^\K0VW6%F)^]!LMM<LQ^^LL<D[LWCD-4RV*1/GW^J5/Y.
M\)_2.UK_ '6V/7K_ -Q+^[-_\S9W^NQ)YS]U'^YE?\Y8G^KR)\6O'R?[MBPS
M949TD'>.#$M;:\+$)2'Q)-Y%!G.N-CQ^<Q,\ ,M"+%B%)*2X8''MUR6#K)VX
M=-QXI+$JY:95^H=9P])R&T^_5K56K&.96F/;P:G+&=@78F15=4R.]E:XUEEC
M!.(0*7L/35IX-I>1J%0S:=.J9K+QC,UR%E?&.+EU95-B.&54=KJT1>1)8MP0
M<V$V9FW5+=ZGY1(2LRUAJ!O.V+HU:+ON]:8QEYIR6F= P;C%/2D4BPF9B8RD
M0D$"UG&+/H[-(Y)HY&9,,N[BX  VNL,SXV'V$TFJBBK%U#4FPW%1R%Z^->NI
MXU6L9>OX==^19C67E*<O.OXY&-=3?D46;7VVMLXW\KM;J%E][78&"N0I<4.:
M;ZC@WV:=1I.2U--=U=6]N/B4[U75V556)O6B %9%TEY\;X,8&UXZ18:V.&IK
MK^<92G7KJ2 9(.?:]TICHE@-'$LY [R0$F(A:[HXAFFJNY+9Y9-7+,;?N=;J
M8W8W1Z6I%ZMGTTX>7A]WS$HMH=,S5/E=K+$%2[VUY'HU-X**]MU9QSG-S.U.
MIV)::",*V[,QLKKXKW):K8V VGBM&YL EE)Y6 [MOL W'T1>:ZYWS_54)<Q&
M&:_@#)T<*0<O.),]-[D,N9Z]@FR(OM1@2/1$WM<CK%C(BLGB C$Q+8U! 4D[
MEY$F@@D(4+E'#S.;V.PM2RUR<K.RV6FO+JQ,=:=,J&&F9@Y&G-73DU:<F>]%
M6/DVFK&OR[:!9TWL6SIH%QA]J<K!Q#31AXRL]F/;DW-;GV=Z;%RZ\T/9COEM
MBK=9=0O4R*J4M*\E0H6<M?-.J#;79XWP[RM6D4<XQ,HHJR, #9D8[&SCE8 Y
M=%NZ0I_(UF!3#O\ HXSC5F3Y!<<\@Z[P629O2BV)E./]A.G.Q/>M1K/>,7)#
M57556+9A]GK^S:=.Q* ]9[GD-D<E(=,I4=&6L&LTCMIJ%:<1AX5GS610%L2V
MQ2,C6*M9?DC6%7VOI6D*P*FEB&#,>4G<9U23DKLF2"D(;IK6R[F'MHD21%,;
M;3--A N RGD$<8.3)R9[//%&@C(QRBE0MPJ5/I,6B3&$ PMQ>"&3(ES7["Z!
MI^-8<K5<Y4RFR:VL<:?4UEF;C:)2XIIQ,"JM[.GV>QW45U-8Q?*NM%F_)-M.
MV.LZAEUC&TO%9\?H,*U?,<)7B7ZO:#;=DY=C)7SUJVLFRT(G"A*PH]%M18KN
M"5:<@CC3FS])PG9,$)3%3: "'[:;;&"J1R:C\2&O3<A!/]=SO74A["5[VE(O
M*094D0"OW$596S'MR8A)WA]7D:7C:KEKJNG:OF:?FUX@TW(RM,;!M%^)8*\Z
MJBY,[#SJ.58O&1C7U(EJ+DOL[5VE9P%U"[2\%L#4-*QL_%LR>^4XV>N54:<I
M"^(]M3XN1C6LKFDTWTNS5N:5]%73E)O!=4$WR]CL.CXN#Q@M;4VM342Q=-S6
MY,ABFNFNHIYI0=W<@:.T_4O26AD+V0[2'RIC"!\D4>B0C@P8(=L2/"0\]^PN
MB+=DY%N;D4_*6H49(1J=*Z@SVU/"U9^CF-IWR@PS,O3U+8SY;T!++EKJ7:@T
M[E7;/5GQZZJ\*BSN&!?0S+;J K.&-.RM-0V8W?3AHV-1F$"\4"UF2HNYWMZD
M2C>9TM1W+LS<4@UQKJ7*[<U);3,RA!>\Z'Q1W$N].(1!11FYC,T!2UB45'PP
M:YR=MY-CAB\</<DT,$,T4$.[9V0Q3H^G:3CZCG8HTO5/E;%S:AAV9*Y7>LK+
M 9<C%MQFK%F4ZA6H)X*H))W)^7J[69"ZQJ&JY&G8F5\J::=+RL)VRJZ6QSCX
MV.W!ZKDR%<KC(219YLVVWAM+<(ZH//M6@(W&XEH#3 )L$$.1, =K8[@)% ,
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M2#RQ5F83%C:\;L$]6'1B6:AB6+CX6#B5U)IK)A67:>V%93FY.*^;;ULK(MQ
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M /HS9;BS]3U0?5>TH_L/?>XFNY 42),S0K7 :$*1L =*L%\73*\Q?DI :7)
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8B*1%(BD12(I$4B*1%(BD12(I$4B*1/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g486549g30y40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g486549g30y40.jpg
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M 0$! 0$! 0$! 0'_P  1"  K ET# 1$  A$! Q$!_\0 '@ !  (" @,!
M          8'!0@#! ()"@O_Q  P$  !! $$ 0,$ @(!!0$    % P0&!P(
M 0@)6!F7U105&M<2$Q$6%PH8(2,D4?_$ !H! 0$! 0$! 0             !
M @@$ P?_Q  W$0 " 0$%!@4# @4% 0       0(1 Q,A,5($$D%1H=$%87&!
MD08B\+'!!P@4,F(C0H+A\7+_V@ , P$  A$#$0 _ /OXT T T T T T T T
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MQB#S'=3=,"*RSDM3<+(3T:8D1IXM5;-!]9KB*P&PYT*K[!P#0E";69FX3%9
M'CA7"+O!\I<A"KYJ891<J'DCUBW!EQC]T+1_E.BXDLE-OU_#+ K:KI&7?LIO
M;BDF3KX2WC$K*-CF<.%8G)+BL=$!'T>!_:Q66+U7>0E1.RR6_P#\NZ^?^<-"
M?L9"9V?7]=DZ^#S>5B8R2M:;I5O7C4JONAG*IRXC<DES>-#<_P"&2?W)S'XE
M('S;!QFBFXS8;,D5,R#MBU<@8^U;@K^DX^)E-DER 4&<FT%KH6['1>62Q5U-
M+,E@B"0,%]OAX,^116DTQ/A8X/<N&B3#[H48MEW2.3A/^0J3>7)OV6+Z%E8Y
M;98XY;?RVVRQVRVVRQRPR_QOM_G;^6&>V.>.7_[CECMECO\ ^,MMM]M]M"'E
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H#UT<@>+4[MBSIM<%:
M[HUA?5:!X2^XW6^65&O8\;?M1TF1L.J;!$!2CB2$:8LUD^$1R>!W[!FZ;NVH
M>?1/#&8P:*DVXJ?QQ7[KS_,CEY"4/9<OXK\9JK Q0E))-6UJ<+Y7.!L:EXJ+
M$&L?HBQ:ZF<_R!29Y)HGDF8R%Q$FRC:PLTQ<N#"X_+9^,;9+$V@J:WF^>]U3
M7#U-KZ1%F ,2*!B,6FT5'LIA*7<;:6//FUCSI^(D1'*6.WQZ0-I),$T4D),?
MD 2-B59;('(^(AX_LZ?(+*YC!XR_RF'8JCA96\\JNJYY'+$CF<9-G>47,.UQ
MK+(J#,;*Q"\^4MN75"5\W($F4:I/\(G/P[,VQ46QS8'6I-HCD\9(M"3T5YX<
MET5/SRY9&D]R\"+[(6Y:=E4E.X]$U MY5QR<XQI/5'.3*'VY9;6.U?S$0DXW
M^7]+@%(:HBA\W%\4,,\UY?>MFJ.=UT\F[/%^?GY^I:JE'CP?MC&C]7YY&X?)
MOC85G=)5!"*DW'M27'BX>-UO0:+'B+AJ%EH_CO.XQ)$X 6,?TO56"QV. W0\
M$>=-7J >6X@#A%!9HR<[;B)XOS37RN__ $<\+J>:R7F <Y3R<"]KP(PXZ"^/
MT6A)<G'R<I/.7=C.K'D\NDVT0,R.,CQ@G-N !0EHVD14HLH^F[TFV#(+C$R(
M<*>=?V_/8TXJ#B7>5><@A%_&X2YEXIEREY>R;&KY!-XVX1@L4Y"R@\6A_(NI
M44)%E&V5E#8T2?5K8D9D#E(@^@<WD2T2?L"8PB*L$5OUR2?MP]W3DJK%<5+>
M7?%KD!:7*V+W]3:R@$I2U!J.:V=&7T8*UO8=Q1^Q?]O$5?:L!(G&1$K!I('R
M<H,I:WP%F*WGJ<5L2*EFQN)M<U1%^<_5?NL.WLJK<_,9/"(Z;L" N:PFCT:V
MSDL'7D8*7)@3&R6.S]H/DT=<+#CHK%S_ &_:RF3<4]>LOZ7#\*'=**CT!"6/
MW*[1FNX:CW)1PECMNDP9J,D7#G+?+;'^":I%VQ9X?X_SOGGDLZ3VVPQR_A_-
M3^*>?FVNVM=GV>UMK#8[?;[6$4X;)LT]EL[:V;:6[">V[1LNS1I7>D[6WLUN
MQEN[T]V$OML]E9VUM9V=KM%ELEG-M3VBVC;SLK))-UE'9K&WMY5INQ5G92^Y
MK>W8[THZB\-ZIL&FHC,(M/@;=BY-S<E+V+\:7&E!^[=^+"#OH%?Z7&#U-XFH
M-46VW^BR:YHY?^7&"NVR6?.?\L_\/OK'^&?TW]2^ ?5_A5CLMOXI]5;=]2;+
MM>P^);%M^QNQVS8/"MB_H[2ZM8[5#:;.>PSM*_TSV>5E)?ZT;1*SE^T?QO\
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M&#E]A0%EFVP5RQ5>E"(@&Q*%V DK.SBO[<VE_<UGYUP(%8W?MV]0F5N(^"[
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MY%)*P785;"V:M?GY>5V/2HO#\VX9/>/D))(,<) <<C/IE"D@21./-UBJ*3O
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%0#0'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g486549g37j02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g486549g37j02.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2,:4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "P< 5H  QLE1QP!6@ #&R5'' (   (  !P"!0 0,35-87)C:%]+965N
M97)?,CA"24T$)0      $"UVQ.FLHO'V$!,7^&GO#N,X0DE-!#H      /\
M   0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
M26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O
M;VP     "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T
M=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E
M='5P     P    !-9" @='EP90    $       !#35E-     $EN=&5E;G5M
M     $EN=&4     26UG(     !-<$)L8F]O; $ .$))300[      (M
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M9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!R&^=P
M"G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M    3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M        4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN
M9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,
M969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!2
M96-T5&]P;&]N9P      .$))30/M       0 \     !  $#P     $  3A"
M24T$)@      #@             _@   .$))30/R       *  #_______\
M #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S       )
M           ! #A"24TG$       "@ !          $X0DE- _0      !(
M-0    $ +0    8       $X0DE- _<      !P  /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M'@      !      X0DE-!!H      S4    &              :Z   '(P
M       !                          $             !R,   :Z
M                  $                         $     $       !N
M=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   :Z
M %)G:'1L;VYG   '(P    9S;&EC97-6;$QS     4]B:F,    !       %
M<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M       &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R
M871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   &N@    !29VAT;&]N9P  !R,
M   #=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$58
M5     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,
M8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T
M   /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU
M;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP
M965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S
M971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T
M<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
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M !$N_P".H_*JWUE__(U3_P"$.G?]5AJY_C/Q\C.^J#L;"J?E9'K4GT:6NL?
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M;[4#_%#B9?3>AYE/4:+,.U^7N8S(8ZIS@:ZQN:VT,W?124U_\5'_ "W]:_\
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M_P#/V&C_ ..S_P 3F%_X=;_YZO0/\9T_MKZISJ?METQI_AL-'_QV?^)S"_\
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M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4
M( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      8I)
M22H "     X   $#  $   !!"@   0$#  $   #*"    @$#  ,   "V
M P$#  $    !    !@$#  $    "    $@$#  $    !    %0$#  $    #
M    &@$%  $   "\    &P$%  $   #$    ' $#  $    !    * $#  $
M   "    ,0$" !X   #,    ,@$" !0   #J    :8<$  $      0  + $
M  @ "  ( " V+  0)P  (#8L ! G  !!9&]B92!0:&]T;W-H;W @0U,V("A7
M:6YD;W=S*0 R,#$W.C X.C(X(#$Q.C,R.C V     P !H ,  0   /__   "
MH 0  0   ",'   #H 0  0   +H&           &  ,! P !    !@   !H!
M!0 !    >@$  !L!!0 !    @@$  "@! P !     @    $"!  !    B@$
M  ("!  !              !(     0   $@    !    .$))30/]       (
M      $   #_X0&,24DJ  @    .   ! P !    00H   $! P !    R@@
M  (! P #    M@    ,! P !     0    8! P !     @   !(! P !
M     !4! P !     P   !H!!0 !    O    !L!!0 !    Q    !P! P !
M     0   "@! P !     @   #$! @ >    S    #(! @ 4    Z@   &F'
M!  !      $  "P!   (  @ " #  P   0   , #   !    061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHP.#HR." Q,3HS,CHP-@    ,
M : #  $   #__P   J $  $    C!P   Z $  $   "Z!@          !@ #
M 0,  0    8    : 04  0   'H!   ; 04  0   ((!   H 0,  0    (
M   ! @0  0   (H!   " @0  0              P ,   $   #  P   0
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M(B,U01I16'.7Q-<D)C(S-%66)4)QE+'2TR=786AR>8&3F,'5UO#_Q  4 0$
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ML97)HSVV2NQ/K4K52M+CEIP0X*583>H% H% H% H% H% H% H% H% H% H%
MH% H%!Y@_28M82J%O':WR/AS+M"%W5YS@^:>UI"DD-Y+WVU<WROM0:9<;8<2
M*I+7K;N-DV<?$C%ZFL6,M;>B)M6]F*M_NPGKX.6Z,&SB#!-$B;A9(*?E>/\
M9EJ\>1A+!OS[]JYI1RRS+)[FA(B-?OUEJQ3?>1'LT_9B=-9GR09Y6V[?4%P]
M H%!T@GZ9YQ53,X<Y)9^A93T&U->3XZ09HE$(W3 VLV#:G><W5?&VM\R,4C=
M@SJTKMFL4,VM/BV*="^^RR3=KW9!_P AGIKF_HVQ3ESY/\*SIB#..AH-+P]*
M(1)5A%U5?$W2MI-<-?'G["7*?@EGPZ5S^%W;_A%7NL,_A]OL!UWW3^BA,/ZI
M8?XQ':"6E!BW>=SYPOD/^I<X_P 22@_#P5_."\=WU/1[^][J#:8H%!D,>E.?
M/-[+_5G-?\JL)T%;GBV^9GX[OKDY/_'@#H-PJ@4"@4"@4"@4"@4"@4"@4"@4
M"@4'G>\W,A27"TV\-R]"\L!J*2FL>Z@$='.!ASAT3UWA-HV0IH6<WHN;X.@!
M7H6:DT/8CV"QYD%\NCLP["YC;4*_99U5-JT+9^"Y/531R#!$J+32'I"5' ?L
M?=Q= 885QU%#I?>]NVO'4, 9TL7&0?O:L-6+,2#A1OL^-!6WOB)R3(E.G8B3
MA+J@4"@\BA7R/U">VZ. P^/.C5\CO4*^7D?(H[D".M8-S-%#IU(9.AL#(>4)
MIWCP]>5'/H=Z3,2)\N\2/+VAB:2(C<5"&&/LS6*;0NRXIV+Y#Z9ZUZ)'X8E>
M#X=D&+^1(O#QN8XG?H.*GL\AA).ZV0W]/&Y4WLY"G9FP=DZ+8[1$V]IU,S]M
M 52,7<'A@8T*_,.W^D=$Q6U!6UT<XTV1U?ICF:Z9$WL93I-;([]"QQ9KQWN:
M@AWL62G6INGR<-FMHPU;M&.[!/KT;,\,\ FU089?D0^8!W-]8G37XU&U!>+Z
M()\XP:^G2<_W$>H-6^@4&)[YHOFT>1?ZP)S_ ([=Z"1?HW/SMN"?V]D7\#)2
MH-C>@4'74P?V2RC_ '=&W\-.=!''QM_+MX*^C#E[\$0>@FG0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*"@3SUD1G'0GQ3+L9S4,QU)L>=-KM@/%I)$,V]#
MZ^D7,BBLT9UD6:X%@[+(AD-*D:LEI>X9N.E.B'L6%.XHWEK=<T>M>$R/$M/Q
M/TKR&W2@9&L F1*HD8^''K5SW#DEP"Q!3L*KTK([Q^>1++SBXGXA*8N[)5Z<
MK2/5TN"E-N9US;HVMBE(X+0LSH% H/(].O)W5<A=0SZP 8'T,UR2;=6]DGXV
M+J8[W-7$XK'$K\#R1SM''4XOT;DPI5"GH0AR= EE>H]SEAY;FDC)S!'C";%J
M8M)ZC";?BQ!#MQZ*#)+U<US)S: Q)XKN4N0C]OEZ)WB'-I1/\>F).^.[,*-+
MZC;5!^PQ@Q;%;;A)#*G7B+ED78)1U\<M.*F^L)_]X:)LO!LP;4SG%F,8? C=
M[HM[&6Y'OPGWA&K;\;.FLAP'OB+NGO-FK/[']UB@OAJSPR46RW7"P>@Q;O.Y
M\X7R'_4N<?XDE!^/@J^<%X[OJ=C[]ZW4&TO0*#(8]*<^>;V7^K.:_P"56$Z"
MMSQ;?,S\=WUR<G_CP!T&X50*!0*!0*!0*!0*!0*!0*!0*!0*#SR]>2J#S]U,
M*)Q.4>C^/.E(&[85^,2.YX@C\C)QK+FSI+E".NSS+5)0+,@L\C5HRV)(]&T*
M+-.W/I8/GXJS/C1>[>[..I"%S?+?/(1RG L>P''CN3$0R!HWF_WI-'5,]F!>
M1%1*]&AJ9E3JB1-J!:1F)H1D!.];6]M;FZSDZJ=;>WHD>&A+J#O^@4"@4"@C
MAU#_ %%!/J/Y7_F,C*@D?089?D0^8!W-]8G37XU&U!>+Z()\XP:^G2<_W$>H
M-6^@4&)[YHOFT>1?ZP)S_CMWH)%^C<_.VX)_;V1?P,E*@V-Z!04W=@>;#Q;P
M$YSMSC+_ %\#A$V!XZ3"1* . Q):MS:B)V$LU3<U[EC2$.#/MW*D[JW[,-B9
MRW)\;*<+;-V&6.RV 1R\9'FO\6[QSCP#RHV=? ZOH)9!G+T$)HSP&9+Q=MLM
M_D]"07[E8K]@1@PV</O9CDR_%9.V+7\1;WOQ_P +_MZ#T/4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@\XGDYZ)B60YO*XX>R#H'G":O'C,G"+O"/3O/KA
M%I07??7R3JI0YW^RU\:RVQ[0IQCAG:,%&B24CLH=E[FV+DJ]DT)][1M:GP+>
M.(^10[C6)" #')$.)D*9$E0_G*8YEDE<Q+#659BDQP3KC Q>= LTL(LS:]FI
M"U,S.P#K*W-;,Q,[8APU*%&I2N5!,.@4"@4"@B7W3^BA,/ZI8?XQ':"6E!BW
M>=SYPOD/^I<X_P 22@_'P5?."\=WU.Q]^];J#:7H%!D,>E.?/-[+_5G-?\JL
M)T%;GBV^9GX[OKDY/_'@#H-PJ@4"@4"@4'5LQR?NB %7&^B-)2EK8A6-J.P5
M#@T@+#I;9Q5X);JT+*Y/8\EW(V^V?Q3ENS<]62=)AGMPU[LK6UW",7*7? EU
MV_/S4#\_=3 C,-/4C"CR=RW&#(( R0XB<S4Q^= F3NA-W]7<K92QO>&G8ALV
M_"[-K(Z98+;X:-=]P3OH% H% H% H% H%!1?W=QGX(D70(W(OD! ("$IQZH>
M'58/'<P'YZ -\B$49CX0)K,,B?$P88_9WYJ'G8-:&Y$O6LKB])<[XM&ASS1N
MN:<+<(!B:'(,AT#BKGU@91B&A%HV)P!C''9:^L:)E<EZQ[RNV.[@Y/"MP2*U
MSFL6ZU.US66S^)O[K;[FVO'$.X*!0*!0*".'4/\ 44$^H_E?^8R,J"1]!AE^
M1#Y@'<WUB=-?C4;4%XOH@GSC!KZ=)S_<1Z@U;Z!08GOFB^;1Y%_K G/^.W>@
MD7Z-S\[;@G]O9%_ R4J#8WH%!C4>D0?.E[__ +W6?\-0:@CIX@_FK>-_ZX.7
M_P 90^@VXJ!0*!0*!0?&3D0^KQ?,TKZS*<!A;O;27-.YHMV(\X)6]&[*4#YE
MKWY6:5J=J<$#GO2K[I]^IO7(UNS#%,IT[,P_L;'-N>FYO>&=P1.S0[(DCFU.
MK8KT+VYR;E^C6J0N#>N2[-J98B6)MNI2D5IMNS0HT;->[3LSUYXY7#^V@4"@
M4"@4"@4"@4"@4"@4"@4%'_DQY#\'RF11/HGR<@$1LQG+CFQ10PRQ*AG*H</N
MKB+-"U>/L#T_C!2S! Q@WM>E;L0NI1L94F[+#+39RW*[ZM606)<8\^<E\VP<
MTA'% Z%CL#/CNYG+'C'QDY'PH\.9%J18.+\UE#F2%>;CI<-3>BM;-*\[D-L=
M&-T^&'M9WR"5U H% H%!$ONG]%"8?U2P_P 8CM!+2@Q;O.Y\X7R'_4N<?XDE
M!^'@K^<%X[OJ>C[][W4&TQ0*#(8]*<^>;V7^K.:_Y583H*W/%M\S/QW?7)R?
M^/ '0;A5 H% H% H%!6WXN_[$Y^__>)>2G^>.=*"R2@4"@4"@4"@4"@4% 'F
MQ2RO,9ES#Q_&P%U',[%,@5T0=RO!'/!US7!S9)X)&CA!S/?::SYT.SNJT<L+
MNDA)TZ('B;)M+"E&6NCXZ/34C$FW-2$IO%;P:!<81L\O4:Q-)_*3#, P 7?.
M+3&;,YX%(0-0!<=MCL5CIID3&*%23RJS/0ZO-MHX^XL*O[O#][H-;MH<=NP+
M6:!0*#R)X]<]A@T;3KU*1%<B,YM,4'>4=7&*!JZC>I7&@(WY?=B_<U8FO(!1
M$Z2.820P:SB>YL$GZ)3C>3O+JW:&[H'26$)ZGQ'0NRXHTKHZZ9ZUYU'YHE><
M8> (NY#E,.))CELAG,K9#J:$D\(9$8=$CEKD]$.]E=F*+XSDE",[G7:RL&V0
ME6X2;V07=VIJ2AVST@:GRO[EC2V&R-J$]737-&C5(V\LC]2S*4Z3H6.=B);@
MP(B106Z]3KMU:4Z?3M9L%";-3AL7:D^K7NSP"<-!AE^1#Y@'<WUB=-?C4;4%
MXOH@GSC!KZ=)S_<1Z@U;Z!08GOFB^;1Y%_K G/\ CMWH)%^C<_.VX)_;V1?P
M,E*@V-Z!08U'I$'SI>__ .]UG_#8&H(Z>(/YJWC?^N#E_P#&4/H-N*@4'0\^
M3^R\^#[(1/<;3Q)FA\>,F72UP'"A_-Q W[<42A==>]L<?,[PX,[/?!/=/BZK
MM.I'DMVIT>.R^_?AC<.F>5>]HJ[#V-:F*8SZ>9A9_";2 -R-*O-DKQ7&1./;
M5+4G1W&STR'VT<>G%SUN^E<UMB%=N6+VU*XKTVO8F;U6>L)O4'^<L;98Y8W]
MJULL;XWOCEEAEZKV]5_9SPOCGCE_S98Y6RQO^?&]KVM>@HWCGPO9QT ]KAB/
MK^>G9PZXT8;QXH<I,Z3VN,%/6DEPWH%XK?+IO8M*;,H0%PB(H'8J=%1\]81T
M\-DAGAY%I?HB@9"Q'ASE%+Q5S@%\\I)&,97TA.YW3)#DZ?#!Z(')BP7[$0:@
M58%YF:XL^0X#(1D;4M(>H&8]^T&A:YA4?@+(YIQ-J"7- H% H% H% H% H%
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M_P#C*'T&W%0*!00 \5/RV^(OILBS^&45!/\ H% H% H% H% H% H% H% H%
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M4HOA;!-GNV9X8Y!."@PR_(A\P#N;ZQ.FOQJ-J"\7T03YQ@U].DY_N(]0:M]
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ME!# \FJ727L)QG)*\HD'[V.V4GOIP<*5SBZ$,B+SB[UM,E+PILX)W;WJ&R5
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MA?\ B63Z#RPLW^^&K]9(?WK50;YP]_N!C_4[9^Y:*#[% H% H% H% H% H%
MH% H%!Y4//;/ GE+42<N3O-/C]%@<B(Q.1(ZBSJ&5NP8V:"1A3Q_,.!^]]+Z
MH!5M#"[QRH*1P<9(C1NR]4+NY1B^,I,DWO.YC3; L[\*DUB$U\=.6X%9N/F8
M8C":Y$B!MU\)!AT&<U+]0:D&MMG4'P/VAG="7)=9WML7EK?H4,[SMMA[E9N7
M)W#'6%NE H%!6U(GDN (?E52(RY!70T9PYB?'T4-74QB+"33#Q!(T;125S*3
M-+,P[#;*:E(O<+ 3J[')N45:XX(W85<$;*3+$V]N7K ^]QYY#0SKHL7 EH5F
MV!2]3"D:=+ 3%-:&/4ZJ3.?);7/38%2<,YQW(,@:&[3L<6+>A(!(MVCIH,*5
MK5J>&%/==A[ =I]T_HH3#^J6'^,1V@EI08MWG<^<+Y#_ *ESC_$DH/Q\%7S@
MO'=]3L??O6Z@VEZ!09#'I3GSS>R_U9S7_*K"=!6YXMOF9^.[ZY.3_P > .@W
M"J!09,/I:WSI9F_NCY__  T::"E?@C].GB[ZLN<_Q@#J#=&H%!E(^E^?.+(_
MIS@S]S(Z#S/ W]=@_P#:D?\ \V24&^?0*#,O]-B^8KS#]%8_^.<W4'C7H-Z:
M#?[%(?\ [K8__A-HH.TJ#QO>ED^2_LWQ_;.(A[E254$>,4WM?1^4H-#I',9R
M&W%?W"603<4Q5HY'$"O0GUM61:_9XZT.M+@IS6XYK,=^:5)?0'BIBOSP^3V$
MW F=XNG<1$78M.BF2'IU;^>.<LW/(N,[88D:]N7JHIWJV9(OUZ[:;,[/N0LZ
M31EMT(T&C3NVX9AK<^/N3S>;>$>,IDDMY^\<BRMRU DBGA!="WMEWLP,XO&"
M(D=OLYI2H6M!]H.[BK5_!MJ)(A3>]]RD3:-&&&O$)?4'GW\TX_VMB?P"<\?A
M6*/6(Q3.KQ(4PAG(,2=82VG2LYSSTZ+H?9$4FLSRI$T)C$J683L81#:%>MDF
M5HN H]STIM[P@WY!8OXQBB<S/A3GLFZ22G"69G4?)=A;>2(Y8H?-5Z9.?%B,
M2>GN)QMF8&J-,B +3CKXA \&O2N$FQQ1,3OO7O"%>X*@GC0*!04>$7#/:'13
MEUJW]88\VK+=#0[/<"QG+X+,4HE#[S?%)^C7ZP 3C2"7_G8'$M6Y2Z) TAF\
ML<I;<"N27\=2WVN6L08@D&%0FURK"70@]+4\=&]1+8932Q,H; \5Z!*!EYL^
M 3 "P#:579G=MA%(#&+D"\B+C&;I =EK78?T(1ADUCC!I>2A4B6ORT/WZ0A*
M*VBX5)C<&MJ0[4]-<T+MY'KW+[K-BMWZ$CE*Y;LM>:S))[2O0J4:]EK)[8VM
MLROACCE:U[!.*@PR_(A\P#N;ZQ.FOQJ-J"\7T03YQ@U].DY_N(]0:M] H,3W
MS1?-H\B_U@3G_';O02+]&Y^=MP3^WLB_@9*5!L;T"@QJ/2(/G2]__P![K/\
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M/_X:--!2OP1^G3Q=]67.?XP!U!NC4"@RD?2_/G%D?TYP9^YD=!YG@;^NP?\
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M0?.E[_\ [W6?\-0:@CIX@_FK^-_ZX.7_ ,90^@VXJ!09'?I7'SNNF_V)YU_
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MOWQF?JGK_P#?.9J#P,T&WYXI?EA>.[Z(^7/P4"J"?E!^.2=/GE?+/1ISRO\
MTY9:L,LK^JWJMZ[WQO>_JM:UOS_\*#],<<<,;8X8XXXV_-;'&UL<;?\ T6MZ
MK6__ (4'^J!0*")G></F707$W64'QW@EWGDL<\2Z AJ)>MU-S<[$Q,#O36RL
M;HX;_P#R="U/S@HT,SHL46RT)F]<IW;M>S5AEAD'2W("24I!Z2ZFZA-X)DOG
M,6E&,^5HD$(\E[: :SMQ>(/SGLC-S14UQT;'K*A9E2J<&0&9U:M\UN#S^3U:
MXZ4.##M8UJ\.5]7Q[)60CD2IYZ,$S7HFB"71D$L R+MK8QJ]D[1[J9<T[CN#
M=CZNQ'5BA.YI,'1R68+]R#2G=\5R+<J3[@[D_)'-/_2MD/\ [-X+_P##B@H'
MDKT3+QJRY(Q_*YV]3<['$G&Q5(9DZ:3?8V:7(K-'U>2$2_4W-NM*WM^I8[N2
MQ1K1($R=&DPV6T)=&G1KUZ\0[\XN]',XX\?LV)>AN63Z9 *5D8R_B"<@<G=F
M-$V#"3X)M;RDNR&34^,N>Q3@DT6P4Y(;J4_L7OHVZ[Y97N%E$WL$]1?$IY(+
M1U ;.+D)L"AV1H7&-X2^"5;M.S5ACJ4_#1[I4>[RMLOZ_=;<,_7:WJRH.U/R
M1S3_ -*V0_\ LW@O_P .*"B:<O16?'=T;,4FSU+9'-9%)\OFC_()Z^I2_!B3
MNQ43N&YT>7#0S,B= SMFM2M4;=N")M1)42>V5M:?1KUXVQL')N8/1B.#..IX
MCSI2 "Z:!&8(L<7-U"2-<2HRA*UK7<?=QA?MW,),B=6)QQW,SXY)L=;@WJ=>
MK/=BHU8X;].K9@%O$HATZ@D92*<-W4ATM< T$+BM"C61O"'PBM8/#[@[IDRK
MW$=Z]WPV_<CPU;_<[->WW6>7N\\,_5E8.0C4;3<]#K \[^J3_3O=F5J<]VK5
M&T&^ZU;5Z'0JV:]7MQUGG[O#/;?'#V\LLO9M;VLKW]=Z"E?I?T7C@GKJ=9'Z
M0G8TG HEN5WK00&[^@)FP:1N;HG:F]FU;]#&/M;<S-V.+>V(]5]*!$GTY9:\
MMM\+[-F>60<8A;T4GQU\^R_%\ZQ:53FQR5#I\)R: O2HO2O29J, A\1$0XXJ
M&AW;UC4YZ4;LWI5&Q XI%*)7AKOH5:-NG//#(+XU$3S5I3[]V/5DA7OJT[=E
MK7C>#/5>^&&65K7]4<>OU7O;\_JH.MX4')XDZ'HMD9VZA-VYT/(^$"]Q0-\;
MPE\"B6D3"@=E25'\3'FY1\+HW*\]6CW^W;M]WCC[S9GGZ\KA5GV#Z-5Q3W=/
M97TOTM($V&DOFJ 8;2$A;'QC$$:M&(#C:*,.O6PBK,TLJ7)*R-"%-LV)D.K-
M3GJR4*,MF_;LV9!TB >B1>-*,3P)DD.(IV;BZ/2X;.!9PW&^M?I0D8F\HG]C
M6;D*U'O1K=29S;TN[8D5Z=R93AA?3OU;-6>6-P]!'Y(YI_Z5LA_]F\%_^'%!
MU7##!/4E@>@L=>H#=O6;2B06*Z9!&\)?#63B!^3"*+=;XF/=VWWRI&QZ%2GU
MYWP^)W;O=8X:O8PQ"MSMST=7D/R'S1JZ ZKDF:#N4=(<Q 6M\:7,<"4MAD;5
M.RUH1?8P@QLS3?:G4/;CGFLNCNKWVW8X;MV>.K5; (BZ/0[_ !9I]VE1J=Y[
MQVI]NO=KRO(&W+U;-6=L\+WQR3WQO:V6-KWM>WJO_1?\U!Z*DT-S&D3)TFCJ
MN1,-"71J3Z<;QQ!N5\=6G7CKUXWRRCF^65[88VM[65[WOZO7>][T'6D6C\\G
MFJ0,W'J W17$92-01%9'&\)>I4W#*M.G2+5/OX]V_P#EBC'=E=1[KW>CVK6]
MWJPMZ[4$ .\O )S#Y*I&#Y7Z\E.9)!-P0)UQZ-.;.J% 30B%=;Z\$F"#:W!8
M\R-ZS;9W?7-1\:J3[5E\-^.B^[W.G5A@$&O^1T^*_P#][3W_ -H6[_\  H/0
M2 \V2-&0(%1N'=0R.W",?"0X$"S?N H57[D(X*,Z-A8T>U<NCW>M6[$K8@2Z
M,U:S?N5*<L+[E&W9MSSSN'..?GTT<D\L,)P7*CAP 9>>@ML(U[,/L2]8RIQ(
M*?DV*U$,MK2T7WZ51 NUVWZ$.G/9IMJQV>WEA[5PD%0*!0*!0*!0*!0*#^?8
ME2[LO;VID^W/U6M[>S3KSR]5OZ+>UEC>_JM_PMZZ#]->K5IQ]C5KUZL/7>_L
M:\,<,?7?^F_LXVM;UW_XW]5!^E H%!T7U#&K_,_,_1$/"CCI9RB6(+EN-1MV
M4;MB?0UOYT $ NSN.Y1IQSVZ-*)Q=4RG9NU89;-6&K+/#'++&UKA4YXU(FZ%
M4=!!4NRKS3(/,(W"?C&YGX@<6.1W&-]RH]EV/#$@*#%P!D\<FIIH<(S!TEDK
M:,E3SFP['[85+OLMFU:4JW+$)I=UQU(KA _0!8GG,K;Q-M G,E3QGH#8UWL=
M]@LWI7;0@R(%0IN,;IEKLTX+U.R[Y=1AEOVIM&W!)CKT8AW$GAZ>-R?1NOU]
M(EK[=.K9>UHL@3U6OGACE>UO7&_K]5KW]5J"CKH+T6'@;J&:I*Z$F@XFPFE6
M7"E>9G;^D(4(\F=B%SOA=8LTLC E;F5LU[?=X^I*VH4J77ZO]GJQ]=Z#_//_
M **_P+S!-,:]!PR<38,RI$96VFH&_JR%$0)FDB:<\MB%9N9'Y*XLSGKU997O
M=(Y(527;;\VW3G:@N6DP"Z!!XXD$U0=;GRU<(!!64(T:N+8'LE5JQ]A7NR=,
MIOICG7NMHW[DF&K=?5LPV6UYY>QECEZLK!^\>1]T 8@ ,7+>MSY(L*@\9)%:
M5-%L#W3)E+XRHG/>G3WVQSGMOHT[56>O5?9GELOKQQ]O+++UWN%276WHS?%G
M<4_''3G24C30;3+(NH7TEA*@=6812.&L-$&(%'\=0^)MS,PH?@QH;:$.=T3=
MHNJV)LUBJ^U7OW[M@=81+Z)QX[(/E2-)HC<OF]ED.(SX/DT$>5!3I=]#29 9
M"W%(RY;FIUTK&ISU(7IK1*=C>Y(U2!9AJNG5I]R?9LUY!>X[1-/3>U.:_7U[
M(>S8A;UJS#7G%D">QGFF3;-V.&7LQQ;+V<LL+6R]5[7]5[^J]KT'6\$#?0\L
M0Q%TF.W6)RV.9X"C94O;FZ+8*R0(E;VUIUV],DNICO:HNGT[-V6&J^[9GM]B
MUO;RRR]=Z"L[L;T;/CSO:<WSH[I^3)F.I<(F8<8'8B;G!A#4RAK%&O2S,>C%
MB$&QE8]&25OT:M.>[2WX;E.6/O5&>W;>^=PZ,COT23QOQ7( -)X24S@V&<<&
M(R>"+GN+<7'4W$X@]HB%@7;6]PUJ4"[6D=6Y)OS1KDZA(JQUWT*=.W3GGAD%
M_GY&IW_Z7\B_]ED!_P#AO0=+\_L_14O1B@.7CJXV:EZLHD9AS1-L6P7DDQT!
M<BE08BWXW51YMW>^5HF!.K56OG?"RK?NMJQPU6PPQ"NOM#T<3D;R!38JZ&ZG
MD^93Z5E@RP""@@;5H\%)LV 8P4ZV9)9D#6IC9<<TV"Q1;-5BALI4>W:^_;LO
MCCZ@BRW^AZ^,%L7(G)&_SGK6-ZM,N2[;F^_9;6I2;L-^C9?7LOEKSMAMUXY7
MPSQRPR]7LY8WQO>U!Z(OR-3O_P!+^1?^RR __#>@Z=A]BZ)D?\J/VEU><-_W
M#F(VC=!\%%T%W^-;1?[,^%<%?OX[V>I:I^.V?$6T^QHM[&/N]>/Y_6$$.[/1
M^>:?)+)@I+W7LN3%(QX% J:-QQV:\A0#THA%(_OQ/H;LVP&9!]M5[<'DE>%-
MUZM+N798J<4^2BZ=/HUZPA'_ ,CH\7'_ +[G3_XY5?\ WZ#T+,'/TRC#$RC;
M-US(Z9H'FAM8VI-G&4$*,D[:TH]*!#IRW[XZV;]^6I*GU:\MV[9GMV7Q]O9G
MEGEEE<.LH[9.BC*1)W#5O5YND11.:"HRT*TL707=4Z)7Z-1 W4*'&VV.\]6.
M_2N(U*/39-AJUW2I]-\\<MU\\\@B-WWX.82\FZB*U79,UR[)6Z%])IHCS)J2
M! !9FU2#F*["K'?B!CH[BZ_'YA8]?7DZ65W1?![+(KZ+*U7O@KO_ .1T>+C_
M -]SI_\ '*K_ ._07T1#R+($%13&L*1GU7);''41@8E&H&RJ(]A1XWM(>$,2
M$;&VW<[.X M=7/:B:&U(FV+W)8J7J\M=]ZM1NW[,]F0<Y@)]D?&2N@HX/Y$<
M)*3QP\1OJ''UV&Q$;<L$Q:#Z"-Q3*- :R,3<HQUK=_LZ-FU+GOPU86QOLOZ[
MT$J:!0*!0*!0*#_&S5KVX^QMUX;</:PS]C9ACGC[>O/'9KR]G*U[>UKV88[,
M,O5Z\<\<<L;VRM:]@_W0=*+ND^>&R:&GG!QG2(4/03\U;7QDA!7(PBGEEU9]
M*!6[;')OC[:[XE2I']DM[BZX[]+5GAL;&YQ<-=\T:!7NTAW70?XV:M>[7EJW
M:\-NK.WLYZ]F&.>O.W_-EAE:^.5O_P!%[7M0?[H% H/\YX8;<,]>S#'9KV8Y
M8;->>-L\,\,[7QRPSQRM?'+'+&]\<L<K7M>U[VO:]KT'_;6MC:V.-K8XXVM;
M'&UK6M:UK>JUK6M^:UK6_-:UOS6M0=1O$]PT/S6&<YODCB[3.,B!)1(H-&B]
MPQ3$Q4&!2YL;BAZ9$VW''4NP:%+LERWHM._)QV(]3FXIT>YO97A4A#MV@4'^
M->O7IUX:M.O#5JU88Z]>K7CCAKUX86MCCAAAC:V.&&.-K6QQQM:V-K6M:UK4
M'0<U=5<X\YN <T3G-,>Q>[R LVHPUH+2%&W.K_\ #*D")>X(FV^6:VS&U+'9
MJ2O)%OT:6!E4.K9I=7)'L<$>.X._Z!0?XUZM>G'V-6O#5A[6>7L:\,<,?:V9
M7SSR]G&UK>UGGEEGG?U>O++*^5_7>][T'Q"DH&P<8(S4R?6D6$!!A=R@J)G]
M>F:F(<&Q]O4.SX^O3HMV:4;:TM#8D5.#BO5[=29&C3[E&_9AJUYY6#^0'-P^
M3 T5D2/29D- 0Y'V@L#BX:<4SN/DPT_H=#FROC*Z(MFU(O;'-O4Z%:-6GV9Z
MMVC;AGCE>UZ#E-!_C#5KU^W[O7AK]YGEMS]C#'#V]F?_ *>S/V;6]K/+U6]K
M._KRR_XWO0?[H.N(HF&*IU#$LBPQ(@;*8$N="!D1&(&0MA.-JW84?' :(T"9
MW:%"I%O4,[\U.#6MPU[LO=*DNS'UWQ]G+(.QZ#_&&K7KOG?7KPPOMSOMV7PP
MQQOLV7QQQOLSOC:WMYWQPQQOGEZ\KXXXV]?JM;U!_N@4"@4"@4"@4"@4"@4"
M@4"@4"@_+?HT*=.U.ITZE"??KRU;M&_7AMT[M6=KXYZ]NK9;+#9KSQO?'+#/
M&^.5KWM>U[4'ZT"@Z6BKI'GJ='H]&X4G.(I=((L==#%)3)&DBB)PZ@+RIW."
M9.V%Z :=W)2/+=ZIH=T>K0ZZTN>Q:T.R/&UU+8NU: [FV:]>[7GJVX8;=6W#
M+7LU[,<<]>S7GC?'/#/#*U\<\,\;WQRQRM?'+&][7M>UZ#_N&&&K##5JPQUZ
M]>..&O7AC;####"UL<,,,,;6QQQQQM;'''&UK8VM:UK6M:@_U0<.#I$ )$P)
MM@ ;B1OK"R]]CXOS$B)I(L!8\%]FG22A9#DTJU>+,5CVY1HTO8^X73NK5MW:
M]2Y)HSSQQN',+VM>U[7M:]KVO:]KV]=KVO\ FO:]K_FO:]OZ;4'YZ=.E-IU)
MT^K5HT:<,=6G1IUX:M.K7A:V.&O5KPMCAKPPQM;''#'&V.-K6M:UK4'ZT'4,
M63[#,W.<I,L3R.,';Q"4D/,0RRUL*^RAP 9)'M*50[B1$CV8:E"-Q2:EFC*V
M?N\TBCU[<4JG?DG46U!V]0?EHT:$VNVE-IU)]5LMF=M6C7AJUVSV[,MNW*V&
MNV.-LMFW//9LR]7KSV9Y9Y7OEE>]P_6@Z6MTASW>:K<W6G*([]"79<R.T'8R
M*)7EK[!UHK.>;M>/;.URJR#%KO\ :EU%VJVO[,MDXVO\'CEOL'=-!^6K1HT>
M\]QIU:??;<]^WW6O#7[W?L]7O-VSV+6]O;GZK>WLR]>>7JM[5[^J@_6@ZYDB
M7XKAU(*+Y6D0-CE$=G@O%P6J,R%K'=!5(YJIVHQ('8-CHI38NI01*-"C!I94
M=]RY99,IV:M.6I-OSUAV-0?EKT:-6>_;JTZM>U3GCL4;->O##-1LPUX:<-F_
M/&ULMN>.G7KU8Y;+Y98Z\,,+7MCCC:P?K0<!E&4XVA( *)5E\Y%HTC4*;OM8
MM.35Z0CPP.MUU&A'@K=7ARW:$:37N6*DR-/[W;;)0L4ITNC'8HWZM>8<W2JD
MJY*F6HE.A8B6:-*I(K2[M:A*J2J->.Y.I3*-.6>K?HWZL\-NG=JSRU[=>6.>
M&66.5KW#_6&C1KV;MVO3JPW*+X74;<->&.S??5A;7KONSQM;+;?7KM;#"^=\
MO8PM;''U6_-0?K0*!0*!0*!0*"I_MSR//'/9H317$PS%2LP 8(<.DS4ZZ,D1
MWB>(U("A(%(@U \6+1X7,C"8I8+#?4W!NUH"AY4RQ\L)AG<3.+@3D@='Y:%9
M3,2JC%)(A5"$U>0YQ8IOEJ2Y:<X%Y7XUU W0L:=7'# -DZR#NK>HI2"G(ACI
MO%6PX'TD2O9\*0"$:82;1AA5R:< ")F;GD/1U 2"6FJ#8<;)[>&@@G!OB\$1
M3 ^L&G0G9'B3$PPV:3AR:M*70D28(5A)@Y*$WPB-$DRU9XYID2/1EK3:@[;H
M% H% H(U]A'JF-.89P,V^4E$(.K+'[Q]E3+H -LI:8D=G7'!F:)->P/4VO&#
MV)@SDO3DQAFX-^QE:A5K>7I\W)&=M7K$X>:O)VZO[@(.5Q;HR-5JSISFJ:E4
M1%/6G*;<TJS& G.3@O%W YM)H\VJ+YLP6Y'PI#$P!4ZQ_M*>>9XY[W2X FK#
M#^\P)(FVAZKHPPDG5'(-JF/<&J97TBK'ID=7'>+QK!%III;D^HC7"&@@UZWQ
M(.KG3%2K:4+M[Y>@1;M2)4K6[=&2S>'.J" O:W;2#F9C#F0*3 I'),DRD,0P
MA?C\V0BD)0:3&S6Z.HV7=*EB'8X/H,).NEI4-@<WIV:[E(YTM&8^:G%A5%*<
M@;PI?9I\=ND)+>Y<V25U\)SL8QW:)S@=X-YZ2(6?J[E2 9RD?6'=(\@R=U&,
M7(V:-W!TFII32YJY_D60R[1H,XZ(F)RP:=#7(EPNU\?03. -!;LBFY3*6B[U
M*)T2Q('3I(N$NS?&T)NN]O\ N.$2W)F#R3W+#?3N3O)$M]Z7&.T70$;<#9EC
M_<6^T-P3EH%!0OUYVOT1&G9;R C:.$^C>-7]K%>:9B@$D95L7R5'G0,@,.TE
M&QIZE(Q6Z1&[3TZ F+>Q0B1FC2D@:0Y%&]\$+9'C [=M!(0!]_PL1+,D,13M
M$T#(:AG,:95)@NCB*>1<LCZ9(FF&,)0<0>Y&$#CHR[F1?$W28$C;9H+FIJ(<
MAD"G)6>;8U<B\./K7%0O)H%!2_Y).T.CN8YFBAR@ OA=[ HU%=QQUW!LJ"A@
MSO-H?/2'$3"^@6>6&E.NW,D7QJ7CSB,S*4!@K(UX2;C-CD>3PMV$,D>M.'1W
MC BN703I#HTIBF+#?GV&2R?BYWGB IH:E34-/">6 E),8/.G.QR%I2V)3LN"
MI&?"Z 2+\G14J Y!Y\;X9(GQ^'#N.4HX^AZ$:!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0?CO4:$NG8H5;]*9/JQ]O;OW[,-.G5C_1[6S;LRQPPQ]=[?GRRM;\_]
M-!09U+Y-,RU;+4-MX?D.00OELOX5DA>R$<B;>\U9&3".]ND69^=>:(SC20#2
MX3!PR2M4IIR0IU-[T> V.\Y#V5&QV!E\BAU! B>?'TFYK8N:NA^II:3BK]SG
M@)%\=\G@W*GC"U\7-6X9?#9RQW[6$HURZ\E43+2@%&A)AEX@D$+F-4A7ML>P
MR,MKZZXAZ6*!053>3_KSH+E%LATAYRV0D4NS>\$\B3;#DHM9UM+S3F\-1MC5
M(AQ&#R$JE+@W80\Z%HR7R9=H!Y-+&P!R<"YA!"C6++Q K"!7#B*2=_??0TT<
MW1>41*PS02PA-'3<+23>VB*),!)Y8'<>>Y=@:8 K24Q'*!Y%A['3E-0Y(@._
M+VN;XIZ">HU,E \9 (BUQF'I.H%!4CY39[Z3B%!!VCD25&L5F).2E4F.D/D<
M-Y24T=-1%&K1JRE>,A!TWW9/B)8$&)YO*X]%04>",IR<. Q@W":W3=M5K$@0
MEXN$9JECMPU[ A^-TD(92TQP)*LC&C4Y;I"Y"ZYB@T3+P266&/9-'6]M=%9@
M&Z \-G>%=Q\$@\K TBELQQU(H@UA4A.!$J#TD4"@J4[=\D[USV:&L8Q(*Q.O
M*(K@C_22/C#HF2G6)XY>@A0_.@D,1]"> X*FQM-4K&IPV: ??H#1Q2.1V\DH
M@E?ESX8E8I'A$%8;*[/;^QR7JYLG;R$DZ.3)7G:6A>'>8>.$,2R?'G6<N/2J
M2':).TNG99#7=Y#%,>;)$'?N@HE-DY]$G&!$X$W;G>6AQ$UHG0/33%"20D$6
MQLAEQT:'R5D0"')).>Q]-9$PO$A)AUNTFCHR(\=6BR1H<"3!R5MJ:VC3;0BW
M:=5M6NV/L6#GU!^*C?@FT;U.RVW+6GT[-^S'1HWJM]\-6&6S.VE,EU[E*G;?
M'&]M>A/JV[]V?JUZM>>S+'&X>0[HOIWH3I^&>G.>9^BJ/^Y8M(,=_7O(!= (
M0]"\@G,& \AI#$2;M40/"U23&^H.=D.7+O3K9'JEHZCYU<W_ %+GV*SM 9-Q
MVC#TB<7CDX!L*MXA-9CG).@>7X)(>DDAP>D$OF<(JV1E=@'=T(/O#&SXLLZ"
M^AP6@A\I;][EH,5@MHD!?@//I8["+ $LZ!0>:[ISJB?9"F[J#E@Q:8]Z?XAZ
MA:9*Y_C)C !O.,.@HME *#5 U-D*(,I'<$@J<3^)Y)=T\QM'4B91SOFF-5N9
M["!T\ZQ1$#$83Q\1 M.@=S*&-QLC7L\(O,>Q^4PR 2 R'@;,\!/[DD=6^7^=
M'D2.QMI>,H;CDR:/M'G=[?%28I01D4-L>N+)]B@@X0/H6P4"@4"@4"@4'\JU
M<B;4VU:XK$J!'I]CWRM:HU)4VKWFS'5K][OWYX:M?M[<\->'M9V]K9GCACZ\
MLK6N%2_DLEUM-@Y;SA$,SH\)W'Y!CE^D3DIE+]\93%UC#"D=)S@O@B+R_+[+
M)V!=)8(,E2M@/P5?I95K^"/48DI:,HG$N6L80SY4\?D9]1\S9=*0LFBSF<F)
MYV8>K.%P^/!E,8!G$AX#"3/&[H+%P>MP'V]:7R0M%G9O[ BYC3"K0@,%#FSL
MRZTAAJ*4%876<S\Y(.>1LNR<30AE:699,+R7.<Q%FA @?),D78-CPA@Z:F%H
MUZ6(/%AX3%!H.!@EATXMHN)#[4AV*7=WN[/[L$DJ!0*!0*"NKLV9>UHS=USI
MS5%3&;",?B,;%CBR+X[*)#*I_+3N6-P,OA6/7 ;D,*11$XB8H@L8$4I&C.9B
M+.G*F)P>6]K'1XG<:#IR9=YGU5%#1W-P1J4,W3L1HI3B5ZAB;A58W-4L#XF6
MNHQ,W)T\@.PD8DNHL&C8==%\9D6@L2-S&>H\,FTSV1?(A8N>0E!P5RT%<O\
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MQX3P"$#P63;"&I@=1\D^S0V74[!*<0;D4L[$P;"+X1R=#)NVO8DZ1P%8A?\
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MHN 72<T<XM/.@L5Z-Y@1RC)\J&>^3YPF(QP0IR:4I+6#P\*;'Y0TM&E,Q"S
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M-[O)3&BD?6M4+EZ[8XA98.B8L(:'-,*#3 ,)GI^>2IYT#[.WLVEV)R-;L<B
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MQSG^#N/)?C&66D :39=.?&FPL[!%SQE:D\?3"Z)ET6'S:]VC9,_DO/PPZOR
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M<HNT]S?K4_DLVQSFZXR!]U=#EMP'%4E^XLRZ'W/6GN@R3;M"O:%Z5 H% H%
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M(*'M(=J8GV .YRO)&R7=1&AU#6K"S1BV;?>;%^2O[$QL];0]B5 H% H% H%
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M&_4+4_!#%#L?3 (&XH$3HWE!.(MI$90R7L#4[H)M_)^*OI$5NL31PZ*IG>%
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MMR7$FE/[)HL)U:-*QMUD"I-N4.NU>%@5 H% H% H% H% H% H% H% H% H%
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M)80[=*9N0Z@]%= H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M"@4"@4"@4"@4"@4"@4'F-](%D*1.:C;DSI-@[H[6@D::G.54JB!.28%A><'
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M)\_$1]H.<>"OYP7CN^IZ/OWO=0;3% H% H% H% H% H% H% H% H% H% H%
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M/2</GE=V?KF"/Y7(1H*]O&A^?R+\%V__ %R.:/QD#:#<<H% H% H% H% H%
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M4GLZG+FQ?@D1(,)"TA#K]\D>E$.QZX(8P)UC^.EB9M<;A;]XKQ\/&/'WS"T
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M6]/I934>48.&I-FCW;%6U/JW9;DJC#6'GHU>CO\ F&PVZL[\5R9ZL=F&5_\
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M(TC@5 H_,WP+HJ#I&;>B(IY]0B>^1W]3H>I!*$(3' .-LSL7R+(Y:OSQOBQ
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M!QB&QH5'&-C:6S2G0^WM"0= H% H% H% H% H% H% H% H% H% H% H% H%
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;DB;3JT:-6O5KPPL'TJ!0*!0*!0*!0*!0?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g486549g42f86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g486549g42f86.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1K04&AO=&]S:&]P(#,N,  X0DE-! 0
M     "<< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP"   "
M.$))300E       0FHFM72AMNB$"R,NI9P4_VSA"24T$.@      Y0   !
M   !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E
M96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;
M   +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!Y            "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \
M   !  $#P     $  3A"24T$)@      #@             _@   .$))300-
M       $    'CA"24T$&0      !    !XX0DE- _,       D
M  $ .$))300*       !   X0DE-)Q        H  0         !.$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$"       $     $   )    "
M0      X0DE-!!X       0     .$))300:      ,U    !@
M   #E0  "=H          0                         !
M  G:   #E0                     !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   #E0    !29VAT;&]N9P  "=H    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   Y4     4F=H
M=&QO;F<   G:     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
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M*:[>N9;:S;BLQ7;1^C+\/&K,@3NVUUNV.9_@_>HGKV42UV*VCTP0#9]AQB^
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M?K^AP[Z7T^W\W_Z,14E/_]DX0DE-!"$      %4    ! 0    \ 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O
M '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !BDE)*@ (
M#@   0,  0   ),B   ! 0,  0   )D,   " 0, !    +8    # 0,  0
M  4    & 0,  0    (    2 0,  0    $    5 0,  0    0    : 04
M 0   +X    ; 04  0   ,8    < 0,  0    $    H 0,  0    (    Q
M 0( '@   ,X    R 0( %    .P   !IAP0  0     !   L 0  "  (  @
M"   "3T $"<    )/0 0)P  061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD ,C Q-SHP.#HR." Q,3HT,SHQ,P #  &@ P !    __\   *@!  !
MV@D   .@!  !    E0,           8  P$#  $    &    &@$%  $   !Z
M 0  &P$%  $   "" 0  * $#  $    "     0($  $   "* 0   @($  $
M             $@    !    2     $    X0DE- _T       @      0
M /_A 8Q)22H "     X   $#  $   "3(@   0$#  $   "9#    @$#  0
M  "V     P$#  $    %    !@$#  $    "    $@$#  $         %0$#
M  $    $    &@$%  $   "^    &P$%  $   #&    ' $#  $    !
M* $#  $    "    ,0$" !X   #.    ,@$" !0   #L    :8<$  $
M 0  + $   @ "  (  @ P ,   $   #  P   0   $%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I #(P,3<Z,#@Z,C@@,3$Z-#,Z,3,  P !H ,  0
M /__   "H 0  0   -H)   #H 0  0   )4#           &  ,! P !
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M4U=UD[6VP=4:)BE#1%5B=I6GX?%25%9RE):BQ]+4V/_$ !T! 0 " @,! 0
M           ! @,%! 8'" G_Q !D$0 ! @0#!04$!@0%"Q$%"0 !  (#!!$A
M!3%!!A)187$3@9&Q\ >AP=$(%"(R8N$50E+Q%B,U<G07)#,T-E1S=9*RLPD8
M)3=#1%-58X*3E+2UPM359)6BT]8F149E=H6CMM+_V@ , P$  A$#$0 _ ._Q
MPB<(HQ1':VB687LB35*KLVP+ZP6E=&O(?V056#)^X,U.$NA4/2D7H^JM200T
M!9:[(XM\R] 44V+F0K'&6<ZJ.?/\*4ISNHKGR-/7KW**!OB[=8Q*X/:$P.T5
MQ<A5Z9.Q))P&OJX!)S5OG>NT(]2DSEJV-!UZ.F*DWVITO.6RSS4M&:M#K\_*
MR,;L&6^R]B9CK;IK3UKWZ'11O#GZI\PMI,>)-U>(9*A1[E%R>WQZ]JZ>:T%6
M+OJ>\;.DW=TW9Z@:Q@X4RD[%L.M)B6LDXJ'+,= V&_"T^MVFIVN\S%:KM@CI
M)Z*'\^G6BFOCPU6==?>XU7['V_%=I6K]K1%=(TQK/><3LBS-ZX;ILK4MN1P\
MG2(W U=V/8[I#6F4&1.N?);/48/.!ZO+2+1+T497#YU2GE35*U\ZZ*0^O=H:
MTVW KM6J=AT;9M7;DCH=RR:]ML!=(%$O%NX9DXI<Q6Y"2CTR4<]G#1P*B,%"
M.YPV0TVK/ER*4S4UKDLY\_+[_IPBC1OSM;K/KS)U*M66)V1>+U>(VTV&NZZT
M_KRR;.O151HR(I5UNA$!6Q2'0*M5UST$(?)&NL*+E)J*A84>4F3QP%DKZZ+/
MJWOC3-K54!X;9M,7+7VC ;*J=8D9T&#N<O1)&-1+CV=%)G'8ZVBQC<>O+YSI
MT*,J,4V^Q)(%(&?:;?!/BL4ENV/6B&+IP!.]-8%F7[8T3J.J,0EOA[$J2V/.
MP9MEB:FZJ *DD1DD= @/R;'S90(ZAUA)]_WI*-:+FAX'BE1QY=_!2$Y")PB<
M(G")PB<(HO\ 8CMOJ_K/+:[KUZA]GV6Q;29O)5/KFJ=96S:%@-!UO$QDY<CW
MH:H 2,BP'#14L(8\Y\.M3C7N^RA:FE)Y(!/=T'FH) ^"TI7_ !0NH]IM<-7H
M&Q; DJ_.F:3C!-L#:EV([IL.6[&56JV_2L38MC-U]4)43[['7:K!1;5L7"MC
MSLR'!23H,DY@?C=/HBMJU\DWA^>E\O7BI)Z:[+Z7[!3NW(#3]T"O#VD+N-KJ
M_P E#MO/0(EN?@(VQN1D3.>C$=/I!!E!QY V'?+"%DVRXU1&2@R&VQ!&8H@(
M.1R6^.0I3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%!_O%J3LOMNI:]A
M.L6U974L^1=EP>Q;+'60F!=B]63D*>1.3\,PPP2F1ND3/0M9!K*LMH=CA9R?
M*;=]O+XY,BFO=UYJ#73T/7[E#N"I7C(Q-=F&<[&U4S(S'R^R#B$QE<O)56E;
MDW'W*S5V#L%DE(=R7$I&Q9JXT5R+FA18!W1T/1U:\E86XA'!D/L\_GQ/+0C.
M_)0-[6WK+NR)\.*VL?K/OY(]9>QM"F[.\9M^8VO<SNO]KI>SD4TZ UO-60Z8
MI+TA8U"$SCLM4I A+LY6Y.;3"R=,'BJZ 0L0>3J4@M4<+5K[U-Z'C?(^%U:#
M&I.3'1Z9/+69)(0J9#+#N7F,G88;P7EEY0X>76LO^Y[;N1!<N(\EY'8SGVDP
MI7N\(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBB/O7O?U+
MZT;!K&J]Y;FA=?; N<7'S-7K4C"6Z1+F8V5DI:( ($(@J]*@>;\A!2[/L.EM
MDM( ?(>9;&]+RE"HJ!F:*7'"E.$6)7V]5/5](M^R+Y,,UVD4*MS5PM]@(',*
M&@ZS78\B6G)@IB/&+-6)&1HI)I61QGG$#L..8;SA.>$7'1&TM?S]WD=<0EHC
MI6ZQ%(JNR)."!^((=!I%XD;%$U"PDEML*CVQ+$?4[(S%-9+^+*1#&D('^&;P
M]DB]JK[#I=TF]@5RKSXDQ-ZKM0=(V!'CME(>K%J/I]6OX<,:HAAEITE^GW6K
M3J%AN$CX%F!D*>22@AADBS3A$X1.$3A$X1.$3A$X1.$3A%&7874#0FT:YLVI
M7&MV@BN;FDYN9VC%0FU-KU >[2=@&UX!)%SF:C=H-PASY/JRE5X#"5MHB*P!
M)5F)2% V6SQ\Q-2$^*P>0\/CJI)'XF2*3<F[&@ZH2@]N"W?O2.N@,M28F&AH
MF8C;B!L@>S1<S),5RNG7.7CI462V'/UZ"L]]*LECAXZ4&5/G[Z_,]-$6T;CU
M<T=?ZT_6;A3S)Q!<%KJN&VDBXWAG9I\7J6;D[)KW!^VP[(-M X^MSTY/2HTP
M5;W9<HR?GG9 XO,U)X*A"*^J+-]<:>UKJ)NQLZWJ<?4A[7(5^2FA(UPS(:W:
MG0:AJ^LBQX9)+XT+$0-$H=5KT5!0K4?"A#Q>26 $'GR11;U\44#?#I@X6M[-
M\3>$KL/%P$,!X@DR@&(A8\2+C T.]6^KQ#J!  66!1TN$/.ON)9:1A;SKCJL
M96M2LR<AT^)5&YNZ_-;G[(>'_P!<NU]A^TNY6-PR)F8:(@EQE1[&;^UO4G@(
M*4?F8U;]&U_LBN4Q^18D2%$JEG8%<H\XT(MTM;@(:V )&7P5B <_BM+&>&]^
M5E::EL;I[O*W:6V37JMM&@24]O O9_<2,FJ5ME[74A-B##;9W.!9Z],5V>U9
M4;#4'HBYM5@60;FFYNHSK,\;G$UXBN7++H.%O)13@:>_S*Q>;\,*3GMG-W:9
M[#&62./M>K=I6V3M.KX@_<]CVSJ?KT5U\BY1G:\/:*_$0.O;5&.MVZZZ[C=:
M^1L\390H2QP4):SP&%;4IQU-+FN7KG6BFEZU]4I\_&U-<-U_X1XVMYO1-CK^
MVZCF3T@/T<2.R?I-#T393NH^I=\:BM4J8"%L>,?"D]LQF\7K ":DTQVDV&HP
MI$A]NF5J9';V=LZ^^GE11NY4M2FF=*^=5<QRJLG")PB<(G"*,V]^H^F>R!;1
M>TVMBF8:@LUM4?5]R;:H4 5%J+)-RB2K%)N<#6Y4G+Y;ON'2<268^RD<4A]T
M405EG63^$26).#IL3#J0^SW84Y-R\,LJ7?:A0(T.&\U)JYS"2*-)+0 -;/83
M)XB09H3#J,[/=A3DW+PRTDD[T*!'APWFI-7.:7$4!)  $7;YX5N@+UL#1TY*
M&W.;UUJE_;QEBUOL'8VX=E*O!>SJC7*J%\+;;7M N6J$?7DU_P",,B8UDR.L
MV"L#2 [&&,.N<B2D8&'LB0Y;M]V(X/=VTU,S)! I]ETQ%BEE12H:0#2X)6:3
MD)>1:YD QRU[M]W;S4S-'>H!]ETS%BN8*#[K2 3<BH!6(VGPR9>:V3LX2N;@
MHU"ZK;8V-U1V!8]"5C1C@MKC!.HT'JN.H5!IVSF-IB5JJTN3D-2UU^4'%U"5
M)B0BB(&'D %J;E6^97QH1XUKYKETN3Q(/A2BF_J+03>J=O\ 9_:+%B8DANQ=
MZUQ<AZT/!)B6Z2WK_2E U!\J2>B3+;G$R>:/FP)*1'0J04R>(KX4K(?S I6P
M'"OO0"Y/&GN4BN0I3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X10E[-5>S3
MO8WP[9J$KTY,0U,[';5F[A+1<4>?&56&D.FW96L@2UC.%8=%A(TVR3D+ "'2
M3HPQ,U+QD6RZLTX5AV1KT^(53F/6H^ /EJJ+(&![2[LO&A-06ZL=W82GU2;J
MVJ>P<LZ+O[743,/C]ENQ!=Q^"V)&/0[D[6RM<2%'9/V!69QR*=JTI#! 6-MT
M#VHUE0V/*QTX>KA,SKSSTKX:7URT6O:#K3L93-?:T$[!PGB(6'05EHO678/8
M&+I<KV>G]QD[XLG5G= .%!8K\BK9T?#0FX8K7(=QJE6(#KM5O NL';K$@PC1
M:N6M?[M;\*4J-/&F9IQLJBN1!IPOF:YGGKD*F]+UM"\.7KGNFU5SM!9.ZYFY
M9/:FQ:]K+1%GK]^LUM?UT94Y#IGUF<V?)TFGR9&:8^3,;=D]EQEDM]:#<&/G
MXZ?B$EY6)(,<J3PTK0ZYV5AQ-;Z'++N'6W)5ZT+4?8.&T?3[UVRUWVI8I3^[
M*YU]WM7M Q>W@]V6+5/4/JI8=)Z$N20]3.@;6D=?7KLZS;MK#$5UU5?)-N].
MGY9PRJK*/78TT-:"U: 7->F1I2GD%&53>G+.PM4TKH=>&E5KO(??34M,W)/;
M$UWVOE-I[9TIO>B2ANK:/LNQRM@[&VKPS?#JA-?VR4=HH+C#DC'7O6^W8-O9
M;/G#P-[@;A%1\R)*K?%<6KIF/#>=\QW*+TR-:'QW10^X\^\K8VTNOW::4MNQ
M]C@8[L?:?$GW)M\$/!W;L0)7\36K-Y=2R.L@<748N7:K:XOY/;-X3]2A&(I8
M-U8Q9CGAYP&KL)AP.7W::UIS^ \N^2,R-ZO?ZS/2E:<IT>$S!=G(_;W9\_?)
M6Y1S2%-,;#B]B5;;\=2S]R_EK[7(78-=67:MUFJ[.-KU\Y7!'?R@JM7M.XU_
MG5*&'GI\4P(*#2@ISX5[Z?'FI%:DG.V5:>_X>:O-Y563A$X1.$3A$X1.$3A$
MX1.$3A$X15K] _UX/%!_E!I7_15ZM<DY#I\2J-S=U^)6YNPFY.V>OY_$3H/I
MKCL##KAXH[[7$]@-;ZM"9E29,AB4@W(.TCD33BXZ,99.;DFDY#*=-;&1C&1B
M%<[7@.$;+3T#M<=VN_0481HK/JC<"Q'$WF$V&UT*.(TL6P0(D5Q889.^UK"X
M_>:N-,QIN&ZDO)?611IWS,0H(J74<*/!=]EMZTO6@4*.T[_8[:%;ZWW&W1/8
M3I[;9WN!IC1EBH>I^R \W'6+4-[FF<V:URAVL<(AQI%>5E18AYR4R<&S'*(]
MS YK&>:S&)/"I&:9"PC&6X[+.EQ$?-C#IK#A#C%T0&!V$Y6(XM:V&_M6_8=V
M@:/M-<LD%\:(S>CP#+OW]T,[5L6K?L_:WF4%R7"F=JZA1T:[%;E@=I1W68/<
MFW2]RU/Q.=M'25->19+AL=72.#ZX[%LU0L1T0^)E=KU@]-8J!44^ZZN%L-U6
M!"M/NS;JPTZB@N:6I;K;GWTX:+-4V&N]>VE3RZ7]^:B1H_LAV2>HUQJA._=Z
M;/H[-EZ@']C^R.J=C[/V2-0M26B[W:*W)*AUJ^ZQC]N=6]]$-!UW&X-7TZ;N
M-?UA123;'58JC&P3LL9-!YT%!7*VMQSU-KJ+Y$]2*Y<,K&]<A;A12*WKV2K-
M4H^@H#47=?N5 &6W<.RHS3]XVV@I%.Q2('85-+FMK;(L16O9;9&\-3UR.#L5
M TA 6YV1D=NGV@MV8-77(!-ZJ\ :D6UTO3W<3PY9*<\B>[2ASXGX^]=E'E59
M.$3A$X11>W[M/LK02V0]$]6$[\9?@'#US)&ZJ+K */G<$DM-P9 %G'(DBTY&
M:',S(B)^'S\5@;'DZTZK&EQ2>QB5>&X9@AQ-IA;QBG$)63:R)O.'9ED?^,=]
MD!V\VWVMW,%>E[";,^SK'83XNV_M..PKH<\V V4A[&XYM-&F)$PX;W3L.-AC
MX<O"(B.B01+Q7=I_%]I=KF@P+[HR_92_Z.I%ZGJ]O;J'>87LSUKUD/!:C[$"
M3+5QUWN/?>IJ1L26G7-:H;$6[&5>3G1(A^5;^)KJGC)D5:$NK4CE89-3\RR*
M[$,+.&/:ZD.&Z<EYSM6[M2\.E[,H[[.Z\;QS"T6V>"[*8)-RD'9+;9NVTK&E
MW19F=9L]BNSGU.8$5S&RIEL5+HL?>A!L7MH)[,;VX?M-OH*6WKMK6^[K-U0'
MW+MZ4VB'XFG4_P#*UI\_,V>R;#M?2<73FCI+9<ZS(/BJ79=;&R$%M-_8,YDE
M<;]I_M U./C29R&7ME04K3]4^-33OR[ET_6E?UO=0$]!^[50SU=V6[4HB-XU
MB%WMO?<2G*YJ:R;?W'KBT['M\KJ769W:BGU7=YLWH'8^K_MAU9[3U_2MCNAP
M6M-762R4T6L5.?M,+4&)6JP4R[-.0I?E6UKVJ+9VSU4"O'.G.EZ'/(^.1[I"
M=E>QM+I>B86,T?W:[J13EIWEL6IZ V'L4^5735G#4C7YDML>T;0G=?SVU]L]
M;-'S<E*DQ,5,9GY#:6P9Z7UR(NR56$B96I10FMAEIGGH!D>-K#WSPN=;G+OM
MX5[CD1OKNAOWQ#H[6O? &,UH-0M<4NCZ5?T#NG7FQK(!=9D^Q;#9C)&1KRA=
M6 9?D+;!?!D6^.CYLAS3^2FHULBYHE\EB@!]FE2:W%O7C[D)-_.XI46TX\/!
M:*OPG8W0.S.O%,[G=M-SZ<TGLZV=M[0#G6/8#8&PK?1*]7M9: %UK3+=N]O6
M%/G]C3+VP5;#M%7A9&BFM!,65-7&)GVQU-HFQ#B!P]YN<S3QM1,J7.?'K^0O
M7.BE3U\O_=&;OGA4SV\K[;(UG;'7W;&=SZG<I U4<.O=;UN'-15ZV@2SA)*+
M+-#R$(6Q3%1E9C*C/(G$?+BCS$,0U3K3C[J^KU05M74>^@\[^')76<A63A$X
M1.$3A$X1.$3A%TW_ !(>]W;'4G<7L#2:'OO85,I-7M\ #&@"V!Z)KD".?6JJ
M8D1MS"2\"M%DOF.8<;0SC.7S,J:6O&'$\AC6[@) )-#6HRWM=>1L0N*Y[P]P
M#CF:#N]?(K3O8GQ0>PDC98>8UKV6V#48J5JDL[*U=%^C<.0$T+,SBV6,.C90
MUA:@D!LBH/88DB$--^3+N'1FW+EL,?JC*NM1H.(%['FH#HG$YCAEKYB^7-1S
MK'B7=U9"K19[O;+;C[[S#CK[SEL)SG&$N/-Y<4IC&,J2A"6\Y1YJRI>?N1Y+
M5FNXTVH*TTXVX ^ K6]Q8*"]X.;J5]U?7-<D7XD/=[(Q@HW:S;SIF127AECV
MAQ+N/;0K"5(0][:UISY.+;SAMWU*PKW/2EGT)G=9HT96XUKPS/7*QS4[[P;N
M.GHGE;QT7OU?Q+.ZE2_*WME^[9[.BH"5DID,F0G; =(0R5BY(PV[,Q[4#-NF
M,/XPVVTVS&%886WZT(:3EXG#<;0$@<\N[CGRRNF^\UH3R%_G;G6MU@6S?& [
M9&RE@5"]M[FP*6R,7%8IL_80Q63BXYI;X0#,K!!FI8$,;>:?9?\ ++#V<_"9
M+#5DU$$,O1HY6_?[Z=5-7VN>?K3A7]Y_@7B=]URHT0U';/="DJ;8:>=^TIBT
M>XZUA7G^AH<5[F5(4WG.6\N,*SA;J<>O.411E,K]+9U_+7IJF]$&9)[]?CQ-
M/$!>Y+>)3WI^626 ^T^YTDX +>:]RTGC/LJ$:R]E2,*;:5G'DWZE+5G'KP[Y
M9PA./1RQ#*&C0#IZYC*MSRL@<^Q+C3E?IESM2W*MRN==\47MW6XF(L\EVWVH
MRU88)QT%@Z<DIL9B5&E@17,I$C4%N)6EM13SPYS>$H%$._L<AYR/'+@M8/U1
M[K>'#W^\P'1#^L;4UIG^5\CDM'C>++W>DGV PNV>\"C,RS#"66IPYHHUAY9'
MJ<'8;4ZPZE#N4,X';?PXYCV,,M+3AW+$4;P'AGG=6J_]HY9\_=GF/>MJQ?B4
M]]S7_@5]C=Z"N.>>&<'6QIA9.6\MH]0CV9!:7_-;[/FTT[[N4N9SE"?9=PW(
M:/V,\C2G.O#+G^=2]VCR>0OPU[[67K2?B;]XD/0'I[3[G'4/90695C%K>0[D
M)9.!B<'-Y2XVT.VO&?<:<Q_Q'L)6CTX]<[K-&Y$5J-.I/CKKQ0.?JXW!I?6F
MM!WK"]@^+CV_C&IF% [3[\#GV)4Q8I49:FSX[#2LMI8$RM]]HAIA'H(=0Y[3
MB%IPAK/MJ6I3%2UM["WO'J_E3(V!?F7$BG@=?EUT6(5KQ8>^<@  ^]VFWXZX
M0YE'FNQE(;?6XZE*\MO+<2T^PA+S6$Y&6HAK#J$I'RI'N\4;3(5Z>N6B$OK]
MZUM3Q'[LU]"#K=/RUKZ[:$M,_(E2\[9-+:MGYJ6.6ITV4EIBC04C(R)CB\84
MX4:82\20M6,*6ZZM6<8SG/,!S/4KD#(= MT\A2G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+^94G&<)RK&%*\_2G
M.<8RKR^N?+'WY\L??Y?=^/A%_>$3A$X1.$3A%6OT#_7@\4'^4&E?]%7JUR3D
M.GQ*HW-W7XE64<A73A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1:9O>
MT92H;7T;KD.M@RL?MR0V"%*3Q$\_'&5C%+ISUJ$=!AFX.09L'S98[H!"'Y>"
M^6I]LIM4AE2AT2!8GA3WJ";@<:^Y;FY"E.$3A$X1:NVENC66E8R-F=G6AJK1
MLN8Y'QY3L9-R:2"VF,DN-91"1LDZSZ6<97[C[;36?TN%Y7G"<D6>P<U&6.%B
M+#"E8-AYZ+CYJ)-PT^Q@N,E!&C@"L,$M,DLX(%?:=PT0RT^WZ_0ZTVYA2<$7
M07\8N3=;[M=N1%"G_"NST".8ID)];"VWJ96\B/)*<0EO*\D(;;<2(_ZT,)(P
MM;>$*9<Y+3_%C/WC7,]=-#<YV'%(_C">?OY=,_552WI:(U;*[:I=<WY8[-2M
M9R9QS-EG:U'L'S<2]B),S!OY"(2XE02IWY8S+X8;R5\J=,4(M@C&'V@I6^2D
MUI;-6,=@]T=3*928W5FCM4T0Z3@528\IM6NV6^F/V@%UQLR/=.C[U](I\9:%
M-N%Q3F6W'OPV0E>1+Q%B6C( U[J>[XY\"L8!=2N7'CKKUM:F?18)2OA=GT1I
MRDU^ "V. U(2*H:MVDF6G9>'$:"P^G[)V08+);[8SA;J$50^0-'PVX:6&R#[
M?P<BXM0.!Y7]>'<CA0T)-/CD*^'519VXJ<S5XV%?KQH!H\@^9)BF/)3\F6E_
MV5,9]E#GI=+QAIY+6,Y;9%SAMQ"U(4[RAKTIYT%?G^]7;3E6^74GY]W<O8ZI
M; T#K^W32NQ.NS;M!R<(,/7Y&#+$:E*Q+ %-G-J'C)F,DX"35,(:P"4Y)Q9&
M0DJPX.G#;I>%FTK<51P)%C13;ENRFJ]U6=BHDZXUCIB@EP2H,6T4_5+0TW'G
MK]68R7L\!46A$D*?=;0[+GU*-5+,+?4?' &983&/6WQEN@#U?UXJNX<ZWKQT
M\#G\;K6DE.U&_@FT1RQF15RJSQD33)R9%E7(39B4FF#I-8ERXV"GHE<TTED\
M2$M\2QEA"VL%&A31#@#LDAU*V-M./KKPJE"VI&7(W'>!QY4XJ,>QH*Y0@V(&
M696#&1SJE,"*:2^1\6\K"'U+=3Y,^A66<^VVUZ,)3G.,+<RK.5T-18JS::&O
MRJ3UUO\ N7*:'W,SIB7GEDU" M;I:8Y8!$DET::@I6))63'S$#.@^S+PQ@I.
M5.Y^6%C()>;:03A]#>&5@::>M+B^8XH16_JGOT)IU6Z;OV)W#N\LF3G9[XQ9
M+J"0QY 8,A."([V5,NNH:0,%DG#K"UI,*&<=SG+6'58<PG.)+G<>!RX'/Q"K
MN@6SZ6/A6]CIYE8%,HC-E0;DU&P M'MD8R[%3T: ;,$Q$@4*C\*P1 QKA[0!
MI'X+90SIB\L%(]T!0S+B6&1H> (]_KYDE3=IS);XG]VJA]98PNOO8;RLIY33
MRUO.+4ZK+^6_)>49^CF$?@^:D+0E:?<0K*T9RO.7*JZF36^[VV)F!<HD5'5*
M*AI-@5,P#'08(S$@S'A#C9DRA2&R?(U_(K2S"0/A4&I8:P6,XXVV0FP>=/7=
MIQ5=P<3[O.EU]*;J<2HWJSUI,6VVRLO0&FR5LLMX:::4_KJN.J;::QC&&VT9
M7E*&\8QA"<83C&/+G&=F>I\UR6Y#H/);_P"0I3A$X1.$3A$X1.$4;^WM\MVL
M^M&X[O0;'7*;=(6H$8K5QN!(H-3I\O)EB1 ELLTC(P5FBHN K2S_ )W+RTW
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M?$'N._CSJ?X<>EB>R+S)9$5(]F+Z7)ZVZ:U UA_X0M\78KD>19MX%Q3WZ(1
MZ5@9T$IOT8<N46ES#Z;4I]ZW+7\N_P %%:Y7\OS[OS6#5?IQNR#[@=4>QO8K
M<^Q>S6UH5W=@1TA6ZZ/KSKEH"&LVLCH_$-1-<0A1#X;=AD"@X-VV[!G[E:;3
MF*CGB'HUP1MAI4;KAEEU-_AR4$'>;KG7@+6]$_)7 \JK)PB<(G"*O;Q,"@_S
M.@4,7"2UDS8-G4(%J!CJ.]L 25P+(O2A3$S73=4;IIAL>P&"0>V/?]?3%=>D
M P\!O1-F3 3<9(SKP!/JXZ*KLAS(%^JEIHEMEG1^FV1P;-&#M:JUXVQ&W5PY
MZY1[**C#I:!MKLG%P<D[9A$82Q/.2$+$'+E6RU%Q<>_EP1J%9=)+Q.[$9(>(
MAV>JA[+!C#MP@$PKC@XS;@*0:55B#6G2ATH(<0IIYTD7!B"$X]MQA"T)4A*N
M3#-FUX$"II2_&ELN>8'%<2(/M./CSRYZ&@Y9G2M..PZR.79$CPD21)')S[HT
M>T$P;[[;.?)\=_ :$$O*>;];SCCB,X:4VEMOTI;PXU) K:I.OF;Y^(1M:7H!
MIIZK6U#[UK ZK33TG\9FL2PKSC3+3H8S;A@SS;:?+SRAQ@@AI[R1A!2\.*0C
M"U(RVUC*4HJK:9]]/"E<_BM]*,CY2NH)$%<$*C7QQW/ATK%*#QZ?995Z\(:R
MR8-EE?Z+G.''L-M*3ZUJ6O-M*\*"O[N@ //H50B].M >)ZZ:ZW!H%G=PF!K?
M36R#<K->6W@9#ZO644Z7@E+2G5D*+RW[C+ZEIQ@MY",*3EII*\90OEC<5XTS
MR!RKGW4IS/.OW3;G^0N/+.ME$<FM4LPX ;,F0.26\M+F"L)']*FU(2VQZO>6
MV1EQO*U.>AAE;?N#L+PXM+BT\R9@X;#DI")+3T:9GHS8QQ"5=)F! D2US>P9
M"F71G&;=$8XE[FP838;F.;5P+23'1C$BA\)K83=SL7B)O/B6/:%\/< AAIIN
M />7BY##]E9.MU^J681GX%XD-MQCTO#N-D880YY)3Y+2TPG"5>OS]&6VEYPK
M&4X4CV7'. /7*O+E\%EN1S'F/"H/OY+94V4Q)GU&2]+'Q2'QRDKPVZVI]#1*
ML,>24-9R@E+C*?;=SC*<N*5Y*SEM'G)TX_(VY'K7RO49.!RY<Q4@=.&BD'9=
M>SFQ& X.N1:I2>F,-L"L^^PM27,IP2EXHA6%M-H9:RXIPG*O8:;:5DC&,^7N
MV+:TIR%]*5&F?/AT*HTT/+D-?SR[]*U6I+QU V52O?%E":9-RJA63S(R DQY
M>1$#);63A[#@ZF<*P*UAMTA0ZUI&2I"B'4I<;2YS'X5B,.0A8JZ3F!AL>*^!
M#G>S<9;MF$-,)T8 PX;R[>;#:]S3%+(G9AW9Q-UVT/M##WAV@9VFYO#>W*EH
M?N_>W2X;M:4#K9E:8C0[#0YMZ)D<^03@SJ\MN9<==';996IQ;A"$XPWZO2I"
MT^X[GSSE32</)PM7 I3.GRITO\#GP*R5!N/E6IIK:].JW=J1@=<4>8XV]AV;
M(7(CY4SC*6%YQZD?@*5E];+WOO.J:2G"LK=:SA;GL9SF6V%>8IX'(5%<QXJC
MM.-*:::CKW'Q6F9ZFR,M<17!@$R0B#!4EAEL+6MP?#Z,/MI;9SE665-Y5A:Q
MU,N^AQ25+5Y^IKER&'SN*33)/#I28G9B(?LP9:#%F'T! <]S8+7N;#;6KWTW
M6#,H^+#@PW1(L1D.&QI<Y[W!C&- K5SGT:T :NL0*K:VT=/Q56A3Y.*J3L*L
M'.'8HI828S*_<6PV/E(BLY0]A];R/4E3SR,(RG"\9QGSYW?$O9EM'AV$SV.A
M^$SV%2#7.C3>'8E#FX;FPW[D;LMUC&[T!U6Q841S(S7,B,;#>\!IZ7L_[1]B
MMIYMV'X'M'A>)SL-SFOEI2;EYB,TM/Z[8$2*6M<W[<-_W(C"'->0:GM%^)/M
MO<^K^CWACM:AVOLO5A5BU%6\6 K6MZM%!-F68G3.LU@L2AE3E8HHP41TXIUD
M0A]T9#SV7,-Y=PA:?G/VF8]/;.;/0\0P^9,I'=BTM+.BB'!BDPHLM//<S=CP
MXK!O/@PW$AH<-VQH2#]_?0E]G&P7M0]KV([.>T7 H>T. 2^P>-8M"D(D]BF'
MM9B4KC&S<K+3(C83.R$TYT.!/3<,0W1S!<(I<^&YS&.;&3PH^VW9-WNC UC:
M?:"Q66I6G6%M!Q =D-[[ F*M(S6;_J,&/:IH-EG)@,K93@DI)B5<-IEETMDV
M4'4[[2W$JZY[+=KL5VGF<9AXC/.G&R<O)Q(33!E86XZ-$CM<?ZW@PBX$0Z?:
M+J4J +KV7Z=WL4]D7LGP+V=3?LRV2A;-3.,XOCTMBT6'BN/8C];@2LEA\65A
MEN,XIB+(791(L9P= ;"<\O(>YS0T#M3:>KN_(.X[Q+V_>Z_;Z7.["S):.BXJ
M.$$E:A0G!,K7"3Y(<#"(+(9*=9%$P\N8+2T X47,FOG+5CV.R_-P5O7N]ZWY
MPI3A$X1.$3A%^5H0XA3;B4K0M*D+0M.%(6A6,I4E258SA258SG"DYQG&<9SC
M./+A%^?99\_5[3?J]:7//T)\_<0C#:'//R\_6E&,(2K],E&,)QG&,>7"*$&N
M_P!D;[:?Q0.B7]+7?SDZ#J?(*-3T'F5./D*54Y?_ !-=GZQC%3MS\,SO%$0&
M;54:8--./=9' S+!?KG":^I8+"&>PKA6%6.W62"APENCM-M/2;#IJA1T/O-3
M2NH]_P DKZ_<I0]>NSNSMUVZ5K5VZ6]D^N$9'5TB;'N6Y7M,.5R7.9D8T%%;
MCTZYVQ?)G$R0P>1)LY+BA8WX*+.PX>@G(HY#O!\?B$4PN0B<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PBZ\?92 KE:[Z"VC8%*A>P,FBTZ(K]UOK&K^P^MZ
MKHN!N^[:A/:;AM@WNA[0OFL;19RY^I4&/^8BZ$C7K! 0E;@=L6J(I)C^6[#+
MQ.8.E]+6KF>E54Y^&AH+VO6F>M[\K+L.<JK*+UNZBZJN;-[9DC+V!G8NRXG<
MED?@;C(PQ+FTZN3IXBB7D5\1*7&)G7F-%:\&IN%9= C@8\\,H(\>3)0J:GU3
MG\RHIU]4X<*66C5>%OU+$^!^S4!=*:F$(J)%79@+Q+OB5/-0C:;',M0,?9/M
M!'-(L#FN-=R]N</$D";%/4:LS)Q"CH_W753XUKSKQ]6T2@]5\UM2V=%NN%S$
M??EZ:Z/>"X'5D 9MN!/76=JD,Z:G2K)1)#[60#4<H27 F#S23CX\,1<JR\.
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MYAJG1B%8:3-:?=MSU_+N\5-*YWY:#Y]_@%9C 5^!JL+%UNKPD16Z["!,1L+
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MD&%.-G6NAAK2(G:M@2X:2XN;V>X:!H=O'>H-V\Y*YR<(G")PB<(G")PB]1
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MX1=TW\B#_=W^_AZQ?Y-_<QQ-._X*-3T'F5W2^8U*<(HE[%_X9_5O_ KVR_\
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M[ !:GTH50*Z!BU;DV]Z837E+8E#8G*8^,D8XZVWNR2T9GXZNTFEQ&%F2LU^
ME^1?BH-E>'Y3#C.KQ+$7R?80)6$V:Q&;B;DI*.?N-<&D&-&C/ <8<"!#JY[Z
M7=N,'VGBFIQ7$'RC(4"5A-F<0FWB'*2Q=N-< 6F-&C/%>SEX$,E\1Y%SNPQ]
MIX7GC.EDUMHT"U=VMGD;_.'(8DH_2M>#+I'6"JEM+;('::UTT<7*;,)C7L+:
M8G-JS5A04SGU(K\;E:FL<1N"OFW"+C<T9]P.\V2A@P,,A',#ZN'%\T6Y!\V^
M('"_9-*P-P=\T1%QF9,^X$.;)L:8&&0G"A ^K!Q=,EI!H^;?%!!J(;,E/&+B
MHN#C08>$C0(>(C!F0HV*BPQX^-CPQT8;8$!!$;9%$&8;3A#+##3;3:,82A"4
MXQCF]:UK&M8QK6,: &M: UK0,@UHH !H *+=M:UC6L8UK&- :UK0&M:!8!K1
M0  9 "@7O\LK)PB<(G"*,7<O6%UW-UHVCK/7E?UK:;;:@:^,!7]MP\+.4B3#
M!M]>EIUD@"RUBZUM-C17P)1ZAR5BJ5C@(2^-5J:F8@Z-CRF%!ZHH(J**DK:^
MJMGZ?\*;OC1-J057KTW&6[2,9#BP\/76)Y-5B NME:JPEMM- U7J36%O<A8&
M'C8&M.Z^K\E&URI1D/5IF<>LL5+QL7;4=WC7O/JJC(.!_.]A:@'PTT5T/>+6
ME]V_U=V=KS6-6J5RN\ZJD/0T%<WW0X]28/8M2L,K+P1[<O )B]AUJ&B9"R:I
MEB9V& B=GQ-0DI*4 CQ22FH%C?+UZ*DW!^*I!=UML#4?7?5E$V?7A8&X1GC'
M]#BS%RLP[:-J2X<K9-)'Q\EN.W,6^_U^R6W [V 84JL7&8C0J*'58PQ$?-!R
M@35AK_-.0H,],OWU4<?YS?,9W]9ZKLW\HK)PBTGNGKMJ+L(# 1^V*W)3[%7/
M>DX%R(NEZHYP!A'PJGE8E*%9:Q)$,K=  )^$++?$28"$:EA)8@[S<@D9)0>N
M:VS"0X5>AHB C/C/ET'& 0\?\PDY*:D/@HP5H(7XZ8FBY"8EC/88;^)DY8\V
M2/>]91Q9)3KKRX1=&#Q$AX.1\3+M6-87T,#.2D6.&8UC.3Q7\U&F9=;B1<.+
M29)%M)P%G*!WW$BND(]C"EY<:[ALK+S9B3>)X?A>&XUB&%0H#Y+#,9G($I@T
M2--1_J\6=QI[X<>8;A6#X=]>Q>8CRL%QEIB1E71HD(1&!_DGMAVHQ[9+95\]
MLWA\:>Q&8G84NZ(V0B3DOA\F(,>9FIR:(G)"!*P]R )9DU.3<O*0XDPUT6(W
M=!6"=B^L^M&F(]>JGJ]%/#")PI^&(7(0!^&!6U/,3+JGW,1U@C<.MO'(=8,]
M#RV2'6Q07@FT_&?T2/I+^T'VC1,7V?\ ;!@\QC3,9QF#@L#%,-V3P[#=HMFC
MB&*3DMA,"!(X9+2$GBFS>(1VQ9G")V8';RS)%KY*'BD[(3JI[>'M^C3M_@TD
MS"_:1"V9Q_9;#L:F\/\ :%B<3$<2Q&==($XGCNS<[,PH;6R\&,^7EYC!H,:?
ME6Q(/V)S#&1($L^LBT;&!K^NSZ^] Y!D,KR:V0DE\C$P^6\RXT\4X0\V3CR\
MF,(']6%+%0/AKT*]25_6N(&&^9FGRTM!@RD"8=*0S*&:BRAW'1-PB/-DS#HD
MPR&Z.P1^SC.9O$0(#&=E"]/AAQ:PESB2 XDM##4\AO4MF*G2KB5S6GX%Z)HY
ML]+BX'E;!DPK&'GE*=2V0PI+"6LM*PA'X6''UK2[A2FUX:RE/M.^O@ML"=:<
M=-?0->EJW<:N K;7/.O#\ES]2$A2X*<D3</E*%DSF, #//,()4GWG&&G'<MJ
M42SAE:'R?;;]Q;(^6L>M"6U\-%B<ZCU?(:9]<A4P[.UM:_'OY5KULI2=<^N]
M)W17EW2_EQ\/!P$FH.U@(FAZ^;"Q2BAHR*(?P6\$^2P>0<ITV5=E8R,AW(I8
M[ DJ9(C!*^</I.^W+:GV'-V/PK978F6Q+$MO-FYW%L!VIV@P_',3P:9QG"YC
M%3BNSV%RN%""PXG(R<A)ETC-2&-S>)/Q5LU)1,,PV1CX@[9;";-RGM(Q#;'9
MG]-;<G:["L5V5D-EM@O9?LYA.+;7;0X-CDL]^,;83N+;0?7\-PO9_ 9BLK%9
M*8-,S9BRLP9J9E&1I9QP[M-&06KX=&O:<ZR@*6RB-BHQL]TX9A#Q++ZI,-W+
MRE>1^&<LGJREEI3S3RR1F#",L,_27LOVWQ#VM_1TV<]I6UVS6$;+[4S&/1\&
MPZ'A.&#!F8IA4HR!O1XDBYSVB%#BQ<2A[T"L%SY>6=#F(S6Q(L[XSL[+X[LS
M[6_:_P"S6/M=-^T+ -A<?@X?)[7STK+24>+B+X3W8K@AEI$Q)5L?"(KI9DPU
MLS,"%$B16P8CI:)+L@Q_ET-UZFC@,YS@UP5@).<ISA32B?;8?<PO"$_[VHCW
M/)M*T)4I.$J3AO*.5/V0*:]_O'AI32N:]4S=?GP'?0\,];6I1>2G1UUKH,2%
M2<#AV!Q\:0.DUF_!R$8A#S:W%DL^PXISW5$^U@?!"<.Y1AI([*'4X<W.SF"S
M.T6-X7@<J=R-B<["EC%IO=A#=]N/,.%"*0(+(D6CJ EH:2*U6NQG%)3!,*Q+
M&9YSF2>%R$U/S!:VKNQE(,2.]K!6CGN#-Q@R<\@5 -1<%'Z.@+%4:_8[ZY9Y
MBQ72P"P<0:PZ 1[CF7EM2DC'QSDQ'I::)(PW%#!93$&#/@/21/S$%2?/XLVV
M^G=[6=B_;#[1=@O9AAGLUP?8GV3?I&)BLIM'A>+SLWCL.6W'P!CV-B''G)2*
M8,.+BLQ,X1#, P,2E\.@&5G(!<O)9C L,QWV9^RGVE8_M_[2HNTOM>F<2?@N
M [ 3& X%AFP'98UBF$8;AT:1QW!9EFV4S$,G+S4VZ-BS8;61WAC8#(42,^H?
MM&I0=N(I[)A4@0 E,D<9(^TLML1I&%#CDN*3CXHATU*A<NX<0M3(V5>2T.>E
M'W)M!$PC%<!V"VPPZ3A85,[<;)8=M-B.$2;XL7#Y.9Q&&V.]TDZ.[M8,O%B1
M(C8$NUIA,A01N[I!=&WGL@VJQO:[9)N)8]+P8<[*XKC.#.CP20)PX-BDWAWU
MI\'?B]C$BMEV/BL$1[&Q'.:UV;6Z2=B)VD:\B_D[R?F,TQDP@CVU8]SXA2E)
M#]"%I;<5EW",.+PAQ2U-82/E>&\NL]1=]EI.M":=*^OF<O4A1SKV:#GYFO33
M76RM]ZWZRT_ ZJ!E+)DDF<M<:DZ^7*6D0?BX\IH-Q47$@0!2'F3XM)I)<>5'
MAX;?$(PZ0>ZSZF"7?GOVQ8O]*O8_VQ8?A/LFEL;A2<L[#IK8# \"PC%IK#MN
MY6?;)OQ'$]HL:@L9)0YF3EXL)T>7Q.!&P:5:^-ATM+/>Z?B1OC+:O:'8_;*=
MQF4]H4S'PB?V>Q7&\.F(T#%8$CB.QQDNV_0+L PIL.%BN,OQUL/ZRZ>E"S%#
MVD..R+)R+)!HK(VG)N[&V:F/"*,)JU.*-#B627',N./N$.J4M2<Y\G&PV5X0
M-Z%)<\E8QCT^PC+GV![19N6F]IHP@R\O+SDI*2DEC8DF"'(Q,?EH6YB[I!C7
M.:)1DWOR\%PAPP\0#$I$#OK$;Z1]F,/:"#L%LO\ PI>Y^-NPF3?.&*7.F?M0
M6NA&><Z(_?Q!T,M?/%KRPS+H@AM8T!C>U-XB326^K/AA,IPI"6]*^VE*L?A)
MPC4NGDX2K_Z6,8\L_7[_ #Y\T>V(TV5A</TW)_\ 9I]=$^D?_<%AW_ZGP_\
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M>0H3A%])#PK/V.SJ'_@;@/\ /&\]BP+^2,/_ *.WS*^M-C_[E\"_Q;+?YBL
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M?+';2(;#9 %55 1)QP!(FOO]]T I7N]PHH^^%YKBEZCM?B2Z[UY"(KE-K7B
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M3C"9$D3 Y1$60^RP8U'Q\>=D?+WF())A.9QC"T8Y2XII76NG=IK^Y7%"2<P
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M TK2=I4Z:RZ2\X0\0V_)OB^X2]@<<=CT,(=L?V1Z^>O%3V/XSX=*>06-[!\
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MP+_%LM_F*P'FV79%H??%RW_3HB!)T!I.J[LF#)$EBP1=JVXQJ,>$C6QL.#2
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M3APC"GLID#,8]APYE1+9+K2\$NC3@"+9CATZJ0'<2#>X/'X94%J76>Q?:SL
MZ&'[W8'<KKCS*D(_VU[SCW2$M^A66L8L+;ZE,+0I64Y:<;2ZV[A;:66GF^2
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MD#5X>=1[V&UY1SJV-;18UM#';,8QB$Q.NAMW($)Y$.5E8=J0I.4A"'*RD$
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M@D#6+$+XSZEP#9><VZVR<(G")PB<(G")PBACN3O3IC5UL=U34V;5V W[EO\
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M-,>),_4L.P7ZM+_6(P8V+&[.'M &]I$$-@<ZE2&-!R"T9J'Q->JFJX2J,O\
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M4SS[;WH>03NC9\;5Z>^REA+K@[U33;UENX9:884VXZ0/W*![.YN6BPQM1CF
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MLQQX32E+SY-)3Y)QKL1V[VLQ.#]5C8S,RTC>F'88(6$8<&FP;]2PR'*R[VM
M ;VD-Y UK=986'24)V^V Q\6W\=&K'C6U[6,7O%[V<+J8R4I0E*$)2A"$X2E
M*<82E*4X\DI2G'EA*4XQC&,8QC&,8\L<ZBN:OUPB<(G")PB<(G"+\J4E"5+6
MI*$(3E2UJSA*4I3CS4I2L^6$I3C&<YSG.,8QCSS]."0 230"Y)L !F25(!)
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MTCW_ *WV/V.D-G)$D:'%]K,5CS@:XU >-FW$"YA_JK^?F?.X]U]:MF]YI"I
MEIS@NN=;]':]H+8^%*SG+05PVBK<]I3Z4Y]*"1U1S^/+U9\U?7C]%;03/]N;
M2/@,=]Z#A6'2TM3^;,S7UR-ER%^*?P]]D6#4&S?L3E\5C0C_ !6(>T3;;'\=
M<^@'VXN$[,#8W#"2;F'$$Q#TI1?U/AT=>YO*'MMRN\.PIB7?=R[O/?>U+G%+
M5^-.:6)9837R6,Y\\_"MU% R<*4E#249RG@;)85$H9^)B6*N!J#B6)3D=O3L
M6184N6_A,$MT I0(?I!;?256;*RNQ6P,$MW0W8G879?!YL"]QC43#9S: O\
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M_/YKC^H_C>_"WP3=_$[Q3\[<G_W1_P 3+^?S7']1_&]^%O@F[^)WBGYVY/\
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MJO6_^8[67_9CBIXGQ*4' > 7/5;J_P!:*-8HFWTKKQHVH6R >()@K15]34*
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*B<(G")PB<(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g486549g49p57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g486549g49p57.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1IN4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    !XX0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              )R   %"          !
M                          $             !0@   )R
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   )R     %)G:'1L
M;VYG   %"     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   "<@    !29VAT;&]N9P  !0@    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     0X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
M      $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%1
M81,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"
MHW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W
M1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%
M,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55
M-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=W
MAY>GM\?_V@ , P$  A$#$0 _ .PP.E-LZ?58W%I?NQZ'U.=529/IL]1KG/'J
M;K7NWN?8KF+T5C]SLG$QJM6[6"BHZ M+_<W_ $C=S$/IW2F7].Q[?6VNOHQG
M%NUIC94&1K]+>M/T,J7;<LD%K V6,.TM^F_VAF[U8_\ ()E&^OVI:N9TGIC&
M-->)0TSK%3./\U0P^F])-)-N)07-DDNK8>/[*NVL>*FL>_U'@"7Q$D?G;6_1
M51H8^NVA[0187,>T\$'Z3>WBGH?&^I?6OJ=O5[R [ QA865X;&MK])C3[?48
MUFZRYS/YU=5_BXZF>J79F#F55]4?5%M5EU3&N:PG8YK["UV_W>ZIG^#_ $BI
M];Z-TC,R2RS'LKRKRP'*8[]*=NX-;ML:ZMS=/[:ZOZ@_5_ Z.,FS"?9:S++7
M>I:X&0P.:QK0UK/H[WI?5-NU1T?#.0XVX%#*RW1I:QPD'EOL]JM?L;I'_<+'
M_P"VF?\ D5:+V#DC3E19?39&QP=.HCS20U_V-TC_ +A8_P#VTS_R*JG#Q,7K
M>%]EIKHWTY ?Z;0S=!QXW;(W+66?E?\ +>!_Q.3^7'24KK<G%J8'/8+,BAC_
M $W.8XM=8P.9ZE98]N_^LLYW3LIM5;A5<][@18WU\AL.'<?KKO8Y:/6?YC'_
M /#>-_Y]8EC=-LH?2\9.X5-+' @F9)=H7OLV?F)LKZ6D(<?HS?3#LAUH)9):
MW(R00Z3XY+_S-G]M!9@4"T-L-Q:9&F3D#4?]?6FRK.:*Q9D-L#1^E_1P7F3Q
M^D_1^U5<HBIX?, .GY%$?RM#C_7+&OZ;]7,G.Z.^]N93L<TF^^R&;F^L[TK+
M7M?MJWKSFKZU?6UUU58Z@ZYUCV 5-W[B'%OM$'W.>U>O95M>3A/I=KN'A(CA
MS2#]+<W\Q<K1TC Q<RN[%P:JW8[BRM[&@%A=[#L]VY%+UC.CX+V!X.1[A/\
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M-N^S[?\ @L<V>GZ?\WM_L):J?__9.$))300A      !5     0$    / $$
M9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0
M &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      7Y-30 J
M    "  , 0   P    $%%    0$  P    $">@   0(  P    ,   "> 08
M P    $  @   1(  P    $  0   14  P    $  P   1H !0    $   "D
M 1L !0    $   "L 2@  P    $  @   3$  @   !X   "T 3(  @   !0
M  #2AVD !     $   #H   !(  (  @ "  MQL   "<0 "W&P   )Q!!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$W.C X.C$W(#$P.C(T.C$U
M      20   '    !# R,C&@ 0 #     ?__  "@ @ $     0  !0B@ P $
M     0   G(         !@$#  ,    !  8   $:  4    !   !;@$;  4
M   !   !=@$H  ,    !  (   (!  0    !   !?@("  0    !
M      !(     0   $@    !.$))30/]       (          #_X0& 34T
M*@    @ # $   ,    !!10   $!  ,    ! GH   $"  ,    #    G@$&
M  ,    !  (   $2  ,    !      $5  ,    !  ,   $:  4    !
MI $;  4    !    K $H  ,    !  (   $Q  (    >    M $R  (    4
M    TH=I  0    !    Z    2  "  (  @   /      0   \     !061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHP.#HQ-R Q,#HR-#HQ
M-0     $D   !P    0P,C(QH $  P    '__P  H ( !     $   4(H ,
M!     $   )R          8! P #     0 &   !&@ %     0   6X!&P %
M     0   78!*  #     0 "   " 0 $     0   7X" @ $     0
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M,\N/7"-,5EPUS^\\CLD+!5<)R-/8778&FFG&A$HSX$OQ]8."BJ/%F20()%W
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M\+\Z/VN_*!6:&\P%OJ+@^"9,.$ZI2I%Y-LX51+N8D'))4AV3/C2W8J=GW<9
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M:>/5%V5$VWWWXW((RB]])&AUWQOX$Y8((,W(&77$V@:;@E[?Q(.7XS.B/;M
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M38^6/TGCF5F&CVL^C0IMPVP6=YW_ /C8*>(HG:+J?<8DNK5W$#O&UJC8.Q3
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M07':N#-(8JV\L'%==;3X3<@B1=#B/("D!$J)T[ELGKPGJ?/K@BEKI]5Q(%;
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MG&IL2%K^H$9<AR1 6U-!(VU5=SW1>"JM%06I\5EMIY=S433?J%=E%21"115
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M8[2>SNY-ZNXO:FKL;S3Y^)2P;"QAPY=M+'*;Y%BUL>0\V].D[N-IV(P.N;N
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MGOCZ[\U#Z=:=92I'5>.T].(I!A@!@*"CSBDZ\NWS[CBDJ*OSZ>G?BI'&><?
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MW53HZ07PYW\D59>?<J\S7>!I)GE2&'Q*%G>PRFBRAP$_!RU90QDJ;<M7E]\
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M&0C12$I[?%OZCJO-(T^SJPHUL/1Q5&H:NT#3K,95EQ:"QS'BH:5#9+@ZLPR
MVZU2P5.HQSCBF M+1L[)\1<X@A@,'P"'ND69<28!YU+YV(F"I"DUNG-M>1'6
M;XIK[]Y710JTI<HM\2D64M^HC9)#;IJVWIVVLHENS&9F.ID&,-/5<F;;>ZQ^
M6,_4]6DVDZAV9B*@Q&RRD\TZCCWG[NKAZCG=VTTZ=*BRCWM7;<QP%2B #MDC
M=# 4ZNTTXJDUP\4DPPC9:=D$P=HE]@0)+':"ZHU YF<NQ'3; <ZHM'+W+[;,
M-/I>H5MB+-LY56&-U]9"QJ;95J/2<?=:DVC'X2,QHC%@W1^_/QECL_W](8AE
MZL?VYCL*W#/PW9+\4^O@?W=>B*^P^DYIHAU!K2"#6_RET[0'^.,W!<Z&#HU:
MM2G5Q8PX#G,8\L!8=D3M.=_JW(3'EOD#I3GTK4;#(N4SL9N,1DR+C*:L\?OE
MCK<0$QS*;C' 6Q2*;D9N5*;JAG.LQWY3#"R%89F2VVQDN?<P.*J8G#MK5:+\
M.]SZC.XJ$&HSNZCJ9#S(!/@)D6=F)!"\M:F*3]@/;4&RT[;39TM!D1^$Y?\
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M428D2E@XU_R'!O8ETW9W4"4L-B+<VD=JXNWO!V96_4[JO[OM'&=G'LP.PQQ
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C<R:K':BN@OVDB!5UD)^>ZP4IV)7PHYNDU%8 (I'/U(^B_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g486549g61b08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g486549g61b08.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1XP4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M   *<')O;V93971U<     ,     360@('1Y<&4    !        0TU930
M  !);G1E96YU;0    !);G1E     $EM9R      37!";&)O;VP! #A"24T$
M.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P
M  !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#
M8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M    16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M  !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M          !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q
M=NT:H         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0
M<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&
M(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7
M:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M#&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M      MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /      0 !
M \     !  $X0DE-!"8       X             /X   #A"24T$#0
M!    '@X0DE-!!D       0    >.$))30/S       )           ! #A"
M24T$"@       0  .$))32<0       *  $          3A"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8             !X,
M  D)          $                          0             )"0
M!X,                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M!X,     4F=H=&QO;F<   D)    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M>ZE_X;O_ //CU]*_:\7_ $U>O'N']Z^:NOD'KO4B""#EWP1J/YQZ2GZ3Z?\
MT#&_XIG_ %(5A5.FWT.P\9C;&.?Z+/:' GZ+?!6TE*22224__]?U5)?*J22G
MZJ27RJDDI^GL_P#96ZO]H>E.RW9ZT1LV?K7T_;Z?H_SV[\Q5,H=!.)8*#A-L
M+#Z3B*7 .C]&=CG,8[_/7S8DDI^B.EMP!9;]N?@/$#TMK*&.^E9]+T[+?\'Z
M*N_]C?Z;TOL?J3^DV^ENW;6[)W?G>GZ?TE\U))*?H5S<P5C;9B']$  64!V^
M'>YY]5U?TMOJ5U_H_P#1V?36B[_FW-?J?8M^[]'/I?2VOG;_ "O2]5?-*22G
MZ2RQAEM0Z<_#8=Y]4EM;QMV/B6[ZO\+Z7T42H=)%+!FG!=D1^D+0QK9_DML<
M]W_27S2DDI^CL@=+./1^R783=600VIP]+;[=ONK]G\W]#_!?S:AL>+_TMV <
M?<S=OJ8);KZK6Q>[;9_*<OG1))3]'9@Z,7#["<)N1O9ZVE!ED6;!=N<Q[:]W
MYU?Z7_1H6.V_>!;;A[(?[_3JVCGT=U3+M_\ *?LN_P!'_P )8OG9))3]&]*;
M0,F@Y3\%UT?H&U,8V\7;'^K#JK+&._0>M_-L6ZOE5))3]5)+Y5224__9 #A"
M24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H
M &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %,
M-@    $ .$))300B      &F24DJ  @    /   ! P !    00H   $! P !
M    R@@   (! P #    P@    ,! P !     0    8! P !     @   !(!
M P !     0   !4! P !     P   !H!!0 !    R    !L!!0 !    T
M !P! P !     0   "@! P !     @   #$! @ >    V    #(! @ 4
M]@   #L! @ 2    "@$  &F'!  !    ' $  $@!   (  @ " #>^#< $"<
M -[X-P 0)P  061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHP
M.#HR." Q,3HS-#HT,0!786=N97(L2V%T:&QE96X@1  #  &@ P !    __\
M  *@!  !    "0D   .@!  !    @P<           8  P$#  $    &
M&@$%  $   "6 0  &P$%  $   "> 0  * $#  $    "     0($  $   "F
M 0   @($  $              $@    !    2     $    X0DE- _T
M  @      0   /_A :A)22H "     \   $#  $   !!"@   0$#  $   #*
M"    @$#  ,   #"     P$#  $    !    !@$#  $    "    $@$#  $
M        %0$#  $    #    &@$%  $   #(    &P$%  $   #0    ' $#
M  $    !    * $#  $    "    ,0$" !X   #8    ,@$" !0   #V
M.P$" !(    * 0  :8<$  $    < 0  2 $   @ "  ( , #   !    P ,
M  $   !!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$W.C X.C(X
M(#$Q.C,T.C0Q %=A9VYE<BQ+871H;&5E;B!$  ,  : #  $   #__P   J $
M  $    )"0   Z $  $   "#!P          !@ # 0,  0    8    : 04
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MCD*, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & 58>8/I+;G?GJ4)I.DB%/,IV!ORD+B;-KX6DR57GAU43!*4$8S
M)M(E&)<8=,CZ2&HUPR3#[(.VB[E%=RVUVXWYU"[.[Y&8E=67,C!T6\:/9NK>
M^9/N_?X;H90*##K:4Z]!J-\=T)G\2A-AJ')R+FBE@W,0FP&(:F3<9U&;"(RR
M91YWOHBZ07W+L]1NS0FNK67.[O;PU%GO7>7"R^NA?=F30P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M1Y$?M699J+]/\49A_5_)ERF9-# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MC;.-2N<L[7K\8Z6(:QR[G<L-E)^NJ4Y>N4]A6C9!%KP79ZR$#NM;YEP&9-#
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M_P#-S_W8!&7I1^XTZD_DR4+]E<4RO5]K\R+1=B\B3>0HP!@# & , 8 P!@#
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MQJ7%!BGQ &9)CE?>&*WJ).U-T?9K:IJZ9<3>3?D:4*5GQYW99AF30P!@# &
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M8&)P/<N92_5://*OFN[PMQUX'L]W)\WO<<L[\-/ ZS9OBB-E9Y:)"M!_7$3
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M,VJ">B+=NBFBEIKIIKKQ"D>>E'[C3J3^3)0OV5Q3*]7VOS(M%V+R)-Y"C &
M, 8 P!@# & , 8!K%V78-S5%Y(KQL*HY]VBB73YWW4ZN0#MG(XG7_0TM48;L
M+8\+ZRUP#AR(&RHP5[5FHE, DIIF.V;8\!?#"48?R]X2B;4EO'2)EETRLKJ[
MM=9\-?+3Z,Y.]VUI=7=O6GGVHV=,YG48!K.S*)=TRUN=OI/V&H^SM1%F0;H$
M=M)I!98\M6#M>O\  N_$[<VO2-40Z#LWAN2L5>J;V6_2E'@(AU,[!6XEQ<I&
MFVMHPV),=W65LK7MIR6;N\L]-? Y.]W=-IZVY7RM_KGVENGCW#;A*AL-$%%S
ML(IQ[V%N0EUSALAB<A@+F.4D\D"6P5F(@LJ%A#T/A;V6Z30S7<>=!1#(? "D
M9TCXUE&M@R&DBX=BOQS]>N!N'CVNV5OD22O>LY#<53R^MHI<%C4)().W&(#K
M<J3>+IV'#MQYP877<1O>:1R6QGA8HU'K@GWQ6.DD^111_P -]$'G+=VA$[/2
MY6KJU[=2I#P,Q(I J1[T0HW.959I>)^5WOA'"=ASG8/O,IP_!SX,+>2V4[1\
M4#![2&1N6JIDUL(#"AG))ZZY8#F37V+9*Q</XHD/'^3-+[LG\JO\NE8]BK\K
M:*SFD$(O7MU6G!XVB\I&.O7B(&)SDZ!#I.WBCOA1VY3'L&^B[G?CC==7C97;
MCC;;G.FY#R\7]SGOQ<_!?8@YV>^4K^47MW0UC]<+EF-//ZQM00S"2YF!I\"!
M+KL&)D8>0U8EVSK==BIP0$L]ME$]>=MDM5$O[RG/.%"EFEYAQ-Y-^1G5+Y7%
MYD$4DT=)[1'J))Z)Z>FB8USSZNFO&NOIY]\^_P ^CCCT\_X<;D/+Q?W&_%S\
M%]BSGPW?*0O)SW5\EO5?J_><PJ(C5%LRB8BI@RCM1 HZ:79A:NG4K8ZL335R
MHX8[ZEP [=3=/3GE1#55#GT:J\\\9BA23:7GS*HHKK/CT/1!SF=1@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & 5P>5.J)W;_ %-> ZO RX]8T:M2H;$A
M/$#+]?04L$2&"3@9(&9L42[/(N*?TU9<-5$R;.0(+JEP[@@':-W/+]1LKJ%I
M//D^?T]6,QZ=ZOV'1_$38-FS6A;>!7.1G#JU*H[)3&LYL,L/[ES:21LBUKJJ
M9BP#J+]0@8*HG3!P!F8B0CG.J3Z2J-3VGQ=_RAJ.9,D22M;BD_5Q#FGV_1<B
MU?,FA@# & , K*\9GZU[[?G->WG^N8KE?T7DB+3O?FRS7(48!6+Y%[N[VT\!
MAKOJ!2[*QE",DW9&G@\#(K).:#> JSG?9_#! <:G'F:1+71! SS)BGONWJH;
M#VNROK:?L'LJV=]G&/5%?!MSM!'A7N:53*>7.JZ/!Z9S?Q"@_P 6(5%1-=5,
M<I[T5.J23[M7B]Y&EG^'^V+:GVH[-TV&S/9_LW#C'OJN*74S::AK\=JE*5,X
M_P#-AM)2RU12X9OY8*EUD]37:!RI;9->@I%:LKJ2!R"YXD+A=@E8G%WY\*,(
MOW?*9)]&A#TMN2'$0 %Q%RNAIP3:O(MS\8U"\MM&_)Q_OSORE^?;3TF"T..X
MG2[/UT[$<+D5U;*IJB=*E0)R959/ER%)G2:FI@K9+IX),<%:OP_XC?<2IY:M
M?]+V0K<?Q'9W":S:;#I&&8O48?03JNEDSIT<2G3J&FFU#GT\^DI8\/J%51SY
M<S#VZG\+[M0.JFQ7W:EG55V##9!<IR*=-Y/8'D*;VQVWGM4]LR[,%'H6ZB$J
MVN(SUJ9G+OYD3<E):TC%>G:KH]?K<74X9MI6!3(/XBSC %&STO1999Y666ML
ML^&M^/6Y]%GR=[O/2^MN[IIDD^1U8@Z\FDB$V'O6UA]L L1B5,]CIU4QZUZF
MZVBKDL.[8E7G7HE65;3N,L*L3CND!+6D]M@=&$AL<B,HEC!I+QJ,D7B+:%2%
M>K=XZY<[:]O+//IU)^;K;/H\EQ[_ )]<F<;.HAW\B'90N: 2+M%.2L3'3NMZ
M.LA"OJ!?1BRTBT[HZ<1..]CR+6NP(H#4NJSZSQI:5P0% S[2)QQPBC)MILRB
MVATMVRT6M]>MK>GKU'YKNU^2=NO-_3+N1-;ID>[AE+4E#>^][A6!:P8TXL=G
M9T.JF-U[$;MTL/="-1WJ^:@(41))K4SFON3+DF8FA&:KI,V-<K*R5O-BE@C>
M(TN'I67U_P!&H7$WFO\ =^'=ZYV8YDT, 8 P!@# & , 8 P!@# (JSUTU8]P
MJ!?/7+=FR9]:^W;IV[=+)MVS5JWL#IXLX<N%U=M$D&Z"6FZJRRN^J:2>NV^^
MW&O'//&E\,7=YF7\4/\ ^7D?!UB:NK(>S/M>?;*(N[Q1#L*E8NDE$W,:ZUQ1
M8FM5FFR*VJ:C0I9S@V?NJ0)JM&)9BG/8[!3Z;I:NQZ^L?!<M>WC]%W!<6^.G
M9W_,D])(Z'EP$M&9 TV?A#C%<:49ZNGC+9RR<Z<Z+(\.Q[AJ];\[Z\\\>U:N
M45M?[^BFO/W\AK7)G 5K6<%IZ% ZZK6.M(G"(TV]RC\<8+/%F ACQMSLFQ8<
M/G+M9NQ;\<^R:,]%>&S-OJFV:)(MTDTM02MDCO6 , 8 P!@# & , 8 P!@%$
MO8&U_#U'O(/!3EJTDE+^YS2Y8;7BEHB*<FYP+"K$C@ZB1\(L"R#K9)M!'6D"
M?]CZ!@P6UR(^2$:]DLXC0)N8!<1XDH VE%NZY>?1?;B8;AWM,[K/AY\"]K,&
MQ@# & , IK\,?[$O(]^>(\B/VK,LU%^G^*,P_J_DSR1.ZG[LCMI^4S?'VIRK
M.QQ(S8 P"\#Y-W]=IT+_ !ZLC[";3S,?PON\T5:KM7F>Q1G$[C & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , IL\SD6G$@Z_BO:R6C#-./I)%HJ<Z]6GT
M8,=X9;>]M2:7@F-11^LX0QOREQZ,@:F=G"_");1\P;)ZJR0D=C@D"0=\ZAM?
M5KLMXW,1WZ-<L[W[CL7A>;@ W5"5PP7%*XK<_ ;VFL6L"IZ^Z<I=''55S3F+
M0&0K1.P*6;6K= ]W-WT</QR:ZS\58!@5+85+88H/V]V9)K+HM=6\M7Z].Y8-
M-+9^M2W',FB'O>(]: >DQHRFYM$Z^L&:7!2$+%R*7SY"L62PLQ:,86ED6%39
MS7MJ) I+.XBQ.P>//=(#)'J!.1(+B1S@PD/2WJ[]'IZX&8G:W:O7K@5,[=P[
ML/#;(-@[@GM=DNL$!I[>-UX_E%96./["7&\[^]H>L5T BT[,55'B]J0$^M0D
M7@56E(@$K ^Q$60S.O@P:=$ J('5DESNGW?ENN_YF;\VTU;)M*^>>BS7D2E\
M@-]6[7LNNU:!W.9JK7KWTB*]F:PB01I!%V=_7"SL&3A58)*M)?%Y$4/1\9Q$
M(1 5XW#7@$CR\OI)VN[YDFL%?!XDLKVUSN[6R^O#L+$VF\_TWX:WMR+4YT=D
MT<A,CD,0@[^Q96*"NB * #3D?CA&5%$4O7;@6A^3OAT;%.'BG]IT?F'[4<CM
M^&NOII^%D5KYNRYZFG>VEWRO]65C^(H_*91 ^ZYZ:P,A64H)^2/M@[,P4H>C
MLG?QI^N0B"SD2Y.Q-\3CQ)9BONHT4=BGSEFONALJW541W3WVL22>3ODL[6X>
MO]DA;:S5LWQ3X]"VC,FA@# & , 8 P!@# & , 8 P!@# & , 8 P!@%!?>GL
M['ICY7.FWC=TA=KJ*7)U_NMU<LW#0<V2B'%)3:6UC)RD41+#DE5/A$_^YZ-5
M-94JVU9!83'+%X4T-:2)9#0=M90M\].W^M>>1AN\27+UY>#+\M--$]-$T]-4
MTT]==---->-=--->.-==--=>.-====>..-=>........../1F#9TJRF<R(0&
M7,J\(:BIPZ OT8J2V+C &K(UNCMPR<<FC5>6R)&<)J^C;WPA6DW:H_[Y6.D=
M?[3R#TRU]='Y,P'T4D]O3GJ+U^GU['D9-9]A5?#Y_(S3<E'R:#S::@V,F9<I
M;1>JJ:#,$TV1-!/0*VA>VX377@6XD\Q7:J2<K7J_7U9(;V5^/KDO7%DL\A1@
M# & , 8 P!@# & , U#>RED5;&/-/+H82ZE5N=G]AVMUC'BP[Y[VRXN.Y5H;
M:71$ZQN:/:A#VW7%E7@AE(Y!89$*QAJH20&NB+@K=\U:O!8T,.Z?I3N\D\^'
M%?2W?DSDW:)Y+-K+5O->>O)]IMY9S.HP!@# & 4U^&/]B7D>_/$>1'[5F6:B
M_3_%&8?U?R9Y(G=3]V1VT_*9OC[4Y5G8XD9L 8!>!\F[^NTZ%_CU9'V$VGF8
M_A?=YHJU7:O,]BC.)W& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!0YY
MR9NTC5;5Z#+]L.M-4CI ]X(A>O5S,+L&6M;D]ATDCDEA<_ZW6;U3D7/:2N+.
MK$RR;\C2];UC:(Q9T:9LY"#]S<[LBFH=7Y\%VW]6\,1<,^[G;D[.S)#>&M9<
MGT[^<Q?JOV ZI3"8VE+I-.P/9ZQ+ MBXK;E3L3%FBUXG[!MH;'[4D+&8"&(<
M$!YL")0P^)#Q%F"3BHD,,$Z*(M=4^Q6786#3-//F[MEKN9-'6Y?#8A8,:+PR
M?16-SB'R!K[D>BDO!BY+&C;+VB:WNA<$::O19)K[9))7W=XU62]HFGOZGK::
M\\ =05HRDEW-<O%J=JQ9Y3J.K>HW2M?1)1S5B&B+9MHA7*^XCE6$(Z-V;-#5
M.,[#--46K9+C7C1!+75<67(_V8I"EI"]C1(_4%7G",,EI>?P]^8@$4)O8G.Y
M 4V-GIK&G3T2NN"EILUML7+R,7NU,$BFVQ!Z\6=\\JX)9<E\C*&"E97C,_6O
M?;\YKV\_US%LK^B\D1:=[\V6:Y"C & , 8 P!@# & , 8 P!@# & , 8 P!@
M&-;=M$!3=?GI_(6Y DD+X8L0T<")(N9)-)<?(M ,-@D49+K-D7\JFTI)"8O'
M&:SELW7+E&FKMTT:<+ND25PW8A-5]6'X)VNI67V2X&E[QMJB>V,VMTT*W4<B
M6)C>;]-&(&NXBY<(-E_H_JN.H,85$MN68]8[J.)3LZPUF4SE#Q[O],7)6M\]
M>U_UH8S3AOJ[W^6G8BR/,&R&7?\ NV>]?>K,_L6J-AZUJI$(5'JZ$/Q7,@5D
M<ED\U !?@(J.)*:/#YAX(=E5&(QAJL\WV;[N4D=]6V_H\'%*NHP_"\1Q"EHX
M:^?14L4Z72S(:B.7-F11RY$F".&EF2I[4<^=*@@AES8(HYL4N7"W%&H8OUOV
M%;%;.^T+VK;););75E3ANR^)U%?'C^)4M738?,P[#,/PFOQ*IKHZ^MDU%'14
M]+#2*;4U55*<B3(AF13'!"M^'$?B2G=FSWHO3[BT0BP-[%Q;6"PS5:/OH]R5
MK&)! @NOCB:+[T<E4"<>3:JH2!IQ[B;2UT?-N=^%=E-_7[.8MB.-8:J_%,,@
MPFJCGS8'1RY-9(@AEP;J@CA@KYL^H_R)N*\4R*%OX;+(^A_Y);!>SKV;^TRH
MV9]ENTG_ )7LI+P7"*R5BW_>83M#O5]5+G.MIWB."R9%%%[F*"#_  J6ILK>
MM,;NBRG/?'X&, 8 P!@# & , 8 P#\ETN'""R&VZJ>JR2B7*B"NZ*Z?"FG.G
M.Z*R?.JB2NO&WK)JZ<\;I[\<;:\\;<<<X!J)71RGU![W5O7XKNR6L2.@^T?5
M&"Z5!/?/?VWE7;1ZA:L_JD0MO,>CZP.1M)B,9NIEN<(0)_(B J6U:GH8,\MQ
M!1^W;=%9J]EHW\/+MR9R=T[7?#CG\EGX&WEG,ZC & , 8!37X8_V)>1[\\1Y
M$?M699J+]/\ %&8?U?R9Y(G=3]V1VT_*9OC[4Y5G8XD9L 8!>!\F[^NTZ%_C
MU9'V$VGF8_A?=YHJU7:O,]BC.)W& 5JWMWVNJG;6EU<17QC=ZK[C\96%)#[;
MJ-KUQ4KN7ZD0(LRX7C>\XO\ ALIY2$NB"X C\6C0S?@N*(<-=7++AJ\<VW5>
M/V,N)K]+?7TO6NA''KAYDYAVHB]9V/4GBU\A1>H[4*-V8"UUQ_6%"(-AG$F<
M14O)".G'8_<_H&CY%B3V*<M@KE_R@-=;,63Q3V*:M:ME=7[_ +6)O.U]WQ_H
MNXS)L8 P!@# & , 8 P!@# & , 8 P!@# & 0Q[IVVIUI@D?['1[K3)NQDKB
MLY@,'-#*KKD[8EW@*FGTS#B+&D%>"(A%)+*#/,5&;Z2\G&-7 (*79A%O?3#5
MTBQU7JSRY];9\.W,S%EG:_=?+CV&4NN786.=F( XL2+U_>-;C&\B?QOX#V I
M>P*)FSE=@P%D-RK*&V0&!'G<;=)ED4!\A09[BW[QH3:-G"BXYWHG/6M_(J=S
M/F"GQ$B0X,.(&##]F*$B63HD4*$72+(>-',4%'3U^_>N=TF[1FS;)*N'3IPH
MFBW03W55WT3TVVX C%]V]U3V1IQVE=$9<L+\C,)FM6%&38Z^#G(?99%@%K:4
MEC#,0N+A,>L,^38QN"&)V[C0^82=?YM1UP2.IJCT[9Y]-2;RYZ^N[O.Z6QV9
MHJC#\1C%K6*)AYN;\*K V;QH9?:(C&Y8, <222/! T@QA4.0/R*/@%YK,W("
M)(G3@@,H:U)$6C599O,-I:LSMD*5E>,S]:]]OSFO;O\ US%<KU[EY(BT[WYL
MLUR%& , 8 P!@# & , 8 P!@# & , 8 P!@# (:P?C[I.X_IB=Z\N*3HPW(H
MQ1+17CGEE/[5;ID(I8U\:Z<\\\.P,5;.#M25&ZYU11>;+VO-V^IL#)JV/,]:
M*W%Z]%R^_P N9E9N_!:=7SY=A\5@V370KOKUM@Q.?0H=-B'77M$FPAS^4@F<
MI>J&I[U6<AM&D?</TRSG<LVC$E<#-46F_+]"/'56O"J8A_LW+X8N[S#?YH>_
MR)AFS8B-!BLAD!)D&!@Q[PL8+$7";5@-&L$-W3U\\<J[:I(-FS=)1997?;C7
M333GGGG[V:E2IDZ9+DRH(IDV;'#+ERX$W%''&U###"EFVVTDCI!!',CA@@AB
MCCCB4,$$*<44443M###"KMQ-M))*[>2*ZXM(T+2>G^^-TLS :C*CCDF,=;H.
MX#OW9!G$VP]QQ*>Q4@CR2"A!S*YB)2<MH$P]UX4C<!W6?-TEWTEW?:^-5U5,
MI4<2G2WAE#O5,RJ42<JNJ9,$:CK(8EE'A]'#%,E8<X6X*J)S\3WILN?AT-)^
MD[7XE0^RC93%MG9U5*H\>JL/BK_:;BT422P#":.%8A!L3+F0.)P1TON96);8
MQ+_+_P!E)I-GXI=/%@V*08CF'Q\S*.S7I5UF<QEZJ_:1BFX!71)=9FY8\\22
MMHP,@\H121=II+;MD#X(@BU=<:>Q>MM$G;;91NLDIMX^'XA38K1R:^DB<4FH
MA<4*BLHX(DVHY<Q)Q)1P1)PQ)-JZNFX6F_P[8[:S!]N-FL)VIP&=%.PS%J?W
MTGWD*@GR)D$<4FHI:F7#%&I=32U$N93SX(8XX%,EQ."..6X8XICYYI],, 8
MP!@# & , 8 P#\E]%%4%DTEMFZJB2FB;C35/?=!3?3G71;3177=+?9+;GC?7
M5339/;G7CC?7;7GGCD#4U-#>_%2]_P!E6)R].V-TVHEV@ZY/*S?[^/GICK6%
MV]4%]ZA4OVP9[VVB5%B/HQ=PX._MF./6"9,#-@Z,0C(6/LC#^8B#++IE;3+M
M=EW?*_;D<G>__P KY?E7SOZM8VS\YG48 P!@# *:_#'^Q+R/?GB/(C]JS+-1
M?I_BC,/ZOY,\D3NI^[([:?E,WQ]J<JSL<2,V , O ^3=_7:="_QZLC[";3S,
M?PON\T5:KM7F>Q1G$[C /\[_ .\V_P#1V_[N< IV\ 'U0/2W\4K&^VZS?]N<
MU%\3]>NIF#X5W^;+B\R:& , 8 P!@# & , 8 P!@# & , 8 P!@%6?F0915U
MT9F#B=V)4,&A :QJ</2Z/WW/I?6-/75'P]CQ]X0H:>S2OAAZ;"@]GII\"$M(
M_')-[^138CST=,Q1R>8+5:\>Y7\#,6GW=K]/7]F._" C".>J%AEJREE*O:XD
M?8^>G834O72=6!9-*=9@KF%UHU4HR!3&RHE!)$49I%61*UC2+6( (V+E-JG1
M,6'H@6+'C+%KQTXJU\WP$&G#7@[ER&9-$9NU]$2SL;6#.M8Q98ZN&2TTC)^9
MHG(%Q8\8L6(1]5R_>5A,(UI+8.Z>PV4%M JLJ8(2)NVD8(8^AQ]F5BTD.BW=
M3L1JZL50P;H%V_AU,Q"GS/%635Y:'3GI=U>M>=LY*]@J=)+=7;;N&;%#4?BW
MPJ8JSQ-S!;CW"QEP*D 98G8,(;E"S., )5N[C5NODXGVW]6^6JN84+2MSMW9
M^.O#B27[A=:NQ-V'KRXKZ%0E0-VBZIR;IA*B<KL3X.2J 4UG=CJ1VZA+$?%C
MVDL'GXA:,A//(HT>B9&,DT7@@97V[0D:.Q8FLKWR=_+J5IN]DLU;/MU[/&_
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MC=\-)CUG#)\S<)\\;HN6JZJ*NG/&VF^W'/IP#EL 8 P!@# & , 8 P!@# &
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MRJJIV_[N1*5XX_=RXID=E=?#+@BB>>D+-PRXYKW)<+CC:=H4KMV3B>3Y)79
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M5R2>"C *>>V7UQWB!_@=\FG\Q.MV:7PQ=WF9?Q0]_D7#9DT, 8 P!@# & ,
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M IK\,?[$O(]^>(\B/VK,LU%^G^*,P_J_DSR1.ZG[LCMI^4S?'VIRK.QQ(S8
MP"\#Y-W]=IT+_'JR/L)M/,Q_"^[S15JNU>9[%&<3N>2_\K&^NIOC^#'KY]D<
M:SM!\*[_ #9QC^)]WDC6WS1D8!DFFOVWZI_A)@W\YQ> >\_GCGD&BW\M_P#V
MEO'Y_"A?/\U*XSI+X]WU.<SAW_0\[O.AS& , ]J[PL?5)^.;\C^C?YC"<X/5
M]K\SM!\*[_-D-OE1OU''=#_.>NOZ4E+98/B7>(_A?<>0UG8XC & >EG\B?\
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M0$%9 R*0]'GX42V,$HY&GCUPYTV7W6C@?E-1/5MMJKZ;H>^MG>[^AF[!1@#
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M37X8_P!B7D>_/$>1'[5F6:B_3_%&8?U?R9Y(G=3]V1VT_*9OC[4Y5G8XD9L
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M.;'#)DPP0**9&W%'$H;Q1.[9GG/7'M!@# & , 8 P!@# & , 8 P!@# & ,
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MTD2X\1$8]<XR[VA>.:#1CA"1*R85#(.@,<+DG),;L#4&.544QB;_ )?;Z/\
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M"E3D$BTK5E\QCYR;/)3*R"0T[%ZLB%GEHH!(,9!8(F-QDX')$JN=[=^>6?\
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MVF4< 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MX8)[L XENU9(KE#!!^6)N=4O>")1\](O55WCI=90-#(6 , 8 P!@# & , 8
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M12N*A9,+BA:O879#C?K;3?8.%$I%%_G=+W8!,9S<XZ)S7D1)]TGZ48?R$8@
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M 8 P!@# & , 8 P!@# & 0/\GOU?G;/^!V1_][;"^_D1Z=Z\T3PP48 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# *S/,'
M]7S</X\]9?TJJ2S4'Q+O\F9C^%]WFBS/,FA@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@%.5O\ R@#Q"4+:5@TK
M;7<N/0^SZKEQV"3Z*N*LODHO'I9&B"PLX(5) JL*!GRC!^W6;[NA9%\Q6YTY
MW;.EDN==^=;L7+Q1G>AY^#( =]/E"?AUM_IQV*K*N>Z4=DLYFM9FP47 HU3?
MS!4J6=<H<MV>CTM5# :VV4]3;T*O7K9#7T?AJZ_>QN1<O%$<4//BN#YHES^J
M6_"#_P >Z,?Q.]C_ .AW&Y%R\5]R[\//P?V,_P#6+S;^+KN7<T9Z^=:>UP.T
M+AF+4^]C<+95Q=$><DVL7 D9,>5T*S"MX\ ;\#P8H@_WU=E6^ZVC;9%MJLYW
M21W.%K-KR&]"^/F6J9DT, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , AUV-\@O2GJ0=%Q/L7V4JVKYD:8ZE!<%+GOB4]=A]U?8ZG-(+'D#$MT
M ^UXV3Y.*ADQ.N^BFNSSCE-3U:DWHB-I:LS%1O8:B>S,(1LGKU;U=W/!%G:X
M[F45O+ TL%-2C7U?>Q!)80[<["C++U].'H<GHT)L^=M>'+1+G;CCF--:A-/1
MF8\%(C]]4YBXZ:]CV4 TF/,O*57(PX5U 5#VDK$*F4-!3F1#DHFS?S!\C&6+
MQU(2PJ&-5)H8##" J(<I21X+63U#\2,Q?"RLVM)%/(]X_P#NQ!( ??;S64R'
ML*'ZG$*@CEC5U'K%%-NNT.FSM+I_7TV-2>Q(BTC[S2P!0L0WF<JY(V_%I],(
M$8:@"X0!'[E==U[N_'B]+:=J[3-VH8K=ULNVR;RMG?DS%/"=3\3M5ZY#V/QX
MN-NRQ91B+3C5[<POB6_<8QM%%XRCS0;\\4:KUM=(XD/VU8:1#7L][V[8Z\6>
ML@XWF;Y77#)<7ER?UOVC+KN\=;9+YZ^LCC.MS*XT9OU\1N)C=W/=9.S^C:\;
M?RQC:RSYMU'2Z0TFV[%M)::42W@V@7Z66_9'2TF,@>\*J7PYB[HJWYECNM5-
MZ[9VTL]+:W\M+=,EQ(N'-N'_ /6WJY)7S3U+=)?KK-K0"=JI]%*B!RCJZTD'
M6@?6U($X1-'J7:*JTEBI.P3E?$;B$N'*Q 8ZW;1V="V*:@%HFBWT1>E$WB"U
MUEGGG?IR-1WL\\LLK=>9=]F#8P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P#Q1O,S];)Y&?RQ[]^T0YG=:+L7D<
M'J^U^96AE(, V)?DJWUW/5K\5.P_Z/MDYF/X7W>:+#JNT]</.)W& , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 47=].Z4^I6R;EH#KZ#J9CV!
MLD?74FC$\I*6PV8]D0@T"TBA6?;77U_>T[:ED/'?-2QZ7MZSF]85#VX+Q^/J
M )/)J+;0^,/B#G:5TFWDKW3\&NE^S-,YQ16;2Z9K7KX<<[>5@_0QX3E?6BMK
M/F4WJNW+2L(&JZL.YJJ:A%!M@.PDBD8P*W-2$-752<221PD7ZL/DSY>L:XUX
MEXN3;MZZ@7#E6*B\O6VBY,U#HN/7O9,K(:& <>Z$BGKT82>C![LB%5<KAW[I
MFV</1*[UHJP>+#'2J>Z[!5VQ769.5&NZ6Z[195NKSNBIOIR!R& , K,\P?U?
M-P_CSUE_2JI+-0?$N_R9F/X7W>:+,\R:& , 8 P!@# & , 8 P!@# & , 8
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, \4;S,_6R>1G\L>_?M$.9W6B[%Y'!ZOM?F5H92# -B7Y*M]=SU:_%3L/^C[
M9.9C^%]WFBP_$NT]</.)W& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M?=YHLSS)H8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8!XHWF9^MD\C/Y8]^_:(<SNM%V+R.#U?:_,K0RD& ;$OR
M5;Z[GJU^*G8?]'VR<S'\+[O-%A^)=IZX><3N, 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , H7\QIZ<<3_ *M?1N:O59C%=[D2MH=U"MGIM4/8
ML$E) <#5KUQM.NU1AFH)@I%TP.ZG8E$D6V\P6V"F#!-%*(BAYG4*R>7*VMN/
M(Q$[-=+WM:_KS+3>F;P@0ZN4F\*K6XN07A+/=TK?4RK>PKAW4X=.]?38$UJ!
MT]K.1'N-==>%2$,=KAMT.&Z:6_M4U>.(]?M?ZYFH7=7[=>TDWD*8"[35L]N#
MKO;]8CXL+G#B;0HH!VA1F;2FMQLP:.^$_B$6<SZ%*I2B'?. ?HY$HR(3MLJ*
M<.TG:Z+AHFX;J59/6W74C5USZ%?I&BNP9WJSV5ZYE(Q-AGW5;ZW0M%Q2Q+9-
M7AQURBJO7J.MF$<NBVS1R9R C%K N6*3<QJF(-SQO$6-J!XH+748,D0XJW67
M19_UU7-\OGFSLUS;MY\_U'$:49VO0O\ 7[LIT4)5E#JY")+GK3],,01.IPAS
MU5CM(HSEQ./<U( I-^9T Y36%I$]]4JE7;/="J\I1WA&,K6Y=G/LOH[YM9BS
MOO6SY7Z6UO;P.A=>NBG92F&54487CT0,0@;<_3+L+*[O#3M#1G%G/6?J-0E#
MRNJPD*?AVLL)+'YK0#7YID$4F\?XKFP"BAD@+-@?@)TW?/M5K=>WK?M04+5K
MKBG>_+AH]/KVG,>:;J9UREW7*;]GI)4T8+W[")1U=$Q2SW7!'YQ QK7M%5;5
MNT9\IODV'LDF\@,I:^U9*;>J07].W//J<Z6!NZ7#/R$:5F^.7F7=Y@V, 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , \4;S,_6R>1G\L>_?M$.9W6B[%Y'!ZOM?F5H92# -B7Y*M]=SU:_%3L/\
MH^V3F8_A?=YHL/Q+M/7#SB=Q@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@%.?D6#^,6N+(JR7=K.@M8=I;JOTVSBHPREUCI6V9^TB46,0&#%)
MS.I99GP7EA7=>O[(KX(\V^.DC>G,D$#XS&RZG*J"&X=YZ.R7/J8BW;YIMOET
M[R>_3R7T;/.LU/2KK9 VM64F3BWJ0:LVD(&UMK7K<:3("C,)<P0*FF'BQ.+2
M1B9"&!(GE<8@69/>6#MZUW2>+Y>OC\\S4-K*VA)7(48 P!@# *S/,']7S</X
M\]9?TJJ2S4'Q+O\ )F8_A?=YHLSS)H8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!XHWF9^MD\C/Y8]^_:(<SNM
M%V+R.#U?:_,K0RD& ;$OR5;Z[GJU^*G8?]'VR<S'\+[O-%A^)=OKU\\CUP\X
MG<8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!1-YR0<>DL&Z\
M""'7ZNNV,F^>\O)0[K<=KCM*3M*S2(\='?>D:CO/JPV*F>O+@8DX1^=4GLN/
MEJM.MGP=O(U!FXAH_3W#QSMIGE;CK?7UH8CX:/IGTTM]RTWJ(+^"=8Z-#_<[
MH]2^!=<QUCIUM;F8S(4J;3;-.$4X3\>ARBL=,;C=-==E20]3G9XJMNN^XU([
MN]=<O5YWZFEHLK="1F0IA7L3/[!J^EI_.*HK(Q<5DAQ**<*KP+['VYR1%B+(
M*.<$?:O6*O$; K$>)%+>1RRIOYKB2_P%@3->X#G55KYY(C=EDKLJ2IGL1=;/
MQ8=I9"6L*W'O9*&3#R,QZ$S2V1(05;<E)UG<=TO6QR"01J_.-%MZNBK9)@'@
MX!F_$0Y:$[1$<.= @311W;?F6663MVI:ZY7\#-\GGI=9ZV\,[7?F8FXMV"?2
M0M72_<2PT?'AIV4+!&?8W[L6PDU.9,CTLC=@HU0CW"VLG:>D(>WL1R:G:;1>
MT7*"D[3=UDLZ<1P=Q7[:VR66=M++F\[6[/2N2^;5WN\'?IP?'73L[^$ZW=@K
M@ETNH U:5YV.GVO)VKT8B 2AB5C'8VSGW62QNC]*3Z];'D/6MN_&Q0ZJK94I
M[!2Z06D\@BL@A4QK9O"F$J#"HLO'UZTL]+6;O;BGIW:+AVA/2[=[I6OP:]=?
M,D;YIZ)F)[KI-KH9]H>P<6B<;E'5U@_ZX1W>EN*+F*R':*JT-BDHU-4T:MWD
M@YW*MG2_S?MH R]X!"/8LTD/B:)*0/-*RXY\="QIV;OEEEZ?T+OLP;& , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MT4TU?.O:A]#D?A0OW+@;\-'_  [C;U^&'N;?W+C?A;WCC?AK[/V'&WO']O\
M6]3T^V_MOI]?\+ /HY:-=G.CW9LWV>)H[MTW?**?+E-NIOJHHAHOSK[75%3?
M33?=+7?C3;?37;;7GG7CG@"M3S!_5\W#^//67]*JDLU!\2[_ "9F/X7W>:+,
M\R:& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M#9=VMP],NZN7+PR1'/S!_5\W#^//67]*JDLL'Q+O\F2/X7W>:+,\R:& , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M825379#5DMTQ[[?7?G5HORG8/B7?Y,1?"^[S1;]F30P!@# & , 8 P!@# &
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MLM'>_(A_QJ2Y;.TO9;5VX7[^J3(K\;=W1M$Q_?&G_P!:;?\ OTO_ -V0I].
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MNKGY' O[:[>SK!IW_1'*/7N^K--3-F!@';8#^SN%?C;'/]<,\ ][='_@DO\
MU>G_ ,/&>.>0?I@# & , \JCY7_]<$2_)HI'_P 28YV@^%=_FSC'\3[O)&K=
MFC(P"P[Q&?6J>-K\NSJA]N<'S,?PON\T:@^)=_DSVVLXG88 P!@# /(;^5&?
M7A=RO\UZ^?HST_G:#X5W^;.#U?:_,U^\T08!>5\FO^NZZ'?CA:WZ/EMYF/X7
MW>:-0?$N_P F>P]G$[# & , 8!XHWF9^MD\C/Y8]^_:(<SNM%V+R.#U?:_,K
M0RD& ;$OR5;Z[GJU^*G8?]'VR<S'\+[O-%A^)=IZX><3N, 8 P!@# & , 8
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MQ4[],[$R\A1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MF5OXM(H.]D47=N4E%PIEW#I=*(PX(,-T'*H*0&!FZG+1^Y24$LG;IH=NP48
MP",;[M[2[.VI#23=&Z9!/(C+HQ Y:I"NKW9R?0&*RR816'S@((DMOPFH)!48
M';YH3Z'R0P[+3AHPC(@XV>R9V(13=;("76?377B9?=V? V-AQVJ7,C:Z3Z5P
MV<V ! :H/EMGL0K8Q7X&;&-R2#50.QU!E;3@351F0(-2+WB0)N!K1XU8%5F(
M77F^F6N>AWI-5-9/15%315)777=-5/?7=-33;CTZ[Z;Z\\Z[Z[<<\<Z[:\\\
M<\<^GCGT8*?[P!@'42L!A)R7Q*P#$3CY2<P)C)QD)EKX4S<R&*#IJF(1E[$
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.. P!@# & , 8 P!@'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g486549g64t03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g486549g64t03.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[12*4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    !XX0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              (X   %/          !
M                          $             !3P   (X
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   (X     %)G:'1L
M;VYG   %/     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   ".     !29VAT;&]N9P  !3P    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     0X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MA5X9RL=U#-6AQ#6ZDO; 'YON_1M5L=/PF6LL90QMM1)K<)!!(-?C^X]R+Z5
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M &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %,
M-@    $ .$))300B      %^34T *@    @ # $   ,    !!48   $!  ,
M   ! E@   $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5
M  ,    !  ,   $:  4    !    I $;  4    !    K $H  ,    !  (
M  $Q  (    >    M $R  (    4    TH=I  0    !    Z    2  "  (
M  @ +=C^   G$  MV/X  "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD ,C Q-SHP.#HQ-R P.3HT.3HR,0     $D   !P    0P,C(QH $  P
M  '__P  H ( !     $   4\H , !     $   (X          8! P #
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M   !,0 "    '@   +0!,@ "    %    -*':0 $     0   .@   $@  @
M"  (   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,3<Z,#@Z,3<@,#DZ-#DZ,C$     !)    <    $,#(R,: !  ,
M   !__\  * "  0    !   %/* #  0    !   ".          & 0,  P
M  $ !@   1H !0    $   %N 1L !0    $   %V 2@  P    $  @   @$
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M 0$! 0$!_\  $0@ M@&L P$1  (1 0,1 ?_$ !\  0 !! ,! 0$
M   $ P4'" (&"0$*"__$ %@0   &  0#! 8' P4,!0T!  $" P0%!@ '$2$(
M,4$246%Q$Q2!D:'P"14BL<'1X187\2,R4E;4&"0S0D5&4UB5EI?5)4."A9(G
M-#9$5%5B9&5R=+3$XO_$ !P! 0 !!0$!               ! @,$!08'"/_$
M $@1  $# P(#!04& P8% P,%  $" Q$ !"$2,05!41-A<8'P!B*1H;$4(S+!
MT>$'0O$5,U)38I(D0W*"TC1CHA8E-41S@Y.S_]H # ,!  (1 Q$ /P#]^QC
M4!$1#;?<<02 )--\"NOR4VBR*83'*737;73W^/AMJ&W,-,:R[OT,).I0Q\,
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M!X*I6-=V>B<+]1!NRN%^IBQ;>P?V?68RXO5BR_GCD9V::LC,62D[6))2/,8
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MR[ZYQ_\ B?[>()*.*MB.7]F<,,<X]ZT*AMM/GS%!+B7S8:Z"I)1COL[:+PK
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M6UJCD2*V.J69=!N8IIURS1KYTH7ME8G4,TD- _G?WD\(W=&$F_:]&F<H<]=
MUQQO$>#<5X;J^V63S+8,%T)"VO\ ^ULK0 >4D'D1U]/X/[6^SO'M*>%\5M;E
MU8U"W*BS<QSBW?2VZ8YZ4D#G622(ZZAIJ/?J'9#SZ /F.-1/>?J?+Y^6*Z(
MJ,#EO@_6I96P\Q'00Y[=W4-A#IST_,:=0Y9[\ 2=OW FK@1&YF? CY@^L;5]
M%K_1./M -.G=IX;>&("CS2?+?UWU)0#S^GY 5'40$O,-0\//3O$=^[OWY8J!
MZ'/?@_/UD15!21)@0.G[_KUY5#.GH&^^OL'R_'J&*P>A(CD<CSQC/09F,9-4
MU!53T$=MON[AU\?8'3%P&1/J:5!4)WAY]VG?B:5",',!PJR9)TS.>_'UV\QO
MDU!4+SVYZAOT'YW\\2-QS[J1J21S'Q_7$<N4"K8L70=?G?\ 77X8KY$;Q![\
M=#D;1MWX$BK>?=5MR.#O\^<=*@F  -IW\O+K[-<4D':/KU.X^.P'U%6U""?C
M5O7+L/AMYAOKMX=^_/;3%:.?H^NG3OF:#8]V8Z^AO^]6PX:>P=-=]NFNWW:Z
M#@9201R.-^4&.O7;$8D9JDC<;_M4(P=D1#N'3&5N 8SO\?7TH"#D;>I^=1U.
MH=V_P#KY  ===_+$1\YD\P,GZG]J1^W=4!8-S;<PY!W_ *>'QZT[I$<HVQRW
MV[Y^<U V&9V^E6U0.8#[?9R^&FOR&"<*&,9(B8GGY<NX?$S4<>8]V^+@!E1[
MICD 1'EO..[%8]77+AT:*S9JRQ= 3GXNQ5EP!NO89DL;0P<OM@I"+D#4.2Q@
MTU'4+=R NS>&?NUMNI\U=D?DX/A/*K]LO1Q"V(_YS3S"O)/;)^!:4!XFMT\:
M.NAIA2F%*84IA2F%*84IA2F%*84IA2F%*84IA2F%*84IA2F%*84IA2F%*84I
MA2F%*U/S*XZ^#O)VT+4S-#B/RGI-G:.WD>_B9RU,FRT8_8-FKQVQEU2F4:Q#
MU)N]:J TDUVKA05@(DF=0IR%K2VXH2E"B -1(&(E29G_ *DJ'D:VS' N,7+"
M;ECAMXXPO\#J6%Z7 8]YN0"XD2)6@*2)$D2*[3D=Q:\,W$L$B&0N>>6N:CB(
M YI2.J-HCI"8CTB*%2%R\A!53EV[,5#D(1ZHR*T4,<@)K&[9=9<9=:CM$*1.
MQ(P? [5C77#KZR"57=H^PE1A*W&U!"CT"XT$]P,]U;#XMUA4PI6@8901#0=9
M27<N=-P38I)MB%'N%5QZT<X#_P#"FD(@&NP\MJUQ%]E8.OW9_FDSMS&?CCQ$
MUXTKV2LP#]H?6Y_I92&P(_U+[0JY[!)Y[9$D*+14"@08LSHY=0$[E\\,<=-Q
M$2HK))AR_P 5(H?''3V?%KY0!;?*1@82B/BH$G/QC8D36"][.\!0GWK0ND<W
M'WB3OR0M"?@D=^V;8\IU'[)@_9]B8/$S@1 ?^VN81U'?<=<;UCB?%"!_QBQ&
M3^&!TQIDXY\L16H?X#[/ '_[9;GK/:;D=2L_#G].G/:+0EA'6NM2 /5-P_1'
MOU#T3PH=^P!\<;)KB_%$$1>N'.?<;4GNPI!.\[QXUH[GV;]FW)GA3(.WNN7+
M9_\ @\!L/ZS%=$E<K:6MVS-AD(\_9$2 BY*X1*8.0&(Z266,&NFH>L%$0_QM
M,;=CV@XB@)"NQ>'/4DH41'(ME"0>ITGG@XKF+SV+X X5%G[5:G.GLW@ZA)[T
MO(6LCN[0$X@S6,I/+QRQ[0LGR#T@".A1(+5?GK_-,HJD.VX@*Q-1UT*(CC<-
M\::= [5I3:CN0KM$X_U:00.<:3\17*7'LF[;$FWN6[E(,!*DEA><;:EH.,Y<
M3/*8KJ_J+Y@L':]*W6(.I1U$IBB4=C$,&G+H<H[;" [ABZNYMGT$85(@F"1'
M,''R,16O39WEJL'WVUI5J&2""(B"#F.1!/=-;#Y<<1>85)5;M9)T>U0*9@*K
M'2ZHJ/$D=0U]0EC%.[04*0.RFFX%VS(4! K8HCV@XCC/LQPB_P"T6PVFRN8E
M+C"80I43]ZP(;(.9*="C,E9KU'V8_B3[2\$4TS>/*XOP]) 7;W:RM]")&+>\
M.MY"@  A+A>92! :!.H>BF769M2S,CA>U]Z;UQN4II&'= 1&3CC&-V0%9$#&
M*J@)MDW3<ZK<^H%$Y50,D3RKB?"KWA3O9W*"$*)#;J"5,N#>$J($* W0H!0W
M@I()^C_9WVFX3[3V_;\.?/:MI!N+-X!%U;DX&M$J2I"C^%UM2FR<2% I&1Q2
M#F'/IK_$//RZ:XULF(_(5TFD3SC'3G\3W;><9K0_C9XALP<@8Z'=T4L"=9_E
M?Q$6Y<)R-6D2_6V6.7[2RUDI 1>LQ*T&26-]9(B(F=M^RD11N8!4Q:><+;2E
M)C4E+A$S$I;4I)WY*&1X]:A*/> .TI$\LD#?SK9NR7J,@;%7Z@,=:'MCMK*2
M7@5&5$S E::FO'MCK>AM68%>J<Y3Z,1P<H$0-:)6.</->S&-)!<2-U,K5[L@
M&9@849)V)TI,)VE1  F3BK"DY&?'\X!.9S[OP,Q7EDTXR.)-3+"JYD6"MTM"
M%JLGQM2?$+(9?1M<M2U3JG#5Q-N,IJVZK-9OF<>5MMF84:'"VV9LMCAH2QR+
MR8@F*3.LQ4C/15=?8RWKE&D-]F?[Q3Q* K2A+@2%)27V2  3F5[1!.]00@S)
M4/P!&8DJ3.2$*&\=.?*O6$1*H0BA1U*<I3%$0$-2' # (E, &#80V$ $-=!#
M7;&SJS4)0  ?'ETT]OB&OO#"K:\9CZ_#P/CF34-8O/W^[4/NPJD85CGB8Z_H
M:MCD/L[:^/=W^\>S\]+@D@1(Q&<C? Y]8Y?**MD86!B(49_(^LU;5 Y#[,1G
M,9@D9F<X^&/SBJ5Y /K.:@KA_.UZA^FOEIL(\^08E)).^?RC:<R1N!XYF8H'
MKP._K?I5K4#01';O]WL[PQ4K;Z?(=1F3\*=#ZQB?E-05/Y^O+4"CSU'D&+R?
M>0.\1C'=UG>J8]V/^H1MB3T'.=ZCJ<]-PVWY^0>6F_\ '$)B).P.(WG?YX']
M)J?G4!4-^UW[?$?/N]GCSQ7_ (@=L^.1)^M0/7U_.K<IT\0T^??B@#,;D0?I
MJ\_*=^<5-0QW]H:?#Y_7%TX4#_B!&-AO\/TGGM85@FHK,YT+?E^\(82&:WR
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M'0[SM/KZUCN6X4DA8U">DY^..Z#\!,6D[$A0^R  &^VWNU#<>?4=\74W,[@
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MMMM;KB&FT*6XXM+;:$@E2UK(2A"0,E2E$  9),5YH9V9_H6AP[:-I!R>)1!
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M) H>#AX"(>.%Y I$D#24I#L(]^L .7Q=IQ'[)P%QIH6C3EW=7!5-SI>9M+-
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ME:[W&VR:3Y%C(-(R/RT-I;U:9A2BN"9 ) !CH#$QG),5;*BJ)Y")ZY)S\8\
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MOKFNYJ9!9*Y<9N4C+FU6RRDG9^D2M:?6*SW#+N&=H2,NI7%&CHJ$4_>)P,O
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M34,43$ _8TL,^VG%N,<.7PB[MK9AY#?;LW:6%!PK:A2M043K6L ZR D&<(3
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MQ970(N)!1!1XKZT]</5!7,V;M6_:!5P<I"H-D$R)E(0B92EQBW=V[=O+N'=
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M E, @ E$!#4! >@ZCMOW8WENLM+"T8.,GGSWVB.8WVYUR#J$W*2VN9SN,]^
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M+2$J?<*P@9"$ !+:)YZ&TI3/.)YUFK%^L.F%*84IA2L'9QY2O\SDH]*-GD(
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M%8(W25,&@!WCJ/D&NG/\ Y@.^,YI(RL\MCF(CEB=O7.L><XY<^\C\IWFHQA
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MKU:KL+'HF.*;9FU3:QT:P:HD.JJ8I$DDR@HLJ;<Y\$I2A(2A*4I3@)2  !W
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MW\XG^OCF>41M-/MCX!X]WQPJ"2!!@]XB9Z$>..D>-4#*  <]?/70/#3"J-X
M$^O+'Y\ZC'4UZ[<M1'<?(.>GSX8F#^<[_3Y]*F0G)R=ATG\_+]#4)58 U !U
MZ![M_'4/AYXK'<,?X@-]^7.<3X>$4*49DYS[J=Q.\F?Z#YU;S'ZCSZ!\[@ #
MR[\08F-]^>9VY[3N9&.ZH)"1F"HCX=P[OKX[1CF[(:[B(\O,>_W]PX;D#!Y1
MUYDB(@GR^L6>?7\ZMRJG37VAKH([[" ] _/KBN-^4]^?+^IP!T@3ZQRQ@>CM
M4$Y@WU'QY#R]G?IRUQ$:E:1SW.\ >9Z9VF!YP9W&>0',],>HJ$(ZB(\L9,0
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M]1$>O("E#<QA A $1 ,74I)(QJ4HP /Q9W&=^8)P.>-ZLDI2DJ4H)2D$DJ,
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M84K0@D@0KY:)?MW<---]0<0TL@9C(I@ B J))*#V'K4VG\F]8*.F2Q=!2<'
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284IA2F%*84IA2F%*84IA2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g486549g70w78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g486549g70w78.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1\24&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   (    X0DE-!"4      !#'71?E
M=+5N]=N^.93 Z7E<.$))300Z      #E    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+            *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M       $    'CA"24T#\P      "0           0 X0DE-)Q        H
M 0         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ !
M *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M   !.$))30/X      !P  #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  ,U    !@             #IP  !.H          0
M       !              3J   #IP                     !
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M;&]N9P   Z<     4F=H=&QO;F<   3J     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M       ! 0 X0DE-!!0       0    $.$))300,     !24     0   *
M  !W   !X   WR   !1X !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" !W * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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MXKC^L9GU@9FOQJ['6L:X":QL:)T9ZQ_-;9N_.L]-9!HS;"'95[*OHDN>\O>
M"ZK<17ZCM]+O;9[O43N%BEE(-5]I>[NZYTFG1^2PGB&^[7D?0GZ7YJI6_6_I
M#/H%]GA @>,^\M_\P_/7(5X>-[0ZVRS@%M;0T=P]K7/]3^M5[/TM?\M&9A4:
M$8[GGVGWV.@Q+7?0]/VO_P# DJ"..9_L'_?.\_Z[X_\ @\9Q_K. Y&X< _\
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M\-+V,V@?2W/8_P#1?3_/_2*33LFI?O?C_:Z0^MW76R;*!Q.M;A$M];P_<_\
M D5GUWS@8?C,)UT,CP>W_HNV?^"K%'VG;(;DM<026@S #7;M=P]NUCO_ #U_
M.J_]DZC5+7W6%LF072-0&NY_>3,DQ")D1LOQ0G.8B#OXNO3]<G.^GBSYM=Y_
M^05JOZUXQCU*G,F)(U D[?)<QOZEF.L&&ZIE=;BUV1< XN=$O].OV_N/]SEG
M9+_K'BY!I=Z=UC>6&I@!\OT7I/53W\IU$0(G:W3CR,0*E/U :BXW]CZ#3]8^
ME6D V[">SA'()\_W5=JS<.X?HKF/^#AX!_\ U#MR\[P\JK-%E>5C/QLJC;Z]
M37 ^UWN%M+G#W,>WZ*8TT ^S(?23 .YAC7?ZGNJ<?S=E?T/SU/AR<=@CAD-P
MT^9QRQ:CU1.SZ8DO.<?+ZS4/U;+W2"8:_62SU'^VW9]'T_\ /6YTGK/7KLAE
M60*VL=8UKC:-KO?MN_1L;]/;3[&?]:4QBP1RV:I__]'NNM?5VK+8Z_'+FY )
M<]FYQ;8'0Y]>UQ]GN;O9L_/6-3T>L:G4\^)G^U^<NT6;G8X9;ZK=&O\ I<"'
M?@B"L,1N'&-73,1P9D755/(D-L>UA+?H[FM<6^U%&;T0"/MF-Y_I6?\ DE8Q
M]QZG?Z0<9QL?Z,G_  F;W]JTFTY3N3L^+C^1G_DDE .,>H=)_P"YF/\ ]NL_
M\DH_;^E_]S,8?]=9_6_>_>6^,9_YUI^#=/\ JMRD,9@Y<]WQ<?X)6GA>?^W]
M)G^G8_\ VXWQ/BY4<GKN&S+MPJ+:Q;355:^VSZ$7[!3Z4;6._GZOTC[/SUV(
MIK'#1\]?RK&Z_P#4[HG7G,MRZW59+!M;D4$,?M!W!C]S7U6M:[W,]6I_I_X-
M"5D::*,7E<SZR]3P<:ZW+;CW8SFN8RVO=7:UQ:0V:CN^B[_25U_\';ZB/GT]
M9;TC&?;C^F=^0_,8' NQJK+6Y#+?^$].FJW>M?IW^+KZOX.4W*>;\U]9#JVY
M+VE@<TAS'>E370RS;M]OK>HNG<UKVECP'-<(<TZ@@]BF@&O4;6QQU1LDC;_I
M?]R\)=G]+VEV)3AB.&OIDQ^Z7>S_ *E6.F973,TV5/Q*&7U-]0[&@L<W7]]N
MYK]P^@KO4/JCT5N7B"EEE#,FYU=C*WD-@57W^QKMWI^^EGT%M].Z3T_IE3J\
M*D5AY!L=)<YQ'^DL?N>Y+@C^Z/L9SER?YR?^-)Q3A],)CT:1K'T:_'8A.P<1
MOZ2BJMCP)!8UH(D;OS5U1:T\@%"?B8SQ#JF'XM"$\<)1(X0+\$PS98ROCD?
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M    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M 0 X0DE-!"(      7Y-30 J    "  , 0   P    $%#0   0$  P    $#
MZ    0(  P    ,   "> 08  P    $  @   1(  P    $  0   14  P
M  $  P   1H !0    $   "D 1L !0    $   "L 2@  P    $  @   3$
M @   !X   "T 3(  @   !0   #2AVD !     $   #H   !(  (  @ "  M
MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R
M,#$W.C X.C$W(# Y.C0R.C$W      20   '    !# R,C&@ 0 #     ?__
M  "@ @ $     0  !.J@ P $     0   Z<         !@$#  ,    !  8
M  $:  4    !   !;@$;  4    !   !=@$H  ,    !  (   (!  0    !
M   !?@("  0    !              !(     0   $@    !.$))30/]
M   (          #_X0& 34T *@    @ # $   ,    !!0T   $!  ,    !
M ^@   $"  ,    #    G@$&  ,    !  (   $2  ,    !      $5  ,
M   !  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q
M  (    >    M $R  (    4    TH=I  0    !    Z    2  "  (  @
M  /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD
M,C Q-SHP.#HQ-R P.3HT,CHQ-P     $D   !P    0P,C(QH $  P    '_
M_P  H ( !     $   3JH , !     $   .G          8! P #     0 &
M   !&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $K 9,# 1$
M A$! Q$!_\0 'P !  $%  ,! 0            <$!08("0(#"@$+_\0 5Q
M 00! P,"! (%!@@("@L  P$"! 4&  <1"!(3%"$)%3%!(E$6(S)A<0H868&1
MEQ<D,Z&QT=CP&25"5IC!U^$X0T124V)R=[CQ*30W.5=C=I6BMM;_Q  = 0$
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MCC6"[J=5VUV:9A"QO<C(.HS9S>0=ED.TT7=*DN,/F['V<N0K(IQ210;*3/W
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M*Y=;*_$/RK,NG:!U=;P8!LEMET_GV+-OM9DQ+J!O-S-W:6B)0QKRLII>V_\
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MHQ()9#%)()9;C9U(BMRW.,BL9-C<V=@^M@V5A)K\?IPIK%S>?$7(AB)6$$Y
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M+>0VXQF08(&<8R,[AG(YVXYJT=<T@7_[,.H6XO\ 8SBV+D.53(8@D;#M*L&
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MX'3=NXZ=:PLUSI0@^*%]!'"690TK>3AT(#*R2JC* 2,$@ Y&":G*GSC%+N/
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MRLY'SFB='@Q,>L)5=<RY3D9^HB4]E#D0[<A#"BPYD:2*2HS!<QM0/WCMM8*
MQ)](QP5)X.'VGAMG7!SR35)AF\D*N2Q*K'D_/OPR(C[1ZI$QY?F#IA?EK\?M
MA-+!<WT<MZ0G-&)KA D,>LA4>1Q/ K4&YPQ,8Q2.\I1J1B]J<.3Q5"QR]1C:
MN[!VD<DJ6(W GTE21M(R"#FK<B,#!Z,EB2PVIO&T#8WE[@"H8,,QX*MAE&
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M..WG>6UA5#B5I61%R<'"2.Q7:HSP2<<@=ZP9=Z-B&M!!/NEMXZ<%Z,6"7/\
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MXC(7IK"+Y3H:"FUVWB(R06/Q,UQ'+9REY4@AB*W:";SHUWF1/*Z^6YVLN &
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MWT0@XX"98KER>VHP:1KVH^)$OM4ACNK*VN0=.C@NA%#;((_+:]FM1: 7&H2
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M!%".N59<US>PT4J*1WEY<C7HCV(OC8G'XF.8U$_/7T3X/T3R(X$Q&<@$Y W
MG .#C@=<\]LD<<_-_B_7!.\I\S."W!Z\#!.?H?X_ABI39BU<.9701/L( 8W9
M(,I1M*2*4:<C<PCQC[/))1CE>I'\N5[6*C5:B=WTFT5-N]&79@L%.X]@".N#
MT[@<< \D?/>LW!D,T@5'<[A&5.,\G'()YQD8QT]J]BXWWR+R>JUDIIH[*^8!
MX6(:;&0@Y'<A$1/&]A@1R(UIT(KV-<YZ.8U-;C;N2SRLR.47"B4%MX(((*X(
MSCC)./8 &N>7B-%#';1M<P"XD#,Z$-Y>U@P'.#M9R>%'(7G/(K$[/"6"K $)
M3%CVBM.^MLXREF/ECEJA&Q)K>9#3-$Q$8Q@R1RL:U."N5Q7.O#,<1;RR&F(,
M3(_R=0%(.X[3GH020>,$<198_/GCM%:WFB@4_%(R%&=^'+JRX :-1MRO"D,6
M!& 8\N=M*21W5,1K8T6>Z2HGSQ,=(J93_,5(PR!:GCC$.T3)3AQPJKU<<@CJ
MU!K420B6RL5WD&=9% "/D@NIZC ..1DYP.,U9R6EEN'6>.*V1_ABC"6.>%5S
M'&ZXP6<C/ISCC(!!8X);[*5-F^498811Z-%;9=KHYV3)1(I1QY5<R)&"4</N
M PLI7B1J+V"=XBR$(M;H)9%BBB]$"YE,;$"1 V=V&P0Q!Y'!)'0D FB&;;'+
M?SS0.TS[+2-U,,B2[<K"1G8RKC!897D>K#<;"])G1!5[B9T[<S<R ZTP3&B#
M2II[.$XD#.;4@Y*-/(\[^6UE*_P&,*.^3&FR_#'4B"%,CN@W4V]MJL2JC:F[
MYE0'(4^^,]< =2 ,UF=$T\N7NKF%E9Y#($?:Z&1P-[1MC=MXX&/S.,UW'&,8
MAL$)C1B$QHQC8U&L&-C4:QC&M1$:UK41K6HB(B(B(G&H=;77GI2FE*:4K6SJ
M$V?9G56S):"L]1F=4,,5%"7QELJ1'G>>"HW.:*0<#SN/%1SFD[5.$:O<5@UN
M1/L;O@\'!P<?CS6-U*Q6[B++'&\\8^Z\S./<CTX//;G%:'1:-U59(X-60$(G
M;',*2[N9&G\JPA"L*\+&.4K4:YZ-:HR=K7+W+PN0RZ,)HH@D;D)ZAE<LH&[+
MAB ?<Y')P:US!DC\J>8+=0;F81$*Q1#N 94ZX.0%'4#D$YK)8E0^/YJB?,$R
MOF-4PF1^7\-5Z=X>UGX41C7M43T14[53AKNWA*2HC;RY)28G&[[OE3[J0<;1
MNYY!X_/%T,DH6Z@A+3QML.["'H<.0,D\ @[<<X)ZU=XE=!. L!12IDZ&U_IB
MJO#^6O7PG5C6(Y.&]K7O>YSE7O15:URJE"@$-&L;._[C\DX!X.,[<$<G^=7S
MO21)<Q10ML:9,!2&(RV3CJ"3@J!TZ=:Y\=/I^M'J'VU_PL5W47@.!@E9_O)0
MP<7B]/M)<DJJG =V\WV^JXY;B5GT.99&/7XS$ES))X43ODE+VL:QK.?-LC '
M>J^62,#"MP<=.#Q]>3VY)J^[6L3&&022"94/K=F7! (.2NT?0 D8'YUL&S9O
MK5.<4D769A92E&5Q01NE^@:9C(X"&*Y1_P"$5J\!8Q[R+V\JQ/P]W"\TO@[7
M,I9NC8!!'4#OR,8Y/XTC\L[X!:,#&69 [[@<'G#%3MR.0!GCZCBJB[&=:3A3
M)(NL3$94(1!"D>3I@QUIQ%.PCFM;'7<D?D:J#<G+5(]'M=RB(K5=X#M8 #(8
M<$KWZ''([\ GV^@J1\T)D,00HQWJTW1>W.S@=1M_3WKS=LAUH!!%C.ZSL!8U
MWB,0S.E_'5FQ&(YKW.,QVY#$>82][&HCN7HQ55&,<Q75YE*M$=BD9;D -WZ'
MN3^F>]4L;9&CE)D9),+@2.Z#@ \*I P21V.>N"*IC[/=9DPHE9UI8B8HW,#&
M]+TKX^DN0<G8U!J)-RE>J/5>P;QO(YR(Q7-:KE1M!9G57,P]!Q@ Y Z?R&>O
MU[45+:-Y(!;2,)5W*6;*,<9P,_*2> <<G'3MZ6[#]:$]9"P^L'&+ <$/J)R1
M.E>@0L<"D43R2&/W$:8C1D>SO5%?X6)RYXQL5$](C5QAV(;&3MYR<<$9R>GN
M.O-4HS/$5%B=T)&$>7 VDG)!*X!!QD8(((]A54?9SKF$")E0NK?;]C'R9,6#
M+B=,&*1C)(%Y'O69#'N(BO<\1E7U)1%:L=S!O.B(UB%!)>-$W'&02GJ"]N-W
MIY]ADU=DDVK#<2*B9RCCSU4;LDG/I&_T\\8P.<#-59-E.M.)D!ZV9UQ;<P(U
M@Q33KZ#TQ41H!TEQTL0-F,%N*QS?4%='8=7#5L?R/12.8PC5J!G,0940>01S
MA0P(X]\]\\CMWJT1:+<2023.?BH]Q!FD(._!7'IVKD#  ;.TX -8R;:;J^6)
M)-)ZW,3C'85&U\&)TM41*Z6T_#94MYA[F-](Y&AC(7N YQ'. -$_#RVMO.$D
M;M.@\S ++SM[X;H<_7WZ>U1D;3WMYHQ#-+\,Q<(6;<>B[H\]%]()'4>W>K07
M:#JW8)A/YY6.&=Y$<?S=*U"ZO=+ 5'.B1S-W*..<U J Q%(QG'G4:L:WL5UH
M*"TJ-,2 <C X8D9)P3D =P._Y5<::$?"W*63ONPC,TFTILP #Z6W$CW(!'&<
MCB[0-ANN$EB6J@]45%,GV45XF0+'I1QAKV0BH.Q'(CO+N&K(*O:,+F2 G85G
M"A83]8[NH81&-6\UBZD#;M&!SS@Y.<X]NP[<5(C)CGEB2P"QR*Q#F3A^,C(V
MX7D<C.0?K5\K>GKKYFU38YNH2AL*"ILQ2YD9>EG&Z^\D%D.&V6&'+?GC+0P2
M@CL$=H/.P"NCD=%<T:JUNC$@.<C;SD$\Y^C=?KD\\UZ!.]NRK9!620;4\P9(
M/)924P<,!D8 (Z-VK@A_*&NG?J%Q#>_:SJ^GXQ9"V[O-LL8VWE9/01B!%@V5
MXC8WJU\')WUCD^32,CJ[2/+JI!G"#)+'G0&$9(B>F;K^LV45T&)C$D3+M8,
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M&S/)4+'M4+D58U 6VH1PZ<UD)+5+:)HKC;!B"ZMXTA5)$<AY$FB+HKH&,81
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M8RHW,VVKB*GXQP:;)!P\QB@>[EZ"7.S@"Y>P &!1@F8Z?3+6?JI4]L$X&?8
MC^?^><=/IEM-R5*D]<$XZ^V<^^.>.@QQC31O\E<W-:16?S]J18R\(G/3PSRH
MB<?1$W*1%7Z_4JI_#[0SH%F>S9Z_/)__ -\=>W/'/4XAG0+0\Y?/XO@]>H+G
M_7Z]JWFZ=_Y-+TA;<6-5D&_FX&X?4A:P/ULC')S8.W6W4Z3Q^!\NCQHDG*)(
M@JB.;'?FK(AU3B5%,)5#J1;Z1:0'< [GV9O2.O08SWZDG\JD0:1:PG)W2'C
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M;=Y6!@#.!NQW&3^73ISU[8^X\23,H"W#9!).3P1T'0]@.W;VY%9#'V1W'@7
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MGIG S^M7#2O::4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*Y]_%2_\
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MO:D=_=VZVC0/M@2=TA\0:/)9%F -W9$S0*3W>WDQ,BJ.I1Y6/54.<#5?$/\
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M13]87]X_1O\ [26E*?SW^J3^BGZPO[Q^C?\ VDM*4_GO]4G]%/UA?WC]&_\
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MQ[<5JNK^.+V_++:1"S1@5WE_,FP01Z2%1$/)YVL1G@\9K=J! @U<.-75L2-
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MC75CT(^?6M:XM:60Z=K6A0WUSICV,9L&NKB*(M%"<VC21QS)Y@RN[?"X8+E
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MT7;SEVEZ@<(M<2RC&[6+/9629$L&*Y_C\.R5K;#&\BB":*WQB_%%, -M5O\
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MC*CY2V\.!G(&,;?Q]6#_  KH>G>/]/A3_O-A*)2<R,@C=7. ,EMRN6.!\R'
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MJ*B\*B^RI[+I2N-'5=\"#X?O55?6.:FP;(-C]P[B?-M;G,=C+>%BCKRRGO\
M+)F76+6U3D.%RCF.KSFDQ<?@39!BD(>61SN=1IK2"?/F(.1@D<9_'%19K."?
MEEPWNO'?//OR.?IQ7(_(_P"2K7+;.2_!^O&RA4BE<L&%D^QE/8V<<'*]C)5E
M6YK BRBM3M1Y15<-C_Q.03.>$QS:'9L<[1^L@_E)SV[=JQS:':M\W/T.\@?0
M8D'^_'M5HZ<OY-CMGNQ5UNXMCU]WVZ&V$NYR2E<NWFS%;A,Z?8X5E-QAN4P(
M]SE-W=OADK<EH+>I*8F,R!//"(>*LB*\)24C0;('.&'OM9\GV^9F'OVJD:#:
M \,X_ GIGIZF8?GC\<UWJZ0?A$]#?1;;5N8;8[7.R;="K0WI-U]S;#],<VAD
MD!4!RT[BQX>/XX5X7$#Y\=H:N4H2E$^0]A'H[)P6<%L (DP1^\3EOU_T%9."
MSM[;^[3U?XFY;]?]JZ:ZDU*II2FE*:4II2O3(.&* TF25@(\<1#',1R,&(0F
MJ\A'N7V:UC$5SE7Z(FO54L0J@LS$*H R22<  #J2> *I=TC1I)&5$12[NQ"J
MJJ,LS$\   DD\ 5SKWKWGF9M9EHZ*0:-BL(G:QK>1/MC,7M=*E(BJJ@1W/I@
M.7M:S@I&(9?P=)T'0ELXQ<SJ'NG7O\L*GG:I('JZ;F]P0IP,GYT\;^-9=:N6
MT^QD>+2X6P-I*M=NO'FR<_W>XD1)TQAW&X@+$4)G#47VYX]_K_#Z?3Z_7W_U
MZRMV>,8QS_+J/K[]ZU*T4<'O[\\]/Q_7/^]Q$G#VJJ>W'U^R?GPB)^_G_=-:
M9JL<C<@$]?K^&>O\>1^%;!9E01TSD_R[_P!=_P :RBOEH/A'(G/'W_9_)4Y_
MS\K]>>./MK6PS*Q)4_@,YXYR!C&/TQSWK8()!QT_'ZGI@]OPX///TR,<X/'O
M^7NB_9$_=Q_J_A]M7/BR!CU#'MS_ "S^N.O6LM'=N@&".W4=>..>1CZFOPD\
M:M5&^WV3^''/U5$3[)]O[-67N6;@9)_3G^LUY).TF-[9_#_;_.K%+>I.5X^_
M+E]_ZD]E_P!*<?EJS&CNP!! )![?0].O0#^C4"9P0?S_ ,P,_G]/;GWH$#RG
M*)QPJ?7[_1%Y_L_T_EQK8[%3&#NSCV^OZ]_:L1,H;IUZ?[X^A./Q[U4-C\_G
M]/=>$]U_>G[_ ,N/].MC@E(Q[8Y_+C\/Z]ZA20@YX^H_/\\\_P!9[^HU>CT^
MB+]_;CZK]?K[_P!FLQ!.0,$_3Z=.!]!]?QJ!+;!@<CCZ=<_^?/;/3VJS'J^?
M?M1W[^/?[_=./;GC\OX^VIZ73>_&.!V_C^')YZUCY+('.!^N<X]_Z_WJQ2:M
M/_,X]U^W'/\ O]4Y_MU?6Y[GKCMQCZ_7\CD^WMCYK+ X'OQ^'Y?7KV]^M60M
M6B<_A3WY^W'U_+A??A/_ ):D"Y'!#-D9Q@]/SSGZC_7BH#V7;:/Y9_GTX_6J
M!]6O*\(OM^7_ 'JGNOY)_GU>6[;&=_;G.3[]CG^0_P!([6/_ "C/X#'Z]3^%
M>CY8B?5O"_P_K_S\KQ_G_/5)NBW[YS] ?]#[9_ _E5/P1'[O'Z8_K/\ &CJU
MO'NB_N_#_9]_M^?&J?BB#\Q/]?A_7O51LCCD ?C]/KC_ #ZUX>B8WV3]_P!D
M3\T7V_/_ %ZLO=9/+'Z_Z 8 _+\OH7P@4< ''<?KWQSUQ_OQ3DBM]^$5%3Z<
MI]^/]7T]]4^=GKT[G\NN.<>_^O2K;1 9QG/7G'\>I^F?YUG6VFZ5]M9?!FUQ
MG'K)!1MN:@CU]-81N].Y>U>4%+&QSEC26-[A/7M?WB<0;\7K&FVNJ0%)!ME0
M?<3 >N,[<XY'J1B!N0GD<C#<C8O"_BG4/"U^L]LQDM9&47MDS'RKB('D@=$F
M0$F*4#*GTG*,R'JYBN44^945?D5')237V 4(-5_"4)$_":-(']1R $1PRL7_
M )2<M5S%:Y>27-M+:3R6\R[9(VP>X([,I[JPY!_SS7UAI>IVFL6-OJ-C)YEO
M<)N4]&5AP\;K^[)&P*L/<<9!!.0ZL5D*:4II2FE*:4II2M=>K/?P?2WT\;H]
M0DW!<DW&Q_:3'2YGF6,8:2#^E;L&JCA)F5W01+(L:#:S\7QU;#)%ISSJ];.+
M528@)H910=RE<Q/Y/YU64?5!T X+'PS!,QH,,V2[-J!YOE@85?&W S*,6;D^
M6NQ.KCR9DI<=Q8.14-0^ZG% ZRO"6\./"$*H61*4KN+I2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4KG1\*;_P "K$?_ 'Q]6G_Q:;W:5X.@_"NB^E>T
MTI32E-*4TI32E:M]3N?OQ['8N+0B>.7D#7FG/1W#F58']OB3CW3U<A.UR_<0
M2-]T>O&R^&[-);HW4H!2WQL!Z&0]^>/2O(^I![<\R^TS7)+#3(]-MR1+J 8S
ML#RMJA V>_WTA"_5$<8(/'/-DQKB>Z_M+]OV?R^W\?HOT^NNCK*I& >/QS[>
MW/U';Z\Y/SCO;?N/&3R3D_4#K^7ZY%957RD5&^Z?FJ>WORG"+^?Y?3Z>_/.K
M,JJX(]SD9QUS^8Y_VK,VTN,=L_\ G^7\.OTS50?)<<@2H\&PO:F#,ED:&-%E
MV,./(D'?^P((3%:4A7?1HV-5SOLB\Z@RZ5<31M,EM.\*@EI%B=E '4[@,87N
M>V.:S5O([#>JN5'5E0E5./WFQA?U';.*R1\J/&&\QSB (;>\A2O:QC&I]W.5
MW':G\./ZUX77WT?SGV1(7=SA54$L3[!0.OY=LXXK(I=X Y_,'W'L.?R%8_0[
MC87DMG:TN/9336UO2-"ZWK(4\19U>R1R@7RHO*&$PBM<UI%9V*Y%;W<^VJ+K
MPM>VJH]S;21)(2$+!<$@9QE6.& YP<$CG'M->>6%4:59$5URC.I"OCV)&"?<
M=N,\$5F#9?*_MI_#GGZ<)]DX_K_/W_/4(:&,YY/]9['@]".O'?M5)U'/[V?K
MU_F*M%YF&-XQ%?-R&[K:2(-BD)(LI0HPAC;QW$(\RM1C$^[W=K$_/WUD[3P[
M=7)/PMK+-MZF-"0#^/3=CMG..>G0MTTK!$5Y'QPJJ6/N3@ X_E5VK+>KN($6
MTJI\.QK9H62H=A!D"E0Y4<C>6'!)"YP2C<GT>QRI]??V7BMM.F@=HI49'1MK
M(5*L&!P0P."#T_(C'%6_B%).X>K.#GC!!Z8/(P>/Q'TXPN=O-M;4953X199O
M0P<JOS>GI::3*0<FS/\ B1!1E<WPD>]S7,&WRIY")XA*\G#=95-#U5(#="T<
M0(I9B64,$!R6\LMYA ')PAP 20!ZJKP[QM<"-VA7@N!Z1^?L.YQ@9[=:D_S"
M7[I^_P#=_#^WG[?G^_4=%<8/0\?GS[?A].M1FDC(P>?RZ?T<?ES5!8V577@?
M(L)D:%'8BJXTHXP#:B(O*]Y'-1$:B*JKSPB>_P!$UD+=)YF$<,4DC'G:B%OQ
M) !(^M1VVD@ %B>  "22<].I)S[?D:L,&UHLBA,L:.TKK> 1SF-FUTR/-BN(
M->",0\9Y!]XW?A>SN[FK[*B?:1(LUO(R31R1.,$I(I5@#TX;KG'&,# .#G-1
MI8]K%74@KU# J1QSD$<<^]8#EFXFWF%GB RO+J*@).E @Q4M)HHS"S)#T& "
ME>J"&0CU1/UCFHWE%>J-7NU-M[&_NHS-!:R/&,G< /4 .=H)#-WQM!)/'O4<
M6QEWF.-I%C&YRJE@H'7)P1GN>Y S[UE+AB>WO:K7(]$5KFJB]R*B*US7)^%>
M45%:OT7E%Y_.#YY4[>XSD#/ '7J>#_N*C-$O7 /UZ?IV_3_6J*0L8 GF.5@!
MC:KB$(]&C8UO"JKE=[-3]Z+]OWKQ>BDDD94B#,SG:JJ"S,<XP%QD_P Q[58,
M:@9) 'Z?[GO@?A6%U&=X3D=K845%D]);7-2-A;*JASXYI\()%[&%D1$?YQB<
M_AOD<SM[E1JJBJU%D7-E>V:K)=6\L4;G:LCKA2V,XSD^K'(!() .!WKQXR@4
MO&RA\E"R,H;'L<<]><9JDS#.,.P:LDV^5W<"DKHH'R9,J6]6L"%O[12(QKGM
M9SPB.[>'.X:WN<O&JK.QN]0)%K"TNWYF!5$'7@N[*N>Y&[@<GBK(0R2"*-&>
M5NBKUXYSGTA5 SR3TZXS5NQC-\3SO'H64X?>0,AQ^Q:Y\.TK3(:,9!O<,C.>
M&O&41&JP@BL84;TX>QO/O1/%/:2F":,QR+@D'!#*>00REE92#PRG!]Z@W"&,
MLDBLKKP488(/YC\P1D8Y%4=G([W*]O\ R4Y1$7Z^WMS]U5/LOMQ^_46>0A2>
MYX Y/XGZD9S]>E08U$D\8[;N>^0._P"GX\9K:KH]W,-5Y5+P.Q/_ ,6Y(UYZ
MY"*J^"[C#Y:T:_LM;-B,()Z<?C**+P[GE':/K]N94%QC+Q<,?>,GG/\ TL0?
MIENW3Z"^SF_^%=M.)Q!= 21J?W;E1S@YQB5 <^Y1 .!73'6I5V"FE*:4II2F
ME*Q7)<WQ3#Q-)D=Y!K%(U7! 4BOEG1/_ $$,+22C>_MRP3DY]N=0[K4+.R*K
M<3HCO\D0R\TG_1#&&E?_ .%2*R^EZ#K&M,5TO3[B["D!Y$3;#&3_ .)/(4A3
MW]3@XK7[..H7:VUI;S%;7&K_ "JCR*HLJ.WKI%;#C5EO46T,\"RKY#;*=',2
M--A'-',Q8JM((KFJJ<JFM>U/Q=;Z7&9)-)UJ5!T9;-(4(^AN9H7S]"@K>[#[
M)/$=Z SW>CVHX#*]W+.ZDC.&%I;3Q@CO][CZUI]T;9)TV="?3SM_TP;887GM
M3@.W([Q*^3,906%I83<CR.UR:WL[0H;""PTJ18W$A5>QBJR,P &HY!-1=*;[
M:O#D,ACN],URW .-_P /:R#CZ"[#?PS]*SX^P7Q1+'OM-6T&X)Z*9KZ(GCH"
M;%QG\3CW-;\83U([.YY(#!I\NBP[,[D8*LO!DIY9"*[M085F(R,<CE5.Q@)!
M7/1R*U%]^-PT7Q_X4UYDCL=5B2=_EMKM7M)B<X"@3!4=B> J.Q)Z9K3M>^R[
MQQX=CDN+[0YY;2,;GN[!DOH%7&2[BW9IHT'.YI8D48.2*G1%14147E%]T5/=
M%1?HJ+K<JY_32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E<Z/A3_ /@5XC_[
MX^K3_P"+3>[2O!T'X5T7TKVFE*:4II2FE*I)\^!50Y-C9S8E=7P@OD3)\^2&
M'#B &G)#R94AXP "Q/=Y"O8QJ>ZN1-*5RYZJKDLW=2SCM-W@@5]/'C*-ZO8X
M1:T$WN8J*K>USYCG<L5&+SW)RYRN7<=$&RS5@<%VD8_4[BOY\(*XSXXB^*UJ
M16&X0PV\8!&< QB3CMR96_7\AK>"4K',17HU7N5K>53\3N%7M;ROU[45>/=R
MHBJGT]\ZDC GDG !..=HXY([<GK[\>U:#<:3&X8JN,#)P.!^G&.QZ=O:L!S;
M=V%0N)C],=L_(RQIADC13C8X(8<4LN;()(>Y!0X\&,)\F?/*OABB8HVJZ6]K
M&;/I]LL4(U/4_N[-.8UDR'N6 )"HG!?=@[5].[!)/EC)MVGAJ?:;RZ;X2P#@
M>;)U?+!56).#(\C<(HXQZV(C4DZ1Y%LE!WYP?!=U,QGSX64AH_T[$$=M: K!
M54W)D;&K8]9WA[#+BJ!E1)2>.<6]<,SE495 W5+GQ5KNI^,HM,TV8VEI%X?:
M^2RC =A=2:K!#"TBX57/P\%Q$22/[TCA%%;<UW'H]Q>VFG63ZRMO<+#;V<+1
M*EY#'8NLA6Y42 RS7S+A_+*>2F P %2=3;^W66UE)M]DEN*4;!<)F95O!DU)
M8&2)!HZ",:*R- M3! ZPRC(Y[(U4AHK$;#(>PD1E\\="/W/4;J#PU!>7TL$,
M=Y,L]R$0,8K*UR[JH+@>8V%V* !YCDDCRU4-8N-$_9TCRR))'=W)0Z=82)YJ
MPF:4 RW,@#1K' AD:-"69S%N?TG%1%08!,V,W)VCWLQ.LF0Y&5TTVWW:K627
MGA0R9'$)E"4[ \/,QZX\M@,223O$^;11Y(VME.+YL+I.NQ'3$LM=E>2;6KJS
MMH7=A)+:ZEJ<CO:^8S-O$"SF.WQ@[0X"JJ*[!;E]2GU72KEV,:-;1:3.\10S
M7.Z:)Y?.( =&<0B50"46;<Q -=1L[WFPW!::#:2K04@]T.*ZDA1&NES)[K!K
M/0-C1!_K3FF.*(<2,C6DD%*UJ=K&E>R18:5+-)(9]MO;6Y(N9I6"*I0X9=QX
M!!RI;) 'NQ45@[72+^[\_;&84M69)YI_1%"R'#AF.<E,$D)N/' )(!U-FX.O
M4<7="CW9A/%0Q\RQ7"*V!%M)(S5<IU3%R'*3&G1")#DWD!)]35J48WQ:@\>?
M717O&Z421@?&7B:ZLTT;3M$F^"@N_$6CZ>9%#+)=6WQ0N+T*1ZU2:&"2!%8C
M=N,CY8@+DUEL=/AL_@[AYY3;WLEPZ;<F?>UO:>:A)V1JZFX\EB6,;Q%UW=,%
MP;*<EV/IS[#XQ9U&22\GR2EQK;:BC>K0-/8V,!H;Z?>R5<^)58V6SAVEY$J(
M?>>7%9(./L&IQEW2&&XMK6UU35UCEDMK58(,Q2"ZN9Q),\<MU-N=,K"4C3[H
M>2B'>[N8T2B=);M$U?5+"33(9)=C6]O][+<[6D6+:&(">9"BR22N8T15V#,C
M@)CN[NQM'F5!GNX%1 //SS#\P%2X'DH#O'8Y)'V^KZZ?G5T?TOXK%S[J5D[J
MR/'5GHPT5?#A(P,1!DP&D>)93JM[JMW*K6HFFMX[?</*EM;")_-BB1LA2UT;
MA-X]6U-[EES49-1F6[T\1^:]G(TG[01(F-O!%()(HX'9EV0IGX=5D) :21@"
M[DYZ%X3O12R=LH>3Y7:PHMQ4-)2Y.!QF1U'D%8U!S/PD=^J#)8@Y['KRQ@)+
M43N?PQTA+)=1NXVTQM]E>0P7]L^X-Y5I=QK/$)MN2LBJ^SRR S;<].:IFT^?
MXKX>VBDG$BK+;[1G?!(-\;EN%&%.UV) #*PXQBM;LLNYV^649+C%HR5'P(.U
M!LG5PYLJND6Q<HL"T>((4L(K),"JE-C7%J&&KFR;$<>%)F(Z&= 'QOC+7&\.
M>%]:30I4AO8=-N/+U/(95OY8VCM@C@'<RS-%N9,[052/J35^%+?3XDEEN8YK
MW]H10SQ0E',5M&OF7"PC.226BA%QG8[-,L> C,80Q$4?H?=FE-!OA66&6,>4
M2)1!-83\CEY$:X<7&V58'-+':=*6WC45]:D(QCIM=$<HGG)Y 9[38+R[L(+C
M67$MM92-,;B57^(FC>"WC^&54*AHC<))+EAN9I2B'87>DIN=:A-Q+9?LZWL5
MCB?4B=Z7<;JLC.D( <R)(WE1QKN5G8L614:K5N7L:3>Q,A#FD(ALWQ' :V6P
M<2<@&0=TMP+!MKCN*1CRB%!Z&@QBL!!N^1M;83K^;8>0<E(CHN'?Q+=W7B#=
M%,UM8Z8D42VPP81+=.K$2(,++*EM&ASC(\_;&1CB'-?"QCA;3A(T9O8D1#"9
M76RB:-;BYFC7(W2>;+*S$_=K;A!A1@[4]-.YDQVTE?4YW.;&OL$JJJ):R)KW
M,(2KEUP9E.5WD1IB'!&<M6=JL<59,%R.5[R=SI4\D6NR0ZIHL,AM=3GO(%B]
M):*]T^\FL;V)RK%%4SPM/&2V##(I.,$"G5;$I=1O8QM+;WS2M;!?60Z2%)8^
M!CA@'7! $;KT -1YN%O)<[ESL3H, -XL<R'<JIP.9D7<YRN1 EM<H'2!$]KS
M3*S'H<TDB[7B)629 (D?S24.]F;\V'P[ T<?EW6L28$K##+9H1O.\],XV@1?
M,S%7D(3:M1!8Q6<TK:K/&D\5G//!9*ZD"<*!;^<V&#S/(RLL R%B#O(0<+4'
M6VS^+;*[@UN^& V]+ADVVMB'N8TY)\]AZYMI>1K*(.**4R9+=?5UI61HE<PC
M!.M*(<M."/(=FH^ )=?\4:7=WDUX;J#4[K5CYUXLLT,,/[:+V9AC\V(BX@LX
M/(B.\(GFL[AU]#>"?4=27]F6]@MQ %622]D=5EM98H8 %\SA2LLGG%V8.R(V
M.?2C>R?.C=0\?&966UA)6.;E9O*!04U@YJ$!MYMVDBVR_)+$/<B,F9'85@,8
MA,02$K*N27TCQ.F&<F4\1Z[LDT_0-.W6UGYZO,R Q2RQ66VYFEDSAQ$\RPQ;
M&Y?S"[\G"8+SDL2\=O)</<+',TLS12(]S<$K&B0I@ND$2OYD*RE6>1=[(S!*
M]O2K!G[)Y9EVUMFY(.&9)D,N?@/JI?F0CV5-3."8<IZM')?=UTSL(\31_P"/
M5#P()A%<W4VXUBPU2 P>8HU+2+&PNKJ5WC1;FTU.XOXH-@R"7M9K%PV =R3J
MW8U?N$EU31;747C<:E9Q1PZM'Y?EG,DDZ F+"E/AW3:P89\N2,MMVG&U&]^\
M>!;![=7^Z&Y$NX@XECP//9R:+&,DR^P8UW=V^*GQ6KM[1[5[50DA8K(<9O!)
M<F.)%(F#OIXK>(R2E@@'.Q&D;)^B@D=N3P!CD"H6A:7=:M>I:V:QM._R^;-%
M G;.7F=%)QT5<N?W0>E:0=%'Q;]@]^,KLMP:&FW'P_"<"W!I:*IM;; \UR.[
MR>1$2):7,U]/MYCN6Q:&M!$F0@1(MC=/O;$AI+BU,$(@/F:Q+J-O?P7059$7
M8T:ED8EVV')(0,%"^G&YLG)R %&>W6/AK4=!O-++RPS3>=%-((I8HTB19%78
MK3/'+,S /NV1 8&T%BU?0C_PHG1=_P _=R/^C1U/?]CFM,KL%/\ A1.B[_G[
MN1_T:.I[_L<TI3_A1.B[_G[N1_T:.I[_ +'-*4_X43HN_P"?NY'_ $:.I[_L
M<TI21\1'8#.J3)ZG9K),QO<^C8_,L:J'>[*;VX76B:,\6&:>>[SO;K',>;Z#
MUK)389K-AYBC\0 E57(D/4))HK*Y>W*K.(F$+,-RI(WI1V7(W!&(8KGG&#Q6
M5T2&SGU;3X]1#M8FYC:[CB<1R2P(=\D,;D'8TRJ8P^"5W;@"0!7(3<GJLW1V
MVZG]B12+"':X%DF.;C6F[[[V)%G6'J3Y7M3AV$Y)%MI+TE0(U)DN=QX]H 16
MP$I[*3*D#1M4!1\STJZO/#LUU>W:C49[FX@C:YDWF1UE2X9R7<$PA3''CG8H
M&P#D@?1>L^(=!G_8NFVO_H?P_<VMU%=V5O&L;V_E-;06S1R0$':&D9YMZH95
M9Y&W,%+0#DOQ!-XLHV]WCG9'E6*8ED.1]15%@W3_ &ECCT%M?@VW66[5X1NK
M46&2Q!PS/NCP<-GW%K+E6:%?\YMH%23]2..-)^J>)+_4;06BZ9N\^)[D*,,R
MA;B:-8]K8+G8J;F5E.'+>D96H'AZ33]%L-1^!U!+:XN-5BLM->Z4R1PV<]K!
M?">Y#N=SI 968,,&4QP\97.#95U89?N]/IKG;O)]SZ0-OTV83N#CF*[;[+Q=
MTXMANC;95NAC.08_GEF;"+\F.5\&XPROQ]K9.2X4!ZQ[DX[H+Q%F0N?S:!;7
MD5V9-/A>=)FB9KB?R70)&AW0*)D$C%B[*#%/^Z#$?E?<XO%TF5ELM4N[=)-#
MM;^VMK+2UOU?4I9]0BFM[MC:W'D1I+;11'-Q: YE;S1C<EBP_J(W9R+=&XVL
MRVOD8*:+NY'QJ7GC:>!(QF!)K]K]N\WD;08K.(1PK;,+J=;Y5-3(+6.:#78W
M63PQCRKY:V+%P%UX1MK<PF%5#&!)-N<3$N\Z&5@-P0(5B!B\S<2Z,JM&2QW3
M1?&EYJFJ-I$LD=HAOUC:_DMT:V(CTG3KR31+(NK":_NYY;SRY9E95MXW2(R7
M#1!/H\Z&=T,MN5N=O,ADS+FMK*L=O16)R/E/K M...:N+)(KGK'D-D +!"Y[
MD H9#1<">U&]O\"B\@TP6EW<S7.S+Q&7U>1'N($2N?64(VL%8G:=P7TG ^;?
MMK71Y?$[W>DV,%COS%=^4!$US<( &EEMT)B69761'>,*9%V&4&0$GHOK>:XS
M32E-*4TI32E-*4TI32E-*4TI32E-*4TI7,# _A[;P;24<S#=H?B(]3&WFW[L
MNS_+Z7"X.VW25D$''I&XV=9%N%>U\&WRWI]O<CF0F9!E%H^(ZVMY\H4=XP*=
MS1MX5Y@?^1(_E69_S0NJK^E$ZHO[G>B?_9GTI@?7]3_K3^:%U5?THG5%_<[T
M3_[,^E,#Z_J?]:?S0NJK^E$ZHO[G>B?_ &9]*8'U_4_ZT_FA=57]*)U1?W.]
M$_\ LSZ4P/K^I_UI_-"ZJOZ43JB_N=Z)_P#9GTI@?7]3_K4?[K]%O5C>[8;A
MT<?XB'4=N0>ZPK)J@.W]YM7T/U=)FI+.FF0FXO<V4OID+'KZF[4Z5]E-((WI
M84@YV@.]C1/4P/K^I_UKCAT>_#$ZO/A[TF+U/43UH9+O/66&/R$K=HZ.$*VV
MOPTHSN&RIJ<RSBJ/GDUE.%T=T4-,S"ZAOF\:5)HPFH39-$+E'^^;;&V/(PNW
M#9(;)!(R2WRXY&>]:#XQ2(20_P#<XO,F0L;S<XE^[(4QE5*HP"[>7W''  P#
M6RN]$3<FPQ<\7;"OBRLB8,DJ.:=:)5!84#%($8C)^,DHKVHP3.^.!57B1*$+
MGG<=,GM+:[6XNEED0(T8A7'E2"0KN\Y3\ZC&X(2!CJIX%:KIC6$,^^_4O#P"
M@0MD9!.1_@P/4.2PXPW;G74UF?T.3[@U]EMENOD%IG&#UV+LR@M);A^3P)4V
M/*R^J97BA2PRIUZ\#88)E=8Q:R)6H-CWR"C,8\R]@?4]9EO[O7K7]FK&D=A;
M*CI'8P!$,J"W#?>W4TJDO*2I\I53("[:S.NV]MK=O;1)JVGVL,,DDG13L8@K
M&(XP8SB)#D(_J:1BVX#:*VZ@;8[H[LO@S\\87;'!H4&'6P<'K)+'Y//JH(1C
MCQ["9'(2)1!*C&))8-9ED1K7C&E4JM<GMK/H6C7MQ?:5:FYU6YM8K.XU6Z^?
MX:%Y)4A@@)V1H)97DQ@;F(+^9M7;9L[K2-&0Q:5&+N\9=KZC<+Z4.3GR(R.
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M>7U<HH129I6CLWT&A:W/-?ZB]SI^J/9-8":!?-MEC9BQD$+ GS"V-Q#*2L:
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MM5KF]S7+PYCFO8[AS'-<B*E+*'4JPRK @@]P:J5F1E="592&5AU!'((KD]U
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MHZ8DB1QSU^93UK%S[6;:R>//@6(OXYXXQ^L9]?K^Q&;J\+V['2YG_P#S7/\
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MGE$]T]^-*5Y:4II2OQSFM17.<C6IQRKE1$3E>$Y5?;W541/W^VE*_=*4TI4
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M;MX77XA8T>5S%RDDXN.6PZZ#81YCUECY@,4KH-MIUG?$SZ=Y]=TV;F5>R&5
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MNCT9:X;!(-7@_P S_,U4]"6U^"T<;H7;5T?I4H_A#=8.(U:?,[@_I<>N=\\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g486549g82r79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g486549g82r79.jpg
M_]C_X16:17AI9@  24DJ  @    .   ! P !    0!\   $! P !    L#8
M  (! P $    M@    ,! P !    !0    8! P !     @   !(! P !
M 0   !4! P !    !    !H!!0 !    O@   !L!!0 !    Q@   !P! P !
M     0   "@! P !     @   #$! @ >    S@   #(! @ 4    [    &F'
M!  !      $  #@!   (  @ "  (  !\D@ 0)P   'R2 ! G  !!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$W.C X.C(X(#$S.C,V.C4Q  0
M ) '  0    P,C(Q : #  $   #__P   J $  $   "T 0   Z $  $    @
M P          !@ # 0,  0    8    : 04  0   (8!   ; 04  0   (X!
M   H 0,  0    (    ! @0  0   )8!   " @0  0   /P3        2
M  $   !(     0   /_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !
M_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,
M# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.
M%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_
MP  1" "@ %<# 2(  A$! Q$!_]T !  &_\0!/P   04! 0$! 0$
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M=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M    0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M
M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0(X
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M_P  .$))300-       $    'CA"24T$&0      !    !XX0DE- _,
M  D           $ .$))300*       !   X0DE-)Q        H  0
M   !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$"       $
M  $   )    "0      X0DE-!!X       0     .$))300:      -!
M!@             #(    ;0    & &< .  R '( -P Y     0
M               !              &T   #(                      !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   #(     !29VAT;&]N9P   ;0
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3001       ! 0 X0DE-!!0       0    ^.$))300,     !08
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MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
M# ,!  (1 Q$ /P#O>OOO:[&%+MCG;]=KB=-GT=F/D_\ 55?]=6?39F-VN.\G
M<YKP_P!1KFL(VNV-^R?I+G>O]#]%_1OT-OTUNV48.>S?EXK;!2Y[6C(K#B(.
MQUE>\.]EK6_2_/K6?F9/U6PZ3D=4KP\1E[CL=<*QZH ]KVR-UGZ*SZ/TTJ"1
M*0T$B/JYGK9+6PVZP5O!K=LKM(  !N:VG[#]%N[Z7_;?_!R;?F6M)<U^S:18
MT-L(%C@\')]V Q_MM;Z6RC]%7O\ 4N_1+6Z:/JQU.@V=-9AY5-8](FEM;@T3
MZOHNVCV>Y_J>FK0Z-T@ @8.. X;7#TF:@Z[3[?HI4.R>.7[TOM+SPNRRQC['
M65A[H;6ZIYW,DM?9N;B'98[W5_9[J-[Z_P!+^B2=9U![7-KM_0M%CJVMKL#M
MOM=M])V)]/\ 25-IW^IZGJ6_Z%=%^R>E3/V+'F(GTF< []OT?W_<AXW3^E7X
MT_L^NICW$NJLI8TRUT;G,C_@][$J'97'+]Z7VEP?M&59<6ML-(M!V!K+G&(+
M!4UUV)6QU/N9ZMSOZ.E9E]1>7.:ZUCWV-=7819^C!,%CO\G-J]/?9Z^^_P#,
M_1_S*Z)O2NEL+"W#H::C-9%3!M)[L]OM2'2>E!I:,+'#71+14R#M.YGYOYCO
MH)4.RN.7[Q^UYU[\FQSVUDLK,$/>;6AHG9;57ZF(YU[FL<US+/SZZ_5_1_I$
MCD]2:PW$V^LYS35::;GAI_2UW-MJKP6?I/58RO\ FOSV6?\ &=$>D=)<YSG8
M6.7.,N)J9),1+O:K:5#LKCF=Y2^TO*8>+D,R+JW8Y#?1?+G5V[3NK]M=?ZFR
MOV_0V?\ 6_1>DNK226O_T/4[-:W#R/Y%YC_C, ;TWI0&P$9%@=Z9GW"FO=OC
M_"_OKTVUI?4]@Y<T@1IR%Y]_C(Z9U/,P^G58>)=E/HN?ZC:*GOVCT:Z_I1[V
M[_\ ")*3?XH/^2^I?^&Q_P">:5WR\_\ \7M/5>C]!ZJZ_!OKRC?ZE%%M5C2^
M*JF^WV?O-70])ZUUK)S6T9V"ZBAP<?5%5K8(C:T^H'-]R2G?24+;J:6[KGMK
M:3&YY#1/]I56YV*+G 7;2\R=X?M$ ?G./I,_LI*;3WN:]H@;"#N=)D$1M@;2
MW_IH;K;=ED;=X=[)#HC3Z>FY,7$FJYA%@=[6EG$/@[_YP-?]!0#2WTZPW2NR
M&Q &K=WJ?SWT/=]!WO\ ^#24SOR_2+0VI]NZ9+&D@1^] 41F6N;N;COY(ASF
MM, D3M>X(.<X-MKWWOKT=#:P0#Q)=#T.FS'> UEE]K@W=(-LNT'NTMV=TE-]
MESG-<2PM<W4-EIGYM.U)0K ^SN^GL+3[3O\ 4_Z3_5224__1]2JL%K2X!P <
MYL.!:?:2SAWYOM]BHY&?T_(8UIR0VK=^E: 9<!IZ+M-S=S]O]?\ ZXDY]V51
M7E-MLQPY[6&ENPB1:*_4WNK<_P!S?Y?]A1OLSJ;MK+76-#A+'!K26'TF[ZK/
M1])SV66.]C]B2FP_J> UI+LAC!J-Q,01+7?2]OMVH&-U+I./4*6Y'T"X/+Y#
MB_<?5>^6M]SK-V]3&1DL<UXW6UO!+6NVAWM!+V14S^<W-]GYBLV/%N,]U9.H
M(!$@R-.SJG_].M"]:ZI(KQO5 [K/3&_2O: 6[@8,$$FO]W]YJ-7BXC0TUTUM
M (<V&@01]%W"K6M?O:"7F6M^B;!!C7=MR%;I=8[=O>Q\0!L!$?O;I<]%#7R>
MHLKQ/M(J<[^= 8\%AFIMMGYXW;7^A[';?^$7.T_77+O'Z/I'J$T^M6*[7/WD
M!A=4W;B_F[_?N_X/_2KH>L6!F$^6L<"VT0\$\4W/TVEKOS?^VUP&'E9Y/3<?
M';6VK(QXQ'"V]H!%8==4T-S_ &LW,_1LN?[ZO31"V1K;\K=IGU^N+<9S>EM#
M<L^TC(TTU_[C?2V)G?XP;]MQ=TMI-+V-+?M$R'&-W]'_ #&NW[5C_8;\?&Q\
M@X>/C_9\D47GU;QZ3W.]&MU>W-_1;-_Z1[G_ ,U=ZW[ZK/AF9F4,QL8NJN87
MM99>[<UYW>Y_VQN^UOT7?H_^#1H>"+(UOK6W]9]4#6C@#[DEG8V?;;T5^8;&
MFQM3WBX,(9+=_N]$OW[6;?\ 2)*/B'#QZU7%MZJ_NK].XK][]&OWO[K_ /_2
M[_%]5V!CO8]@I]7WMVDEQ-XV/KL]3V?YEBM9VXN8&@EVTD <G:^EYVC^JU2R
MVV-I8VBL.:U["YC=##7-=[!HW^LI6UWVM <RN6N#FDDF""'?NI*:OL++K*'.
M K NI DD;FNW?H[-VUCO]'L4_M-+6646F&'<YMC07 AQ>]VCF.9NK:H>G&(R
MS(#<<UR!:Y_IN:2XL'O]S?=N^@YVQZD#?EL=4-KS6)KRF.AFX[V>WT_I.J;_
M #C'(2%ZC==$B@):5U">S!KL<UQ<1L&T>VLZ1'Y]3O\ H)V8FR=EKVR9,"L3
M_FU(-E>12T,I:0+'$#TW AA=N=ZCFOK_ )MKU<9OVC?&[O'"06M3J O9@O:S
M].=EF][PTN ].TM+6-:UCG>IZ=7\VO/Z<>X/P!8]C:,W$#B^RBLBJT,%;_M'
MIX_M?O\ TU5?Z.OU?T;UW_5Z[;,0BH^Z+/SMI,TW-;M.GY[F_P#5KBL2K&-[
M'Y&9;]FRL7;E;;&-=4\"O]RY_P";[WWX[/\ !5/]7],G!!:3:,IV)5:_(K8\
MY!IR6NQJP_TRYU?VDM^R_P!&VL]?^I_74KGNJR,XL<"675LPVTX32UVYS?5]
M%[J?YECOT?K6V6?H_4_X-3L%[&]+-;LBQV/8X7/=D4M98QKPXC%9]I_26V.=
MZGZ7^9M4LAGJ#J!I=E4LN?6ZFMV140'>WVW.;EN]'];]3]#O_FT4#ZO6X5-@
MZ+9TES_UKT;* XL<VK<18-S'%NYS?WDE=;TVX6!_VAQ #@09,AQW-]I/TJTD
M+UOQM/".'AKTUPUX/__3]0!R/2=N#/5E^P G;$N]'<Z-WT-GJ*EDYVVAM-^9
M1T_,)$DEKP8]S]C;_2]C_<S>C=1#2[$!<&GUQL)_>].W;MT=[EY3_C6I(ZYC
M-N<+K6X+0ZTM +B+;?=M;[6I*?4*Z\_(KV_:B-CCO]7&V[Q])OM>6^QO\E%H
MQ,VE@8,BN >&TA@X/YK;/W]JN;F[@V1N.H;.L)TE(L=F2QKAD6MM=,M<UFR!
M ]I;OL_/WHJP?JY];\'ZPW74XU%U)I8VR;0V"UQ+6_S;W^_VK>0!!U" 018-
MM/J5;K6U5-C=8Y[6D\ FF\>!7+8_U2ZE39B7BBDV5TBC*8;WP6@5C]#8VIKW
M?S;FM;;[/1?Z2Z7.SK\#!;D9(K-@>0=L[0/?LC=[MWI_37*W_7@BPBJNRRN2
M?4;9M;J9]-DL=_83@N$#+86SQOJMGUU68S,.DLJRA?C/==8QS&[P^RG7&=79
M[6O8Q]7[ZEE?4_*L=F"C#I97DBKT]V0Z0^OFVS] [W;O?]-_T%JM^LAMP1E!
MK!4_ETENT1+O=^;M651]<\2YXI9:\&3M>^S:UW]M[-OYOM2U3''*5D1)X=_!
M[5)9F%U8Y'2[\]VQK:@]S2'>PM:T6;R_]U)!%&ZZO__4]/R,<W&J'E@K?O,3
M)&U]>SVN;_I%Y%_C5./5UO%K99+&X+0PN>7DCU;N;'N>]_\ :<O8U0QZ[+,@
MN;4,?"IEC*]C0ZQWT7606_HZ&?X'Z'J_SG\SZ?JI3Q'5NK]0K_QD583,ZYF.
M<C&9]F%A#-KZV.>STI^C8[Z2O]&^M'5,OZZ9/2;K*CBUV9-8:& .VTN<*O?N
M72-M-+'Y6<QM-;SLQL,!A>9^B'?OY5SF_P S79Z:FUN53ANMNQVY&2\C9CUA
MH:R2&UU>J[\RKZ5U_P#QCZZO\$G99<?MT.#@ !K]-?BG& R"4!/C%1)_R?\
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M)))2DDDDE/\ _]DX0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "
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M(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_^X #D%D;V)E &1
M     ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$! @(! @(#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,#_\  $0@#( &T P$1  (1 0,1 ?_=  0 -__$ :(    & @,!
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M;8;;-%(DE+"88IJA5J3ZD!#>T\W7*P;=:7;QM=RFU"EC1Y!//)'(P&*^&%'
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M9[SZ6ZBZ,^/8Z[P_0ORVW/T7W+T7D?[@]EY+=-7B]IY:>AC[)JFJJ:CR$O\
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M1U?YE'\PSMGX,_(;I9-G=6[8[=ZPJOB!\YOD9V_M"OWGMGK3=7\)^+<WQZW
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M'?F[-X9;'[ZW5@<QVGU+BXLECEH\X\AEIZF"EEIZ9OM/4./]7SZU4>8Z,/\
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M8Z]4<.@^ZB_F6_"3Y ;?P.X>\OY<&P*.7Y,?'OKK?^WNCL3T1U=VOW!W1O\
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MIYO='7M;F,SMK:T%9%6Y'$4%*LS#V3Y\>O=HKT=>7Y9_RB^F=M=X]*9W<_\
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MW_VMMH]*? ^3I.78/<-+DOE/CNWLIUQB,.E7+3P45>N-PD^9JSK>IR;>R?\
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M]J]?][[C[VWUTC\B^IOC9D:+:F^?C3\@<[3=_P"0[6[J[0ZJ/?N2BZ_KM_\
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MZYG:V\-OYG:VY</4;5ZQBI\K@-P8ZIQ.9QLTM-L>"JCBKL=621,T<B2!6NK
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MN_=RT>/QF,Q^[LO2T-!0TD&12"EHZ2FB6..-%"HB@   >U2*-*]HSTCD9@[
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M>N_DPE'UV^'3=VY,MGUQC9";>0KFH!DZJI%*U6*.(2%+:Q&M_H/;$P%%P/\
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MZU_] 7:__P!:_?NO=>_T,=/?\^HZU_\ 0%VO_P#6OW[KW7O]#'3W_/J.M?\
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MNTQ%3456ZFE.M4Z-/[UUOKWOW7NO>_=>Z][]U[KWOW7NO>_=>ZZ50H"J JJ
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MJFHH("V1WY?+K7'RZ1_\_2:>#^6QV9)!'Y67?O47D0/XV,)W[B!+HD_LMHN
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M<E]C$\*M-$D-0L9#%GB*>-)O/O#]V>_WSDNSV/W)2WV;>(OT;_PWDVUY&^"
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M]U;WW+V!NKL+L^NHQ4/F-S24OEP>S-J8:&EVSUUL'#T]%&F/P6+ABHJ9VEE
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M@[8K,QLK</Q^EQ\*8^D&XZVCJS5Q28R"KD@KH/54U)&?]CKU#ZXZ46=^-_\
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M3^2W]@,=NWX9]A=>;8SV,QF0W+WK0;9F7O?,43PB+<V;-3!43/4T5!C=6/\
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M#:F/FY5B2=35/ 881-"  *  . 'V ?X/3HU/4/8^UZ7K&/;>Z:#<&.Q>&RF
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MU$2S1,\%0D4\+F-@2CJKJ>" ;CWKK?4CW[KW7%_T-_P5O]Z/OW7NB!?RL/\
MMWK\4_\ Q&%-_P"[G+^[/\1ZT.'1_P#W7K?1#OF%_P SO_EJ?^+M[A_^ <^9
MGO8X-]G^7K1\NA@^9%+4UWQ#^5-%14\]96UGQP[OI:2DI89*BJJJJHZSW/%!
M34T$*O+///*X5$52S,0 "3[0[DI;;K]0*DPO_P =/19O@9MDWA5!+&UEH!FI
M\-O+SZH]^.'\Q#LGKGX]=%=?2=M_&W;TFQNGNM=H/@-T?%?YY97<N$?;>S<-
MAWQ&X<IMC;K[;R.;QS4?AJIZ FBFG1GA/C*^SK9M[]L(-HVN'</WT+]+>,2:
M/"T>($ ?36$G3JK2I)IQ)Z!6S\S1VNT;5:RW2++';1*0;>Z)!5%!!(2A((H:
M8],=6=_R\OF)N[Y=8KO:HW7)U_7'J3M*FV#B<]UWM7L?9>)W#03;6Q.>.2J-
MO=IU#[NQ]0T^19 E1!2L$4$Q\W*S=YN3KA;";E#<;B>)HJS+,*/%)J-$)$<:
MGMH:KJ&>/0JV'>X]Z2^:-U80S:*A9$_"&X2 -Y^E.K&/9-T?]$"_FE_]N_?E
M!_X8%/\ ^]/@/80Y]_Y5'>O^::_]7$ZR2^Z#_P")*^T?_2S/_5B;H\6VO^/<
MP'_:DQ7_ +@P>Q1:_P"XUO\ Z1?\ ZQ\W7_DI[C_ ,UY/^/GJJOXK?)+J'HR
M'Y%;/[2S>Y-L;AKOEMWYN6CH5ZT[.SL53@LMN:"/'9*#([;V=F,9)!5-12Z;
M3:K+J( ()AWD[FC9>7AS38[O--%<MO=Y(!]/</5&D[6#)$RD&AIGKT\+R^$T
M8!41J.(_RGH\G6/RPZ$[BWB^P.O=ZUF7WA'@:S<YP>0V1V!M:H; X^LH<?69
M**;=NU<%230P5N2AC(21G)?A2 Q$@[3SGRYO=\=LVV_9[X1F30T4T9T*0I8&
M2- 0"P&#Y_;TF>"6-=3KVU]0?\!Z,7[%'3/7O?NO=>]^Z]U[W[KW5<';'P[^
M6':=/O7"#^9%W!LK:&[<E75%'@]F],=(X/+;7Q$V7_B>-PF%WQC,!0[QC7%0
MQQ4PJONQ4U$*'RLVM[E?TFX"8R#=6T5)TF-"*>E<''V^70?;:]Y-P\J\R2B(
ML2$,,)4 G"UTAB!ZZJFF3T,W3/1_R3V#O6/<':7S3WCWIM5<97TC[#S?2W2V
MQ:&6OJ1$*/+'/;%VYC,\LN.*,5B$OBDU^L&P]N6UK>Q2ZY]R:6.GPE$7\Z@5
MQT]8;?N=M/XMWOTMS#0C0T<*BOD:HBG'VTSPZF_*CHG<G?2=$8;#9+!8_ ;+
M[N.^NP8MPXRBW!0Y/:$73/<>T*:@3:V6HJW![FJ%WKO##U"TU:$AB$!JE;ST
M\2L8@TK]G1R16G10ZWX0=I[;W#G<%L:7%[AI9L#T;B.M_D/OSL2OINUNH9]A
M;FW!G=[9'!X7![)=:N&KI\JD%!A::MQ^'K*6*/'58CH58'PIY]>IT9O*] =O
MR8'Y)838_=.ZNM\CV=W'1;_Z_P!VKG*S?68PFWINI.KMM9O N=ZT^:DVQC)=
M][<RU534.+:*GI*=X5I_#%)) OA3&.O>O2%H/COV51]NYO-;OVALGN63-]H;
M.W=AN_=V[ZRVV=[[*Z]Q&S=H[=W)U_2[/VGMBB2&*MKL+DY(\+C:VEVKF1F9
M9\K$7-13U>NO=,5!\5][]5YS;V\NIMA]<G)8/Y;[V[4K,#C,_P#W$3-=+YGI
M;M7K[:^TI<M2;6R$8;;VZ=]TM?'C)('HH5A=XW$@6^SGKU.'RZP?Z!/FC5=M
M[F[\Q7:_6FQ]T=B1[YZ]J=B5.$W9OO"=7=82;?&/ZHSF.KI]X;?VWO\ W3LW
M>>VJ;<D] ^#PZF;=F>HQD9Z>.D#^].O4/1DOB5U5V;TMU VP>V-[4_8>YJ3L
M7MK.TFZXZC<M;79/;>[^R]T;KV])FJW=FX-R96?+G'9E3)&*C[>B0I20AHZ=
M99/'KPZ,S[UUOKWOW7NO>_=>Z][]U[KWOW7NJN/D_LZ(_.#XE=HU\W0$>.V?
MN?;V#M'/147RBEK=\4W8&RL9#3T>8HLSB]W=6#-;HI"$2.BK\*&RE523&:59
M*?8X'K5.@=_G])"_\NG>'G1'C7L[JR0B1/(H\>?=PV@WO8CW:/XC]G57KIQQ
MZU'/A5\>]K=U[LK=P;V["VWUCL/;%9B9/X_E'R:U%=FJVICJ<;%@H,3#]Y*^
M.BHVJ*F13>%%!4.S >U<<9<@ 5)P!4<?]7V?X>DSG*BO^H]'<_FD=8],;![7
MVUOGK+L_&=BY1DPL_8-+-ELSNZKK?X%M+#[+HJA,Y205=(U9+2XEJF7S54;^
M69PSED!;S"A!(H?3_!UNN2M2<?ZOV]5X0YO'93%?Q*EEQW@5::2F@9I:B:5:
M@-([TU3%%)1,D0B(D#SQB[  /(3;WD?3IL*:X-&_/KOI.LVI79C)9?+SQXZM
MI\E2)C,944JU/BJ$-36U%0U"LIFJ:F6EI6IUA\,_B,YE=HS'%J&/)-I+=7^X
MK:VD=W>_0RB.!YFM5E:0",K]4HUV^A7:0R1_J40K%5F!$5^]B;K+[>;U8[18
MRS75SHC+)*L1B4L&,Q+LJL(]-2CUB8?VP,6L=#CNOJ>7M"3)9C*YC<&W=S;<
M=\SL^JR>SZB7#;BQS1M1UNW,M_!HY,EB\M/#7)/35!AE14IFCD7]T-"(>=K?
MV_AY<Y2LN4-^Y?A6V;P7MX=RAFI/.BN8UN)I%>8AT8*9*2.7U%$);J+/9#FS
MDKE/9[[:]RWF&UW-V1Y@9Y'B\1>QI$UDQHI4(9##2 4^-E"N2P;@VUF,;O>'
M95/32MDJK;]-N;$&6C%+/G,1505,OGQE U3),U5$U%+$:=Y8V62.QX]QY-MS
M6.Y#;]UUQ:642%4U,H-":(S1U(!RI9<@BO64<5W%=V<=U82)+'(@9&#41@15
M2& /:12C '&0#U95\*,+UAT!"G>>Z<]2;MW )J?+8?:U5E=E8:EI'I)4J5HY
M8LC'N3)3Y*5M4DD=- 2D.A1J9@C&<7+MWNEU=#ENPO;NR5PBMX)U'4: N$+I
M'7YR&E14\2"Y=T%G:6\G,,]I:7I5B5$U4&BI)5Y%B9@J4+G0NGY@ D0/FG'U
MU\M#C-R;#ZTKJ/M;+5.2W8-S8_<-9BL-F<IE9:6:NV_3X7>.%PM;G]Q--,?'
M'3U6N=/\U&9'*^R>:UB2^WC9TW&SEWW;FTW5K'<0RW, HQ\26&)W=(:(?U'"
MK7'D3T2;'[A<G\QS>!L^\K([R%$+)-$LKH3K2!YHXTG>/'B+"7,892P 85IG
MV? N3WI4;+W%D(MJ5L594XQY<S2F!8,I%4_P],>4FDH@U1)4.=0D:-D1&_4P
M5'0CB.AJPJI(_P!0_P!7^3H]?2'5=9U+V+BMS=U[+:3'X'>$V#P/WGWDN*JM
MR0%GIPE/AGFF>JFB):-)!)3Z7\MV.CV?[%RWNO,$EZNV0J[6\+2OJ=$HB\2-
M; 'CY>OY]%NX;G:;;' UV[!99%C6B._<U: Z%-!BNIJ+CCFG1K_E1WG@,QUW
MN+:&Z.MMN9?<.1IJ#^"56"Q<60^SQH00XI,82ZU-+#21T47BF@E2(QI%=4!0
M,H@Y:W2ZV^>^B@8HA?M$<K.?#%7^&-E73Q;Q&2E"<TZ3R;S9P;G'M<I=9FC#
MAV4B*A8(B"5@$,K'A&I+T +* REJ)LZ\V/KZO%9&"2F>DD:.6*OC2&2'4)BD
M=4A5O&S*;MH)3@'Z^D!CC2GIT>"GRH?]7'_/_EZL4^$NP^S<?ANR^SMO9G:>
MQ<1F-O1=9U%9O,XG&T^Y,)NO,;?GST>)FW1B\KB)12Q85%J'%/>.A^XD+!D
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M/5<,:11=K?+B**)%CCC3Y>_(5(XXT4*B(B[_  J(B@     >R <G;<  -PW
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M.[LVGOC=&S.S-L9;(=6K@-LUE/N':V3SN<R]+%5XC$!X14>H3UZO[>AJV_\
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M8&,>(U<#T\3TU27B90R$>]=;Z%7W[KW7O?NO=?_4V$/F;M_L7#?+;';6^/\
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M\1ZT.'1__=>M]>]^Z]T GRJ_[)?^2'_B!.X/_?>[B]^ZT>!ZA?$+_LDWXO\
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M"=P?^^]W%[]UH\#U"^(7_9)OQ?\ _%=^E/\ WVNVO?NM]$\_E]?]E#?S0O\
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MD6T?[F;Y_P ]'_/HZ"/+?_)3YO\ ^>\?]6H^K2_9[T+NB ?S3?\ MWY\G_\
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M3\1/EL  23_<OK;@#ZG_ )FO^/;W]<;H9/).]?\ .*#_ +:>M> /]_Q_M/\
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M #$W_'!T$-X '-O)E /AO/\ JTG0J?S3?^W?GR?_ /#"I?\ WJ=O>Y:]K_\
ME?N6?^:Y_P"./T=;[_R2+[_2?Y1T:S:_9'7B;:VZK[]V6K+@\0K*VZ<$K*PH
M*<%64UP(((_U[^PM<[;N!N;@K83$%V_ WJ?ET8)-%H7]5> \QT(&*S.'SM*:
MW"9;&9FC65H#5XJNI<A2B>,*SPF>DEFB$J*ZDK>X!']?9?+#-;MHGB9'I6C
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MJT%#2[@^%STU'2T[M\TNIU+P4\,+%?X+O(Z6:-%.FX!Y_(]EW/L<:77(16,
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M?CZ6GH:"@HNVNZ*6CHJ*DB2"EHZ2E@[$C@IJ6F@C5(XT541%   'OW7N@Z^
MFVL9L/LC^87UOMN7,Q;+V#\P=O8;9F$R^Y=Q[H7;F(R7P^^+&ZJ[&8RNW1E<
MSDX:&HW%N"MK#%YR@GJI& &H^]G@OV?Y>M#SZ3/RD_[>;_RKO^U1\Y__ 'R^
MT_9%??\ );V/[)O^.#H([Q_RMO)G^EO/^K2=61[NV?M/?^V\ML[?.VL%O#:>
M>IUI,WMK<N+HLW@LO2K-%4+3Y+%Y&&HHJR%:B!'"R(RAD!^H'L26EW=6%S%=
MV-R\-TAJKHQ5E/"H84(-/3H621QRHT<J!HR,@BH/V@]%U_V1'X4_]XE_'/\
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M\'-EXZ;X<]-S;2EHY=UY#:6-R.=I88'^YJZK.XHY%8#4K#/#)6O'+Q'KC?6
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M)#YG-0S,"DBABW#E3C@1QZ?&,'@>B+?R^MQ8K9_?-*TV1VWCJR2J2HQF3W'
MAH&QE;"(R2TCLHFB * JCD-/8!N+-I@GK;U[:C-.MK:7K;:F^.KJ7-[4IVR&
M FH9L'D&IZ.9Z>CK*"".CE,<T,D:14E7/&DU/(=3.DA++&7;QV!H:&E>K$!E
MJH_;\NB*?)+XA[7[IV!6[2P\<&7W#2XVMRFSYFIJ&AEP&Z,?CGHZ>JEKJ5XX
MEI7KXHJ6I0^)9(I5]!");9 *T.#U6E,KD?\ %=5X_P KGJ+8>[:SO/&]R[)H
M\SD^OMTXH1;>S-*M4^VLY34II=QRM3.LD-1%45D<<<\#AZ>4J'(8JES';-XW
M;:A=IMFY3V_C*%?PW9-0S2NDCA4T/$ FA 8@IKFRM+L0_56T<BHP9=0#48$$
M$5'$&A!]0#Q4=6Y+T=UY65V06MQ>V=S4T#19:AHLCB:6NH06@>GA@?$UT,LR
M''Q-I676JF"=XCXXV;4Q;7EY8R-/9W4D,Q!!9&9"02"02I%150:>H4\0*7FM
M[>ZC:&Y@62%@0590P-001I.*4)!]02/,]$I_F9]+[<I.I]GT]'1T&$_@]')1
M8?#T.'H:6FHX$,%7,:=J2*-TGJJ@O5NS:GDE=W+&VE&9Y9;AVEFD9I32I)J<
M  ?D   .   % .M06\%G##!:VZ1VR"BJ@"J!Z!1@#Y 4ST3?^6QU[CZ[8?8V
MZLI22*V6W/6X:GS,0,@H:?"TU#$_AD5?N(]%= [/H8$E2#];^VT&,\.GV%&H
M/3JTW;6(P>+I7PK9*BNBR10T]-C::*6+Z3J\L1?PQ-#)$RQNS LI(M8EUM05
M/KU3CU1]\KMB8C9ORYZ7K\-0P0FK[-Z_IJZ>D6*.&9VW53",2T\;A(V4QJ/T
M:24+ FX);E%.T_ZJ_P#%?EY4J:N1G.D\.OH0^T/2WKWOW7NO>_=>Z][]U[KW
MOW7NO__1VI?YM/9'>'7W4?QQQO06X^R-O;S[4^97374>1BZDSW7FUNP=R[7W
M?@>PI<GM;;6Y^U<-GM@[>R65J\53&*LR5,]-#)$I?T:@;* :U].M'RZ.;\5M
MO]A;:Z*V3C>U*WMVLWZR9FLW!'WIO#JS?O9N.FK<]DYZ7&9_=O2VW]L=;9>.
MCH&B%*V.I%$=*8TE9YED8UZWT8;W[KW7O?NO=5E_S1^[>ZNFNINGJ3H[-YS:
MFXNU>]:;KS.;OVU7]2X?<& VY1]0=O\ 9;_P;.=YX[+]786LR^<Z\H:)Y\G2
MSF2EGF@I5%;-3.NQ3S/6B2!CHGO5GS?[M[$^2G0&1P_;^9SNQ=\Y?XV;"I>A
MJ_9'6VU:SLS8'<_\O[>ORIS7?>2QGV.3WKM3>,'96)I\:L='N$[8QU-CZFB=
M)I7:H&Z8./\ 57K5<\>K8OC5\A*WY XSM(9[J3>G2F\.G^U)NIMZ[#WWF=A[
MAR]'G5Z[Z[[-I*ZGS'6^Z=X[5K<=7;9[,Q[(8:YY$E$B.JLMO>B*=;!KT93W
MKK?1</DU\5NI?EOLW"["[CHLSD-MX++;HS5)28;*?PJ26KW=U+V7TMEQ53?;
M5+21?W+[7ROATZ'BK/#,&O%I;P-.'6B*]%AP'\JWX[[(Q6UL=UCO+O?JBLV=
MEJ++X/<?7?9,6#W/3U%)T+U9\<9HI,Q-MZOEDARG7/4&(^[.D2S9!JBIU@RZ
M5W7KVD=.VX/Y8'QTS6+VMM7';A[MVAUWA]F[0V#O/K#;':F678W<^V=D[SS/
M8.'A[;H\]2Y[,YS,U6[]R9*LR.6H*W%Y?*G(3)654\95%]4U)\^O4Z$[9?P8
MZ3V#W'2=QX#(=H"3"[O[$[%V?U?7]F;GKNE=A=B]LIEU['WSL[K>:J_A.*SN
MZGW+EI9%=IJ*DGR];+24]/).S>_5Q3KU!TT;K_E]?'[>67[4S>93>IK>XL'\
MC]O;Q^UW+'!"V.^4VT>JMD]I#&1G&2&AG;"=.888Y[O]G*)W(D\ME]J..O4'
M37OW^7'\<NQ\=O[%[D3?1I>R,_V3N7<OV.Z(Z61LEVK\9L+\3=UFA<XN44D#
M=38&G6G6S>')!JF[ ^,>KBG7J>?2DP?P3Z9P79N8[/BRO8E9797?._\ L6#;
M-9N:C3:^#W1VGU9C^H>P:O"+CL)0;CIXMR[8Q<$KK-DIS35T8DI3 G[?OU3Z
M]>IT"W6W\J'XZ]48O:M!L[>/=-'6;,W]UAV#@,[)N?9W\2I*WJ?KC?W3VWL%
M]I2]?TFWCM_)]6=DY/"Y-10"LK4<5C5*Y,RUTOJ_+K=.E-MC^6+\<MH3[*I<
M'E.V*?9FRL3U9$.LGWQ%)L#=&\^E>I<=TCUEVMNO&?P5<I7=A;8Z[PN/I1)3
MUM)BZN?&T=354,]12P2IZI]>M4Z&SK7X>]/]48'<VW-J+N@8W=G0?3_QNRPR
M6<2LG_T;]'[2W;LO8ZTTHH8?#G1AMZ5OW=40PJ)2C:$TV/B:]> ITE=A? SH
M;KG(;$R>W$WD*GKOLKKWM;;OWVXXZJ,;KZR^*D'PWVR:Y!CHONL<.G*=5J(;
MJ9<I>I#*/VO?JD]> IUCS7P8ZYS79?;_ &(>RN]\5CN^\E-E>W.J\)V'#C>I
M][5E5U3MWIBM?*;:BP#9%?O=B;3H()#%7QMY:=9%*GCWKK?22ZR_EO=%=997
M;VX(MT=P;UW-MS*465I=R;\WGC<KE*J7%?'C<?Q<P]-6IB]M83&FCQ74.Y9:
M2)(:>'75PQU4IDF\K2[KY=:H.'1=J?\ EE;AVM\DNC]S==;GP6VOCOU!N+H3
M>,N!DWEV'4;QW/G?CWT3D.B]I3[EV0U)+U[GMVUVVX\923;E2LQP3$4"4[8F
M:J1,@-UP?7KU/3JXOW7K?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=51CL;+5?\ -+K.NZ3?NQ<&]%MG%5>0P&4SFS\=N3>^
MQ\)U/65\VP\'M,;%J]YYW<VV]\]D46Y8\O/G:.G7#2UE)01SBES$<>Z&E?+K
M5<TZ&/\ FDH9/Y>GRU0&Q;J#. 'GZ_<47]%8_P"\'WM/B'7FX'K3"_EU?)"F
MZ8W95XO-U.+;!YN=Z7(XW*UD= E10U2I&ZTCU,=13M)YHB\@*%KMJ7E@WM6A
MXBO2%F#,U :@T."/('!(HV",K45J.((&Q+5;1VSVG@:#)[.["VGBLHJ4F4AV
MW49; NQP]52_<-4TN67(U,-53PQ)ZV6"E.L$V!5F1PDXKPZ]2HPWG_J^W]G1
M3?DVOQXI^HM[=*[BWKLK=&Z*O8M7O_ 8[*Y/$/7#-(U4J9S8^7H*F(5N2AJ(
M$"TU,#KJ(F!C>4N)-&E#GKP!%//[/]7^K_#2]T;V9FNNMMY;9&XMP5&,V)N5
MXJC+08#<.RTRDT(CIJJMAGPN6KGR4=/(<=&ZRO3M$.196=2%VS[G+L^XVNYP
MPQR30-J42!BM:4%0K*32M::J$X:JU!3W]E%?VD]G+J$$R%&TDJ:$48!AD5%1
M44(\B#0]7&? KMSXYTO8C=>[2[B02;^."J=PT.]<'2X.3$RXJGRL<M7MZLV]
M]_B<OD<HN5TS32144TR1T\?CB]3*NO\ >(MRMTAECN/$1Y70O<SW1!E*$QA[
MJ265($*$QPB0JAD<@YZ"7)?(]ER-#N-KMVY7D\%S,LA%PZOH(4J0FA$^+&IF
MU.VE=;,17H;OD1V[\2MD]@;,R>].\</N3"];[RRVVZW:NTJ*HR.Z<Y4;FVN<
M3EEW%MZ2IJHHL+CJ;*L\-4E+Y*1H)&$B:XV]Z@OYMOV?<+(6I"WZH"[ 4 BD
M61?#[:U\GHU*,M0<="V2UM;BZM+G76:W+4H2*>(M&!%:&H&*K4$=I )ZUPMZ
MXC;N+[;S>X]@[@VWBL%1[NS.2V9230[GJZ X&;+5==CL</X7@J^.EH##,8RD
M\E/)"C*"%T\$%*L2/7I4W:M/]7Y=6_\ Q'_FP;*Z 5<=N/KNMW+GQ4T=%4UF
MW\[EL)M&:&OBF7,5E>N0P]**\TM2T:I'/004VH22"K5+#WMCJ&FO7EJF=-?]
M7^K_ %4Z,/WW_.)V%L_*4\NR/CQM;<>V-R93 SR;RVYO;#[RQ+9K'UU-5[FQ
M3+AI::A6J@Q]*0M&):=GGO()64'7X*0*EB1^75M08G !/1*?Y>'?6'ZO^3O9
M>\.TLS2XG'=UT>6R^4J=T[6RVWUP66J:VKJIYZK#5V/K-M4U/58IU$$-1D4E
MD:&):=III%7W[C6N*_Y/LZJ,>=:?ZO\ 5Y=7Y8GLCX4[XR&%SV$^0FUZE8<K
MG\!-@]L5_P!_55>XL'3T.0GAQ;0+D6CBJJ6H$E**HM')#.N@N%4AQ([EXYI(
MH&:.,#4P%56M::CP6M#2M*TQUYI( \<;2@2,&H"<G32I'F0*BOI4=5=?/KYW
M?'NJV1FMO;'W+5;MW.FZ<QA,?@3C&BBP&/Q\<=%$(JL/78V-9(F FITE)1XO
M)XXS(--:Z0 >M'N."/\ BNB(_ 7Y;=3]"]:;VVYVC/5X9).P,GO'%TVWOX9F
MHMUXG<LRUN4P-;BHZ2MR%%!BIVFC!GC7TM')&'D/HTI !J:?ZO\ 5\^MGCC/
ME7UZLLH?DE\/<?%N3M.FW;NF/$/CA4[;J-Q;7GP& F84_P!F9*/<&03[?(4E
M-7Q%:6.5*=9YHE5S%*8H1J2XLH]XON73NUBW,5K$DLUHEU;O<Q1R(DB2/#'*
MSJC))&P:G!P>'13;[SMMRHDCD<0O=26R2/%+'"]S$-4MO'+(BQRS1KW/'&S,
MJY8 =5*_)3OSK;MSOKI^IZTJ<ANK&Y3L7KNH_O/DT1,A^WNK!-/2SJ\L_AEI
MI8RHBB9XQJ9PQ+,?;DP*'0Q!(]"#YGS!(.?F<?(#HUCR03@#_+UO[>R[I=U[
MW[KW7O?NO=>]^Z]U[W[KW7__TM]?<&T=J;L.".ZML;=W,=K[AQV[MLG<&%QN
M9.W=UXA*F/$[GP1R--4G$;AQ<=9,M/6T_CJ81*X1U#-?W7NE#[]U[KWOW7NO
M>_=>Z2.^-@;$[.VU7;,[*V3M'L+9^3>EDR6U-\;;PV[-M9%Z&JBK:)Z[!9^B
MR&+JWHZR".:(R1,8Y45ELP!]^Z]U!3J[K*/>6*[&CZYV(G86!VV=F8/?:;1V
M^N\\-L\R&5MJ8K= QXS>.VV96+&@AG2EU&^B_OW7NBP?$G_F;7\P_P#\77Q_
M_P !;\.?>SP7[/\ +U5?/[>CM^]=6Z][]U[ICW-N'&[3VYN#=.8>5,3MG!Y7
M<.5:GB,]0F-PU#49&M>&!2&FE%-2OI4?J86]^Z]T2*F_F']0978&Y.Q,'M7L
MB3;N&Q$]=BLYN'#X;:VT-TY:FW7)L^LV]@][9#/2;<JJW$9"EJJO(3)-)3T6
M)H*NM9VAIW]^ZU4?GT7_ !W\X?IG+QT<E!U1VHIR=-VA48VFR<FSL77,_6>U
M)]R5-%DJ*?<338S)9::CDA$#:WHZ:>BK*C13UL)][H<_+K18#[>K2NOMYXSL
M;86R.P<*)%P^^]H[;WEB5E6:.5<9N;#46:H1(E3!2U"NM-7)J#Q1N#]54\#7
M5NE?[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJN=S
MUE9'_,8V5!B^S<MAZ^HW-C*'/=68[:VS<?-NS8*?&WM3)G<>9KL=N3&[_P!P
M;!Q&^(<?&<_D*'(XJGSPIL1!'!+$:GWORX=:\^C_ /;O5.R^\>M-Y]2=B4%3
ME-D;^PL^W]S8^CR%7BZFKQE2\;S0PY"AEAJZ1V:(>J-E8>_ T-1UX@$$'AU6
M"_\ (F_EQ2*5?JS>+*?J#VMO[DB]B2,U<L#R">>![MXC>O53&IXCI:X?^3?\
M)=OYA\]A,1W#B\I+3T])/447?7:L J*6D01TM/40KN;PSP4Z"R(ZE$OP/=TG
MDCD204)!!H0"#3R(-01Z@X/3<EO')&\9J 014$@BHI@BA!]#Q!ZZW-_)F^!6
M[\U59_/==[RK<E5T])2/++VMV#,J4M#"(*2F@%1GIVAIX8QPBD+>YM=F)TEQ
M<*EL&F+31+36:!V(8L&9@!J85H&XA54< .D5AM-KM]J]G'+/+ S,3XTLD[=W
M%=<S.Y7R"EB ,#'3,?Y(W\O,VU=7[L:U@"W:&^F(L01I)S-U-P/I8\#^@]UU
MMZ]&'A)Z?SZBS?R./Y<]0R/-U+N1Y(R&64]E[Y$H*FZWE&9#M8\\GZ_7W[Q'
MQGKWA)4GSZ2_;/\ *W_E:].=?1[M[>VW4['V3M>HK =Y9WL?>U*V,_B<,E3+
M05>X(*]\@]'5O1::>":1T:H\<,(\CQQLIDW&^G@M[6:[DDMHJZ$9F*I7CH4F
MBU\Z 5ITV+:!&=UC =OB(%":<*GSIY=%4SOQN_D1X3&[@KVWB^5DVYB,_EZK
M'87L_LVMKZ^CVYMJKW1D7QFJKAH*^%L?3&"*I\PHWR+QT?F%6ZQ%GQ9#3JWA
M1Y-.AJZK_EB?RK>YMR[GQFPNM^R\B=L[<Z^W<FY*K>G96-VWN;;'9V+R&7VC
MF]K9.LRT1R^/KJ+$RD2&.+6@22+R0O'*U-;UK7/5C&AQ3'0_0_R4_P"7U#CL
MKB?]%VYIJ',/1S5451V3O69XZJ@D\E+6T50^6-105L?Z3)"ZLT?I:X  ]XCT
M(K@]>\-<?+IJ;^1U_+K>5YY.J]U2U#J%-1-V?OF:;2%50HEES#N %6W^Q/\
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M"Y?B[\:TI31)T#TTE&U#/BS3)UIL](#C*K +M:IQWC7#A?L*C;B"B>&WC>F
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M3/.]-#+**[R214[U4K(I-E:5B+:C?WBRUKXC5^T_ZO/K7UU[4M]9+J/]-O\
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MC?\ F7_\YK_Q,/9G_P +N^+7O9X#[/\ *>J>3?GU\KGV_P!6Z][]U[J9CO\
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M&5F J$0M8I&6((IJD5?5AT<+V>]1STVYG_BSY7_M6UW_ +BR^ZO\#_8>JO\
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M66FBD*!9DU@+*S3"S2,RBW/]GT^RPHH$<@&%;/0PL["QCO[>::NJJD?ZOY]
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MUS=?X&^P]?*!?];_ /!F_P![/N"!P'6%77#WOKW1O/Y?W_9=/PZ_\6;Z/_\
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M(U*^H-X:8.3\CT:CZF$LUS*JVB_"?QL6))!X#XJ!0.(I4>?2.VMA!EMO;K-
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M"O!-<+&K,0#AF[F4G^B213RIZ=!IMBI3.5#4\LDWGD>M<U$D=EB?2RT=.8E
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M>G2V_P"&S?Y=/_>"/Q"_])UZF_\ L4]^U-ZGKU!Z=2/^&V/Y>?\ W@W\2O\
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M-NA#*V6_U4Z@I-SDCF22,TIG_B^BOY[XO;>KYYJ^/'_>1Q-(TE#HC2ZO96_
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MOS[03T.D*U1T_:MHD#/_ *L=%?GZVWRR-)%LK=.K4P53MS+$$B_$MJ-7&M>
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M"E)D)!_B'3-_HN[*5'4=>[VXD)9/[HY]@X!/J1C1A4(3_8>VBI)JRYX=;-S
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M+7F!:MJ$@75*='OW@G^(=;\3%=#?ZOSZ<<;\U_CWFLCA\/A]^[:RV7W"DDF
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ME/3;MJMPUFX%5Z/<L#&7(5>ZJZ42,6DADF#1,ACCT>*_YNO!Z\.)_P"*^?\
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MGG[T."HNU]E9A-ST./JHYJB;;E?FL35=CU>2IQHJ:+[6LKZD.8#4R'W://\
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MFO3N,A2'C^ 8>W_+?<)'_N_M_3WHFF?/_5\NMA2U1BGY_P"?[./7'^(4?(&
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MJ+7?\ ZO_J%J/K]/\TWUOQ[]UH\#U7H*J2WZ*;_#_(Z/^AM_NCVN*CI(KO\
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MP_;_ *CPZ[\F4_XZUW_4VH_/U_(%Q[]CY=>&H^O\_P#-Y?ZO+KQERGXDKO\
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M>Q6M?]7^K\^M&E-(_P!7S_U#(_;U(JZ=?NZH_<TXO43C]4G_ !U<V/[9_/\
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M''TX/TN?ZW/OW7NMJ'_A,'_Q^WS"_P##6Z9_UO\ B[]C_3_#W)_MC_N5N_\
MS3C_ ,+]8%??H_Y)?MQ_S7O?^.6W6WK[F#KG9U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1:[_ (!5G_4+4?\ 6I_\
M1[]UH\#UK\[PV]\8MU]J[Q?)=G]G[3WGB^T,;G-ZXUM@U^#PV1R%)3_%O R[
M,ARN[^O:C%YG;>3K-D; KIY\16R5JQYE:B*MBHJZ-@M\VQ_J_9TFI0*<\/\
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M*W+47953U]E]W[JVE)2=(QU6Y\G7;ARV*Q&/CF$E3C@U*8M<#\^MG\]/^?\
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MSU?_  (G) I(38F5KB_WPXX]^%33'^K\^O'2*Y]?]1I_EZCZ*$ ?OU=A]/\
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M,G@H'HI\?'+MJEVA+!2JG[,<$V!I%BDC":))GFJ6!J9YYI-:33-.O:B33/\
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M&G^'_-\NNM4')\4GX_W>O^M_RK7/T]^&OAUMJ4K2OV_ZOV_9UWJ@O_FI;_\
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M\/I;CG_.5P_K^#6"_OPJ?/'^KTZU0  !>[C_ *N'^K\^I%5/#]W4_P"0TO\
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MF'HBZ][]U[KZ7_\ *>_[=P_#S_Q#&W_^M];[YR^Z7_3P^;?^>QO\ ZE/:/\
MDF6/_-,=5\_\*3_^R%.MO_%H-C_^^R[@]X_>Y/\ R1;3_GI7_CDG6:?W*/\
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MS1/;W7NO>_=>Z,9\/?\ LK?XM_\ BQG2/_OS-L>]'@>O=?8*]L=;Z^>G_/\
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M9S?8UM+L@X?9&S]K;,&%QVY\;!F5_P!Q9J*JN5HZR6IHI9:-_&4$UH>MA&
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MN/ZLQE)BKL'6.6KGJS5UM7-5-[Q5Q0''7M#>9'1C?] >9_YWN+_/^Z:O\_\
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M32K#%JE:.%V"V5B)/_UUO;O_ *:RU_:W_0/11^Y=T_Y0G_E_GZ</]ED^3/\
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M<<OD& +\GH_M(<<W)_WZGTY^ON)_ZI\Q_P#1HE_E_GZZ%?\ ! >S/_A1-O\
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MONO3?1DOAK_V5]\5/_%D>C?_ 'Y^U_:S;O\ DH6/_-9/^/#HWV#_ )+VR?\
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*>_=>Z][]U[K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g486549g85w22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g486549g85w22.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2364&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   (    X0DE-!"4      !#'71?E
M=+5N]=N^.93 Z7E<.$))300Z      #E    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'D            *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M       $    'CA"24T#\P      "0           0 X0DE-! H       $
M #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              6A   )V@         !
M                          $             "=H   6A
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   6A     %)G:'1L
M;VYG   )V@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   %H0    !29VAT;&]N9P  "=H    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !    ! X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M_1HMN>99=^;Z^^OU?^-L3_\ -BTM9[>FLL%PLM>S ;[V ,;LVV76>G=[7O\
M6_J?HOS[(M^K>=7+:V])#+&&NUOV PYGTJV6?K6ZYK/1Q_9O_P"$_P '4EP1
M_='V*]R?[TOM15W9+;V4Y-#:F[FLM<>JO+F"&V.?Z45_I6TV>MM_J>FK-E]6
M+7;90:;WU6EE-;L][&^DZL>Z[U77,]7>YWZ/9_PJ5_U>S+R'V#I3[7,+;;+.
MGEY<1N;1]++_ )NNGTJ_3=O^@G_YN6G,-UE?3'UE[20< >IL ;6]C;OM'T_3
M]798YEG\[^Y[$N"/[H^Q1R9#^E+[47KO/3O4NJ8W*;%.-CCJ+A5:P.#;+1D_
M2=96V[W>K3:_V5,3/R'XU&)::JOM%UCG^C9U)X;Z=9<YN16]^YF3N_1V75^E
M^>I#ZLYHIKH;^S!77#@'8&\BQX8_-L'ZS76W[5>UWT*:_P!'Z?\ HT5W0,VP
MU4VNZ>[ K8U@P_L(+&Z-=>^G?D%M?JW;]K=GILJ]/^<M_2I<$?W1]BO<G^]+
M[6G]JSF6MJ^P5F\O!=0WJKBYK@/7]U-C6-V,]-_M_P"#_F_20L*FG)ZG6;\>
MJC[38<ESZ>JVO)<0ZMM].&QU;/?>ST6^G[%H4= SVW&^X]-?8_>;;!@D6.+V
MEECG6_:G?ST_I_\ @_T2C^P.HL;6^H],-^,?U8'!VLK:T#T:J-F1ZM.RPW6;
M]W^%^@B(@; !$I2EN2?-SV^LVY[&X#;'6--4/ZQ8]EGJ!U'IM99N_2[/^!]G
MJ?H%J?5IU7JY-3&-K+&52&Y[\X 3<VMGIW._5-K6?FL_3_\ 6/T=>OZL9M5C
M+:?V55;6[<+6=.#7RT[F6;OM/MM_J?OK7Z5T[[%79OKQFW6.+GOQ:?0#@3O]
M[-]SG/:]]GO]1%:__]#U5))))2E5S>HT81K]9EI;9/OKJ?8U@:-SG7OJ:]M+
M/Y5BRNI=0=]KMKNNMPOLMK68?I$EN0]U+;]F0WTK/T3'NV?36GE9_20]^%EY
M&.'N;[\>U[ 2UT_2J>?H/VN24B_;V#I%>6=TQ^IY7;G_ +3I/Z[ALW;JLOVD
M"?LF009C7=Z&WO[E7Q\#ZI96[&QJ<'() >^JL5O,-E@L<UNYW^$=[UPM'^,1
MF-D.R,?H6+5>=S3:RPM<03[_ '-Q_P ]S4^&.4[X1=*M]3267]6NKV=;Z)C=
M3LJ%#\C?-37%X&RRRGZ9:SZ7I_NH75<G"N&3CYP96,1S'8MC[-NZ]U=CZQ6W
M]'^E9^8W<]-(()!W&BG4RLFK%H?D7;O3K$NV,=8Z/*NEMEC_ .PQ4G_6'I3'
M.8;+-S##@*+B09V_FU'\X(V7?F5LVX]#[W.82"S8W:= V79%C&N=KN^C^9^D
M5#IO4Z[LXT'J=5USF0,-UF.YX>W^>;Z>*UMGJ4^F_P!3]-:Q( G;HILO^L/2
MF?2?;H [^8N.A^%*TD*NQSGO8X&61K$ R)]NKMR*@I22R.JY&%D5VT7XM]YQ
M+JP/3:XQ86>M7>/2>UWI5;_TCG+0I>_T*SM<\EC272-3'\IR2FM^W>G>F^R;
MME9#7'[/?R=NUK1Z.Y_T_P Q*OKO3;+FT-?9ZCG^FT&FYHW [?IOJ:S;_P )
MN]-.S)ZP;:P_!J92YK3:X7RYKB/>QE?H!MFS_C:TL;K?3,G+=AU95#[Q(;6V
MZMSR1/J-%5;W/_1;?TB!(&_5(B39 NM2WTDDD4*22224_P#_T?54DDDE//VC
MJ/VKJYJ>T4&UGJ"T.<#7]FJW,Q/3>S9=ZGTO4WJSF]9^J;+[*,_.Z>V]OZ.V
MN^VD/$3^CL9:[?\ GN]CD_4>EL/KWMQ6YM^1:U]8VU--3FUBAN1ZEGIO>YFS
MZ>]]O^#K^@O*?KA]2.M9?UCS\XNQ<6O*M]6IF1D5UO+'>UKMI=_(>DI];Z5=
M]7LDOMZ,_#N-8#'OQ#4[:#JUCW8\[=VSZ*\-')_K._*5Z)_BOZ%U3ZOX>:<F
MEN2S+L8:K<6VJQI]/U*[/<;*_H/]JY._ZI]7Q;G49+L6FT;G%C\@ @?SL_1_
M<>K/+3C'BXB!=;HD'TC_ !>?^(_I_P#U[_S_ '(UKFMS.K^INM+S4RIK6NM]
M-QH<&NV5M?\ 9Z_I_IOYM+ZF8.;TSH&+T[-I].Z@6%SVN:]AWVV6M]-S';_H
M/;]*M:>32:V9%M%;[KLC:US-^D?S4L;<\55-K:[U'^G]/_C%!D(,Y$=9%(>>
MP?\ &/T'+Z^/J]55DC+]5^/O<Q@KWU[P_P!PM<_9^B_T:X[ZI ?^.&TP)^TY
MWY,A$Z-]2>OXWU]?UAS*7TTY5F3;2RYAN8R_UC3OJW>USMRO_5WZM=9Q/K>_
MJ;ZZK:,>_(==75?6^UGKBTU,?5+=EGZ5F[<]289 1R FKCH@]'._Q?-:/K@(
M'YF1^5=;]5?KQ;U_J;\)^&,=IJ=>UWJ[X#377Z<>C5NW>KNWK'^J/U:ZSTWK
M[NHVU5VTU>M58*+JWN:]_N]-S=S-KV3[VN<B?4;ZM]8Z5UE^3DUU/J94_&M-
M-S+"RQQINVV-]NW:QO\ 75+$)  41KK_ ,UM?$LG'G@<<N*'"!(AZ>UF3ZO4
MMF2,;=?40ZRL$.9Z-3755EWI-?ZKMWZ3?;L>N$Q?\8/UC/U['0=](Z>W/=A"
MOT_=Z3+#2/TD[_5]-OTO^@O2,["QG46N&&S)ML>VPMVLEU@#:67%UVUN^BO\
M_P"GL9^C7F>/]1?K"WZ_NZQLI=2S..;94+F&YM-EMEE;GU?O/:U^W^HIVLW.
MB=8ZM;_C%=B6YES\8YF96:7.EFRL91IKV_N5;?8JGU0 _P"?X_XW,_)<M/I'
MU:ZQ1]>;>JNKJ?15E9%]M5=S'7,;DMR/LXLITV/=ZK'>YZE]7?JSUC#^M3NJ
M65U6456W^HVJUCK&FT/+&/9+=KV^HS=[D>;J4\1AJ !=?WFWR>2,<?,"4J,X
M$1O]+YF7U+^L_7^I_6 8F=EF['-=KO3].MHEA:&>ZJMC_P []Y>@KS[ZF_5G
MK'3>ONR\FNIU-0LIM-5K'N8^ST[6M>S3;MK<UR]!3(76OXM'%Q</JN[ZJ222
M3E[_ /_2]5252S,OKS6T.QG?9WP&Y0<S;O/^#]+=ZW]K:K+PXL<&G:X@@.B8
M/C"2F22S3A]<@@=29]%H!^S#ENW?9_/?X7WJUAU9M37C+R&Y+G.EA;7Z0:(
MV1OMW>[W)*;"22KY&4ZBRMII>^NQP:ZUI9M87'8W>U[V6?2<W^;8])384+6O
M?4]E;S4]S2&V  EI(]KPU\M=M_E*:S+*.IVVO;C]4K:TNWM9Z+'O:-Q_1EWJ
M!KJ]OZ/^:]3_ (1)2?%Z91B83\3&<^LV;G69 (-KK'_SF2^QX=OO<[W>YO\
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M_P#7_+ZM7U$G#;2[%P[,VLFTV"6@;*"T54>S^5O4@B3&4ND=UX%D#J='N (
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      8I)22H "
M  X   $#  $   !,'0   0$#  $   "4$0   @$#  0   "V     P$#  $
M   %    !@$#  $    "    $@$#  $    !    %0$#  $    $    &@$%
M  $   "^    &P$%  $   #&    ' $#  $    !    * $#  $    "
M,0$" !X   #.    ,@$" !0   #L    :8<$  $      0  + $   @ "  (
M  @   D] ! G    "3T $"<  $%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,3<Z,#@Z,C@@,3$Z-#@Z,#4  P !H ,  0   /__   "H 0  0
M -H)   #H 0  0   *$%           &  ,! P !    !@   !H!!0 !
M>@$  !L!!0 !    @@$  "@! P !     @    $"!  !    B@$   ("!  !
M              !(     0   $@    !    .$))30/]       (      $
M  #_X0&,24DJ  @    .   ! P !    3!T   $! P !    E!$   (! P $
M    M@    ,! P !    !0    8! P !     @   !(! P !         !4!
M P !    !    !H!!0 !    O@   !L!!0 !    Q@   !P! P !     0
M "@! P !     @   #$! @ >    S@   #(! @ 4    [    &F'!  !
M  $  "P!   (  @ "  ( , #   !    P ,   $   !!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*0 R,#$W.C X.C(X(#$Q.C0X.C U  ,  : #  $
M  #__P   J $  $   #:"0   Z $  $   "A!0          !@ # 0,  0
M  8    : 04  0   'H!   ; 04  0   ((!   H 0,  0    (    ! @0
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MZUH[05\MLZ^GZ.VV,\OTFFHLE0:G-0'.9%@R^NQS7OAN#NL8+A\-S7MP.;7
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MU\O-&4B2HBRWQ^9[?W<[02[KBYIEC&I#3D*9V65L<>;G%W-)"ZB$<Q#:\)S
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MVJ3L ' S;$TY8) "F9&_JZ?-TAX4L^+LT(\X=%&+)D\&KO;;(VRO8[C;&V[
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M=AZWVS5SX@BVZYN/#GASEO\ R?&WY+.!+BKK%HN#5&!O7LU*JYJD>P=QR/\
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MZ[DL:QBO4,S(DRW@FR3@4,AY)$H)D2^!'9V"WOVY>ZZN(.Z_;CL[MER=RO\
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MNE >LYRLZ7(-;$"(LI:$<2*M7@Q^ 1)3(DA!\2W/=?G=MLFMP[S@,[9GQ7U
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M2Q6/MA6\RET<#GY7L9),4'&CGV*6&[G-?Y?^&YT7)RJ)S9_UFK5S)X3)"TN
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MZ )E' ^81E PP,0M](1#J/E1,N$!9$+?'8B:4:.T TD'."4?+:$&NR[/C)"
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M%>DO5-661Z=?81AR$PB=Y2#LI'9$ST)L"@F\)7'AD3D\_;.61%OM[PD$<"B
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M/!)%:70KPU#E#1L,YD,?&0WL VM:PKBC5Y]=SK8D98JM3B]8S@)9M>GRB#<
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M?3U:L<%Y%;"<8L/%^L*3F4+O"7**P>:N',*$Q-(@WJ*$!G:35Y!!(!-Y*4!
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MYN:'#ARMQ/H$L;@GA_YO>%,_MEUX[^3?N_.25*O;9K.B+.MWIJPFMF4S+8!
MI<4I^#=9.]+2U6*LCW6^>.PP=<4CZ_C=]5FRQ<>],L2<,RSU9EBPYA;C]8^M
M#>^'.#NSAMPS5:\AV\7+KU7O7$5V"LGNR>UOR?>&" L%G#[8J3-T$;;DL&[B
M.>Z=+TV:V-!(Y%M%1$8II7 ]4J(#/# ]@3B<NQ*GI<SM<,>%[9Y7%O;[<%/E
M89X]AWWML&0YNNPM.O?C%@11FSSD [%E;@LZ@>D=0R^Q(1:-2,;L$PJONS?>
MV9.FDU4"SZ$;SZ;PNH)SUX#7"+@=H5.]E,BE!DH+MU(:'EN'0D86WGT&_C?/
MO5%^.-AQM<Y]UK[>_%9>I.F?&X/(TG,+KG?9P!+800\*F*RR)B[5J]E$91'"
M,]L"'^(Q(YH'$%"+.2F@%7I0^1J%]'VRZQI9*00I U(,N-D6&.['ZO/ZT%\-
M^!/B0?+/9N&U1JI/K]XRM)0WH93E75]W,@P"EY)#%KK(D[@J _ 90D8[NR9_
M?C$C'F=I GWN#'7MZ+D,=DAU*WMY2U//14&KFOY,,.3]9<;=H\[8&_$Y\>"@
M!L!:UN.\XC=EOOXKM5-=1?%/I*GD@E6U]V0CLBA=13F 3\\^F]$/+TDP@SXE
M<:LVU176BQ3TI?LQDDG?55W+9#7A"5D0HC$[=GWZ>@N7NH^_X%MMO.V1W<;)
MC89W -\B<P<,]E[+(TNI7QQ9374]?QF<]O8AB%]=^W,WZJ1HA;M-M[<+V2S[
M10!YT[KOM$4#&2D7FL\VHMQ/%Y*UV-/XV] I!P4^E1"2M'S=X%MN\>&WGPLJ
M=:V'KQ%K^?AB2MI^#2PM+F\D6+P"7U^H FDFB;%O,-HOLK+!<??Y9L)]'?FM
M)9,EK#Y<CCWE'-3BH64:LLXP>C01WYM<8K)=WX1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A%^*3=!#*VR"**.7"V7"^4D]$\KK[::)[++9TUQE1;;1-/3*F_
MI;YT3TUSMY:ZXP1?MPB^1J/8,<N=F+)HSR]<J/'F6K9%OEV\5QKJJ[<Y1TTR
MNY4UTTPHNKZ:N^--<;;9QKCR(OKX1.$3A$X1.$3A$X1.$7^=]-%--DU-==T]
M]=M-]-]<;:;Z;8SKMKMKMC.NVNVN<XVUSC.,XSG&<>7"+\V[=!H@BU:H(MFS
M9)-!NV;IZ(H-T$=,)I(HHIZZII)))ZZZ)IZ:ZZ:::XUUQC7&,<(OVX1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%\[5HT8HX;LFK=FWUW54P@U13;
MHX4<*[KKJ822UTTQNLNHHLKMC7TE%5-U-\YWWVSDB^CA$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%^2J""^4LK(I+905U71RJGHIE%?
M3&VNBR7IXSZM777??7533RWUQMMC&<8VSYD7Z\(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"
M)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PBIK[T=X>QO6CL8G%89&P1FDGD"ZJ GICYHE3<@AUP=C
M.R-CP43(33YH_3:?8Y>0NJ34%=:;LLN@]CSJN"6[O00Y*Z:Y "W&Y[P+8=N.
M"Q)(/<+=IOY88^2QITL\2+L?/Z9[+W)VD@ F''*6ZO:]@ZOIT6.;A%[JK:-A
MK%>F[I1L!(A)V0I.8S2%$X"A6S<+L9J8.+C4IFNA9_9HD2'$#  WX_5[=J G
M$G*UQY\<_#S7P!?&N.EGT802ZP#B3 S,AD;;FHO<Q4\(LE@<F=215=_UU?+4
MP*TMYY4;&UG$F[%L"&D%TJL/6MAK-W4G1$*.4&KQ[O><APWX)K;AAL.5^P9X
M;3VK@H?X[C,[7D>L(QUM9-1,PB[@]$BL;NIQ(8B>D;JO.IMCA:D'REY4 #VV
MVV8SLK)Q$ZB3$4YWB1JCYBFW7.MUBRL1:O'FY!)X A37'E[L!QQQW+"S/QS;
MQ0&LH"VI"KCMEB@$#,S&P9;/)7!8D$W-WEUHB,H2D<%3KQT6 A&=6=B%Y4)G
MXF22F&M5*\ECYZY*$(O-X5&@ ..-N[/'#/AVF^0NA<1A8'+&]OV7YR*S2X\:
MB;0V/%'1CK$1F3V.P&W9JX8;6$M&9[)D(!$NT$^9R2.Q!G5)(6O337]CV+JB
M3VCL;1<@+2L:-@=HB55U:KR& 7\0.&.&?.&U4NMF.?"^X7.TK.]R>(3=PN@X
MO,8W7,4KJS2/8/NI1<E8NBA6RXFS==2*1[=6*Q(18LZCU>$#.UE'^O,9]V-R
M<:&*M@1Z0MD='3Q@P).%L<]V/;;CQ0DVW&_;L)PRS]N]1EA'C*W,7*"7QJGJ
MYQ%VL5C<7-R_[(AL=0ZTWDDNZ^#UKC*WHK6>[V)55"F=OGX'8([>MRV\?N6%
MGX3N8]E'.#[>ZOCNR.W9B=W<4UL;&W'AEMP[.U=W:^-G*WS)L^VZ?%HIN0C-
M2E70"?V>6C4JJY*S4NI:KNSKX#ZU"^TK?K=',=HR?G<*;PZ](:4=8VR\)%;M
MR:,7:O'PQWX#><O'&V%VMPW=U[9X8#CX!26\,#NE<G;%C-V-RC(KH7"U;1]M
MCBL/'O1XE!*W95?\*>0SS>^K4([@5:&2E+8LJT'/'HN?CL.!S5)%KC80!SP!
M[L_)&F_/;AW>U6P\Q62<(G")PB<(G")PB<(G")PBJ3[.^*L&ZR6+>->GJ5)F
MU:I!SDY$S&DV]WM+/2JWIQ+>W-DL6#=O##*X I%&;.N89NP6R6<%D;*3E@G1
MUI$S,?4H%^>('M4)ML[/,V\EEL?XBD&1Z\ >P\JK.?BV$ON^;4C&:S#9#N+4
M9'XB:G@O1E8T?GCJLQE<S!1I7APD=AA0V^4CN5Q;'4T7<O<>@(M?A]7O2^%^
MWRWY6R/#BL/X\:3J*[C J8@@ESR2/RGWZ^@CP;$(NR4G<5B(6_CDUF@9I(YV
M"=APD10ZR7"U("YPC$9J7>1]CK$(G)6Y\*Y>M4\]WO'-U-8<]_N/L7.R/Q<^
MN(N3"0H0;)C@U,W:0^:F7ZX**?-P;6+3NHQW?"FITBDV+OY1-^D%@Q@$+D)2
M$(8'2>*2)Z5;;*O0R"WL\[>]-8=O)];+I$$\9BF9Z=(I,:@M8=%-R<6C<++$
M'4&Q)K"F<TWZ^A@$/!QAO)U@X,E\^NP\5AA0M.)I%8DR71]_-9$2 ;%7P&VX
M[_*]SY=O! X'GL]_9Q6>Z>\3;KM=THD\9B JT&F(K6\TLA[(#\5%L8^[0K:!
MT)8MBQ4<JSDI(JM*8;'>RM49(86$-XV6>%R*$5DDAT#OED\;<^/N5OC;G9[U
M%XCXUE90H)(G]M4W*J_>14K3.3"S:4CYE&,1:=P/I=/+3+LB8$)\ZESM+CNY
MT6V4CSJ!L1UBM8]E6*2G0H5)!(KEJ\=_MMXV[MJA=:V';Y>.:RR?\8?JK#V<
MW>S,%<<63J<<.(7.F]BL5*JU-B3B3)JNVDBQ%IW($Y2ZLAB#>;QW-5*6(T!*
M;H)6,Z@V^ROJ9;ZN-L_#BFMP.S=MRVK,G5_O&V[(6&=@+JICU8.6;*X'034_
M*0$B,/%J-O$C2=@C9 RBVA".@WP]ZZ@QEGN%F$O&DOG.5',R*J,7P6.2WL\Q
M=4&_/([,<<=RGIPJG")PB<(G")PB<(G")PB<(G"*J43XC,\E;.O%8;2=.NR-
MTRX$,JD1)>UB0 FTAQN&]G9FG)+O#"J/E4FIXVFWZS&PR8!M'I['7,B,D 6L
M]3+0:5LFEL-YPX=@PQQS6-SN[,>W/ VRY*_QTW\3=WW8DED1RN:(^:>P6D*P
MN6J",_LM<</LC[(,/C<@+1PZN#K>0)Q#,#.RD9$Y.6BF]JY8OLJ;$A8HCNT"
MNA%@#?:0;;+>_/8@=<D6V7Q_9L.!628;X@P7/7#J]?%M5H]B1?M-$1M@1> 5
MQ+Q]C)Q6#OH(WLHA(I/,IP'I$=G2*1%VV=2<4*&/C:A!3(Z&C9ELGNMB*@X#
M#/=CLOCDL00GQ>*KMB94D"JRJ+%(1FYS@\0PE,_2WKMTV9&I=UX"QZ4 P6XN
M1(2J,R",=B(_+6#Q$Z*>LU@Y")'QP61I$VP6VMY>WW*:P-N-_+'TR7!R?Q:-
MPUV)UL*Z_."\)2MD/51*PG$ZEK)TS=%.YEG]'U3*HH724A@81LSM>J)$0;,Y
M_;4%7E(!R*9PA232Y[I&,75PO?FP/;MW=N&*:V-K<W(OY+G*V\8_KW8$8J9Y
MBO[92F]R0X8;@T*",H@4;R^6,8[6YRU(-%)3(99"V"3BHUK/C[$U(;,9U:%E
M^FKEY7:LJ]5NVTEL^&!.[/W)K#ROL[_#C;@ONK/Q;JDNN<Q ?5-=3(Y4\N*U
M*,'6T>?#HSN22MRWK.H 67 U_ND2DRHH/<E?(1 GK+=X295:D"TG'AW<>#AW
MTM$6SYR]A0.O[_'VBVQ6R\BR3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X15Y>(@;N<7"Z;CE72: #8W=-YU_UQ
MM>.6'3^MN!I!!;R,-X<9=JCU)A%F[=L&$*E]'PU\F1&GFY3V9_EH@VS[11A[
M.!WJ&^P[<K7OSZ*N^7>-4L%B4CC,%ZAAYJI :@DL@FL/=6^YCXN-YKR =RYC
M.JF)-1U+R?<?+!T2ZAZBQL>>#6NNYBUXV,+IA1XI0@6H&5\+\.SB-ZE]V-NW
MCAD<<-J[S&?%8,5OK$ZA']-@</'P!Q-ZJ1@\0M$CHU694Y=?8OKPDVZZ OL*
MATK @=8!^N FP;A<ODJ_VJ"K;,@Q%L)D^VS9H26S-^/C8X]M\,[XI>UA:V?9
MA?LW<,+9KM'8OQ&^SU3UOT\O 31M=?->UNO'8#LS<58-I[*#LG2#5_7L,F%9
M5M$IRO5XD>R-'M9^'UF9<I#TM19-F28@4R[$7J[D,L-^T#Z^?%"2-GKO MYX
M>BQM-_&EN6OM+W&2#HXQS):2M(74I!73L]# \+2-Z$[1#EY'8!R6PB.2.I8!
M+'59(NZ+F$UAC1C;0NPH$NDG'G1EJS=W5RQSX<W/ 9%-8[O/ZL.%[7S6?>WO
M?:65I8%00P-U#BMK$'$/IB[!Y&Q;17B;BN)G:*-Y@@[<5B.U!:S7<]$-*Z)L
M#<A%&6>514N=LAV%VRVV2,MV^%_:$)(V;+Y]N&7 [EC6LO%YETTLK$4=4&D.
M#R)T(.1O623LR*DAH<5ZM=.;STJRGP@.I#R=L7"D4[)GTW$=+EH0/:A88[-O
M)&R&.':<9I;SLS([LD#N=N0.6-SC[KJ=_A]=OI!W;H/[-$CJ5K3KS,K=1U".
MC;.C%M"B#-*,Q22:%&,JC#4=H@X8N),YB4ACQP.&D("6Q>0#WXU-)-JLO"+;
M;JM-QNQLIC#8Q' Q:1GA(,4.-R]X/(2DNS8MVY*0O10EF"&.3#Q-/5P04'!A
M[(8RRY44PU9M]$4<::>EC,57.\(G")PB<(G"+@I07=Q^-2$\P#.I&^"@RI9E
M'F+\,+>GG@]@N[:A69.1D0\?'NRJZ*;%L^.EA8=JLOHN3(LF2:SE,BK.J7Q5
M:QLN1Q\,5JJS(*,>"9DWEITJT:EW$(L2"YO=Z=KTC" F'-C.GZ,;ZZ6(<44Q
M$6AH:\W 0\]&!$V<FX_'R@<#O';[-]N"L7KBQX7;D) 6-7AO210V4-EG80QH
MQ)C,NDFSUR.=:+#3+(<6'NFC]F[9.V1%BT>-73=9!P@FHGMK@JN[\(G"+H,A
MJBKI<JY7E=;0&3KO'1%\\6D,.CII5T]+P]Q7I9XY4)#G.Z[HG 7;J#D7"N=E
M7L/<N(TYW5"K*,MB+J%D=;Z*MY@R$V/5L-E8=K8C&UW08D&:9#2"?CHPZAC2
M13 2DFF.FCA.+NO<NZ$J;&&:S)F*26;J>Z!>6A0@',<5P,PZC=8YZ5#F971-
M7E7H>PT;6VQM#0;=G(; :0":5B/DDW'M&:#">O!<,L&4C!&DS;G&XEP]:EQR
M+8N)$OF2Y]G<K8>WO7:WW7F@2;Z4DR5'4^0)3AP[>34@^K.%NWTP=OP9J,OG
M4I=KA%'$@</8W(Y#'G:Y91VJX!GC0E;;=@4?-UR6&[//BOPQUPZ\:MBC+6A:
M8PS. =HJ::8JZ#X;&(QNOLZWCA1# +U1 #NYWV<;!W>BP_9?;9;+?*F<[9):
M^:[2+JFK@:NS@)6\"#.-A;H)EP)B$?&KY#/@<2C#T3ZYD/05P-=QJ P2/.6.
M-\-EPD*B0I5+9A&PR#(BZ+"^KW7BOQ@8;&::KM%0)%H##&YTI%A,AF#^.U:U
M!M*\9R*;'VI*6RE>(Z1J/KA2,C,E"31\''DM'?O!LDYU);R7,#.O=!!=(NF&
MH^GQ*<(;21G"TQE:0MAI$&<RU7TE[2+Z-0J6H!M*M'+G22("<-$CFKA?4GJZ
MPJIC9<[\\U+#<%_8)0-,U?(]Y/6]<Q:!O\PT= &K&'BT(Y&Q44&R Y*-1P.)
M"-6D7!*$#L@>/SI 0(9D9#LU")&W;]"/ TAY6P]G<LO\(G")PB<(G"+CBY1H
M$$E#3_;.C$0.>E'F^,Z8SHT'ME7;C;&5=TDL9U12WSC*BB>F,X_;[Z:^>V"*
MJ^AO&#ZYWX\KE(3!;B@XR<MMUS<@GXVOA8FKMR *\)1#4;"P*L0T3:XG$<Z[
MVB5%.X\-D+$.B-#YE;D G(12J]L<>'U>EQ=8AP-N/EGGVV5DE96E7-T0H58]
M33:-V) SBY=L'EL2*M30$BYCYHC&SC=H19J*-U5Q!\04#$4M=_6-"0]VS7UT
M704TUBRSQ"[[PB<(G"+"QOK;UVDK.2#I'0=+'Q\QE3>=2YB;JR#%6<JF[1NY
M:M9E)&KX$N@<E39J]>-F\A)Z.BZ+=VY13>:IKJZ[D7>05>P"+GY#*HU!X?'9
M1+D0S>5R0%&0HD_)V\<9>[8\A(3#!DW(FD00[.6 9(DX<Z"V6?96.J"']#X1
M<>3J>K#4?B<2,UI7Y:*P%^!*06,DX;'7\?A9.*H9;1<C$PSH:J.CC^-MLY;@
M7@=LS<!T,Y2'J-T\YUX1<6$HJD8TN@ZCE.57'W+4T0DC9P$KV(BEV\B+DQ1L
MJ?068"$%$C1,R""%R!5/;5\])AQ3]RNHZ'M%426&Y=7&]6>N0R59G.E*5J0F
MB4NDTZ%RT_$0LDDL;D\R-/)-*7\1/'F9$K$4SLH)F90081MV,'K20Z>.>RX)
M&2+ARN5+#=Q\5RKGKCUY>,CPUW0U,.ATJ#Q6/2<>YJZ#KLI& @J35O" 9YJJ
M#V0,!X<@P8HQ4803<,H\DS:IB$&>C='70K8;E^#WK;0SR3C9GK4T%&2H=-0-
MAJ'P$>'1PH<E\6"%(_&"TM> 4!RTQS&V!9=0"TE.Y=B()LPQA@V0*@@[QB19
MNX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X10
M(\32&]O+$Z6W;!.D+T>+OB60^0B Y7-C/*JEK$8I&CBZR=8S9O&9*T#V,8+-
MPL= NRZL18,FQ@F31L"#EF(R1L*+7%\O%0WL;9\Y<=RA37%?>)?!K_[.VY*#
MVT.CF:/.F(\]LB>E^P?7=U(VD4ZJ$:^BE?U &M6K)4*)5I\R.W$>GTSVCU-K
MS0W9L,FKY>QD4O<T<N%A^P[<_+>H-:YO[QC:PS&(Q5P=,3,C8]/5/89ANR9E
MYY6L$F91H-T73'-2,HBXHX^;L$W*[ISHR0<OE4FNCARX7U0U3U5764QLIMBL
MEDKA$X1/+&?IQY^7QQ^/[_"+_/HZ_P#].O\ %CZ_/S_NY_CS]_/"+^^CC[V/
MK^K'U_3_ !_7]_Z^$3.NN?AG&,XQ\,>>,?#'T>7")Y8SY_#'Q\O/X8^/E]'G
M]_R^KA$SKC/QSC&<_?SC'U?1_%YY_CX1,:ZX^C&,?BQC'U>7]SX?B^'"+^XQ
MC'PQCR_%^'XY_M\(G")PB<(G")PB<(N%DD;CTQCQV(RT&(D\5E <G'9+&Y .
M:& ,@ &F2PXP$-"2"+A@4$E![EPQ(CWJ"S1XT76;N$E$E-],D6)H5UBZYUO(
MXY,(!1E4PV61&*O8/&)-&X)&Q!\'$B1HM)"0 :79#D7[8>0D$@D!Q^EHOC+P
MM(#Q!SLJZ-%%7:YWI8;ET'I%]KC%_P!^]X_KWLKA%+'A$X18JO2U&%%TI;EU
M%0Y*1#*CK6;V40 !\Z8+&V4(C9*2.A(O*NNR?O @B-W:,_3UVT]H53]+&<?#
MA%$-#NY8A*#VK+VO5VQA*$0J.:36NW9=M*W0ZUYW&&K_  *A,82&P++]X,F#
ML:Y(1(XS3<F#D74&E-8HQ(D]0S7*PPQS.[+CSXK&YQ%MG<>>;*+SSQ*NU#97
M5)#IG('Z?L=;K)O$(_<FC<CK*:Y$S5L19)[5SNLV8VW,"+^F:Q;/M4W<&F4?
M(%;5V:L5VXO66X\\XY8Y9X*@G=AASAA;OPS."L9ZQ7M*;["V@9E552^HE(5<
M4HK\ "FT=E<;.&XH*#QHP!E;EK*@ #*JQAL>WT?>X-3$;8$FCT0,D9_4>H4<
MB+;;\\^J W\3P[%)GD53A$X1.$3A$X1.$3A$X1.$7R/V#$JQ>BR;-J0&DFCE
M@0'O4$G3)\Q>([MW;-VV7UW1<-7*"BB+A!;3=)9+?=-37;3;.,D49*^Z2]4Z
MJD<+F%?TA#8U*:]P1^:,A:)D7!<:J2&' 6[I=\_(.W!A\.C\FDD;CC\WN1>Q
M2-2$['8RN("%R#!P4L/#M7R=,OW*)U^=CWH_Z:5]\IS[AZ!!EWGU*ECR*IPB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"
M)PB<(G")PB<(G"*H/QC.TL@Z[49"0$#N)_1=B6E+'K4%8#)[4#3+ %'63=M*
M,I)VS9%?(NB@OYU!Y6#9A_>[<R4C2$7E*H./2%T2YDT7*Q>2!AO4V.D<I/3;
MJ-UUELGF#J?GY!4\0)E9D^(@S#V0.G Q+;9\[-QM^4!GG.=?127/CWRZ9U5+
M8NIZM=XJBGB<RJ,0%E^X/W);1_)U-OT:)\*KI75;[6#KA^06G_U>QWA%GKA$
MX1.$3A$X1.$3A%YR4[\7[Q)Q<XF0P?VRL!LP'2N1,&3;09"LZ-VC,N\;MD-,
M[Q;;?.J2*>B>N=]MMLXUQG;;.?///T'D>B;HZBR4G%B:+2+HD25EXCW&+.W<
M]\%CG.-IH#$DG  +K")6ZJV)$ G(@ >X :L+ !Q _N%U3^;&^)E_NN;"_P#=
M<(_S5Y]7[D71Q_BI(?Z6=_YI8?9VK?X;$_[L+^HG\V-\3+_=<V%_[KA'^:O'
M[D71Q_BI(?Z6=_YI/L[5O\-B?]V%_43^;&^)E_NN;"_]UPC_ #5X_<BZ./\
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M(E5?2,9&&+HX#/L2]?GI1ARFF6].-!9H*@DWC5%L<O/V*&]QG;A;PQY\BIN
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MMD11HRP@P7QE5D$(K>LRGKAOG7;;;6%A O@J'@FV*V4>8K).$7DVV7^Z//\
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MU!F.T>J\GXOY>]BGT_ @]\\_5\'"OP_']6/H^CX9\_I\HG,]I]5_0#+_ '/
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MN>;>X%8.Z*]*GMJ57UCL?LI J]%U]6L5IFYNO]81;::C3!NVR("9R"7]B.R
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M8=RMWQCR^&/AC'PQC'U<BR3A%P,HB\:F\:/PV9  \JB4J#DH])HS(1K0P!D
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M3,2QFTQ$M" [T6CQ=?"W.WW[5=4$WYV>[9BL4,O _P"OX[YLJ-[2L5XO#HC
M8N'TD</HZ7#S.(+ Z.KUOK93"3U:5Q;,7R(H6+DXW K 7.12O9,9D!^#, CU
MK#<Q&ZQ\>WCENSYQO-4>GE;/?EZ\+<C /!MK*EST9+5?:$X):CY9UY=F'ED)
M1 S+747H6_*M[%HX)SP'# TUL"42"6U$#B+=Y.Y ]816"'28F.HLF8D>*=R_
MM\^&7@!XXIJX^'EB./CWY*YOD62<(G")PB<(G")PB_PHHFEIE1531+3&=<9W
M4VUTTQG?;&FN,[;9QC&=M]M==<>?QVSC7'GG.,<(O\X70RMLVPLEEQHGHMNA
MA33*VB*FV^B:NR7GZ>J:FZ:FFBF=<:[;)[ZZYSG7;&"+]>$3A$X1.$3A%6/;
M/A2]=+G!MP\Q.V)EP+<=AR$;D Y[$D)#%3'9#MC"^X,N*@23B(.]V2HR?P8;
M$!S7&NS,M6!$_$Y:A(MRZY'%O[/(6]%CJ\]]_58%H3P?1=%W);)L1:*CFG9G
MU>LOK;&0Z@&-ZV6V;6S#>LT//2,[+A$5CCA7>.MNN*"T:!Y(EXL,UEJC"%1R
MM@H3<.;I-_&_(Y]P-MX6&_':3A^Q=O!^#U4;N3H69.K'G6UD&&,!?S3$#'UQ
M&(Z[E,4C_7@63;##&*[WL=Y 7C_KG$R(J&R:9%A@EV^?%FJ")IJ">A9?GQ]_
M.*6QOV;/''/$<5Q8'P0NKX'$4T0L&Y5TXIK&Q:&,I4H.4>16(+T:X "=7(.F
M13F/RQ-3K[!??%U0Y:.7Q(M7!W!FS'?I1S,:7/KOV]_'L\2K;V;!L[NSP"S)
MU;\-6$]2+#@Q^N9V>.1&+"[-7?CY0#@0@Z]E$MK3JM2L4RRUJ^$UW$VL> UK
MUJ2VD";F.NSTLFQ_65$B^[INOJN)OSW[;^7M0"W/"W#9S@K,^15.$3A$X1.$
M3A$X1.$6,XE<M6SV;V-6\-G("2SFHGP<99<;$NLNW\+)'QVI80..>AIZAJ^>
M#=]'F&>%MW"**B>SA-+*FF-B+)G")PB<(G"*O!UX:-#/>QJW9QS([71GR\CF
M<ERU!S96(#6SZ?PJR(%*5!9.'L@$Q"/R &PFR>D@#2EA)&>\#A&&1=NB/(I%
M+<VML_9[O,J6QOSSBL4%?![Z^.I0>FP:Q[OCLJ,V,RM5L9TD45DSD)-F5UO[
MQV,,=YQ#9.J_<EY!\U04E<2%8R[DT=KV&Z&W+PTQ?&2-UN ^JUK<[5"W=@?K
MO[%^\C\(+K[,S# O+[$N,VJM$[@BDW616JF-G[(0OL]?DLMKYT3R)56!L-J
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ML>GD-3C-EPQYLNZADT */B7M@&W//AEO0B_/GSQ4+;5Z"47U_HH<JQU/V22
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M=3TZ12FV%'$,@DIE,QK!G-GCB(CI&/!%!0!<4RD$M1:%0X=>-0H02,2)D#'
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M_P#ZDZ(Y1F.T>JP/S3VG\Y>29S76DG"+>Y^0]?NF^(I^\3K;^D%R\TXFSO\
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MY<^$S]QZ'_2:U^BIBYEHA\^?_P V6]8ZN;\='[F'V(_X;4/ZZ*__ )?>^_\
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MLI(=QF8??ZY^/J7\[P7LY.$3A$X1.$6N5XA'W*CQ[/W]W_\ J3HCE&8[1ZK
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MMA?G;[BE\;<[/>M*#Y0E>]+7EX)WABU!2]JP"V+6KD]UP6G];US*@TSG$+2
M]3IG&3BLHB\?=D#(-,/(W;4"34),V^K$NY0'.<INU4TMLVD:QQW^JQ?B!;?[
M"M'=6N;";I[*KP.9HI:>7I*JQ<VFGKZ6V-=?2WW8ZZZ^EMMC7'GG'GMG&,?'
M..9W&\>*T['<?!?I]C.R/ZWTW_Y*'O\ _@XN-X\0ECN/@5ZXWA+]]ND=8>&1
MT,KNQ^VO76!SZ%=5J7C4PA<OM^"QZ41>0B82):% <@!%3;4D(+#G2:C9\/?-
MD'35=/=%=+137;7&B<SVE:K?FCO]5K&>.-=-17+X@L]G=26;!++A;Z!U@R9R
MN"RD-*(\Z>#8FT:D&K<N&>/&*KADYTV0=(Z+Y406URFIKKMC..>T.A72W1>D
M:!2,E5=(J+3IQD]4GOE9VI2DM,-9$FGNAN="C16/#7M(<TEMG#$7"X%I!)3D
M>I1(D&6CQ6&'! ?#A/<TD,%Q< C#:J@/?H7VCV7WL.]JPC[1[-[8A[1[/Z>4
M\+^I]9ZSU.5,93PIZ/H>GCT/2]+X<[8_= T%_P <-&O]M4__ )A;)]C*C_@,
MU_H(G]57#^!G=504SX@4-G5N6? ZSA;.O+-8NI7.Y4%BT>;O2,<W;L&BQ8R\
M9L4W+U?.$6J&R^%%U/VB>NVWPYU+TV:6:+UC0.;DJ5I#1:E..J%-B-E9&I2D
MU,.9#CWB/$*#%>\M8,7$-LT8FP6^:/24W J3(D:6CPF=5%&O$A/:VY;@+EML
M<;8CV+<#[0>(MT&DO6CL1'(]W/ZPFCY^C+;" PPR[J[>DBQ@K ) Q&C![-"0
M;KNWS]ZNBU:-D=-UG#A5-)/7;??7&?$%7AQ(M)J<.$Q\2)%I\ZR'#8TN?$>Z
M6BM:QC6@ESG.(#6M!))  NNZ-!)F7DM-]#9R<CP964E-*M'IF:F9B(R#+RTO
M J\G%CQX\:(6PX4&#"8Z)%B/<UC&-<YQ#02O.I]]AOH][C/+SSGX/VO\'E_1
ML?1_!_#SSO\ :]7_ .1*M_LZ;_X*_9G]U_HG_P IN@'_ (PT?_\ 4%^3>21U
MVBFY:G@KILOIZ:3EN38K(JZY\\8W2526VT4US\<8VUVSC\/PSYOM>KW\B5;_
M &=-_P#!3]U_HG_RF: ?^+]'_P#U!;K'@@]V^G5,]"8G"+;[1T#6LR;V)91%
MQ%IO;$(C)]NQ(G=56#M826--7J3=XEC*K57='719/R43SMIG&<]T:#2DU)T%
MD&;EH\K&^-3+C"F(42#$U7%FJ[4B-:ZQV&UCL7YC?"DKM$TBZ6JA4]'ZO3*Y
M38E&HD)D_2)^5J4D^+!E2R+#;,R<6-!,2$[Y,1@?K,.#@%!_Y1-VJZSWV,ZE
M:4C?]/6WO%WUW;232N;#BLQW ZF&]4X$[E] 1-]L/U)9&$<,=G6$M766+O".
M=\MU?1QTNDYN;$C\5EH\QJ&8U^IA/B:NL(.KK:@-M:QM?.QMD5X6Z6*;4:A#
MH0D*?.SYA/J)BB3E9B9ZL/;)!G6=1#?U>OJNU-:VMJNM?5-M8A231U+9+58X
M)3RX5]0AJH_:Z967]!17"*.-E,955RDDJIZO3SW]!)3?T?1UVSCA?V'JW\FS
MW^JQOZBZ:^UK2/9H_7+_ )*G\O\ 5\/KQR64Z3E\5$7/498K) 8X6+LZ!$")
M%^39M&3!@RE0ER\?/72ZR:#9JU024<.7"V^J2**>RF^VNNNV>:TO2*JV8@.=
M3IT-;&A$DRT8  /:22=3  8DK[J7H[I!#J5/?$H-99#9/2CXCWTN>:QC63#'
M.<YSH'R6M:"2XD "Y)LO39I[MAUB["%BP&B>P5.7$; CDRYL36MBQ6:$1(I5
MSHR2(D6<?*/UV;)1VJFVT<KZ:([+[Z)8WSOMC'.X%ZV4@>$3A$X15!]D.\T(
ML*E>_=/Y@-D#'\7IF[(#""0>,&+'>6=('!2[NO+UH)B-:#95*X_NUMJM#H=H
MJ?&-V! &_!2'V]HF[?LA>0%B.T=VW'9DL2;W%MA[]GJM5GY5[K+N]2/A^:]2
MJ;[(7=M5 /L*UL/$6ZP=B6OS6<2S2A\1U-_[_K /ZS)7,7/^SY9^TZX]V+^M
MV3\TO69,(%[FV7M6+P3:POG[%IPENBO=P BT<'>G/:@*W?E!0-BN6Z]VV.1>
MFSCY 6$#M%7D11T<E#!-RV'"AZ.V[L@^<(-&B*SA5-/;.XWCQ6%CN/@N5_F?
M/??_ '$/;W_FUW-_F7Q<;QXA+'<? KUWNM/?'KA#.N5 0^3OKG$26*4G54:D
M(EQU4[5;N!9P%!0(LL.7W0I99#99D_:N&RNR*JJ6VZ6V4U-],XVSH+76F7XG
MT7LJ[.^G9&TZLHSLE,J_F4Q%$8S)AW6>_P!%D79(P^-CU7#=(A6[-YIJF\9N
M4-M7#9'?TT=O+7./+.?;/1KTDZ#T?0;1VF5/2*3DY^4DXD.9EHK)DOA/,W,/
M#7%D![,6/:X6<<"-JZ]J])J,Q49J-!E8D2&][2QX++. AL!(NX',$9*O9"H+
MO<F2,;;=?NQ2\A##A!<N!0Z]W0J9%"9 N8: 2A$6G!MGS$<;=1Z0-A#UR@DV
M). 1A%DJLH,>ZH\Y_=<Z.?\ &J0_T<WX?<RV[["57_ HOBS^NKJ? P?G^L/=
M,M9%]5-V)K:$+TA.8RC(3/6/L0Z:*'2DA@[M@.U2#U@2=^N<MQCY73;+?"6-
M6V_IJ:YSKC;J#ILT\T1TDT.@T^AUR5J,ZVM24R9>"V.'B!#EYUD2)>)!8W5:
MZ*QI^5>[A8$8K?='J;/2D^Z+,2SX4,R\1@<[5MK%T,@8.)Q#3X+9C[K=W^OU
ME]/^T->09:Z)#,YQ0=L12* 6O5?M,BY,R$]"#0T0,;K/:9;-$UGSYR@V2W<N
M$$-=U-<J*Z:>>V/&U=@19JC527@,,2-&D9F'"AMMK/>Z$X-:+V%W' 7.:[PZ
M,*G(4;I'T#J]4F8<G3:9I?H]/S\W%UNJEI.5JLK&F(\34:YVI"A,<]VJUQU6
MFP*T-,4=V!\_AUN[-?3_ +F^\?CCR^CRQ ?+\&/+^#S\_AT/]J6D?\D37A#_
M *Z_6C^R&Z%O\H5#\)W_ )1<<(J2[#XH:<!T!V*-!#+!F5#F!/7NZ"(LH,((
M)NF)$:0:019H^8OFJR3EH\:JK-W#=1-9%11/;7;+[4M(_P"2)KPA_P!=/[(;
MH6_RA4/_ .]_Y1;GO@]]J*HZ\=#*NJNYQEXP*P DBLQX5C)3JWV>=O638U8$
MA*BU55A-0$&6</![IN[3U3=;[:IJZX4UTW\]<=RZ&R4U3Z#+RTY!?+QVQIES
MH3[:P#XSW-)L2,001CDOS2^$?I+0M+NEJO5W1NI2]7I$U)T.'+STKUG4Q7RU
M'DY>.UO6,AOO#C0WPW7:/E--KC%0.\?VUP_:YMU2UZ\P>_K0V@:]W;2[ 3J]
MV3:9":R9.I, LN<&JH%^LP1]P&,(^S>O]#+%3UWJ_22]9HZ5T^=G_B'Q2 Z/
MU7QKK-4L&KUGQ?4OK.;\[4=E?+&V"\9=*-$JM991!2Y&/.F7=4#'$$-/5B*)
M+JR[6(^<8;[6_O3>RUM'M4W4-6&-B/7_ +',%S3_ -U!D7O7:[6JQ8IAB^*9
M&C$EX&GN_?\ NP82(>QM=57&&(]\[]5[.T743X?]KU9_P"+_ -Z%_P 1=0_:
M1I7_ "%/;?[EG=_=\A9>I*K;JC=S5'(CG7GLR-"@;.@)HP07ZTWSE%@+%2H4
M^(/%<)5XHIE)JT0674PGIOOG33/HZ;;>6,ZTM0:NR8@/=(Q0UD:$YQUH6#6O
M:2?X38 ONIFAFE,&I4^+%HDZR%"GI2)$>6,LUC)B&Y[C9][-:"3G@%Z.M/\
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MS2?^28O^L27_ #*O]DKT&_Y09#_96D7_ *-SX+T#:D[@U='*JK*/&H#V\9&
M-?0P,69;= ^]:NS0F+C@UB_:[*M^N:J"NS=T@JEE1%51'?.GI)J;Z9UVSZ!D
MH3X4G*0X@#7PY: Q[2YIU7LA,:X8$C @C D;E^0.D,U G*_7)N6B=;+S58J<
MQ+Q6M>!$@QYV/%A1 '-:X!['-< YH< <0#@M53QG*[O#L]W5(VC175GN=/X&
MO6<"!)2!ITI[8AT=BPA(GJ19^QR2FPQ+&S;+A'&RN66$%/3_ *$KOZ._H\(T
MCHU2G:DZ/*RIBPC!A-#Q$@@:S0ZXLZ(TX=GJO.72'HKI!6=(/CE,ID6;EOB,
MM"ZUD66ACK(;HNNW5C1X;[C6;CJVL<"<;5!.^KO:\?(@D1?=1.WS*5R<>=+Q
MV-.^J/89 Z>%1?<,C)"(<2K6VC\BQ *R$ F9=LT%41NYH5J\41R0:X5V+[7*
MU_@+O]++_P#%7!_M TQ/_44>VS^V) '/Z5SFI;]+NM_:FK^WG6*R)WT[[J1^
M$P.^:IETM.+=-NT#Q(/'8]-@I4P34:#:G>D'.C)@U7<;(,F;EVKA/.B""JFV
MNF?LIU J\&H2,:+)N9#A3<O$B/,2 0UC(K7.<0(I)L 3@"5O6CFA6E,C7J/-
MS5'C09:6J4I'CQ3'DG"'"AQFN>\M9,.B$- )(:''<TE;]<+[+UU/?>7N.-]@
M6'NGV/VKYZ=3>T];^M]O]K]1[M^R'3<7]\^K]C6]L]S^W>[O3:>\/9?;F/M'
M:-CP\1[UZ3N./@?<I \BJ<(L:UI3=44TTDC"IZ[A]=,IC*2$VE+6'@1X% ]+
M"C=FS>GB:8]!#5T059#A[#153&<-Q[!DP;:HLVJ"*:]\U  ,@LE<*JO&5]UJ
M)7[HP+K*=#"):6"**%HA8L?</I,O65ZJL9! 3$5F )*.HZQ)N2AEAMHF*LH&
M?E$>8RJ:OJKL_6LI/**O:V?=GKS[._?;&^-O/CSF=F15AW(LDX18=NZ[H;14
M+?R>2*[%CRXX_F 5F%?!_LC7#+ @ C(4*YJF-DR(Y>93TXU&.$P\>&;JNU]L
M;+*82:I+KIE";>[:>Q8FZ@W=35]1RRYS7($'"K(=VO, _9. MS,<,3",7;5Q
M%;KP;3GCB./7B+IYN+I 6*AYMUJS4DE=@XD::LFS%TV1TIOA?=AZ^U 0;VWX
M^GL4N^15.$4'^S_;'K[6KUK4MP!W,VK2>,9/"NP$B$,A\MKV@XD>#B1;5]V;
M39O%7M>5[/\ 67-@"<A-,?=;-F[>2$_D;"!$FDX)SQ[E#S]?/E=3:;IH)(()
M-M4]&R:*:;?1+R]5JAIIKJEJGZ/[7U>J>-<:>7P]'&/+X<*K]N$3A% .&]RJ
M$L#O3974:2Q@A%.R5%CEE*Y*'6;8BPL.N)K7M76#,3,'D K9UH 59KF 0F11
M*4^YC!36-IG8[H?&,#>\?ML+[%+X\1Z88]BGYR*IPB<(G"+$=QT/4/8*/BHK
M<L%$3V/A#GSC&#"^[Y)!N44!FXL^SML.=LEG(XW%)-)8E)0CI5<+*(E(CT7D
M0\H ,D1SDBXJ)];:2A%I'[JC,$:,;2E#4^S.3%<M(2I%ZE*B00G(M]42Y=^P
M:.S&\7B Q\_8LVSY:-0F"Q'+C$6A$3#AW!2PO>V*SCPJJ_\ N]W$H'KSM7M=
M7.R"34199UEK.X6R.IN9]%JZ10.%&UIL*W:LG!J>Q\')8IA8T%!O&<I^; 6:
M2R(AYFI 3X#% OMMVJ$VW\;7P&_R4]V;QH19M2#!R@\8OFR#QD\:JZ+MG;1T
MEJNV<MUD\[)K(+H[Z*I*Z;;:*)[:[ZYSKG&>15?3PBX&3RJ+PD"1E,SD@&(Q
M@0DFN6D<G,#P $6BJNDU26(ERKAH/9)*.5T6Z:CEPEINNLDEKG*BFFN2*%_6
M[LW2?8FY+"VQ7<AJ+L/!P3>*HQ:V,1T%:DKI!ZTB-B!)D&B@V2%RK2&KN9_'
ME#(XXP%R6(R(DT%R<:-W)!]B-MAP/KN[5 03QXBQM[E.[D53A%'?L7V;KOK-
M#7,SFK.62C4>_B6"L2K( K.[#'1>3R\9$G]@_,$.OM*2D*A7O!>02Y\!&%B3
M8$(*9$"C)9-L)=$)LN]TRPJD;5, ;49M%U*>WBXM]6Z\)?MRL1=Q$FWU)!WT
M<)-7+QL_$/FSO5XR=MW2Z*Z*^JB:FVFV,\(LF\(G"* MF]P.N@3NQ5?3.XP)
M<)9Q6/Q&Y^O$S,CLO85+)X>UN6%.HJ (B7#IZ!G8.+QB7.M?G2P&@C0<VZ;"
M";DLTV9;6QM?9S[U+XVVYJ?7(JG")PB<(G"+H$7JBL(1*IQ.8;7<(BDTLUT-
M?6-+(Y%@H61SMX&T>:"74N-#F3<A(7 W4B1RR5*N'6[;<B_42SJH]<[*DMMV
MKO\ PBKG[,=SZ0KKL11_7:?P\;9K.42T,Z/KB@T@F4@IRT!S@/-Z6D3J+-H6
M2!OT6^!128&W .7[6A5X=C'K:<5\O432;63!;;;SQ]>_MP4)V9Y=V[W[QFK&
M.15.$6/K)M:MJ> -Y/:,ZB,!"/S(R,B2$PDH.,-3<I.J[-@$5#.3S\<U(R0^
M[URT"A6Z^SXBY\TVR6^==\ZD)LHK=2.S5;=AIE;6S^L&=(=I(FV@D9N&L)"0
MCI.W1U?:Q49:U.KS-P(0;E6XAJ&O0@F@#--T4(K8CZTHL)6+Y$$SA&GMN.>?
M!0&]\+<Y\[E.KD53A%$SL;V_K_KNL'&*AY!:\OV)BGLSK&HM64TMN!50Y8GW
MQZ[R]9#'"LM>UW$4@*^2SM@.W>E5U4041;2.:/P,4-K?MV)?]FU9ZK%Q7;NM
MX ZJ%2++52YAD97K16#^[\PQ2!*AF6\1WB?NGR%_-O8#LPR%P.QAE@=EOAKC
M"/H8X1=YX1?S;;737;;;;&NNN,[;;;9QC777&//.VV<^6,8QC'GG.?AC'QSP
MBK_L?NM243[VUCTGMJ&NF,WE<%B5QT!8KQHQD4>*3D\ZNJ$&8UHV;(+&J^D8
M>-Q$JB.F9!'2+G4YQF%[G0\D+QT),+;"_<?)2XO;O'GSWJP'D53A$X1.$3A%
MT*0U76$NF$*L.5US!)-/ZUW+J5U.)!$0!F7P)0^UT9'=X9)"(]R9B^YIFFFT
M*[!'C')!LGH@[RJEKC7!%WWA%@;LG=H>@ZED<W>$A[21KMW8&N!;^-6#,\2F
MR'PHD[B\=3B%3QJ969(6ZZHYR2.MX1%#QL9%AAZ08898AWJZ),EU7IQ=42[
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M><DW-R"0R,O2<X?AY+<E7=,[>#/8C89KKN2L 6V$VL2F#.(J/X*4D<HM:G#
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KOOILHVV7;[;(+;([:951VV2WSMIG.O"+ZN$3A$X1.$3A$X1.$3A$X1?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g486549g98r06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g486549g98r06.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1=R4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    !XX0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              '(   %(P         !
M                          $             !2,   '(
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   '(     %)G:'1L
M;VYG   %(P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   !R     !29VAT;&]N9P  !2,    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     0X0DE-! P
M    #.4    !    H    #<   '@  !G(   #,D &  !_]C_[0 ,061O8F5?
M0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/
M%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!
M#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,#/_  !$( #< H ,!(@ "$0$#$0'_W0 $  K_
MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MYGYBL(&=_0LC_BG_ /4E)3SV3CU8[;+KJ*Z<5VW;9=DW,<YONC?N?])K'?\
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M@?1JGW/=^[6SZ3_I>Y(D 64 $D "R4MV512^MEKPUUK@U@UU)T''T?=[?<B
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M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %^34T
M*@    @ # $   ,    !!48   $!  ,    ! ?0   $"  ,    #    G@$&
M  ,    !  (   $2  ,    !  $   $5  ,    !  ,   $:  4    !
MI $;  4    !    K $H  ,    !  (   $Q  (    >    M $R  (    4
M    TH=I  0    !    Z    2  "  (  @ +<;    G$  MQL   "<0061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHP.#HQ-R P.3HU,CHS
M-      $D   !P    0P,C(QH $  P    '__P  H ( !     $   4CH ,
M!     $   '(          8! P #     0 &   !&@ %     0   6X!&P %
M     0   78!*  #     0 "   " 0 $     0   7X" @ $     0
M        2     $   !(     3A"24T#_0      "           _^$!@$U-
M "H    (  P!   #     05&   ! 0 #     0'T   ! @ #     P   )X!
M!@ #     0 "   !$@ #     0     !%0 #     0 #   !&@ %     0
M *0!&P %     0   *P!*  #     0 "   !,0 "    '@   +0!,@ "
M%    -*':0 $     0   .@   $@  @ "  (   #P     $   /      4%D
M;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3<Z,#@Z,3<@,#DZ-3(Z
M,S0     !)    <    $,#(R,: !  ,    !__\  * "  0    !   %(Z #
M  0    !   !R          & 0,  P    $ !@   1H !0    $   %N 1L
M!0    $   %V 2@  P    $  @   @$ !     $   %^ @( !     $
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M",R),6//RD>](#@/'@M&O"(=;%<-$0^IM1+.%L93%'[*ZCH9W6XC77_TNV0
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MU)P-:3;,_=!10S6&I#*B@0TV%QW,3*%QKD>(4HM]F/(('<,)>9P\IJ7T^?\
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MRUUK2BRO6P]*LMCNO=Q*9$DA9YG,4T"PQK)IO-(QD+9KS6/2D+KGJ%,V?8;
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MC7;\,A0%^X]/MCL_;7K.M4X?@>3X5JHU,?/BMVOW9)3\V]N6,ES&YD*P1UY
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MK&PRQ@<P852',*1>^( YMTZ35:+]N-<Q"O&DDURO3#=$B$5>J6,32PEH_/%
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MR/L41$QN'Q&93!\B(2)("2T$XUESVB3 7W&I=EW#GOF P)&4'#'4^?@D.RW
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M T!F56D%01*L2 OVF+C4LA+%E;L3]7B,FHU)([*"-$Z-G'TP^HV$@9.5TQ:
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M\*EH&5&EB24 R=MHH/9[U:NW#3T(IQ3G= \AB)[K#,A1W9Y.TF^H?QJ44AB
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M1L4)EST00FUJ0,.AME*LX1C/+>7<X/\ R/@_^LKU@_\ ?[.?_P"=QC*QZ_\
M0]D$_4)O_73,];/4M4D2S=4BJW1-2WN3KMGMT36*Q%0+K^_-FRWW)[8N)982
MV$UZ-JE?&B($*O13<Y(/Q/OR&,M<WYU0TCIV@9N2OL1;P&!(@URNS"X5U^KV
M679C\/A0R;4$Z9'01IC^7&/*T*A<)P(84G#K"1EE1[F/B2EP@G-V"\@CKR30
M2)5DDKVW1"_R\%B/O$MHZ(6"PT,CA6>-7C4MDDX'X9M_$%BK#3LT1Y[4->=9
M+,:6*B2R",V)*TACEEA78)>L)E#,D;LCN%SK+:PWU(5DQ,4FJF(FSZZ#B$M
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M<Y\WEMCIPEU*%,(\LNN>64X5A2<9SY(\LY[I4E.%)PE*5=XQ97;H"5T%]O[
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M;BJ&B5H%2VG+I#V97?Y2S6J%+/X#/$8NY4[96![_ $!MOJ,: 9NS.K?_ ,P
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M."EADM@B*/;?SZ#J%% 1#;J!'&FTI:-]-YG"L.I;X^D(B!OCVM6VLH\:F0R
M!Z_8 GZV<LLOVV#](]$KG=;/(2EX>-JEN]V@5F@,A412R!)O&64DAD6,)])
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MIZL#^AR%VYZ([A!!*&O+&>ZL9[=^V?SVS^>_\^^?S_#/(ORE9NI91^8/Y_\
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M2TS'(9:'8Q\(0ZXMJ3\=7XSDN8@-[YRA:H25YZM1'0U7BB2>=69PS2.\\ZN
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MV-J2P0NX-:U+;M9!D!@+I76)=L(\)3!HO[;K9 16<*5CNP>V4A!(BG!7VO\
M.A7'6WV\9S6C\@$B#093L:.]C8*@G1]'>ON-;9=AAO3"?Y67Y:5AW5TTP=6
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MEOF6E^)3'(\*5;W&4)+TX64/YU6*,R/$44K%'MEG,2[ $CE&"(#F.ZDCMO\
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M4IUQYG!$)*-",,$K7F&+=9'].-VO@N@(X%X:1^%^6C=(Z]55:E)V ">6NX)
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BMU:E,9SW&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
